1. ITLE PAGE  
 
Clinical Study Protocol  747-209 
OBETICHOLIC ACID  
  
A Phase 2, Randomized, Double -Blind, Placebo-Controlled Clinical Study 
Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on 
Lipoprotein Metabolism in Subjects with Nonalcoholic Steatohepatitis  
 
The CONTROL Study  
Combination OCA aNd STatins for Monito Ring Of Lipi[INVESTIGATOR_575542] 4: 19 December 2016 
 
Sponsor 
Intercept Pharmaceuticals, Inc.  
4760 Eastgate Mall 
San Diego, CA [ZIP_CODE] 
[LOCATION_003] 
 
TEL:  +[PHONE_349]  
FAX:  +[PHONE_350]  
 
 
CONFIDENTIAL  
The information contained herein is the property of Intercept Pharmaceuticals, Inc. and may not 
be reproduced, published, or disclosed to others without written authorization of Intercept 
Pharmaceuticals, Inc.  
Page 1 of 364
Page 2 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 3 
 
Confidential and Proprietary  INVESTIGATORâ€™S AGREEMENT  
 
I have received and read the current version of the Investigatorâ€™s Brochure (IB) for obeticholic 
acid (OCA) and this Protocol 747-209.  Having fully considered all the information available, 
I agree that it is ethically justifiable to give OCA to selected subjects according to this protocol.  
I understand that all information concerning OCA supplied to me by [CONTACT_1034], Intercept 
Pharmaceuticals, Inc., and/or its agents in connection with this study and not previously published is confidential information.  This includes the IB, clinical study protocol, electronic case report forms ( eCRFs), and any other preclinical and clinical data provided by [CONTACT_1034]. 
I understand that no data are to be made public or published without prior knowledge and written approval by [CONTACT_1034]. 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, understood and agreed to abide by [CONTACT_18983], instructions and restrictions contained in Protocol 747-209 and in accordance with 
Good Clinical Practice (CPMP/ICH/135/95), the Declaration of Helsinki and all regulatory requirements for protection of human subjects in clinical studies and privacy requirements for 
the protection of individual and company data. 
I acknowledge that the Sponsor of the study has the right to discontinue the study at any time.  
 
 
   
Investigatorâ€™s Name (Printed)    
 
  
 
Investigatorâ€™s Signature   [CONTACT_238395] 3 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755544] INFORMATION 
Medical Monitor 
Investigators are encouraged to call the PRA Medical Support Center phone number for the 
[LOCATION_002] and Canada at +[PHONE_5343] or send an email to the NASH medical monitor at 
[EMAIL_10976] with safety  questions as these lines of contact [CONTACT_575759] [ADDRESS_755545]: 
 
Phone: 
Email Emad Basta, MD  
(Lead) Medical Monitor/Medical Expert  
[CONTACT_30372] 
+[PHONE_5343] 
CONTROL@ prahs.com 
Secondary Contact: [CONTACT_575760],  MD, PhD 
Medical Director, Clinical Development  
Intercept Pharmaceuticals, Inc. (Intercept)  
Mobile Phone: Email [PHONE_11939]  8886 (Pacific time zone)  
[EMAIL_10977]  
Secondary Contact: [CONTACT_575761], MD,  
Medical Director, Drug Safety  
Intercept  
Mobile Phone: 
Email: +[PHONE_11930] (Pacific time zone)  [EMAIL_379]  
 
Clinical Operations and Project Management  
Contact: [CONTACT_575762],  Clinical Operations   
Intercept 
Telephone: 
Mobile: 
Fax: 
Email: + [PHONE_11931] (Pacific time zone)  
+ [PHONE_11932] + [PHONE_350] 
[EMAIL_10978] 
 
Page 4 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 5 
 
Confidential and Proprietary  2. SYNOPSIS  
Name [CONTACT_790]/Company:   
Intercept Pharmaceuticals, Inc. 
Name [CONTACT_791]:   
Obeticholic Acid  
Name [CONTACT_3261]:  
Obeticholic Acid (OCA); 6Î± -ethyl-chenodeoxycholic acid (6- ECDCA); INT-747; DSP -1747 
Title of Study:   
A Phase 2, Randomized, Double -Blind, Placebo -Controlled Clinical Study Investigating the Effects of 
Obeticholic Acid and Atorvastatin Treatment on Lipopr otein Metabolism in Subjects with Nonalcoholic 
Steatohepatitis  
Study Center(s):  
Approximately 30 investigational sites in the [LOCATION_002]  
Study Period:  
Duration of individual subject participation:  up to 5 weeks in Screening (depending 
on current statin use) and 16  weeks during the double -blind treatment phase, 
followed by [CONTACT_185591] -label long -term safety extension (LTSE) expected to 
last approximately 2  years.  Phase of Development:  
Phase 2  
 
Objectives:  
Primary Objective  
â€¢ To evaluate the effect of OCA on low -density lipoprotein (LDL) metabolism in subjects with 
biopsy-confirmed nonalcoholic steatohepatitis (NASH) and to assess the ability of atorvastatin to 
modulate this effect  
Secondary Objectives  
â€¢ To evaluate the safety and tolerability of OCA alone and in combination with atorvastatin therapy in 
subjects with biopsy -confirmed NASH  
â€¢ To evaluate the effect of OCA , with and without atorvastatin therapy , on  
âˆ’ High-density lipoprotein (HDL), very low-density lipoprotein (VLDL), triglycerides  (TGs), total 
cholesterol, and apolipoprotein concentrations  
âˆ’ Components of the reverse cholesterol transport  pathway 
Exploratory Objectives  
â€¢ To evaluate the effect of OCA on  
âˆ’ Liver biochemistry, inflammation, and apoptosis  
âˆ’ Markers of glucose metabolism including C -peptide, insulin, fasting plasma glucose, hemoglobin -
specific A1c fraction (HbA1c), homeostatic model assessment â€“beta-cell function (HOMA -Î²) and 
homeosta tic model assessment  â€“ insulin resistance (HOMA -IR) 
âˆ’ Anthropometric measures  including height (measured at Screening Visit 1 only), weight, and waist 
and hip circumference measurements; and body mass index (BMI) , and waist-to-hip ratio calculations  
âˆ’ Cardiovascular risk scores (eg, Framingham Risk Score [FRS] and Reynolds score)  
â€¢ To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of OCA and its conjugates  
â€¢ To evaluate the bioanalytical concentrations of atorvastatin and its metabolite s 
â€¢ To evaluate improvement in noninvasive -radiological assessment of fibrosis via transient 
elastography  (TE; at sites where available)  
Page 5 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 6 
 
Confidential and Proprietary  Methodology:  
This Phase  2, double-blind, randomized, placebo-controlled, multicenter study, with an open- label LTSE, will 
evaluate the effect of OCA, and the subsequent addition of statin therapy, on lipoprotein metabolism in subjects 
with NASH with fibrosis stage 1  to 4, but no evidence of hepatic decompensation.   Approximately 80 subjects 
with histological evidence of definite or probable NASH, who meet all inclusion and none of the exclusion 
criteria will be enrolled.  The histological evidence of definite or probable NASH will be based on the central 
reading of a liver biopsy obtained no more than 1 year prior to randomization and a nonalcoholic  fatty liver 
disease activity score (NAS) of 4 or greater.  Subjects not using statin therapy (ie, statin -free) and statin -treated 
subjects may be enrolled in the study.  Statin -treated subjects will be required to stop statin treatment (after 
signing informed consent)  for up to 5 weeks, including a 4 -week washout period, prior to R andomization /Day 1.   
Screening Period : 
Subjects will have a screening period of up to 5 weeks prior to Randomization/Day  1.   
Subjects using statins within 30 days of the initial Screening visit (Screening Visit 1) are required to stop statin 
therapy immediately following this initial visit and must undergo a [ADDRESS_755546] a pre- randomization visit for assessment of 
their fasting LDL cholesterol levels.  Subjects with fasting LDL cholesterol values >200  mg/dL at Screening 
Visit [ADDRESS_755547] of care.  
Subjects who are not using statin therapy at Screening Visit 1 are required to provide a fasting blood sample at 
Screening Visit  2, which can occur at any time prior to randomization but after signing of the ICF .  Statin-free 
subjects with fasting LDL choles terol values  >200 mg/dL at either Screening Visit will be excluded from the 
study and should be managed according to standard of care.  
Double-Blind Phase : 
At the Randomization ( Day 1) Visit, subjects will be randomized in a 1:1:1:1 ratio to receive OCA 5  mg, 
OCA 10 mg, OCA 25  mg or placebo, orally once daily, for 16 weeks.  Randomization will be stratified by [CONTACT_575763] ( fasting serum LDL cholesterol at Screening Visit  2; â‰¤125 mg/dL or >125 mg/dL)  and baseline 
fibrosis stage (stage 1, 2 or stage 3,  4). 
At the Week  4 Visit, all subjects will initiate treatment with atorvastatin at a dose of 10  mg once daily.  At the 
Week 8 Visit, atorvastatin will be increased to 20  mg once daily  (if 10 mg daily is tolerated) , and continued for 
an additional 4  weeks.  After 4 weeks of treatment at 20 mg, the atorvastatin dose may be titrated (up or down) 
as clinically indicated.  The final visit during the double -blind phase will occur at Week  16, after which subjects 
may continue into the open -label LTSE phase.  
Subjects who discontinue investigational product or atorvastatin during the double -blind phase are still expected 
to attend scheduled study visits and  are to be followed through the Week 16 Visit.  
Subjects who discontinue atorvastatin during the double-blind pha se are eligible to continue OCA during the 
double-blind phase and enroll into the LTSE at the discretion of the Investigator , provided they continue to meet 
the LDLc cutoff of exclusion criteria #4 ( ie, LDLc <200 mg/dL).    
LTSE Phase:  
During the LTSE phase, all subjects will be treated with open-label OCA 10 mg or OCA 25 mg .  Subjects 
randomized to placebo or OCA 5  mg during the double -blind phase will be randomized in a 1:1 ratio to receive 
OCA 10 mg or OCA 25 mg  upon entry into and throughout the LTSE phase.  Subjects randomized to OCA 
10 mg or OCA 25 mg during the double -blind phase will continue on the same dose throughout  the LTSE.   
During the LTSE, subjects may continue with atorvastatin therapy as clinically indicated.   
Page 6 of 364
3URWRFRO 9HUVLRQ'HF
3DJH
&RQILGHQWLDODQG3URSULHWDU\ 6WXG\'HVLJQ'LDJUDP

/76( ORQJWHUPVDIHW\H[WHQVLRQ:N ZHHN
1RWH6WDWLQWKHUDS\UHIHUVWRDWRUYDVWDWLQ
Ç» 7HOHSKRQHVDIHW\FRQWDFWDW:HHN:HHNDQG:HHN 
1XPEHURI6XEMHFWV3ODQQHG
$SSUR[LPDWHO\VXEMHFWVZLWKELRSV\FRQILUPHG1$6+DQGHYLGHQ FHRIOLYHUILEURVLVEXWQRKHSDWLF
GHFRPSHQVDWLRQZKRPHHWHOLJLELOLW\FULWHULDZLOOEHUDQGRPL] HGLQDUDWLRWRRIWUHDWPHQWJURXSV
$PD[LPXPRIRIVXEMHFWVZLOOKDYHVWDJHILEURVLV 
'LDJQRVLVDQG0DLQ&ULWHULDIRU,QFOXVLRQ 
,QFOXVLRQ&ULWHULD
6XEMHFWVPXVWVDWLVI\DOORIWKHIROORZLQJFULWHULDWREHHOLJL EOHIRUHQUROOPHQW
$JHÂ•\HDUVRIDJH
+LVWRORJLFHYLGHQFHRI1$6+DVDVVHVVHGE\FHQWUDOUHDGLQJRID OLYHUELRSV\REWDLQHGQRPRUHWKDQ
\HDUSULRUWRUDQGRPL]DWLRQGHILQHGE\WKHSUHVHQFHRIDOO NH\KLVWRORJLFDOIHDWXUHVRI1$6+ZLWKD
VFRUHRIDWOHDVWIRUHDFKDQGDFRPELQHGVFRUHRIRUJUHDW HURXWRIDSRVVLEOHSRLQWVDFFRUGLQJWR
1$6+&OLQLFDO5HVHDUFK1HWZRUN&51FULWHULD
+LVWRORJLFHYLGHQFHRIILEURVLVVWDJHWRVWDJHDVGHILQHGE\ WKH1$6+&51VFRULQJRIILEURVLV
ZLWKRXWDQ\HYLGHQFHRIK HSDWLFGHFRPSHQVDWLRQ
,IVXEMHFWKDVW\SHGLDEHWHVLVRQVWDEOHGRVHRIDQWLGLDEH WLFPHGLFDWLRQH[FHSWWKLD]ROLGLQHGLRQHV
>7='V@IRUÂ•PRQWKVSULRUWR'D\
,VHLWKHUQRWWDNLQJRULVRQVWD EOHGRVHVRI7='VDQGRU9LWDP LQ(IRUÂ•PRQWKVSULRUWR'D\
&RQWUDFHSWLRQ)HPDOHVXEMHFWVRI FKLOGEHDULQJSRWHQWLDOPXVW XVHÂ•HIIHFWLYHPHWKRGRI
FRQWUDFHSWLRQGXULQJWKHVWXG\DQGXQWLOGD\VIROORZLQJWKH ODVWGRVHRILQYHVWLJDWLRQDOSURGXFW
(IIHFWLYHPHWKRGVRIFRQWUDFHSWLR QDUHFRQVLGHUHGWREHWKRVHO LVWHGEHORZ
Page 7 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 8 
 
Confidential and Proprietary  â€¢ Barrier method, ie, condom (male or female) with spermicide  or diaphragm with spermicide  
â€¢ Intrauterine device  
â€¢ Vasectomy (partner)  
â€¢ Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular implant or injection)  
â€¢ Abstinence  (defined as refraining from heterosexual intercourse)  
7. Must provide written informed consent and agree to comply with the study protocol including 
adherence to protocol -described statin withdrawal and statin therapy. 
Exclusion Criteria  
Subjects who satisfy any of the following exclusion criteria will be ineligible for enrollment:  
1. Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening Visit 1 (significant alcohol consumption is defined as more than 
2 units/day in females and more than 4  units/day in males, on average) . 
2. Prior intolerance to treatment with atorvastatin or other 3-hydroxy-3-methyl-glutaryl (HMG) 
Coenzyme A reductase inhibitor s (including but not limited to rhabdomyolysis) .  
3. LDL cholesterol  â‰¥190 mg/dL and already on statin therapy at Screening Visit 1. 
4. LDL cholesterol >200 mg/dL at any Screening visit in subjects who are not on statin therapy, or  at 
Screening Visit  2 in statin washout subjects .  
5. Planned change in diet or exercise habits during  participation in the double -blind period, or a 
significant weight change of >5% in the prior [ADDRESS_755548] undergone gastric by[CONTACT_109133] (gastric lap band is acceptable) or ileal 
resection or plan to undergo either of these procedures.     
7. History of biliary diversion . 
8. Uncontrolled diabetes defined as HbA1c  â‰¥9.5% within 60  days prior to randomization (Day  1).  
9. Administration of any of the following medications as specified below:  
â€¢ Prohibited 30 days prior to Day  1:   
âˆ’ bile acid sequestrant s including cholestyramine  and itâ€™s derivatives , colesevelam, colestipol, 
or 
âˆ’ omega-3 fatty acid -containing dietary supplements  
â€¢ Prohibited 3 months prior to Day  1:   
âˆ’ nicotinic acid and derivatives, ezetimibe, or  
âˆ’ any prescription or over -the-counter medicat ion or herbal remedy with putative NASH 
efficacy ( except Vitamin E or TZDs), or 
âˆ’ ursodeoxycholic acid, or  
âˆ’ fenofibrate or other fibrates, or  
âˆ’ Any over -the-counter or health foods used to treat lipi[INVESTIGATOR_575543]  
â€¢ Prohibited 6 months prior to Day  1:  
âˆ’ azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, mofetil, pentoxifylline; 
budesonide and other systemic corticosteroids, or  
âˆ’ potentially hepatotoxic drugs (including Î± -methyl-dopa, sodium valproic acid, isoniazide, or 
nitrofurantoin)  
Page 8 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 9 
 
Confidential and Proprietary  â€¢ Prohibited 12 months  prior to Day  1:  
âˆ’ antibodies or immunotherapy directed against interleukins, or  
âˆ’ other cytokines or chemokines  
10. Evidence of other forms of known chronic liver disease including but not limited to:  
â€¢ Positive test result at Screening for hepatitis B surface antigen  
â€¢ Active hepatitis C  virus (HCV) infection  (positive for HCV ribonucleic acid [RNA]  at Screening ) 
or history of positive HCV RNA test result  
â€¢ Primary biliary cirrhosis (also known as primary biliary cholangitis ), primary sclerosing 
cholangitis, autoimmune hepatitis or overlap syndrome  
â€¢ Alcoholic liver disease  
â€¢ Wilsonâ€™s disease or hemochromatosis or iron overload as defined by [CONTACT_18451] 3+ or 
4+ stainable iron on liver biopsy  
â€¢ Alpha-1-antitrypsin (A1AT) deficiency as d efined by [CONTACT_575764] 
(confirmed by A1AT level less than normal; exclusion at the Investigatorâ€™s discretion)  
â€¢ Prior known drug -induced liver injury within 5  years before Day  1 
â€¢ Known or suspected hepatocellular carcinoma  
11. History of liver transplant, current placement on a liver transplant list, or current Model for End-Stage 
Liver Disease (MELD) score >12.  Subjects who are placed on a transplant list despi[INVESTIGATOR_040] a relatively 
early disease stage ( eg, per regional guidelines) may be eli gible as long as they do not meet any of the 
other exclusion criteria.  
12. Presence of hepatic decompensation, including:  
âˆ’ Gastroesophageal varices  
âˆ’ Ascites 
âˆ’ Hepatic encephalopathy  
âˆ’ Spontaneous bacterial peritonitis  
âˆ’ Hepatorenal or hepatopulmonary syndromes  
13. Total bilirubin â‰¥ 2x upper limit of normal ( ULN) at any Screening  visit (subjects with Gilbertâ€™s 
syndrome may be enrolled despi[INVESTIGATOR_040] a total bilirubin level > 2x ULN if their conjugated bilirubin is 
<2x ULN). 
14. Creatine phosphokinase >5x ULN at Screening  Visit 2. 
15. Serum creatinine â‰¥1.5 mg/dL at any Screening visit . 
16. Serum ALT >300 U/L at any Screening visit . 
17. Platelet count < 75 000/mm3 at any Screening visit . 
18. Known positivity for human immunodeficiency virus  (HIV) infection. 
19. Subjects with recent history (within 1 year  of randomization) of cardiovascular disease or with history 
or planned cardiovascular interventions to treat atherosclerotic cardiovascular disease, including:  
a. Peripheral or Coronary revascularization (percutaneous coronary intervention or coronary artery  
by[CONTACT_15806])  
b. Coronary angioplasty, stenting, or carotid atherectomy 
c. Cardiac pacemaker or defibrillator ( placement of cardiac pacemaker or defibrillator for reasons 
other than atherosclerotic cardiovascular disease [eg, for treatment of atrial fibrillation subsequent 
to nodal ablation ] is not exclusionary)  
Page 9 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755549], unstable angina, or acute coronary syndrome  
f. Other clinically significant atherosclerotic cardiovascular disease 
g. Cerebrovascular accident (stroke), cerebrovascular ischemia, or transient ischemic attack  
h. Unstable hypertension  
i. Familial hypercholesterolemia or other genetic lipid abnormality  
20. Other concomitant disease, malignancy, or condition likely to significantly decrease life expectancy to 
<5 years, including known cancers (except carcinomas in situ or other stable, relatively benign 
conditions such as chronic lymphocy tic leukemia) and moderate to severe congestive heart failure. 
21. Known substance abuse, including inhaled or injected drugs in the year before Screening . 
22. For female subjects:  pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use 
effective birth control during the study, or breastfeeding .  
23. Participation in a clinical research study with any investigational product being evaluated for the 
treatment of diabetes or NASH in the [ADDRESS_755550] not being evaluated for the treatment of diabetes or NASH from 
Screening Visit 1 to Day 1, within 30  days prior to Day  1, or within 5 half-lives of the compound 
before Day  1 (whichever was longer) . 
25. Previous exposure to OCA . 
26. History of known or suspected clinically significant hypersensitivity to OCA or any of its components . 
27. Mental instability or incompetence, such that the validity of  informed consent or ability to be compliant 
with the study is uncertain . 
28. Any other condition which, in the opi[INVESTIGATOR_689], would impede compliance or hinder completion of the study .  
29. Acute cholecystitis or acute biliary obstruction
 
Investiga tional Product, Dosage and Mode of Administration:   
OCA:  5 mg, 10 mg, or 25 mg or placebo tablets, once daily, oral administration   
Study Medication, Dosage and Mode of Administration : 
Atorvastatin:  [ADDRESS_755551] Participation:  
â€¢ Screening period for statin-using subjects:  Up to 5 weeks (including a 4-week statin washout period)  
â€¢ Screening period for non- statin-using subjects:  Up to 5 weeks  
â€¢ Double-Blind period:  16 weeks 
â€¢ LTSE:  2 years 
Duration of Treatment:  
Double-Blind period: 
â€¢ OCA/placebo:  16 weeks (Day 1 to Week 16)  
â€¢ Atorvastatin:  12 weeks (Week 4 to Week 16), administered open -label 
LTSE: 
â€¢ OCA:  2 years  
â€¢ Atorvastatin:  As clinically indicated  
Reference Therapy, Dosage and Mode of Administration:  
Not applicable  
Page 10 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 11 
 
Confidential and Proprietary  Criteria for Evaluation:  
Statistical Methods: 
The assessments supporting the primary, secondary, and exploratory objectiv es of the study are as follows:  
Primary Endpoints  Assessment  
LDL metabolism  LDL cholesterol concentration, particle size, and particle concentration 
Secondary Endpoints  
Lipoprotein metabolism  HDL cholesterol concentration, particle size and particle concentration ; 
VLDL cholesterol concentration, particle size and particle 
concentration ; TG and total cholesterol concentrations; apolipoprotein 
(Apo)A1, ApoB, ApoE, ApoCII, ApoCIII and Lp(a) concentrations ; 
PCSK9 concentration  
Reverse cholesterol transport  Pre-Î²1 HDL concentration, macrophage cholesterol efflux; LCAT 
activity; CETP activity   
Safety and tolerability  TEAEs (including cardiovascular events) , physical exams, ECGs, vital 
signs, clinical laboratory assessments (including lipid profile changes)  
Exploratory Endpoints  
Liver biochemistry and markers of 
liver function Albumin, ALP  (isoenzymes) , ALT, AST, , direct bilirubin, GGT, INR,  
total bilirubin  
Markers of liver inflammation  IL-6, hs-CRP, and TNF -Î± 
Marker for hepatic apoptosis and 
fibrosis CK-18-M30 and CK-18-M65 
Glycemic Control Glucose, insulin, C -peptide, HbA1c, HOMA-Î², and HOMA -IR 
OCA pharmacokinetics  OCA, tauro-OCA, glyco -OCA, total OCA, potentially other conjugates 
or metabolites not yet identified   
Atorvastatin bioanalytical concentrations  Atorvastatin and its metabolite s     
Anthropometric measures  Height (at Screening Visit  1 only), weight, and waist and hip 
circumference measurements; and body mass index (BMI), and waist -
to-hip ratio calculations  
Pharmacodynamics  C4 (7Î±-hydroxy-4-cholesten -3-one), and FGF -19; possible  analysis of 
conjugated and unconjugated endogenous bile acids  
Noninvasive radiological liver fibrosis measurements  By [CONTACT_783] (where available ) 
Cardiovascular risk scores FRS and Reynolds scores  
ALP = alkaline phosphatase; ALT = alanine aminotransferase; Ap oA1 = apolipoprotein A1; ApoB = apolipoprotein B; 
ApoCII = apolipoprote in CII; ApoCIII = apolipoprotein CIII; ApoE = apolipoprotein E; AST = aspartate aminotransferase;  
BMI = body mass index; C4 = 7Î±-hydroxy-4-cholesten -3-one; CK -18-M30 = cytokeratin -18 neoepi[INVESTIGATOR_9230] M30;  
CK-18-M65  = cytokeratin -18 neoepi[INVESTIGATOR_9230] M65; CTEP = cholesterol ester transfer protein; FGF-19 = fibroblast growth 
factor-19; FRS = Framingham Risk Score; GGT = gamma-glutamyl transferase; HbA1c = hemoglobin -specific A1c fraction; 
HDL = high -density lipoprotein; HOMA-Î²:  homeostatic model assessment â€“beta-cell function; HOMA-IR = homeostatic 
model assessment â€“ insulin resistance; hs-CRP = high sensitivity C -reactive protein; IL -6 = interleukin -6; 
INR = international normalized ratio; LCAT = le cithin cholesterol acyltransferase; LDL = low -density lipoprotein; 
Lp(a) = lipoprotein(a); PCSK9 = proprotein convertase subtilisin/kexin  type 9; PD = pharmacodynamics;  TE = transient 
elastography; TEAE = treatment emergent adverse event; TG = triglyceride; TNF-Î± = tumor necrosis factor -Î±; 
VLDL = very low-density lipoprotein   
Page 11 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 12 
 
Confidential and Proprietary  Analysis Populations : 
The following analysis populations will be used:  
Intent-to-Treat (ITT) Population  
All randomized subjects who receive any amount of investigational product will be included in the ITT 
Population.  Treatment assignment will be based on the randomized treatment allocation.   
Safety Population  
The Safety Population will include all subjects who receive any amount of investigational product.  Treatment 
assignment will be based on the treatment actually received.  The Safety Population will be used for the analysis 
of all safety data.  
Efficacy Evaluable Population  
All subjects who complete th e double-blind phase according to the indicated doses of investigational product 
and atorvastatin without any significant protocol deviations.  The Efficacy Evaluable Population will be the primary population used for efficacy analyses.  
Pharmacokinetic Pop ulations 
The OCA PK Population will include all OCA subjects who consent to participate in the PK assessments and 
have at least one confirmed fasted analyzable sample. Subjects must have been fasting for approximately [ADDRESS_755552]  as part of the LTSE will be included in the 
LTSE Population.  
Efficacy Analyses : 
The primary efficacy analyses will be based on the Efficacy Evaluable P opulation.  
The primary efficacy parameter, changes in LDL cholesterol, particle size and particle concentration  at Week 16 
(end of the double-blind phase) compared to Baseline will be summarized by [CONTACT_1570].  
Analyses of observed LDL values will be carried out using an analysis of covariance ( ANCOVA ) model at each 
visit with change from baseline as the dependent variable, including treatment group and randomization 
stratification factor as fixed effects and baseline as a covariate.  The same analysis will be car ried out using 
percentage change from baseline as the dependent variable.  
Descriptive statistics of the values will be summarized by [CONTACT_6982].  The results, change from baseline, and percentage change from baseline values as well as estimates of least -square (LS) means, standard 
errors, and 95%  confidence intervals ( CIs) will be presented by [CONTACT_1570].   
The comparison of LDL change from baseline and percentage change from baseline values between each active treatment group and placebo group will be performed as exploratory analysis.  Estimates of the LS mean difference between each active treatment group and placebo group, the standard error of the difference, and 95% CI of the difference will be presented.  
The secondary parameters will be analyzed in the same manner as the primary efficacy variables.   Descriptive 
statistics will be generated  and will include  change from baseline, percentage change from baseline, and 
estimates of LS means, standard errors, and 95%  CIs presented by [CONTACT_1570].  
The secondary parameters related to lipoprotein metabolism include HDL cholesterol concentration, particle size and particle concentration; VLDL cholesterol concentration, particle size and particle concentration ; TG 
and total cholesterol conc entrations; and apolipoprotein (Apo)A1, ApoB, ApoE, ApoCII, ApoCIII and Lp(a) 
concentrations . 
The secondary parameters related to reverse cholesterol metabolism include pre- Î²1 HDL concentration, 
macrophage cholesterol efflux; lecithin cholesterol acyltransferase (LCAT) activity; and cholesterol ester 
transfer protein (CETP) activity.  
The baseline value for efficacy analyses is defined as the last value prior to administration of investigational 
product on Day 1 (predose).    
Page 12 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 13 
 
Confidential and Proprietary  The following exploratory parameters will be analyzed in the same manner as the secondary efficacy variable :  
markers of liver biochemistry, liver function, liver inflammation, apoptosis, liver fibrosis, glycemic control, and 
bile acids.  Additionally, descriptive statistics will be generated  and will include change from baseline, 
percentage change from baseline, and estimates of  LS means, standard errors, and 95% CIs presented by 
[CONTACT_1570].  Changes from baseline will be summarized for anthropometric measures .  PK analysis will be 
done using non -compartmental methods.  The values will be summarized by [CONTACT_575765].  Only samples that have a confirmed fasting of approximately 8 hours or more before their 
visit will be incl uded in the PK analysis.  Further details regarding specific parameters and methods will be 
described in the Statistical Analysis Plan . 
Safety Analyses : 
All safety analyses will be based on the Safety Population.  The incidence of treatment -emergent adverse events 
(TEAEs) and serious AEs ( SAEs) will be tabulated by [CONTACT_575766], and similarly by [CONTACT_22056].  The incidence of pre- treatment AEs and 
pre-treatment SAEs occurring  after informed consent form signoff and before the first dosing of investigational 
product (OCA or placebo) will be tabulated in the same manner as above for all subjects participating in the 
washout period.  
Laboratory parameters, physical examinations i ncluding vital signs, and ECGs will be summarized by [CONTACT_575767] -Baseline visit.  The absolute change 
from baseline will also be summarized.  
LTSE Analyses: 
Similar analyses to that which are described above will be conducted for the LTSE using the double -blind 
baseline value.  Analyses based on the double -blind baseline will be performed using randomized treatment 
groups (placebo, OCA 5 mg, OCA 10 mg, or OCA 25 mg).   Sensitivity analyses may be conducted using the 
last value prior to first dose in the LTSE for all subjects.   
Sample Size Justification: 
It is the intent of this study to characterize the components of LDL metabolism (cholesterol concentration, 
particle size, particle concentration ) in subjects with NASH before and after treatment with OCA and to assess 
the changes induced by [CONTACT_575768] A reductase inhibitor (atorvastatin) therapy.  Assuming  a 22 mg/dL 
increase from baseline with a standard deviation of 24 in LDL in the OCA 25 mg group  without atorvastatin 
therapy after 16 weeks of treatment based on data from FLINT , a sample size of 2 0 subjects per group will 
provide greater than 97.3% power to demonstrate the statistically  significant difference of LDL increase from  
baseline with a 2-sided type I error of 0.05.   
 
Page 13 of 364
Protocol 747-209  Version 4:  [ADDRESS_755553] an d Use of 
Atorvastatin .................................................................................................................32 Â 
5.6.1.Â Rational for Study Design ..........................................................................................32 Â 
5.6.2.Â Rationale for Placebo Control Group ........................... ..............................................33 Â 
5.6.3.Â Rationale for OCA Doses ...........................................................................................33 Â 
5.6.4.Â Rationale for the Use of Atorvastatin ......................... ................................................34 Â 
[IP_ADDRESS].Â Rationale for Statin Withdrawal ............................... ..................................................[ADDRESS_755554] . ...........................36 Â 
5.8.Â Summary of Known Potential Risks with Atorvastatin ............ ..................................36 Â 
6.Â  STUDY OBJECTIVES AND PURPOSE .................................. ................................38 Â 
6.1.Â Primary Objective .......................................................................................................38 Â 
6.2.Â Secondary Objectives .................................................................................................38 Â 
6.3.Â Exploratory Objectives ...............................................................................................38 Â 
7.Â  INVESTIGATIONAL PLAN .....................................................................................39 Â 
7.1.Â Overall Study Design .......................................... ........................................................39 Â 
7.1.1.Â Study Design ...............................................................................................................40 Â 
7.1.2.Â Schedule of Study Procedures ....................................................................................41 Â 
7.1.3.Â Study Duration ............................................................................................................46 Â 
Page 14 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755555] or Atorvastatin  .................................................................................................................52
 
[IP_ADDRESS].  Adverse Events â‰¥Grade [ADDRESS_755556] ..............................................................................52
 
[IP_ADDRESS].  Pregnancy  ...................................................................................................................52  
[IP_ADDRESS].  Severe Drug -Induced Liver Injury  ..............................................................................52  
[IP_ADDRESS].  Myonecrosis ................................................................................................................[ADDRESS_755557] ................................53  
[IP_ADDRESS].  Adverse Events â‰¥Grade [ADDRESS_755558] ...............................................................................................53
 
[IP_ADDRESS].  Suspected Mild or Moderate Drug- Induced Liver Injury ...........................................[ADDRESS_755559] and Atorvastatin Treatment Regimen  ...................................54  
9.1.1.  Double-Blind Period ...................................................................................................55  
9.1.2.  LTSE ...........................................................................................................................55  
9.2. Concomitant Medications ...........................................................................................55  
9.2.1.  Medications with Potential NASH -Modifying Properties  ..........................................55  
9.2.2.  Diabetes-Specific Therapy  ..........................................................................................56  
9.2.3.  Management of Changes in Cholesterol .....................................................................56  
Page 15 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755560] Numbers .........................................................................................................62  
9.6. Restrictions  .................................................................................................................62  
9.6.1.  Fasting Requirement at Study Visits  ..........................................................................62  
9.6.2.  Grapefruit and Grapefruit Juice ..................................................................................62  
9.6.3.  Diet and Exercise  ........................................................................................................62  
9.7. Visit Procedures  ..........................................................................................................62  
9.7.1.  Visit Windows  ............................................................................................................62  
9.7.2.  Informed Consent Procedures.....................................................................................63  
9.7.3.  Screening Visit  1 Procedures  ......................................................................................64  
9.7.4.  Screening Visit  2 Visit Procedures .............................................................................65  
9.7.5.  Randomization/Day [ADDRESS_755561]  .............................................................................................72  
9.7.13.  Week 16 Visit Procedures ..........................................................................................72  
[IP_ADDRESS].  Additional Week 16 Procedures for PK Subjects .......................................................73  
9.7.14.  Additional Procedures at Week 16/LTSE Day 1 Visit for Subjects 
Continuing into the LTSE ...........................................................................................73  
9.7.15.  Early Termination/End of Study Procedures:  Double-Blind Period .........................74  
9.7.16.  LTSE Visits  ................................................................................................................75  
9.7.17.  LTSE Month 1 Visit Procedures .................................................................................75  
Page 16 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 17 
 
Confidential and Proprietary  9.7.18.  LTSE Month 3, Month 6, Month 9, Month 15, Month 18, and Month 21 
Visit Procedures  ..........................................................................................................77  
9.7.19.  LTSE Month 12 Visit Procedures ...............................................................................78  
9.7.20.  LTSE End of Study/Early Termination Procedures ...................................................[ADDRESS_755562] (OCA or Placebo) .................................................................[ADDRESS_755563] Dispensation .........................................................................82  
10.4.2.  Missed Doses ..............................................................................................................82  
10.5.  Atorvastatin Tablets  ....................................................................................................82  
10.5.1.  Atorvastatin Packaging and Labeling .........................................................................83  
[IP_ADDRESS].  Atorvastatin Storage ...................................................................................................[ADDRESS_755564] and Atorvastatin Accountability and Disposal .....................84  
11. ASSESSMENT OF EFFICA CY AND PHARMACOKINET ICS .............................84  
11.1.  Efficacy Assessments  .................................................................................................84  
11.1.1.  Efficacy Laboratory Assessments  ...............................................................................86  
11.1.2.  Liver Biopsy ...............................................................................................................86  
[IP_ADDRESS].  Central Reading of Liver Histology  ...........................................................................86  
11.1.3.  Noninvasive Radiological Liver Fibrosis Measurements ...........................................87  
11.1.4.  Blood Samples for Future Analysis ............................................................................87  
11.2.  Pharmacokinetic and Pharmacodynamic Assessments  ..............................................87  
11.2.1.  Pharmacodynamic Assessments  .................................................................................87  
11.2.2.  Pharmacokinetic Assessments  ....................................................................................88  
11.3.  Anthropometric Assessments .....................................................................................88  
11.3.1.  BMI .............................................................................................................................88  
11.3.2.  Body Wei ght ...............................................................................................................88  
Page 17 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755565] and Hip Circumference:  ...................................................................................88  
12. ASSESSMENT OF SAFETY  .....................................................................................89  
12.1.  Adverse Events and Serious Adverse Events .............................................................89  
12.1.1.  Definitions  ..................................................................................................................89  
[IP_ADDRESS].  Adverse Event  .............................................................................................................89  
[IP_ADDRESS].  Treatment -Emergent Adverse Event  ..........................................................................89  
[IP_ADDRESS].  Serious Adverse Event ................................................................................................[ADDRESS_755566] or Study Medication ....................................90  
12.1.3.  Relationship to Liver Biopsy ......................................................................................91  
12.1.4.  Recording Adverse Event Severity  .............................................................................91  
[IP_ADDRESS].  Severity of Pruritus (as an AE)  ...................................................................................92  
12.1.5.  Reporting of Adverse Events and Serious Adverse Events ........................................93  
[IP_ADDRESS].  Reporting of Adverse Events ......................................................................................93  
[IP_ADDRESS].  Reporting of Serious Adverse Events .........................................................................[ADDRESS_755567]- Study SAEs  ................................................................................94  
12.1.8.  Follow-Up of Adverse Events and Serious Adverse Events ......................................95  
[IP_ADDRESS].  Pregnancy and Follow- Up ..........................................................................................95  
12.2.  Other Safety Parameters  .............................................................................................96  
12.2.1.  Medical History/Demographics  ..................................................................................[ADDRESS_755568] Population and Demographic Characteristics ..............................................100  
13.6.  Efficacy Analysis  ......................................................................................................100  
Page 18 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 19 
 
Confidential and Proprietary  13.6.1.  Primary Efficacy Analysis  ........................................................................................101  
13.6.2.  Secondary Efficacy Analysis  ....................................................................................101  
13.6.3.  Additional Exploratory Efficacy Analyses ...............................................................101  
[IP_ADDRESS].  Liver Biochemistry, Hepatobiliary Damage, and Liver Function ............................101  
[IP_ADDRESS].  Markers of Inflammation, Fibrosis, and/or Apoptosis..............................................102  
[IP_ADDRESS].  Glycemic Control Measures  .....................................................................................102  
[IP_ADDRESS].  Anthropometric Measures and Blood Pressure ........................................................102  
[IP_ADDRESS].  Noninvasive Radiological Liver Fibrosis Measurements .........................................103  
[IP_ADDRESS].  Pharmacodynamic Analysis ......................................................................................103  
[IP_ADDRESS].  Pharmacokinetic Analysis  ........................................................................................103  
[IP_ADDRESS].  Cardiovascular Risk Scores  ......................................................................................103  
13.6.4.  LTSE Analyses  .........................................................................................................104  
13.7.  Safety Analysis  .........................................................................................................104  
13.7.1.  Adverse Events  .........................................................................................................104  
13.7.2.  Clinical Laboratory Evaluations ...............................................................................104  
13.7.3.  Lipoprotein Evaluations ............................................................................................104  
13.7.4.  Additional Safety Analysis  .......................................................................................105  
[IP_ADDRESS].  Vital Signs  ................................................................................................................105  
[IP_ADDRESS].  Electrocardiograms  ...................................................................................................[ADDRESS_755569] ACCESS TO SOU RCE DATA/DOCUMENTS .......................................[ADDRESS_755570] Confidentiality and Data Protection  ............................................................109  
17. INVESTIGATOR OBLIGATIONS  .........................................................................109  
Page 19 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755571] OF REFERENCES  ..........................................................................................113  
APPENDIX A. AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART 
ASSOCIATION GUIDANCE  FOR THE USE OF STATINS  .......................[ADDRESS_755572] OF TABLES  
Table 1:  Schedule of Study Procedures:  Double-Blind Period ................................................41  
Table 2:  Schedule of Study Procedure s:  LTSE ........................................................................44  
Table 3:  Medications Prohibited Prior to Randomization and/or During Study 
Participation  ................................................................................................................58  
Table 4:  List of Planned Assessments ......................................................................................85  
Table 5:  NASH CRN Scoring System for Determining Eligibility and Primary Histological Endpoint Assessment .............................................................................87
 
Table 6:  Relationship of Adverse Events to Investigational Product or Study 
Medication  ..................................................................................................................91  
Table 7:  Relationship of Adverse Events to Liver Biopsy .......................................................91  
Table 8:  Severity of Adverse Events ........................................................................................92  
Table 9:  Severity of Pruritus  .....................................................................................................92  
Table 10:  List of Laboratory Analytes to be Tested  ...................................................................98  
 
Page 20 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755573] OF FIGURES  
Figure 1: Study Design Schematic  .............................................................................................40  
Page 21 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755574] aspartate aminotransferase  
Î²-hCG beta human chorionic gonadotropin 
BAS bile acid sequestrants  
BMI body mass index 
BNP B-type natriuretic peptide 
BUN blood urea nitrogen 
C4 7Î±-hydroxy-4- cholesten -3-one 
CAC Cardiovascular Adjudication Committee  
CDCA chenodeoxycholic acid 
CETP cholesterol ester transfer protein  
CI confidence interval  
CK-18-M30 cytokeratin -18 neoepi[INVESTIGATOR_9230] M30  
CK-18-M65 cytokeratin -18 neoepi[INVESTIGATOR_9230] M65  
COX-2 cyclooxygenase-2 
CPK creatine phosphokinase 
CRA Clinical Research Associate 
CRF case report form(s)  
CRN clinical research network  
CTCAE Common Terminology Criteria for Adverse Events 
Page 22 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755575] Term Explanation 
DMC Data Monitoring C ommittee  
eCRF electronic case report form(s)  
ECG electrocardiogram  
EDC electronic data capture 
EOS End of Study 
ET Early Termination  
FGF-[ADDRESS_755576] growth factor -19 
FLINT Farnesoid X R eceptor Ligand Obeticholic Acid in NASH 
Treatment  
FRS Framingham Risk Score  
FXR farnesoid X receptor  
GCP Good Clinical Practice  
GGT gamma-glutamyl transferase 
glyco-OCA glycine conjugate of OCA  
GMP Good Manufacturing Practice 
HbA1c hemoglobin- specific A1c fraction  
HCC hepatocellular carcinoma 
HDL high-density lipoprotein  
HDLc high-density lipoprotein cholesterol  
HDPE High-density polyethylene 
HIV human immunodeficiency virus 
HMG 3-hydroxy-3- methyl-glutaryl 
HOMA-Î² homeostatic model assessment â€“beta-cell function  
HOMA-IR homeostatic model assessment  â€“ insulin resistance  
hs-CRP high-sensitivity C-reactive protein  
IB Investigat orâ€™s Brochure 
ICF informed consent form  
ICH International Conference on Harmonis ation 
ICMJE International Committee of Medical Journal Editors  
IEC Independent Ethics Committee 
IND investigational new drug  
iNOS inducible nitric oxide synthase 
Page 23 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755577]  
ISF Investigator site file  
ITT intent-to-treat 
IWRS interactive web response system  
LCAT lecithin cholesterol acyltransferase  
LDL low-density lipoprotein  
LDLc low-density lipoprotein cholesterol  
Lp(a) lipoprotein(a)  
LS least-square 
LTSE long-term safety extension  
MedDRA  Medical Dictionary for Regulatory Activities  
MELD Model for  End-Stage Liver Disease 
NAFLD nonalcoholic fatty liver disease  
NAS nonalcoholic fatty liver disease activity score  
NASH nonalcoholic steatohepatitis 
NMR nuclear magnetic resonance  
OCA obeticholic acid  
PAI-1 plasminogen activator inhibitor -1 
PBC primary biliary cirrhosis (also known as primary biliary 
cholangitis 
PCSK9 proprotein convertase subtilisin/ kexin type 9 
PD pharmacodynamics(s)  
PI [INVESTIGATOR_244278](s)  
PSC primary sclerosing cholangitis 
QTcF QT interval corrected by [CONTACT_6550]â€™s formula  
SAE serious adverse event  
SAP Statistical Analysis Plan 
SAR suspected adverse reaction  
SREBP1c  sterol regulatory element binding protein  
S[LOCATION_003]R suspected unexpected serious adverse reaction  
Page 24 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755578] upper limit of normal 
VLDL very low-density lipoprotein 
 
Page 25 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 26 
 
Confidential and Proprietary  5. INTRODUCTION 
5.1. Overview of Nonalcoholic Steatohepatitis and Obeticholic Acid  
Nonalcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of 
metabolic syndrome, a cluster of closely related clinical features linked to visceral obesity and 
characterized by [CONTACT_30361], dyslipi[INVESTIGATOR_035], and hypertension ( Chalasani 2012, 
Angulo 2011).  NAFLD is the most common cause of chronic liver disease in the western 
hemisphere, and as the prevalence of obesity and metabolic syndrome rises, a parallel rise of 
NAFLD across  the world is generally expected.  NAFLD is thought to be represented by a 
spectrum of histological disease, which progresses from pure fatty liver (simple steatosis) to 
nonalcoholic steatohepatitis (NASH).  While NAFLD itself is considered a relatively be nign and 
reversible condition, up to one-third of patients in the spectrum of NAFLD develop NASH, a chronic, serious, life- threatening, inflammatory liver disease characterized by [CONTACT_575769], inflammation, and progressive fibrosis.  As opposed t o simple steatosis, NASH is 
associated with significant morbidity and progression that, if left untreated, can progress to advanced fibrosis, cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and liver-related death (Vernon 2011). 
Of all the histologic features of NASH, fibrosis is considered the strongest predictor of adverse clinical outcomes, including liver -related death (Younossi 2011, Ekstedt 2014) .  Patients with 
NASH develop progressive fibrosis over a period of 4 to 6 years ( Pagadala 2012) and 21% to 
26% of these patients develop cirrhosis in 8.2 years ( Loomba 2013).  In patients with NASH who 
have progressed to cirrhosis, it is estimated 38% to 45% have liver failure after 7 years to 10 years, and 2% to 5% of this population will develop HCC per year ( Organisation 2012).  
Accumulating evidence suggests that  patients with NASH can progress to HCC, even in the 
absence of apparent cirrhosis (Williams 2013 , Ertle 2011).  
There are currently no approved therapi[INVESTIGATOR_575544].  The therapeutic options for NASH are largely limited to lifestyle modifications and 
treatment of concurrent conditions such as diabetes ( Chalasani 2012, Neuschwander-Tetri 2003, 
Sanyal 2010, Belfort 2006), although practice guidelines from the American Association for the 
Study of Liver Diseases recommend the use of vitamin E as first line therapy for patients with NASH without diabetes. 
In view of the serious nature of the disease, the increasing prevalence, the complications that 
arise from the disease, and the clear unmet medical need, evaluation of therapi[INVESTIGATOR_575545].  
Obeticholic acid (OCA) is a modified bile acid and farnesoid  X receptor (FXR) agonist that is 
derived from the primary bile acid chenodeoxycholic acid (CDCA).  CDCA is the natural ligand 
for FXR, which is a nuclear receptor expressed at high levels in the liver, intestine, kidney, and adrenal glands.  In the liver, FXR is expressed in hepatocytes, Kupffer cells, and endothelial 
cells, and at a low level in hepatic stellate cells.  Nuclear receptors constitute a family of 
ligand-activated transcription factors that can either  activate or repress a variety of target genes.  
OCA is [ADDRESS_755579] CDCA, which makes OCA an 
attractive novel therapeutic agent for NAFLD and NASH due to its multiple FXR- mediated 
effects, including an increase in in sulin sensitivity, glucose and lipid metabolism; hepatocyte 
Page 26 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755580] bile acid -induced cytotoxicity; anti- inflammatory effects in liver and 
vasculature; and prevention and reversal of liver fibrosis ( Mudaliar 2013, Adorini 2012).  Thus, 
there is strong rationale to advance OCA for the treatment of NASH based on its FXR -mediated 
hepatoprotective properties, and results that indicate OCA improves glycemia by [CONTACT_575770], enhances glucose -stimulated insulin secretion, and inhibits hepatic 
lipid synthesis and content while inducing lipid uptake by [CONTACT_575771]. 
5.2. NASH, Lipoprotein Metabolism, and Statins  
NAFLD is the most common cause of incidental abnormal serum liver enzymes and is associated 
with dyslipi[INVESTIGATOR_575546] -risk of cardiovascular events.  Statins have been shown to reduce the 
risk of major coronary and vascular events in NAFLD ( Pastori 2015).  There has been some 
concern that patients with underlying liver disease are at an increased risk of hepatotoxicity because the statins are hepatically cleared and can cause elevations in liver enzymes.   However, 
there have also been studies that have shown that elevated serum transaminases secondary to comorbid conditions like NAFLD or NASH may be improved by [CONTACT_575772] ( Athyros 2010, 
Pastori 2015).  Atherogenic hyperlipi[INVESTIGATOR_035], which is defined by [CONTACT_575773]  (TGs), 
decreased high-density lipoprotein ( HDL), and the presence of small, dense low-density 
lipoprotein ( LDL), is frequently associated with NAFLD, thus the treatment of dyslipi[INVESTIGATOR_575547] a critical role in the overall management of NAFLD and NASH. 
In the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) Trial 
conducted by [CONTACT_575774] (CRN) at the National Institute of Diabetes 
and Digestive and Kidney Diseases, subjects with non- cirrhotic NASH were randomized to  
either placebo or 25-mg OCA for 72 weeks ( Neuschwander-Tetri 2014).  Subjects in this study 
were representative of the NASH population with baseline total cholesterol and LDL cholesterol 
(LDLc) levels at the high end of normal, HDLc levels within the normal range, and TG levels 
borderline high.  Approximately 50% of subjects were receiving antilipi[INVESTIGATOR_575548].  
Increases in total cholesterol, LDL c, and TG were observed in both treatment groups with 
OCA-treatment being associated with a somewhat greater percentage of subjects exhibiting 
increased concentrations of total cholesterol and LDLc.  Similarly, decreases in HDL cholesterol 
(HDLc) were observed in both treatment groups with a higher percentage of OCA- treated 
subjects compared with placebo.   While the OCA- related changes in lipi[INVESTIGATOR_575549] c trended back towards baseline values with 
continued treatment, it is important to characterize the mechanism of OCA treatment on lipi[INVESTIGATOR_575550].  
Using nuclear magnetic resonance ( NMR) lipid profiling, it will be possible to characterize the 
effect of OCA on the actual concentration  and sizes of the particles within each lipoprotein class.  
While a standard lipid panel measures the cholesterol or TG content of lipoproteins, it does not 
measure the actual particle concentration .  The cholesterol and TG content of LDL, HDL, and 
very low-density lipoprotein ( VLDL) particles is not constant, but varies widely among 
individuals and over time.  Even within a given lipoprotein class, the sizes of the particles are not uniform as the relative amounts of cholesterol and TG carried in the core of a lipoprotein particle 
varies across individuals.  Compositional differences also relate to plasma TG levels with LDL and HDL particles becoming more cholesterol -depleted and TG -rich as plasma TG levels 
increase.  Thus, presentation of the same measured  concentration of LDL in 2 patients may 
Page 27 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 28 
 
Confidential and Proprietary  represent significantly different numbers of LDL particles and, therefore, a different risk for 
cardiovascular disease (Jeyarajah 2006, Otvos 2006).  The patient with the higher number of 
small, atherogenic LDL particles would be considered to be at higher cardiovascular risk.  Thus, 
NMR lipid profiling, which allows differentiation of particle size and number, will provide a 
better understa nding of the mechanistic impact of OCA treatment on lipi[INVESTIGATOR_805].  
Recent evidence also suggests that HDL -mediated atheroprotection is largely governed through 
regulation of reverse cholesterol transport from macrophages within atherosclerotic plaques to HDL acceptor particles for ultimate return to the liver and biliary excretion (Rohatgi 2014).  
Thus, this study will also assess macrophage efflux and candidate components of this pathway to 
further elucid ate the mechanism of OCA and atorvastatin treatment on lipi[INVESTIGATOR_575551]. 
5.3. Mechanism of Action of Obeticholic Acid  
CDCA is the principal natural ligand of FXR in humans.  When cellular levels are high, the negative feedback pathway inhibits the further synthesis of bile.  OCA is structurally related to CDCA and differs by [CONTACT_1121] a single ethyl group ( the chemical name [CONTACT_22167] 
3Î± 7Î±-dihydroxy-6Î±- ethyl-5Î²cholan-24- oic acid.  It is also referred to as 
6Î±-ethyl-chenodeoxycholic acid, or (6- ECDCA) and as an agonist it is approximately 100-fold 
more potent than CDCA in vitro ( Pellicciari 2002 ).  OCA is also highly selective for FXR and 
does not bind other nuclear receptors, and with the exception of weakly activating the dedicated bile acid receptor TGR5, it does not activate any G -protein coupled receptors ( CEREP 2008).  
OCA is an attractive novel therapeutic agent for NAFLD and NASH due to its multiple 
FXR-mediated effects including an increase in insulin sensitivity, hepatocyte protection against 
bile acid-induced cytotoxicity, anti-inflammatory effects in liver and vasculature, and prevention 
and reversal of liver fibrosis (Adorini 2012, Mudaliar 2013) .  Specifically:  
â€¢ FXR and other identified bile acid receptors, such as TGR5, play a role in regulating key aspects of carbohydrate and lipid metabolism; thus, serving as important 
mediators of energy expenditure and metabolic homeostasis. 
â€¢ FXR agonists have been shown to suppress hepatic fatty acid and TG synthesis 
through down-regulation of sterol regulatory element binding protein (SREBP1c) and increase hepatic fatty acid  oxidation through up-regulation of pyruvate 
dehydrogenase kinase 4 ( Lefebvre 2009). 
â€¢ FXR activation has insulin -sensitizing effects.  In mice fed a high-fat diet, treatment 
with recombinant fibroblast growth factor-19 ( FGF-19) improves indices of 
dyslipi[INVESTIGATOR_035], hepatic steatosis, hyperinsulinemia, hyperleptinemia, and insulin 
sensitivity, while reducing body weight and adiposity ( Fu 2004).  Studies in FXR 
knockout mice show that FXR is involved in the regulation of insulin signaling 
pathways and the receptor appears to have a beneficial role in decreasing insulin 
resistance (both hepatic and in skeletal muscle) and gluconeogenesis, as well as in 
regulating TG, free fatty acid, and lipid levels.  
Page 28 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 29 
 
Confidential and Proprietary  â€¢ Treatment of OCA at doses of 25 mg and 50 mg for 6  weeks resulted in increased 
insulin sensitivity and reduced markers of liver inflammation and fibrosis in subjects 
with NAFLD a nd type 2 diabetes mellitus  (Mudaliar 2013). 
â€¢ Treatment with OCA at a dose of 25 mg for 72 weeks was superior to placebo in 
improving not only the key histologic features important in the underlying 
pathophysiology of the disease (inflammation, ballooning, steatosis), but notably that OCA was superior to placebo in improving fibrosis, a strong predictor of liver- related 
death (Neuschwander -Tetri 2014). 
The FXR-SHP cascade is postulated to mediate the links between lipid and glucose metabolism 
(Zhang 2008, Cariou 2006, Rizzo 2006, Ma 2006, Shulman 2005). 
OCA induces lipid uptake by [CONTACT_575775] (3T3-L1) and primary human adipocytes, which correlate with reduced hepatic and circulating lipid levels, together with increased insulin sensitivity (Rizzo 2009, Rizzo 2006).  Moreover, OCA significantly enhances adiponectin and 
leptin secretion by [CONTACT_575776], which can enhance insulin sensitivity in peripheral tissues.  Pancreatic beta cells express FXR messenger ribonucleic acid (mRNA) and protein, and OCA significantly enhances insulin secretion by [CONTACT_38383] Î²- TC6 cells and human 
pancreatic islets (Rizzo 2009) .  
Collectively, these results indicate that OCA improves glycemia by [CONTACT_575777], enhancing glucose- stimulated insulin secretion, and inhibiting hepatic lipid synthesis and 
content while inducing lipid uptake by [CONTACT_575771] ( Adorini 2012, Mudaliar 2013). 
5.4. Nonclinical Experience with Obeticholic Acid  
Nonclinical studies have shown several potentially beneficial properties of FXR agonism in NASH, including 
Effects of OCA on g lycemic, metabolic, and cardiovascular properties  
â€¢ FXR plays a role in bile acid homeostasis, metabolism, and clearance (Zhang 2008, 
Ma 2006, Cariou 2006). 
â€¢ FXR controls glucose metabolism through regulation of gluconeogenesis and 
glycogenolysis in the liver, as well as regulation of peripheral insulin sensitivity in 
striated muscle and adipose tissue (Mudaliar 2013,  Zhang 2006). 
â€¢ In nonclinical models, FXR agonism is associated with beneficial effects on body 
weight and composition ( Xu 2009, Fu 2004). 
â€¢ The absence of endogenous intact FXR signaling results in dyslipi[INVESTIGATOR_83281] a hepatic 
phenotype similar to NASH patients (Zhang 2008 ).  Conversely, FXR agonists lower 
plasma TGs by [CONTACT_575778]  1-c 
(Watanabe 2004) and increased hepatic fatty acid oxidation (Savkur 2005). 
â€¢ In addition, OCA and other FXR agonists are anti- atherogenic and cardioprotective in 
animal models (Hartman 2009, Miyazaki -Anzai 2010). 
Page 29 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 30 
 
Confidential and Proprietary  Anti-inflammatory and a nti-fibrotic effects of OCA  
â€¢ OCA exerts direct effects on serum -starved LX2 cells (an immortalized hepatic 
stellate cell line) to reduce the expression of key fibrotic genes (collagen I, alpha 
smooth muscle actin, transforming growth factor Î²- 1 and matrix metalloproteinases; 
(Albanis 2005).  
â€¢ In primary and cultured hepatocytes treated with pro -inflammatory mediators, OCA 
exerted direct effects to inhibit pro-inflammatory gene expression (eg, tumor necrosis 
factor-Î± [TNF-Î±], cyclooxygenase-2 [ COX-2], and inducible nitric oxide synthase 
[iNOS]; (Wang 2008, Li 2007).  
â€¢ FXR activation (with WAY -362450) reduced inflammatory cell infiltration and 
hepatic fibrosis in a mouse model of NASH ( Zhang 2009). 
â€¢ OCA improved portal hypertension in cirrhosis models ( Mookerjee 2014). 
â€¢ OCA inhibited gastrointestinal inflammation and pre serves intestinal barrier function 
in models of inflammatory bowel diseases (Gadaleta 2011).   
Effects of OCA on diabetic nephropathy 
â€¢ OCA ameliorates TG accumulation by [CONTACT_575779] a murine model of diet-induced obesity ( Wang 2009) 
â€¢ In the same murine model of diet-induced obesity, OCA improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix 
proteins, and increased expression of pro -fibrotic growth factors and fibrosis markers, 
and reduces inflammation and oxidative stress ( Wang 2009 ) 
â€¢ In a murine model of diabetes, OCA improves renal injury by [CONTACT_575780], 
glomerulosclerosis, and tubulointerstitial fibrosis, and modulating renal lipid 
metabolism, macrophage infiltration, renal expression of SREBPs, pro-fibrotic growth factors, and oxidative stress enzymes (Wang 2010 ) 
In summary, there is strong rationale to advance OCA for the treatment of NASH based on its FXR-mediated hepatoprotective properties and results indicating that OCA imp roves glycemia 
by [CONTACT_575777], enhances glucose -stimulated insulin secretion, and 
inhibits hepatic lipid synthesis and content while inducing lipid uptake by [CONTACT_575771]. 
5.5. Clinical Experience with Obeticholic Acid  
OCA is under investigation for the treatment of multiple chronic liver diseases, including the treatment of NASH, primary biliary cirrhosis (PBC, also known as primary biliary cholangitis  
[Beuers 2015a , Beuers 2015b, Beuers 2015c ]), primary sclerosing cholangitis (PSC), and biliary 
atresia.  The clinical development program for OCA includes the following 3 studies conducted 
using subjects with  NAFLD or NASH:  
â€¢ Study 747-203:  A proof-of-concept, Phase 2 study in subjects with type 2 diabetes and 
NAFLD to evaluate the effects of OCA on insulin sensitivity ( Mudaliar 2013) 
Page 30 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 31 
 
Confidential and Proprietary  â€¢ FXR Ligand OCA in N ASH Treatment (FLINT):  A Phase 2 study conducte d by [CONTACT_575781] 
(Neuschwander- Tetri 2014) 
â€¢ Study D8602001:  A Phase 2 study conducted by [CONTACT_575782]â€™s Asian development partner 
(Sumitomo Dainippon Pharma Co., Ltd) to evaluate the efficacy and safety of [ADDRESS_755581] and supporting the potential of 
OCA to treat NAFLD and/or NASH.  With the exception of weight loss, OCA [ADDRESS_755582] as effective as OCA 50 mg for the majority of endpoints evaluated.   
The FLINT study demonstrated that OCA was superior to placebo in improving not only the key 
histologic features important in the underlying pathophysiology of the disease (inflammation, 
ballooning, steatosis), but notably that OCA was superior to placebo in improving fibrosis, a 
strong predictor of liver- related death.  OCA treatment was also associated with improvement in 
markers of hepatocellular injury and some cardiometabolic features including weight and 
systolic blood pressure.  Salutary effects on weight and blood pressure are important 
considerations since patients with NASH present with higher cardiovascular risk given the comorbidities of obesity and diabetes.  
On average, LDL cholesterol demonstrated a significant increase in subjects treated with OCA 
compared to placebo; however, this increase was reversed and LDL cholesterol returned to below baseline levels in subjects who initiated statin therapy.   The change in lipid profile, which 
was attenuated with continued treatment and reversed post-treatment, needs to be further 
investigated mechanistically and with respect to clinical management with standard of care statin therapy.  With the exception of pruritus, which occurred more frequently in the OCA- treated 
subjects (23% OCA versus 6% placebo) and led to 1 discontinuation, the gene ral adverse event 
(AE) profile was similar across both groups.  There were 2 deaths in the FLINT study, both in 
OCA treatment groups (one from sepsis and congestive heart failure, and the other from cardiac 
ischemia or infarction  (Neuschwander -Tetri 2014) .  The event of cardiac ischemia or infarction 
was assessed by [CONTACT_575783]  (Data on File) . 
Study D8602001 demonstrated a dose- dependent increase i n the percentage of OCA- treated 
subjects compared to placebo subjects who achieved the primary endpoint (p = 0.053, not significant).  The 40 mg OCA dose group achieved statistical significance for the primary 
endpoint compared to placebo (p = 0.0496).  Dose -dependent trends not reaching statistical 
significance were also observed for several other pre-specified histologic endpoints, including 
the proportion of subjects with steatosis and inflammation improvement, ballooning resolution, 
and NASH resolution.  In the completer analysis, similar dose -dependent effects were observed, 
with 51% of patients in the 40 mg dose group compared to 22% in the placebo group meeting the 
primary endpoint (p = 0.0061).  With the exception of dose-dependent pruritus, OCA appe ared to 
be generally safe and well tolerated.  The number of pruritus-associated discontinuations were 0, 0, 2, and 5 subjects in the placebo, 10 mg, 20 mg, and 40 mg OCA groups, respectively.  Changes in lipid parameters were directionally similar to thos e observed in the FLINT study.  
Page 31 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755583] of treatment with OCA, it is important to characterize the changes observed in circulating cholesterol associated with OCA treatment and the potential for management of those changes.  
FXR has been shown to play an important role in lipid homeostasis and atherosclerosis with  the 
potential to modulate circulating levels of both LDL and HDL cholesterol, which are 
components of cardiovascular prognosis in rodents ( Gautier 2013, Zhang 2010 , Nissen 2007).  
Similarly, the FLINT study demonstrated OCA -related changes in LDL and HDL cholesterol 
(Neuschwander-Tetri 2014).  While the observed changes in LDL cholesterol in both rodents and 
humans run counter to changes that have been typi[INVESTIGATOR_575552], animal data have consistently shown FXR agonism to be associated with reductions in 
atherosclerotic plaque formation.  Rodent studies have shown that this anti- atherogenic effect 
with FXR agonism is possibly due to an increase in the hepatic clearance of excess cholesterol 
(Mencarelli 2009, Hartman 2009, Zhang 2010).  It should be noted that the relevance of these 
findings to humans needs further evaluation due to differences in human and rodent lipid 
physiology.   
In addition to cholesterol concentration, lipoprotein particle concentr ation and sizes have 
emerged as important factors in the evaluation of cardiovascular risk ( Jeyarajah 2006) .  A recent 
Veterans Affairs study assessing LDL  and HDL cholesterol concentrations, as well as particle 
size and numbers, in subjects treated with gemfibrozil demonstrated that these factors were 
stronger predictors of cardiovascular risk or benefit, respectively, than cholesterol concentrations (Otvos 2006).  Consistently, examination of LDL and HDL cholesterol concentrations and 
particle concentration  from the Framingham Offspring cohort (n = 3066), showed that LDL 
particle concentration  was more predictive of cardiovascular risk (Cromwell 2007). 
Given the complex role of FXR in lipid homeostasis, the observations of OCA on HDL and LDL 
concentrations in NAFLD and NASH, and the importance of evaluating the underlying function 
and composition of apolipoproteins, it is essential to evaluate the effect of OCA on these lipid-driven mechanisms of cardiovascular risk/benefit when considering OCA as a potential 
treatment for NASH. As such, this study, 747-209, will evaluate the effect of OCA on lipid 
Page 32 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755584] analysis of 
efficacy and safety data.  As the intent of the present study is to assess the effects of multiple 
doses of OCA and the subsequent addition of atorvastatin on cholesterol metabolism as well as the safety and tolerability of OCA in subjects with NASH, it is important to include a placebo 
control group to understand the relationship to OCA of any changes observed.  In addition, the combination of OCA and atorvastatin (or any other statin) has not been previously evaluated in clinical studies; thus, the placebo control group, which will be treated with atorvastatin, will 
provide comparative information regarding the safety and tolerability of the OCA and 
atorvastatin combination compared to atorvastatin alone.  
5.6.3. Rationale for OCA Doses 
The selection of OCA doses for the present study (5 mg, 10 mg, and 25 mg) was guided by [CONTACT_575784], double-blind, placebo-controlled Phase 2 
and Phase 3 studies in subjects with NAFLD, NASH, and  PBC as described in Section  5.5 
above. 
In Study 747-203, subjects with type 2 diabetes and NAFLD were treated with placebo, OCA 
25 mg, or OCA 50 mg for 6  weeks.  Although both doses were similarly efficacious, there were 
clinically significant increases in the LDL c levels in both OCA dose groups, with a significant 
reduction in HDL observed in the OCA 50  mg treatment group.  Similarly, OCA was efficacious 
and well-tolerated in the subsequent, Phase 2, randomized, double- blind FLINT study, which 
evaluated OCA 25 mg and placebo in subjects with NASH over a period of72 weeks.  In this 
study, small but statistically significant changes in the levels of total cholesterol and LDL c levels 
(increase from Baseline), and HDL levels (decrease from Baseline) were observed with OCA 
treatment.  Due to the similarity in efficacy and the observed lipoprotein changes in the two 
Phase [ADDRESS_755585] of OCA on pruritus and serum lipid levels, both 5 mg and 10 mg daily will be 
evaluated in the proposed NASH study in addition to the 25-mg dose. 
Page 33 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 34 
 
Confidential and Proprietary  5.6.4. Rationale for the Use of Atorvastatin 
Subsequent to diet and lifestyle modification, statin therapy is recommended for the management 
of cholesterol to reduce cardiovascular risk globally ( Perk 2012, NICE 2014, Stone 2014).  
Atorvastatin is one of the most commonly used statins worldwide ( Jackevicius 2012).  
Historically, statin therapy has been contraindicated  in subjects with elevations in liver 
aminotransferases .  However, several studies have evaluated statin use in chronic liver diseases 
where cardiovascular risk is a sig nificant concern and the consensus findings ha ve not shown an 
increased risk  of hepatotoxicity in subjects with elevated liver  aminotransferases.  Calderon et al 
reported that statin treatment is safe and can improve both liver aminotransferase levels and 
reduce cardiovascular morbidity ( Calderon 2010, Tikkanen 2013, Athyros 2010). 
The increase in L DL cholesterol levels in the OCA -treated NASH population observed in 
clinical studies may predispose these subjects to  increased cardiovascular risk.   Atorvasta tin is 
one of the most widely prescribed statins for dyslipi[INVESTIGATOR_575553] (Jackevicius 2012, 
Jackevicius 2013).  The atorvastatin prescribing information suggests a starting dose of 10 mg, 
with dose adjustments every 2 to 4 weeks.  In line with this recommendation, all subjects will be 
started at an atorvastatin dose of 10 mg at Week 4 , titrating to 20  mg atorvastatin at Week 8  (if 
10 mg daily is tolerated) , and allowing for further dose adjustments at Week [ADDRESS_755586] indicated dose (10 mg once daily), subjects with excessive ( >300 U/L) elevations in 
alanine aminotransferase (ALT), pre-existing cardiovascular dise ase, and those with elevated 
cardiovascular risk (eg , unstable hypertension) will be e xcluded.  Finally, liver function, 
cholesterol levels, and vital signs will be monitored at all visits in this study, and investigational 
product will be withdrawn or its dosing interrupted in subjects who develop elevated levels of 
liver enzymes per protocol discontinuation criteria (see Section  8.4.1).  
[IP_ADDRESS]. Rationale for Statin Withdrawal  
The intent of this study is to assess the increase in LDL cholesterol with OCA and then to 
determine the extent to which this can be mitigated with appropriate use of statin therapy.  
Therefore, participating subjects need to either be statin-free or have washed off of their current 
statin therapy.  Given the clear role of statins in reducing cardiovascular risk, it is imperative to minimize the potential risk associated with withdrawing statin therapy.  These steps include 
minimizing  the duration of statin withdrawal and exclusion of subjects for whom removal of 
statin therapy is of significant concern.  
Duration of stat in withdrawal  
A statin withdrawal period of 5  weeks was selected and is similar to other recent studies in 
statin-using patients where a 4 -week washout period was employed ( Teramoto 2012, 
Teramoto  2014).  The extra week in the present study allows for the assessment of LDL levels 
after 4 weeks of washout, and based on prior studies, assumes levels of LDL to be stable after 
4 weeks, and enables the stratification of subjects at randomization on Day 1 by [CONTACT_500099].   
Following randomization, subjects will be treated with OCA or placebo for 4 weeks prior to the 
introduction of atorvastatin.  Based on data in healthy subjects, PBC, and NAFLD, 4 weeks is 
Page 34 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755587] 
subjects.   
Overall, statin therapy will be withheld from subjects for a maximum of 9  weeks:  5 weeks prior 
to randomization on Day 1 and 4 weeks following randomization.  This duration of statin 
withdrawal is less than the combined withdrawa l period used in the Teramoto et al study, which 
included a group of subjects who had statin therapy withheld for a total of 16 weeks (4 week 
washout period followed by 12 weeks of placebo treatment) ( Teramoto 2014).  There was no 
appreciable difference in the safety profile of these pati ents compared to those who had statin 
therapy reintroduced after the washout period.  Further support for the minimal impact of short-term discontinuation of statins is seen in follow -up analyses of the Treating to New Target 
study which showed that even i n patients with stable coronary artery disease, that a [ADDRESS_755588] cardiac events ( McGowan 2004). 
Exclusion of subjects at elevated risk 
Subjects where the removal of a statin would be considered to be clinically concerning are 
excluded from participation in this study.  At risk subjects include subjects with existing cardiovascular disease (including but not limited to stable or unstable angina, previous 
myocardial infarction or stroke or a previous peripheral or  coronary revascularization procedure), 
significant dyslipi[INVESTIGATOR_035] (as defined by [CONTACT_575785] â‰¥190 mg/dL) despi[INVESTIGATOR_575554], 
unstable hypertension, and familial hypercholesterolemia.  
Safety monitoring during the off-statin period 
All subjects will have frequent safety assessments prior to and following the reintroduction of 
statin therapy.  Following Screening  Visit 1, subjects will hav e 4 visits to the study site over the 
9-week period prior to initiation of atorvastatin:  Screening Visit  2/Week -1, 
Randomization/Day 1, Week  [ADDRESS_755589] of sustained 
treatment with  OCA; all subjects will then initiate atorvastatin therapy, in addition to their 
blinded treatment, and the effect on lipoprotein metabolism will be evaluated over an additional 
[ADDRESS_755590] of atorvastatin on the OCA  treatment -induced alterations in the 
lipoprotein profile of statin-naÃ¯ve and stat in-washed out NASH subjects. 
Following the double-blind phase, subjects may volunteer to continue in a 2 -year open -label 
long-term safety extension ( LTSE) during which all subjects will receive OCA.  During the 
LTSE, LDL cholesterol will be managed as clinically indicated.  The LTSE will evaluate the 
long-term safety of OCA and atorvastatin  treatment and the effect of OCA and atorvastatin on 
histological markers of NASH.  
Page 35 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 36 
 
Confidential and Proprietary  5.6.6. Rationale for Timing of Unblinding Process and Implications in LTSE  
As Study 747-209 is  a randomized, double-blind study, the double-blind data will not be 
unblinded until all double-blind data are final and the database is locked.  Accordingly,  all 
subjects continuing in the LTSE, Investigators, and the Sponsor will remain blinded to subjectsâ€™  
double-blind treatment regimen.  Subjects who were receiving placebo or [ADDRESS_755591] frequency observed in subjects with PBC. 
An increase in liver enzymes and hepatic AEs, including jaundice, were observed in subjects 
with liver disease at OCA doses between 10  mg and 50 mg .  Elevated liver enzymes were 
observed in healthy subjects who were treated at doses â‰¥100 mg in Phase 1, multiple -dose 
studies; however, these elevations were only considered to be of clinical concern at the maximum dose of [ADDRESS_755592] baseline values with continued 
treatment through to 72 weeks. 
Refer to the Investigatorâ€™s Brochure (IB) for additional information regarding the known 
potential risks with the investigational product.  
5.8. Summary of Known Potential R isks with Atorvastatin  
Muscle complaints are the most frequent adverse reports among patients treated with statins with 
the most severe side effects including myopathy and rhabdomyolysis.  The Statin Muscle Safety 
Task Force ( Rosenson 2014) has provided a classification of the spectrum of statin- associated 
muscle AEs that may be seen in clinical practice and can be used in characterizing reports of 
muscle-related events.  
a. Myalgia â€“ unexplained muscle discomfort often described as â€œflu -likeâ€ symptoms  
âˆ’ Muscle aches  
âˆ’ Muscle soreness  
âˆ’ Muscle stiffness  
âˆ’ Muscle tenderness  
âˆ’ Muscle cramps with or shortly after exercise (not nocturnal crampi[INVESTIGATOR_007]) 
Page 36 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 37 
 
Confidential and Proprietary  b. Myopathy â€“ muscle weakness (not attributed to pain and not necessarily associated 
with elevated CPK)  
c. Myositis â€“ muscle inflammation  
d. Myonecrosis â€“ muscle enzyme elevations or hyperCPKemia 
âˆ’ Mild >3x baseline or ULN 
âˆ’ Moderate â‰¥10x baseline or ULN 
âˆ’ Severe â‰¥50x baseline or ULN 
e. Clinical Rhabdomyol ysis - Myonecrosis with myoglobinuria or acute renal failure 
(increase in serum creatinine â‰¥0.5 mg/dL  
There is no evidence that these muscle- related AEs are a continuum beginning with myalgia and 
progressing to more severe manifestations of myopathy; rather events occur independent of each 
other.  Myalgia events, with frequencies ranging from 1 % to 5% in clinical trials to 11% to 29% 
in observational cohorts, typi[INVESTIGATOR_380618] 1 month of statin initiation and resolve within 
2 weeks of stati n cessation ( Rosenson 2014).   Retrospective analyses have suggested that 
patients who discontinue statins due to intolerance are able to tolerate statins long- term following 
re-challenge ( Zhang 2013, Mampuya 2013).    
Historically, statins have been associated with biochemical abnormalities of liver function, but 
available data suggest that increases in liver transaminases associated with statins are asymptomatic and generally reversible ( Desai 2014 ).  In the absence of liver disease, US 
guidelines ( Stone 2013) recommend that baseline transaminase levels should be checked before 
initiating statin therapy and subsequent testing should only be done in the presence of symptoms suggestive of hepatic disease.   As this study is being conducted in subjects with conf irmed 
NASH, liver enzymes will be frequently monitored and Section  [IP_ADDRESS], Section  [IP_ADDRESS], and 
Appendix B  provide detailed guidance for handling elevated liver biochemistry values.  
Statins modestly increase the risk of type 2 diabetes mellitus in individuals with risk factors for 
diabetes.  Individuals receiving statin therapy should be evaluated for new- onset diabetes 
according to the current diabetes screening guidelines ( American Diabetes Association 2013).  
Confusion and memory loss have been reported with statins, but medical evidence supporting a 
causal effect is weak or nonexistent ( Simic 2015).   However, any reports of cognitive events 
should be appropriately evaluated, particularly in individuals whose symptoms persist despi[INVESTIGATOR_575555]. 
In this study, any AE s (including signs and symptoms described above) regardless of relationship 
to investigational product or s tudy medication, must be documented appropr iately 
(see Section  12). 
If treatment with statins is initiated, women of childbearing potential must be informed that statin 
use is contraindicated  during pregnancy.  Methods of contraception should be reviewed and 
modified, if necessary, to ensure highly effective methods with failure rates <1% per year, such 
as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual 
abstinence, or history of vasectomy of partner are used. 
Page 37 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 38 
 
Confidential and Proprietary  6. STUDY OBJECTIVES AND PURPOSE  
6.1. Primary Objective  
The primary objective of the study is: 
â€¢ To evaluate the effect of OCA on LDL metabolism in subjects with biopsy-confirmed 
NASH and to assess the ability o f atorvastatin to modulate this effect  
6.2. Secondary Objectives  
The secondary objectives of the study are:  
â€¢ To evaluate the safety and tolerability of OCA alone and in combination with 
atorvastatin therapy in subjects with biopsy -confirmed NASH  
â€¢ To evaluate the effect of OCA with and without atorvastatin  therapy, on  
âˆ’ HDL, VLDL, TGs, total cholesterol, and apolipoprotein concentrations 
âˆ’ Components of the reverse cholesterol transport  pathway 
6.3. Exploratory Objectives  
The exploratory objectives of the study are:  
â€¢ To evaluate the effect of OCA on  
âˆ’ Liver biochemistry, inflammation, and apoptosis 
âˆ’ Markers of glucose metabolism including C-peptide, insulin, fasting plasma 
glucose, hemoglobin- specific A1c fraction (HbA1c), homeostatic model 
assessment â€“beta-cell function (HOMAâ€‘Î² ), and homeostatic model assessment  â€“ 
insulin resistance ( HOMA-IR) 
âˆ’ Anthropometric measures including height (measured at Screening Visit 1 only), 
weight, and waist and hip circumference measurements; and body mass index 
(BMI), and waist- to-hip ratio calculations  
âˆ’ Cardiovascular risk scores (eg, Framingham Risk Score [FRS] and Reynolds 
score) 
â€¢ To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of OCA and its 
conjugates 
â€¢ To evaluate the bioanalytical concentrations of atorvastatin and its metabolite s 
â€¢ To evaluate improvement in noninvasive-radiological assessment of fibrosis via 
transient elastography ( TE; at sites where available) 
Page 38 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755593] s with histological evidence of definite or 
probable NASH, who meet all inclusion and none of the exclusion criteria will be enrolled in the study.  The histological evidence of definite or probable NASH will be based on the central  
read of a liver biopsy obtained no more than 1 year prior to randomization and a nonalcoholic 
fatty liver disease activity score (NAS) of 4 or greater.  Subjects not using statin therapy 
(ie, statin-free) and statin -treated subjects may be enrolled.  Statin- treated subjects will be 
required to stop statin treatment (after signing informed consent) for up to 5 weeks , including 
a 4-week statin washout period, prior to Randomization/Day  1. 
Screening Period:  
Subjects will have a screening period of up to 5 week s prior to Randomization/Day 1.     
Subjects using statins within 30 days of the initial Screening Visit (Screening Visit 1) are 
required to stop statin therapy immediately following this initial visit and must undergo a [ADDRESS_755594] a 
pre-randomization visit for assessment of their fasting LDL cholesterol levels.  Subjects with 
fasting LDL cholesterol values >200 mg/dL at Screening Visit [ADDRESS_755595] of care.  
Subjects who are not using statin therapy at Screening Visit 1 are required to provide a fasting 
blood sample at Screening Visit 2, which can occur at any time prior to randomization but after 
signing of the ICF.  Statin free subjects with fasting LDL cholesterol values >200 mg/dL at either Screening Visit will be excluded from the study and should be managed according to 
standard of c are. 
Double-Blind Phase:  
At the Randomization (Day 1) Visit, subjects will be randomized in a 1:1:1:1 ratio to receive 
OCA 5 mg , OCA 10 mg , OCA 25 mg , or placebo, orally, once daily, for 16 weeks.  
Randomization will be stratified by [CONTACT_7416] -randomization fasted serum LDL cholesterol 
concentration (â‰¤125 mg/dL or >125 mg/dL) and baseline fibrosis stage (stage 1, 2 or stage 3, 4). 
At the Week  4 Visit, all subjects will initiate treatment with atorvastatin at a dose of 10  mg once 
daily.  At the Week  8 Visit, atorvastatin will be increased to 20  mg once daily (if 10 mg daily is 
tolerated) , and continued for an additional 4 weeks .  After 4 weeks of treatment at 20 mg, the 
atorvastatin dose may be titrated (up or down) as clinically indicated.  The final visit during the 
double-blind phase will occur at Week  16, after which subjects may continue into the open- label 
LTSE.  
Subjects who discontinue investigational product or atorvastatin during the double-blind phase 
are still expected to attend scheduled study visits and are to be followed through the Week 16 
Visit. 
Page 39 of 364
3URWRFRO 9HUVLRQ'HF
3DJH
&RQILGHQWLDODQG3URSULHWDU\ 6XEMHFWVZKRGLVFRQWLQXHDWRUYDV WDWLQGXULQJWKHGRXEOHEOLQGS KDVHDUHHOLJLEO HWRFRQWLQXH
2&$GXULQJWKHGRXEOHEOLQGSKDVHD QGHQUROOLQWRWKH/76(DWW KHGLVFUHWLRQRIWKH,QYHVWLJDWRU
SURYLGHGWKH\FRQWLQXHWRPHHWW KH/'/FFXWRIIRIH[FOXVLRQFUL WHULDLH/'/FPJG/ 
/76(3KDVH
'XULQJWKH/76(SKDVHDOOVXEM HFWVZLOOEHWUHDWHGZLWKRSHQO DEHO2&$PJRU2&$PJ
6XEMHFWVUDQGRPL]HGWRSODFHERRU 2&$PJGXULQJWKHGRXEOHEO LQGSKDVHZLOOEHUDQGRPL]HG
LQDUDWLRWRUHFHLYH2&$ PJRU2&$PJXSRQHQWU\LQW RDQGWKURXJKRXWWKH/76(
SKDVH6XEMHFWVUDQGRPL]HGWR2 &$PJRU2&$PJGXULQJWK HGRXEOHEOLQGSKDVHZLOO
FRQWLQXHRQWKHVDPHGRVHWKURXJ KRXWWKH/76(,QWKHHYHQWR I2&$UHODWHGWROHUDELOLW\
FRQFHUQVWKH,QYHVWLJDWRUPD\UHI HUWRWKH,%IRUSRVVLEOHWUH DWPHQWRSWLRQV6XEMHFWVPD\
FRQWLQXHGLVFRQWLQXHRUPRGLI\W KHDWRUYDVWDWLQWKHUDS\DVFO LQLFDOO\LQGLFDWHG
6WXG\'HVLJQ
)LJXUH 6WXG\'HVLJQ6FKHPDWLF

/76(ORQJWHUPVDIHW\H[WHQVLRQ:N ZHHN
1RWH6WDWLQWKHUDS\UHIHUVWRDWRUYDVWDWLQÇ» 7HOHSKRQH6DIHW\&RQWDFWDW:HHN:HHNDQG:HHN
Page 40 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 41 
 
Confidential and Proprietary   7.1.2. Schedule of Study Procedures  
Table 1: Schedule of Study Procedures:  Double -Blind Period  
Study Visits Screening 
Visit 1a Screening 
Visit 2b Randomi -
zation/ Day 1 Wk 2 Wk 4 Wk 6 
(Contact)  Wk8 Wk 10 
(Contact)  Wk 12 Wk 14 
(Contact)  Wk 16/ 
LTSE Day 1  ET/ 
EOSc 
Week -5 to -1 -1 to 1 1 2 4 6 8 10 12 14 16  
Visit Window (Days)  -35 to -7 -7 to -1  Â±4 Â±4 Â±4 Â±4 Â±4 Â±4 Â±4 Â±4 Â±7c 
STUDY PROCEDURES  
Fast â‰¥8 h Prior to Visit  X X X X  X  X  X X 
Informed Consent  X     
    
   
Medical History  X            
Inclusion/Exclusion 
Criteria X X X          
Physical Exam  X          X X 
Vital Signsd  X  X X X  X  X  X X 
Anthropometric Measurese X  X X X  X  X  X X 
12- Lead 
Electrocardiogram  X  X        X X 
AUDIT Alcohol Intake 
Questionnaire  X  X        X X 
Liver Biopsyf  X     
    
   
Transient Elastographyg X X X   
    
 X X 
AEsh Xh Xh X X X X X X X X X X 
Prior and Concomitant Medications  X X X X X X X X X X X X 
Randomization/Treatment 
Assignedi   Xi        Xi  
Dispense/Administer Investigational Product
k   X X X  X  X  Xj  
Dispense/Administer 
Open-Label Atorvastatink     X  X  X  Xj  
Page 41 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 42 
 
Confidential and Proprietary   Table 1: Schedule of Study Procedures:  Double -Blind Period (Continued)  
Study Visits  Screening 
Visit 1a Screening 
Visit 2/ 
Wk -1b Randomi -
zation/ 
Day 1 Wk 2 Wk 4 Wk 6 
(Contact)  Wk8 Wk 10 
(Contact)  Wk 
12 Wk 14 
(Contact)  Wk 16/ 
LTSE 
Day 1 ET/ 
EOSc 
Collect 
Bottles/Investigational 
Product 
Accountability/Compliance     X X X X X X X X X 
Collect Bottles/Atorvastatin  
Accountability/Compliance        X X X X X X 
CLINICAL LABORATORY EVALUATIONSk 
Hepatitis B Virus and 
Hepatitis C Virus Tests X            
Serum Chemistryl, m 
/Hematology/ Coagulation 
Parameters  X X X X X  X  X  X X 
Lipoprotein Analysesn   X X X  X  X  X X 
Reverse Cholesterol 
Transport Analyteso   X X X  X  X  X X 
PD Assessments    X  X  X  X  X X 
Markers of Inflammation, Fibrosis, and Apoptosis   X  X  X  X  X X 
Vitamin D   X  X  X  X  X X 
Markers of Glucose 
Metabolism Including 
C-peptide, Insulin, Fasting 
Plasma Glucose, and 
HbA1cp   
X  X  X  X  X X 
Thyroid Function Tests:  
T3, T4, and TSH    X        X X 
Urinalysis  X  X   
    
 X X 
Pregnancy Testq Xq  X X X  X  X  X X 
Blood Sample for Future 
Exploratory Analysisr   X    X    X X 
PK Assessmentss   Xs        Xs  
Page 42 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 43 
 
Confidential and Proprietary   AE = adverse event; AUDIT = Alcohol Use Disorders Identification Test; Î²-hCG = beta human chorionic gonadotropin; BMI = body mass index;  
CPK = creatine phosphokinase; EOS = End of Study; E T = Early Termination ; HbA1c = hemoglobin -specific A1c fraction ; hs-CRP = high- sensitivity C -reactive 
protein; PD = pharmacodynamics; PK = pharmacokinetics; T3 = triiodothyronine; T4 = thyroxine; TSH = thy roid-stimulating hormone ; Wk = Week  
Note:  No study- related procedures , including Screening procedures, will be performed prior to obtaining  informed consent  from the subject.  Historical 
procedures (eg , liver biopsy samples collected, FibroScan) completed  as part of standard of care, may be used for screening analysis if collected within the 
allowed windows specified in the protocol . 
a  Subjects using statins within [ADDRESS_755596] 8  hours prior to the visit.  The Randomization/Day 1 Visit may occur 
as soon as screening labs are available and eligibility is confirmed for all subjects.  For subjects undergoing a 4 -week washout period, Screening Visit 2 may 
occur on day 28 ( Â±1) day of the washout period.  For subjects not taking statins at Screening  Visit 1, Screening Visit [ADDRESS_755597] be completed â‰¤35 days prior to the  Randomization/Day [ADDRESS_755598] dose taken.  The EOS Visit will occur Â±1 week (7 days) 
relative to the EOS date announced by [CONTACT_1034].  
d  Sitting heart rate, blood pressure, body temperature, and respi[INVESTIGATOR_697]. 
e  Weight, waist and hip circumference (and height at Screening  Visit 1).  BMI and w aist-to-hip ratio will be calculated via electronic data capture ( EDC). 
f  Liver biopsy will be performed to histologically confirm NASH only if slides from historic biopsy (within 1 year of Day  1) are not available.  A central reader 
designated by [CONTACT_575786]; the results of which must be available prior to randomization on D ay 1. 
g  Transient elastography (TE) will be conducted at selected trial sites where the FibroScanÂ® TE device is available.  TE is scheduled for Screening Visit 1; however, 
it may be performed any time after Screening Visit 1  and prior to randomization.   In addition, if TE has been done within 3 months of Day 1 and a report /adequate 
data are available, a pretreatment TE at Day 1 is not required.  
h  AEs occurring after the signing of the informed consent form ( ICF) must be entered on the AE eCRF. 
i   Only those subjects who were statin naive at Screening or who have successfully completed the washout period and meet all other inclusion  criteria, and none 
of the exclusion criteria , may be randomized.  Subjects randomized to placebo or OCA 5 mg during the double -blind period will be randomized to OCA 10 or 
25 mg during the LTSE.  
j  Only applies to subjects continuing in LTSE.  
k  Blood samples for all analyses will be collected predose (before administering investigational product  or atorvastatin ) on indic ated visit days.  
l  CPK will be assessed in all subjects at Screening Visit 2 and as clinically indicated, including anytime myopathy is suspected.  
m  Serum chemistry will include a basic lipid panel and also liver biochemistry panel (see  Table 10). 
n  Serum and plasma samples will be collected for  lipoprotein analysis, which will include cholesterol concentration in LDL, HDL, and VLDL, their particle 
concentration  and sizes; concentrations of apolipoprotein (Apo)A1, ApoB, ApoE, ApoCII, ApoCIII and Lp(a) ; and proprotein convertase subtilisin /kexin type 
9 (PCSK9) .  
o  Reverse cholesterol transport analysis will include following analytes:  Pre-Î²1 HDL con centration, macrophage cholesterol efflux, lecithin cholesterol 
acyltransferase activity, and cholesterol ester transfer protein activity.  
p  The homeostatic model assessment â€“beta-cell function (HOMA -Î²) and homeostatic model assessment â€“ insulin resistance  (HOMA-IR) index es will be 
calculated using fasting plasma glucose and serum insulin values.  
q  Serum pregnancy test will be administered if urine -based Î²-hCG pregnancy test is positive .  Screening pregnancy tests will be serum-based tests . 
r  Includes markers of cardiovascular risk (adiponectin, plasminogen activator inhibitor -[(PAI-1], and B-type natriuretic peptide [BNP]) . 
s  At selected investigational sites, subjects will have the option to provide blood samples for measurement of PK for OCA (Day 1 and Week 16), and for 
atorvastatin (Week 16) .  PK samples will  be collected within [ADDRESS_755599]  and will remain fasted until the 1 hour sample is collected .  
Page 43 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 44 
 
Confidential and Proprietary   Table 2: Schedule of Study Procedures:  LTSE  
  Annual Schedule (Year 1 through Study Termination)b 
Study Visits  Month 1a Month 3, 
Month 15 Month 6,  
Month 18 Month 9,  
Month 21 Month 12  EOS/ETc 
Visit Windows (weeks)  Â±1 Â±1 Â±1 Â±1 Â±1 Â±1/ N/Ac 
STUDY PROCEDURES  
Fast â‰¥8 h Prior to Visit  X X X X X X 
Physical Exam   X   X X 
12-Lead Electrocardiogram   X X X X X 
Vital Signsd X X X X X X 
Anthropometric Measurese  X X X X X 
AUDIT Alcohol Intake Questionnaire    X  X X 
AEs X X X X X X 
Prior and Concomitant Medications  X X X X X X 
Transient Elastographyf     
X X 
Dispense/Administer  Investigational Productg  X X X X  
Dispense/Administer  Atorvastating,h,i  X X X X  
Collect Bottles/Investigational Product  
Accountability/Compliance  X X X X X X 
Collect Bottles/Atorvastatin  
Accountability/Compliance  X X X X X X 
LABORATORY EVALUATIONSg 
Serum Chemistryj,k/Hematology/ Coagulation Parameters  X X X X X X 
Lipoprotein Analysesl  X X X X X 
Reverse Cholesterol Transport Analysism   X  X X 
PD Assessment s  X X X X X 
Markers of Inflammation, Fibrosis, and Apoptosis  X X X X X 
Vitamin D   X X X X X 
Markers of Glucose Metabolism Including C -peptide, 
Insulin, Fasting Plasma Glucose, HbA1cn X X X X X X 
Thyroid Function Tests:  T3, T4, and TSH     X X 
Urinalysis      
X X 
Urine Based Î² -hCG Pregnancy Testo X X X X X X 
Blood Sample for Future Exploratory Analysisp     X X 
 
Page 44 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 45 
 
Confidential and Proprietary   AE = adverse event; AUDIT = Alcohol Use Disorders Identification Test; Î²-hCG = beta human chorionic gonadotropin; BMI = body mass index;  
CPK = creatine phosphokinase; EOS = End of Study; E T = Early Termination ; HbA1c = hemoglobin- specific A1c fraction; PD = pharmacodynamics ;  
T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid -stimulating hormone  
a  The first visit after start of LTSE (Month  1 Visit) is relative to Week  16 Visit of the double -blind phase (LTSE Day 1 Visit).   
b  After the Month 12 Visit, the procedures will be performed as listed for Month 3, Month 6 , and Month 9 visits (at 15 months, 18 months, and 21 months, 
respectively, into the LTSE). 
c  The ET Visit will occur as soon as possible upon study discontinuation and as near as possible to last dose taken.  The EOS Visit will occur Â±1 week (7 days) 
relative to the EOS date announced by [CONTACT_1034].  
d  Sitting heart rate, blood pressure, body temperature, and respi[INVESTIGATOR_697]. 
e  Weight, waist and hip circumference.  BMI and waist -to-hip ratio will be calculated via electronic data capture (EDC).  
f  Transient elastography (TE) will be conducted during the LTSE at selected trial sites where the FibroScan Â® TE device is available.  
g  Blood samples for all analyses will be collected predose (before administering investigational product) on indicated visit days.  
h  Atorvastatin may be continued or subjects may change or discontinue statins as clinically indicated.  
i  NOTE:  Any time atorvastatin is up -titrated or re -initiated, a telephone safety contact [CONTACT_575787], concomitant medications , and 
atorvastatin compliance . 
j CPK will be assessed in all subjects only as clinically indicated, including anytime myopathy is suspected, in subjects taking statins.  
k  Serum chemistry will include a basic lipid panel and liver biochemistry panel (see  Table 10).   
l  Serum samples will be collected for lipoprotein analyses, which will include cholesterol concentration in LDL, HDL, and VLDL, their particle concentration  
and sizes; concentrations of apolipoprotein (Apo)A1, ApoB, ApoE, ApoCII, ApoCIII and Lp(a) ; and propr otein convertase subtilisin /kexin type 9 (PCSK9 ). 
m Reverse cholesterol transport analysis will include following analytes:  Pre-Î²1 HDL concentration, macrophage cholesterol efflux, lecithin cholesterol 
acyltransferase activity, and cholesterol ester trans fer protein activity.  
n The homeostatic model assessment â€“beta-cell function (HOMA -Î²) and homeostasis model assessment â€“ insulin resistance (HOMA -IR) index es will be 
calculated using fasting plasma glucose and serum insulin values.  
o  Serum pregnancy test w ill be administered if urine -based Î²-hCG pregnancy test is positive.  
p  Blood sample for future exploratory analysis , including markers of cardiovascular risk (adiponectin, plasminogen activator inhibitor -[(PAI-1], and B-type 
natriuretic peptide [BNP]) . 
 
Page 45 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 46 
 
Confidential and Proprietary  7.1.3. Study Duration  
The overall study duration is up to 125 weeks including a Screening period of up to 5 weeks 
(depending on current statin use), a 16-week double-blind treatment phase, and a 2- year, 
open-label LTSE.   The LTSE may be terminated earlier by [CONTACT_575788], or for other reasons as described in Section 8.4.3. 
7.2. Number of Subjects  
Approximately 80 subjects who meet the eligibility criteria , including biopsy-confirmed NASH 
and evidence of liver fibrosis, but no hepatic decompensation, will be included in this study .  A 
maximum of 30% of subjects will have stage 4 fibrosis. 
7.3. Treatment Assignment  
Eligible subjects will be randomized into 4 groups in a 1:1:1:1 ratio to receive OCA 5 mg, 
OCA 10 mg, OCA 25  mg, or placebo during the double-blind phase of the study.  
Randomization will be stratified by [CONTACT_575789] ( fasting serum LDL cholesterol at  
Screening Visit 2; â‰¤125 mg/dL or >125 mg/ dL) and baseline fibrosis stage (stage 1, 2 or stage 3, 
4).  All subjects will also receive atorvastatin starting at We ek 4 at 10 mg daily, escalating to 
20 mg at Week  8 (if 10 mg daily is tolerated) , with further dose adjustments to be performed as 
clinically indicated at Week  12, and throughout the LTSE phase.  Subjects will receive 
open-label OCA 10 mg or OCA 25 mg  during the LTSE  depending on their double-blind 
randomized dose (see Section 7.1 ).  The study design schematic is shown in Figure  1.  
7.4. Dose Adjustment Criteria 
7.4.1. Investigational Product Dose Adjustments 
Dose adjustments of investigational product are not permitted during the double-blind phase.  
Please refer to Section 8.4.[ADDRESS_755600] is discontinued. 
During the LTSE phase, al l subjects will be treated with open-label OCA 10 mg or 25 mg.  
Subjects randomized to placebo or OCA 5 mg during the double-blind phase will be 
re-randomized in a 1:1 ratio  through IWRS to OCA 10 mg or OCA 25 mg upon entry into and 
throughout the LTSE phase.  Subjects randomized to OCA 10 mg will continue to receive OCA 
10 mg throughout the LTSE.  Subjects randomized to OCA 25 mg will continue to receive OCA 
25 mg throughout the LTSE.  Subjects may continue with atorvastatin t herapy as clinically 
indicated.  
7.4.2. Atorvastatin D ose Adjustments  
For all subjects, atorvastatin therapy will be initiated at a dose of 10  mg at Week  4.  At Week  8 
the dose will be increased to 20 mg  (if 10 mg daily is tolerated), and following the Week 12 
Visit, the dose can be adjusted to manage cholesterol as clinically indicated ( Section 9 and 
Appendix A ).  During the LTSE, subjects may continue with atorvastatin therapy as clinically 
indicated.  
Page 46 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 47 
 
Confidential and Proprietary  If at any time during the double-blind or LTSE phases, serum chemistry results indicate  
LDLc<40 mg /dL, the subject should be brought back to the site within [ADDRESS_755601] 
result is obtained for an unscheduled (repeat) laboratory assessment.  If LDLc<40 mg/dL is 
obtained on [ADDRESS_755602] may discontinue or reduce the dose of atorvastatin.  
Subjects may also interrupt or discontinue atorvastatin due to tolerability issues  including 
muscle-related symptoms ( Section 5.8) and abnormal liver biochemistry.  Any muscle- related 
complaints should be assessed per the ACC/AHA Guidelines ( Appendix A ) and statin dose 
adjusted accordingly:   
â€¢ To avoid unnecessary discontinuation of statins, obtain a history of prior or current 
muscle symptoms to establish a baseline prior to initiation of statin therapy . 
â€¢ If mild to moderate muscle symptoms develop during statin therapy:  
âˆ’ Discontinue the statin until symptoms can be evaluated . 
âˆ’ Evaluate the patient for other conditions that might increase the risk for muscle symptoms . 
âˆ’ If muscle symptoms resolve , and if no contraindication exists, re- challenge the 
subject with the same or a reduced dose of atorvastatin to establish a causal 
relationship between the muscle symptoms and statin therapy . 
âˆ’ Once a low dose statin is tolerated, the dose may be gradually increased as 
tolerated and clinically indicated . 
âˆ’ If after 2 months without statin treatment, muscle symptoms or elevated C PK 
levels do not completely resolve, consider other causes of muscle symptoms. 
âˆ’ If persistent muscle symptoms are determined to arise f rom a condition unrelated 
to statin therapy, or if the predisposing condition has been treated, resume statin 
therapy at the original dose . 
â€¢ If unexplained severe muscle symptoms or fatigue develop during statin therapy, 
discontinue the statin and address the possibility of rhabdomyolysis by [CONTACT_575790] K 
and serum creatinine, and performing urinalysis for myoglobinuria. 
Elevations in liver biochemistry should be monitored per protocol subject withdrawal criteria 
(Section 8.4 and Appendix B ). 
Subjects who discontinue atorvastatin may continue on investigational product through the 
double-blind and LTSE phases, as deemed appropriate by [CONTACT_24318], 
and provided they continue to meet exclusion criteria #4 (LDLc <200 mg/dL). 
7.4.3. Safety Criteria for Adjustment or Stoppi[INVESTIGATOR_575556] C ommittee (DMC) will review safety data from this study as well as other 
ongoing OCA studies on a periodic basis ( Section 13.8).  Adjustments to or discontinuation of 
treatment may be considered based on DMC evaluation of OCA safety and tolerability.  The criteria for study termination are described in Section 7.5.  
Page 47 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755603] completed the study.  In addition, the Sponsor may terminate the study at an investigational site, at any time (eg, Good Clinical Practice [GCP] noncompliance, poorly performing sites, as determined by [CONTACT_575791]).  
The Investigator and/or the Sponsor (or designee) must notify the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) of discontinuation of a site or the study and the 
reason(s) for doing so. 
Investigators will be informed by [CONTACT_575792], 
and should then schedule all subjects for the End of Study (EOS) or E arly Termination (ET) 
Visit. 
8. SELECTION AND WITHDR AWAL OF SUBJECTS  
8.1. Subject Population  
Approximately 80 subjects with biopsy- confirmed NASH  without evidence of hepatic 
decompensation who meet eligibility criteria will be enrolled at approximately 30 investigational 
sites in the US.  Prospective subjects will be identified primarily from the hospi[INVESTIGATOR_3491]/or 
physicianâ€™s database of patients with NASH, or may be referred from other physicians.  Subjects 
may self-refer to an Investigator if they become aware of the study through local, national, or 
international NASH patient societies, forums, or networks.  Subjects will be selected according 
to the inclusion and exclusion criteria below. 
8.2. Subject Inclusion Criteria  
Subjects must satisfy all of the following criteria to be eligible  for enrollment:  
1. Age â‰¥[ADDRESS_755604]  1 for each and a combined score of 
4 or greater out of a possible 8 points according to NASH CRN criteria .  
3. Histologic evidence of fibrosis stage  1 to stage 4 (as defined by [CONTACT_575793]) without any evidence of hepatic decompensation. 
4. If subject has type 2 diabetes , is on stable dose of anti-diabetic medication  (except 
thiazolidinediones [TZDs]) for â‰¥3  months prior to Day 1. 
5. Is either not taking or is on stable doses of TZDs and/or Vitamin E for â‰¥6 months prior to Day 1 
6. Contraception:  Female subjects of childbearing potential must use â‰¥[ADDRESS_755605] dose of 
Page 48 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755606].  Effective methods of contraception are considered to be those 
listed below.  
â€¢ Barrier method, ie, condom (male or female)  with spermicide  or diaphragm with 
spermicide  
â€¢ Intrauterine device  
â€¢ Vasectomy (partner)  
â€¢ Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular implant or injection) 
â€¢ Abstinence (defined as refraining from heterosexual intercourse).   
7. Must provide written informed consent and agree to comply with the study protocol, including adherence to protocol- described statin withdrawal and statin therapy. 
8.3. Subject Exclusion Criteria  
Subjects who satisfy any of the following exclusion criteria will be ineligible for enrollment:  
1. Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening Visit 1 (significant alco hol 
consumption is defined as more than 2 units/day in females and more than 4 units/day in 
males, on average) . 
2. Prior intolerance to treatment with atorvastatin or other 3-hydroxy-3- methyl-glutaryl 
(HMG) Coenzyme A reductase inhibitors (including but not limited to rhabdomyolysis). 
3. LDLc â‰¥190 mg/dL and already on statin therapy at Screening Visit  1.  
4. LDL cholesterol >200 mg/dL at any Screening Visit in subjects who are not on statin 
therapy, or at Screening Visit  2 in statin washout subjects . 
5. Planned change in diet or exercise habits during participation in the double-blind period, 
or a significant weight change of  >5% in the prior [ADDRESS_755607] undergone gastric by[CONTACT_109133] (gastric lap band is acceptable) or ileal resection or plan to undergo either of these procedures.  
7. History of biliary diversion . 
8. Uncontrolled diabetes defined as HbA1c â‰¥9.5% within 60 days prior to randomization (Day 1). 
9. Administration of any of the following medications as specified below: 
â€¢ Prohibited 30 days  prior to Day 1:   
âˆ’ bile acid sequestrants (BAS) including cholestyramine and its derivatives, 
colesevelam, colestipol, or 
âˆ’ omega-3 fatty acid containing dietary supplements 
Page 49 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 50 
 
Confidential and Proprietary  â€¢ Prohibited 3 months prior to Day  1:   
âˆ’ nicotinic acid and derivatives, ezetimibe, or  
âˆ’ any prescription or over-the-counter medication or herbal remedy with putative 
NASH efficacy ( except Vitamin E  or TZDs), or  
âˆ’ ursodeoxycholic acid, or 
âˆ’ fenofibrate or other fibrates, or 
âˆ’ Any over-the-counter or health foods used to treat lipi[INVESTIGATOR_575557] 
â€¢ Prohibited 6 months prior to Day 1:   
âˆ’ azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, mofetil, pentoxifylline; budesonide and other systemic corticosteroids; or 
âˆ’ potentially hepatotoxic drugs (including Î±- methyl-dopa, sodium valproic acid, 
isoniazide, or nitrofurantoin) 
â€¢ Prohibited 12 months prior to Day 1:  
âˆ’ antibodies or immunotherapy directed against interleukins, or  
âˆ’ other cytokines or chemokines 
10. Evidence of other forms of known chronic liver disease including but not limited to:  
â€¢ Positive test result at Screening for hepatitis B surface antigen  
â€¢ Active hepatitis C virus (HCV) infection (positive for HCV ribonucleic acid [RNA] at Screening) or history of positive HCV RNA test result 
â€¢ PBC, PSC, autoimmune hepatitis or overlap syndrome 
â€¢ Alcoholic liver disease  
â€¢ Wilsonâ€™s disease or hemochromatosis or iron overload as defined by [CONTACT_18451] 3+ 
or 4+ stainable iron on liver biopsy  
â€¢ Alpha-1-antitrypsin (A1AT) deficiency as defined by [CONTACT_575794] (confirmed by A1AT level less than normal; exclusion at the Investigatorâ€™s 
discretion) 
â€¢ Prior known drug-induced liver injury within 5 years before Day  1 
â€¢ Known or suspected HCC  
11. History of liver transplant, current placement on a liver transplant l ist, or current Model 
for End-Stage Liver Disease ( MELD) score >[ADDRESS_755608] despi[INVESTIGATOR_040] a relatively early disease stage ( eg, per regional guidelines) may be eligible as 
long as they do not meet any of the other exclusion criteria.  
Page 50 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 51 
 
Confidential and Proprietary  12. Presence of hepatic decompensation including:  
âˆ’ Gastroesophageal varices  
âˆ’ Ascites 
âˆ’ Hepatic encephalopathy  
âˆ’ Spontaneous bacterial peritonitis 
âˆ’ Hepatorenal or hepatopulmonary syndromes 
13. Total bilirubin â‰¥ 2x upper limit of normal (ULN) at any Screening Visit (subjects with 
Gilbertâ€™s syndrome may be enrolled despi[INVESTIGATOR_040] a total bilirubin level > 2x ULN if their 
conjugated bilirubin is <2x ULN )  
14. Creatine phosphokinase (CPK) >5x ULN at Screening V isit 2 
15. Serum creatinine â‰¥1.5 mg/dL at any Screening V isit 
16. Serum ALT  >300 U/L at any Screening  Visit 
17. Platelet count < 75 000 /mm3 at any Screening V isit 
18. Known positivity for human immunodeficiency virus (HIV) infection 
19. Subjects with recent history (within 1 year of randomization) of cardiovascular disease or 
with history or planned cardiovascular interventions to treat atherosclerotic 
cardiovascular disease, including: 
a) Peripheral or  Coronary revascularization (percutaneous coronary intervention or 
coronary artery by[CONTACT_15806])  
b) Coronary angioplasty, stenting, or carotid atherectomy  
c) Cardiac pacemaker or defibrillator  (placement of cardiac pacemaker or defibrillator 
for reasons other than atherosclerotic cardiovascular disease [eg, for treatment of 
atrial fibrillation subsequent to nodal ablation ] is not exclusionary) 
d) Prosthetic heart valves  
e) Myocardial infarct, unstable angina, or acute coronary syndrome 
f) Other clinically significant atherosclerotic cardiovascular disease  
g) Cerebrovascular accident (stroke), cerebrovascular ischemia, or transient ischemic 
attack 
h) Unstable hypertension 
i) Familial hypercholesterolemia  or other genetic lipid  abnormality 
20. Other concomitant disease, malignancy, or condition likely to significantly decrease life 
expectancy to <5  years, including known cancers (except carcinomas in situ or other 
stable, relatively benign conditions such as chronic lymphocyt ic leukemia) and moderate 
to severe congestive heart failure. 
21. Known substance abuse, including inhaled or injected drugs in the year before Screening 
Page 51 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 52 
 
Confidential and Proprietary  22. For female subjects:  pregnancy, planned pregnancy, potential for pregnancy and 
unwillingness to use effective birth control during the study, or breastfeeding  
23. Participation in a clinical research study with any investigational product being evaluated 
for the treatment of diabetes or NASH in the [ADDRESS_755609] not being evaluated for the treatment of diabetes or NASH from Screening Visit 1 to Day 1,  within 30 days prior to Day 1, or within 
5 half-lives of the compound before Day 1 (whichever was longer)  
25. Previous exposure to OCA 
26. History of known or suspected clinically significant hypersensitivity to OCA or any of its components 
27. Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain 
28. Any other condition which, in the opi[INVESTIGATOR_689], would impede compliance 
or hinder completion of the study  
29. Acute cholecystitis or acute biliary obstruction  
8.4. Subject Withdrawal Criteria  
8.4.1. Reasons for Mandatory Discontinuation of Investigational Product  or 
Atorvastatin 
[IP_ADDRESS]. Adverse Events â‰¥Grade [ADDRESS_755610] experiences an AE that is â‰¥Grade 3 in severity ( Section 12.1.4) that is considered 
possibly, probably, or definitely related to investigational product, the investigational product 
must be discontinued. 
[IP_ADDRESS]. Pregnancy  
Whenever the site is notified of a possible pregnancy, the subject should be asked to come in for 
an unscheduled visit to perform a serum pregnancy test.  If a female subject becomes pregnant, 
she must discontinue treatment with  investigational product and  atorvastatin immediately , but 
should continue with the study visit schedule and must be followed by [CONTACT_22108].  The mother (and infant) will be followed as considered appropriate by [CONTACT_512235].  As described in Section [IP_ADDRESS], pregnancy is not 
considered an AE for reporting purposes. 
[IP_ADDRESS]. Severe Drug -Induced Liver Injury  
If a subject develops  signs and symptoms of a severe drug-induced liver injury, regardless of 
causality, investigational product and atorvastatin  should be interrupted until the event has 
resolved or returned to baseline, but the subject should continue with the study visit schedule.  
Subjects who develop significant drug-induced liver injury, which is considered to be causally 
Page 52 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755611] be followed until the AE has resolved, stabilized, or is not of clinical concern.  
[IP_ADDRESS]. Myonecrosis  
Moderate myonecrosis as defined by [CONTACT_575795] â‰¥10x the untreated baseline levels or ULN.  
Muscle-related symptoms that do not necessitate mandatory discontinuation of investigational 
product or atorvastatin  are detailed in Section 5.8. 
8.4.2. Reasons for Mandatory Interruption of Investigational Product 
[IP_ADDRESS]. Adverse Events â‰¥Grade [ADDRESS_755612] experiences an AE categorized as â‰¥Grade [ADDRESS_755613] is required. 
[IP_ADDRESS]. Suspected Mild or Modera te Drug-Induced Liver Injury  
Because transient fluctuations of ALT or AST are common, and progression to severe drug-
induced liver injury or acute liver failure is uncommon, automatic discontinuation of investigational product with an elevation of ALT or AST that is >3x ULN/baseline/nadir or total 
bilirubin >2x ULN/baseline/nadir, as described in Appendix B , may be unnecessary.  If a subject 
develops signs of a mild or moderate event of drug-induced liver injury, regardless of causality, investigational product should be interrupted until the event has resolved or returned to baseline, 
but the subject should continue with the study visit schedule.  The subject may restart treatment 
after resolution of the event or return to baseline.  Follow-up procedures, including laboratory evaluations and physical examinations, must be performed after a maximum of [ADDRESS_755614] 
will be allowed to continue treatment. 
Page 53 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755615] be made to determine the reason(s) why a subject fails to return for 
his/her final visit or is discontinued from the study.  This information and date must be recorded 
on the appropriate electronic case report form ( eCRF).  The following events are considered 
appropriate reasons for a subject to discontinue from the study: 
â€¢ The subject decides that it is in his/her best interest.  It is fully understood that all subjects volunteer for the study and that they may withdraw their consent to continue 
in the study at any time  
â€¢ The Investigator or Sponsor considers that it is advisable or in the best interest of the subject  
â€¢ There is a major violation of the clinical study protocol 
â€¢ Noncompliance of the subject  
â€¢ An inability to provide plasma or urine samples  
8.4.4. Subject Discontinuation Notification  
The Investigator must notify the Sponsor as soon as possible if any subject prematurely 
discontinues from the study.  The date when the subject is withdrawn and the reason for discontinuation must be recorded in the eCRF; additional information may be requested by [CONTACT_575796] a discontinuation narrative.  Subjects will be considered â€œlost to follow-upâ€ 
only after reasonable, documented attempts to reach the subject prove unsuccessful.  In all cases, 
a reasonable effort must be made to determine the reason(s) that a subject fails to return for 
required study visits or discontinues from the study.  This information must be documented in 
the eCRF.  
If a subject is withdrawn from the study early (regardless of the cause), all of the ET evaluations, 
with the exception of PK procedures, should be performed at the time of withdrawal, to the 
extent possible. 
9. TREATMENT OF SUBJECTS 
9.1. Investigational Product  and Atorvastatin  Treatment Regimen  
While placebo, OCA , and atorvastatin are all study medications provided by [CONTACT_1034], for the 
purposes of this protocol , investigational product refers to  OCA or placebo , and study 
medication, where used, refers to atorvastatin.  
Four treatment groups will be evaluated:  placebo, OCA 5 mg, OCA 10  mg, and OCA 25 mg.  
Each dose will be made up of 1 tablet (ie, 1 placebo tablet, 1 OCA 5 -mg tablet, 1 OCA 10 -mg 
tablet, or 1 OCA 25 -mg tablet).  The list of excipi[INVESTIGATOR_575558]. 
Investigational product will be taken orally with water, once daily for the duration of the study.  
Subjects will be instructed to begin dosing on Day [ADDRESS_755616] at 
Page 54 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755617] ructed to swallow the tablets whole 
with water; they must not chew, divide, or crush the tablets. 
9.1.1. Double-Blind Period  
Subjects enrolled in the study will be randomized to receive one of the following treatments: 
OCA 5 mg , OCA 10 mg , OCA 25 mg , or placebo, starting on Day 1. 
At the Week  4 Visit, all subjects will also initiate treatment with atorvastatin at a dose of 10  mg 
once daily.  At the Week  8 Visit, atorvastatin will be increased to 20 mg once daily  (if 10 mg 
daily is tolerated) , and continued for an additional 4 weeks.  A fter 4 weeks of treatment at 20 mg, 
the atorvastatin dose may be titrated (up or down) at the Week 12 Visit as clinically indicated 
using the atorvastatin prescribing information and the guidance for lipid management (see Appendix A ).  Blinded treatment with investigational product and open- label atorvastatin will 
continue through the Week [ADDRESS_755618] will be dispensed in bottles of 
30 tablets.  
9.1.2. LTSE 
Subjects who complete the Week  16 Visit of the double-blind phase will be able to participate in 
an open-label LTSE.  The Week  16 Visit of the double-blind phase will be Day 1 of the LTSE 
phase of the study. 
Following completion of Week 16 Visit procedures , all subjects will be treated with open-label 
OCA 10 mg or OCA 25 mg.  S ubjects randomized to placebo or OCA 5 mg during the 
double-blind phase will be randomized in a 1:[ADDRESS_755619] during the LTSE period will be dispensed in bottles of 30 or 100 tablets, 
and subjects will be instructed to take one or more tablets per day per his/her OCA dose 
assignment.  During the LTSE phase, the dose of atorvastatin may remain the same as during the 
double-blind phase or may be modified as clinically indicated per atorvastatin prescribing 
information and lipid management guidelines ( Appendix A ). 
9.2. Concomitant Medications  
Relevant information about all concomitant medications (including prescribed, over- the-counter, 
or herbal preparations) taken prior to (ie, within 12  months of Day 1) and during the study must 
be recorded in the source documents and eCRF, as well as any dose or dose regimen changes that occur during the study. 
9.2.1. Medications with Potential NASH- Modifying Properties  
Doses of TZDs and Vitamin E should be stable 6 months before Day 1 through Week 16.  
Ideally, subjects should generally remain on baseline TZDs and/ or Vitamin  E throughout both 
the double-blind and LTSE phases of the study unless the baseline therapy is no longer 
considered clinically appropriate by [CONTACT_3433] e Investigator.  
Page 55 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 56 
 
Confidential and Proprietary  9.2.2. Diabetes-Specific Therapy  
All diabetes -specific therapi[INVESTIGATOR_575559] a stable dose for â‰¥[ADDRESS_755620] be at a stable dose for â‰¥6  months prior to Day 1 through 
Week 16.  Ideally, subjects s hould remain on B aseline diabetes -specific therapi[INVESTIGATOR_575560], but will be allowed to make changes if the B aseline therapy is no longer 
considered clinically appropriate by [CONTACT_737].  
9.2.3. Management of Changes in Cholesterol 
During the double-blind phase of the study, the dose of atorvastatin administration should be as 
described in this protocol through Week 12 unless tolerability issues develop as referenced in 
Section 7.4.2.  At the Week  12 Visit, I nvestigators may increase or decrease the dose of 
atorvastatin as clinically indicated.  
During the LTSE, I nvestigators may add or change the management of treatment as clinically 
appropriate.  Appendix A  provides a general guidance for cholesterol managem ent including 
monitoring, triggers for intervention, and treatment goals. 
9.2.4. Prohibited Medications  
The medications prohibited per the study enrollment exclusion criteria  and or during the study 
are listed below and summarized in Table 3: 
â€¢ Prohibited 30 days  prior to Day 1:   
âˆ’ BAS including cholestyramine, colesevelam, colestipol, or 
âˆ’ omega-3 fatty acid containing dietary supplements 
â€¢ Prohibited 3 months prior t o Day 1 and throughout the double-blind period:   
âˆ’ nicotinic acid and derivatives, ezetimibe, or  
âˆ’ fenofibrate or other fibrates  
âˆ’ any over-the-counter or health foods used to treat lipi[INVESTIGATOR_575561] 
â€¢ Prohibited 3 months prior to Day 1 and throughout the double-blind period and 
LTSE: 
âˆ’ any prescription or over-the-counter medication or herbal remedy with putative NASH efficacy (except Vitamin E or TZD s)  
âˆ’ ursodeoxycholic acid 
â€¢ Prohibited 6 months prior to Day 1 and throughout the double-blind period and LTSE: 
âˆ’ azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, mofetil, pentoxifylline; budesonide and other systemic corticosteroids;  
Page 56 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 57 
 
Confidential and Proprietary  âˆ’ potentially hepatotoxic drugs (including Î±- methyl-dopa, sodium valproic acid, 
isoniazide, or nitrofurantoin) 
â€¢ Prohibited 12 months prior to Day 1 and throughout the double-blind period:  
âˆ’ antibodies or immunotherapy directed against interleukins or  
âˆ’ other cytokines or chemokines 
â€¢ Prohibited throughout the double-blind phase of the study: âˆ’ weight loss drugs including appetite suppressants (eg, orlistat, lorcaserin) 
âˆ’ medications contraindicated in the atorvastatin label, including HIV and 
Hepatitis C protease inhibitors, clarithromycin, and itraconazole (refer to 
atorvastatin prescribing information in Appendix E  for complete list).   These 
medications are also prohibited during the LTSE phase if the subject continues to 
receive atorvastatin during the LTSE. 
â€¢ Prohibited during the double-blind and LTSE phases of the study: 
âˆ’ medications historically associated with NAFLD including:  amiodarone, 
tetracyclines, tamoxifen, estrogens (at doses greater than those used for hormone 
replacement), anabolic steroids 
Page 57 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 58 
 
Confidential and Proprietary  Table 3: Medications Prohibited Prior to Randomization and/or During Study Participation 
 Use Prohibited Prior to Randomization  Use Prohibited During Study  
Medications  -12 Months -6 Months -3 Months -30 Days Double-Blind 
Phase LTSE 
Bile acid sequestrants including 
cholestyramine, colesevelam, 
colestipol    X   
Omega-3 fatty acid containing dietary 
supplements    X   
Nicotinic acid and derivatives    X X X  
Ezetimibe    X X X  
Fenofibrate or other fibrates   X X X  
Any over-the-counter or health foods 
used to treat lipi[INVESTIGATOR_575562]    X X X  
Any prescription or over -the-counter 
medication or herbal remedy with 
putative NASH efficacy (except 
Vitamin E or TZDs )   X X X X 
Ursodeoxycholic acid   X X X X 
Azathioprine, colchicine, 
cyclosporine, methotrexate, 
mycophenolate, mofetil, 
pentoxifylline; budesonide and other 
systemic corticosteroids   X X X X X 
Potentially hepatotoxic drugs (including Î±- methyl-dopa, sodium 
valproic acid, isoniazide, or 
nitrofurantoin)   X X X X X 
Page 58 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 59 
 
Confidential and Proprietary  Table 3: Medications Prohibited Prior to Randomization and/or During Study Participation (Continued)  
 Use Prohibited Prior to Randomization  Use Prohibited During Study  
Medications  -[ADDRESS_755621] interleukins X X X X X  
Other cytokines or chemokines  X X X X X  
Weight loss drugs including appetite suppressants (eg, orlistat, lorcaserin)      X  
HIV and Hepatitis C protease inhibitors, clarithromycin, 
itraconazole      X X 
Medications historically associated with NAFLD including:  amiodarone,  
tetracyclines, tamoxifen, estrogens (at doses greater than those used for hormone replacement), anabolic 
steroids     X X 
Note:  For clarity, only prior months and study periods with prohibited use are  indicated with â€œXâ€; other periods with no restrictions are shaded grey.  
 
Page 59 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755622] of Care and Other Concomitant Medications  
With the exception of Vitamin E,  TZDs and other diabetes -specific therapy, allowed concomitant 
medications should be at a stable dose 30 days before Day  1.  Concomitant medications will be 
used at the discretion of the usual care provider (or Investigator if also the usual care provider).  
Relevant information about all concomitant medications taken before (ie, within 12 months of 
Day 1; Table 3) and during the study must be recorded in the source documents and e CRF, as 
well as any dose or dose regimen changes that occur during the study. 
Subjects taking BAS (including cholestyramine and its derivatives, colestipol, colesevelam, or 
other sequestr ants) or aluminum hydroxide- or smectite -containing antacids should be instructed 
to stagger their dosing of investigational product, ensuring at least 4 hours between doses of the 
BAS and/or antacids and the investigational product (ie, BAS should be admi nistered [ADDRESS_755623] administration).  
Taken concomitantly, OCA and warfarin may decrease INR, thus INR should be monitored and the dosage of warfarin adjusted, as needed, to maintain the target INR range.  
The effect of OCA on drug metabolizing enzymes has been evaluated in both in vitro and clinical 
studies.  The PK profile of caffeine, a sensitive CYP1A2 substrate, showed weak effect of OCA on CYP1A2.  Based on these results, OCA may increase the exposure of narrow therapeutic 
index drugs that are substrates for CYP1A2, such as theophylline and tizanidine. 
9.3. Treatment Compliance  
The Investigator should assess the subjectâ€™s compliance with dosing of investigational product 
and open-label atorvastatin on an ongoing basis throughout the study and confirm by [CONTACT_22088] (ie, count of returned tablets) during subjectsâ€™ onsite visits.  
Subjects should be instructed to retain all bottles of investigational product and atorvastatin , even 
if empty, and to return them to the Investigator at the subsequent visit (refer to Table 1 and Table 2).  The Investigator or designee should perform drug accountability and, if applicable, 
follow up with the subject to retrieve any investigational product and atorvastatin  bottles that 
have not been returned.  
If the Investigator has concerns about a subjectâ€™s dosing compliance s/he should discuss this with 
the subject, assess the reasons for noncompliance and the likelihood that the subject will remain 
noncompliant, and notify the Sponsor accordingly.  Continued study eligibility should be assessed based on the subjectâ€™s compliance with investigational product and atorvastatin  dosing 
and clinic visits.  
9.4. Randomization and Blinding  
The initial phase of the study will be conducted in a double-blind, placebo -controlled manner.  
Enrolled subjects will be randomized in a 1:1:1:1 ratio to 1 of 4 treatment groups (OCA 5 mg, 
OCA 10 mg, OCA 25  mg, or placebo) based on a predefined randomization code (generated by 
[CONTACT_35886]) using an IWRS.  The IW RS will serve as the investigational product 
inventory and management system and may be integrated with the study database.  
Page 60 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755624] (OCA or 
placebo) dispensing information will be provided (eg, bottle numbers allocated) while 
maintaining the study blind.  The subjects, Investigator, and study site staff will be blinded to the 
subjectsâ€™ treatment allocation in the double-blind phase of the study until all subjects have 
completed the double-blind phase of the study and the database is locked. 
In the LTSE phase, all subjects will be treated with open -label OCA 10 mg or OCA 25 mg: 
subjects randomized to placebo or OCA 5 mg during the double-blind phase will be randomized in a 1:[ADDRESS_755625] treatment response are ran domized in 
equal proportions to the different treatment groups, subjects will be stratified by [CONTACT_575797] (Screening Visit 2 LDL cholesterol value for statin washout subjects or Screening LDL cholesterol value for statin -free subjects).  Randomization will be stratified by [CONTACT_195226]-randomization fasted serum LDL cholesterol concentration (â‰¤125 mg/dl or >125 mg/dL) and 
baseline fibrosis stage (stage 1,  2 or stage 3, 4). 
9.4.2. Emergency Unblinding Procedures  
Randomization codes and corresponding t reatment assignment s will be made available to the 
Investigator and the Medical Monitor for emergency use only through the IWRS system.  When possible, the Medical Monitor should be consulted in the event that a medical emergency necessitates unblinding (ie, in situations where knowledge of the blinded treatment is necessary 
for further medical management of the subject).  If it is not reasonable to inform the Medical 
Monitor in advance of unblinding, the Investigator must promptly document the case in the 
subjectâ€™s source record.  Subsequently, the Investigator should contact [CONTACT_575798] ( eg, accidental unblinding or 
unblinding due to a serious AE  [SAE]).  Procedures for unblinding a subjec tâ€™s treatment will be 
provided separately to the Investigator.  The  Medical Monitor will document within study 
correspondence the rationale, circumstances, and the person (s) being informed about the 
unblinding.   
The DMC  (refer to Section 13.8) will have access to the IWRS and will be able to unblind 
individual subjects.  The DMC will review aggregate data during closed sessions.  The DMC 
will document details about any subject who was unblinded in the closed session DMC minutes, 
which will be made available to the Sponsor only after the double-blind database is locked and 
unblinded.  
Access to randomization  codes and corresponding treatment assignments will also be made 
available through the IWRS system to the appropriate, named individual(s) responsible for 
reporting SAEs and suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) to the regulatory 
authorities. 
Page 61 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755626] 8 hours prior to Screening Visit 2 (Week  -1 Visit) 
and all subsequent study visits , as all analytes will be assayed in fast ing blood, serum, or plasma 
samples (Table 1 and Table  2).  Water is permitted during the fasting period.  
If the subject reports having eaten within [ADDRESS_755627] 8 -hour fasting 
is required prior to all study visits, but water is permitted.  The blood sample will still be 
collected during the visit with the exception of Screening Visit 2, which will require rescheduling of the visit. 
9.6.2. Grapefruit and Grapefruit Juice  
Grapefruit and grapefruit juice consumption should be discouraged following initiation of 
atorvastatin  due to possible increases in plasma concentration of atorvastatin (please refer to 
atorvastatin prescribing information [ Appendix E ]). 
9.6.3. Diet and Exercise  
Consistent with the exclusion criteria ( Section 8.3), subjects should not make significant changes 
to their diet and exercise habits during the double-blind phase.  This is not intended to override physician advice for lifestyle modification , and inclusion in the study should preferably be after 
lifestyle modifications have been made and are stable.  
9.7. Visit Procedures 
9.7.1. Visit Windows  
All Screening assessments should occur â‰¤35 days prior to the Randomization/ Day 1 Visit.  
Subjects who are taking statins at the time of screening or within 30 days of Screening Visit 1 are 
required to stop statin therapy for 4  weeks (28 (Â±1) days) , and provide a fasting blood sample at 
Screening Visit  [ADDRESS_755628] not taken statins within 30 days of 
Screening Visit  1 are not required to enter into the washout period and m ay proceed to Screening 
Page 62 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 63 
 
Confidential and Proprietary  Visit 2 to provide a fasting blood sample.  The Randomization/Day 1 Visit may occur as soon as 
all screening labs are available and eligibility is confirmed.  
All visits durin g the double-blind phase will be relative to Day 1 (eg, if the Week  2 Visit occurs 
4 days late, the Week  4 Visit should still be 4  weeks from Day  1), and should occur within 
Â±4 days of the visit day.  The timing of all study visits during the LTSE is relative to 
Week 16/LTSE Day  1.  LTSE Visits should occur within Â±1 week of the visit day. 
The visit windows are summarized below: 
Visit or Procedure Visit Window and/or Interval  
Screening  Visit 1 Visit(s) are to occur â‰¤5 weeks (35  days) prior to Day 1.  
Screening Visit  2 (Week -1) Â±1 day  
Randomization ( Day 1) This is the day of Randomization and the first day of dosing with 
investigational product.  On -treatment visit scheduling should be 
calculated from this point going forward unless stated otherwise.   
Week 2, Week 4, Week 8, and 
Week 12 Â±4 days; the visits during double-blind phase will be relative to Day  1 
(ie, first dose of investigational product)  
Week 6, Week 10, and Week 14  
(Contact [CONTACT_41995])  Â±4 days 
Week 16 (LTSE Day  1) Â±4 days 
LTSE Visits:  Month 1, Month 3, 
Month 6, Month 9, Month 12, 
Month 15, Month  18, and Month 21 Â±1 week (7 days); the LTSE visits are relative to LTSE Day  1 (ie, 
Week 16 of double-blind phase) 
EOS Â±1 week (7 days) relative to the EOS date announced by [CONTACT_575799] = End of Study; ET = Early Termination  
9.7.2. Informed Consent Procedures  
The Investigator or designee will explain the nature, purpose possible risks and benefits of the 
study to the subject and will provide him/her with a copy of the written information and 
informed consent form (ICF).  The subject will be given sufficient time to consider the study 
before deciding whether or not to participate.  The subject will be infor med that participation is 
voluntary and that his/her future medical treatment will not be compromised by [CONTACT_575800].  The subject must be 
willing and able to provide written informed consent before entering the study.  The Investigator or a medically qualified designee is responsible for administering and documenting the written 
informed consent of the subject.  The subject will be given a copy of the written information 
sheet and his/her signed and dated consent form ).  At selected study sites, subjects will have the 
option to consent to participate in an additional PK assessment.  Subjects may also be required to 
sign a new consent form prior to entering the LTSE phase of the study.  Subjects will be 
requested to provide blood samples for exploratory future analysis of analytes such as adiponectin, plasminogen activator inhibitor- 1(PAI-1), and B- type natriuretic peptide (BNP;  
Table 10).    
Page 63 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755629] be performed â‰¤[ADDRESS_755630] meets all the inclusion criteria and none of the exclusion criteria.  Subjects 
who do not fulfill all eligibility criteria will not be enrolled in the study.   
Subjects who are statin -free (ie, no st atin use within 30 days of Screening) must return for fasted 
serum chemistry labs at Screening Visit  2, and may proceed to the Randomization/Day 1 V isit 
once screening labs are available and eligibility is confi rmed; subjects who need to wash out 
statin therapy are required to return for Screening Visit 2  following the washout period.   
Screening Visit procedures for all subjects are as follows:  
â€¢ Review ICFs and obtain signatures before performing any study- related procedures, 
including Screening procedures. 
â€¢ Collect medical history . 
â€¢ Verify inclusion and exclusion criteria for eligibility . 
â€¢ Perform a physical examination.  
â€¢ Perform a standard 12 -lead electrocardiogram (ECG) . 
â€¢ Assess and record vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure).  
â€¢ Assess and record anthropometric measures:  body weight, waist and hip 
circumference, and height . 
â€¢ Determine alcohol consumption (using AUDIT questionnaire). 
â€¢ Assess availability of liver biopsy samples :  If >[ADDRESS_755631] be submitted for central read su ch that the 
report is available prior to Day 1.  
â€¢ For participating sites only:  TE is scheduled for Screening Visit  1; however, it may 
be performed any time between Screening Visit 1 and prior to Randomization 
(Day 1).  In addition, if TE has been done wit hin 3 months of Day 1 and a 
report/adequate data is/are available, a pretreatment TE at Day 1 is not required .     
â€¢ Assess and record any pretreatment -emergent AEs (after the ICF has been signed) . 
â€¢ Record prior (if within 12 months of Day 1) and current concomitant medications . 
â€¢ Obtain serum sample for hepatitis B surface antigen or hepatitis C antibody (and 
positive HCV ribonucleic acid [RNA]) testing to confirm study eligibility . 
â€¢ Schedule laboratory visit for fasted blood samples for  
âˆ’ Serum chemistry (in cludes basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
Page 64 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 65 
 
Confidential and Proprietary  â€¢ Obtain urine sample for urinalysis. 
â€¢ Perform serum pregnancy test in females of childbearing potential.  
â€¢ Instruct the subject to fast overnight (at least 8 hours) before the next visit (water is 
permitted) . 
Additional Screening Visit 1 procedure for subjects currently taking statins: 
â€¢ Subjects who are currently taking statins,  defined as statin use within 30 days of 
Screening, will be instructed to discontinue statin therapy following Screening 
Visit 1.  After 4  weeks of statin washout, subjects will return for Screening Visit  2 to 
provide blood samples for fasted serum chemistry. 
9.7.4. Screening Visit  2 Visit Procedures  
All subjects will return for Screening Visit 2 to confirm eligibility criteria and provide blood 
samples for fasted serum chemistry.  
For subjects who were receiving statin therapy at the time of screening:  
â€¢ Verify that subjects have completed  a 4-week washout period. 
For all subjects: 
â€¢ Review inclusion and exclusion criteria for eligibility . 
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within 8 hours, the visit should be rescheduled. 
â€¢ Obtain blood samples for  
âˆ’ Serum chemistry (will include basic lipid and liver biochemistry panel ), 
hematology, and coagulation 
âˆ’ CPK 
â€¢ Assess and  record pretreatment -emergent AEs . 
â€¢ Assess and record new concomitant medications. 
â€¢ For participating sites only:  Perform TE if not done during Screening Visit 1 or a 
report/adequate data from a scan done within 3  months and Day 1 is /are not available. 
9.7.5. Randomization/Day 1 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755632] 8 -hour fasting is required 
prior to all study visits , but water is permitted . 
Page 65 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 66 
 
Confidential and Proprietary  â€¢ Review inclusion and exclusion criteria for eligibility . 
â€¢ Perform a standard 12- lead ECG . 
â€¢ Assess and record vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, and waist and hip 
circumference. 
â€¢ Determine alcohol con sumption (using AUDIT questionnaire). 
â€¢ Assess and re cord any pretreatment -emergent AEs. 
â€¢ Record prior ( since Screening Visit 1) and current concomitant medications. 
â€¢ For participating sites only:  Perform TE if not done during Screening Visit 1 or 
Screening V isit 2, or if a report/adequate data from a scan done within 3  months and 
Day 1 is/are not available . 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry (includes basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes  
âˆ’ CPK, if myopathy suspected 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10) 
âˆ’ Vitamin D  
âˆ’ Blood sample for future exploratory analysis of biomarkers adiponectin, PAI-1, and BNP 
âˆ’ Thyroid Funct ion Tests:  TSH, T4, and T3 
âˆ’ Possible analysis of conjugated and unconjugated bile acids 
â€¢ Obtain urine sample for urinalysis. 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Randomize the subject only if s/he meets all inclusion criteria and no exclusion criteria:  Record the visit in IWRS along with the subjectâ€™s  Screening Visit 2 
(Week -1) fasting LDL cholesterol value, randomize the subject to study treatment 
group, and dispense investigational product according to IWRS instructions. 
â€¢ Administer the first dose of investigational product at the study site.  Instruct the subject to swallow the tablet whole with water; s/he must not chew, divide, or crush 
the tablet.  
Page 66 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 67 
 
Confidential and Proprietary  â€¢ Schedule the next visit, reiterate dosing instructions, and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product on the morning of the next visit 
âˆ’ To bring the investigational product bottle(s); s/he will dose at the clinic  
âˆ’ To fast overnight (at least 8 hours) before the next visit, but water is permitted  
Additional Day [ADDRESS_755633] and 
will remain fasted until the 1-hour sample is collected.  Meal will be provided following 
collection of the 1-hour PK sample, and will be a meal replacement drink with nutrition information that has been submitted to and approved by [CONTACT_22134]. 
9.7.6. Week 2 Visit Procedures  
â€¢ Verify that the subject has fas ted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755634] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference.  
â€¢ Assess and record AEs. 
â€¢ Review and record co ncomitant medications . 
â€¢ Collect used bottles of investigational product, assess investigational product compliance, and perform investigational product accountability. 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry (includes basic lipid panel and liver biochemis try panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes 
Page 67 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 68 
 
Confidential and Proprietary  âˆ’ CPK, if myopathy suspected 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in fem ales of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Schedule the next visit, reiterate dosing instructions and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product on the morning of the next visit  
âˆ’ To bring the investigational product bottle(s); s/he will dose at the clinic  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit, but water is permitted  
9.7.7. Week 4 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours . 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755635] that fasting is required prior to all study visits, but water is permitted.  
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference.  
â€¢ Assess and record AEs. 
â€¢ Review and record  concomitant medications . 
â€¢ Collect used bottles of investigational product, assess investigational product compliance, and perform investigational product accountability. 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry (includes basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and Table 10)   
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subject s of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
Page 68 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 69 
 
Confidential and Proprietary  â€¢ Record the visit in IWRS and dispense investigational product and atorvastatin as 
instructed . 
â€¢ Administer the daily dose of investigational product at the study site.  Instruct the subject to swallow the tablet whole; s/he must not chew, divide, or crush the tablet. 
â€¢ Administer the daily dose of atorvastatin at the study site.  Instruct the subject to 
swallow the tablet whole; s/he must not chew, divide, or crush the tablet. 
â€¢ Schedule the next visit, reiterate dosing instructions and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product or atorvastatin on the morning of the next 
visit  
âˆ’ To bring the investigational product and atorvastatin bottle(s); s/he will dose at 
the clinic 
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all study visits, but water is permitted.  
9.7.8. Week [ADDRESS_755636] 
â€¢ This is a telephone contact [CONTACT_575801]  
âˆ’ Review and record AEs  
âˆ’ Review and record concomitant medications  
âˆ’ Assess investigational product and atorvastatin compliance 
9.7.9. Week 8 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755637] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference 
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
â€¢ Collect used bottles of investigational product, assess investigational product 
compliance, and perform investigational product accountability. 
Page 69 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 70 
 
Confidential and Proprietary  â€¢ Collect used bottles of atorvastatin, assess atorvastatin compliance, and perform 
atorvastatin accountability .  
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry (includes basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10)   
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
âˆ’ Blood sample for future exploratory analysis of biomarkers adiponectin, PAI-1, and BNP 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive.  
â€¢ Record the visit in IWRS and dispense investigational product and atorvastatin as 
instructed .  
â€¢ Administer the daily dose of investigational product at the study site.  Instruct the subject to swallow the tablet whole; s/he mus t not chew, divide, or crush the tablet. 
â€¢ Administer the daily dose of atorvastatin at the study site.  Instruct the subject to swallow the tablet whole; s/he must not chew, divide, or crush the tablet. 
â€¢ Reiterate dosing instructions and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product or atorvastatin on the morning of the next 
visit 
âˆ’ To bring the investigational product and atorvastatin bottle(s); s/he will dose at 
the clinic 
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all study visits, but water is permitted.  
9.7.10. Week [ADDRESS_755638] 
â€¢ This is a telephone contact [CONTACT_575801]:  
âˆ’ Review and record AEs  
âˆ’ Review and record concomitant medications  
âˆ’ Assess investigational product and atorvastatin compliance 
Page 70 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 71 
 
Confidential and Proprietary  9.7.11. Week 12 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755639] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference. 
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
â€¢ Collect used bottles of investigational product, assess investigational product 
compliance, and perform investigational product accountability . 
â€¢ Collect used bottles of atorvastatin, assess atorvastatin compliance, and perform 
atorvastatin accountability . 
â€¢ Obtain blood samples for: 
âˆ’ Serum chemistry (includes basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10)  
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Record the visit in IWRS and dispense investigational product and atorvastatin as instructed.  
â€¢ Administer the daily dose of investigational product at the study site.  Instruct the subject to swallow the tablet whole; s/he must not chew, divide, or crush the tablet. 
â€¢ Administer the daily dose of atorvastatin at the study site.  Instruct the subject to swallow the tablet whole; s/he must not chew, divide, or crush the tablet. 
â€¢ Reiterate dosing instructions and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
Page 71 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 72 
 
Confidential and Proprietary  âˆ’ NOT to take investigational product or atorvastatin on the morning of the next 
visit 
âˆ’ To bring the investigational product and atorvastatin bottle(s); s/he will dose at 
the clinic 
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all study visits; water is permitted.  
9.7.12. Week [ADDRESS_755640] 
â€¢ This is a telephone contact [CONTACT_575801]:  
âˆ’ Review and record AEs  
âˆ’ Review and record concomitant medications  
âˆ’ Assess investigational product and atorvastatin compliance 
9.7.13. Week 16 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755641] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Perform a physical examination . 
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference.  
â€¢ Perform a standard 12 -lead ECG . 
â€¢ Determine alcohol consumption (using AUDIT questionnaire). 
â€¢ For participating sites only:  perform TE 
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
â€¢ Collect all used and unused bottles of investigational product, assess investigational 
product compliance, and perform investigational product accountability. 
â€¢ Collect used bottles of atorvastatin, assess atorvastatin compliance, and perform 
atorvastatin accountability .  
Page 72 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 73 
 
Confidential and Proprietary  â€¢ Obtain blood samples for:  
âˆ’ Serum chemi stry (includes basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10) 
âˆ’ Vitamin D  
âˆ’ CPK, if my opathy suspected  
âˆ’ Blood sample for future exploratory analysis of biomarkers adiponectin, PAI-1, 
and BNP 
âˆ’ Thyroid Function Tests:  TSH, T4, and T3 
âˆ’ Possible analysis of conjugated and unconjugated bile acids 
â€¢ Obtain urine sample for urinalysis. 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine Î²-hCG pregnancy test is positive. 
â€¢ Record the visit in IWRS and indicate if the subject is continuing into the LTSE . 
[IP_ADDRESS]. Additional Week [ADDRESS_755642] and will remain fasted until the 1-hour 
sample is collec ted.  The m eal will be provided following collection of the 1-hour PK sample, 
and will be a meal replacement drink with nutrition information that has been submitted to and 
approved by [CONTACT_22134]. 
9.7.14. Additional Procedures at Week 16/LTSE Day 1 Vis it for Subjects Continuing 
into the LTSE  
Subjects who continue into the LTSE phase after completing the procedures listed for the 
Week 16 Visit ( Section 9.7.13) will undergo the following procedures after signing the 
LTSE-specific ICF: 
Page 73 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 74 
 
Confidential and Proprietary  â€¢ Record the visit in IWRS, randomize the subject to one of the open- label treatment 
groups, and dispense open- label investigational product according to IWRS 
instructions. 
â€¢ If the subject is continuing with atorvastatin therapy, dispense  (via IWRS)  and 
provide dosing instructions as clinically indicated ( Appendix A ). 
â€¢ Reiterate dosing instructions for investigational product and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product or atorvastatin on the morning of the next 
visit 
âˆ’ To bring the investigational product and atorvastatin bottle(s); s/he will dose at 
the clinic 
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all study visits, but water is permitted.  
9.7.15. Early Termination /End of Study Procedures:   Double-Blind Period  
Subjects who terminate participation in the study prior to the Week [ADDRESS_755643] an early 
termination (ET) Visit as soon as possible following the decision to discontinue therapy.  If the 
study is terminated early  by [CONTACT_1034] ( Section 7.5), the subject will be asked to return to the 
site for ET/EOS procedures  as soon as possible.  The procedures to be performed at the double-
blind phase ET/EOS  Visit are as follows:  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755644] that fasting is required prior to all study visits, but water is permitted.  
â€¢ Perform a physical examination . 
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference. 
â€¢ Perform a standard 12 -lead ECG . 
â€¢ Determine alcohol consumption (using AUDIT questionnaire). 
â€¢ For participating sites only:  p erform TE  
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
Page 74 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 75 
 
Confidential and Proprietary  â€¢ Collect used and unused bottles of investigational product, assess investigational 
product compliance, and perform investigational product accountability. 
â€¢ Collect used and unused bottles of atorvastatin, assess atorvastatin compliance, and perform atorvastatin accountability .  
â€¢ Obtain blood samples for:  
âˆ’ Serum chemistry (will include basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes  
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10)     
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
âˆ’ Blood sample for future exploratory analysis of biomarkers adiponectin, PAI-1, and BNP 
âˆ’ Thyroid Function Tests:  TSH, T4, and T3 
âˆ’ Possible analysis of conjugated and unconjugated bile acids 
â€¢ Obtain urine sample for urinalysis. 
â€¢ Perform a urine -based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Obtain urine sample for urinalysis. 
â€¢ Record the visit in the IWRS. 
9.7.16. LTSE Visits  
LTSE Visits should occur within Â±1 week of the visit day and the timing of all visits should be 
relative to the double-blind Week 16 Visit (ie, the start of the LTSE; LTSE Day  1).  For 
example, if the Month [ADDRESS_755645] LTSE visit following LTS E Day 1 will occur at LTSE Month 1.  The next visit will 
occur at LTSE Month 3 and every 3 months thereafter  (eg, at Months 6, 9, and 12) for the 
duration of the LTSE.  The quarterly visit procedures described below will repeat annually for 
the duration of the LTSE.  For example, once a subject completes a year (Month 12 V isit) in the 
LTSE, their next visit should be 3 months later and the procedures described for the Month 3 LTSE Visit should be followed. 
9.7.17. LTSE Month 1 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. 
Page 75 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 76 
 
Confidential and Proprietary  âˆ’ Record fasting status in the source and eCRF.  
âˆ’ If the subject reports having eaten within [ADDRESS_755646] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Assess and record vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record AEs.  
â€¢ Review and record concomitant medications.  
â€¢ Collect used bottles of investigational product, assess investigational product 
compliance, and perform investigational product accountability.  Following product accountability, redispense the same bottle of investigational product for use until the 
next visit.  
â€¢ Collect used bottles of atorvastatin, assess atorvastatin compliance, and perform 
atorvastatin accountability.  Following atorvastatin accountability, if the subject is 
continuing with the same dose of atorvastatin, redispense the same bottle for use until 
the next visit.   
âˆ’ NOTE:  If atorvastatin dose is up -titrated or re -initiated after dose interruption, a 
telephone safety contact [CONTACT_575802] [ADDRESS_755647] and 
atorvastatin compliance.  
â€¢ Obtain blood samples for:  
âˆ’ Serum chemistry (will include basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Markers of glucose metabolism  
âˆ’ CPK, if myopathy suspected 
â€¢ Perform a urine based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbearing potential if urine Î²-hCG pregnancy test is positive. 
â€¢ Reiterate dosing instructions for investigational product and  advise the subject:  
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product or atorvastatin (if applicable) or on the 
morning of the next visit 
âˆ’ To bring the investigational product and atorvastatin (if applicable) bottle(s); s/he will dose at the clinic  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all study visits, but water is permitted.  
Page 76 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 77 
 
Confidential and Proprietary  9.7.18. LTSE Month 3, Month 6, Month 9 , Month 15, Month 18, and Month 21  Visit 
Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755648] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Perform a physical examination (only at Month 3 and Month 15 Visits). 
â€¢ Perform a standard 12 -lead ECG . 
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting b lood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference.  
â€¢ Determine alcohol consumption (using AUDIT questionnaire [only at Month 6 and 
Month 18 Visits]). 
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
â€¢ Collect used bottles of investigational product, assess investigational product compliance, and perform investigational product accountability. 
â€¢ Collect used bottles of atorvastatin, assess atorvastatin compliance, and perform atorvastatin acco untability .   
âˆ’ NOTE:  If atorvastatin dose is up -titrated or re -initiated after dose interruption, a 
telephone safety contact [CONTACT_575802] [ADDRESS_755649] and 
atorvastatin compliance.  
â€¢ Obtain blood samples for:  
âˆ’ Serum chemistry (will include basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses  
âˆ’ Reverse cholesterol transport analytes  (only at Month 6 and Month 18) 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10) 
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
Page 77 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 78 
 
Confidential and Proprietary  â€¢ Perform a urine based Î²-hCG pregnancy test in female subjects of childbearing 
potential.  Perform serum pregnancy test in females of childbea ring potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Record the visit in IWRS and dispense investigational product and atorvastatin (if applicable) as instructed .  
â€¢ Reiterate dosing instructions for investigational product and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product or atorvastatin (if applicable) or on the 
morning of the next visit 
âˆ’ To bring the investigational product and atorvastatin (if applicable) bottle(s); s/h e 
will dose at the clinic  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior 
to all study visits, but water is permitted.  
9.7.19. LTSE Month 12 Visit Procedures  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
âˆ’ If the subject reports having eaten within [ADDRESS_755650] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Perform a physical exam ination. 
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pressure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference. 
â€¢ Perform a standard 12 -lead ECG . 
â€¢ Determine alcohol consumption (using AUDIT questionnaire). 
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
â€¢ For participating sites only:  Perform TE 
â€¢ Collect used bottles of investigational product, assess investigational product compliance, and per form investigational product accountability . 
â€¢ Collect used bottles of atorvastatin, assess atorvastatin compliance, and perform 
atorvastatin accountability .  
Page 78 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 79 
 
Confidential and Proprietary  â€¢ Obtain blood samples for:  
âˆ’ Serum chemistry (will include basic lipid panel and liver biochemistry p anel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes 
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10)   
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
âˆ’ Blood sample for future exploratory analysis of biomarkers adiponectin, PAI-1, 
and BNP 
âˆ’ Thyroid Function Tests:  TSH, T4, and T3 
â€¢ Obtain urine sample for urinalysis. 
â€¢ Perform a urine based Î²-hCG pregnancy test in female subjects of childbearing potential.  Pe rform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Record the visit in IWRS and dispense investigational product and atorvastatin (if applicable) as instructed .  
â€¢ Reiterate dosing instructions for investigational product and advise the subject: 
âˆ’ Take the investigational product at approximately the same time each day  
âˆ’ NOT to take investigational product or on the morning of the next visit, and  
âˆ’ To bring the investigational product and atorvastatin (if applicable) bottle(s); s/he 
will dose at the clinic, and  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all study visits, but water is permitted.  
9.7.20. LTSE End of Study /Early Termination  Procedures  
When the LTSE concludes, subjects will be asked to return to the site for EOS  procedures as 
soon as possible.  Subjects who terminate participation in the study during the LTSE should have 
an ET Visit  as soon as possible following the decision to discontinue therapy.  I f the study is 
terminated by [CONTACT_1034] ( Section 7.5), the subjects will be asked to return to the site for the 
ET/EOS procedures as soon as possible.  The procedures to be performed at the LTSE ET/EOS Visit are as follows  
â€¢ Verify that the subject has fasted for at least 8 hours. 
âˆ’ Record fasting status in the source and eCRF . 
Page 79 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 80 
 
Confidential and Proprietary  âˆ’ If the subject reports having eaten within [ADDRESS_755651] that fasting is required prior to all study 
visits, but water is permitted.  
â€¢ Perform a physical examination . 
â€¢ Assess and r ecord vital signs (body temperature, sitting heart rate, respi[INVESTIGATOR_697], 
and sitting blood pr essure). 
â€¢ Assess and record anthropometric measures :  body weight, waist and hip 
circumference. 
â€¢ Perform a standard 12 -lead ECG . 
â€¢ Determine alcohol consumption (using AUDIT questionnaire). 
â€¢ Assess and record AEs. 
â€¢ Review and record concomitant medications . 
â€¢ For participating sites only:  Perform TE  
â€¢ Collect used and unused bottles of investigational product, assess investigational 
product compliance, and perform investigational product accountability. 
â€¢ Collect used and unused bottles of atorvastatin, assess atorvastatin compliance, and perform atorvastatin accountability .  
â€¢ Obtain blood samples for:  
âˆ’ Serum chemistry (will include basic lipid panel and liver biochemistry panel), 
hematology, and coagulation 
âˆ’ Lipoprotein analyses and reverse cholesterol transport analytes  
âˆ’ PD assessments; markers of inflammation, fibrosis and apoptosis; and markers of 
glucose metabolism (see Table 4 and  Table 10) 
âˆ’ Vitamin D  
âˆ’ CPK, if myopathy suspected 
âˆ’ Blood sample for future exploratory analysis of biomarkers adiponectin, PAI-1, and BNP 
âˆ’ Thyroid Function Tests:  TSH, T4, and T3 
â€¢ Obtain urine sample for urinalysis. 
â€¢ Perform a urine based Î²-hCG pregnancy test in female subjects of childbearing potential.  Perform serum pregnancy test in females of childbearing potential if urine 
Î²-hCG pregnancy test is positive. 
â€¢ Record the visit in I WRS. 
Page 80 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 81 
 
Confidential and Proprietary  9.7.21. Unscheduled Safety Visits  
The Investigator may schedule an at -clinic Unscheduled/Safety Visit at any time if clinically 
warranted or requested by [CONTACT_1689].  Unscheduled and/or repeat assessments, 
including additional laboratory tests or investigations, may be conducted.   
An increase in aminotra nsferases (ALT or AST) to >3Ã— baseline (and >ULN) or total bilirubin 
>2Ã— baseline (and >ULN) should be followed by [CONTACT_94525] 48 to 72 hours of the 
serum chemistry to confirm the abnormalities and to determine if they ar e increasing or 
decreasing  (Appendix B ).  AE information should also be collected.  If symptoms persist or 
repeat testing shows ALT >3Ã— baseline (an d >ULN) or total bilirubin >2Ã— baseline (and >ULN), 
subjects should be followed until resolution of the abnormality and as clinically indicated depending on other laboratory and clinical signs and symptoms. 
As appropriate, the Medical Monitor should be contact[INVESTIGATOR_530].  
10. INVESTIGATIONAL PRODUCT AND STUDY MEDICATION 
10.1. Investigational Product (OCA or Placebo)  
Double-Blind Phase:  
Investigational Product will be supplied as white, round, film- coated tablets containing OCA 
5 mg, OCA 10  mg, OCA 25 mg, or placebo.  All tablets will be debossed with â€œINTâ€ on one side 
and â€œ3547â€ on the other side, and will be of the same size and appearance.   The tablets contain 
the following inactive ingredients:  microcrystalline cellulose, sodium starch glycolate, and 
magnesium stearate.  The [ADDRESS_755652] 
tablets will be provided in high-density polyethylene (HDPE) bottles with an induction seal and 
child-resistant caps.  All investigational product will be manufa ctured according to Good 
Manufacturing Practice (GMP).  
LTSE Phase:  
10-mg and 25- mg OCA tablets for the LTSE Phase will be supplied as white tablets.   
â€¢ White OCA tablets are round and debossed with  â€œINTâ€ on one side and â€œ3547â€ on 
the other side. 
The tablets  contain the following inactive ingredients:  microcrystalline cellulose, sodium starch 
glycolate, and magnesium stearate.  The [ADDRESS_755653] 
Page 81 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755654] should be stored in the containers in which they are received from t he 
Sponsorâ€™s supplier, at 15Â°C to 25Â°C. 
10.4. Investigational Product Administration  
Subjects will begin dosing at the clinic following Randomization and will be instructed to take investigational product at approximately the same time each day with water.  Subjects must be 
instructed to swallow one tablet whole; they must not chew, divide, or crush the tablet. 
10.4.1. Investigational Product Dispensation 
On Randomization/Day 1, after confirmation of subject eligibility, the Investigator or designee 
will dispense inv estigational product to the subject.  Before leaving the clinic, study site staff 
will ensure that the subject fully understands the dosing instructions. 
Investigational product will be dispensed at clinic visits after confirmation of continued subject 
compliance and eligibility.  If necessary, in exceptional circumstances, and only after approval 
by [CONTACT_1034], investigational product may be delivered to subjects by [CONTACT_30367], with proper 
precautions and documentation of shippi[INVESTIGATOR_007]. 
10.4.2. Missed Doses  
Subjects who miss a dose of investigational product should be instructed to take it later the same 
day, as soon as they remember.  â€œ Missedâ€ doses should not be taken on a subsequent day (ie, the 
subject should not take more than the prescribed daily dose).  Subjects will be asked to record the day they miss a dose.   
10.5. Atorvastatin Tablets  
Atorvastatin tablets for oral administration contain 10  mg, 20 mg, and 40 mg atorvastatin and the 
following inactive ingredients:  calcium carbonate, USP; candelilla wax, FCC; croscarmellose 
sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS -1-7040 (hypromellose, polyethylene glycol, 
talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion. 
Page 82 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755655] and dosed as instructed by [CONTACT_8784]. 
[IP_ADDRESS]. Atorvastatin Storage 
Atorvastatin should be stored in the containers in which they are received from the Sponsorâ€™s supplier, at the manufacturerâ€™s recommended storage conditions. 
10.5.2. Atorvastatin Administration 
Subjects will be instructed to begin atorvastatin dosing on the day following their Week [ADDRESS_755656]â€™s study visit ( Table 1).  
Atorvastatin can be administered as a single dose with water at any time of the day, with or 
without food. 
10.5.3. Atorvastatin Dispensation 
At the subjectâ€™s Week [ADDRESS_755657]â€™s Week [ADDRESS_755658] compliance and eligibility, a torvastatin will be 
dispensed using IWRS inventory management during study visits. 
10.5.4. Missed Doses of Atorvastatin 
Subjects who miss a dose of atorvastatin should be instructed to take it later the same day, as 
soon as they remember. â€œMissedâ€ doses should not be taken if it has been more than 12 hours 
since when they would normally take it; the next dose should be taken when they would 
normally dose.  Subjects should be instructed not to take [ADDRESS_755659] should be treated symptomatically, and supportive measures instituted as required.  Due 
to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly 
enhance atorvastatin clearance.  
Page 83 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755660] and Atorvastatin Accountability and 
Disposal 
The Sponsorâ€™s representative will ship investigational product and atorvastatin to the study site 
under appropriate storage conditions.  All shipments of investigational product and atorvastatin 
should be unpacked and the contents reviewed immediately upon receipt.  If it is not possible to 
verify the contents immediately, they must be stored under the appropriate storage conditions until verification of the contents is possible (ideally, within 1 business day from receipt).  The 
pharmacist or designee should verify the investigational product and atorvastatin against the 
shipment documentation.  The pharmacist or designee should contact [CONTACT_22095].  
All investigational product and atorvastatin will be provided for use only in this study and is not to be used for any other purpose.  The Investigator or designee will maintain a full record of investigational product and atorvastatin accountability, including records of individual subject 
dispensing and final return or disposition (as directed by [CONTACT_1034]).  
The study monitor, also known as the Clinical Research Associate (CRA), will review 
accountability records against dispensed and in stock investigational product and atorvastatin  
during onsite monitoring visits , at study completion , and in the event of premature  study 
termination .  The CRA will retrieve documentation detailing and confirming the return or 
destruction of investigational product and atorvastatin.  
11. ASSESSMENT OF EFFICACY AND PHARMACOKINE TICS 
11.1. Efficacy Assessments  
An overview of parameters supporting primary, secondary, and exploratory objectives of the 
study are summarized in Table 4.  Samples for the assessment of efficacy variables will be 
collected according to the schedule of study procedures for the double-blind period ( Table 1) and 
LTSE (Table 2).  For a complete list of variables, please refer to Appendix A .  
Page 84 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 85 
 
Confidential and Proprietary  Table 4: List of Planned Assessments  
The efficacy assessments supporting the primary, secondary, and exploratory objectives of the 
study are as follows:  
 Parameters  
Primary Endpoints  
LDL metabolism  LDL cholesterol concentration, particle size, and particle concentration 
Secondary Endpoints  
Lipoprotein metabolism  HDL cholesterol concentration, particle size and particle concentration ; 
VLDL cholesterol concentration, particle size and particle 
concentration ; TG and total cholesterol concentrations; ApoA1, ApoB, 
ApoE, ApoCII, ApoCIII and Lp(a) concentrations ; PCSK9 
concentration  
Reverse cholesterol transport  Pre-Î²1 HDL concentration, macrophage cholesterol efflux; LCAT 
activity; CETP activity  
Exploratory Endpoints  
Liver biochemistry and markers of 
liver functiona Albumin, ALP, ALT  (isoenzymes) , AST, direct bilirubin, GGT, INR, 
total bilirubin  
Markers of liver inflammation  IL-6, hs-CRP, and TNF -Î± 
Marker for hepatic apoptosis and fibrosis CK-18-M30 and CK-18-M65 
Glycemic Controlb Glucose, insulin, C -peptide, HbA1c, HOMA -Î², and HOMA- IR 
OCA pharmacokinetics  OCA, tauro -OCA, glyco -OCA, total OCA , potentially other conjugates 
or metabolites not yet identified  
Atorvastatin bioanalytical concentrations  Atorvastatin and its metabolite s 
Anthropometric measuresc Height, weight, and waist and hip circumference measurements; and 
BMI, and waist -to-hip ratio calculations  
Pharmacodynamics  C4 (7Î±-hydroxy-4-cholesten -3-one) and FGF -19; possible analysis of 
conjugated and unconjugated bile acids  
Noninvasive radiological liver fibrosis measurements  By [CONTACT_783] (where available)  
Cardiovascular risk scores  FRS and Reynolds scores  
ALP = alkaline phosphatase; ALT = alanine aminotransferase; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein 
B; ApoCII = apolipoprotein CII; ApoCIII  = apolipoprotein CIII; ApoE = apolipoprotein E; AST = aspartate 
aminotransferase; BMI = body mass index; C4 = 7Î±- hydroxy-4-cholesten -3-one; CK-18-M30 = cytokeratin -18 
neoepi[INVESTIGATOR_9230] M30; CK-18-M65 = cytokeratin -18 neoepi[INVESTIGATOR_9230] M65 ; CTEP = cholesterol ester transfer protein;  
ECG = electrocardiogram; FGF-19 = fibroblast growth factor -19; FRS = Framingham Risk Score; GGT = gamma -
glutamyl transferase; HbA1c = hemoglobin -specific A1c fraction; HDL = high -density lipoprotein;  
HOMA-Î² = homeostatic model assessment â€“beta-cell function, HOMA-IR = homeostatic model assessment â€“ insulin 
resistance; hs-CRP = high -sensitivity C -reactive protein; IL-6 = interleukin -6; LCAT = lecithin cholesterol 
acyltransferase; LDL = low -density lipoprotein; L p(a) = lipoprotein(a);  PCSK9 = proprotein convertase 
subtilisin/kexin type 9;TE = transient elastography; TEAE = treatment -emergent adverse event; TG = triglycerides; 
TNF-Î± = tumor necrosis factor -Î±; VLDL = very low -density lipoprotein  
Page 85 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 86 
 
Confidential and Proprietary  a  Liver biochemistry panel will be included in the serum biochemistry (see  Table 10). 
b  HOMA-IR is calculated from fasting plasma glucose and fasting serum insulin values . 
c  Height will be measured at Screening only.  BMI and w aist-to-hip ratio will be calculated via EDC from waist and 
hip circumference measurements . 
Please note that there are [ADDRESS_755661] lipid assessments:  the assessment of lipoprotein metabolism 
and the safety lipi[INVESTIGATOR_575563].  The latter will be used for 
randomization and safety assessments and the lipoprotein analysis samples will be used for the 
efficacy assessment.  
11.1.1. Efficacy Laboratory Assessments 
The complete list of planned laboratory assessments supporting primary, secondary, and 
exploratory objectives of the study is shown in Table  4, and includes parameters related to LDL 
metabolism, lipoprotein metabolism, reverse cholesterol transport, liver biochemistry and 
markers of liver function, markers of inflammation, glycemic control, OCA PD markers, and 
NASH disease severity marker s CK-18-M30 and CK -18-M65. 
Fasting (8  hours) blood samples are required for efficacy analyses.  During each visit, the 
Investigator or designee will verify that the subject has fasted for at least [ADDRESS_755662] reports having eaten (water is permitted) 
within [ADDRESS_755663] that fasting is required prior to onsite visits.  
Blood samples w ill be collected at visits indicated in the Schedule of Study Procedures ( Table 1 
and Table 2).   
11.1.2. Liver Biopsy  
Liver biopsy will be scheduled at Screening  Visit 1 for confirmation of NASH (inclusion 
criteria) if no biopsy slides or tissue collected within [ADDRESS_755664] 2 cm in length.  All biopsies will be read centrally by a Sponsor-
designated central reader . 
[IP_ADDRESS]. Central R eading of Liver Histology  
Full instructions concerning the number and type of samples to be collected at each visit, the 
sample collection methods, sample processing, labeling, and shippi[INVESTIGATOR_575564] a study-specific histology m anual. 
All biopsy assessments,  including determination of study eligibility based on NASH diagnosis 
and fibrosis staging during Screening, will be perform ed centrally by [CONTACT_575803].  
The central pathologist must confirm histological presence of NASH and a minimum NAS of [ADDRESS_755665] 1 in each component of NAS.  Key features of NASH (ie, steatosis, 
lobular inflammation, and hepatocellular ballooning) will be graded in accordance with the 
NASH CRN criteria for scoring (Kleiner 2005) as summarized in Table 5.  Fibrosis staging for 
eligibility will also be performed in accordance with NASH CRN criteria for fibrosis staging.   
Page 86 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 87 
 
Confidential and Proprietary  Table 5: NASH CRN Scoring System for Determining Eligibility and Primary 
Histological Endpoint Assessment  
NAFLD Activity Score (NAS)  Fibrosis Staging  
Parameter  Scoring Criteria  Parameter  Staging Criteria  
Steatosis 0 = <5%  
1 = 5% - 33% 
2 = >33% - 66%  
3 = >66%  Stage 0 No Fibrosis  
Lobular 
Inflammation  0 = No Foci  
1 = <2 Foci per 200 Ã— field  
2 = 2 - 4 Foci per 200 Ã— field   
3 = >4 Foci per 200 Ã— field  Stage 1  
Stage 1a 
Stage 1b 
Stage 1c  Perisinusoidal or Periportal 
Mild, zone 3, per isinusoidal  
Moderate, zone 3, perisinusoidal  
Portal / periportal   
Ballooning  0 = None  
1 = Few balloon cells  
2 = Many cells / prominent ballooning  Stage 2 Perisinusoidal and portal / periportal  
Stage 3 Bridging fibrosis  
Stage 4 Cirrhosis  
In addition to the primary scoring system of NASH CRN, biopsy samples will also be scored 
based on modified Ishak scoring ( Ishak 1995 ) for all subjects.  Any extra biopsy tissue may 
undergo exploratory histological evaluations. 
11.1.3. Noninvasive Radiological Liver Fibrosis Measurements 
Liver stiffness will be a ssessed during LTSE using a noninvasive radiological method TE at 
study sites where available.  
11.1.4. Blood Samples for Future Analysis 
Blood samples for exploratory future analysis may be assessed for analytes such as adiponectin, 
plasminogen activator inhibitor -1(PAI-1), and B- type natriuretic peptide (BNP ; Table 10).    
Blood samples may also be used to assess other disease or investigational product characteristics.  
The samples will be stored for up to 1 year after the end of the study and destroyed if not 
analyzed.  
11.2. Pharmacokinetic  and Pharmacodynamic  Assessments  
Parent OCA and its major conjugates (glyco -OCA and tauro- OCA), C4, and FGF-19 
concentrations will be determined for OCA PK and FXR activity in OCA -treated subjects.  
Concentrations of atorvastatin and its metabolites  will be assessed in PK sampled subjects.  
Samples will be obtained for possible assessment of conjugated and unconjugated bile acids. 
11.2.1. Pharmacodynamic Assessments  
PD assessments will be collected according to the Schedule of Study Procedures (Table 1 and  
Table 2) from all subjects to measu re C4, FGF-19, and possibly conjugated and unconjugated 
bile acids (dependent on the results of the C4 and FGF- 19 assessments).  
Page 87 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755666] (predose) 
on Day [ADDRESS_755667] and will remain fasted until after the 1 -hour sample is collected.  A meal 
will be provided following collection of the 1- hour PK sample; the meal will be a meal 
replacement drink with nutrition information that has been submitted to and approved by [CONTACT_22134].  
11.3. Anthropometric Assessments  
Anthropometric measures include height (measured at Screening Visit 1 only), weight, and waist 
and hip circumference measurements.  Waist -to-hip ratio will be calculated by [CONTACT_575804] (EDC) system and will be calculated as ( [Waist Circumference in Centimeters ] / [Hip 
Circumfere nce in Centimeters ]).  Height will also be collected at Screening  Visit 1.  
Anthropometric measures will be performed during the visits indicated in  Table 1 and Table 2.  
11.3.1. BMI 
BMI will be calculated as (Weight in Kilograms / [Height in Meters Ã— Height in Meters ]).   
Instructions for measuring body weight and waist and hip circumference are described below.  All three measures are to be obtained after the subject has fasted for at least [ADDRESS_755668] decimal point (eg, 97.1 kg) by [CONTACT_464].  
11.3.3. Waist and Hip C ircumference:   
The subject should be wearing little clothing and standing upright during the measurements, with 
arms relaxed at the side, feet close together , and body weight evenly distribut ed.  Waist 
circumference should be measured at the end of several consecutive natural breaths, midpoint 
between the top of the iliac crest and the lower margin of the last palpable rib in the mid -axillary 
line.  Hip circumference should be measured at the largest circumference of the buttocks.  Both measurements should be made with a Sponsor-provided measuring tape that is wrapped snugly around the subject, but not to the point that the tape is constricting.  The tape must be level and 
parallel to the floor  at the point of measurement.  Each measurement should be repeated twice; if 
Page 88 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 89 
 
Confidential and Proprietary  the measurements are within 1 cm of one another, the average should be calculated.  If the 
difference between the 2 measurements exceeds 1 cm, the 2 measurements should be repeated.  
12. ASSESSMENT OF SAFETY 
Safety will be monitored and assessed by [CONTACT_2695]/SAEs, medical history, physical examination, 
vital signs measurements, ECG results, and clinical laboratory assessments.  Refer to Section 17.1 for AE reporting procedures.  
12.1. Adverse Events and Serious Adverse Events  
12.1.1. Definition s 
[IP_ADDRESS]. Adverse Event  
An AE is defined as any untoward medical occurrence associated with the use of the investigational product in humans, whether or not considered related to investigational product.  
An AE can be any unfavorable and unintended sign (eg, an abnormal laboratory finding), 
symptom, or disease temporally associated with any use of the investigational product, without 
any judgment about causality and irrespective of route of administration, formulation, or dose, including an overdose.  For this study, investigational product refers to OCA or placebo, and 
study medication refers to  atorvastatin.  
AEs inclu de, but are not limited to: (1) a worsening or change in nature, severity, or frequency of 
condition(s) present at the start of the study; (2) subject deterioration due to primary illness; (3) intercurrent illness; and (4)  drug interaction. 
Subjects should be questioned in a general way, without leading the subject or asking about the 
occurrence of any specific symptom.  The Investigator should attempt to establish a diagnosis of 
the event based on signs, symptoms, and/or other clinical information.  The diagnosis and not the 
individual signs/symptoms should be documented as the AE.  For example, if the underlying disease process is a stroke, it would not be appropriate to record the AE by [CONTACT_22103] â€œsudden numbness, dizziness, and difficulty s peaking.â€  The AE medical term of 
â€œstroke or cerebrovascular accidentâ€ should be recorded as it more accurately describes the AE.  
[IP_ADDRESS]. Treatment -Emergent Adverse Event  
A treatment -emergent AE (TEAE) is any event not present before the initiation of the 
investigational product or any event already present that worsens in either intensity or frequency 
following exposure to the investigational product. 
[IP_ADDRESS]. Serious Adverse Event  
An AE is considered â€˜seriousâ€™ if, in the view of either the Investigator or Sponsor , it results in 
any of the following outcomes: 
â€¢ Death 
â€¢ Is immediately life threatening  
Page 89 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 90 
 
Confidential and Proprietary  â€¢ Requires in -patient hospi[INVESTIGATOR_1081]  
â€¢ Results in persistent or significant disability or incapacity  
â€¢ Results in a congenital abnormality or birth defect 
â€¢ Is an important medical event that may jeopardize the subject or may require medical 
intervention to prevent one of the outcomes listed above 
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]: 
â€¢ Routine monitoring of the studied indication and not associated with any deterioration in condition or AE ; 
â€¢ Elective treatment for a pre-existing condition that did not worsen; 
â€¢ Respi[INVESTIGATOR_22017].  
12.1.2. Relationship to Investigational Product or Study Medication 
The Investigator will document her/his opi[INVESTIGATOR_575565]  (atorvastatin ) using the criteria outlined in  Table 6.  
Each AE will be assessed for relationship to investigational product and atorvastatin independently.  An AE for which there is a â€œreasonable possibilityâ€ that either investigational 
product or atorvastatin caused the AE is otherwise referred to as a suspected adverse reactions 
(SARs).  â€œReasonable possibilityâ€ means there is evidence to suggest a causal relationship 
between the investigational product and/or atorvastatin and the AE.   
If the relationship between a SAE and the investigational product is determined to be â€œ definite,â€ 
â€œprobable,â€ or â€œpossible ,â€ the event will be considered to be related to the investigational product 
for the purpose of assessing expedited regulatory reporting. 
If the relationship between an SAE and the atorvastatin is determined to be â€œdefinite,â€ 
â€œprobable,â€ or â€œpossible,â€ the event will be considered to be related to atorvastatin for the 
purpose of assessing expedited safety  reporting and reporting to the manufacturer. 
Page 90 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 91 
 
Confidential and Proprietary  Table 6: Relationship of Adverse Events to Investigational Product or Study 
Medication  
Relationship  Description  
Definite A reaction that follows a reasonable temporal sequence from administration of the 
investigational product or study medication  in which the investigational product or study 
medication level has been established in body fluids or tissue; that follows a known  or 
expected response pattern to the suspected investigational product or study medication;; and 
that is confirmed by [CONTACT_3895][INVESTIGATOR_575566], and reappearance of the reaction on repeated exposure. 
Probable  A reaction that follows a reasonable temporal sequence from administration of  the 
investigational product or  study medication; that follows a known or expected response 
pattern to the suspected investigational product or study medication; that is confirmed by 
[CONTACT_13635][INVESTIGATOR_575567]; and that 
could not be reasonably explained by [CONTACT_20612]â€™s clinical state.  
Possible A reaction that follows a reasonable temporal sequence from administration of the 
investigational product or study medication; that follows a known or expected response 
pattern to the suspected investigational product or study medication; but that could readily be 
produced by a number of other factors.  
Unlikely An event that does not follow a reasonable temporal sequence from administration of the 
investigational product or study medication; that does not follow a known or suspected 
response pattern to the suspected investigational product or study medication; and that could reasonably be explained by [CONTACT_11176]â€™s clinical state.  
Not Related  Any event that does not meet the above criteria.  
12.1.3. Relationship to Liver Biopsy 
The Investigator will document her/his opi[INVESTIGATOR_575568]  7.  
Table 7: Relationship of Adverse Events to Liver Biopsy  
Relationship  Description  
Definite A reaction that follows a reasonable temporal sequence from the liver biopsy , and that 
follows a known or expected response pattern to the liver biopsy.  
Not Related  Any event that does not meet the above criteria.  
12.1.4. Recording Adverse Event Severity  
AEs must be graded for severity (ie, intensity) using Common Terminology Criteria for Adverse 
Events (CTCE) Version 4.03 ( Appendix C ).  A severity category of mild, moderate, severe, 
life-threatening, or death as defined in Table 8, must be entered on the AE eCRF.  It should be 
noted that the term â€œsevereâ€ used to grade intensity is not synonymous with the term â€œserious.â€  The assessment of severity is made regardless o f investigational product relationship or of the 
seriousness of the AE.  When reporting AEs, reference should be made to the CTCAE manual 
for guidance on appropriate grading. 
Page 91 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 92 
 
Confidential and Proprietary  Table 8: Severity of Adverse Events  
Grade Clinical Description of Severity  
1 = Mild Asymptomatic or mild symptoms, clinical or diagnostic observations only, or intervention 
not indicated.  
2 = Moderate  Minimal, local or noninvasive intervention indicated; or limiting age -appropriate 
instrumental activities of daily living.a 
3 = Severe Medically significant but not immediately life -threatening, hospi[INVESTIGATOR_77081], disabling, or limiting self -care activities of daily living.b 
4 = Life-
Threatening  Urgent intervention indicated  
5 = Death  Death related to AE  
a  Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc.  
b  Self-care activities of daily living refer to bathin g, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.  
[IP_ADDRESS]. Severity of Pruritus (as an AE)  
Pruritus was the most common AE seen in the Phase  2 PBC studies of OCA and thus may occur 
in this study.  
To ensure consistency in reporting, the following guidelines for assessing severity of pruritus 
should be used for AE reporting.  As pruritus is a subjective symptom, clinical judgment should 
be used to determine its severity and management (Table 9).  
Table 9: Severity of Pruritus  
Pruritus Grade  Clinical Description of Severity for Pruritus and Medical Intervention  
1 = Mild Generally localized; causing no limitation of usual activities or minimal sleep disturbance; 
the subject may experience slight discomfort.   
Medicinal intervention is not indicated.  
2 = Moderate  Intense or widespread; causing some limitation of usual acti vities or sleep disturbance; the 
subject may experience annoying discomfort.   
Medicinal intervention may be indicated.  
3 = Severe Intense or widespread and interfering with activities of daily living, ie, causing inability to 
carry out usual activities, or severe sleep disturbance; the subject may experience 
intolerable discomfort.  
Medicinal intervention is typi[INVESTIGATOR_575569].  
Since pruritus is a subjective symptom and the occurrence and magnitude of which are not 
readily measured by [CONTACT_575805], clinical judgment needs to be applied in the management of 
each subject.  Managing OCA -related pruritus may help improve tolerance in those subjects who 
experience problematic pruritus and may otherwise discontinue from the study prematurely.  
General guidance for the management of subjects experiencing significant pruritus includes: 
Page 92 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 93 
 
Confidential and Proprietary  â€¢ Drug holiday:  A drug holiday is defined as an Investigator â€˜prescribedâ€™ complete 
interruption of dosing for 1 or more consecutive days (ie, non-daily dosing does not 
constitute  a drug holiday).  Details of drug holidays and/or nondaily dosing regimens 
should be recorded in the CRF.   Per Section [IP_ADDRESS], subjects with pruritus â‰¥Grade [ADDRESS_755669].     
â€¢ Prescribe BAS.  Subjects taking BAS (including colestyramine and its derivatives, 
colestipol, colesevelam, or other sequestrants) should be instructed to stagger their 
dosing of investigational product, ensuring at least [ADDRESS_755670].   
â€¢ Other therapi[INVESTIGATOR_22023].  
â€¢ Less frequent dosing of investigational product (eg, on alternate days) may be tried, 
after which subjects may return to their original daily dose as soon as tolerated.   
12.1.5. Reporting of Adverse Events and Serious Adverse Events  
[IP_ADDRESS]. Reporting of Adverse Events  
AE data will be collected from the time that signed informed consent is obtained until the subject 
fully completes her/his study participation.  
All AEs, whether believed by [CONTACT_575806], must be documented in the subjectâ€™s medical records, in accordance with the 
Investigatorâ€™s normal clinical practice and  in the eCRF in the EDC system .  Each AE is to be 
evaluated for duration, intensity, frequency, seriousness, outcome, other actions taken, and 
relationship to the investigational product or study medication . 
[IP_ADDRESS]. Reporting of Serious Adverse Events  
In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities for 
immediate reporting of SAEs to the Sponsor.  Immediate  reporting implies within [ADDRESS_755671] be reported to the Sponsor .  SAEs are reported by [CONTACT_22104].  Entering the SAE data into the EDC system will automatically 
notify the Sponsor of the event.  In the event that the EDC system is inaccessible, an SAE may be reported by: 
â€¢ E-mail to the SAE email address:  [EMAIL_380]  
â€¢ Fax using a paper SAE report form:  +[PHONE_352] 
â€¢ Telephone:  +[PHONE_11933]  
If an SAE is reported by [CONTACT_12221], an SAE Report form must also be completed in the EDC system as soon as the EDC system is accessible.  At a minimum, the following information should be provided at the time of the initial report: 
Page 93 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 94 
 
Confidential and Proprietary  â€¢ Subject numbe r  
â€¢ Event term  
â€¢ At least 1 criterion classifying the event as serious  
â€¢ Name [CONTACT_22168]  
â€¢ Causal relationship to the investigational product or study medication  
The Investigator will assess whether the event is causally related to t he investigational product or 
study medication .  The Sponsor will also assess whether the event is causally related to the 
investigational product, in addition to assessing the overall safety profile of the investigational 
product.  The Sponsor will notify the appropriate regulatory agencies as well as all participating 
Investigators of investigational new drug (IND) Safety Reports/Expedited Safety Reports  that 
occur during the study within the time frames required by [CONTACT_22105].  
Following the initial report, any additional information obtained by [CONTACT_575807].  Any supporting source documentation should be faxed to +[PHONE_352] or emailed to [EMAIL_380] as soon as possible.  
The Investigator is responsible for submitting information on IND S afety Reports/Expedited 
Safety Reports received from the Sponsor to her/ his local IRB/IEC , as directed by [CONTACT_575808] . 
Documentation of the submissions to IRBs/IECs must be retained in the appropriate study file(s).  As instructed by [CONTACT_1034], IND Safety Reports/Expedited Safety Reports should be retained 
in the appropriate investigative site study files , or with the IB.  
12.1.6. Additional Investigator Responsibilities for SAEs 
The safety data recorded in the EDC represent the official record of all AEs and SAEs reported 
in the study.  The Investigator should comply with requests by [CONTACT_575809]â€™s AE eCRF in the EDC.  Other supporting 
documents such as radiology reports, hospi[INVESTIGATOR_8838], and autopsy reports should also be provided, when appropriate.  Additionally, upon request by [CONTACT_1034], the Investigator should provide input into the SAE narrative and provide timely information to ensure prompt 
follow-up and closure of the SAE report. 
The Investigator and supporting personnel responsible for subject care should discuss with the 
Medical Monitor any need for supplemental investigations of SAEs.  The results of these 
additional assessments must be reported to the Medical Monitor.   
12.1.7. Notification of Post- Study SAEs  
If an Investigator becomes aware of an SAE that may be attributable to the investigational 
product at any time after the end of the study, the Sponsor should be notified immediately 
(ie, within 24 hours). 
Page 94 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755672] be reported to the Sponsor within 
24 hours by [CONTACT_575810]  [IP_ADDRESS]. 
12.1.8. Follow-Up of Adverse Events and Serious Adverse Events  
All AEs must be followed during the course of the study until the AE resolves, is no longer of clinical concern, has stabilized or is otherwise explained, or the subject is lost to follow-up. 
AEs ongoing at the final visit that are deemed to be â€œpossibly, probably, or definitelyâ€ related or 
of other clinical significance must be followed for as long as necessary to adequately evaluate 
the safety of the subject or until the event stabilizes, resolves, or is no longer of clinical concern.  
If resolved, a resolution date for the AE should be documented in the EDC.  The Investigator 
must ensure that follow-up includes any supplemental investigations indicated to elucidate the nature and/or causality of the AE.  This may include additional laboratory tests or investigations, 
or consultation with other healthcare professionals, as considered clinically appropriate by [CONTACT_737]. 
All subjects sh owing possible drug-induced liver injury should be followed until all 
abnormalities return to normal or to the baseline state.  Drug-induced liver injury may develop or 
progress even after the causative drug has been stopped.  Results should be recorded in the CRF.  
Note that longer follow- up can sometimes reveal an off -drug repetition of what had appeared to 
be drug-induced liver injury, indicating that liver injury was related to underlying liver disease. 
[IP_ADDRESS]. Pregnancy and Follow- Up  
Pregnancies are not consi dered AEs in and of themselves; however, if a female study participant 
becomes pregnant while she is enrolled in the clinical study, she must discontinue treatment with 
investigational product and atorvastatin immediately (see Section [IP_ADDRESS]) and the Sponsor must 
be notified within 24 hours of the Investigatorâ€™s awareness of the pregnancy by [CONTACT_575811].  The Pregnancy Report Form must be emailed to [EMAIL_380]  or faxed to 
+[PHONE_11934].  The subject and neonate must be followed for outcome information and/or as 
considered appropriate by [CONTACT_2725]. 
Women who discontinue the study due to pregnancy may not re-enroll in the study at any point, 
but should continue with the study visit schedule and must be followed by [CONTACT_575812].  Similarly, if a subjectâ€™s pregnancy is terminated early (planned or 
unplanned), the subject will also be removed from the study. 
Completing the Pregnancy Report Form is not a substitute for reporting an AE/SAE if an 
AE/SAE has occurred  related to or concurrent  with the pregnancy.  In the situation when an 
AE/SAE has occurred, the AE/SAE reporting procedures described in Section  17.[ADDRESS_755673] also be 
followed. 
Page 95 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 96 
 
Confidential and Proprietary  12.2. Other Safety Parameters  
12.2.1. Medical History/Demographics  
A complete medical history will be obtained from the subject at Screening Visit 1.  Alcohol 
consumption history will be recorded.  Demographic characteristics (age, gender, race, and 
ethnicity) will be recorded.  
12.2.2. Physical Examination 
To assess for clinical findings, the Investigator or designee will perform a physical examination 
at the timepoints specified in  the Schedule of Study Procedures ( Table 1 and Table 2).  This 
includes height , which is only measured and recorded at Screening  Visit 1.  The physical 
examination must include the following:  
â€¢ General appearance  
â€¢ Height (Screening Visit 1 only) 
â€¢ Weight (and BMI, if applicable) 
â€¢ Skin 
â€¢ Head, eyes, ears, nose, and throat 
â€¢ Neck 
â€¢ Lymph nodes 
â€¢ Chest/Respi[INVESTIGATOR_2133] 
â€¢ Cardiovascular system  
â€¢ Abdominal region 
â€¢ Extremities  
â€¢ Musculoskeletal system  
â€¢ Mental status  
â€¢ Neurological system  
12.2.3. Vital Signs  
Vital signs will be assessed at indicated visits (Table 1 and Table 2 ).  Vital signs include body 
temperature, sitting heart rate, respi[INVESTIGATOR_697] , and sitting blood pressure.  When taking heart 
rate, respi[INVESTIGATOR_697], and blood pressure readings, subjects should be seated quietly for a minimum of [ADDRESS_755674] 12- lead ECGs will be collected at the visits specified in  Table 1 and Table 2.  The 
Investigator or designee will review the 12-lead ECG and findings will be recorded in the e CRF 
as normal, abnormal but not clinically significant, or abnormal and clinically significant .  Any 
Page 96 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 97 
 
Confidential and Proprietary  clinically significant abnormalities on ECGs recorded after Randomization/Day 1 will also be 
documented as AEs and entered on the AE page of the e CRF, whereas abnormalities on ECGs 
up to Randomization/Day 1, prior to administration of the investigational product, will be 
recorded as pre- treatment AEs.  
Investigative sites must retain a copy of all [ADDRESS_755675]â€™s alcohol consumption will be collected during the visits indicated in Table [ADDRESS_755676] (AUDIT).  AUDIT is a 10-item questionnair e that uses the domains of alcohol consumption, drinking behavior, and 
alcohol-related problems ( Saunders 1993).  
12.2.6. Laboratory Assessments 
Except for Screening  Visit 1, subjects will be instructed to attend each study visit in a fasted 
state, and subjects should remain fasted until their blood samples have been collected.  For visits 
that require fasting, the Investigator or designee will verify that the subject has fas ted for at least 
[ADDRESS_755677] reports having eaten 
(water is permitted) within the past [ADDRESS_755678] that fasting is required before all 
study visits  (see Section 9.6.1). 
Blood, and urine samples for laboratory assessments will be collected at the visits specified in  
Table [ADDRESS_755679] of laboratory analytes to be tested is shown in Table 10. 
  
Page 97 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 98 
 
Confidential and Proprietary  Table 10: List of Laboratory Analytes to be Tested 
 Laboratory Assessment  Analyte 
All Subjects  
Serum chemistry  Albumin, BUN, creatinine,  conjugated (  direct) bilirubin, total bilirubin, AST, 
ALT, ALP  (isoenzymes) , GGT, creatine  phosphokinase , electrolytes (calcium, 
chloride, magnesium, phosphorus, potassium, sodium), total protein, 
bicarbonate, free fatty acids; and blood  lipi[INVESTIGATOR_805] (total cholesterol, LDL, HDL, 
and VLDL fractions and  TGs) 
Hematology Hemoglobin, hematocrit, white blood count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), platelets, red blood cell 
count (including MCV, MCH , MCHC) 
Urinalysis  pH, specific gravity, protein, glucose, ketones, bilirubin, blood, microscopic 
exam 
Coagulation  PT, PTT, INR 
Glycemic control measures  Fasting plasma glucose, insulin, C -peptide, HbA1c, HOMA-Î², and HOMA-IR 
Lipoprotein analysisa LDL, HD L, VLDL, total cholesterol, triglycerides, ApoA1, ApoB, ApoE, 
ApoCII, ApoCIII and Lp(a), PCSK9  
Reverse Cholesterol Transport  Pre-Î² HDL, macrophage cholesterol efflux, LCAT and CETP 
Markers of Inflammation  IL-6, hs-CRP, and TNF -Î± 
Markers of fibrosis and apoptosis  CK-18-M30 and CK-18-M65 
Vitamin D levels  Vitamin D  
Thyroid function tests  T3, T4, TSH  
PD Assessment  C4 and FGF-19; possible analysis of conjugated and unconjugated bile acids  
Blood sample for future analysis, 
including markers of cardiovascular risk  Adiponectin, PAI -1, BNP 
Pregnancy Test (female subjects of childbearing potential)  Î²-hCG 
Virus screening tests  Hepatitis B surface antigen, hepatitis C antibody, and HCV ribonucleic acid 
[RNA] 
Subset of Subjects 
PK analytes  OCA, tauro-OCA, glyco -OCA, and possible other conjugates or metabolites 
not yet identified  
Atorvastatin and its metabolite s 
ALP = alkaline phosphatase; ALT = alanine aminotransferase; ApoA1 = apolipoprotein A1;  
ApoB = apolipoprotein B; ApoC I = apolipoprotein C I; ApoCII = apolipoprotein C II; ApoE = apolipoprotein E;  
AST = aspartate aminotransferase; BNP = B -type natriuretic peptide; BUN = blood urea nitrogen; C4 = 7Î± -hydroxy-
4-cholesten -3-one; CETP = cholesterol ester transfer protein;  CK -18-M30 = cytokeratin -18 neoepi[INVESTIGATOR_9230] M30;   
CK-18-M65 = cytokeratin -18 neoepi[INVESTIGATOR_9230] M65; GGT = gamma -glutamyl transferase; HbA1c = hemoglobin -specific 
Page 98 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 99 
 
Confidential and Proprietary  All subjects with laboratory tests containing clinically significant abnormal values are to be 
followed regularly until the values return to normal ranges; until a valid reason, other than 
investigational product related AE, is identified; or until further follow -up is deemed medically 
unnecessary.  
The Investigator should m anage subjects with clinically significant lipoprotein abnormalities 
using local standard of care procedures as appropriate after assessing the individual subjectâ€™s total cardiovascular risk profile. 
Urine-based Î²-hCG pregnancy tests will be performed for female subjects of childbearing 
potential at the visits specified in  Table [ADDRESS_755680] be performed to confirm the result ( Table 1, Table 2, and 
Section 9.7).  If positive, the Sponsor must be notified and the subject will be followed, as 
outlined in Section  [IP_ADDRESS] through pregnancy outcome. 
International normalized ratio (INR) will be calculated based on prothrombin time value by [CONTACT_19979].  HOMA -IR values will be calculated based  on fasting plasma glucose and 
insulin concentrations.  Total OCA will be calculated based on OCA, tauro -OCA, and glyco-
OCA concentrations. 
13. STATISTICS  
13.1. Analysis Sets 
The following subject populations will be used for presentation and analysis of data: 
â€¢ Intent-to-Treat (ITT) Population:  All randomized subjects who receive any amount 
of investigational product will be included in the ITT Population.  Treatment 
assignment will be based on the randomized treatment allocation.   
â€¢ Safety Population:  The Safety Population will include all subje cts who receive any 
amount of investigational product.  Treatment assignment will be based on the treatment actually received.  The Safety Population will be used for the analysis of all 
safety data.  
â€¢ Efficacy Evaluable Population:  All subjects who complete the double-blind phase 
according to the indicated doses of investigational product and atorvastatin without A1c fraction;  HDL = high -density lipoprotein; HOMA-Î² = homeostatic model assessment â€“beta-cell function ;  
HOMA-IR = homeostatic model assessment â€“ insulin resistance; hs-CRP = high -sensitivity C -reactive protein;  
IL-6 = interleukin -6; INR = international normalized ratio; LCAT = lecithin cholesterol acyltransferase;  
LDL = low -density lipoprotein; L p(a) = lipoprotein(a); MCH = mean corpuscular hemoglobin; MCHC = mean 
corpuscular hemoglobin concentration; MCV = mean corpuscular volume; PAI- 1 = plasminogen activator 
inhibitor-1; PCSK9 = proprotein convertase subtilisin/kexin  type 9; PK = pharmacokinetic; PT = pr othrombin time;  
PTT = partial thromboplastin time; Pre-Î²-HDL = pre-Î²-high-density lipoprotein; TGs = triglycerides;  
T3 = triiodothyronine; T4 = thyroxine; TNF -Î± = tumor necrosis factor -Î±; TSH = thyroid -stimulating hormone; 
VLDL = very low -density lipoprotein  
a  NMR-based panel will be used for LDL, HDL, and VLDL cholesterol concentrations, particle sizes, and particle 
concentrations . ApoA1, ApoB, ApoE , ApoCII, ApoCIII Lp(a ), and PCSK9  concentrations  will be measured using 
appropriate methods at central or specialty laboratories .  Serum chemistry panel will be used for LDL, HDL, 
VLDL, TG, and total cholesterol concentration.  
Page 99 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 100 
 
Confidential and Proprietary  any significant protocol deviations.  The Efficacy Evaluable Population will be the 
primary population used for efficacy analyses.  
â€¢ Pharmacokinetic Populations :  The OCA PK Population will include all OCA 
subjects who consent to participate in the PK assessments and have at least one 
confirmed fasted analyzable sample.  Subjects must have been fasting for approximately [ADDRESS_755681] one confirmed fasted analyzable sample.  
â€¢ LTSE Pop ulation:  All subjects who receive any amount of investigational product as 
part of the LTSE will be included in the LTSE Population. 
13.2. Determination of Sample Size  
It is the intent of this study to characterize the components of LDL metabolism (cholesterol concentration, particle size, particle concentration ) in subjects with NASH before and after 
treatment with OCA and to assess the changes induced by [CONTACT_575768]  A reductase inhibitor 
(atorvastatin) therapy.  Assuming, 22 mg/dL increase from baseline with a standard deviation 
of 24 in LDL c in the OCA 25 mg  group without atorvastatin therapy after 16 weeks of treatment 
based on data from FLINT , a sample size of 2 0 subjects per group will provide greater than 
97.3% power to demonstrate the statistically  significant difference of LDL c increase from 
baseline with a 2-sided type  I error of 0.05.   
13.3. General Statistical Considerations  
A Statistical Analysis Plan (SAP), providing details about the specific planned analyses and 
statistical tests for both the double -blind phase and the LTSE phase, will be prepared and 
approved by [CONTACT_575813].  
13.4. Handling of Dropout and Missing Data  
Primary analysis of efficacy endpoints will be done using observed data only; missing values will not be imputed.  A sensitivity analysis using a last observation carried forward approach 
may be considered.  
13.5. Subject Population and Demographic Characteristics  
Approximately [ADDRESS_755682].  Demographic characteristics including age, gender, race, and ethnicity 
will be summarized descriptively.  
13.6. Efficacy Analysis  
All efficacy analyses will be conducted using the Efficacy Evaluable Population.  In addition, the 
ITT Population will be used for sensitivity analysis of the primary analyses.  
Page 100 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755683] on Day 1 (predose). 
13.6.1. Primary Efficacy Analysis 
The primary efficacy analysis, changes in LDL cholesterol, particle size and particle 
concentration  at Week 16 (end of double- blind phase) compared to Baseline will be summarized 
by [CONTACT_1570]. 
Analyses of observed values will be carried out using an analysis of covariance ( ANCOVA) 
model at each visit with change from baseline as the dependent variable, including treatment 
group and randomization stratification factor as fixed effects and baseline as a covariate.  The 
same analysis will be carried out using percentage change from baseline as the dependent variable. 
Descriptive statistics of the values will be summarized by [CONTACT_6982].  The results, change from baseline, and percentage change from baseline values as well as estimates of least -
square (LS) means, standard errors, and 95% confidence intervals ( CIs) will be presented by 
[CONTACT_1570]. 
The comparison of LDLc change from baseline and percentage change from baseline values 
between each active treatment group and placebo group will be performed as exploratory 
analysis.  Estimates of the LS mean difference between each active treatment group and placebo 
group, the standard error of the difference, and 95% CI of the difference will be presented.  
Sensitivity  analysis for primary efficacy analysis will be performed using the ITT Population. 
13.6.2. Secondary Efficacy Analysis 
The secondary efficacy parameters will be analyzed in the same manner as the primary efficacy variables.  Descriptive  statistics will be generated  and will include change from baseline, 
percentage change from baseline, and estimates of LS means, standard errors, and 95% CIs 
presented by [CONTACT_1570]. 
The secondary parameters related to lipoprotein metabolism include HDL cholesterol 
concentration, particle size and particle concentration ; VLDL cholesterol concentration, particle 
size and particle concentration ; TG and total cholesterol concentrations; and ApoA1, ApoB, 
ApoE, ApoCII, ApoCIII and Lp(a) concentrations. 
The secondary parameters related to reverse cholesterol metabolism include pre -Î²1 HDL 
concentration, macrophage cholesterol efflux , lecithin cholesterol acyltransferase (LCAT) 
activity, cholesterol ester transfer protein (CETP) activity , and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) enzyme levels.  
13.6.3. Additional Exploratory Efficacy Analyses 
[IP_ADDRESS]. Liver Biochemistry, Hepatobiliary Damage, and Liver Function 
The following laboratory parameters will be summarized by [CONTACT_1570]:  ALT, AST, 
gamma-glutamyl transferase ( GGT), alkaline phosphatase ( ALP), total and conjugated ( direct) 
bilirubin, albumin, INR, and platelets.  
Page 101 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 102 
 
Confidential and Proprietary  Analyses of observed laboratory values will be carried out using an ANCOVA model at each 
visit with change from baseline as the dependent variable, including tre atment group and 
randomization stratification factor as fixed effects and baseline as a covariate.  The same analysis 
will be carried out using percentage change from baseline as the dependent variable.  
Descriptive statistics will be used to summarize the laboratory values by [CONTACT_29013].  The results, change from baseline, and percentage change from baseline; as well as estimates of LS means, standard errors, and 95% CIs will be presented by [CONTACT_1570].  
Estimates of the mean difference between each active treatment group and placebo group, the 
standard error of the difference, and 95% CI of the difference will be presented. 
[IP_ADDRESS]. Markers of Inflammation, Fibrosis, and/or Apoptosis 
Markers of hepatic fibrosis, inflammation, and/or apoptosis inc lude IL-6, hs-CRP, TNF -Î±, and 
CK-18-M30 and CK-18-M65.  These biomarkers will be summarized by [CONTACT_575814] -Baseline visit.  The absolute and percentage 
change from baseline will be analyzed usin g the Wilcoxon Rank Sum Test to compare treatment 
groups.  The median differences and 95% CI of the median differences between treatment groups 
will be constructed using a Hodges-Lehmann estimate.  If the median differences between 
treatments are not symmetrical around the median, the Sign Test may be used. 
[IP_ADDRESS]. Glycemic Control Measures  
Glycemic control measures include fasting glucose, fasting insulin, C -peptide, HbA1c, 
HOMA-Î², and HOMA- IR.  These measures will be summarized by [CONTACT_575815] -study evaluation.  The change from baseline will 
also be summarized.  Baseline is defined as the last fasting assessment prior to tre atment.  
Treatment groups will be compared using an ANCOVA model at each visit with change from baseline as the dependent variable, including treatment group and randomization stratification 
factor as fixed effects and baseline as a covariate.  The same an alysis will be carried out using 
percentage change from baseline as the dependent variable.  Estimates of LS means, standard 
errors, and 95% CIs will be presented by [CONTACT_1570].  Estimates of the mean difference between each active treatment group and  placebo group, the standard error of the difference, and 
95% CI of the difference will be presented.  The distribution of glycemic control measures will 
be evaluated for normality assumptions.  If normality assumptions are violated, non- parametric 
methods, such as a rank ANCOVA model, will be used. 
Subgroup analyses will also be presented by [CONTACT_284680], excluding the randomization 
stratification factor from the ANCOVA model.  
[IP_ADDRESS]. Anthropometric Measures and Blood Pressure  
Anthropometric measures include he ight (measured and recorded only at Screening Visit  1), 
body weight, and waist and hip circumference measurements; and BMI  and waist -to-hip ratio 
calculations .  Anthropometric and blood pressure measures will be summarized by [CONTACT_575816] -study evaluation.  The change from 
Baseline will also be summarized.  Baseline is defined as the last assessment prior to treatment.  
Treatment groups will be compared using an ANCOVA model at each visit with chang e from 
Page 102 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755684] errors, and 95% CIs will be presented by [CONTACT_1570].  Estimates of the mean difference 
between each active treatment group and placebo group, the standard error of the difference, and 
95% CI of the difference will be presented.   
Subgroup analyses will also be presented by [CONTACT_284680], excluding the randomization 
stratification factor from the ANCOVA model.  Subgroup analyses of blood pressure will also be 
presented by [CONTACT_575817]. 
[IP_ADDRESS]. Noninvasive Radiological Liver Fibrosis Measurements  
Noninvasive radiological methods to assess liver stiffness will be conducted at selected centers 
where the devices are available.  These assessments include TE.  Measurements (based on 
available data) will be summarized by [CONTACT_575818] -Baseline Visit.  The proportion of fibrosis improvement based on TE measurement 
will be summarized by [CONTACT_431842] 16 of the double-blind phase, and year 1 and 
year 2 of the LTSE phase .  The correlation with histological assessment based on biopsy at 
Baseline will also be assessed . 
[IP_ADDRESS]. Pharmacodynamic Analysis 
C4, FGF-19, conjugated and unconjugated bile acids, and total bile acids will be summarized by 
[CONTACT_22113] -Baseline Visit.  
The absolute change from baseline will also be summarized.  Baseline is defined as the mean of 
all available evaluations prior to treatment.   
[IP_ADDRESS]. Pharmacokinetic Analysis 
The PK Population will be used for analysis of PK parameters, which include plasma OCA 
(parent) and its conjugates (glyco -OCA and tauro -OCA), total OCA, atorvastatin and its 
metabolite s, and potentially other analytes  not yet identified.  PK analysis will be conducted 
using standard non- compartmental method ologies.   
For the analysis of OCA and its conjugates, values will be summarized by [CONTACT_575819].  Only samples that have a confirmed fasting of approximately 8  hours 
or more before their visit will be included in the analysis.   
Further details regarding the methods for calculating PK and the specific parameter s to be 
reported will be described in the SAP.  
[IP_ADDRESS]. Cardiovascular R isk Scores  
The cardiovascular risk score include s the FRS and Reynolds scores.  Each score is derived from 
a subjectâ€™s age, sex, smoking status, total cholesterol and HDL levels, and other factors including 
family history, BMI, ethnicity, and medications.  C ardiovascular scores will be calculated at the 
time of data analysis.   These markers will be summarized by [CONTACT_575820] 103 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 104 
 
Confidential and Proprietary  statistics at Baseline and at each on -study evaluation.  The change and percentage change from 
Baseline will also be summarized.  
13.6.4. LTSE Analyses  
Similar analyses to that which are described ab ove will be conducted for the LTSE using the 
double-blind baseline value.  Analyses based on the double- blind baseline will be  performed 
using randomized treatment groups (placebo, OCA 5 mg, OCA 10 mg, or 
OCA 25 mg).   Sensitivity analyses may be conducted using the last value prior to first dose in 
the LTSE for all subjects.   
13.7. Safety Analysis 
Safety data, including AEs and clinical laboratory observations, will be summarized by [CONTACT_575821].  The evaluation of safety data will be conducted for both the 
end of double-blind phase and final analyses at the end of the LTSE.  
13.7.1. Adverse Events  
AEs will be coded using the Medical Dictionary of Regulatory Activities (MedDRA).  Summary 
tables of TEAEs will be provided.  The incidence of TE AEs and SAEs will be tabulated by 
[CONTACT_20623], and by [CONTACT_575822].  Tables of TEAEs leading to investigational product discontinuation and SAEs will 
be provided.  The incidence o f pre-treatment AEs and pre- treatment SAEs occurring after ICF 
signoff and before the first dosing of investigational product (OCA or placebo) will be tabulated 
in the same manner as above for all subjects participating in the washout period. 
13.7.2. Clinical Labo ratory Evaluations 
Laboratory parameters will be summarized by [CONTACT_575823]- Baseline Visit.  The absolute change from Baseline will also 
be summarized.  Baseline is defined as the mean of all available evaluations  (using fasting blood 
sample values for lipi[INVESTIGATOR_442093]) prior to treatment.  
In addition, shift tables (ie, low-normal-high at Baseline versus low-normal-high at post- Baseline 
Visit in a 3-by-3 contingency table) from Baseline to worst value, last value, and at each 
scheduled post- Baseline Visit will be provided for hematology, coagulation, and serum 
chemistry by [CONTACT_575824]-study evaluation. 
13.7.3. Lipoprotein Evaluations 
Serum chemistry based assessments are the standard safety tool for monitoring subjectsâ€™ serum 
lipi[INVESTIGATOR_805].  Baseline is defined as the last fasting assessment prior to treatment.  This analysis will 
only include samples that have a confirmed fasting of approximately 8  hours or more prior to the 
visit at which they were collected .  Further analyses of lipoprotein analytes will be specified in 
the SAP. 
Subgroup analyses will also be presented by [CONTACT_575825].  
Page 104 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 105 
 
Confidential and Proprietary  13.7.4. Additional Safety Analysis  
[IP_ADDRESS]. Vital Signs  
The results and change from baseline to each on -study evaluation visit will be summarized for 
body temperature, sitting heart rate, and respi[INVESTIGATOR_697].   
[IP_ADDRESS]. Electrocardiograms   
The ECG data analysis will b e conducted based on methodology recommended in the 
International Conference on Harmonisation ( ICH) E14 guideline, The Clinical Evaluation of 
QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs.   
Baseline is defined as the  mean of all available evaluations prior to treatment.  Descriptive 
statistics of ECG parameters (time between 2 consecutive R waves [RR], PR, QRS, QT, and QT 
interval corrected by [CONTACT_6550]â€™s formula [QTcF]) at baseline and at each post -baseline timepoint 
will be summarized by [CONTACT_1570]; absolute changes from baseline will also be 
summarized.   
A categorical summary of abnormal QTcF values will be presented by [CONTACT_1570].  The 
number of patients with values of >450 msec, >480 msec, and >500 msec will be presented, and the number of patients with change from baseline values of >30 msec and >60 msec will also be 
presented.   
Overall interpretatio n results for ECGs and the I nvestigator interpretation results are collected as 
normal, abnormal not clinically significant, and abnormal clinically significant.  Subjects whose 
interpretation shifts from normal to abnormal will be listed separately including description of 
the abnormality and any associated comments.  
13.7.5. Adjudicated Cardiovascular Events 
Adjudicated cardiovascular events include core major adverse cardiovascular events ( MACE; 
cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) and expanded MACE (unstable angina requiring hospi[INVESTIGATOR_059], transient ischemic attack, peripheral or coronary revascularization procedures, hospi[INVESTIGATOR_126042]).  Othe r events 
potentially related to adverse cardiovascular outcomes are defined in Appendix D  and will be 
included in the Cardiovascular Adjudication Committee  (CAC) Charter for adjudication .  
Undetermined cause of death will be classified as a cardiovascular death by [CONTACT_575826]. 
Summaries of adjudicated cardiovascular events will include the incidence of TEAEs and the 
incidence of serious TEAEs.  All summaries of incidence will include the associated exact binomial 95% CI.  
13.8. Data Monitoring Committee  
An independent DMC that includes hepat ologists, pharmaceutical physicians, 
epi[INVESTIGATOR_623]/cardiology expert(s), and statistician(s) not involved in the study as Investigators, or consultants.  The DMC will have oversight over the study conduct as defined by [CONTACT_575827].  All members will hav e considerable experience with clinical study conduct and DMCs.  
Any candidate found to have a conflict of interest or whose name [CONTACT_576375] 105 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755685] treatment information; 
however, the DMC will have access to the database and may unblind individual subject data as 
appropriate.  Summary tables reviewed by [CONTACT_575828], ie, the actual treatment groups are used, but are not identified.  Data reviewed 
during the meetings will include, at a minimum, disposition, demographics, exposure, clinical 
laboratory results, MedDRA coded AEs, and AEs leading to early withdrawal of investigational product.  At each meeting, detailed narratives of interval SAEs (including events resulting in 
death) are reviewed by [CONTACT_277842] a cumulative list of all SAEs.  
The DMC may agree to adjust meeting frequency based upon actual and projected safety and 
efficacy data availability.  
All Investigators and responsible IRBs/IECs will be informed of any decisions made by [CONTACT_575829].  The Investigators will inform the subjects of such actions and the 
protocol, patient information sheet, and ICF will be revised, as appropriate. 
13.9. Adjudication Committees  
All suspected MACE, and drug-related hepatic injury events that occur after administration of 
the first dose of investigational product will be reviewed by [CONTACT_575830], depending on event type, before inclusion in any anal ysis.  The 2 committees and 
event types they are responsible for adjudicating are as follows: 
â€¢ Cardiovascular Adjudication Committee (C AC):  Adjudicates all suspected MACE  
(Appendix D ), including all deaths 
â€¢ Hepatic Safety Committee:  Adjudicates all suspected drug -related hepatic injury events  
Each adjudication committee will have a charter that documents the reporting of events by [CONTACT_3452] ; definition of the suspected events to be adjudicated; supply of source documentation 
to the committee ; and the entire data flow and process from committee membership, review of 
the events by [CONTACT_942], reporting of the final assessment, and the working procedures of the committee.   
The adjudication committee members will include experts with relevant adjudication experience; they will not be involved in the study as Investigators, DMC members, or consultants.  Any candidate found to have a conflict or whos e name [CONTACT_576376] 106 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755686] they will be replaced.  
The adjudication of suspected events will be based on available source documentation, including 
but not limited to individual clinical study data, hospi[INVESTIGATOR_1097], histology, discharge summaries, 
and/or death certificates.  The adjudication committees will not receive any individual subject 
treatment or site -specific information.  The assessment of events will be conducted in 
compliance with study -specific procedures, manuals, GCP, and all other applicable regulatory 
requirements, including the archiving of essential documents.    
14. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
14.1. Study Monitoring  
Study records at each site will be monitored at regular intervals by a representative of the Sponsor, the CRA.  The role of the CRA is to aid the Investigator in the maintenance and documentation of complete, accurate, legibl e, well organized and easily retrievable data.  In 
addition, the CRA will ensure the Investigator's understanding of all applicable regulations concerning the clinical evaluation of the investigational product and will ensure an understanding of the protocol, reporting responsibilities and the validity of the data.  This will include ensuring 
that full and appropriate essential documentation is available. 
In order to perform this role, the CRA must perform source data verification and as such, must 
be given access to the subjectâ€™s primary source documentation (eg, paper or electronic medical 
records such as consent to participate in the study, visit dates, screening and randomization numbers, demographic information, medical history, disease history, physica l examination, vital 
signs, laboratory assessments [copy of laboratory reports], AEs, concomitant medications, dates 
of dispensing investigational product, ECGs, etc) that support data entries in the eCRF.  The 
eCRF must be completed promptly after each visit to allow the progress and results of the study 
to be closely followed by [CONTACT_1689]. 
The Investigator may exercise judgment in allowing the CRA access to particular sections of the 
subject's medical records if these are deemed irrelevant to the performance, observations or 
conduct of this study. 
14.2. Audits and Inspections  
The Investigator should understand that it may be necessary for the Sponsor, the IRB /IEC and/or 
a regulatory agency to conduct one or more site audits during or after the study and agrees to allow access to all study -related documentation and information and be available for discussion 
about the study.   
15. QUALITY CONTROL AND QUALITY ASSURANCE  
Logic and consistency checks will be performed on all data entered into the e CRF or ultimately 
transferred into the database to ensure accuracy and completeness.   
Training sessions, regular monitoring of the study at the study site by [CONTACT_22121] (eg, CRA), instruction manuals, data verification, cross-checking and dat a audits will 
Page 107 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 108 
 
Confidential and Proprietary  be performed to ensure quality of all study data.  Investigatorsâ€™ meetings and/or onsite study 
initiations will be performed to prepare Investigators and other study site personnel for 
appropriate collection of study data. 
To ensure compliance with GCP and all applicable regulatory requirements, the Sponsor may 
conduct a quality assurance audit.  
16. ETHICS 
16.1. Ethics Review  
The final study protocol, including the final version of the ICF and/or other subject information, 
must be approved or given a favorable opi[INVESTIGATOR_3952] /IEC as appropriate.  The 
Investigator must submit written IRB/IEC approval to the Sponsor before he or she can enroll 
any subject into the study.  The Investigator is responsible for providing the IB and any other 
available safety information and information about payments and compensation available to 
study subjects to the ethics committee for review.  
The Investigator is responsible for informing the IRB/IEC of any amendment to the protocol in accordance with local requ irements.  A favorable opi[INVESTIGATOR_575570], unless the amendment is necessary to reduce immediate risk to 
study participants.  In addition, the IRB/IEC must approve all advertising used to recruit subj ects 
for the study.  The protocol must be reapproved by [CONTACT_1201]/IEC upon receipt of amendments and 
annually, as local regulations require. 
The Investigator is also responsible for providing the IRB/IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the investigational product.  The Sponsor will provide this information to the Investigator. 
Progress reports and notifications of SARs will be provided to the IRB/IEC according to local 
regulations and guidelines.  Investigators or the Sponsor or its designee will provide reports to the IRB/IEC as requested, as a minimum annually, and after the study is complete.  
16.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that h ave their origin in the 
Declaration of Helsinki and are consistent with ICH/GCP, applicable regulatory requirements, and the Sponsorâ€™s policies. 
16.3. Written Informed Consent  
The Investigator(s) at each center will ensure that the subject is given full and adequate oral and 
written information about the nature, purpose, possible risk and benefit of the study.  Subjects 
must also be notified that they are free to discontinue from the study at any time.  The subject should be given the opportunity to ask questions and allowed time to consider the information 
provided. 
The subjectâ€™s signed and dated ICF must be obtained before conducting any study procedures. 
Page 108 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 109 
 
Confidential and Proprietary  The Investigator(s) must maintain the original, signed ICF.  A copy of the ICF must be given to 
the subject. 
16.4. Subject Confidentiality and Data Protection  
All information obtained during the conduct of the study with respect to the subject will be 
regarded as confidential and confidentiality of all subjects will be maintained.  Monitors (eg, CRA, Medical Monitor), auditors and inspectors will require access to a subjectâ€™s medical notes 
for the purpose of source document verification but the subjectâ€™s confidentiality will be 
maintained at all times.  An agreement for disclosure of any such information will be ob tained in 
writing and is included in the statement of informed consent.  The study data shall not be 
disclosed to a third party (with the exception of auditors and/or regulatory authorities) without 
the written consent of the Sponsor.  All reports and comm unications relating to subjects in this 
study that are disclosed to an authorized third party will identify subjects only by [CONTACT_575831] a secure manner.  All data shall be secured against 
unauthorized access. 
The Investigator will maintain a list of subject names and identifying information (eg, subjectsâ€™ 
hospi[INVESTIGATOR_42871], unique subject numbers).  This list will not be collected by [CONTACT_1034]. The written information sheet will explain that study data will be stored  in a computer database, 
maintaining confidentiality in accordance with national data protection legislation.  All data 
computer processed by [CONTACT_575832]/randomization code/site number, only.   
When personal subject data are stored or processed by [CONTACT_22123], the data must be protected to 
prevent their disclosure to unauthorized third parties.  The pertinent sections of the data 
protection laws in which the country is being conducted will be complied with in full. 
The written information sheet and ICF will explain that, for data verification purposes, 
authorized representatives of the Sponsor, a regulatory authority, or an IRB/IEC may require 
direct access to parts of the hospi[INVESTIGATOR_575571], including subject medical history.  
17. INVESTIGATOR OBLIGAT IONS 
The Investigator or a medically trained designee will be responsible for obtaining written 
informed consent and for the care of the subjects for the duration of the study .  If the Investigator 
is not present at the study site during the assessment, he or she will leave instructions for the 
study site staff and a telephone number where he or she can be reached.  
Named physician(s) will be responsible for the medical follow -up of subjects, as applicable. 
17.1. AE Reporting 
The Investigator is responsible for recording AEs reported by [CONTACT_575833].  In agreeing to the provisions of this protocol, the Investigator 
accepts all legal responsib ilities for immediate reporting of SAEs to the Sponsor. 
Page 109 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755687] without 
proper notification to the Sponsor (or designee).  Only the Sponsor may amend the protocol.  
Any change in study conduct considered necessary by [CONTACT_22125], who will then issue a formal protocol amendment to implement 
the change and obtain regulatory approval.  The only exception is when the Investigator 
considers a subjectâ€™s safety to be compromised if immediate action is not taken. 
17.3. Regulatory Documentation  
The following regulatory documentation must be completed or provided, and maintained: 
â€¢ Approved Patient Information Sheets and ICF (all versions) 
â€¢ IRB/IEC approvals (of protocol/amendments, subject questionnaires, etc.) 
â€¢ Form FDA 1572  
â€¢ Current medical license of Principal Investigator s 
â€¢ Curriculum vitae  of Principal Investigator s 
â€¢ Laboratory certification and reference ranges  
â€¢ Financial disclosure forms 
17.4. Ethics Review  
Please see Section 16.1 for the I nvestigatorâ€™s responsibilities regarding ethics review.  
17.5. Archiving and Record Retention  
The Investigator should retain all correspondence relating to this study in the Investigator Site 
File (ISF).  Any study documents stored elsewhere should have their location referenced in the ISF. 
All documents relating to the study inclu ding the ISF itself, source documents and subject 
medical files, completed study subject log and confidential subject identification list will be retained by [CONTACT_941] I nvestigator in accordance with regulations.  US Federal regulations require that 
records of d rug disposition, eCRFs, source documents, and all reports of this investig ation shall 
be retained by [CONTACT_941] I nvestigator for a minimum of [ADDRESS_755688] been notified of the study's termination, or [ADDRESS_755689] be notified of the individual who will be 
assuming this responsibility.  In the e vent that storage of records becomes a problem at any time 
during this period, the Sponsor should be consulted for assistance.  At the end of the minimum 
period, the Investigator should obtain written authorization from the Sponsor prior to the 
destruction of any records.  The I nvestigator will notify the Sponsor if ownership of documents 
or responsibility for the study site is transfe rred.  The Sponsor will inform Investigators should it 
become aware of any changes in storage requirements.  
Page 110 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 111 
 
Confidential and Proprietary  18. PUBLICATION POLI CY 
The Sponsor intends to publish the results of all of the clinical studies that it Sponsors consistent 
with the Declaration of Helsinki ( 64th WMA General Assembly, Fortaleza, Brazil, 
October 2013).  Consistent with the recommendations of the editors of s everal leading medical 
journals, the International Committee of Medical Journal Editors (ICMJE), authorship of publications resulting from Intercept sponsored studies should fairly recognize the activities of 
those that have made a significant contribution to the study (http://www.icmje.org).  Thus, it is 
anticipated that authorship will reflect the contribution made by [CONTACT_22127], the Investigators and others involved, such as statisticians. 
In recent years, issues about conflicts of interest and accuracy of the study data have been raised 
in the medical press.  Accordingly, the Sponsor has developed publication guidelines for clinical studies that are appropriate for this study.  Key issues include the following: 
â€¢ Clinical Study Registries (eg, clinicaltrials.gov):  A description of the study and 
relevant design elements (eg, basic design, objectives and endpoints, sample size, 
study population, and key inclusion/exclusion criteria) and results (when available) will be published online in a manner consistent with applicable regulatory guidelines. 
â€¢ Overview:  Investigators, reviewers , and editors will have the right to audit the data to 
verify its accuracy.  
â€¢ Responsibility:  Each Investigator is responsible for the accuracy and completeness of 
all data from her/his site.  The Sponsor (or its representatives) is responsible for the 
accuracy of the data entered into the study databases and the analyses conducted.  
â€¢ Data Management:  The Sponsor will establish data management and the SAP.  The 
Investigators will have the opportunity to provide input into the plans.  The 
Investigators will have the right to review the audit reports and data resolution 
decisions before the establishment of a clean file.  The Investigators will have the 
right to appoint appropriately qualified auditors, with GCP experience, to audit the Sponsorâ€™s data before the establishment of a clean file.  The Investigators must 
provide adequate notice (at least 2 months) to the Sponsor of their intention to audit a 
study.  The audit should be conducted in a timely manner to allow the resolution of discrepancies before a clean file is established.  The Investigators will bear all the 
costs for the conduct of audits that they initiate, except those related to the resolution 
of data queries which the Sponsor will bear.  Such audits must be conducted in such a manner as to minimize the time to create the clean file.  
â€¢ Authorship:  The Sponsor, in collaboration with the Investigators, will establish the 
appropriate authorship and responsibility for drafting study documents in accordance 
with the principles of the ICMJE.  All manuscripts will be reviewed and agreed upon before submission for publication by [CONTACT_15064]. 
â€¢ Single Center Publication and Additional Publications:  This is a multicenter study  
and is designed to be published with complete data from all the study sites.  Single 
center publications are therefore not considered appropriate.  Any such publications 
should clearly state that the data are â€œextractedâ€ from a multicenter study and that the 
Page 111 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 112 
 
Confidential and Proprietary  study was not intended, or statistically powered, for data presentation by a single 
study site.  
â€¢ Intercept Review of External Manuscripts:  Consistent with this, Investigators must submit any drafts of any publications or presentations that may arise from this study 
to the Sponsor for review and approval and to ensure consistency with the policy in this protocol at least [ADDRESS_755690] facts and to 
represent its, or the Publication Committeeâ€™s, opi[INVESTIGATOR_575572]. 
â€¢ Confidentiality:  Investigators will conduct all interactions with the company and 
with third parties consistent with the executed confidentiality agreements.  While 
publication, by [CONTACT_7586], presents the critical scientific data in a public forum, some information (such as future plans, results of preclinical studies, or chemical formulae) 
may still need to remain confidential.  
â€¢ Medical Jo urnal Review:  Upon request, all pertinent study data and information will 
be made available as supplemental information for journal editors and reviewers to 
evaluate and audit  (eg, protocol and amendments, data tabulations, etc).  
Arrangements will be mad e to maintain the confidentiality of such supplemental 
information.  Arrangements will also be made to maintain the confidentiality of the identity of journal reviewers.  Records will be maintained of which documents and datasets were reviewed . 
Page 112 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755691] OF REF ERENCES  
Adorini L, Pruzanski M, Shapi[INVESTIGATOR_2152] D. Farnesoid X receptor targeting to treat nonalcoholic 
steatohepatitis. Drug Discov Today. 2012 Sep;17(17-18):988-997. 
Albanis E, Alvarez CE, Pruzanski M, et al. INT- 747, a novel FXR activator, reverses hepatic 
fibrosis and cirrhosis in thiocetamideinduced liver injury in rats. Hepatology. 
2005;42(Supplement 1):Abstract 1040. 
American Diabetes Association.  Standards of medical care in diabetes -2013. Diabetes Care.  
2013;36(Suppl 1):S11-S66. 
Angulo P. Clinical trials: Trial design in NASH â€“realities and challenges. NatRev.  Gastroenterol 
Hepatol. 2011 Aug;8(8):424-425. 
Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long- term statin treatment 
for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the 
Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010 Dec 4;376(9756):1916-1922. 
Belfort R, Harrison SA, Brown K, et al. A placebo- controlled trial of pi[INVESTIGATOR_341543] e in subjects 
with nonalcoholic steatohepatitis.  N Engl J Med . 2006 Nov 30;355(22):2297-2307. 
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to 
â€˜cholangitisâ€™. Dig Liver Dis. 2015a;47(11):924-6. 
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to 
â€˜cholangitisâ€™. Gastroenterology. 2015b;149(6):1627-9. 
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 
'cholangitis'. Hepatology. 2015c;62(5):1620-2. 
Calderon RM, Cubeddu LX, Goldberg RB, et al. Statins in the treatment of dyslipi[INVESTIGATOR_575573]: a therapeutic dilemma. Mayo Clinic proceedings. 2010 Apr;85(4):349-356. 
Cariou B, van Harmelen K, Duran- Sandoval D, et al. The farnesoid X receptor modulates 
adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006 Apr 21;281(16):[ZIP_CODE]-
[ZIP_CODE]. 
CEREP. In Vitro pharmacology:High- throughput profile - Study of INT -747. 2008 June 7, 
2008;Study #[ZIP_CODE]. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non- alcoholic fatty 
liver disease: practice Guideline by [CONTACT_66274], 
American College of Gastroenterology, and the American Gastroentero logical Association. 
Hepatology. 2012 Jun;55(6):2005-2023. 
Cromwell WC, Otvos JD, Keyes MJ, et al. LDL Particle Number and Risk of Future 
Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL 
Management. J Clin Lipi[INVESTIGATOR_37487]. 2007 Dec;1(6):583-592. 
Desai CS, Martin SS, Blumenthal RS.  Non-cardiovascular effects associated with statins.  BMJ 
2014;349:g3743. 
Page 113 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755692] predictor for disease-
specific mortality in NAFLD after up to 33 years of follow -up. Hepatology. 2015;61:1547-1554. 
Ertle J, Dechene A, Sowa JP, et al. Non -alcoholic fatty liver disease progresses to hepatocellular 
carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011 May 15;128(10):2436-2443. 
FDA. Guidance  for Industry Drug-Induced Liver Injury:Premarketing Clinical Evaluation. Drug 
Safety Report. [ADDRESS_755693] growth factor 19 increases metabolic rate and 
reverses dietary and leptin -deficient diabetes. Endocrinology. 2004 Jun;145(6):2594-2603. 
Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011 Apr;60(4):463-472. 
Gautier T, de Haan W, Grober J, et al. Farnesoid X receptor activation increases cholesteryl ester 
transfer protein expression in humans and transgenic mice. J Lipid Res. 2013 Aug;54(8):2195-2205. 
Hartman HB, Gardell SJ, Petucci CJ, et al. Activation of farnesoid X receptor prevents 
atherosclerotic lesion formation in LDLR -/- and apoE -/- mice. J Lipid Res. 2009 Jun;50(6):1090-
1100. 
Jackevicius CA, Chou MM, Ross JS, et al. Generic atorvastatin and health care costs.  N Engl J 
Med. 2012 Jan 19;366(3):201-204. 
Jackevicius CA, Tu JV, Krumholz HM. Statins: is it safe and effective to use generic 
"equivalents"? Can J Cardiol . 2013 Apr;29(4):408-410. 
Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by [CONTACT_575834]. Clin Lab Med. 2006 Dec;26(4):847-870. 
Kleiner D, Brunt E, Van Natta M, et al. Design and Validation of a Histological Scoring System 
for Nonalcoholic Fatty Liver Disease. Hepatology. 2005;41:1313-1321. 
Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic 
regulation. Physiol Rev. 2009 Jan;89(1):147-191. 
Li YT, Swales KE, Thomas GJ, et al. Farnesoid x receptor ligands inhibit vascular smooth 
muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-2611. 
Loomba R, Sanyal AJ. The global NAFLD epi[INVESTIGATOR_901]. Nat Rev Gastroenterol Hepatol . 2013 
Nov;10(11):686-690. 
Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. 
J Clin Invest. 2006 Apr;116(4):1102-1109. 
Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin 
intolerance:   the Cleveland Clinic experience.  Am Heart J.  2013;166:597-603. 
Page 114 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755694] 19;110(16):2333-2335. 
Mencarelli A, Renga B, Distrutti E, et al. Antiatherosclerotic effect of farnesoid X receptor. 
American journal of physiology Heart and circulatory physiology. 2009 Feb;296(2):H272- H281. 
Miyazaki -Anzai S, Levi M, Kratzer A, et al. Farnesoid X receptor activation prevents the 
development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ Res. 2010 Jun 25;106(12):1807-1817. 
Mookerjee RP, Mehta G, Balasubramaniyan V, et al. Hepatic dimethylarginine-
dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol . 2015;62:325-331. 
Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013 Sep;145(3):574-[ADDRESS_755695];38(4):1008-1017. Neuschwander -Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand 
obeticholic acid for non- cirrhotic, non- alcoholic steatohepatitis (FLINT): a multicentre, 
randomised, placebo-controlled trial. The Lancet. 2014;S0140-6736:1-11. NICE.  Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood 
Lipi[INVESTIGATOR_575574]. National Institute for Health and Clinical Excellence: Guidance. London 2014. 
Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary 
atherosclerosis. N Engl J Med. 2007 Mar 29;356(13):1304-1316. 
Organisation WG. World Gastroenterology Organisation Global Guidelines: nonalcoholic fatty 
liver disease and nonalcholic steatohepatitis. [ADDRESS_755696] coronary events and are favorably changed by [CONTACT_575835] -Density Lipoprotein Intervention Trial. Circulation. 2006 Mar 
28;113(12):1556-1563. 
Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically 
meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012 Aug;16(3):487-504. 
Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-
alcoholic fatt y liver disease. Digestive and liver disease : official journal of the Italian Society of 
Gastroenterology and the Italian Association for the Study of the Liver. 2015 Jan;47(1):4-11. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha -ethyl-chenodeoxycholic acid (6 -ECDCA), a 
potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem . 2002 Aug 
15;45(17):3569-3572. 
Page 115 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 116 
 
Confidential and Proprietary  Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention 
in clinical practice (ver sion 2012). The Fifth Joint Task Force of the European Society of 
Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice 
(constituted by [CONTACT_522675]). Eur Heart J . 2012 
Jul;33(13):1635-1701. 
Rizzo G, Disante M, Mencarelli A, et al. The farnesoid X receptor promotes adipocyte 
differentiation and regulates adipose cell function in vivo. Mol Pharmacol. [ADDRESS_755697];70(4):1164-1173. 
Rizzo G, Passeri D, De Franco F. In vitro human ERG inhibition by [CONTACT_121195] -747. Internal Report 
hERG-001. 2009. 
Rohatgi A, Khera A, Berry JD, et al. HDL Cholesterol Efflux Capacity and Incident 
Cardiovascular Events. N Engl J Med . 2014 Dec 18;371(25):2383-2393. 
Rosenson RS, Baker SK, Jacobson TA et al. An assessmen t by [CONTACT_575836]: 2014 update. J Clin Lipid. 2014;8:S58-S71. 
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pi[INVESTIGATOR_051], vitamin E, or placebo for nonalcoholic 
steatohepatitis. N Engl J Med . 2010 May 6;362(18):1675-1685. 
Saunders JB, Aasland OG, Babor TF. Development of the Alcohol Use Disorders Identification 
Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol 
Consumption-- II. Addiction. 1993 Jun;88(6):791-804. 
Savkur RS, Thomas JS, Bramlett KS, et al. Ligand -dependent coactivation of the human bile 
acid receptor FXR by [CONTACT_27226]- activated receptor gamma coactivator -1alpha. 
J Pharmacol Exp Ther. 2005 Jan;312(1):170-178. 
Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N 
Engl J Med . 2005 Aug 11;353(6):604-615. 
Simic I, Reiner Z. Adverse effects of statins â€“ myths and r eality. Curr Pharm Des . 2015;21:1220-
1226. 
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of 
blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.  J Am 
Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-2934. 
Teramoto T, S awada T, Iwamoto K, et al. Clinical efficacy and tolerability of ezetimibe in 
combination w ith atorvastatin in Japanese patients with hypercholesterolemia-e zetimibe phase 
IV randomized controlled t rial in patients with hypercholesterolemia. Curr Ther Res Clin Exp. 
2012 Feb;73(1- 2):16-40. 
Teramoto T, Takeuchi M, Morisaki Y, et al. Efficacy, safety, tolerability, and pharmacokinetic 
profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipi[INVESTIGATOR_035]. Am J Cardiol . 2014 Jun 15;113(12):2021-2029. 
Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild -to-moderate baseline 
elevations in alanine aminotransferase levels.  Int J Cardiol. [ADDRESS_755698] 9;168(4):3846-3852. 
Page 116 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 117 
 
Confidential and Proprietary  Vernon G, Baranova A, Younossi ZM. Systematic review: the epi[INVESTIGATOR_575575]-alcoholic fatty liver disease and non -alcoholic steatohepatitis in adults.  Aliment 
Pharmacol Ther . 2011 Aug;34(3):274-285. 
Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol. 2009 Dec;297(6):F1587- F1596. 
Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by [CONTACT_575837] X receptor deficiency and inhibited by [CONTACT_575837] X receptor activation in a type 1 diabetes model. Diabetes. 2010 Nov;59(11):2916- 2927. 
Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008 Nov;48(5):1632-1643. 
Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway 
involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004 May;113(10):1408-1418. 
Williams R, Horton R. Liver disease in the [LOCATION_006]: a Lancet Commission. Lancet. 2013 Nov 
9;382(9904):1537-1538. 
Xu J, Stanislaus S, Chinookoswong N, et al. Acute glucose-lowering and insulin- sensitizing 
action of FGF21 in insulin- resistant mouse models --association with liver and adipose tissue 
effects. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1105- E1114. 
Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: 
interprotocol agre ement and ability to predict liver -related mortality. Hepatology. 2011 
Jun;53(6):1874-1882. 
Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort 
study.  Ann Intern Med. 2013:158:526-534.  
Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver 
inflammation and fibrosis in murine model of non- alcoholic steatohepatitis. J Hepatol . 2009 
Aug;51(2):380-388. 
Zhang Y, Lee FY, Barrera G, et al. Activation of the nucl ear receptor FXR improves 
hyperglycemia and hyperlipi[INVESTIGATOR_569919]. Proc Natl Acad Sci U S A. 2006 Jan 
24;103(4):1006-1011. 
Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 2008 Jan 
9;582(1):10-18. 
Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid 
X receptor -mediated hypocholesterolemia.  J Biol Chem. 2010 Jan 29;285(5):3035-3043. 
Page 117 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 118 
 
Confidential and Proprietary  APPENDIX A. AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN 
HEART ASSOCIATION GUIDANCE FOR THE USE  OF 
STATINS  
 
Page 118 of 364
PRACTICE GUIDELINE
2013 ACC/AHA Guideline on the
Treatment of Blood Cholesterol to ReduceAtherosclerotic Cardiovascular Risk in Adults
q
A Report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines
Endorsed by [CONTACT_575838], American Association of Cardiovascular and
Pulmonary Rehabilitation, American Pharmacists Association, American Society for Preventive Cardiology,Association of Black Cardiologists, Preventive Cardiovascular Nurses Association, andWomenHeart: The National Coalition for Women With Heart Disease
Expert Panel
MembersNeil J. Stone, MD, MACP, FAHA, FACC,
Chair
Jennifer G. Robinson, MD, MPH, FAHA,
Vice Chair
Alice H. Lichtenstein, DS C, FAHA, Vice Chair
C. Noel Bairey Merz, MD, FAHA, FACC
Conrad B. Blum, MD, FAHA
Robert H. Eckel, MD, FAHA
Anne C. Goldberg, MD, FACP, FAHA
David Gordon, MD*Daniel Levy, MD*
Donald M. Lloyd-Jones, MD, S CM, FACC,
FAHA
Patrick McBride, MD, MPH, FAHAJ. Sanford Schwartz, MD
Susan T. Shero, MS, RN*
Sidney C. Smith, J
R, MD, FACC, FAHA
Karol Watson, MD, P HD, FACC, FAHA
Peter W. F. Wilson, MD, FAHA
*Ex-Of ï¬cio Members.
Methodology
MembersKaren M. Eddleman, BS
Nicole M. Jarrett
Ken LaBresh, MDLev Nevo, MD
Janusz Wnek, P HD
ACC/AHA Task
Force MembersJeffrey L. Anderson, MD, FACC, FAHA, Chair
Jonathan L. Halperin, MD, FACC, FAHA,
Chair-Elect
Nancy M. Albert, P HD, CCNS, CCRN, FAHA
Biykem Bozkurt, MD, P HD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC
Lesley H. Curtis, P HD, FAHADavid DeMets, P HD
Judith S. Hochman, MD, FACC, FAHA
Richard J. Kovacs, MD, FACC, FAHA
E. Magnus Ohman, MD, FACC
Susan J. Pressler, P HD, RN, FAAN, FAHA
Frank W. Sellke, MD, FACC, FAHA
Win-Kuang Shen, MD, FACC, FAHA
Subcommittee on
Prevention
GuidelinesSidney C. Smith, J R, MD, FACC, FAHA, Chair Gordon F. Tomaselli, MD, FACC, FAHA, Co-Chair
qThe Journal of the American College of Cardiology is published on behalf of
the American College of Cardiology Foundation by [CONTACT_342323].; Circulation
is published on behalf of the American Heart Association, Inc., by [CONTACT_575839]
K l u w e r .T h i si sa no p e na c c e s sa r t i c l eu n d e rt h et e r m so ft h eC r e a t i v eC o m m o n sAttribution Non-Commercial-NoDervis License, which permits use, distribu-tion, and reproduction in any medium, provided that the Contribution isproperly cited, the use is noncommercial, and no modi ï¬cations or adaptations
are made.
This document was approved by [CONTACT_575840] 2013. The Academy of Nutrition and Dietetics af ï¬rms the
value of this guideline.The American College of Cardiology requests that this document be cited as fol-
lows: Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, EckelRH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS,Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the
treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a
report of the American College of Cardiology/American Heart Association TaskForce on Practice Guidelines. J Am Coll Cardiol 2014;63:2889 â€“934.
This article is copublished in Circulation .
Copi[INVESTIGATOR_014]: This document is available on the World Wide Web sites of the American
College of Cardiology (http://www.cardiosource.org) and the American Heart As-
sociation (my.americanheart.org). For copi[INVESTIGATOR_575576], please contact [CONTACT_575841]. Reprint Department, fax ([PHONE_11935], e-mail [EMAIL_10979].
Journal of the American College of Cardiology
/C2112014 The Expert Panel Members
Published by [CONTACT_342323].Vol. 63, No. 25, 2014
ISSN 0735-1097/$36.00
http://dx.doi.org/10.1016/j.jacc.2013.11.002
Page 117 of 356Page 119 of 364
TABLE OF CONTENTS
Preamble and Transition to ACC/AHA Guidelines to
Reduce Cardiovascular Risk . . . . . . . . . . . . . . . . . . . . . . 2890
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2891
1.1. Organization of the Panel . . . . . . . . . . . . . . . . 2891
1.2. Document Review and Approval . . . . . . . . . . 2891
1.3. Scope of Guideline . . . . . . . . . . . . . . . . . . . . . . . 2892
1.4. Methodology and Evidence Review . . . . . . . 2894
2. Overview of the Guideline . . . . . . . . . . . . . . . . . . . . 2895
2.1. Lifestyle as the Foundation for
ASCVD Risk-Reduction Efforts . . . . . . . . . . . . 2895
2.2. Initiation of Statin Therapy . . . . . . . . . . . . . . . 2897
3. Critical Questions and Conclusions . . . . . . . . . . . 2897
3.1. Identi ï¬cation of CQs . . . . . . . . . . . . . . . . . . . . . 2897
3.1.1. CQ1: LDL-C and Non â€“HDL-C Goals in
Secondary Prevention . . . . . . . . . . . . . . . . . 2899
3.1.2. CQ2: LDL-C and Non â€“HDL-C Goals in
Primary Prevention . . . . . . . . . . . . . . . . . . . 2899
3.1.3. CQ3: Ef ï¬cacy and Safety of
Cholesterol-Lowering Medications . . . . . 2899
4. Statin Treatment: Recommendations . . . . . . . . . 2899
4.1. Intensity of Statin Therapy in Primary and
Secondary Prevention . . . . . . . . . . . . . . . . . . . . 2899
4.2. LDL-C and Nonâ€“ HDL-C Treatment Goals . . . . 2901
4.3. Secondary Prevention . . . . . . . . . . . . . . . . . . . . 2902
4.4. Primary Prevention in Individuals â€¡21 Years of
Age With LDL-C â€¡190 mg/dL . . . . . . . . . . . . . . 2903
4.5. Primary Prevention in Individuals With
Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2905
4.6. Primary Prevention in Individuals Without
Diabetes and With LDL-C 70 to 189 mg/dL 2905
4.7. Risk Assessment in Primary Prevention . . . 2906
4.8. Heart Failure and Hemodialysis . . . . . . . . . . . 2907
5. Safety: Recommendations . . . . . . . . . . . . . . . . . . . 2907
6. Managing Statin Therapy:
Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2911
6.1. Monitoring Statin Therapy . . . . . . . . . . . . . . . . 2911
6.2. Optimizing Statin Therapy . . . . . . . . . . . . . . . . 2912
6.3. Insuf ï¬cient Response to Statin Therapy . . 2912
6.3.1. Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2912
6.3.2. Nonstatins Added to Statins or in
Statin-Intolerant Individuals . . . . . . . . . . . 2913
7. Selected Clinical and Population
Subgroups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2913
7.1. Sex and Racial and Ethnic Subgroups . . . . . 2913
7.2. Individuals >75 Years of Age . . . . . . . . . . . . . [ZIP_CODE]. Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2914
9. Evidence Gaps and Future Research Needs . . 2914
10. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2914
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2915
Appendix 1. Author Relationships With Industryand Other Entities (Relevant) . . . . . . . . . . . . . . . . . . . . . 2919
Appendix 2. Expert Reviewer Relationships WithIndustry and Other Entities . . . . . . . . . . . . . . . . . . . . . . . 2922
Appendix 3. Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . 2923
Appendix 4. Evidence Statements . . . . . . . . . . . . . . . . 2923
Appendix 5. Expanded Discussion ofWhat â€™s New in the Guideline . . . . . . . . . . . . . . . . . . . . . . 2932
Preamble and Transition to ACC/AHA
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC)
and the American Heart Association (AHA) are to prevent
cardiovascular diseases; improve the management of peoplewho have these diseases through professional educationand research; and develop guidelines, standards, and pol-icies that promote optimal patient care and cardiovascular
health. Toward these objectives, the ACC and AHA have
collaborated with the National Heart, Lung, and BloodInstitute (NHLBI) and stakeholder and professional or-ganizations to develop clinical practice guidelines forassessment of cardiovascular risk, lifestyle modi ï¬cations to
reduce cardiovascular risk, management of blood choles-terol in adults, and management of overweight and obesityin adults.
In 2008, the NHLBI initiated these guidelines by
[CONTACT_575842]-tions (CQs), interpret the evidence, and craft recommen-dations. In response to the 2011 report from the Instituteof Medicine on the development of trustworthy clinicalguidelines (1), the NHLBI Advisory Council recom-mended that the NHLBI focus speci ï¬cally on reviewing
the highest-quality evidence and partner with other orga-nizations to develop recommendations (2,3). Accordingly,in June [ADDRESS_755699] possible constituency.Recognizing that the Expert Panels/Work Groups did notStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342890
Page 118 of 356Page 120 of 364
consider evidence beyond 2011 (except as speci ï¬ed in the
methodology), the ACC, AHA, and collaborating societies
plan to begin updating these guidelines starting in 2014.
The joint ACC/AHA Task Force on Practice Guide-
lines (Task Force) appointed a subcommittee to shepherdthis transition, communicate the rationale and expectationsto the writing panels and partnering organizations, andexpeditiously publish the documents. The ACC/AHA andpartner organizations recruited a limited number of expert
reviewers for ï¬duciary examination of content, recognizing
that each document had undergone extensive peer review
by [CONTACT_575843], keyfederal agencies, and scienti ï¬c experts. Each writing panel
responded to comments from these reviewers. Clari ï¬ca-
tions were incorporated where appropriate, but there wereno substantive changes because the bulk of the content wasundisputed.
Although the Task Force led the ï¬nal development of
these prevention guidelines, they differ from other ACC/AHA guidelines. First, as opposed to an extensive com-pendium of clinical information, these documents aresigniï¬cantly more limited in scope and focus on selected
CQs on each topic, based on the highest-quality evidenceavailable. Recommendations were derived from randomizedtrials, meta-analyses, and observational studies evaluated for
quality and were not formulated when suf ï¬cient evidence
was not available. Second, the text accompanying each
recommendation is succinct, summarizing the evidence foreach question. The Full Panel/Work Group Reports includemore detailed information about the evidence statementsthat serve as the basis for recommendations. Third, theformat of the recommendations differs from other ACC/AHA guidelines. Each recommendation has been mapped
from the NHLBI grading format to the ACC/AHA Clas-
siï¬cation of Recommendation/Level of Evidence (COR/
LOE) construct ( Table 1 ) and is expressed in both formats.
Because of the inherent differences in grading systems andthe clinical questions driving the recommendations, align-ment between the NHLBI and ACC/AHA formats is insome cases imperfect. Explanations of these variations arenoted in the recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by
[CONTACT_575844] (RWI) are outlined in themethods section of each panel report. These policies werein effect when this effort began in 2008 and throughoutthe writing process and voting on recommendations, untilthe process was transferred to ACC/AHA in 2013. In theinterest of transparency, the ACC/AHA requested that
panel authors resubmit RWI disclosures as of July 2013.
Relationships relevant to this guideline are disclosed inAppendix 1 . None of the ACC/AHA expert reviewers had
relevant RWI ( Appendix 2 ). See Appendix [ADDRESS_755700] of
abbreviations used in the guideline.
Systematic evidence reports and accompanying sum-
mary tables were developed by [CONTACT_575845]. The guideline was reviewed by [CONTACT_197006]/
AHA Task Force and approved by [CONTACT_575846], and the AHA Science Advisory and Coor-dinating Committee. In addition, ACC/AHA soughtendorsement from other stakeholders, including profes-sional organizations. It is the hope of the writing panels,stakeholders, professional organizations, NHLBI, andTask Force that the guidelines will garner the widestpossible readership for the bene ï¬t of patients, providers,
and the public health.
These guidelines are meant to deï¬ ne practices that
meet the needs of patients in most circumstances andare not a replacement for clinical judgment. The ulti-mate decision about care of a particular patient must bemade by [CONTACT_575847]. As a result,situations might arise in which deviations from these
guidelines may be appropriate. These considerations
notwithstanding, in caring for most patients, clinicianscan employ the recommendations con ï¬dently to reduce
the risks of atherosclerotic cardiovascular disease(ASCVD) events.
SeeTables 1a and1bfor an explanation of the NHLBI
recommendation grading methodology.
1. Introduction
1.1. Organization of the Panel
The Blood Cholesterol Expert Panel (Expert Panel) was
originally convened as the Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterolin Adults (Adult Treatment Panel IV) appointed by[CONTACT_15792]. The Expert Panel was composed of 13members and [ADDRESS_755701] information to the full panel in
advance of the deliberations; members with con ï¬‚icts were
asked to recuse themselves from voting on any aspectof the guideline for which a con ï¬‚ict might exist. All 16
members of the NHLBI Adult Treatment Panel IV Panel
transitioned to the ACC/AHA guideline Expert Panel.
Independent contractors performed the systematic reviewwith the assistance of the Expert Panel and providedmethodological guidance to the Expert Panel.
1.2. Document Review and Approval
A formal peer review process was initially completed under
the auspi[INVESTIGATOR_575577] 23 expert re-viewers and representatives of federal agencies. This doc-ument was also reviewed by 4 expert reviewers nominatedby [CONTACT_575848]/AHA. The ACC andJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2891
Page 119 of 356Page 121 of 364
AHA reviewers â€™RWI information is published in this
document ( Appendix 2 ).
This document was approved for publication by [CONTACT_575849], AmericanAssociation of Cardiovascular and Pulmonary Rehabilita-tion, American Pharmacists Association, American Societyfor Preventive Cardiology, Association of Black Cardiol-
ogists, Preventive Cardiovascular Nurses Association, and
WomenHeart: The National Coalition for Women withHeart Disease.
1.3. Scope of Guideline
This guideline is based on the Full Panel Report, which
is provided as an online-only data supplement to theguideline. The Full Panel Report contains background andadditional material related to content, methodology, evi-dence synthesis, rationale, and references and is supportedby [CONTACT_575850], which can befound at http://www.nhlbi.nih.gov/guidelines/cholesterol/ser/ .
Table 2 provides an overview to facilitate understanding
what is new in the present guideline.
The Expert Panel was charged with using data from
randomized controlled trials (RCTs) and systematic reviewsand meta-analyses of RCTs to update the clinical practicerecommendations for the treatment of blood cholesterollevels to reduce ASCVD risk. For this guideline, ASCVDincludes coronary heart disease (CHD), stroke, and pe-ripheral arterial disease, all of presumed atheroscleroticorigin. These recommendations are intended to provide aTable 1. Applying Classi ï¬cation of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efï¬ cacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
failure, and prior aspi[INVESTIGATOR_34308].yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“[ADDRESS_755702] likely
to bene ï¬tfrom cholesterol-lowering statin therapy, the
recommendations will be of value to primary care cliniciansas well as specialists concerned with ASCVD prevention.Importantly, the recommendations were designed to beeasy to use in the clinical setting, facilitating the imple-mentation of a strategy of risk assessment and treatmentfocused on the prevention of ASCVD. The presentguideline is intended to address treatment of adults ( /C2121
years of age) to complement the NHLBI cardiovascular
health risk-reduction guideline for children and adoles-
cents (4).
The members of the Expert Panel acknowledge the
important contributions arising from decades of geneticand biochemical studies, observational epi[INVESTIGATOR_575578], and in vitro and animal experi-ments that associated higher low-density lipoproteincholesterol (LDL-C) levels with greater ASCVD risk.These studies provided the rationale for RCTs, which inturn demonstrated that lowering cholesterol levels reducedASCVD events and thereby [CONTACT_123817] a central, causalrole of atherogenic cholesterol-containing lipoproteinparticles, particularly LDL, in the genesis of CHD andASCVD.
Other strategies for using drug therapy to reduce
ASCVD events have been advocated, including treat-to-cholesterol target, lowest-is-best, and risk-based treat-ment approaches. However, only 1 approach has beenevaluated in multiple RCTs dthe use of ï¬xed doses of
cholesterol-lowering drugs to reduce ASCVD risk. Becausethe overwhelming body of evidence came from statinTable 1a. NHLBI Grading of the Strength of
Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net bene ï¬ty
is substantial.
B Moderate recommendationThere is moderate certainty based on evidence that the net bene ï¬ti s
moderate to substantial, or there is high certainty that the netbeneï¬ t is moderate.
C Weak recommendationThere is at least moderate certainty based on evidence that there is a
small net bene ï¬t.
D Recommendation againstThere is at least moderate certainty based on evidence that
there is no net bene ï¬t or that risks/harms outweigh bene ï¬ts.
E Expert opi[INVESTIGATOR_1649] ( â€œThere is insuf ï¬cient evidence or evidence is
unclear or con ï¬‚icting, but this is what the Work Group
recommends. â€)
Net bene ï¬t is unclear. Balance of bene ï¬ts and harms cannot be
determined because of no evidence, insuf ï¬cient evidence,
unclear evidence, or con ï¬‚icting evidence, but the Work Group
thought it was important to provide clinical guidance andmake a recommendation. Further research is recommendedin this area.
N No recommendation for or against ( â€œThere is insuf ï¬cient evidence or
evidence is unclear or con ï¬‚icting.â€ )
Net bene ï¬t is unclear. Balance of bene ï¬ts and harms cannot be
determined because of no evidence, insuf ï¬cient evidence, unclear
evidence, or con ï¬‚icting evidence, and the Work Group thought
no recommendation should be made. Further research is
recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned with the quality
of the evidence; however, under some circumstances, there may be valid reasons for making
recommendations that are not closely aligned with the quality of the evidence (e.g., strong
recommendation when the evidence quality is moderate, such as smoking cessation to reducecardiovascular disease risk or ordering an ECG as part of the initial diagnostic work-up for a
patient presenting with possible MI). Those situations should be limited and the rationale
explained clearly by [CONTACT_575851].
yNet bene ï¬ti sd e ï¬ned as bene ï¬ts minus risks/harms of the service/intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, National Heart, Lung,
and Blood Institute.Table 1b. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
/C15Well-designed, well-executed yRCT that adequately
represent populations to which the results are applied
and directly assess effects on health outcomes.
/C15Meta-analyses of such studies.
Highly certain about the estimate of effect. Furtherresearch is unlikely to change our con ï¬dence in the
estimate of effect.High
/C15RCT with minor limitations zaffecting con ï¬dence in,
or applicability of, the results.
/C15Well-designed, well-executed nonrandomized controlledstudies xand well-designed, well-executed observational
studies k.
/C15Meta-analyses of such studies.
Moderately certain about the estimate of effect. Furtherresearch may have an impact on our con ï¬dence in the
estimate of effect and may change the estimate.Moderate
/C15RCT with major limitations.
/C15Nonrandomized controlled studies and observationalstudies with major limitations affecting con ï¬dence in,
or applicability of, the results.
/C15Uncontrolled clinical observations without an appropriatecomparison group (e.g., case series, case reports).
/C15Physiological studies in humans.
/C15Meta-analyses of such studies.
Low certainty about the estimate of effect. Further
research is likely to have an impact on our con ï¬dence
in the estimate of effect and is likely to change the
estimate.Low
*In some cases, other evidence, such as large all-or-none case series (e.g., jumpi[INVESTIGATOR_575579]-
planes or tall structures), can represent high- or moderate-quality evidence. In such cases, the
rationale for the evidence rating exception should be explained by [CONTACT_575852]ï¬ed.
yâ€œWell-designed, well-executed â€refers to studies that directly address the question; use
adequate randomization, blinding, and allocation concealment; are adequately powered; useintention-to-treat analyses; and have high follow-up rates.
zLimitations include concerns with the design and execution of a study that result in decreased
conï¬dence in the true estimate of the effect. Examples of such limitations include but are not
limited to: inadequate randomization, lack of blinding of study participants or outcome asses-sors, inadequate power, outcomes of interest that are not prespeci ï¬ed for the primary out-
comes, low follow-up rates, and ï¬ndings based on subgroup analyses. Whether the limitations
are considered minor or major is based on the number and severity of ï¬‚aws in design or
execution. Rules for determining whether the limitations are considered minor or major and how
they will affect rating of the individual studies will be developed collaboratively with the meth-
odology team.
xNonrandomized controlled studies refer to intervention studies where assignment to inter-
vention and comparison groups is not random (e.g., quasi-experimental study design).
jjObservational studies include prospective and retrospective cohort, case-control, and cross-
sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, randomized controlled
trials.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2893
Page 121 of 356Page 123 of 364
RCTs, the Expert Panel appropriately focused on these
statin RCTs to develop evidence-based guidelines for thereduction of ASCVD risk. We recognize that this repre-sents a signi ï¬cant departure from current strategies. This
should not come as a surprise to clinicians. The recent
guideline on heart failure has changed long-standing para-
digms on the basis of the evidence, and this guideline doesas well (5). Future RCTs will be needed to determine the
optimal treatment strategy to provide the greatest reductionin ASCVD events with best margin of safety.
The Expert Panel acknowledges that our process did not
provide for a comprehensive approach to the detection,evaluation, and treatment of lipid disorders as was done in
the prior Adult Treatment Panel III Report (6). However,
the present guideline was never intended to be a compre-hensive approach to lipid management for purposes otherthan ASCVD risk reduction. A limited number of expertopi[INVESTIGATOR_575580] a thorough consider-ation of what the Expert Panel had learned from theRCTs. For the many questions about complex lipid dis-
orders that are beyond the scope of our systematic evidence
review, or for which little or no RCT data are available, itis anticipated that clinicians with lipid expertise cancontribute to their management.
1.4. Methodology and Evidence Review
Although the Expert Panel was convened before the
Institute of Medicine reports on practice guidelines, ourevidence-based process followed most of the standardsfrom the Institute of Medicine report, â€œClinical Practice
Guidelines We Can Trust â€(1). The systematic review was
limited to RCTs with ASCVD outcomes and systematic
reviews and meta-analyses of RCTs with ASCVD out-
comes. Observational studies and those with <18 months
(CQ1 and CQ2) or <12 months (CQ3) of follow-up were
excluded. Support was provided by a methodology con-tractor and a systematic review and general support con-tractor and included the following steps:
/C15The Expert Panel constructed CQs relevant toclinical practice.
/C15The Expert Panel identi ï¬ed (a priori) inclusion/
exclusion criteria for each CQ.
/C15An independent contractor developed a literature
search strategy, based on inclusion/exclusion criteria,
for each CQ.
/C15An independent contractor executed a systematicelectronic search of the published literature fromrelevant bibliographic databases for each CQ. Thedate range for the overall literature search wasJanuary 1, 1995, through December 1, 2009. How-ever, RCTs with hard ASCVD outcomes of myo-
cardial infarction (MI), stroke, and cardiovascular
death published after that date range were eligiblefor consideration until the Expert Panel began de-liberations on relevant recommendations.
/C15RCTs that met the inclusion criteria and wereindependently graded as fair or good quality wereincluded in the evidence tables for the considerationof the Expert Panel. RCTs that were graded as poor
quality were excluded.
/C15With the assistance of independent methodologists,
this evidence base was used to develop a series ofevidence statements graded on the level of the evi-dence (high, medium, or low).
/C15The Expert Panel then synthesized the evidence state-ments into treatment recommendations/summariesTable 2. What â€™s New in the Guideline? *
1 Focus on ASCVD Risk Reduction: 4 Statin Bene ï¬t Groups
1. This guideline is based on a comprehensive set of data from RCTs
from which 4 statin bene ï¬t groups were identi ï¬ed that focus efforts
to reduce ASCVD events in secondary and primary prevention.
2. This guideline identi ï¬es high-intensity and moderate-intensity
statin therapy for use in secondary and primary prevention.
2 A New Perspective on LDL-C and/or Non â€“HDL-C Treatment Goals
1. The Expert Panel was unable to ï¬nd RCT evidence to support
continued use of speci ï¬c LDL-C or non â€“HDL-C treatment targets.
2. The appropriate intensity of statin therapy should be used to
reduce ASCVD risk in those most likely to bene ï¬t.
3. Nonstatin therapi[INVESTIGATOR_014], as compared with statin therapy,
do not provide acceptable ASCVD risk-reduction bene ï¬ts relative
to their potential for adverse effects in the routine prevention
of ASCVD.
[ADDRESS_755703] data, those high-risk groups
that might not bene ï¬t.
4. This guideline recommends a discussion between clinicians
and patients before initiation of statin therapy.
4 Safety Recommendations
1. This guideline used RCTs to identify important safety
considerations in individuals receiving treatment of blood
cholesterol to reduce ASCVD risk.
2. Using RCTs to determine statin adverse effects facilitates
understanding of the net bene ï¬t from statin therapy.
3. This guideline provides expert guidance on management of
statin-associated adverse effects, including muscle symptoms.
5 Role of Biomarkers and Noninvasive Tests
1. Treatment decisions in selected individuals who are not included
in the 4 statin bene ï¬t groups may be informed by [CONTACT_575853].
6 Future Updates to the Blood Cholesterol Guideline
1. This is a comprehensive guideline for the evidence-based treatment
of blood cholesterol to reduce ASCVD risk.
2. Future updates will build on this foundation to provide expert
guidance on the management of complex lipid disorders andincorporate re ï¬nements in risk strati ï¬cation based on critical
review of emerging data.
3. RCTs comparing alternative treatment strategies are needed in
order to inform future evidence-based guidelines for the optimumASCVD risk-reduction approach.
*See Appendix 5 , for an expanded discussion of what â€™s new in the guideline.
ASCVD indicates atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; and RCT, randomized controlled trial.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342894
Page 122 of 356Page 124 of 364
graded as A (strong), B (moderate), C (weak), D
(recommend against), E (expert), and N (no
recommendation).
/C15The ï¬nal evidence statements and treatment rec-
ommendations were approved by [CONTACT_2669] a majorityof voting members of the Expert Panel.
/C15Guideline implementability appraisals, planned andcoordinated by [CONTACT_575854], were performed to identify and address bar-
riers to guideline implementation.
In addition, the Expert Panel was able to include major
RCTs and meta-analyses of RCTs published through July2013 in our discussion and as part of the process of
determining ACC/AHA grading of the NHLBI expert-level recommendations.
2. Overview of the Guideline
The RCTs identi ï¬ed in the systematic evidence review
indicated a consistent reduction in ASCVD events from3-hydroxy-3-methylglutaryl-coenzyme A reductase inhib-itor (statin) therapy in secondary- and primary-preventionpopulations, with the exception of no ASCVD eventreduction when statin therapy was initiated in those with
[LOCATION_001] Heart Association class II to IV heart failure or
those receiving maintenance hemodialysis. The RCTseither compared ï¬xed doses of statins with placebo or
untreated controls, or compared ï¬xed doses of higher-
intensity statins with moderate-intensity statins. Thesetrials were not designed to evaluate the effect of titrated(dose-adjusted) statin treatment to achieve prespeci ï¬ed
LDL-C or non â€“HDL-C goals.Therefore, the Expert Panel was unable to ï¬nd RCT
evidence to support titrating cholesterol-lowering drugtherapy to achieve target LDL-C or non â€“HDL-C levels,
as recommended by [CONTACT_278317] (6 â€“8).
Notably, the Expert Panel did ï¬nd RCT evidence that use
of therapy (e.g., niacin) to additionally lower non â€“HDL-C,
once an LDL-C target was achieved, did not furtherreduce ASCVD outcomes (9). The Expert Panel also
found extensive RCT evidence that the appropriate in-
tensity of statin therapy should be used to reduce
ASCVD risk in those most likely to bene ï¬t. The work of
the Expert Panel was informed by [CONTACT_575855] (10) and Risk Assessment Work
Groups (11) (Figure 1 ). A summary of the major rec-
ommendations for the treatment of cholesterol to reduceASCVD risk is provided in Table [ADDRESS_755704] be emphasized that lifestyle modiï¬ cation (i.e.,
adhering to a heart-healthy diet, regular exercise habits,
avoidance of tobacco products, and maintenance of ahealthy weight) remains a crucial component of healthpromotion and ASCVD risk reduction, both prior to and in
concert with the use of cholesterol-lowering drug therapi[INVESTIGATOR_014].
Healthy diet or lifestyle modiï¬ cations were recommended
as background therapy for the RCTs of cholesterol-lowering drug therapy. See the â€œ2013 AHA/ACC Guide-
line on Lifestyle Management to Reduce CardiovascularRisk â€(10) for lifestyle recommendations for healthy adults.
Drug therapy for lifestyle-related risk factors such as hy-pertension is often needed and smoking should be avoided.
Figure 1. Overview of the Expert Panelâ€™ s Guideline
RCTs indicates randomized controlled trials.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2895
Page 123 of 356Page 125 of 364
Table 3. Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
(See Tables 4, 8,9, and 10for the complete recommendations; and Table 5 for de ï¬nition of statin intensity)
Recommendations ACC/AHA COR ACC/AHA LOE
A. Heart-healthy lifestyle habits should be encouraged for all individuals
B.The appropriate intensity of statin therapy should be initiated or continued:
1. Clinical ASCVD *
a. Age /C2075 y and no safety concerns: High-intensity statin IA
b. Age >75 y or safety concerns: Moderate-intensity statin IA
2. Primary prevention â€“Primary LDL-C â€¡190 mg/dL
a. Rule out secondary causes of hyperlipi[INVESTIGATOR_035] ( Table 6 ) IB
b. Age /C2121 y: High-intensity statin IB
c. Achieve at least a 50% reduction in LDL-C IIa B
d. LDL-C lowering nonstatin therapy may be considered to further reduce LDL-C IIb C
3. Primary prevention dDiabetes 40 â€“75 years of age and LDL-C 70 â€“189 mg/dL
a. Moderate-intensity statin IA
b. Consider high-intensity statin when /C217.5% 10-y ASCVD risk using the Pooled Cohort Equations y IIa B
4. Primary prevention â€“No diabetes 40 â€“75 years of age and LDL-C 70 â€“189 mg/dL
a. Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equations yin those NOT receiving a statin;
estimate risk every 4 â€“6yIB
b. To determine whether to initiate a statin, engage in a clinician-patient discussion of the potential for ASCVD risk reduction,
adverse effects, drug â€“drug interactions, and patient preferences
c. Re-emphasize heart-healthy lifestyle habits and address other risk factorsIIa C
i.â€¡7.5% 10-y ASCVD risk : Moderate- or high-intensity statin IA
ii.5t o <7.5% 10-y ASCVD risk : Consider moderate-intensity statin IIa B
iii.Other factors may be considered z: LDL-C /C21160 mg/dL, family history of premature ASCVD, hs-CRP /C212.0 mg/L,
CAC score /C21300 Agaston units, ABI <0.9, or lifetime ASCVD riskIIb C
5. Primary prevention when LDL-C <190 mg/dL and age <40 or >75 y, or <5% 10-y ASCVD risk
a. Statin therapy may be considered in selected individuals zIIb C
6. Statin therapy is not routinely recommended for individuals with NYHA class II-IV heart failure or who are receiving
maintenance hemodialysis
C. Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments
1. Assess adherence, response to therapy, and adverse effects within 4 â€“12 wk following statin initiation or change in therapy IA
a. Measure a fasting lipid panel IA
b. Do not routinely monitor ALT or CK unless symptomatic IIa C
c. Screen and treat type 2 diabetes according to current practice guidelines. Heart-healthy lifestyle habits should be encouraged
to prevent progression to diabetesIB
d. Anticipated therapeutic response: approximately /C2150% reduction in LDL-C from baseline for high-intensity statin and
30% to <50% for moderate-intensity statinIIa B
i. Insuf ï¬cient evidence for LDL-C or non â€“HDL-C treatment targets from RCTs
ii. For those with unknown baseline LDL-C, an LDL-C <100 mg/dL was observed in RCTs of high-intensity statin therapy
e. Less than anticipated therapeutic response:
i. Reinforce improved adherence to lifestyle and drug therapy IA
ii. Evaluate for secondary causes of hyperlipi[INVESTIGATOR_575581] (Table 6) IA
iii. Increase statin intensity, or if on maximally-tolerated statin intensity, consider addition of nonstatin therapy in selected
high-risk individuals xIIb C
f. Regularly monitor adherence to lifestyle and drug therapy every 3 â€“12 mo once adherence has been established. Continue
assessment of adherence for optimal ASCVD risk reduction and safetyIA
D. In individuals intolerant of the recommended intensity of statin therapy, use the maximally tolerated intensity of
statin.IB
1. If there are muscle or other symptoms, establish that they are related to the statin IIa B
2. For speci ï¬c recommendations on managing muscle symptoms ( Table 8 )
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of
atherosclerotic origin.
yEstimated 10-year or â€œhard â€ASCVD risk includes ï¬rst occurrence of nonfatal MI, CHD death, and nonfatal and fatal stroke as used by [CONTACT_575856][INVESTIGATOR_575582] (http://my.americanheart.org/cvriskcalculator and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.as px).
zThese factors may include primary LDL-C /C21160 mg/dL or other evidence of genetic hyperlipi[INVESTIGATOR_125270]; family history of premature ASCVD with onset <[ADDRESS_755705]-degree male relative or <[ADDRESS_755706]-degree female relative; hs-CRP /C212 mg/L; CAC score /C21300 Agatston units or /C2175th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/
CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional factors that might aid in individual risk assessment could be identi ï¬ed in the future.
xHigh-risk individuals include those with clinical ASCVD, an untreated LDL-C /C21190 mg/dL suggesting genetic hypercholesterolemia, or individuals with diabetes 40 to 75 years of age and LDL-C 70 to
189 mg/dL.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ALT, alanine aminotransferase, a test of hepatic function; ASCVD, atherosclerotic cardiovascular
disease; CAC, coronary artery calcium; CHD, coronary heart disease; CK, creatine kinase, a test of muscle injury; COR, Class of Recommendation; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-
sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; NYHA, [LOCATION_001] Heart Association; RCTs, randomized
controlled trials; and TIA, transient ischemic attack.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342896
Page 124 of 356Page 126 of 364
2.2. Initiation of Statin Therapy
The Expert Panel found extensive and consistent evidence
supporting the use of statins for the prevention of ASCVD
in many higher-risk primary- and all secondary-preventionindividuals without [LOCATION_001] Heart Association classIIâ€“IV heart failure who were not receiving hemodialysis.
In the RCTs reviewed, initiation of moderate-intensitytherapy (lowering LDL-C by [CONTACT_3450] 30%to<50%) or high-intensity statin therapy (lowering LDL-C
by [CONTACT_3450] /C2150%) is a critical factor in reducing
ASCVD events. Moreover, statin therapy reduces ASCVDevents across the spectrum of baseline LDL-Clevels /C2170 mg/dL. In addition, the relative reduction
in ASCVD risk is consistent for primary and secondaryprevention and for various patient subgroups. Of note,the absolute reduction in ASCVD events is proportionalto baseline absolute ASCVD risk. Therefore, statin
therapy is recommended for individuals at increased
ASCVD risk who are most likely to experience a netbeneï¬t in terms of the potential for ASCVD risk
reduction and the potential for adverse effects ( Table 3;
Figure 2 ).
On the basis of this large and consistent body of evi-
dence, 4 major statin bene ï¬t groups were identi ï¬ed for
whom the ASCVD risk reduction clearly outweighs the
risk of adverse events based on a strong body of evidence.
These are 1) secondary prevention in individuals withclinical ASCVD, 2) primary prevention in individuals with
primary elevations of LDL-C /C21190 mg/dL, 3) primary
prevention in individuals with diabetes [ADDRESS_755707] LDL-C 70 to 189 mg/dL, and 4) primaryprevention in individuals without diabetes and with esti-mated 10-year ASCVD risk /C217.5%, [ADDRESS_755708] LDL-C 70 to 189 mg/dL. Moderate evidencesupports the use of statins for primary prevention in in-dividuals with 5% to <7.5% 10-year ASCVD risk, 40 to
75 years of age with LDL-C 70 to 189 mg/dL. Selectedindividuals with <5% 10-year ASCVD risk, or <40 or
>75 years of age may also bene ï¬t from statin therapy.
Clinicians and patients should engage in a discussion of thepotential for ASCVD risk-reduction bene ï¬ts, adverse ef-
fects, drug â€“drug interactions, and consider patient prefer-
ences for treatment. This discussion also provides theopportunity to re-emphasize healthy-lifestyle habits andaddress other risk factors.
Clinical ASCVD is deï¬ ned by [CONTACT_575857]-prevention statin RCTs (acute coronarys y n d r o m e s ,ah i s t o r yo fM I ,s t a b l eo ru n s t a b l ea n g i n a ,coronary or other arterial revascularization, stroke, tran-
sient ischemic attack, or peripheral arterial disease pre-
sumed to be of atherosclerotic origin). For primaryprevention in individuals without clinical ASCVD ordiabetes who have an LDL-C 70 to 189 mg/dL, theestimated absolute 10-year risk of ASCVD (de ï¬ned as
nonfatal MI, CHD death, or nonfatal and fatal stroke)should be used to guide the initiation of statin therapy.
The 10-year ASCVD risk should be estimated with the
Pooled Cohort Equations ( Section 4.7 ). For the primary
prevention of ASCVD in individuals with diabetes(diabetes mellitus type 1 an dt y p e2 ) ,e s t i m a t e d1 0 - y e a r
ASCVD risk can also be used to guide the intensity ofstatin therapy. For those with clinical ASCVD or with
LDL-C /C21190 mg/dL who are already in a statin bene ï¬t
group, it is not appropriate to estimate 10-year ASCVD
risk. In primary prevention, additional factors may in-
ï¬‚uence ASCVD risk in those for whom a risk-based
decision is unclear. These include a primary LDL-C/C21160 mg/dL or other evidence of genetic hyperlip-
idemias, family history of premature ASCVD withonset<[ADDRESS_755709]-degree male relative
or<[ADDRESS_755710]-degree female relative, high-
sensitivity C-reactive protein /C212 mg/L, coronary artery
calcium score /C21300 Agatston units or /C2175th percentile
f o ra g e ,s e x ,a n de t h n i c i t y( f o ra d d i t i o n a li n f o r m a t i o n ,seehttp://www.mesa-nhlbi.o rg/CACReference.aspx .), ankle-
brachial index <0.9, and elevated lifetime risk of
ASCVD.
Theï¬ndings support the use of statins to prevent both
nonfatal and fatal ASCVD events. Such an approach canreduce the large burden of disability from nonfatal stroke
(for which women are at higher risk than men) and
nonfatal CHD events. Primary and secondary preventionof ASCVD with statins can positively impact risinghealthcare costs. In addition, a high level of evidence wasfound that statins reduce total mortality in individuals witha history of prior ASCVD events (e.g., secondary-prevention settings). In individuals with no prior historyof ASCVD events (e.g., primary-prevention settings),
there is moderate evidence that statins reduce total mor-
tality in individuals at increased ASCVD risk. It should benoted that 2 meta-analyses published after the completionof the Expert Panelâ€™s systematic review provide strongevidence that statins reduce total mortality in primaryprevention (12,13).
3. Critical Questions and Conclusions
3.1. Identi ï¬cation of CQs
Although limited to [ADDRESS_755711] important to answer in order to identifywhom to treat and with what treatment(s) and to considerhow intensively the treatments should be used. The ï¬rst 2
CQs evaluated the evidence for LDL-C and non â€“HDL-C
goals for the secondary and primary prevention of ASCVDwith cholesterol-lowering drug therapy. Titration to spe-
ciï¬c LDL-C goals has been considered a fundamental
therapeutic strategy in deciding on the adequacy of
cholesterol-lowering therapy for secondary and primaryprevention. Therefore, a comprehensive systematic reviewJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2897
Page 125 of 356Page 127 of 364
YesAge â‰¤ 75 y
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin) Age â‰¥21 y and a candidate 
for statin therapyYes
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)YesNo
Moderate-intensity statinNo
Primary prevention 
(No diabetes, LDL-C 70 to 189 mg/dL, and not receiving statin therapy)
Estimate 10-y ASCVD risk every 4-6 y
using Pooled Cohort Equationsâ€ No
In selected individuals, additional 
factors may be considered to inform 
treatment decision makingÂ§Heart-healthy lifestyle habits are the foundation of ASCVD prevention
(See 2013 AHA/ACC Lifestyle Management Guideline)
Yes
Estimated 10-y ASCVD risk â‰¥7.5%â€ 
High-intensity statinAge >75 y OR if not candidate for 
high-intensity statin
Moderate-intensity statinYes
YesClinical 
ASCVD
LDL-C â‰¥190 
mg/dL
Diabetes
LDL-C 70-189 mg/dL
Age 40-75 yDefinitions of High- and Moderate-
Intensity Statin Therapy*
(See Table 5)
High
Daily dose lowers 
LDL-C by [CONTACT_101432]. 
â‰¥50%Moderate
Daily dose lowers LDL-C by [CONTACT_101432]. 
30% to <50%
â‰¥7.5%
10-y ASCVD risk
(Moderate- or high-
intensity statin)5% to <7.5%
10-y ASCVD risk
(Moderate-intensity 
statin)<5%
10-y ASCVD 
riskâ€¡Age <40 or >75 y 
and LDL-C <190 
mg/dL â€¡
Clinician-Patient Discussion
Prior to initiating statin therapy, discuss:
    1. Potential for ASCVD risk-reduction benefits â•‘
    2. Potential for adverse effects and drugâ€“ drug interactions Â¶
    3. Heart-healthy lifestyle
    4. Management of other risk factors
    5. Patient preferences    6. If decision is unclear, consider primary LDL-C â‰¥160 mg/dL, family history of premature 
        ASCVD, lifetime ASCVD risk, abnormal CAC score or ABI, or hs-CRP â‰¥2 mg/LÂ§No to statin
Yes to statin
 Encourage adherence to lifestyle 
 Initiate statin at appropriate intensity Manage other risk factors Monitor adherence* (See Fig 5) Emphasize adherence to lifestyle  Manage other risk factors
 Monitor adherenceDM age <40 
or >75 y or 
LDL-C <70 
mg/dLRegularly monitor adherence to 
lifestyle and d rug therapy with 
lipid and safety  assessments 
(See Fig 5)
Figure 2. Summary of Statin Initiation Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
(See Figures 3, 4, and 5for More Detailed Management Information)
Colors correspond to the Classes of Recommendation in Table 1 . Assessment of the potential for bene ï¬t and risk from statin therapy for ASCVD prevention provides the
framework for clinical decision making incorporating patient preferences.
*Percent reduction in LDL-C can be used as an indication of response and adherence to therapy, but is not in itself a treatment goal.
yThe Pooled Cohort Equations can be used to estimate 10-year ASCVD risk in individuals with and without diabetes. The estimator within this application should be used to
inform decision making in primary prevention patients not on a statin.
zConsider moderate-intensity statin as more appropriate in low-risk individuals.
xFor those in whom a risk assessment is uncertain, consider factors such as primary LDL-C /C21160 mg/dL or other evidence of genetic hyperlipi[INVESTIGATOR_125270], family history of
premature ASCVD with onset <[ADDRESS_755712]-degree male relative or <[ADDRESS_755713]-degree female relative, hs-CRP /C212 mg/L, CAC score /C21300 Agatston
units, or /C2175th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/CACReference.aspx), ABI <0.9, or lifetime risk of ASCVD.
Additional factors that may aid in individual risk assessment may be identi ï¬ed in the future.
kPotential ASCVD risk-reduction bene ï¬ts. The absolute reduction in ASCVD events from moderate- or high-intensity statin therapy can be approximated by [CONTACT_575858]
10-year ASCVD risk by [CONTACT_575859]-risk reduction from the intensity of statin initiated ( w30% for moderate-intensity statin or w45% for high-intensity statin therapy).
The net ASCVD risk-reduction bene ï¬t is estimated from the number of potential ASCVD events prevented with a statin, compared to the number of potential excess adverse effects.
{Potential adverse effects. The excess risk of diabetes is the main consideration in w0.1 excess cases per 100 individuals treated with a moderate-intensity statin for
1 year and w0.3 excess cases per 100 individuals treated with a high-intensity statin for 1 year. In RCTs, both statin-treated and placebo-treated participants experienced the
same rate of muscle symptoms. The actual rate of statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms attributed to statin therapy should
be evaluated (see Table 8 , Safety Recommendation 8).
ABI indicates ankle-brachial index; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density
lipoprotein cholesterol; MI, myocardial infarction; and RCT, randomized controlled trial.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“[ADDRESS_755714] CQ had several objectives:
/C15Identify groups of patients who will bene ï¬t from
pharmacological treatment,
/C15Deï¬ne the pharmacological treatment(s) for which
there is the best evidence of net bene ï¬t, and
/C15Provide guidance on the appropriate intensity of
pharmacological treatment to reduce ASCVD risk.
3.1.1. CQ1: LDL-C and Non â€“HDL-C Goals
in Secondary Prevention
CQ1: What is the evidence for LDL-C and non â€“HDL-C
goals for the secondary prevention of ASCVD?
The Expert Panel reviewed 19 RCTs to answer CQ1.
Although CQ1 is supported conceptually by [CONTACT_575860]-
lation of observational studies and observational data fromR C T s ,n od a t aw e r ei d e n t i ï¬ed for treatment or titration
to a speci ï¬c LDL-C goal in adults with clinical ASCVD.
The majority of studies con ï¬rming the efï¬ cacy of
cholesterol reduction in improving clinical outcomes inpatients with clinical ASCVD used a single ï¬xed-dose
statin to lower LDL-C levels. In the 4S trial, 37% had
the dose of simvastatin raised from 20 mg/d to 40 mg/d to
achieve a total cholesterol level <200 mg/dL (16). The
Expert Panel was unable to ï¬nd any RCTs that evaluated
titration of all individuals in a treatment group to speciï¬cLDL-C targets <100 mg/dL or <70 mg/dL, nor were any
RCTs comparing 2 LDL-C treatment targets identi ï¬ed.
No statin RCTs reporting on-treatment non â€“HDL-C
levels were identi ï¬ed. (In CQ3, statin-nonstatin combina-
tion therapy was evaluated.)
3.1.2. CQ2: LDL-C and Non â€“HDL-C Goals in
Primary Prevention
C Q 2 :W h a ti st h ee v i d e n c ef o rL D L - Ca n dn o n â€“HDL-C
goals for the primary prevention of ASCVD?The Expert Panel reviewed 6 RCTs. The 4 studies con-
ï¬rming the ef ï¬cacy of cholesterol reduction in improving
clinical outcomes in patients without ASCVD used ï¬xed-
dose statin therapy to lower LDL-C levels. In theAFCAPS-TEXCAPS (Air Force/[LOCATION_007] CoronaryAtherosclerosis Prevention Study) trial (17), in 50% ofparticipants, the lovastatin dose was raised from 20 mg to40 mg to achieve an LDL-C level <110 mg/dL. In the
MEGA (Management of Elevated Cholesterol in thePrimary Prevention Group of Adult Japanese) trial (18),
the dose of pravastatin could be uptitrated from 10 mg to
20 mg to achieve a total cholesterol level <220 mg/dL.
The Expert Panel did not ï¬nd any RCTs that evaluated
titration of all individuals in a treatment group to speci ï¬c
LDL-C targets<100 mg/dL or <70 mg/dL, nor were any
RCTs comparing 2 LDL-C treatment targets identi ï¬ed.
No trials reported on-treatment non â€“HDL-C levels.3.1.3. CQ3: Ef ï¬cacy and Safety of
Cholesterol-Lowering Medications
CQ3: For primary and secondary prevention, what is
the impact on lipid levels, effectiveness, and safety of
speciï¬c cholesterol-modifying drugs used for lipid
management in general and in selected subgroups?
The populations examined included primary-prevention
adult patients who could not have a diagnosis of CHD
or cardiovascular disease. Interventions included pharma-
cotherapy with single-drug therapi[INVESTIGATOR_575583]-drugtherapi[INVESTIGATOR_575584], including statins, ï¬brates (feno ï¬brate, gem ï¬-
brozil), nicotinic acid (niacin in immediate-, slow-, orextended-release form), bile acid sequestrants, ezetimibe,omega-3 fatty acids (also called marine fatty acids, in-cluding eicosapentaenoic acid alone, docosahexanoic acid
alone, eicosapentaenoic acid plus docosahexanoic acid, and
alpha-linolenic acid). There were no ASCVD outcomesidenti ï¬ed for plant sterols, sterol esters, stanols, or stanol
esters. A single ASCVD outcomes trial (19) used Xuez-hikang, an extract from red yeast Chinese rice, which wasnot available in the [LOCATION_002] during the timeframefor evidence review, so no recommendations were maderegarding its use.
The recommendations synthesize the evidence retrieved
for answering CQ3, along with the evidence from the trialsincluded in CQ1 and CQ2, to guide the use of cholesterol-lowering drugs for secondary or primary prevention ofASCVD.
4. Statin Treatment: Recommendations
For each recommendation, the grades of the recom-
mendation by [CONTACT_575861]/AHA
methods are provided. Major treatment recommenda-
tions are listed in Table 4 , and statin intensities are
deï¬ned in Table 5. The safety (statin and nonstatin)
recommendations are in Section 5 . A complete listing
of the evidence statements supporting each recom-mendation, along with the references, is provided inAppendix 4 .
4.1. Intensity of Statin Therapy in
Primary and Secondary Prevention
The Expert Panel de ï¬nes the intensity of statin therapy
on the basis of the average expected LDL-C response to
as p e c i ï¬c statin and dose. â€œHigh-intensity,â€â€œ moderate-
intensity,â€ and â€œlow-intensity â€statin therapy de ï¬nitions
were derived from the systematic reviews for CQ1 andCQ2. The basis for differentiation among speci ï¬c statins
and doses arose from the RCTs included in CQ1, wherethere was a high level of evidence that high-intensitystatin therapy with atorvastatin 40 mg to 80 mgreduced ASCVD risk more than moderate-intensityJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2899
Page 127 of 356Page 129 of 364
Table 4. Recommendations for Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults d
Statin Treatment (High, Moderate, and Low Statin Intensities are De ï¬ned in Table 5 )
Recommendations NHLBI GradeNHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Treatment Targets
1. The Expert Panel makes no recommendations for or
against speci ï¬c LDL-C or non â€“HDL-C targets for the
primary or secondary prevention of ASCVD.N (No recommendation) 1â€“[ADDRESS_755715]-line therapy in women and men
/C2075 years of age who have clinical ASCVD *, unless
contraindicated.A (Strong) 1,6 â€“8,10 â€“23,26 â€“28 IA
2. In individuals with clinical ASCVD * in whom high-
intensity statin therapy would otherwise be used, when
high-intensity statin therapy is contraindicated yor
when characteristics predisposing to statin-associated
adverse effects are present, moderate-intensity statinshould be used as the second option if tolerated(Table 8 for Safety of Statins, Recommendation 1).A (Strong) 13â€“22,24,27,28 I A
3. In individuals with clinical ASCVD >75 years of age, it
is reasonable to evaluate the potential for ASCVD risk-reduction bene ï¬ts and for adverse effects and drug â€“drug
interactions and to consider patient preferences wheninitiating a moderate- or high-intensity statin. It isreasonable to continue statin therapy in those who are
tolerating it.E (Expert Opi[INVESTIGATOR_1649]) d IIa B
(16,20 â€“43)
Primary Prevention in Individuals â€¡21 Years of Age With LDL-C â€¡190 mg/dL
1. Individuals with LDL-C /C21190 mg/dL or triglycerides
/C21500 mg/dL should be evaluated for secondary causes
of hyperlipi[INVESTIGATOR_035] ( Table 6 ).B (Moderate) 75 Iz B
(44,45)
2. Adults /C2121 years of age with primary LDL-C /C21190 mg/
dL should be treated with statin therapy (10-year ASCVD
risk estimation is not required):
/C15Use high-intensity statin therapy unlesscontraindicated.
/C15For individuals unable to tolerate high-intensity statintherapy, use the maximum tolerated statin intensity.B (Moderate) 6,19,28,33 â€“35,37,38 Ix B
3.For individuals /C2121 years of age with an untreated
primary LDL-C /C21190 mg/dL, it is reasonable to intensify
statin therapy to achieve at least a 50% LDL-C reduction.E (Expert Opi[INVESTIGATOR_1649]) d IIa B
(20,46 â€“50)
4. For individuals /C2121 years of age with an untreated pri-
mary LDL-C /C21190 mg/dL, after the maximum intensity
of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C.Evaluate the potential for ASCVD risk-reduction bene ï¬ts,
adverse effects, and drug â€“drug interactions, and consider
patient preferences.E (Expert Opi[INVESTIGATOR_1649]) d IIb C
(51)
Primary Prevention in Individuals With Diabetes and LDL-C 70â€“ 189 mg/dL
1. Moderate-intensity statin therapy should be initiated
or continued for adults 40 â€“75 years of age with diabetes.A (Strong) 19,29 â€“34,40 IA
2. High-intensity statin therapy is reasonable for adults
40â€“75 years of age with diabetes with a /C217.5%
estimated 10-year ASCVD risk kunless contraindicated.E (Expert Opi[INVESTIGATOR_1649]) d IIa B
(49,52)
3. In adults with diabetes, who are <40 years of age or
>75 years of age, or with LDL <70 mg/dL it is reason-
able to evaluate the potential for ASCVD bene ï¬ts and for
adverse effects and drug â€“drug interactions and to
consider patient preferences when deciding to initiate,continue, or intensify statin therapy.E (Expert Opi[INVESTIGATOR_1649]) d IIa C
(53 â€“62)
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342900
Page 128 of 356Page 130 of 364
statin therapy with atorvastatin 10 mg, pravastatin 40 mg,
or simvastatin 20 mg to 40 mg twice daily. Classifyingspeciï¬c statins and doses by [CONTACT_575862]-C level is based on evidence that the relativereduction in ASCVD risk from statin therapy is related tothe degree by [CONTACT_575863]-C is lowered. However, no
variation in the relative reduction in ASCVD risk was
observed after the data were adjusted for LDL-C reduc-tion. Furthermore, there is no differentiation between thespeciï¬c statins and doses used in primary- and secondary-
prevention RCTs, according to a high level of evidencethat statins reduce ASCVD risk similarly in bothpopulations.Percent reductions in LDL-C for a speci ï¬c statin and
dose were calculated for the RCTs included in individualmeta-analyses conducted by [CONTACT_575864] (CTT) in 2010 (20), in which statin therapyreduced ASCVD events. High-intensity statin therapyon average lowers LDL-C by [CONTACT_3450] /C2150%,
moderate-intensity statin therapy lowers LDL-C by[CONTACT_3450] 30% to <50%, and lower-intensity statin
therapy lowers LDL-C by <30% ( Table 5).
4.2. LDL-C and Non â€“HDL-C Treatment Goals
The Expert Panel did not ï¬nd evidence to support titrating
cholesterol-lowering drug therapy to achieve optimalTable 4. Continued
Recommendations NHLBI GradeNHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Primary Prevention in Individuals Without Diabetes and With LDL-C 70 â€“189 mg/dL
1. The Pooled Cohort Equations should be used to estimate
10-year ASCVD krisk for individuals with LDL-C 70 â€“189
mg/dL without clinical ASCVD * to guide initiation of
statin therapy for the primary prevention of ASCVD.E (Expert Opi[INVESTIGATOR_1649]) d IB
(11)
2. Adults 40 â€“75 years of age with LDL-C 70 â€“189 mg/dL,
without clinical ASCVD* or diabetes, and with an
estimated 10-year ASCVD krisk/C217.5% should be treated
with moderate- to high-intensity statin therapy.A (Strong) 28,34 â€“36,38,42 â€“44,
47,49 â€“56,76IA
3. It is reasonable to offer treatment with a moderate-
intensity statin to adults 40 â€“75 years of age, with LDL-C
70â€“189 mg/dL, without clinical ASCVD* or diabetes, and
with an estimated 10-year ASCVD krisk of 5% to <7.5%.C (Weak) 28,34 â€“36,38,42 â€“44,
47,49 â€“56,76IIa B
4. Before initiation of statin therapy for the primary pre-
vention of ASCVD in adults with LDL-C 70 â€“189 mg/dL
without clinical ASCVD* or diabetes, it is reasonable for
clinicians and patients to engage in a discussion that
considers the potential for ASCVD risk-reduction beneï¬ ts
and for adverse effects and drug â€“drug interactions, as
well as patient preferences for treatment.E (Expert Opi[INVESTIGATOR_1649]) d IIa C
(63)
5. In adults with LDL-C <190 mg/dL who are not otherwise
identi ï¬ed in a statin bene ï¬t group, or for whom after
quantitative risk assessment a risk-based treatmentdecision is uncertain, additional factors {may be
considered to inform treatment decision making. Inthese individuals, statin therapy for primary preventionmay be considered after evaluation of the potential forASCVD risk-reduction bene ï¬ts, adverse effects, and drugâ€“
drug interactions and consider patient preferences.E (Expert Opi[INVESTIGATOR_1649]) d IIb C
(11,13)
Heart Failure and Hemodialysis
1. The Expert Panel makes no recommendations regarding
the initiation or discontinuation of statins in patients withNYHA class II â€“IV ischemic systolic heart failure or in pa-
tients on maintenance hemodialysis.N (No Recommendation) 71,72 dd
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of
atherosclerotic origin.
yContraindications, warnings, and precautions are de ï¬ned for each statin according to the manufacturer â€™s prescribing information (64 â€“70).
zIndividuals with secondary causes of hyperlipi[INVESTIGATOR_293759]. A triglyceride level /C21500 mg/dL was an exclusion criterion for almost all RCTs. Therefore, ruling out secondary
causes is necessary to avoid inappropriate statin therapy.
xNo RCTs included only individuals with LDL-C /C21190 mg/dL. However, many trials did include individuals with LDL-C /C21190 mg/dL, and all of these trials consistently demonstrated a reduction in ASCVD
events. In addition, the Cholesterol Treatment Trialists meta-analyses have shown that each 39-mg/dL reduction in LDL-C with statin therapy reduced ASCVD events by 22%, and the relative reductions in
ASCVD events were consistent across the range of LDL-C levels. Therefore, individuals with primary LDL-C /C21190 mg/dL should be treated with statin therapy.
kEstimated 10-year or â€œhard â€ASCVD risk includes ï¬rst occurrence of nonfatal MI, coronary heart disease death, and nonfatal and fatal stroke as used by [CONTACT_575856][INVESTIGATOR_575585].
{These factors may include primary LDL-C /C21160 mg/dL or other evidence of genetic hyperlipi[INVESTIGATOR_125270]; family history of premature ASCVD with onset <[ADDRESS_755716]-degree male relative or <[ADDRESS_755717]-degree female relative; high-sensitivity C-reactive protein /C212 mg/L; CAC score /C21300 Agatston units or /C2175th percentile for age, sex, and ethnicity (for additional information, see
http://www.mesa-nhlbi.org/CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional factors that might aid in individual risk assessment could be identi ï¬ed in the future.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; COR, Class of
Recommendation; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; NYHA, [LOCATION_001] Heart
Association; RCTs, randomized controlled trials; TIA, transient ischemic attack; and d, not applicable.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2901
Page 129 of 356Page 131 of 364
LDL-C or non â€“HDL-C levels because the clinical trials
were essentially ï¬xed-dose trials (CQ1 and CQ2). Dosage
increases did occur in a few RCTs with the intent of
maximizing statin therapy. Therefore, these were not trulytests of de ï¬ning optimal goals for LDL-C in primary and
secondary prevention because not all individuals in thestatin treatment groups received drug therapy titratedto achieve a speciï¬ c LDL-C or non â€“HDL-C goal, nor
were speci ï¬c treatment targets compared. One RCT in
CQ3 was identi ï¬ed that showed no additional ASCVD
event reduction from the addition of nonstatin therapy tofurther lower non â€“HDL-C levels once an LDL-C goal
had been reached. In AIM-HIGH (AtherothrombosisIntervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Out-comes), the additional reduction in non â€“HDL-C levels
(as well as further reductions in apolipoprotein B, lipo-protein[a], and triglycerides in addition to HDL-Cincreases) with niacin therapy did not further reduceASCVD risk in individuals treated to LDL-C levels of 40to 80 mg/dL (9).
Therefore, given the absence of data on titration of drug
therapy to speciï¬ c goals, no recommendations are made for
or against speciï¬ c LDL-C or non â€“HDL-C goals for the
primary or secondary prevention of ASCVD.
4.3. Secondary Prevention
Women and men with clinical ASCVD (de ï¬ned from the
RCT inclusion criteria as acute coronary syndromes; historyof MI, stable or unstable angina, coronary or other arterialrevascularization, stroke, transient ischemic attack, or pe-ripheral arterial disease presumed to be of atherosclerotic
origin) arterial revascularization, stroke, transient ischemic
attack, or peripheral arterial disease presumed to be ofatherosclerotic origin are at increased risk for recurrentASCVD and ASCVD death. An extensive body of evi-dence demonstrates that high-intensity statin therapy re-duces ASCVD events more than moderate-intensity statintherapy ( Table 4 ) in individuals with clinical ASCVD.High-intensity statin therapy should be initiated for
adults /C2075 years of age with clinical ASCVD who are not
receiving statin therapy, or the intensity should be increasedin those receiving a low- or moderate-intensity statin, un-less they have a history of intolerance to high-intensitystatin therapy or other characteristics that could inï¬‚ uence
safety (Section 5). This is consistent with RCT data. In
2 trials, patients were previously treated with a moderately
intensive statin (46,47), and in 2 trials, 75% to 97% of
patients had not received prior statin therapy (48,78). Thehigh-intensity statins atorvastatin 80 mg and rosuvastatin20 mg daily reduce LDL-C /C2150% on average and have
been shown to reduce ASCVD events in RCTs.
Although atorvastatin 40 mg reduces LDL-C by [CONTACT_97458]-
roximately /C2150%, this dose was used in only [ADDRESS_755718] if the
participant was unable to tolerate atorvastatin 80 mg/dL.
Whether an individual receiving atorvastatin 40 mg should
be uptitrated to atorvastatin 80 mg should be based on thepotential for an ASCVD risk-reduction bene ï¬t and the
potential for adverse effects, drug â€“drug interactions, and
consider patient preferences.
In individuals with clinical ASCVD in whom high-
intensity statin therapy would otherwise be used, eitherwhen high-intensity statin therapy is contraindicated or when
characteristics predisposing to statin-associated adverse ef-
fects are present, moderate-intensity statin should be used asthe second option, if tolerated ( Section 5 ). In the relatively
few individuals >[ADDRESS_755719], individuals >75 years of age did experience a
reduction in ASCVD events in the trials of mostly moderate-intensity statin therapy, as compared with control. Therefore,moderate-intensity statin therapy should be considered forindividuals >75 years of age with clinical ASCVD. However,
in acknowledgment that older participants in RCTs werelikely tobehealthier than many older individualsin the generalpopulation, the use of statin therapy should be individualizedTable 5. High-, Moderate-, and Low-Intensity Statin Therapy (Used in the RCTs Reviewed by [CONTACT_293810]) *
High-Intensity Statin Therapy Moderate-Intensity Statin Therapy Low-Intensity Statin Therapy
Daily dose lowers LDL-C, on average,
by [CONTACT_3450] /C2150%Daily dose lowers LDL-C, on average,
by [CONTACT_3450] 30% to <50%Daily dose lowers LDL-C,
on average, by <30%
Atorvastatin (40 y)â€“80 mg
Rosuvastatin 20 (40)mgAtorvastatin 10 (20)mg
Rosuvastatin (5)10 mg
Simvastatin 20 â€“40 mg z
Pravastatin 40 (80)mg
Lovastatin 40 mg
Fluvastatin XL 80 mgFluvastatin 40 mg BID
Pi[INVESTIGATOR_2830] 2 â€“4m gSimvastatin 10 mg
Pravastatin 10 â€“20 mg
Lovastatin 20 mgFluvastatin 20 â€“40 mg
Pi[INVESTIGATOR_2830] 1 mg
Boldface type indicates speci ï¬c statins and doses that were evaluated in RCTs (16 â€“18,46 â€“49,64 â€“75,77) included in CQ1, CQ2, and the Cholesterol Treatment Trialists 2010 meta-analysis included in
CQ3 (20). All of these RCTs demonstrated a reduction in major cardiovascular events. Italic type indicates statins and doses that have been approved by [CONTACT_575865].
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice. There might be a biological basis for a less-than-average response.
yEvidence from [ADDRESS_755720] only: down-titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental Decrease through Aggressive Lipid Lowering) study (47).
zAlthough simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by [CONTACT_575866], including
rhabdomyolysis.
BID indicates twice daily; CQ, critical question; FDA, Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; and RCTs, randomized controlled trials.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342902
Page 130 of 356Page 132 of 364
in persons >75 years of age with clinical ASCVD, according
to the potential for ASCVD risk-reduction bene ï¬ts, adverse
effects, drug â€“drug interactions, and consider patient prefer-
ences. The Expert Panel considers it reasonable to continue
statin therapy in persons >[ADDRESS_755721] clinical
ASCVD and are tolerating statin therapy.
Theï¬‚ow diagram for the initiation and management of
statin therapy in individuals with clinical ASCVD is pro-
vided in Figure 3.
4.4. Primary Prevention in Individuals
â€¡21 Years of Age With LDL-C â€¡190 mg/dL
This guideline recognizes that individuals /C2121 years of age
with primary, severe elevations of LDL-C ( /C21190 mg/dL)
have a high lifetime risk for ASCVD events. This is due to
their lifetime exposure to markedly elevated LDL-Clevels arising from genetic causes. Thus, at age 21, theseindividuals should receive statin therapy if they havenot already been diagnosed and treated before this
age. Although in most clinical trials individuals with
LDL-C /C21190 mg/dL were not included because of their
need for treatment, extensive evidence shows that each 39-mg/dL reduction in LDL-C by [CONTACT_575867] 20%. Patients with primary elevationsof LDL-C /C21190 mg/dL require even more substantial re-
ductions in their LDL-C levels and intensive managementFigure 3. Initiating Statin Therapy in Individuals With Clinical ASCVD
Colors correspond to the Classes of Recommendation in Table 1 .
*Fasting lipid panel preferred. In a nonfasting individual, a nonâ€“ HDL-C level /C21220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a
secondary etiology. If nonfasting triglycerides are /C21500 mg/dL, a fasting lipid panel is required.
yIt is reasonable to evaluate the potential for ASCVD bene ï¬ts and for adverse effects, and to consider patient preferences, in initiating or continuing a moderate- or high-intensity
statin in individuals with ASCVD who are >75 years of age.
ALT indicates alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CK, creatine kinase; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein
cholesterol; and ULN, upper limit of normal.
Table 6. Secondary Causes of Hyperlipi[INVESTIGATOR_575586]-CElevated
Triglycerides
Diet Saturated or trans fats,
weight gain, anorexia
nervosaWeight gain, very-low-fat
diets, high intakeof re ï¬ned carbohydrates,
excessive alcohol intake
Drugs Diuretics, cyclosporine,
glucocorticoids,amiodaroneOral estrogens,
glucocorticoids, bile acidsequestrants,protease inhibitors,
retinoic acid, anabolic
steroids, sirolimus,raloxifene, tamoxifen,beta blockers(not carvedilol), thiazides
Diseases Biliary obstruction,
nephrotic syndromeNephrotic syndrome,
chronic renal failure,lipodystrophies
Disorders and
altered statesof metabolismHypothyroidism,
obesity, pregnancy*Diabetes (poorly controlled),
hypothyroidism, obesity;pregnancy*
Adapted with permission from Stone et al (80).
*Cholesterol and triglycerides rise progressively throughout pregnancy (80); treatment with
statins, niacin, and ezetimibe are contraindicated during pregnancy and lactation.
LDL-C indicates low-density lipoprotein cholesterol.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2903
Page 131 of 356Page 133 of 364
Figure 4. Initiating Statin Therapy in Individuals Without Clinical ASCVD
Colors correspond to the Classes of Recommendation in Table 1 .
*Fasting lipid panel preferred. In a nonfasting individual, a nonâ€“ HDL-C level /C21220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a
secondary etiology. If nonfasting triglycerides are /C21500 mg/dL, a fasting lipid panel is required.
yThe Pooled Cohort Equations can be used to estimate 10-year ASCVD risk in individuals with and without diabetes.
A downloadable spreadsheet enabling estimation of 10-year and lifetime risk for ASCVD and a Web-based calculator are available at http://my.americanheart.org/cvriskcalculator
and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx.
zFor those in whom a risk assessment is uncertain, consider factors such as primary LDL-C /C21160 mg/dL or other evidence of genetic hyperlipi[INVESTIGATOR_125270]; family history of
premature ASCVD with onset <[ADDRESS_755722]-degree male relative or <[ADDRESS_755723]-degree female relative, high-sensitivity C-reactive protein /C212 mg/L;
CAC/C21300 Agatston units or /C2175th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/CACReference.aspx); ABI <0.9; or lifetime
risk of ASCVD. Additional factors that may aid in individual risk assessment could be identi ï¬ed in the future.
x1) Potential ASCVD risk-reduction bene ï¬ts. The absolute reduction in ASCVD events from moderate- or high-intensity statin therapy can be approximated by [CONTACT_575868] 10-year ASCVD risk by [CONTACT_575859]-risk reduction from the intensity of statin initiated ( w30% for moderate-intensity statin or w45% for high-intensity statin
therapy). The net ASCVD risk-reduction bene ï¬t is estimated from the number of potential ASCVD events prevented with a statin, compared to the number of potential excess
adverse effects. 2) Potential adverse effects. The excess risk of diabetes is the main consideration in w0.1 excess cases per 100 individuals treated with a moderate-intensity
statin for 1 year and w0.3 excess cases per 100 individuals treated with a high-intensity statin for 1 year. In RCTs, both statin-treated and placebo-treated participants expe-
rienced the same rate of muscle symptoms. The actual rate of statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms attributed to statin therapyshould be evaluated (see Table 8 , Safety Recommendation 8).
ABI indicates ankle-brachial index; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CK, creatine kinase; FH, familialhypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; RCT, randomized controlled trial; and ULN, upper limit of normal.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“[ADDRESS_755724] a 50% reduction. It is recognized thatmaximal statin therapy might not be adequate to lowerLDL-C suf ï¬ciently to reduce ASCVD event risk in in-
dividuals with primary severe elevations of LDL-C. Inaddition to a maximally tolerated dose of statin, nonstatincholesterol-lowering medications are often needed to lowerLDL-C to acceptable levels in these individuals. Because
the hypercholesterolemia in these high-risk individuals is
often genetically determined, family screening is especiallyimportant in this group to identify additional family mem-bers who would bene ï¬t from assessment and early treatment.
Secondary causes of severe elevations of LDL-C /C21190
mg/dL and triglycerides /C21500 mg/dL often contribute to
the magnitude of the hyperlipi[INVESTIGATOR_575587]-uated and treated appropriately. For guidance, we note that
in a lipid specialty clinic, the most frequently encountered
secondary conditions were excessive alcohol intake, un-controlled diabetes, and overt albuminuria (79) .Table [ADDRESS_755725] likelyencountered in clinical practice (80). Management of in-
dividuals with fasting triglycerides /C21500 mg/dL has been
addressed in an AHA statement (45).
Theï¬‚ow diagram for the initiation and management of
statin therapy in individuals with LDL-C /C21190 mg/dL is
provided in Figure 4 .
4.5. Primary Prevention in
Individuals With Diabetes
A high level of evidence supports the use of moderate-
intensity statin therapy in persons with diabetes who are
40 to 75 years of age. The only trial of high-intensity statin
therapy in primary prevention was performed in a popu-
lation without diabetes. However, a high level of evidenceexisted for event reduction with statin therapy in in-dividuals with a /C217.5% estimated 10-year ASCVD risk
(Section 4.6) who did not have diabetes to recommend
high-intensity statin therapy preferentially for individualswith diabetes and a /C217.5% estimated 10-year ASCVD risk
(Section 4.7 ). This consideration for those with diabetes
who are 40 to 75 years of age recognizes that these in-dividuals are at substantially increased lifetime risk forASCVD events and death. Moreover, individuals withdiabetes experience greater morbidity and worse survivalafter the onset of clinical ASCVD. In persons with dia-betes who are <40 years of age or >75 years of age, or
whose LDL-C is <70 mg/dL, statin therapy should be
individualized on the basis of considerations of ASCVD
risk-reduction bene ï¬ts, the potential for adverse effects and
drugâ€“ drug interactions, and patient preferences (Figure 4).
4.6. Primary Prevention in Individuals Without
Diabetes and With LDL-C 70 to 189 mg/dL
In individuals 40 to 75 years of age with LDL-C 70 to
189 mg/dL who do not have clinical ASCVD or diabetes,Table 7. Rationale for the Expert Panel Approach to
Primary-Prevention Guidelines
1. Cholesterol-lowering medications, particularly statins, are ef ï¬cacious and
effective for reducing risk of initial cardiovascular events.
2. Statins are associated with similar relative risk reductions for cardiovas-
cular events across the majority of primary-prevention patient groups
studied.*
3. The extent of relative risk reduction for ASCVD is proportional to the degree
of LDL-C lowering observed on statin therapy. Therefore, more intensivestatin therapy could reduce risk more than moderate- or lower-intensitystatin therapy.
4. According to consistent ï¬ndings, the absolute bene ï¬t in ASCVD risk
reduction is proportional to the baseline risk of the patient group or indi-vidual and to the intensity of statin therapy.
5. Patients or groups at higher baseline absolute risk, therefore, will derive
greater absolute bene ï¬t from initiation of statin therapy over a period of
5 to 10 years.
6. The absolute risk for adverse outcomes, including a small excess in cases
of newly diagnosed diabetes, also appears to be proportional to the in-tensity of statin therapy. However, the adverse outcome of incident (orearlier diagnosis of) diabetes must be weighed in the context of thepotentially fatal or debilitating occurrence of MI or stroke that could beprevented by [CONTACT_275084].
7. The Expert Panel emphasizes that the occurrence of a major ASCVD event
(MI or stroke) represents a much greater harm to health status than doesan increase in blood glucose leading to a diagnosis of diabetes. The net
absolute bene ï¬tof statin therapy can be considered as a comparison of the
absolute risk reduction for ASCVD with the absolute excess risks, including
that for diabetes. Bene ï¬t also could be understood as a comparison of the
number of statin-treated patients that would result in the prevention of 1case of major ASCVD (NNT) with the number of statin-treated patients thatwould result in 1 excess case of diabetes (NNH).
8. Because the absolute bene ï¬t in terms of ASCVD risk reduction depends on
the baseline absolute risk for ASCVD, the absolute bene ï¬tfrom initiation of
statin therapy is lower and would approach the risk for adverse effects inpatients with lower baseline levels of predicted ASCVD risk.
9. Available RCT evidence indicates a clear net absolute beneï¬ t of initiation of
moderate-to-intensive statin therapy at a baseline estimated 10-yearASCVD risk of /C217.5%.
10.Available RCT evidence indicates that when baseline ASCVD risk is 5.0%
to<7.5%, there is still net absolute bene ï¬t with moderate-intensity statin
therapy. However, the tradeoffs between the ASCVD risk-reduction bene ï¬t
and adverse effects are less clear. Thus, a clinician-patient discussion iseven more important for individuals with this range of ASCVD risk. The netbene ï¬t of high-intensity statin therapy may be marginal in such individuals.
Conclusion
On the basis of the above tenets and its review of the evidence, thisguideline recommends initiation of moderate or intensive statin therapy forpatients who are eligible for primary ASCVD prevention and have apredicted 10-year â€œhard â€ASCVD risk of /C217.5%. This guideline recommends
that initiation of moderate-intensity statin therapy be considered forpatients with predicted 10-year â€œhard â€ASCVD risk of 5.0% to <7.5%.
*Available evidence suggests that initiation of statin therapy might not achieve a signiï¬ cant
reduction of CVD risk in patients with higher classes of NYHA heart failure or who are receiving
maintenance hemodialysis.
ASCVD indicates atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL-C,
low-density lipoprotein cholesterol; MI, myocardial infarction; NNH, number needed to harm;
NNT, number needed to treat; NYHA, [LOCATION_001] Heart Association; and RCT, randomized
controlled trial.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2905
Page 133 of 356Page 135 of 364
initiation of statin therapy based on estimated 10-year
ASCVD risk is recommended, regardless of sex, race, or
ethnicity (Section 4.7). Point estimates of statin-associatedreductions in the relative risk of ASCVD in primary pre-vention are similar for both women and men. There also isno evidence that the ASCVD risk-reduction bene ï¬to r
adverse-effect pro ï¬les differ by [CONTACT_545].
To better identify those individuals without ASCVD
who would most bene ï¬t from statin therapy to reduce
ASCVD risk, data were used from the 3 exclusivelyprimary-prevention RCTs that included individuals withLDL-C levels <190 mg/dL, almost all of whom had
LDL-C levels /C2170 mg/dL (17,18,49). From these trials,
an estimate of the expected 10-year ASCVD event rateswas derived from the placebo groups. The rates of excessadverse events in the statin treatment groups were obtainedfrom meta-analyses of statin RCTs. A high level of evi-
dence for an ASCVD risk-reduction bene ï¬t from initia-
tion of moderate- or high-intensity statin therapy in
individuals 40 to 75 years of age with /C217.5% estimated 10-
year ASCVD risk was found (Section 4.7). The reductionin ASCVD risk clearly outweighs the potential for adverseeffects ( Table 7 ). Thus, it is recommended that individuals
40 to 75 years of age, who are not already candidates forstatin therapy on the basis of the presence of clinical
ASCVD, diabetes, or LDL-C /C21190 mg/dL, receive statin
therapy if they have a /C217.5% estimated 10-year risk for
ASCVD and LDL-C 70 to 189 mg/dL. Although only [ADDRESS_755726] included individualswith LDL-C 70 to <100 mg/dL, the Cholesterol Treat-
ment Trialists 2010 meta-analysis found a relative reduc-tion in ASCVD events of similar magnitude across thespectrum of LDL-C levels /C2170 mg/dL (20). Given that
the relative risk reduction is similar across the range ofLDL-C 70 to 189 mg/dL, the absolute bene ï¬t of statin
therapy in primary prevention is determined by [CONTACT_575869]ï¬‚ected in the estimated 10-year ASCVD risk.
A conservative estimate of adverse events includes excess
cases of new-onset diabetes and rare cases of myopathyand hemorrhagic stroke. The rate of excess diabetes varies
by [CONTACT_575870]. For moderate-intensity statins, approxi-
mately 0.1 excess case of diabetes per 100 statin-treatedindividuals per year has been observed, and for high-intensity statins, approximately 0.3 excess case of diabetesper 100 statin-treated individuals per year has been observed(52,81). The long-term adverse effects of statin-associated
cases of diabetes over a 10-year period are unclear and areunlikely to be equivalent to an MI, stroke, or ASCVD
death. Myopathy ( w0.01 excess case per 100) and hemor-
rhagic stroke ( w0.01 excess case per 100) make minimal
contributions to excess risk from statin therapy (13).
Although a similar level of evidence of a reduction in
ASCVD events from moderate- and high-intensity statin
therapy is present for those with a 5% to <7.5% estimated
10-year ASCVD risk, the potential for adverse effects mayoutweigh the potential for ASCVD risk-reduction bene ï¬t
when high-intensity statin therapy is used in this risk group.However, for moderate-intensity statin therapy, the ASCVDrisk reduction clearly exceeds the potential for adverse effects.
Before initiating statin therapy for the primary preven-
tion of ASCVD in adults with /C217.5% or 5% to <7.5%
estimated 10-year ASCVD risk, it is reasonable for clini-cians and patients to engage in a discussion of the proposedtherapy. This discussion should include the potential for
ASCVD bene ï¬t, the potential for adverse effects and
drug â€“drug interactions, and consideration of patient pref-
erences for treatment.
No primary-prevention RCT data were available for
individuals 21 to 39 years of age, and few data were
available for individuals >75 years of age. Additionally, in
individuals 40 to 75 years of age with <5% estimated 10-
year ASCVD risk, the net bene ï¬t from statin therapy over
a 10-year period may be small. Therefore, in adults withLDL-C <190 mg/dL who are not otherwise identi ï¬ed in
a statin bene ï¬t group or for whom a risk-based treatment
decision is uncertain after quantitative risk assessment,clinician knowledge, experience, and skill ( â€œthe art of
medicine â€) and patient preferences all contribute to the
decision to initiate statin therapy (82). Before initiation ofstatin therapy, the clinician-patient discussion should
include consideration of the potential for ASCVD risk-
reduction bene ï¬ts, adverse effects, and drugâ€“ drug in-
teractions. Additional factors may also be considered toinform treatment decision making in selected individuals.Factors that can contribute to assessment of ASCVD riskinclude primary LDL-C /C21160 mg/dL or other evidence of
genetic hyperlipi[INVESTIGATOR_125270]; family history of prematureASCVD with onset <[ADDRESS_755727]-degree male
relative or <[ADDRESS_755728]-degree female relative;
high-sensitivity C-reactive protein /C212 mg/L, coronary
artery calcium score /C21300 Agatston units or /C2175th
percentile for age, sex, and ethnicity (for additional infor-mation, see http://www.mesa-nhlbi.org/CACReference.aspx);
ankle-brachial index <0.9; or elevated lifetime risk of
ASCVD. Additional factors that might aid in individualrisk assessment could be identi ï¬ed in the future.
For an individual <40 years of age, the 10-year horizon
might not be optimal for predicting lifetime risk ofASCVD (see 2013 ACC/AHA Guideline on theAssessment of Cardiovascular Risk) (11). Future RCTswill be needed to determine the optimal age at which toinitiate statin therapy to reduce ASCVD risk, as well as todetermine the optimum duration of statin therapy.
4.7. Risk Assessment in Primary Prevention
To estimate more closely the total burden of ASCVD, this
guideline recommends a comprehensive assessment of theestimated 10-year risk for an ASCVD event that includesboth CHD and stroke. This is in contrast to the use of anestimated 10-year risk for hard CHD (de ï¬ned as nonfatal
MI and CHD death) (83).Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342906
Page 134 of 356Page 136 of 364
This guideline recommends using the new Pooled
Cohort Risk Assessment Equations developed by [CONTACT_575871] 10-year ASCVDrisk (de ï¬ned as ï¬rst-occurrence nonfatal and fatal MI and
nonfatal and fatal stroke) for the identi ï¬cation of candi-
dates for statin therapy (see http://my.americanheart.org/cvriskcalculator and http://www.cardiosource.org/en/
Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx for risk
calculator). These equations should be used to predict
stroke as well as CHD events in non-Hispanic, Caucasian,and African-American women and men [ADDRESS_755729] LDL-C levels 70 to189 mg/dL and are not receiving statin therapy. A morecomplete discussion of risk assessment is provided in theFull Panel Report Supplement.
This guideline does not require speci ï¬c risk factor
counting for risk assessment or the use of RCT risk factorinclusion criteria to determine statin eligibility. Rather, aglobal ASCVD risk assessment to guide initiation of statintherapy was chosen for several important reasons (seerationale in Table 7 and further discussion in Section 7.3 of
the Full Panel Report Supplement): 1) The CholesterolTreatment Trialists individual-level meta-analyses wereused to evaluate the effect of statins in various important
patient subgroups, including risk factor cutpoints used for
RCT eligibility. The Expert Panel found that statin ther-apy reduces ASCVD events regardless of risk factorcharacteristics in both primary and secondary prevention.Therefore, the rationale for using ï¬xed cutpoints to
determine whether statin therapy should be used is refutedby a consideration of the total body of evidence. 2) Use ofabsolute ASCVD risk facilitates a quantitative assessment
of the potential for an ASCVD risk-reduction bene ï¬ta s
compared with the potential for adverse effects. 3) Use of
an RCT eligibility criteria â€“based approach results in failure
to identify a substantial proportion of higher-risk in-dividuals who could bene ï¬t from statin therapy and over-
identi ï¬cation of very-low-risk individuals who might not
experience a net bene ï¬t from statin therapy over a 10-year
period.
4.8. Heart Failure and Hemodialysis
No recommendation was made with regard to the initia-
tion or continuation of statin therapy in 2 speci ï¬c groups:
1) individuals with [LOCATION_001] Heart Association class II â€“
IV heart failure, and 2) individuals undergoing mainte-nance hemodialysis. In the 4 RCTs reviewed that specif-ically addressed statin treatment in these groups, there
were individuals with and without heart disease (84 â€“87).
Although statin therapy did not reduce ASCVD events in
2 RCTs for each condition (84 â€“87), there was insuf ï¬cient
information on which to base recommendations for oragainst statin treatment. Future research may identifysubgroups of patients with these conditions that maybeneï¬t from statin therapy. In individuals with theseconditions, the potential for ASCVD risk-reduction ben-
eï¬ts, adverse effects, and drug â€“drug interactions, along
with other cautions and contraindications to statin therapy
and choice of statin dose, must also be considered by [CONTACT_575872].
5. Safety: Recommendations
See safety recommendations for statins ( Table 8 ) and
nonstatin drugs ( Table 9).
RCT data were also used to examine the safety of lipid
medications. From the statin RCTs and meta-analyses,patient characteristics and monitoring strategies wereidenti ï¬ed that should enhance the safe use of high- and
moderate-intensity statin therapy. Patient characteristicsthat may inï¬‚uence statin safety include but are not limited
to: multiple or serious comorbidities, including impaired
renal or hepatic function; a history of previous statinintolerance or muscle disorders; concomitant use of drugsaffecting statin metabolism; a history of hemorrhagicstroke; and age >[ADDRESS_755730] routine measure-
ment of creatine kinase in individuals receiving statin
therapy. This measurement should be reserved for those
with muscle symptoms. However, measurement of a base-line creatine kinase may be useful in those at increased riskof adverse muscle events. Such individuals include thosewith a personal or family history of statin intolerance ormuscle disease, clinical presentation, or concomitant drugtherapy that might increase the likelihood of myopathy.
Expert recommendations are also provided for managing
muscle symptoms while a patient is on statin therapy.These useful management suggestions were derived fromother clinical trial data and clinical experience to enhancethe safety and tolerability of statin therapy. Consistent withthe protocols of the RCTs, patients should be asked at eachvisit, both before and after initiation of statin therapy,about muscle symptoms such as muscle weakness or fa-tigue, aching, pain, tenderness, cramps, or stiffness. The
recommended approach for management of muscle
symptoms is described in Table 8, Recommendation 8.
This guideline recommends that baseline measurement
of transaminase (alanine transaminase; ALT) levels shouldbe performed before initiation of statin therapy. Thisapproach was taken in the RCTs reviewed for this report.There is no recommendation to monitor transaminase(ALT) levels because ALT monitoring was performed in
the RCTs, and there was no signi ï¬cant difference between
placebo groups and statin treatment groups in the rates of
ALT elevations. In addition, the U.S. Food and DrugAdministration has indicated that if the baseline hepatictransaminases are normal, further hepatic monitoring isnot needed. During statin therapy, it is reasonable tomeasure hepatic function if symptoms suggestingJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2907
Page 135 of 356Page 137 of 364
hepatotoxicity arise (e.g., unusual fatigue or weakness, loss
of appetite, abdominal pain, dark-colored urine, or yel-
lowing of the skin or sclera).
Decreasing the statin dose may be considered when
2 consecutive values of LDL-C are <40 mg/dL. This
recommendation was based on the approach taken in [ADDRESS_755731]-risk
individuals ( Section 4.5 ). All individuals receiving statins
should be counseled on healthy-lifestyle habits. In-dividuals receiving statin therapy should be evaluated fornew-onset diabetes according to the current diabetesscreening guidelines (91). Those who develop diabetesTable 8. Statin Safety Recommendations
Recommendations NHLBI GradeNHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Safety
1. To maximize the safety of statins, selection of the appropriate statin and dose
in men and nonpregnant/nonnursing women should be based on patient
characteristics, level of ASCVD* risk, and potential for adverse effects.
Moderate-intensity statin therapy should be used in individuals in whomhigh-intensity statin therapy would otherwise be recommended whencharacteristics predisposing them to statin-associated adverse effects arepresent.
Characteristics predisposing individuals to statin adverse effects include but
are not limited to:
/C15Multiple or serious comorbidities, including impaired renal or hepaticfunction.
/C15History of previous statin intolerance or muscle disorders.
/C15Unexplained ALT elevations /C213 times ULN.
/C15Patient characteristics or concomitant use of drugs affecting statinmetabolism.
/C15Age>75 years.
Additional characteristics that could modify the decision to use higher statinintensities might include but are not limited to:
/C15History of hemorrhagic stroke.
/C15Asian ancestry.A (Strong) 46 â€“55 IB
2a. CK should not be routinely measured in individuals receiving statin therapy. A (Strong) 45,49 â€“51,54,55 III: No Bene ï¬tA
2b. Baseline measurement of CK is reasonable for individuals believed to be at
increased risk for adverse muscle events because of a personal or familyhistory of statin intolerance or muscle disease, clinical presentation, orconcomitant drug therapy that might increase the risk of myopathy.E (Expert Opi[INVESTIGATOR_1649]) d IIa C
(88)
2c. During statin therapy, it is reasonable to measure CK in individuals with
muscle symptoms, including pain, tenderness, stiffness, crampi[INVESTIGATOR_007],weakness, or generalized fatigue.E (Expert Opi[INVESTIGATOR_1649]) d IIa C
(88)
3a. Baseline measurement of hepatic transaminase levels (ALT) should be
performed before initiation of statin therapy.B (Moderate) 46,52,53 Iy B
3b. During statin therapy, it is reasonable to measure hepatic function if
symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness,loss of appetite, abdominal pain, dark-colored urine, or yellowing of the skinor sclera).E (Expert Opi[INVESTIGATOR_1649]) d IIa C
(89)
4. Decreasing the statin dose may be considered when 2 consecutive values
of LDL-C levels are <40 mg/dL.C (Weak) 45 IIb C
5. It may be harmful to initiate simvastatin at 80 mg daily or increase the
dose of simvastatin to 80 mg daily.B (Moderate) 6,54 III: Harm A
(67,90)
6. Individuals receiving statin therapy should be evaluated for new-onset diabetes
according to the current diabetes screening guidelines (91). Those whodevelop diabetes during statin therapy should be encouraged to adhere toa heart-healthy dietary pattern, engage in physical activity, achieve andmaintain a healthy body weight, cease tobacco use, and continue statintherapy to reduce their risk of ASCVD events.B (Moderate) 44 Iz B
7. For individuals taking any dose of statins, it is reasonable to use caution in
individuals >75 years of age, as well as in individuals who are taking
concomitant medications that alter drug metabolism, taking multiple drugs,or taking drugs for conditions that require complex medication regimens(e.g., those who have undergone solid organ transplantation or are receivingtreatment for HIV). A review of the manufacturer â€™s prescribing information may
be useful before initiation of any cholesterol-lowering drug.E (Expert Opi[INVESTIGATOR_1649]) d IIa C
(16,64 â€“70,
89,92 â€“94)
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342908
Page 136 of 356Page 138 of 364
during statin therapy should be encouraged to adhere to a
heart-healthy dietary pattern, engage in physical activity,achieve and maintain a healthy body weight, cease tobacco
use, and continue statin therapy to reduce their risk of
ASCVD events.
Statins are listed as pregnancy category X and should
not be used in women of childbearing potential unlessthese women are using effective contraception and are notnursing.
For individuals taking any dose of statins, it is reason-
able to use caution in individuals >75 years of age, as well
as in individuals who are takin g concomitant medications
that alter drug metabolism, taking multiple drugs, ortaking drugs for conditions that require complex medi-cation regimens (e.g., those who have undergone solidorgan transplantation or are receiving treatment for HIV).A review of the manufacturer â€™s prescribing information
might be useful before initiation of any cholesterol-
lowering drug, because RCTs considered deï¬ ned pop-
ulations and many patients in everyday practice would not
qualify for clinical trials. Thus, clinicians should alsoconsult other sources of safety data, such as pharmacists,drug information centers, and manufacturers â€™prescribing
information on a regular basis for up-to-date guidanceabout lipid medications and medication interactions.
Statins used in combination with other cholesterol-
lowering drug therapi[INVESTIGATOR_575588]. The safety of nonstatin agents was reviewed,and that information is included in Table 9 and the Full
Panel Report Supplement. Warnings about the use ofTable 8. Continued
Recommendations NHLBI GradeNHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
8. It is reasonable to evaluate and treat muscle symptoms, including pain,
tenderness, stiffness, crampi[INVESTIGATOR_007], weakness, or fatigue, in statin-treated
patients according to the following management algorithm:
/C15To avoid unnecessary discontinuation of statins, obtain a history of prior orcurrent muscle symptoms to establish a baseline before initiation of statintherapy.
/C15If unexplained severe muscle symptoms or fatigue develop during statin
therapy, promptly discontinue the statin and address the possibility ofrhabdomyolysis by [CONTACT_575873].
/C15Ifmild to moderate muscle symptoms develop during statin therapy:
â€“Discontinue the statin until the symptoms can be evaluated.
â€“Evaluate the patient for other conditions that might increase the risk formuscle symptoms (e.g., hypothyroidism, reduced renal or hepatic func-tion, rheumatologic disorders such as polymyalgia rheumatica, steroidmyopathy, vitamin D de ï¬ciency, or primary muscle diseases).
â€“If muscle symptoms resolve, and if no contraindication exists, give thepatient the original or a lower dose of the same statin to establish acausal relationship between the muscle symptoms and statin therapy.
â€“If a causal relationship exists, discontinue the original statin. Oncemuscle symptoms resolve, use a low dose of a different statin.
â€“Once a low dose of a statin is tolerated, gradually increase the dose astolerated.
â€“If, after 2 months without statin treatment, muscle symptoms orelevated CK levels do not resolve completely, consider other causes ofmuscle symptoms listed above.
â€“If persistent muscle symptoms are determined to arise from a conditionunrelated to statin therapy, or if the predisposing condition has been
treated, resume statin therapy at the original dose.E (Expert Opi[INVESTIGATOR_1649]) d IIa B
(15,88,96 â€“98)
9. For individuals presenting with a confusional state or memory impairment
while on statin therapy, it may be reasonable to evaluate the patient for
nonstatin causes, such as exposure to other drugs, as well as for systemic andneuropsychiatric causes, in addition to the possibility of adverse effectsassociated with statin drug therapy.E (Expert Opi[INVESTIGATOR_1649]) d IIb C
(38,89,99,100)
*Based on the presence of clinical ASCVD, diabetes, LDL-C /C21190 mg/dL, or level of estimated 10-year ASCVD risk.
yIndividuals with elevated ALT levels (usually >1.[ADDRESS_755732]) were excluded from RCT participation. Unexplained ALT /C213 times ULN is a contraindication to statin therapy as listed in manufacturer â€™s
prescribing information.
zStatin use is associated with a very modest excess risk of new-onset diabetes in RCTs and meta-analyses of RCTs (i.e., w0.1 excess cases per 100 individuals treated for 1 year with moderate-intensity
statin therapy and w0.3 excess cases per 100 individuals treated for 1 year with high-intensity statin therapy. The increased risk of new-onset diabetes appears to be con ï¬ned to those with risk factors
for diabetes. These individuals are also at higher risk of ASCVD because of these risk factors. Therefore, if a statin-treated individual develops diabetes as detected by [CONTACT_575874], he or she should be counseled to adhere to a heart-healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statintherapy to reduce the risk of ASCVD events.
ACC indicates American College of Cardiology; AHA, American Heart Association; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CK, creatine kinase; COR, Class of
Recommendation; NHLBI, National Heart, Lung, and Blood Institute; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; RCTs, randomized controlled trials; ULN, upper limit of normal;
andd, not applicable.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2909
Page 137 of 356Page 139 of 364
Table 9. Nonstatin Safety Recommendations
Recommendations NHLBI GradeNHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Safety of Niacin
1. Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c,
and uric acid should be obtained before initiation of niacin, and again during
up-titration to a maintenance dose and every 6 months thereafter.B (Moderate) 77 IB
2. Niacin should not be used if:
/C15Hepatic transaminase elevations are higher than [ADDRESS_755733]. A (Strong) 79 III: Harm B
/C15Persistent severe cutaneous symptoms, persistent hyperglycemia, acutegout, or unexplained abdominal pain or gastrointestinal symptoms occur.B (Moderate) 78,79 III: Harm B
/C15New-onset atrial ï¬brillation or weight loss occurs. C (Weak) 80 III: Harm B
3. In individuals with adverse effects from niacin, the potential for ASCVD
bene ï¬ts and the potential for adverse effects should be reconsidered before
reinitiation of niacin therapy.E (Expert) d IB
(9,101 â€“104)
4. To reduce the frequency and severity of adverse cutaneous symptoms, it is
reasonable to:
/C15Start niacin at a low dose and titrate to a higher dose over a period ofweeks as tolerated.
/C15Take niacin with food or premedicate with aspi[INVESTIGATOR_248] 325 mg 30 minutesbefore niacin dosing to alleviate ï¬‚ushing symptoms.
/C15If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over 4 to8 weeks, with the dose of extended-release niacin increasing not more
than weekly.
/C15If immediate-release niacin is chosen, start at a dose of 100 mg 3 times
daily and up-titrate to 3 g/day, divided into 2 or 3 doses.E (Expert) d IIa C
(9,101 â€“104)
Safety of BAS
1. BAS should not be used in individuals with baseline fasting triglyceride
levels /C21300 mg/dL or type III hyperlipoproteinemia, because severe
triglyceride elevations might occur. (A fasting lipid panel should be obtainedbefore BAS is initiated, 3 months after initiation, and every 6 to 12 monthsthereafter.)C (Weak) 60 III: Harm B
2. It is reasonable to use BAS with caution if baseline triglyceride levels are
250 to 299 mg/dL, and evaluate a fasting lipid panel in 4 to 6 weeks afterinitiation. Discontinue the BAS if triglycerides exceed 400 mg/dL.E (Expert) d IIa C
(105)
Safety of Cholesterol-Absorption Inhibitors
1. It is reasonable to obtain baseline hepatic transaminases before initiation of
ezetimibe. When ezetimibe is coadministered with a statin, monitor trans-aminase levels as clinically indicated, and discontinue ezetimibe if persistentALT elevations /C213 times ULN occur.C (Weak) 61 â€“64 IIa B
Safety of Fibrates
1. Gem ï¬brozil should not be initiated in patients on statin therapy because of an
increased risk for muscle symptoms and rhabdomyolysis.B (Moderate) 46 III: Harm B
2. Feno ï¬brate may be considered concomitantly with a low- or moderate-
intensity statin only if the bene ï¬ts from ASCVD risk reduction or triglyceride
lowering when triglycerides are /C21500 mg/dL are judged to outweigh the
potential risk for adverse effects.E (Expert) d IIb C
(14)
3. Renal status should be evaluated before feno ï¬brate initiation, within 3
months after initiation, and every 6 months thereafter. Assess renal safetywith both a serum creatinine level and an eGFR based on creatinine.B (Moderate) 66,67 IB
/C15Feno ï¬brate should not be used if moderate or severe renal impairment,
deï¬ned as eGFR <30 mL/min per 1.73 m
2, is present.
/C15If eGFR is between 30 and 59 mL/min per 1.73 m2, the dose of feno ï¬brate
should not exceed 54 mg/day.*
/C15If, during follow-up, the eGFR decreases persistently to /C2030 mL/min per
1.73 m2, feno ï¬brate should be discontinued.III: Harm B
Safety of Omega-3 Fatty Acids
1. If EPA and/or DHA are used for the management of severe
hypertriglyceridemia, de ï¬ned as triglycerides /C21500 mg/dL, it is reasonable to
evaluate the patient for gastrointestinal disturbances, skin changes, andbleeding.C (Weak) 70 IIa B
*Consult the manufacturer â€™s prescribing information as there are several forms of feno ï¬brate available.
ACC indicates American College of Cardiology; AHA, American Heart Association; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; BAS, bile acid sequestrants; COR, Class of
Recommendation; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; eGFR, estimated glomerular ï¬ltration rate; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; ULN,
upper limit of normal; and d, not applicable.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342910
Page 138 of 356Page 140 of 364
cholesterol-lowering agents in pregnancy and lactation also
apply to nonstatins, and the manufacturer â€™s prescribing
information should be consulted.
6. Managing Statin Therapy:
Recommendations
See Table [ADDRESS_755734] evidence supports the use of an
initial fasting lipid panel (total cholesterol, triglycerides,
HDL-C, and calculated LDL -C), followed by a second
lipid panel 4 to 12 weeks after in itiation of statin therapy,
to determine a patient â€™s adherence. Thereafter, assess-
ments should be performed every 3 to 12 months asclinically indicated. Adherence to both medication andlifestyle regimens are required for ASCVD risk reduc-tion. After statin therapy has been initiated, someTable 10. Recommendations for Monitoring, Optimizing, and Addressing Insuf ï¬cient Response to Statin Therapy
Recommendations NHLBI GradeNHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Monitoring Statin Therapy
1. Adherence to medication and lifestyle, therapeutic response to statin
therapy, and safety should be regularly assessed. This should also
include a fasting lipid panel performed within 4 â€“12 weeks after initiation
or dose adjustment, and every 3 â€“12 months thereafter. Other safety
measurements should be measured as clinically indicated.A (Strong) 45 IA
Optimizing Statin Therapy
1. The maximum tolerated intensity of statin should be used in individuals for
whom a high- or moderate-intensity statin is recommended but not tolerated.B (Moderate) 25,26,27,45 I* B
Insuf ï¬cient Response to Statin Therapy
1. In individuals who have a less-than-anticipated therapeutic response or are
intolerant of the recommended intensity of statin therapy, the following shouldbe performed:
/C15Reinforce medication adherence.
/C15Reinforce adherence to intensive lifestyle changes.
/C15Exclude secondary causes of hyperlipi[INVESTIGATOR_035].A (Strong) 45 IA
2. It is reasonable to use the following as indicators of anticipated therapeutic
response to the recommended intensity of statin therapy. Focus is on theintensity of the statin therapy. As an aid to monitoring:
/C15High-intensity statin therapy ygenerally results in an average LDL-C
reduction of /C2150% from the untreated baseline.
/C15Moderate-intensity statin therapy generally results in an averageLDL-C reduction of 30% to <50% from the untreated baseline.
/C15LDL-C levels and percents reduction are to be used only to assessresponse to therapy and adherence. They are not to be used asperformance standards.E (Expert Opi[INVESTIGATOR_1649]) d IIa B
(46 â€“48,78,
106,107)
3. In individuals at higher ASCVD risk receiving the maximum tolerated
intensity of statin therapy who continue to have a less-than-anticipatedtherapeutic response, addition of nonstatin cholesterol-lowering drug(s) maybe considered if the ASCVD risk-reduction bene ï¬ts outweigh the potential for
adverse effects.Higher-risk individuals include:
/C15Individuals with clinical ASCVD z<75 years of age.
/C15Individuals with baseline LDL-C /C21190 mg/dL.
/C15Individuals 40 â€“75 years of age with diabetes.
Preference should be given to nonstatin cholesterol-lowering drugs shown to
reduce ASCVD events in RCTs.E (Expert Opi[INVESTIGATOR_1649]) d IIb C
(9,14,108 â€“110)
4. In individuals who are candidates for statin treatment but are completely
statin intolerant, it is reasonable to use nonstatin cholesterol-lowering drugsthat have been shown to reduce ASCVD events in RCTs if the ASCVD risk-reduction bene ï¬ts outweigh the potential for adverse effects.E (Expert Opi[INVESTIGATOR_1649]) d IIa B
(88,101,111â€“ 116)
*Several RCTs found that low-intensity and low-moderate â€“intensity statin therapy reduced ASCVD events. In addition, the Cholesterol Treatment Trialists meta-analyses found that each 39-mg/dL
reduction in LDL-C reduces ASCVD risk by 22%. Therefore, the Panel considered that submaximal statin therapy should be used to reduce ASCVD risk in those unable to tolerate moderate- or high-
intensity statin therapy.
yIn those already on a statin, in whom baseline LDL-C is unknown, an LDL-C level <100 mg/dL was observed in most individuals receiving high-intensity statin therapy.
zClinical ASCVD includes acute coronary syndromes, or a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or
peripheral arterial disease presumed to be of atherosclerotic origin.
ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; COR, Class of Recommendation; LDL-C, low-density lipoprotein
cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; RCTs, randomized controlled trials; and d, not applicable.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2911
Page [ADDRESS_755735] been identi ï¬ed (Table 8 ,
Recommendation 8).
See Figure [ADDRESS_755736] evidence to support the use of speci ï¬c
LDL-C or non â€“HDL-C targets was not identi ï¬ed. The
f o c u si so nt h ei n t e n s i t yo ft h es t a t i nt h e r a p y ,b u ta sa na i dt omonitoring response to therapy and adherence, it is reason-able to use the following as indicators of anticipated thera-peutic response to statin therapy:
/C15High-intensity statin therapy generally results in anaverage LDL-C reduction of /C2150% from the un-
treated baseline.
/C15Moderate-intensity statin therapy generally results inan average LDL-C reduction of 30% to <50% from
the untreated baseline.
/C15LDL-C levels and percent reduction are to beused only to assess response to therapy and adherence.They are not to be used as performance standards.Figure 5. Statin Therapy: Monitoring Therapeutic Response and Adherence
Colors correspond to the Classes of Recommendation in Table 1 .
*Fasting lipid panel preferred. In a nonfasting individual, a nonâ€“ HDL-C level /C21220 mg/dL may indicate genetic hypercholesterolemia that requires further evaluation or a secondary
etiology. If nonfasting triglycerides are /C21500 mg/dL, a fasting lipid panel is required.
yIn those already on a statin, in whom baseline LDL-C is unknown, an LDL-C <100 mg/dL was observed in most individuals receiving high-intensity statin therapy in RCTs.
zSee Section 6.3.1.
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and RCTs, randomized clinical trials.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342912
Page 140 of 356Page 142 of 364
In those already on a statin, in whom the baseline LDL-
C is unknown, an LDL-C <100 mg/dL was observed in
most individuals receiving high-intensity statin therapy in
RCTs.
However, there are many limitations of using LDL-C
<100 mg/dL as a ï¬xed target. If a moderate- or low-intensity
statin results in an LDL-C level <100 mg/dL in a patient
with ASCVD, the evidence suggests that a high-intensitystatin, if tolerated, provides a greater reduction in ASCVD
events. Conversely, in those with LDL-C levels slightly
>100 mg/dL on a high-intensity statin, some options such as
niacin might require down-titration of the statin intensity inan effort to improve safety. This would result in a suboptimalintensity of evidence-based statin therapy. Additional limi-tations to using LDL-C treatment targets are discussed in theFull Panel Report Supplement.
No evidence was found that titration or combination-
drug therapy to achieve speci ï¬c LDL-C or non â€“HDL-C
levels or percent reductions improved ASCVD outcomes.Therefore, this guideline does not recommend their use asperformance measures.
The percent LDL-C reduction may not only indicate
adherence, but also may re ï¬‚ect biological variability in
the response to statin therapy. This acknowledges that someindividuals may have less than an average response. Attention
to adherence of statin and lifestyle therapy and evaluation
and treatment of secondary causes ( Table 6 ) that might el-
evate LDL-C, may address less-than-anticipated responsesto a speci ï¬c statin dosage. Whether the dose of statin therapy
should be increased on the basis of a less-than-anticipatedaverage response should be left to clinical judgment.
6.3.2. Nonstatins Added to Statins or
in Statin-Intolerant Individuals
Adherence to lifestyle changes and to statin therapy should
be reemphasized before the addition of a nonstatin drug isconsidered ( Figure 5 ). RCTs evaluating the ASCVD event
reductions from nonstatins used as monotherapy werereviewed, as were RCTs evaluating the additional reduc-tion in ASCVD events from nonstatin therapy added tostatin therapy. The Expert Panel could ï¬nd no data sup-
porting the routine use of nonstatin drugs combined withstatin therapy to further reduce ASCVD events. In addi-tion, no RCTs that assessed ASCVD outcomes in statin-intolerant patients were found.
Clinicians treating high-risk patients who have a less-
than-anticipated response to statins, who are unable totolerate a less-than-recommended intensity of a statin, orwho are completely statin intolerant, may consider the
addition of a nonstatin cholesterol-lowering therapy.
High-risk individuals include those with ASCVD, thosewith LDL-C /C21190 mg/dL, and those with diabetes
40â€“[ADDRESS_755737] been shown in RCTs to provide ASCVD risk-reduction bene ï¬ts that outweigh the potential for adverseeffects and drug â€“drug interactions, and consider patient
preferences.
7. Selected Clinical and
Population Subgroups
7.1. Sex and Racial and Ethnic Subgroups
Because the RCT evidence shows that the absolute bene ï¬t
of statin treatment is proportional to baseline ASCVD
risk, treatment decisions for women and racial and ethnicsubgroups should be based on the level of ASCVD risk.This conclusion is a departure from previous approachesthat focused on LDL-C levels to guide treatment de-cisions. Statin treatment based on estimated 10-yearASCVD risk avoids the overtreatment of lower-riskgroups, such as younger, non-Hispanic white women
who, despi[INVESTIGATOR_575589]-C, are typi[INVESTIGATOR_575590] ï¬cantly increased risk for ASCVD in the next
[ADDRESS_755738] likely to provide ASCVD risk reduction
on the basis of the estimated 10-year risk of ASCVD.
7.2. Individuals >75 Years of Age
Fewer people >[ADDRESS_755739] evidence does support the contin-uation of statins beyond 75 years of age in persons who arealready taking and tolerating these drugs. A larger amount
of data supports the use of moderate-intensity statin
therapy for secondary prevention in individuals with clin-ical ASCVD who are >75 years of age. However, the
limited information available did not clearly supportinitiation of high-intensity statin therapy for secondaryprevention in individuals >75 years of age.
Few data were available to indicate an ASCVD event
reduction bene ï¬t in primary prevention among individuals
>[ADDRESS_755740] clinical ASCVD.
Therefore, initiation of statins for primary prevention ofASCVD in individuals >75 years of age requires consid-
eration of additional factors, including increasing comor-bidities, safety considerations, and priorities of care. ThePooled Cohort Equations can also provide information onexpected 10-year ASCVD risk for those 76 to 79 years ofage that may inform the treatment decision. These factors
may in ï¬‚uence decisions about cholesterol-lowering drug
therapy, especially in the primary-prevention setting.
Accordingly, a discussion of the potential ASCVD risk-reduction bene ï¬ts, risk of adverse effects, drugâ€“ drug in-
teractions, and consideration of patient preferences shouldprecede the initiation of statin therapy for primary pre-vention in older individuals.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2913
Page 141 of 356Page 143 of 364
8. Limitations
The evidence-based recommendations in this guideline
focus on patient groups who are well represented in RCTs
and/or are highly likely to have high-risk genetic condi-
tions, so the recommendations are designed to informrather than replace clinical judgment. However, there areother patient groups for which a robust evidence base islacking but that may nevertheless include some persons forwhom statin treatment should be considered (after takingpatient preferences into account) on the basis of the po-tential for ASCVD bene ï¬ts to exceed the risk of adverse
events and drug â€“drug interactions. Clinician judgment is
especially important for several patient groups for whichthe RCT evidence is insuf ï¬cient for guiding clinical rec-
ommendations. These patient groups include youngeradults ( <40 years of age) who have a low estimated 10-year
ASCVD risk but a high lifetime ASCVD risk basedon single strong factors or multiple risk factors. Othergroups include those with serious comorbidities and
increased ASCVD risk (e.g., individuals with HIV or
rheumatologic or inï¬‚ ammatory diseases, or who have un-
dergone a solid organ transplantation). This guidelineencourages clinicians to use clinical judgment in thesesituations, weighing potential bene ï¬ts, adverse effects,
drugâ€“ drug interactions, and consider patient preferences.
Previous guidelines have taken less rigorous approaches
to identifying the evidence to support their recommen-
dations. In contrast, to minimize various sources of bias,
the present recommendations are based on data availablefrom RCTs and systematic reviews and meta-analyses ofRCTs that were graded as fair to good quality by [CONTACT_575875], with the assistance of an independent methodolo-gist. To avoid biases, evidence from post-hoc analyses ofincluded RCTs, from poor-quality RCTs, and from
observational studies was not considered. This approach
resulted in a comprehensive set of evidence-based clinicalrecommendations for the treatment of blood cholesterol toreduce ASCVD risk.
9. Evidence Gaps and
Future Research Needs
After a systematic review of the literature, several research
priorities are suggested that address existing evidence gaps
and offer the greatest potential to inform and inï¬‚ uence
clinical practice and reduce ASCVD morbidity and mor-tality. High-priority research areas are:
1. Outcomes of RCTs to evaluate statins for the pri-
mary prevention of ASCVD in adults >75 years of
age.
2. Outcomes of RCTs to evaluate alternative treatment
strategies for ASCVD risk reduction. These RCTsmay compare titration to speci ï¬c cholesterol or
apolipoprotein goals versus ï¬xed-dose statin therapy
in high-risk patients.
3. RCTs to determine whether submaximal statin
doses, combined with nonstatin therapi[INVESTIGATOR_014], reduceASCVD risk in statin-intolerant patients.
4. Evaluation of the incidence, pathophysiology, clin-
ical course, and clinical outcomes of new-onsetdiabetes associated with statin therapy.
5. Outcomes of RCTs of new lipid-modifying agents to
determine the incremental ASCVD event-reductionbeneï¬ts when added to evidence-based statin therapy.
Additional research recommendations are included in
the Full Panel Report Supplement.
10. Conclusions
These recommendations arose from careful consideration
of an extensive body of higher-quality evidence derivedfrom RCTs and systematic reviews and meta-analyses ofRCTs. Rather than LDL-C or non â€“HDL-C targets, this
guideline used the intensity of statin therapy as the goal oftreatment. Through a rigorous process, [ADDRESS_755741] evidence demonstrated a reduction in ASCVD
events with a good margin of safety from moderate- orhigh-intensity statin therapy:
Four Statin Bene ï¬t Groups:
1. Individuals with clinical ASCVD2. Individuals with primary elevations of LDL-C /C21190
mg/dL
3. Individuals 40 to 75 years of age with diabetes and
LDL-C 70 to 189 mg/dL without clinical ASCVD
4. Individuals without clinical ASCVD or diabetes
who are [ADDRESS_755742] LDL-C 70 to
189 mg/dL and an estimated 10-year ASCVD risk of
/C217.5%. This requires a clinician-patient discussion.
Individuals in the last group can be identi ï¬ed by [CONTACT_575876]. Lifestylecounseling should occur at the initial and follow-up visitsas the foundation for statin therapy and may improve theoverall risk factor pro ï¬le.
Most importantly, our focus is on those individuals most
likely to bene ï¬t from evidence-based statin therapy to
reduce ASCVD risk. Implementation of these ASCVD
risk-reduction guidelines will help to substantially address
the large burden of fatal and nonfatal ASCVD in the[LOCATION_002]. We realize that these guidelines represent achange from previous guidelines, but clinicians have becomeaccustomed to change when that change is consistent withthe current evidence. Continued accumulation of qualitytrial data will inform future cholesterol treatment guidelines.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342914
Page 142 of 356Page 144 of 364
Presidents and Staff
American College of Cardiology
John Gordon Harold, MD, MACC, President
Shalom Jacobovitz, Chief Executive Of ï¬cer
William J. Oetgen, MD, MBA, FACC, Executive Vice
President, Science, Education, & Quality
Charlene May, Senior Director, Science and Clinical Policy
American College of Cardiology/American Heart Association
Lisa Brad ï¬eld, CAE, Director, Science and Clinical Policy
Emily Schiller, Specialist, Science and Clinical Policy
American Heart Association
Mariell Jessup, MD, FACC, FAHA, PresidentNancy Brown, Chief Executive Of ï¬cer
Rose Marie Robertson, MD, FAHA, Chief Science
Ofï¬cer
Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior
Vice President, Of ï¬ce of Science Operations
Marco Di Buono, PhD, Vice President of Science and
Research
Jody Hundley, Production Manager, Scienti ï¬c Publications,
Ofï¬ce of Science Operations
National Heart, Lung, and Blood Institute
Glen Bennett, MPHDenise Simons-Morton, MD, PhD
REFERENCES
1. Institute of Medicine (U.S.) Committee on Standards for Devel-
opi[INVESTIGATOR_575591], Graham R. ClinicalPractice Guidelines We Can Trust. Washington, D.C.: National
Academies Press; 2011.
2. Gibbons GH, Harold JG, Jessup M, et al. The next steps in
developi[INVESTIGATOR_575592]. J Am CollCardiol 2013;62:1399 â€“400.
3. Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the
agenda on cardiovascular guidelines: an announcement from theNational Heart, Lung, and Blood Institute. Circulation 2013;128:
1713 â€“5.
4. Expert Panel on Integrated Guidelines for Cardiovascular Health
and Risk Reduction in Children and Adolescents, National HeartLung and Blood Institute. Expert panel on integrated guidelines forcardiovascular health and risk reduction in children and adolescents:summary report. Pediatrics 2011;[ADDRESS_755743] 5:S213 â€“56.
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA
guideline for the management of heart failure: executive summery: areport of the American College of Cardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. J Am CollCardiol 2013;62:1495 â€“539.
6. National Cholesterol Education Program (U.S.), National Heart,
Lung, and Blood Institute, National Institutes of Health. Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) Final Report. Bethesda, MD: NationalCholesterol Education Program, National Heart, Lung, and BloodInstitute, National Institutes of Health; 2002. NIH Publication No.02â€“5215.
7. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical
trials for the National Cholesterol Education Program Adult
Treatment Panel III guidelines. Circulation 2004;110:227 â€“39.
8. National Cholesterol Education Program (U.S.) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol inAdults (Adult Treatment Panel III). Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detec-
tion, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adults Treatment Panel III) Final report. Circulation 2002;106:3143 â€“421.
9. AIM-HIGH Investigators, Boden WE, Probst ï¬eld JL. Niacin in
patients with low HDL cholesterol levels receiving intensive statintherapy. N Engl J Med 2011;67:2255 â€“67.
10. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline
on lifestyle management to red uce cardiovascular risk: a report of
the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2960 â€“84.
11. Goff DC Jr., Lloyd-Jones DM, D â€™Agostino RB Sr., et al. 2013
ACC/AHA guideline on the assessment of cardiovascular risk. J Am
Coll Cardiol 2014;63:2935 â€“59.
12. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary
prevention of cardiovascular disease. Cochrane Database Syst Rev2013.
13. Cholesterol Treatment Trialists â€™(CTT) Collaborators, Mihaylova B,
Emberson J, et al. The effects of lowering LDL cholesterol withstatin therapy in people at low risk of vascular disease: meta-analysis
of individual data from 27 randomised trials. Lancet 2012;380:
581 â€“90.
14. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of
combination lipid therapy in type 2 diabetes mellitus. N Engl J Med2010;362:1563 â€“74.
15. Taylor F, Ward K, Moore TH, et al. Statins for the primary pre-
vention of cardiovascular disease. Cochrane Database Syst Rev 2011.
CD004816.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in 20,536high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7 â€“22.
17. Downs JR, Clear ï¬eld M, Weis S, et al. Primary prevention of
acute coronary events with lovastatin in men and women withaverage cholesterol levels: results of AFCAPS/TexCAPS. Air Force/[LOCATION_007] Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615 â€“22.
18. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of
cardiovascular disease with pravastatin in Japan (MEGA Study):
a prospective randomised controlled trial. Lancet 2006;368:
1155 â€“63.
19. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract
from red yeast Chinese rice, on coronary events in a Chinese pop-ulation with previous myocardial infarction. Am J Cardiol 2008;101:1689 â€“93.
20. Cholesterol Treatment Trialists â€™(CTT) Collaboration, Baigent C,
Blackwell L. Ef ï¬
cacy and safety of more intensive lowering of LDL
cholesterol: a meta-analysis of data from 170,000 participants in 26randomised trials. Lancet 2010;376:1670 â€“81.
21. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of ef ï¬cacy and
safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in pa-tients aged <65 versus >orÂ¼65 years with coronary heart disease
(from the Incremental Decrease through Aggressive Lipid Lowering
[IDEAL] study). Am J Cardiol 2009;103:577 â€“82.
22. Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering
medication appropriateness for patients late in life. Arch Intern Med2006;166:605 â€“9.
23. Akushevich I, Kravchenko J, Ukraintseva S, et al. Age patterns of
incidence of geriatric disease in the U.S. elderly population:
Medicare-based analysis. J Am Geriatr Soc 2012;60:323 â€“7.
24. Wolff JL, Star ï¬eld B, Anderson G. Prevalence, expenditures, and
complications of multiple chronic conditions in the elderly. ArchIntern Med 2002;162:2269 â€“76.
25. Fried TR, Tinetti ME, Towle V, et al. Effects of bene ï¬ts and harms
on older persons â€™willingness to take medication for primary car-
diovascular prevention. Arch Intern Med 2011;171:923 â€“8.
26. Robinson JG, Bakris G, Torner J, et al. Is it time for a cardiovascular
primary prevention trial in the elderly? Stroke 2007;38:441 â€“50.
27. Porock D, Oliver D, Zweig S, et al. Predicting death in the nursing
home: development and validation of the 6-month Minimum DataSet mortality risk index. J Gerontol A Biol Sci Med Sci 2005;60:
491 â€“8.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2915
Page 143 of 356Page 145 of 364
28. Stineman MG, Xie D, Pan Q, et al. All-cause 1-, 5-, and 10-year
mortality in elderly people according to activities of daily living
stage. J Am Geriatr Soc 2012;60:485 â€“92.
29. Schonberg MA, Davis RB, McCarthy EP, et al. External validation
of an index to predict up to 9-year mortality of community-dwellingadults aged 65 and older. J Am Geriatr Soc 2011;59:1444 â€“51.
30. Fried TR, Tinetti ME, Iannone L, et al. Health outcome prioriti-
zation as a tool for decision making among older persons withmultiple chronic conditions. Arch Intern Med 2011;171:1854 â€“6.
31. Barry MJ, Edgman-Levitan S. Shared decision making dpi[INVESTIGATOR_575593]-centered care. N Engl J Med 2012;366:780 â€“1.
32. Man-Son-Hing M, Gage B, Montgomery AA. Preference-based
antithrombotic therapy in atrial ï¬brillation: implications for clinical
decision making. Med Decis Making 2005;25:548 â€“59.
33. Fried TR, Bradley EH, Towle VR, et al. Understanding the treat-
ment preferences of seriously ill patients. N Engl J Med 2002;346:
1061 â€“6.
34. Ditto PH, Druley JA, Moore KA, et al. Fates worse than death: the
role of valued life activities in health-state evaluations. Health Psy-chol 1996;15:332 â€“43.
35. Rosenfeld KE, Wenger NS, Kagawa-Singer M. End-of-life decision
making: a qualitative study of elderly individuals. J Gen Intern Med
2000;15:620 â€“5.
36. Nease RJ, Kneeland T, O â€™Connor GT, et al. Variation in patient
utilities for outcomes of the management of chronic stable angina:Implications for clinical practice guidelines. Ischemic Heart DiseasePatient Outcomes Research Team. JAMA 1995;273:1185 â€“90.
37. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for
primary prevention in older persons with elevated C-reactive protein
and low to average low-density lipoprotein cholesterol levels:exploratory analysis of a randomized trial. Ann Int Med 2010;152:488 â€“96. W174.
38. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly
individuals at risk of vascular disease (PROSPER): a randomised
controlled trial. Lancet 2002;360:1623 â€“30.
39. Trompet S, van Vliet P, de Craen AJM, et al. Pravastatin and
cognitive function in the elderly. Results of the PROSPER study.J Neurol 2010;257:85 â€“90.
40. Gray SL, Boudreau RM, Newman AB, et al. Angiotensin-
converting enzyme inhibitor and statin use and incident mobilitylimitation in community-dwelling older adults: the Health,
Aging and Body Composition Study. J Am Geriatr Soc 2011;59:
2226 â€“32.
41. LaCroix AZ, Gray SL, Aragaki A, et al. Statin use and incident
frailty in women aged 65 years or older: prospective ï¬ndings from
the Women â€™s Health Initiative Observational Study. J Gerontol A
Biol Sci Med Sci 2008;63:369 â€“75.
42. Hippi[INVESTIGATOR_356112]-C ox J, Pringle M, Cater R, et al. Coronary heart disease
prevention and age inequalities: the ï¬rst year of the National Service
Framework for CHD. Br J Gen Pract 2005;55:369 â€“75.
43. Forman DE, Rich MW, Alexander KP, et al. Cardiac care for
older adults. Time for a new paradigm. J Am Coll Cardiol 2011;57:1801 â€“10.
44. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and
treatment of hypertriglyceridemia: an Endocrine Society clinical
practice guideline. J Clin Endocrinol Metab 2012;97:2969 â€“89.
45. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardio-
vascular disease: a scienti ï¬c statement from the American Heart
Association. Circulation 2011;123:2292 â€“333.
46. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering
with atorvastatin in patients with stable coronary disease. N Engl JMed 2005;352:1425 â€“35.
47. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose ator-
vastatin vs usual-dose simvastatin for secondary prevention aftermyocardial infarction: the IDEAL study: a randomized controlledtrial. JAMA 2005;294:2437 â€“45.
48. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus
moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med 2004;350:1495 â€“504.
49. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to
prevent vascular events in men and women with elevated C-reactiveprotein. N Engl J Med 2008;359:2195 â€“207.
50. Baigent C, Keech A, Kearney P, et al. Ef ï¬cacy and safety of
cholesterol-lowering treatment: prospective meta-analysis of datafrom 90,056 participants in 14 randomised trials of statins. Lancet
2005;366:1267 â€“78.
51. Thompson GR, Packard CJ, Stone NJ. Goals of statin therapy: three
viewpoints. 2002. Atheroscler Suppl 2004;5:107 â€“14.
52. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular
beneï¬ts and diabetes risks of statin therapy in primary prevention: an
analysis from the JUPI[INVESTIGATOR_245039]. Lancet 2012;380:565 â€“71.
53. Rof ï¬M, Angiolillo DJ, Kappetein AP. Current concepts on coro-
nary revascularization in diabetic patients. Eur Heart J 2011;32:
2748 â€“57.
54. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes
treatment and cardiovascular disease in patients with type 1 diabetes.N Engl J Med 2005;353:2643 â€“53.
55.Rhodes ET, Prosser LA, Hoerger TJ, et al. Estimated morbidity
andmortality in adolescents and young adults diagnosed with Type
2 diabetes mellitus. Diabet Med 2012;29:453 â€“63.
56. Paynter NP, Mazer NA, Pradhan AD, et al. Cardiovascular risk pre-
diction in diabetic men and women using hemoglobin A1c vs diabetes
as a high-risk equivalent. Arch Intern Med 2011;171:1712 â€“8.
57. Elley CR, Robinson E, Kenealy T, et al. Derivation and validation
of a new cardiovascular risk score for people with type 2 diabetes:
the New Zealand Diabetes Cohort Study. Diabetes Care 2010;33:
1347 â€“52.
58. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for
myocardial infarction case fatality and stroke case fatality in type 2diabetes: [LOCATION_006]PDS 66. Diabetes Care 2004;27:201 â€“7.
59. Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent
overweight and future adult coronary heart disease. N Engl J Med
2007;357:2371 â€“9.
60. Daniels SR, Jacobson MS, McCrindle BW, et al. American Heart
Association Childhood Obesity Research Summit Report. Circula-tion 2009;119:e489 â€“517.
61. Jacob M, Cho L. Asian Americans and cardiometabolic risk: why
and how to study them. J Am Coll Cardiol 2010;55:974 â€“5.
62. Bainey KR, Jugdutt BI. Increased burden of coronary artery disease
in South-Asians living in North America. Need for an aggressivemanagement algorithm. Atherosclerosis 2009;204:1 â€“10.
63. Yu T, Vollenweider D, Varadhan R, et al. Support of personalized
medicine through risk-strati ï¬ed treatment recommendations - an
environmental scan of clinical practice guidelines. BMC Med 2013;
11:7.
64. Lescol ( ï¬‚uvastatin sodium) [prescribing information]. [COMPANY_001]
Pharmaceuticals. East Hanover, NJ; 2012.
65. Pravachol (pravastatin sodium) [prescribing information]. Bristol
Myers Squibb Co. Princeton, NJ; 2012.
66. Livalo (pi[INVESTIGATOR_575594]) [prescribing information]. Kowa Pharmaceuti-
cals. Montgomery, AL; 2012.
67. Zocor (Simvastatin) [prescribing information]. [COMPANY_006] & Co.
Whitehouse Station, NJ; 2012.
68. Mevacor (Lovastatin) [prescribing information]. [COMPANY_006] & Co.
Whitehouse Station, NJ; 2012.
69. Lipi[INVESTIGATOR_17133] (atorvastatin calcium) [prescribing information]. P ï¬zer Inc.
[LOCATION_001], NY; 2012.
70. Crestor (rosuvastatin calcium) [prescribing information]. AstraZe-
neca Pharmaceuticals. Wilmington, DE; 2013.
71. Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival Study(4S). Lancet 1994;344:1383 â€“9.
72. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart
disease with pravastatin in men with hypercholesterolemia. West of
Scotland Coronary Prevention Study Group. N Engl J Med 1995;
333:1301 â€“7.
73. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on
coronary events after myocardial infarction in patients with averagecholesterol levels. Cholesterol and Recurrent Events Trial in-vestigators. N Engl J Med 1996;335:1001 â€“9.
74. Prevention of cardiovascular events and death with pravastatin in
patients with coronary heart disease and a broad range of initial
cholesterol levels. The Long-Term Intervention with Pravastatin inIschaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349 â€“57.
75. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary pre-
vention of cardiovascular disease with atorvastatin in type 2 diabetes
in the Collaborative Atorvastatin Diabetes Study (CARDS):Stone et al.
JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342916
Page 144 of 356Page 146 of 364
multicentre randomised placebo-controlled trial. Lancet 2004;364:
685 â€“96.
76. Deleted in Press.77. Amarenco P, Bogousslavsky J, Callahan Ar, et al. High-dose ator-
vastatin after stroke or transient ischemic attack. N Engl J Med2006;355:549â€“ 59.
78. The Stroke Prevention by [CONTACT_575877] (SPARCL) Investigators. High-dose atorvastatin after strokeor transient ischemic attack. N Engl J Med 2006;355:549 â€“59.
79. Vodnala D, Ruben ï¬re M, Brook RD. Secondary causes of dyslipi-
demia. Am J Cardiol 2012;110:823 â€“5.
80. Stone NJ, Blum CB. Management of Lipi[INVESTIGATOR_575595]. 7th
ed. Caddo, OK: Professional Communications; 2008.
81. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident
diabetes: a collaborative meta-analysis of randomised statin trials.
Lancet 2010;375:735 â€“42.
82. Guiding the guidelines. Lancet 2011;377:1125.
83. Expert Panel on Detection Evaluation and Treatment of High
Blood Cholesterol in Adults. Executive Summary of the ThirdReport of the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults (Adult Treatment Panel III). JAMA
2001;285:2486 â€“97.
84. FellstrÃ¶m BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and
cardiovascular events in patients undergoing hemodialysis. N Engl J
Med 2009;360:1395 â€“407.
85. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients
with systolic heart failure. N Engl J Med 2007;357:2248â€“ 61.
86. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of
rosuvastatin in patients with chronic heart failure (the GISSI-HFtrial): a randomised, double-blind, placebo-controlled trial. Lancet2008;372:1231 â€“9.
87. Wanner C, Krane V, MÃ¤rz W, et al. Atorvastatin in patients with
type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med
2005;353:238â€“ 48.
88. Eckel RH. Approach to the patient who is intolerant of statin
therapy. J Clin Endocrinol Metab 2010;95:2015â€“ 22.
89. U.S. Food and Drug Administration. FDA Drug Safety Commu-
nication: important safety label changes to cholesterol-lowering
statin drugs. Rockville, MD: U.S. Food and Drug Administration;2012.
90. U.S. Food and Drug Administration. FDA Drug Safety Commu-
nication: ongoing safety review of high-dose Zocor (simvastatin) andincreased risk of muscle injury. Rockville, MD: U.S. Food and DrugAdministration; 2010.
91. Association AD. Standards of medical care in diabetes â€“2013. Dia-
betes Care 2013;[ADDRESS_755744] 1:S11 â€“66.
92. Rawlins M. De testimonio: on the evidence for decisions about the
use of therapeutic interventions. Lancet 2008;372:2152 â€“61.
93.Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of ator-vastatin on early recurrent ischemic events in acute coronary syn-
dromes: the MIRACL study: a randomized controlled trial. JAMA2001;285:1711 â€“8.
94.Shepherd J, Barter P, Carmena R, et al. Effect of lowering
LDL cholesterol substantially below currently recommended
levels in patients with coronary heart disease and diabetes: theTreating to New Targets (TNT) study. Diabetes Care 2006;29:1220 â€“6.
95. Deleted in Press.96. Baigent C, Blackwell L, Emberson J, et al. Efï¬cacy and safety of
more intensive lowering of LDL cholesterol: a meta-analysis of datafrom 170,000 participants in 26 randomised trials. Lancet 2010;376:1670 â€“81.
97. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovas-
cular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol2008;52:1769 â€“81.
98. Dale KM, White CM, Henyan NN, et al. Impact of statin dosing
intensity on transaminase and creatine kinase. Am J Med 2007;120:706 â€“12.
99. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering
with simvastatin on stroke and other major vascular events in 20536people with cerebrovascular disease or other high-risk conditions.
Lancet 2004;363:757 â€“67.100. Roberts MD. Crestor (rosuvastatin calcium) NDA 21 â€“336 JUPI[INVESTIGATOR_247470].
Paper presented at U.S. Food and Drug Administration, Endocri-nologic and Metabolic Drugs Advisory Meeting, December 15, 2009.
Gaithersburg, MD: U.S. Food and Drug Administration; 2009.
101. Clo ï¬brate and niacin in coronary heart disease. JAMA 1975;231:
360 â€“81.
102. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am
J Cardiol 2007;99:22C â€“31C.
103. Brown BG, Zhao XQ. Nicotinic acid, alone and in combina-
tions, for reduction of cardiovascular risk. Am J Cardiol 2008;101:58B â€“62B.
104. Grundy SM, Vega GL, McGovern ME, et al. Efï¬cacy, safety, and
tolerability of once-daily niacin for the treatment of dyslipi[INVESTIGATOR_575596] 2 diabetes: results of the assessment of diabetescontrol and evaluation of the ef ï¬cacy of niaspan trial. Arch Intern
Med 2002;162:1568 â€“76.
105. Crouse JR 3rd Hypertriglyceridemia: a contraindication to the use of
bile acid binding resins. Am J Med 1987;83:243 â€“8.
106. Thompson GR, HEART-[LOCATION_006] LDL Apheresis Working Group.
Recommendations for the use of LDL apheresis. Atherosclerosis2008;198:247 â€“55.
107. Schwertz DW, Badellino KO. High-dose statin therapy for sec-
ondary prevention of stroke: stroke prevention by [CONTACT_575878]. J Cardiovasc Nurs 2008;23:8 â€“13.
108. Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline
characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis(SEAS) study. Am J Cardiol 2007;99:970 â€“3.
109. Sharp Collaborative Group. Study of Heart and Renal Protection
(SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronickidney disease. Am Heart J 2010;160:785 â€“794. e10.
110. Yokoyama M, Origasa H, JELIS Investigators. Effects of eicosa-
pentaenoic acid on cardiovascular events in Japanese patients with
hypercholesterolemia: rationale, design, and baseline characteristics
of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J2003;146:613 â€“20.
111. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-
prevention trial with gem ï¬brozil in middle-aged men with dyslipi-
demia. Safety of treatment, changes in risk factors, and incidence ofcoronary heart disease. N Engl J Med 1987;317:1237 â€“45.
112. The Lipid Research Clinics Coronary Primary Prevention Trial
results. II. The relationship of reduction in incidence of coronaryheart disease to cholesterol lowering. JAMA 1984;251:365 â€“74.
113. The Lipid Research Clinics Coronary Primary Prevention Trial
results. I. Reduction in incidence of coronary heart disease. JAMA1984;251:351 â€“64.
114. Rubins HB, Robins SJ, Collins D, et al. Gem ï¬brozil for the sec-
ondary prevention of coronary heart disease in men with low levelsof high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.N Engl J Med 1999;341:410â€“ 8.
115. Keech A, Simes RJ, Barter P, et al. Effects of long-term feno ï¬brate
therapy on cardiovascular events in 9795 people with type 2 diabetes
mellitus (the FIELD study): randomised controlled trial. Lancet
2005;366:1849 â€“61.
116. HPS2-THRIVE Collaborative Group. HPS2-THRIVE random-
ized placebo-controlled trial in 25 673 high-risk patients of ERniacin/laropi[INVESTIGATOR_105169]: trial design, pre-speciï¬ed muscle and liver out-comes, and reasons for stoppi[INVESTIGATOR_262]. Eur Heart J 2013;
34:1279 â€“91.
117. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a
delayed conservative simvastatin strategy in patients with acute
coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307 â€“16.
118. Koren MJ, Hunninghake DB, ALLIANCE Investigators. Clinical
outcomes in managed-care patients with coronary heart disease
treated aggressively in lipid-lowering disease management clinics:
the ALLIANCE study. J Am Coll Cardiol 2004;44:1772 â€“9.
119. Knopp RH, d â€™Emden M, Smilde JG, et al. Ef ï¬cacy and safety of
atorvastatin in the prevention of cardiovascular end points in subjectswith type 2 diabetes: the Atorvastatin Study for Prevention ofCoronary Heart Disease Endpoints in nonâ€“ insulin-dependent dia-
betes mellitus (ASPEN). Diabetes Care 2006;29:1478 â€“85.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2917
Page 145 of 356Page 147 of 364
120. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment
with atorvastatin to the National Cholesterol Educational Program
goal versus â€œusual â€care in secondary coronary heart disease pre-
vention. The GREek Atorvastatin and Coronary-heart-disease
Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220 â€“8.
121. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin,
antioxidant vitamins, or the combination for the prevention ofcoronary disease. N Engl J Med 2001;345:1583 â€“92.
122. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for pre-
vention of cardiac events following successful ï¬rst percutaneous
coronary intervention: a randomized controlled trial. JAMA 2002;287:3215 â€“22.
123. Sakamoto T, Kojima S, Ogawa H, et al. Effects of early statin
treatment on symptomatic heart failure and ischemic events afteracute myocardial infarction in Japanese. Am J Cardiol 2006;97:
1165 â€“71.
124. Study of the Effectiveness of Additional Reductions in Cholesterol
and Homocysteine (SEARCH) Collaborative Group, Armitage J,
Bowman L, et al. Intensive lowering of LDL cholesterol with80 mg versus 20 mg simvastatin daily in 12,064 survivors ofmyocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658 â€“69.
125. Ahmed S, Cannon CP, Murphy SA, et al. Acute coronary syn-
dromes and diabetes: is intensive lipid lowering bene ï¬cial? Results of
the PROVE IT-TIMI 22 trial. Eur Heart J 2006;27:2323â€“9.
126. Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of
using high- or low-dose atorvastatin in patients 65 years of age orolder with stable coronary heart disease. Ann Int Med 2007;147:
1â€“9.
127. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in
elderly patients with a recent stroke or transient ischemic attack.
Neurology 2009;72:688 â€“94.
128. Shepherd J, Kastelein JJP, Bittner V, et al. Intensive lipid lowering
with atorvastatin in patients with coronary heart disease and chronic
kidney disease: The TNT (Treating to New Targets) study. J Am
Coll Cardiol 2008;51:1448 â€“54.
129. Shepherd J, Kastelein JP, Bittner VA, et al. Intensive lipid lowering
with atorvastatin in patients with coronary artery disease, diabetes,and chronic kidney disease. Mayo Clin Proc 2008;83:870 â€“9.
130. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on
coronary events after myocardial infarction in patients with average
cholesterol levels. Cholesterol and Recurrent Events Trial In-
vestigators. N Engl J Med 1996;335:1001 â€“9.
131. ALLHAT Of ï¬cers and Coordinators for the ALLHAT Collabo-
rative Research Group. Major outcomes in moderately hypercho-lesterolemic, hypertensive patients randomized to pravastatin vsusual care: The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:
2998 â€“3007.
132. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular
events with atorvastatin in 2,532 patients with type 2 diabetes:Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm(ASCOT-LLA). Diabetes Care 2005;28:1151 â€“7.
133. Holdaas H, FellstrÃ¶m B, Cole E, et al. Long-term cardiac outcomes
in renal transplant recipi[INVESTIGATOR_513160] ï¬‚uvastatin: the ALERT
extension study. Am J Transplant 2005;5:2929 â€“36.
134. Cholesterol Treatment Trialists Collaboration, Kearney PM,
Blackwell L, et al. Efï¬cacy of cholesterol-lowering therapy in 18,686people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117 â€“25.
135. Messerli FH, Pi[INVESTIGATOR_1946] L, Tang SSK, et al. Impact of systemic hy-
pertension on the cardiovascular bene ï¬ts of statin therapy â€“a meta-
analysis. Am J Cardiol 2008;101:319 â€“25.
136. Kizer JR, Madias C, Wilner B, et al. Relation of different measures
of low-density lipoprotein cholesterol to risk of coronary arterydisease and death in a meta-regression analysis of large-scale trials of
statin therapy. Am J Cardiol 2010;105:1289 â€“96.
137. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mor-
tality in high-risk primary prevention: a meta-analysis of 11 ran-
domized controlled trials involving 65,229 participants. Arch InternMed 2010;170:1024 â€“31.
138. Brugts JJ, Yetgin T, Hoeks SE, et al. The bene ï¬ts of statins in
people without established cardiovascular disease but with cardio-
vascular risk factors: meta-analysis of randomised controlled trials.
BMJ 2009;338:b2376.
139. Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary
prevention of cardiovascular mortality in women: a systematic reviewand meta-analysis. Prev Cardiol 2010;13:84 â€“90.
140. Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in
primary prevention of cardiovascular events in women: analysis of theManagement of Elevated Cholesterol in the Primary Prevention Groupof Adult Japanese (MEGA study). Circulation 2008;117:494 â€“502.
141. Bonovas S, Filioussi K, Tsantes A, et al. Use of statins and risk of
haematological malignancies: a meta-analysis of six randomizedclinical trials and eight observational studies. Br J Clin Pharmacol
2007;64:255 â€“62.
142. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes
with intensive-dose compared with moderate-dose statin therapy: a
meta-analysis. JAMA 2011;305:2556 â€“64.
143. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in
Coronary Drug Project patients: long-term bene ï¬t with niacin.
J Am Coll Cardiol 1986;8:1245 â€“55.
144. Parolari A, Tremoli E, Cavallotti L, et al. Do statins improve
outcomes and delay the progression of non-rheumatic calci ï¬c aortic
stenosis? Heart 2011;97:523 â€“9.
Key Words: ACC/AHA Practice Guideline
-biomarkers,
pharmacological -cardiovascular disease -cholesterol -diabetes
mellitus -drug therapy -hydroxymethylglutaryl-CoA reductase
inhibitors/statins -hypercholesterolemia -lipi[INVESTIGATOR_805]-patient
compliance -primary prevention -risk assessment -risk reduction
behavior -secondary prevention.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342918
Page 146 of 356Page 148 of 364
Appendix 1. Author Relationships With Industry and Other Entities (Relevant) d
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol in Adults to
Reduce Atherosclerotic Cardiovascular Risk
Panel Member Employment ConsultantSpeakers
BureauOwnership/
Partnership/
PrincipalPersonal
Research Expert Witness
Neil J. Stone
ChairNorthwestern Memorial
Hospi[INVESTIGATOR_575597],
Feinberg School ofMedicine, Northwestern
University2008â€“2012:
None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Jennifer G. Robinson
Co-ChairUniversity of Iowa d
Professor of
Epi[INVESTIGATOR_575598]; Prevention
Intervention
CenterdDirector2008â€“2012:
None2008â€“2012:None2008 â€“2012:
None2008â€“2012:
/C15Aegerion
/C15Amarin*
/C15[COMPANY_010]*
/C15[COMPANY_008]*
/C15Esperion
/C15Genentech/
Hoffman La[COMPANY_002]*
/C15GlaxoSmithKline*
/C15[COMPANY_006]*
/C15Sano ï¬-aventis/
Regeneron *2008 â€“2012:
None
2013:
None2013:None2013:None2013:
/C15Amarin*
/C15[COMPANY_010]*
/C15[COMPANY_008]*
/C15Genentech/
Hoffman La[COMPANY_002]*
/C15GlaxoSmithKline*
/C15[COMPANY_006]*
/C15Sano ï¬-aventis/
Regeneron*2013:
None
Alice H. Lichtenstein
Co-ChairTufts University, USDA
Human NutritionResearch Center
on Aging dGershoff
Professor of Nutrition
Science and Policy;
Professor of Public
Health and Family
Medicine2008â€“2012:None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
C. Noel Bairey Merz Cedars-Sinai Medical
CenterdWomen â€™s
Guild Endowed Chair
in Women â€™s Health
Barbara Streisand
Women â€™s Heart
CenterdDirector;
Preventive CardiacCenterdProfessor
of Medicine2008â€“2012:
/C15Abbott Vascular
/C15Bayer
/C15Bristol-Myers Squibb
/C15[COMPANY_009]
/C15[COMPANY_001]
/C15Pï¬zer
/C15Posen2008â€“2012:
None2008 â€“2012:
/C15ATS Medical
/C15[LOCATION_011] Scienti ï¬c
/C15Eli Lilly
/C15Johnson &
Johnson
/C15Medtronic
/C15TevaPharmaceuticals2008â€“2012:
/C15RWISE
/C15Ranexa Microvascular
/C15Ranexa Angina2008 â€“2012:
None
2013:
/C15[COMPANY_010]*
/C15[COMPANY_009]
/C15Bristol-MyersSquibb(DSMB)2013:
None2013:None2013:
/C15RWISE2013:None
Conrad Blum Columbia University
Medical Center,Columbia University
College of Physicians
and Surgeons d
Professor of Medicine2008â€“2012:None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:None2013:None2013:None2013:None2013:None
Continued on the next pageJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2919
Page 147 of 356Page 149 of 364
Appendix 1. Continued
Panel Member Employment ConsultantSpeakers
BureauOwnership/
Partnership/
PrincipalPersonal
Research Expert Witness
Robert H. Eckel University of Colorado,
Denver School of
Medicine dProfessor of
Medicine; Professor of
Physiology and
Biophysics; and Charles
A. Boettcher II Chair in
Atherosclerosis2008â€“2012:
/C15Foodminds
/C15[COMPANY_006]
/C15Pï¬zer
/C15Abbott2008â€“2012:
None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
/C15Amylin
/C15Eli Lilly
/C15Esperion
/C15Foodminds
/C15[COMPANY_012]
/C15Novo Nordisk
/C15Vivus2013:None2013:None2013:
/C15GlaxoSmithKline*
/C15Sano ï¬-aventis/
Regeneron2013:None
Anne Carol Goldberg Washington University
School of Medicine d
Associate Professor of
Medicine2008â€“2012:
/C15Abbott
/C15[COMPANY_002]
/C15ISIS/Genzyme
/C15Sano ï¬-aventis
/C15Unilever
/C15[COMPANY_006]2008â€“2012:
None2008 â€“2012:
None2008â€“2012:
/C15Abbott*
/C15Aegerion*
/C15Amarin*
/C15[COMPANY_010]*
/C15Genentech/[COMPANY_002]*
/C15GlaxoSmithKline*
/C15ISIS/Genzyme*
/C15[COMPANY_006]*
/C15[COMPANY_001]
/C15Reliant*
/C15Sano ï¬-aventis/Regeneron*
/C15Sano ï¬-aventis*2008 â€“2012:
None
2013:
/C15[COMPANY_006]2013:
None2013:None2013:
/C15Abbott*
/C15Amarin*
/C15[COMPANY_010]*
/C15Genentech/[COMPANY_002]*
/C15GlaxoSmithKline*
/C15ISIS/Genzyme*
/C15[COMPANY_006]*
/C15Sano ï¬-aventis/Regeneron*2013:None
David Gordon,
Ex-Of ï¬cioNHLBIdSpecial Assistant
for Clinical Studies,Division of
CardiovascularDiseases2008â€“2012:None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Daniel Levy,
Ex-Of ï¬cioNHLBIdDirector of the
Center for Population
Studies2008â€“2012:
None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Donald M. Lloyd-Jones Northwestern University
Feinberg School ofMedicine dSenior
Associate Dean; Chair
and Professor of
Preventive Medicine;Professor of Medicine
(Cardiology)2008â€“2012:None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Patrick McBride University of Wisconsin
School of Medicine and
Public Health d
Professor of Medicine
and Family Medicine2008â€“2012:None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342920
Page 148 of 356Page 150 of 364
Appendix 1. Continued
Panel Member Employment ConsultantSpeakers
BureauOwnership/
Partnership/
PrincipalPersonal
Research Expert Witness
J. Sanford Schwartz University of Pennsylvania
School of Medicine d
Leon Hess Professor of
Internal Medicine,Health Management
and Economics2008â€“2012:
/C15Abbott
/C15Allergan
/C15[COMPANY_010]
/C15Daiichi-Sankyo
/C15Genentech
/C15[COMPANY_012]
/C15[COMPANY_006]
/C15Pï¬zer
/C15Shire Pharmaceuticals2008â€“2012:
None2008 â€“2012:
None2008â€“2012:
/C15Pï¬zer2008 â€“2012:
None
2013:
/C15Abbott
/C15Allergan
/C15[COMPANY_010]
/C15Daiichi-Sankyo
/C15Genentech
/C15[COMPANY_012]
/C15[COMPANY_006]
/C15Pï¬zer
/C15Shire Pharmaceuticals2013:None2013:None2013:
/C15Pï¬zer2013:None
Susan T. Shero
Ex-Of ï¬cioNHLBIdPublic Health
Advisor2008â€“2012:
None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Sidney C. Smith, Jr University of North
CarolinadProfessor of
Medicine; Center forCardiovascular Science
and Medicine dDirector2008â€“2012:
None2008â€“2012:None2008 â€“2012:
None2008â€“2012:None2008 â€“2012:
None
2013:
None2013:None2013:None2013:None2013:None
Karol Watson University of [LOCATION_004],
Los Angeles School of
Medicine dCo-Director2008â€“2012:
/C15Abbott
/C15[COMPANY_008]
/C15Genzyme
/C15GlaxoSmithKline
/C15Kos
/C15Medtronic
/C15[COMPANY_006]
/C15[COMPANY_001]
/C15Pï¬zer2008â€“2012:None2008 â€“2012:
None2008â€“2012:
/C15[COMPANY_006]2008 â€“2012:
None
2013:
None2013:None2013:None2013:
/C15[COMPANY_006]2013:None
Peter W.F. Wilson Atlanta VA Medical Center
and Emory University
School of Medicine d
Professor of Medicine2008â€“2012:
/C15[COMPANY_006]
/C15XZK2008â€“2012:None2008 â€“2012:
None2008â€“2012:
/C15[COMPANY_006]
/C15Liposcience2008 â€“2012:
None
2013:None2013:None2013:None2013:
/C15[COMPANY_006]2013:None
This table re ï¬‚ects the relevant healthcare-related relationships of authors with industry and other entities provided by [CONTACT_575879] (2008 â€“2012). Both
compensated and uncompensated relationships are reported. These relationships were reviewed and updated in conjunction with all meetings and conference calls of the Expert Panel during the
document development process. Authors with relevant relationships during the document development process recused themselves from voting on recommendations relevant to their relationships. In
the spi[INVESTIGATOR_575599], the ACC and AHA asked Expert Panel members to provide updates and approve the ï¬nal version of this table, which includes current relevant relationships (2013). To review
the NHLBI and ACC/AHA â€™s current comprehensive policies for managing relationships with industry and other entities, please refer to http://www.nhlbi.nih.gov/guidelines/cvd_adult/coi-rwi_policy.htm
and http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx. Per ACC/AHA policy: A person is deemed to have a signiï¬ cant
interest in a business if the interest represents ownership of /C215% of the voting stock or share of the business entity, or ownership of /C21$10,000 of the fair market value of the business entity; or if funds
received by [CONTACT_575880] 5% of the person â€™s gross income for the previous year. Relationships that exist with no ï¬nancial bene ï¬t are also included for the purpose of
transparency. Relationships in this table are modest unless otherwise noted.
*Signi ï¬cant relationship.
ACC indicates American College of Cardiology; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; and USDA, U.S. Department of Agriculture.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2921
Page 149 of 356Page 151 of 364
Appendix 2. Expert Reviewers Relationships With Industry and Other Entities d
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol in Adults to
Reduce Atherosclerotic Cardiovascular Risk
Reviewer Employment Representation ConsultantSpeakers
BureauOwnership/
Partnership/
PrincipalPersonal
ResearchExpert
Witness
Roger Blumenthal Johns Hopkins Hospi[INVESTIGATOR_575600]/AHA None None None None None
William Virgil Brown Emory University School
of MedicineNLA /C15Abbott
/C15[COMPANY_010]
/C15Anthera
/C15Bristol-Myers Squibb
/C15Catabasis
/C15Cerenis
/C15GlaxoSmithKline
/C15Genzyme
/C15LipoScience
/C15[COMPANY_006]
/C15Pï¬zer
/C15RegeneronNone None None None
Linda Hemphill [LOCATION_005] General
Hospi[INVESTIGATOR_575601],
LDL Apheresis ProgramNLA /C15Regeneron None None None None
Matthew Ito Oregon Health & Science
University, Departmentof Pharmacy Practice d
ProfessorNLA /C15Aegeron
/C15KowaNone None None None
Terry Jacobson Emory University NLA /C15Abbott
/C15[COMPANY_006]None None /C15Amarin
/C15HealthCoreNone
Andrew Kates Washington University School
of Medicine in St. Louis d
Cardiovascular FellowshipProgram DirectorACC/AHA None None None None None
James M. McKenney Virginia Commonwealth
University dProfessor
EmeritusNLA None None None None None
E. Magnus Ohman Duke Clinical Research
InstitutedProfessor of
Medicine; Program for
Advanced Coronary
DiseasedDirectorACC/AHA Task
Force onPractice
GuidelinesNone None None None None
Carl E. Orringer Case Western Reserve University
School of Medicine dAssociat e
Professor of MedicineNLA None None None None None
Robert S. Rosenson Mount Sinai Hospi[INVESTIGATOR_307] d
Director, Preventive
Cardiology; Professorof Medicine, CardiologyNLA /C15[COMPANY_010]
/C15LipoScience
/C15[COMPANY_001]
/C15Pï¬zer
/C15Sano ï¬-aventis/
RegeneronNone /C15LipoScience None None
John Rumsfeld Denver VA Medical Center,
University of Colorado d
National Director ofCardiology, U.S. VeteransHealth AdministrationACC/AHA None None None None None
Robert A. Wild University of Oklahoma, College
of Medicine, Department ofObstetrics and Gynecology d
ProfessorNLA /C15Atherotec None None None None
This table represents the relationships of reviewers with industry and other entities that were self-disclosed at the time of peer review. It does not necessarily re ï¬‚ect relationships with industry at the time
of publication. To review the NHLBI and ACC/AHA â€™s current comprehensive policies for managing relationships with industry and other entities, please refer to http://www.nhlbi.nih.gov/guidelines/cvd_
adult/coi-rwi_policy.htm and http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx .
ACC indicates American College of Cardiology; AHA, American Heart Association; NLA, National Lipid Association; and VA, Veterans Affairs.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342922
Page 150 of 356Page 152 of 364
Appendix 3. Abbreviations
ALTÂ¼alanine transaminase
ASCVD Â¼atherosclerotic cardiovascular disease
CHD Â¼coronary heart disease
COR Â¼Class of Recommendation
CQÂ¼critical question
HDL-C Â¼high-density lipoprotein cholesterol
LDL-C Â¼low-density lipoprotein cholesterol
LOEÂ¼Level of Evidence
MIÂ¼myocardial infarction
NHLBI Â¼National Heart, Lung, and Blood Institute
RCTÂ¼randomized controlled trial
RWIÂ¼relationships with industry and other entities
Appendix 4. Evidence Statements
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
1 Data are not available regarding treatment or titration to a speci ï¬c LDL-C
goal in adults with CHD/CVD. The Expert Panel found insuf ï¬cient
evidence to support setting LDL-C goals in CHD/CVD patients.I Secondary Prevention Conclusion after reviewing 19 RCTs in CQ1 Evidence
Table:
4D (87) ,Aâ€“Z (117), ACCORD (14), ALLIANCE (118),
ASPEN (119), AURORA (84), CARE (73),
CORONA (85), GREACE (120), HATS (121), HPS
(16), IDEAL (47), LIPID (74), LIPS (122), MIRACL(93), MUSHASHI-AMI (123), PROVE-IT (48),
SPARCL (78,107), TNT (46)
2 The Expert Panel did not identify any trials in adults with CHD/CVD
reporting mean or median on-treatment non â€“HDL-C levels in adults with
CHD/CVD.Secondary Prevention N/A
3 LDL-C goals <130 mg/dL or <100 mg/dL in patients without CHD/CVD.
Randomized trial data are not available regarding dose titration toachieve a speci ï¬c LDL-C goal.I Primary Prevention Conclusion after reviewing 6 RCTs included in CQ2:
AFCAPS (17), ASPEN (119), AURORA (84), CARDS
(75), JUPI[INVESTIGATOR_247470] (49), MEGA (18)
4 There was insuf ï¬cient evidence in women without CHD/CVD to evaluate
the reduction in CVD risk with achieved LDL-C levels <130 mg/dL
or<100 mg/dL.I Primary Prevention N/A
5 The Expert Panel did not identify any trials in adults without CHD/CVD
reporting on-treatment non â€“HDL-C levels in adults with CHD/CVD.Primary Prevention N/A
6 In adults with CHD/CVD, ï¬xed high-intensity statin treatment (atorvastatin
40â€“80mg) that achieved a mean LDL-C 67 â€“79 mg/dL reduced the
RR for CHD/CVD events more than ï¬xed lower-dose statin treatment
that achieved a mean LDL-C 97 â€“102 mg/dL. In these trials, the
mean LDL-C levels achieved differed by 23 â€“30 mg/dL, or 22% â€“32%,
between the 2 groups. Simvastatin 80 mg did not decrease CVD
events compared with simvastatin 20 â€“40 mg.
See Table 4 for de ï¬nitions of high, moderate, and low intensity for statins.
Higher intensity Â¼atorvastatin 40 â€“80 mg
Moderate intensity Â¼atorvastatin 10 mg, pravastatin 40 mg,
or simvastatin 20 â€“40 mgH Secondary Prevention Bene ï¬t:
TNT (46), IDEAL (47), PROVE-IT (48)
Lower LDL-C reductions, no bene ï¬t:
Aâ€“Z (117), ACCORD (14)
No difference in LDL-C between groups: (SEARCH
(124) not included in CQ1)
7 In adults with CHD/CVD who do not have Class II â€“IV heart failure, ï¬xed
high-intensity statin (atorvastatin 80 mg) or statin-niacin treatment thatachieved a mean LDL-C 72 â€“79 mg/dL reduced the RR for CHD/CVD
events compared with placebo with a mean LDL-C 112 â€“135 mg/dL.
In these trials, the mean LDL-C levels were reduced by 45 â€“57 mg/dL
or by 45% (HATS [121]) to 53% (SPARCL [107]).H Secondary Prevention SPARCL (107)
HATS (121)MIRACL (93)CORONA (85) â€“no bene ï¬t
Continued on the next pageJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2923
Page 151 of 356Page 153 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
8 In adults with CHD/CVD and diabetes, ï¬xed high-intensity statin treatment
(atorvastatin 80 mg) that achieved a mean LDL-C of 57 â€“77 mg/dL
reduced the RR for CHD/CVD events more than ï¬xed lower-intensity
statin treatment that achieved a mean LDL-C of 81 â€“99 mg/dL. In these
trials, the mean LDL-C levels achieved differed by 22â€“ 24 mg/dL,
or 22% â€“30%, between the 2 groups.M to H Secondary Prevention
(diabetes subgroup
included)TNT (46,94), PROVE-IT (48,125)No diabetes subgroup publications found for MIRACL
(93) or IDEAL (47)
9I n a d u l t s /C2165 years of age with CHD/CVD, ï¬xed high-intensity statin
treatment (atorvastatin 80 mg) that achieved a mean LDL-C of 72 mg/dLreduced CHD/CVD events more than ï¬xed lower-intensity statin treatment
that achieved a mean LDL-C of 97 mg/dL. In this trial, the mean LDL-Clevels achieved differed by 25 mg/dL, or 26%, between the 2 groups. Inadults /C2165 years of age with a history of stroke or TIA, higher ï¬xed-dose
statin treatment that achieved a mean LDL-C of 72 mg/dL reduced CHDevents more than placebo, with a mean LDL-C of 129 mg/dL. In this trial,the mean LDL-C level was reduced by 61 mg/dL, or 46%, from baseline in
those /C2165 years of age.L Secondary Prevention (age
subgroups included)TNT (46,126), SPARCL (107,127)No publications by [CONTACT_575881]:
PROVE-IT (48)
IDEAL (47)
HATS (121)
10 In adults with CHD/CVD and CKD (excluding hemodialysis), ï¬xed high-
intensity statin treatment (atorvastatin 80 mg) that achieved a mean
LDL-C of 79 mg/dL reduced CHD/CVD events more than ï¬xed lower-
dose statin treatment that achieved a mean LDL-C of 99 mg/dL. In this
trial, the mean LDL-C levels achieved differed by 20 mg/dL, or 20%
between the 2 groups.L Secondary Prevention (CKD
subgroup included)TNT (46,128)
TNT (46,129)
No publications included for CKD:
PROVE-IT (48)IDEAL (47)
11 In adults with CHD or acute coronary syndromes, more intensive-dose
statin therapy reduced LDL-C to a greater degree (by 20 mg/dL or anadditional 20%) than less intensive-dose statin therapy or placebo and
produced a greater reduction in CVD events.
Each 1-mmol/L (38.7-mg/dL) reduction in LDL-C reduced the RR for CVD
events by [CONTACT_3450] 28%.
See Table 4 for de ï¬nitions of high-, moderate-, and low-intensity statin
therapy.
More intensive statin therapy Â¼atorvastatin 80 mg, simvastatin 80 mg.
Less intensive statin therapy Â¼atorvastatin 10 mg, pravastatin 40 mg,
or simvastatin 20 â€“40 mg.H Secondary Prevention CTT 2010 (20) ddata from 5 trials
TNT (46)
IDEAL (47)
PROVE-IT (48)
Aâ€“Z (117)
SEARCH (124) (not included in CQ1)
12 In trials of more intensive statin therapy (atorvastatin 80 mg, simvastatin
80 mg) compared with less intensive statin therapy (atorvastatin 10mg, pravastatin 40 mg, or simvastatin 20 â€“40 mg), women with CHD or
acute coronary syndromes experienced a similar (approximately 25%)
magnitude of relative CVD reduction as men (approximately 29%).
Women also experienced a similar magnitude of absolute risk
reduction as men.H Secondary Prevention
(women included)CTT 2010 (20) d5 trials
TNT (46)
IDEAL (47)PROVE-IT (48)
Aâ€“Z (117)
SEARCH (124) (not included in CQ1)
13 In adults with and without CVD, in trials comparing more intensive to less
intensive statin therapy or statin therapy with placebo/control, the
relative CVD risk reduction was similar for those <65 years, 65 to /C2075,
or>75 years of age. There is less information to estimate the
magnitude of bene ï¬t in those under age 45 or over age 75 years,
because fewer participants in these age groups were enrolled in clinical
trials. More intensive statin therapy did not appear to reduce CVD risk,
compared with less intensive statin therapy, in those with ASCVD and
age>75 years. Statin therapy, compared with control (most RCTs
evaluated moderate-intensity statin therapy), had a similar magnitude
of RR reduction in those >75 as in those /C2075 years of age with and
without ASCVD.
Statin therapy vs. control trials Â¼atorvastatin (A) 10 â€“20 mg, ï¬‚uvastatin (F)
80 mg, lovastatin (L) 40 â€“80 mg, pravastatin (P) 40 mg, rosuvastatin (R)
10â€“20 mg, simvastatin (S) 40 mg.
See Table 4 for the Expert Panel â€™sd eï¬nitions for high-, moderate-, and low-
intensity statin therapy.
The Panel uses moderate intensity to refer to statin drugs and doses that
lower LDL-C by 30% to approximately 50%.
This dose refers to atorvastatin 10 mg, ï¬‚uvastatin 80 mg, lovastatin 40
mg, pravastatin 40 mg, rosuvastatin 10 mg, and simvastatin 40 mg.H Primary Prevention,
Secondary PreventionCTT 2010 (20) d26 trials
Included:More vs. less statin
TNT (46)
IDEAL (47)PROVE-IT (48)
Aâ€“Z (117)
SEARCH (124)Statin vs. control (statin/dose, percent LDL-C
reduction)
4S (47) S20 â€“40, â€“36%
WOSCOPS (72) P40, â€“22%
CARE (130) P40, â€“29%
AFCAPS/TexCAPS (17) L20-40, â€“24%
LIPID (74) P40, â€“27%
GISSI-P (86) P20, â€“9%
LIPS (122) F40 BID, â€“27%
HPS (16) S40, â€“38%
PROSPER (38) P40, â€“27%
ALLHAT-LLT (131) P40, â€“14%
ASCOT-LLA (132) A10, â€“31%
ALERT (133) F40, â€“20%
CARDS (75) A10, â€“38%
ALLIANCE (118) dNA
4D (87)dA20, â€“27%
ASPEN (119) A10, â€“34%
MEGA (18) P10 â€“20, â€“17%
JUPI[INVESTIGATOR_247470] (49) R20, â€“40%
GISSI-HF (86) R10, â€“30%
AURORA (84) R10, â€“38%
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342924
Page 152 of 356Page 154 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
14 In adults with CHD (including acute coronary syndromes, or a history of MI,
stable or unstable angina, coronary revascularization), statin therapy
reduced the RR for CVD events by [CONTACT_3450] 21% per 1-mmol/L
(38.7-mg/dL) LDL-C reduction. This relationship was similar for more
intensive compared with less intensive statin therapy and for statintherapy compared with placebo/control.H Secondary Prevention CTT 2010 (20) d26 trialsdsee above
15 In adults with CVD other than CHD (including stroke, TIA presumed to be of
atherosclerotic origin, or peripheral arterial disease orrevascularization), statin therapy reduced the RR for CVD events by
[CONTACT_3450] 19% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
This relationship was similar for more intensive compared with lessintensive statin therapy and for statin therapy compared with
placebo/control.H Secondary Prevention CTT 2010 (20) d26 trials
16 In adults with diabetes and CHD or other CVD, moderate-dose statin
therapy reduced CVD events by [CONTACT_3450] 20% per 1-mmol/L
(38.7-mg/dL) LDL-C reduction.H Secondary Prevention
(diabetes subgroupi[INVESTIGATOR_575602])CTT 2008 (134) d14 trials
17 In adults with and without CVD, statin therapy reduced CVD events in both
men and women.H Primary Prevention,
Secondary PreventionCTT 2010 (20) d26 trials
18 In adults with and without CVD, in trials comparing more* intensive with
less intensive statin therapy, or statin therapy with placebo/control,
there were no clinically important differences in the CVD risk reduction
between the subgroups listed below:
/C15Treated hypertension or all others
/C15Systolic blood pressure <140, /C21140 to <160, and /C21160 mm Hg
/C15Diastolic blood pressure <80, /C2180 to <90, and /C2190 mm Hg
/C15Body mass index <25, /C2125 to<30, and /C2130 kg/m
2
/C15Current smoking and nonsmokers
GFR<60, 60 to <90, /C2190 mL/min per 1.73 m2)
/C15Post-MI
/C15Total cholesterol /C205.2 (201 mg/dL), >5.2 to 6.5, >6.5
(251 mg/dL) mmol/L
/C15Triglycerides /C201.4 (124 mg/dL), >1.4 to 2.0, >2.0 (177 mg/dL)
mmol/L
/C15HDL-C /C201.0 (39 mg/dL), >1.0 to /C201.3,>1.3 (50 mg/dL) mmol/LH Primary Prevention,
Secondary PreventionCTT 2010 (20) d26 trials
19 In more vs. less statin and statin vs. control trials combined, each 1-mmol/L
(38.7-mg/dL) reduction in LDL-C resulted in approximately 22%reductions in CVD risk across baseline LDL-C levels [ <2 mmol/L (77
mg/dL), /C212t o<2.5 mmol/L (97 mg/dL), /C212.5 to <3.0 mmol/L (116
mg/dL), /C213.0 to <3.5 mmol/L (135 mg/dL), and /C213.5 mmol/L, either
untreated or on statin therapy]. In the statin vs. placebo/control trials,
those with LDL-C <2 mmol/L may have experienced less bene ï¬t than
those with higher LDL-C level.M CTT 2010 (20) d26 trials
20 In adults, statins reduce the RR for CVD, CHD, and fatal CHD similarly in
those with or without hypertension. This beneï¬ t applies across all levels
of baseline systolic and diastolic blood pressure and in those with
treated hypertension.H Primary Prevention,
Secondary PreventionCTT 2010 (20), Messerli AJC 2008 (135)
21 In adults with and without CVD who received more intensive compared
with less intensive statin therapy, or statin therapy compared with
placebo/control, the RR for ï¬rst stroke was reduced by [CONTACT_3450]
16% per 1-mmol/L (38.7-mg/dL) LDL-C reduction, primarily because ofan approximately 21% reduction in the RR for ischemic stroke.M to H Primary Prevention,
Secondary PreventionCTT 2010 (20) d26 trials
22 In adults with and without CHD/CVD who received more intensive
compared with less intensive statin therapy, or statin therapy compared
with placebo/control:
/C15The RR for major coronary events was reduced by [CONTACT_3450]24% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
/C15The RR for nonfatal myocardial infarction was reduced by [CONTACT_575882]-
mately 27% per 1-mmol/L LDL-C reduction.
/C15Total mortality was reduced by [CONTACT_3450] 10% per 1-mmol/L
(38.7-mg/dL) LDL-C reduction, primarily because of a 16%
reduction in the risk for cardiac death.
/C15The risk for CVD mortality was reduced by [CONTACT_3450] 14% per1-mmol/L (38-mg/dL) LDL-C reduction, primarily because of a 16%
reduction in the risk for cardiac death.H Primary Prevention,
Secondary PreventionCTT 2010 (20) d26 trials
Continued on the next pageJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2925
Page 153 of 356Page 155 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
23 In adults with CHD or acute coronary syndromes who received more
intensive compared with less intensive statin therapy, the RR for
coronary revascularization was reduced by [CONTACT_3450] 34% per
1-mmol/L (38.7-mg/dL) LDL-C reduction.H Secondary Prevention CTT 2010 (20) d5 trials
24 In adults with and without CVD who received statin therapy compared with
placebo/control, the RR for coronary revascularization was reduced by
[CONTACT_3450] 24% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.H Primary Prevention,
Secondary PreventionCTT 2010 (20) d21 trials
25 In adults with and without CVD who received statin therapy, a larger
absolute reduction in LDL-C (mmol/L or mg/dL) was associated with agreater reduction in the risk for CVD.M Primary Prevention,
Secondary PreventionCTT2010 (20), Kizer 2010 (136)
26 In adults with and without CVD who received statin therapy, there was no
variation in the relative reduction of CVD risk among the trials afteradjustment for LDL-C reduction. Thus, LDL-C reduction appeared toaccount for the reduction in CVD risk.M Primary Prevention,
Secondary PreventionCTT 2010 (20)
27 Consistent 23% â€“28% relative reductions in CVD risk per 39-mg/dL
(1-mmol/L) reduction in LDL-C were observed after 1 year to beyond5 years of statin treatment.H Secondary Prevention,
Primary PreventionCTT 2008 (134), 2005 (50) CTT 2010 (96)
28 Statins reduce the RR for CVD similarly in primary- and secondary-
prevention populations.H Primary Prevention;
Secondary PreventionCTT 2010 (20) CTT 2010 Web appendix (50)
29 In adults with diabetes (some of whom had CHD), statin therapy reduced
the RR for CVD events by [CONTACT_3450] 20% per 1-mmol/L (38.7-mg/dL)LDL-C reduction. This 1-mmol (20%) risk-reduction relationship was
similar for more intensive compared with less intensive statin therapy
and for statin therapy compared with placebo/control.H Secondary Prevention
(includes diabetessubgroup)
Primary Prevention in
Individuals WithDiabetesCTT 2010 (20) CTT 2008 (134)
30 Adults with type 2, type 1, and no diabetes had similar RRRs in CVD per
1-mmol/L (38.7-mg/dL) LDL-C reduction.H Primary Prevention in
Individuals WithDiabetesCTT 2010 (20)
31 In adults with diabetes without CVD, moderate-dose statin therapy,
compared with placebo/control, reduced the RR for CVD events by
[CONTACT_3450] 27% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.H Primary Prevention in
Individuals WithDiabetesCTT 2008 (134) d14 trials
32 In adults with diabetes, statin therapy reduced the RR for CVD by a similar
magnitude for subgroups of diabetic men and women, <65 and /C2165
years of age; treated hypertension; body mass index <25,>25 to <30,
and/C2130; systolic blood pressure <160 and /C21160 mm Hg; diastolic
blood pressure <90 and /C2190 mm Hg; current smokers and
nonsmokers; estimated GFR <60, /C2160 to <90, and /C2190 mL/min/
1.73 m
2; and predicted annual risk for CVD <4.5%, >4.5% to <8.0%,
and/C218.0%. Whereas RRRs are similar across these subgroups,
absolute risk reductions may differ for various subgroups.H Primary Prevention in
Individuals With
DiabetesCTT 2008 (134) d14 trials
33 In adults 40 to 75 years of age with diabetes and /C211 risk factor, ï¬xed
moderate-dose statin therapy that achieved a mean LDL-C of 72 mg/dLreduced the RR for CVD by 37% (in this trial, LDL-C was reduced by
46 mg/dL or 39%).M Primary Prevention in
Individuals With
DiabetesCARDS (75)
34 In men and postmenopausal women 40 to 73 years of age without CHD/
CVD, the majority of whom did not have diabetes and had baseline LDL-
C levels <190 mg/dL, ï¬xed low- to moderate-dose statin therapy that
achieved a mean LDL-C of 115 â€“127 mg/dL reduced the RR for CVD by
24% â€“25%, compared with placebo, with mean LDL-C levels of 153 â€“
156 mg/dL. (In these trials, LDL-C was reduced by 29 â€“35 mg/dL and
19% â€“25% from baseline with a low- to moderate-dose statin.)H Primary Prevention AFCAPS (17); MEGA (18)
35 In men /C2150 years and women /C2160 years of age without CHD/CVD with
LDL<130 mg/dL and hs-CRP /C212 mg/L, ï¬xed intensive-dose statin that
achieved a mean LDL-C of 53 mg/dL reduced the RR for CVD events by
44% compared with placebo, which had a mean LDL-C 110 mg/dL. In
this trial, LDL-C was reduced by 53 mg/dL, or 49%.M Primary Prevention JUPI[INVESTIGATOR_247470] (49)
36 In adults without CVD (some of whom had diabetes) who received more
intensive or less intensive statin therapy, or statin therapy compared
with placebo/control, the RR for CVD events was reduced by
[CONTACT_3450] 25% per 1-mmol/L LDL-C reduction. This was similar to
the CVD RRR observed in those with CHD or CVD.H Primary Prevention CTT 2010 (20)
37 Statin therapy reduces CHD and stroke events in adults /C2140 years of age
without CHD/CVD, and with a wide range of baseline LDL-C levels.H Primary Prevention CTT 2010 (20)
JUPI[INVESTIGATOR_247470] (49)
AFCAPS (17)
MEGA (18)
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342926
Page 154 of 356Page 156 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
38 Statin therapy, with a range of LDL-C lowering, reduces all-cause mortality,
compared with placebo, in primary-prevention clinical trials of adults
who were in general /C2140 years of age and had at least 1 risk factor,
and with a wide range of baseline LDL-C levels.M Primary Prevention CTT 2010 (20)
39 There is insuf ï¬cient evidence to determine the bene ï¬t of statins in primary
prevention on all-cause mortality separately for women and men or withadvancing age.I Primary Prevention CTT 2010 (20)
40 In MEGA (18), AFCAPS (17), JUPI[INVESTIGATOR_247470] (49), and CARDS (75), the 10-year
NNTs to prevent [ADDRESS_755745] RRRs of 24%, 26%, 44%, and 37%,
respectively, and placebo event rates for major CVD calculated at 10years of 5.1%, 6.9%, 7.6%, and 18%, respectively.M Primary Prevention CTT 2010 (20) appendix individual trials dprojected
calculation
41 In adults without CVD (some of whom had diabetes) overall, who received
statin therapy compared with placebo/control, the RR for CVD events
was reduced by [CONTACT_3450] 25% per 1-mmol/L LDL-C reduction. This
was similar to the CVD RRR observed in those with CHD or CVD.H Primary Prevention,
Primary Prevention in
Individuals WithDiabetesCTT 2010 (20)
42 Statin therapy, with a range of LDL-C lowering, reduces all-cause mortality
by [CONTACT_2902] 10%, compared with placebo, in primary-prevention clinical
trials of adults who were /C2140 years of age and in general who had at
least 1 risk factor, and with a wide range of baseline LDL-C levels.M Primary Prevention,
efï¬cacyCochrane (15), Ray (137), Brugts (138),
Bukkapatnam (139), JUPI[INVESTIGATOR_247470] (49)
MEGAdwomen (140)
43 In adults with and without CVD, intensive- and moderate-dose statins do
not increase the risk for death from noncardiovascular causes,
regardless of baseline LDL-C. Statins do not increase (or decrease) therisk for incident cancer overall or cancer of any type, or the risk for
cancer death.H Primary Prevention,
Secondary Prevention,
Safety of StatinsCTT 2010 (20), Mills 2008 (97), Cochrane (15),
Bonovas (141)
44 In adults with or without CVD, statin therapy is associated with an excess
risk for incident diabetes.
/C15Statin therapy was associated with 1 excess case of incident
diabetes per 1,000 individuals treated for 1 year, compared with
placebo/control, with little heterogeneity among 13 trials (includingJUPI[INVESTIGATOR_247470] [49]). Risk for diabetes was highest in older persons
(NNH Â¼1,002 per year).
/C15Statin therapy resulted in 5.4 fewer major CVD events per 1-mmol/LLDL-C reduction per 1,000 individuals treated for 1 year compared
with placebo (NNT to beneï¬ t, 185 per year).
/C15High-intensity statin therapy was associated with 2 excess cases of
incident diabetes per 1,000 individuals treated for 1 year, compared
with moderate-intensity statins (NNH Â¼498 per year). High-intensity
statin therapy resulted in 6.5 fewer major CVD events per 1,000
individuals treated for 1 year, compared with moderate-intensity
statin therapy (NNT Â¼155 per year). Rosuvastatin 20 mg was
associated with 3 excess cases of incident diabetes per 1,000individuals treated for 1 year, compared with placebo (NNH Â¼332 per
year).
/C15Rosuvastatin 20 mg resulted in 5.9 fewer major CVD events per1,000 individuals treated for 1 year, compared with placebo(NNTÂ¼169 per year).M Primary Prevention,
Secondary Prevention,Safety of StatinsSattar 2010 (81)Preiss (142), PROVE-IT (48) ,Aâ€“Z (117),
TNT (46), IDEAL (47), SEARCH (124),
JUPI[INVESTIGATOR_247470] (49)
Continued on the next pageJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2927
Page 155 of 356Page 157 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
45 In trials of high-intensity compared with moderate-intensity statins (clinical
CVD), moderate-intensity statin compared with placebo
(diabetes dprimary prevention), high-intensity statin compared with
placebo (secondary and primary prevention), or statin-niacin versusplacebo, participants were:
/C15Seen at visits that occurred at 4 â€“13 weeks after randomization, and
every 3 â€“6 months thereafter.
/C15Counseled on diet (IDEAL [47], AFCAPS [17], MEGA [18], PROVE-IT
[48], SPARCL [107]) and lifestyle (JUPI[INVESTIGATOR_247470] [49]) at baseline and
regularly thereafter or when LDL-C increased (JUPI[INVESTIGATOR_247470] [49], CARDS
[75]).
/C15Assessed for adherence to study medication at every visit.
/C15Assessed for adverse effects by [CONTACT_575883].
/C15Able to reduce the statin dose for adverse events so that atorvastatin80 mg could be reduced to 40 mg (IDEAL [47], PROVE-IT [48] )o r
pravastatin 40 mg could be reduced to 20 mg (PROVE-IT [48] )o r
simvastatin reduced by 10 mg/d (HATS [121]).
/C15Able to reduce the statin dose if LDL-C decreased to <39 mg/dL
(1.0 mmol/L) (per investigator discretion in IDEAL [47]) or reducethe statin dose if total cholesterol was <100 mg/dL on 2
successive visits (AFCAPS [17]) or reduce by 10 mg simvastatin
per day if LDL-C was <40 mg/d (HATS [121]), although they
continued on study drug no matter how low the cholesterol in
CARDS (75).
/C15Allowed to have their statin doses uptitrated or switched to morepotent statin to further reduce
/C15LDL-C (IDEAL [47], CARDS [75], AFCAPS [17], MEGA [18], PROVE-IT
[48]dpravastatin to 80 mg) if LDL-C exceeded 125 mg/dL.
/C15Given counseling on diet and/or glycemic control when LDL-C or
triglyceride levels increased (CARDS [75]).
/C15Had study medication discontinued for CK /C2110 /C2ULN with muscle
aches or weakness, or persistent ALT /C213/C2ULN on 2 consecutive
tests (JUPI[INVESTIGATOR_247470] [49], CARDS [75]); the dose of atorvastatin or
pravastatin could be halved for abnormal LFTs, CK elevations, or
myalgias (PROVE-IT [48]).H Statin Adherence Reï¬‚ects review of TNT (46), IDEAL (47), PROVE-IT
(48), CARDS (75), JUPI[INVESTIGATOR_247470] (49), SPARCL (107),
MEGA (18), AFCAPS (17) baseline and mainpapers; these were statin trials that
demonstrated signi ï¬cant CVD risk reduction (and
were the basis of recommendations arising from
CQ1 and CQ2) HATS (121)
[ADDRESS_755746] RCTs of moderate-intensity statin therapy and all RCTs of high-
intensity statin therapy excluded subjects with serious comorbidities
and other conditions or concomitant drug therapy predisposing to
adverse events from statin therapy (see Table 9).H Primary Prevention,
Secondary Prevention,
Safety of Statins,
Safety of NonstatinsRCTs included in CQ1, 2, and 3:
Aâ€“Z (117), ACCORD (14), AIM-HIGH (9), ASPEN
(119), CARE (130), CDP (101), FIELD (115),
GREACE (120), HATS (121), HHS (111), HPS
(16), IDEAL (47), JUPI[INVESTIGATOR_247470] (49), LIPID (74), LIPS
(122), LRC (113), MIRACL (93), MUSHASHI-AMI
(123), PROVE-IT (48), SEAS (108), SHARP (109),
SPARCL (107), TNT (46)
47 In adults with and without CVD who received more intensive compared
with less intensive statin therapy, or statin therapy compared withplacebo/control, overall the RR for ï¬rst hemorrhagic stroke was not
increased. Hemorrhagic stroke comprised 11% of total strokes in the
more intensive/statin group, compared with 8% in the less intensive/
control groups.M Primary Prevention,
Secondary Prevention,Safety of StatinsCTT 2010 (20)
48 In adults with and without CVD, statin-treated individuals in clinical trials
are not more likely to discontinue treatment than placebo-treated
individuals.H Primary Prevention,
Secondary Prevention,Safety of StatinsCochrane d14 trials (15), CTT 2010 (20)
49 In adults with and without CVD in clinical trials, low- to moderate-dose
statins do not increase the risk for myalgias or muscle pain.H Primary Prevention,
Secondary Prevention,
Safety of StatinsCochrane d14 trials (15), CTT 2010 (20)
50 In adults selected for participation in clinical trials of statin therapy,
rhabdomyolysis occurred rarely ( <0.06% over a mean 4.8- to 5.1-year
treatment period).H Primary Prevention,
Secondary Prevention,Safety of StatinsCTT 2010 (20)
51 In adults with CHD, the rate of creatine kinase elevation /C213 times ULN
occurs infrequently and at a similar rate in those treated with intensive-or moderate-dose statin therapy.H Primary Prevention,
Secondary Prevention,Safety of StatinsDale (98), CTT 2010 (20)
52 In adults with CHD, although uncommon ( <1.5% over 5 years), intensive
statin therapy increases the risk for elevated hepatic transaminase (ALT
and/or AST) levels /C212â€“[ADDRESS_755747] more than moderate-dose statin
therapy. No cases of hepatic failure were reported.H Primary Prevention,
Safety of StatinsDale (98), Cochrane (15), CTT 2010 (20), TNT (46),
IDEAL (47), PROVE-IT (48), JUPI[INVESTIGATOR_247470] (49)
53 Low- to moderate-dose statin therapy has similar rates of elevated hepatic
transaminase levels as placebo/no statin treatment. In general, clinicaltrials tend to underestimate those likely to have side effects, often
related to selection procedures.H Primary Prevention,
Safety of StatinsCTT 2010 (20)
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342928
Page 156 of 356Page 158 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
54 With the exception of simvastatin 80 mg, intensive- and moderate-dose
statins did not increase the risk for rhabdomyolysis.L Safety of Statins CTT 2010 (20), Cochrane (15), Mills (97)
55 In adults with CHD, CK elevation /C213 times ULN occurs infrequently
and at a similar rate in those treated with intensive- or moderate-dose
statin therapy (0.02% [moderate-dose statin] to 0.1% [higher-dose
statin]) over a 1- to 5-year treatment period (RR 2.63, 95% CI0.88 â€“7.85).H Secondary Prevention,
SafetyDale 2007 (98)
[ADDRESS_755748]
on cognitive changes or risk of dementia.I Safety of Statins Reviewed RCTs in CQ1, CQ2; assessment of
cognitive function only reported in HPS (16)
57 In men with CHD who are 30 to 64 years of age, immediate-release
niacin (with an approximately 2-g dose):
/C15Decreased total cholesterol by 10% and triglycerides by 27%.
/C15Markedly increased the risk for adverse skin events (includingï¬‚ushing, pruritus, acanthosis nigricans, and other types of skin rash).
/C15Increased the risk for other adverse events:
/C15Atrial ï¬brillation
/C15Gastrointestinal events (including nausea, stomach pain,
decreased appetite, and unexplained weight loss)
/C15Gout
/C15Elevated levels of uric acid, serum glutamic oxaloacetic
transaminase, alkaline phosphatase, and glucose
/C15Lipi[INVESTIGATOR_805], LFTs, uric acid, and glucose were monitored during up-titration
and every 4 â€“12 months thereafter.L Secondary Prevention,
Safety,Monotherapy,
Safety,Efï¬cacyCDP (101,143)
58 In a trial in 67 adults with CHD and low HDL-C, slow-release niacin (at a
mean 2.4-g dose) plus low-dose simvastatin resulted in the following:
/C15Low levels of LDL-C and raised levels of HDL-C.
/C15Although not powered to detect a reduction in CVD events, the rate ofmajor clinical events was 90% lower than that in the placebo group.
/C15Slow-release niacin did not cause ï¬‚ushing in this trial.
/C15The simvastatin-niacin group had increased ALT, CK, uric acid,and homocysteine.
/C15Antioxidant vitamins diminished the bene ï¬cial effect of niacin
on HDL-C.
/C15Lipi[INVESTIGATOR_805], LFTs, uric acid, and glucose were monitored during up-titration
and every 2 â€“4 months thereafter.L Secondary Prevention,
Combination TreatmentHATS Investigators (121)
59 In adults 45 years of age and older with established CVD and low HDL-C
(<40 mg/dL in men or <50 mg/dL in women), elevated triglycerides
(150 â€“400 mg/dL), and LDL-C <180 mg/dL off statin, in whom the
dose of simvastatin was adjusted, or ezetimibe was added, to maintain
LDL-C in a range of 40â€“ 80 mg/dL, extended-release niacin 1,500 â€“
2,000 mg/day plus simvastatin (9.5% also on ezetimibe 10 mg)compared with placebo (with 50 mg immediate-release niacin) plussimvastatin (21.5% also on ezetimibe 10 mg:
/C15Improved the lipid pro ï¬le without a further decrease in CVD events.
Speci ï¬cally, it lowered LDL-C levels an additional 6%, increased HDL-
C by [CONTACT_33018] 14%, reduced triglycerides by [CONTACT_33018] 23%,
lowered apolipoprotein B by [CONTACT_33018] 10%, and reduced
lipoprotein(a) by [CONTACT_33018] 19%.
/C15There were similar rates of CVD events in subgroups by [CONTACT_654], sex, ordiabetes, metabolic syndrome, or previous myocardial infarctionstatus, as well as similar rates of adverse events, including liver
function abnormalities, muscle symptoms, and rhabdomyolysis.
/C15Lipi[INVESTIGATOR_805], LFTs, uric acid, and glucose were monitored during up-titration
and every 3 â€“12 months thereafter.M Secondary Prevention,
Combination TreatmentAIM-HIGH Investigators (9)
60 In men 35 â€“59 years of age without CHD, hypertension, diabetes, or obesity
and with LDL-C /C21175 mg/dL and triglycerides <300 mg/dL,
cholestyramine:
/C15Reduced LDL-C by 13%, with minimal changes in triglycerides or
HDL-C levels.
/C15Reduced the RR for CHD events by 19%.
/C15Increased the risk for adverse gastrointestinal effects, including
constipation, heartburn, abdominal pain, belching, bloating, gas,nausea.
/C15Adherence was only modest.L Primary Prevention,
Safety,Efï¬cacyLRC (113)
61 Insuf ï¬cient data to evaluate the efï¬ cacy and safety of ezetimibe
monotherapy.IE f ï¬cacy,
Safety,Nonstatin
Continued on the next pageJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2929
Page 157 of 356Page 159 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
62 Insuf ï¬cient data to evaluate the additional ef ï¬cacy and safety of ezetimibe
in combination with a statin compared with a statin alone.I Safety,
Efï¬cacy,
Combination Treatment
63 In adults 45 â€“85 years of age with mild to moderate aortic stenosis and
without CVD or diabetes, simvastatin 40 mg coadministered with
ezetimibe 10 mg, compared with placebo:
/C15Decreased LDL-C by [CONTACT_5554] 50%.
/C15Reduced the RR for CVD events by 22% over 4.35 years of treatment.
/C15Increased the risk for elevated hepatic transaminases.L Safety,
Efï¬cacy,
Combination TreatmentSEAS (108)
64 In adults /C2140 years of age with CKD, of whom 33% were receiving dialysis
(peritoneal or hemodialysis), ezetimibe 10 mg coadministered withsimvastatin 20 mg, compared with placebo:
/C15Lowered LDL-C by 37 mg/dL (33%) in those who were not
receiving dialysis and by 23% in those who were receiving dialysis.
/C15Reduced the risk for CVD events by 17% overall and 21% in
those without CVD.
/C15Reduced the risk for CVD events by 22% in those who werenot receiving dialysis.
/C15Did not reduce CVD events in those with CVD or in those receivinghemodialysis.
/C15Modestly increased the risk for muscle symptoms requiring
discontinuation of treatment (1.1% vs. 0.6% with p Â¼0.02).
/C15Did not increase the risk for elevated hepatic transaminases, cancer,
hemorrhagic stroke, or noncardiovascular mortality.L Safety,
Efï¬cacy,
Combination Treatment,CKDSHARP (109)
65 Ezetimibe coadministered with simvastatin does not appear to increase
the risk for cancer compared with placebo.L Safety,
Combination TreatmentSHARP (109)
66 In adults 50 â€“75 years of age with diabetes dwith total cholesterol <250
mg/dL, and total cholesterol/HDL ratio /C214.0 or triglycerides <450
mg/dLdfenoï¬brate, compared with placebo:
/C15Modestly reduced LDL-C, minimally increased HDL-C, andsubstantially reduced triglycerides.
/C15In those without clinical CVD, reduced the risk for CHD/CVD events.
/C15In those with clinical CVD, did not reduce the risk forCHD/CVD events.
/C15Was no different than placebo for myositis or rhabdomyolysis, CK orALT elevations, renal disease requiring hemodialysis, or cancer.
/C15Was associated with higher rates of pancreatitis and pulmonary
embolism, and increased creatinine levels on average by
0.113 â€“0.136 mg/dL (10 â€“12 mmol/L).L Safety,
Efï¬cacy,
Nonstatin TreatmentFIELD (115)
67 In adults 40 â€“79 years of age with diabetes, CVD, and/or CVD risk factors,
with LDL-C 60 â€“180 mg/dL, HDL-C <55 mg/dL in women and black
individuals, HDL-C <50 mg/dL for all others, and triglycerides
<750 mg/dL on no medication or <400 mg/dL on medication:
/C15Feno ï¬brate added to simvastatin did not additionally reduce LDL-C,
minimally increased HDL-C (1 mg/dL or 2%), and moderately
reduced triglycerides (23 mg/dL or 14%), compared with simvastatin
therapy, which had on-treatment mean LDL-C of 80 mg/dL, HDL-C of
40.5 mg/dL, and triglycerides of 170 mg/dL.
/C15In the trial overall, and in those without and with clinical CVD,fenoï¬brate-simvastatin did not reduce the risk for CVD events
compared with simvastatin alone.
/C15Those with triglycerides /C21204 mg/dL and HDL-C /C2040 mg/dL may
have experienced a reduction in CVD events from feno ï¬brate-
simvastatin, compared with simvastatin alone.
/C15Feno ï¬brate-simvastatin had similar rates as simvastatin alone for
myopathy, myositis, or rhabdomyolysis; CK or ALT elevations,renal disease requiring hemodialysis; cancer death; or pulmonary
embolism/thrombosis.
/C15Feno ï¬brate-simvastatin was more likely to increase ALT >[ADDRESS_755749] and to increase creatinine level.
/C15CVD event rates were higher in women with well-controlled diabetes
who received feno ï¬brate-simvastatin compared with simvastatin alone.M Safety,
Efï¬cacy,
Nonstatin TreatmentACCORD (14)
68 In men 40 â€“55 years of age without CHD or CHF and non â€“HDL-C /C21200 mg/dL,
gemï¬brozil:
/C15Reduced LDL-C by 10% and triglycerides by 43%, and increasedHDL-C by 10%.
/C15Reduced the RR for CHD by 37%, compared with placebo.
/C15Increased skin cancer, increased gastrointestinal surgery, and
increased severe upper gastrointestinal symptoms, especially in ï¬rst
year. There was no difference in diarrhea, constipation, nausea, or
vomiting. Total mortality was not reported.M Safety,
Efï¬cacy,
Nonstatin TreatmentHelsinki Heart Study (111)
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342930
Page 158 of 356Page 160 of 364
Appendix 4. Continued
ES No. Evidence StatementLevel of
EvidenceRecommendation(s)/
Section References
69 In men with CHD who were <74 years of age with HDL-C /C2040 mg/dL and
LDL-C /C20140 mg/dL, and triglycerides /C20300 mg/dL, gem ï¬brozil,
compared with placebo:
/C15Did not reduce LDL-C, but did reduce triglycerides by 31% and
increase HDL-C by 6%.
/C15Reduced the RR for CVD by 24%.ME f ï¬cacy,
Nonstatin TreatmentVA-HIT (114)
70 In Japanese men who were 40 â€“75 years of age and postmenopausal
women /C2075 years of age with and without CHD and LDL-C /C21170 mg/dL,
EPA 1,800 mg added to statin therapy:
/C15Did not reduce LDL-C and modestly reduced triglycerides (5%),compared with statin therapy alone.
/C15Reduced the risk for CHD events (including revascularization and
unstable angina) by 19%, compared with statin therapy alone.
/C15Caused a similar magnitude of risk reduction in primary- and
secondary-prevention populations, but the study was insuf ï¬ciently
powered to evaluate these populations separately.
/C15Increased the risk for gastrointestinal disturbance, skin abnormal-
ities, hemorrhage, and abnormal serum glutamic oxaloacetic
transaminase.ME f ï¬cacy,
Safety,Combination TreatmentJELIS (110)
71 In individuals with NYHA Classes II â€“IV systolic or ischemic heart failure,
initiation of a statin did not change the absolute or RR for CVD
compared with placebo.ME f ï¬cacy,
Selected Population
SubgroupsCORONA (85) from CQ1
72 In individuals receiving maintenance hemodialysis, initiation of a statin did
not change the relative or absolute risk for CVD compared with placebo.ME f ï¬cacy,
Selected Population
Subgroups4D (87) and AURORA (84) CQ1 & CQ2,
SHARP (109) dHD subgroup
73 In men and women of mean age 58 to 68 years with aortic stenosis,
treatment with statin or statin plus ezetimibe for a mean of 2.1 â€“4.4
years resulted in a reduction in LDL-C of 50%â€“ 55% (67 â€“73 mg/dL)
from a baseline LDL-C of 123 â€“140 mg/dL and did not alter the
progression of aortic stenosis as assessed by [CONTACT_575884],
peak aortic valve jet velocity, peak or mean aortic valve gradient,or need for aortic valve surgery.H Aortic Stenosis,
Combination TreatmentParolari (144)
74 Women who were pregnant or nursing were excluded from statin,
fenoï¬brate, niacin-statin, and ezetimibe-statin RCTs.
Only men were enrolled in RCTs of niacin, BAS, and gem ï¬brozil.H Primary Prevention,
Secondary PreventionAll RCTs CQ1, CQ2, and CQ3
75 Only individuals with primary hypercholesterolemia were included in RCTs. H Primary Prevention,
Secondary PreventionAFCAPS (17)JUPI[INVESTIGATOR_247470] (49)
JELIS (110)HATS (121)
FIELD (115)
ACCORD (14)
MEGA (18)
76 In the 3 exclusively primary-prevention RCTs, low-, moderate-, and high-
intensity statin therapy reduced the risk for ASCVD when LDL-C levels
were approximately 70 â€“130 mg/dL, 130 â€“190 mg/dL, and 160 â€“200
mg/dL.H Primary Prevention JUPI[INVESTIGATOR_247470] (49)
MEGA (18)AFCAPS (17)
77 Lipi[INVESTIGATOR_805], liver function, uric acid, and glucose tests were obtained at
baseline, during up-titration, and every 2 â€“12 months thereafter.H Secondary Prevention CDP (101) (fair) 4 â€“12 months;
HATS (121) (good) 2 â€“4 months;
AIM-HIGH (9) (good) 3 â€“12 months
78 Immediate- and extended-release niacin increase cutaneous adverse
effects.M Secondary Prevention CDP (101), AIM-HIGH (9) (not HATS [121] d
Slo-Niacin)
79 When used as monotherapy or with a statin, niacin increases:
/C15Hepatic function tests.
/C15Hyperglycemia.
/C15Gastrointestinal adverse effects.
/C15Gout or increased uric acid.H
M
M
MSecondary Prevention,Safety(CDP [101], HATS [121], AIM-HIGH [9])(CDP [101], AIM-HIGH [9] dniacin dose reduced or
discontinued)
(CDP [101], AIM-HIGH [9] dniacin dose reduced or
discontinued)
Gout (CDP [101])Increased uric acid (HATS [121])
80 Niacin increases the incidence of atrial ï¬brillation and weight loss. L Secondary Prevention,
SafetyCDP (101) (atrial ï¬brillation not reported in
AIM-HIGH [9] or HATS [121] )
ALT indicates alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; BAS, bile acid sequestrant; BID, twice daily; CHD, coronary heart disease; CHF, congestive heart failure; CK, creatine
kinase; CKD, chronic kidney disease; CVD, cardiovascular disease; EPA, eicosapentaenoic acid; GFR, glomerular ï¬ltration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; LFT, liver function test; MI, myocardial infarction; NNH, number needed to harm; NNT, number needed to treat; NYHA, [LOCATION_001] Heart Association; RCT, randomized controlled trial; RR,relative risk; RRR, relative risk reduction; TIA, transient ischemic attack; and ULN, upper limit of normal.JACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2931
Page 159 of 356Page 161 of 364
Appendix 5. Expanded Discussion of What â€™s New in the Guideline
Focus on ASCVD Risk Reduction: 4 Statin Bene ï¬t Groups
/C15The 2013 guideline focuses on treatment of blood cholesterol to reduce ASCVD risk. Each Expert Panel was limited in the number of CQs it could choose. When
the CQs from the Risk Assessment and Lifestyle Work Groups were combined with the 3 Cholesterol Panel CQs, there were 8 CQs in total that were systematically
reviewed. All 3 CQs of the Cholesterol Panel evaluated evidence from RCTs with ASCVD outcomes. CQ1 and CQ2 evaluated the evidence for LDL-C and nonâ€“ HDL-C
goals in secondary and primary prevention. CQ3 was a comprehensive evaluation of the reduction in ASCVD events and safety for each of the cholesterol-loweringdrugs available in the [LOCATION_002].
/C15The systematic review of evidence from the highest-quality RCTs with ASCVD outcomes identi ï¬ed strong evidence to indicate who
should get which therapy at what
intensity .
/C15The statin RCTs provided the most extensive evidence for the greatest magnitude of ASCVD event reduction, with the best margin of safety.
/C15Four statin bene ï¬t groups were identi ï¬ed, in which the potential for an ASCVD risk-reduction bene ï¬t clearly exceeds the potential for adverse effects in:
1. Individuals with clinical ASCVD2. Individuals with primary elevations of LDL-C /C21190 mg/dL
3. Individuals 40 â€“75 years of age with diabetes but without clinical ASCVD and LDL-C 70 â€“189 mg/dL
4. Individuals 40 â€“75 years of age without diabetes or clinical ASCVD with LDL-C 70 â€“189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher.
This requires a clinician-patient discussion.
/C15Because few trials have been performed with nonstatin cholesterol-lowering drugs in the statin era, and those that have been performed were unable to
demonstrate signi ï¬cant additional ASCVD event reductions in the RCT populations studied, there was less evidence to support the use of nonstatin drugs for
ASCVD prevention.
/C15It is dif ï¬cult to determine how observational data could override the conclusions from the extensive body of evidence from the statin RCTs and the paucity of
evidence from nonstatin RCTs. Inherent biases of observational data are well understood and include biases in the decisions on whom to treat and who is adherent
to therapy, as well as multiple measurement biases, including veri ï¬cation of statin use, type and dose of statin used, consistency of use over time, and outcome
ascertainment. All of these problems are addressed in intent-to-treat analyses of RCTs, which is why the FDA requires well-designed RCTs to determine drug ef ï¬cacy
for ASCVD event reduction and common adverse effects.
/C15Other approaches to treatment of blood cholesterol have been advocated, including:
A. Treat to target dThis strategy has been the most widely used in the past [ADDRESS_755750], this strategy does not take into account potential adverse effects from statin monotherapy or from multidrug therapy that might be neededto achieve a speci ï¬c goal. Thus, in the absence of these data, this approach is less useful than it appears ( Section 3 ). It is possible that future clinical trials may
provide information warranting reconsideration of this strategy.
B. Lowest is best dThis approach was not taken because it does not consider the potential adverse effects of multidrug therapy with an unknown magnitude of
ASCVD event reduction. Ongoing RCTs of new LDL-C â€“lowering drugs in the setting of maximal statin therapy may address this question.
C. Treat level of ASCVD risk dA modiï¬ ed version of this approach was taken, which considers both the ASCVD risk-reduction bene ï¬ts and the adverse effects of
statin treatment on the basis of an extensive body of RCT evidence to determine the [ADDRESS_755751] strategies. There are also important exceptions for routine initiation of statin treatment for
individuals requiring hemodialysis or with NYHA class II to IV heart failure.
D. Lifetime risk dTreatment strategies based on lifetime ASCVD risk are problematic because of the lack of data on the long-term follow-up of RCTs >15 years, the
safety and ASCVD event reduction when statins are used for periods >10 years, and treatment of individuals <40 years of age.
A New Perspective on LDL-C and/or Non â€“HDL-C Goals
/C15The dif ï¬culty of giving up the treat-to-goal paradigm was deliberated extensively over a 3-year period. Many clinicians use targets such as LDL-C <70 mg/dL and
LDL-C<100 mg/dL for secondary and primary ASCVD prevention (non â€“HDL-C targets are 30 mg/dL higher). However, the RCT evidence clearly shows that ASCVD
events are reduced by [CONTACT_575885]-tolerated statin intensity in those groups shown to bene ï¬t. After a comprehensive review, no RCTs were identiï¬ ed that
titrated drug therapy to speci ï¬c LDL-C or non â€“HDL-C goals to improve ASCVD outcomes. However, one RCT was identiï¬ ed that showed no additional ASCVD event
reduction from the addition of nonstatin therapy to further treat non â€“HDL-C levels once an LDL-C goal was reached. In AIM-HIGH (9), the additional reduction in non â€“
HDL-C levels [as well as additional reductions in Apo B, Lp(a), and triglycerides in addition to HDL-C increases] with niacin therapy DID NOT further reduce ASCVD risk
in individuals treated to LDL-C levels of 40 â€“80 mg/dL.
/C15Use of LDL-C targets may result in under treatment with evidence-based statin therapy or overtreatment with nonstatin drugs that have not been shown to reduce
ASCVD events in RCTs (even though the drug may additionally lower LDL-C and/or non â€“HDL-C). Implications of treating to an LDL-C goal may mean that a
suboptimal intensity of statin is used because the goal has been achieved, or that adding a nonstatin therapy to achieve a speci ï¬c target results in down-titration of
the evidence-based intensity of statin for safety reasons. However, when RCT evidence is available that a nonstatin therapy further reduces ASCVD events whenadded to statin therapy, the nonstatin therapy may be considered.
/C15Some examples comparing a strategy based on the 4 statin bene ï¬t groups to a strategy using LDL-C/non â€“HDL-C targets:
A. Secondary prevention dEvidence supports high-intensity statin therapy for this group to maximally lower LDL-C. It does not support the use of an LDL-C target.
For example, if a secondary-prevention patient achieves an LDL-C of 78 mg/dL on a dose of 80 mg of atorvastatin, he/she is receiving evidence-based therapy.As of yet, there are no data to show that adding nonstatin drug(s) to high-intensity statin therapy will provide incremental ASCVD risk-reduction bene ï¬t with an
acceptable margin of safety. Indeed, AIM-HIGH (9) demonstrated the futility of adding niacin in individuals with low HDL-C and high triglycerides, and ACCORD
(14) demonstrated the futility of adding fenoï¬ brate in persons with diabetes. Although an ACCORD subgroup analysis of those with high triglycerides and low
HDL-C levels suggested that feno ï¬brate may reduce ASCVD events in patients with diabetes, this is hypothesis generating and needs further testing in
comparison to the evidence-based use of a high-intensity statin. In addition, not having a goal of <70 mg/dL for LDL-C means that the patient who is adhering to
optimal lifestyle management and receiving a high-intensity statin avoids additional, non â€“evidence-based therapy just because his/her LDL-C is higher than an
arbitrary cutpoint. Indeed, the LDL-C goal approach can make this patient unnecessarily feel like a failure.
Continued on the next pageStone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342932
Page 160 of 356Page 162 of 364
Appendix 5. Continued
B. Familial hypercholesterolemia with LDL-C /C21190 mg/dL dIn many cases, individuals with familial hypercholesterolemia are unable to achieve an LDL-C
goal<100 mg/dL. For example, an individual with familial hypercholesterolemia may achieve an LDL-C of only 120 mg/dL despi[INVESTIGATOR_449567] [ADDRESS_755752] fallen short of the 100-mg/dL goal, he/she has decreased his/her LDL-C by >50% (starting from an untreated
LDL-C level of w325 â€“400 mg/dL). These patients are not treatment failures, as observational data has shown signi ï¬cant reductions in ASCVD events without
achieving speciï¬ c LDL-C targets. This is an area where observational data supports the recommended approach.
C. Type 2 diabetesd For those 40 â€“[ADDRESS_755753] lower LDL-C levels than those without diabetes, â€œgoal â€-directed therapy often encourages use of a lower statin dose than is
supported by [CONTACT_575886], and nonstatin drugs may be added to address low HDL-C or high triglycerides, for which RCT evidence of an ASCVD event reduction is
lacking. Giving a maximally tolerated statin intensity should receive primary emphasis because it most accurately re ï¬‚ects the data that statins reduce the
relative risk of ASCVD events similarly in individuals with and without diabetes, and in primary and secondary prevention in those with diabetes, along withevidence that high-intensity statins reduce ASCVD events more than moderate-intensity statins.
D. Estimated 10-year ASCVD risk â€¡7.5%dData have shown that statins used for primary prevention have substantial ASCVD risk-reduction bene ï¬ts across the
range of LDL-C levels of 70 â€“189 mg/dL. Moreover, the Cochrane meta-analysis (15), as well as a meta-analysis by [CONTACT_575887] (13),
conï¬rms that primary prevention with statins reduces total mortality as well as nonfatal ASCVD events.
/C15RCTs are used to identify those who are unlikely to bene ï¬t from initiation of statin therapy despi[INVESTIGATOR_575603], such as those with higher NYHA classes
of heart failure or those on hemodialysis.
Global Risk Assessment for Primary Prevention
/C15Use of the new Pooled Cohort Equations is recommended to estimate 10-year ASCVD risk in both white and black men and women who do not have clinical ASCVD.
/C15By [CONTACT_575888]-risk individuals for statin therapy, the guideline focuses statin therapy on those most likely to bene ï¬t.
/C15It also indicates, on the basis of RCT data, those high-risk groups that might not bene ï¬t. The Expert Panel emphasizes that the guideline is â€œpatient centered â€in
primary prevention. It is recommended that the potential for an ASCVD risk-reduction bene ï¬ts, adverse effects, and drugâ€“ drug interactions, along with patient
preferences, must be considered before statins are initiated for the primary prevention of ASCVD. Other factors such as LDL-C /C21160 mg/dL may also be considered.
This gives clinicians and patients the opportunity for input into treatment decisions rather than a simplistic â€œone-treatment- ï¬ts-all â€approach to drug therapy.
/C15These guidelines are not a replacement for clinical judgment; they are meant to guide and inform decision making.
/C15Some worry that a person 70 years of age without other risk factors will receive statin treatment on the basis of age alone. The estimated 10-year risk is still /C217.5%,
a risk threshold for which a reduction in ASCVD risk events has been demonstrated in RCTs. Most ASCVD events occur after age 70 years, giving individuals /C2170
years of age the greatest potential for absolute risk reduction.
/C15Some have proposed using selected inclusion criteria from RCTs to determine the threshold for statin initiation. However, the Cholesterol Treatment Trialistsindividual-level meta-analysis showed that statin therapy reduces ASCVD events regardless of categorical risk factors in both primary and secondary prevention.Therefore, the rationale for using ï¬xed cutpoints to determine whether statin therapy should be initiated is refuted by a consideration of the total body of evidence
from RCTs.
/C15In addition, a trial-based strategy identi ï¬es those at increased ASCVD risk less accurately than does a strategy based on an assessment of global ASCVD risk. This
selective use of inclusion criteria excludes well-established risk factors, such as smoking and advancing age (the strongest risk factor because it representscumulative risk factor exposure).
/C15The poor discrimination of RCT inclusion criteria for identifying those at increased 10-year ASCVD risk is shown by a calculation performed by [CONTACT_575889]. Use of the RCT inclusion criteria (from RCTs that found a reduction in ASCVD events to guideinitiation of statin therapy) would result in the treatment of 16% of individuals with <2.5% estimated 10-year ASCVD risk and 45% of those with 2.5% to <5%
estimated 10-year ASCVD risk (many would say inappropriately), whereas 38% of those with /C217.5% 10-year ASCVD risk would not have been identi ï¬ed as
candidates for statin therapy.
Safety
/C15RCTs are used to identify important safety considerations in individuals receiving treatment of blood cholesterol to reduce ASCVD risk and to determine statinadverse effects to facilitate understanding of the net bene ï¬t from statin therapy.
/C15Safety issues that are uncommon or unlikely to be seen in the populations studied in RCTs require more than analyses of single RCTs. This limitation was overcome,in part, by [CONTACT_575890]-quality systematic reviews and meta-analyses of statin RCTs.
/C15Expert guidance is provided on management of statin-associated adverse effects, including muscle symptoms.
/C15This guideline emphasizes the importance of using additional sources of information on safety, including FDA reports, manufacturers â€™prescribing information, and
pharmacists, to aid in the safe use of cholesterol-lowering drug therapy.
Role of Biomarkers and Noninvasive Tests
/C15There is a concern about other factors that may indicate elevated ASCVD risk but were not included in the Pooled Cohort Equations for predicting 10-year ASCVDrisk.
/C15The Risk Assessment Work Group has performed an updated systematic review of nontraditional risk factors, such as CAC, and has included recommendations toconsider their use to the extent that the evidence allows.
/C15In selected individuals who are not in 1 of the 4 statin bene ï¬t groups, and for whom a decision to initiate statin therapy is otherwise unclear, additional factors may
be considered to inform treatment decision making.
/C15These factors include primary LDL-C /C21160 mg/dL or other evidence of genetic hyperlipi[INVESTIGATOR_125270]; family history of premature ASCVD with onset <[ADDRESS_755754]-degree male relative or <[ADDRESS_755755]-degree female relative; high-sensitivity C-reactive protein /C212 mg/L; CAC score /C21300 Agatston units or /C2175th
percentile for age, sex, and ethnicity; ankle-brachial index <0.9; and elevated lifetime risk of ASCVD. Additional factors may be identi ï¬ed in the future.
Continued on the next pageJACC Vol. 63, No. 25, 2014 Stone et al.
July 1, 2014:2889 â€“934 2013 ACC/AHA Blood Cholesterol Guideline2933
Page 161 of 356Page 163 of 364
Appendix 5. Continued
Future Updates to the Blood Cholesterol Guideline
/C15This guideline focuses on treatments proven to reduce ASCVD events. It is not and was never intended to be a comprehensive approach to lipid management.
/C15Using RCT evidence assessed for quality provides a strong foundation for treatment of blood cholesterol to reduce ASCVD risk that can be used now. There are many
clinical questions for which there is an absence of RCT data available to develop high-quality, evidence-based recommendations. For these questions, expert opi[INVESTIGATOR_575604].
/C15CQs for future guidelines could examine:
1. the treatment of hypertriglyceridemia;2. the use of non â€“HDL-C in treatment decision making;
3. whether on-treatment markers such as Apo B, Lp(a), or LDL particles are useful for guiding treatment decisions;4. the best approaches to using noninvasive imaging for re ï¬ning risk estimates to guide treatment decisions;
5. how lifetime ASCVD risk should be used to inform treatment decisions and the optimal age for initiating statin therapy to reduce lifetime risk of ASCVD;6. subgroups of individuals with heart failure or undergoing hemodialysis who might bene ï¬t from statin therapy;
7. long-term effects of statin-associated new-onset diabetes and management;8. ef ï¬cacy and safety of statins in patient groups excluded from RCTs to date (e.g., those who are HIV positive or have received a solid organ transplant); and
9. role of pharmacogenetic testing.
*For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.
AIM-HIGH indicates Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes; ACCORD, Action to Control Cardiovascular Risk in
Diabetes; Apo B, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CQ, critical question; FDA, U.S. Food and Drug Administration; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); NHANES, National Health and Nutrition Examination Survey; and RCTs, randomized controlled trials.Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889 â€“9342934
Page 162 of 356Page 164 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 165 
 
Confidential and Proprietary  APPENDIX B.  GUIDANCE FOR ELEVATE D LIVER BIOCHEMISTRY  
VALUES  
For subjects who progress to cirrhosis and decompensation while participating in the study, 
elevation in liver biochemistry and development of other laboratory and clinical abnormalities 
may be expected.  Clinical adverse events  (AEs) should be reported and recorded as described in 
Section 12.1.[ADDRESS_755756] use and 
study participation as des cribed in Section 8.4. 
However, if these abnormalities are not consistent with the pattern of change attributable to 
disease progression (as assessed  by [CONTACT_737]) and no other cause is readily apparent 
(eg, acute biliary obstruction caused by [CONTACT_575891]), further actions are 
appropriate as outlined below.  The Sponsor should be contact[CONTACT_575892]. 
Per guidance from the FDA ( FDA 2009) , subjects with normal ALT/AST a nd bilirubin at 
baseline, an increase in ALT/AST to >3Ã— ULN or total bilirubin >2Ã— ULN should be followed by 
[CONTACT_94525] [ADDRESS_755757] or repeat testing shows ALT/AST >3Ã— ULN or total bilirubin >2Ã— ULN, subjects should be closely monitored.  In 
subjects with abnormal ALT/AST or bilirubin at baseline, fold increase should be assessed against baseline levels instead of ULN as follows:  3Ã— baseline ALT/AST, or total bilirubin 
>2Ã— baseline (and >2 mg/dL).  In subjects with abnormal values at baseline who develop a nadir 
value during the study, the reference points noted above should be changed from baseline to the 
nadir value for subsequent assessments. 
In subjects who are far from their study site, it may be difficult for the subjects to return to the 
site promptly.  In this case, the subjects should be retested locally, but normal laboratory ranges should be recorded, results should be made available to the Investigator immediately, and the 
data should be included in the case reports.  If symptoms persist or repeat testing shows 
persistent abnormality as described above, it is appropriate to initiate close observation (defined below) to determine whether the abnormalities are improving or worsening.  
If close observation is not possible, investigational product should be interrupted until further 
investigation can be performed. 
Close observation may include:  
â€¢ Repeating liver enzyme and serum bilirubin tests [ADDRESS_755758] is asymptomatic.  
â€¢ Obtaining a more detailed history of symptoms and prior or concurrent diseases.  
â€¢ Obtaining a history of concomitant drug use (including nonprescription medications 
and herbal and dietary supplement preparations), alcohol use, recreational drug use, 
and special diets.  
â€¢ Ruling out acute viral hepatitis types A, B, C, D, and E; autoimmune or alcoholic 
hepatitis; hypoxic/ischemic hepatopathy; and other biliary tract disease.  
Page 165 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 166 
 
Confidential and Proprietary  â€¢ Obtaining a history of exposure to environmental chemical agents.  
â€¢ Obtaining additional tests to evaluate liver function, as appropriate (eg, INR, direct 
bilirubin).  
Discontinuation of treat ment should be considered if the following abnormality or group of 
abnormalities occur (in subjects with baseline values within the normal range):  
â€¢ ALT or AST >8 Ã— ULN  
â€¢ ALT or AST >5 Ã— ULN for more than 2 weeks  
â€¢ ALT or AST >3 Ã— ULN and total bilirubin >2 Ã— ULN or INR >1.5)  
â€¢ ALT or AST >3 Ã— ULN with the appearance of new onset fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
In subjects with abnormal baseline values, the reference point should be changed from ULN to 
baseline.  In subjects with abnormal values at baseline who develop a nadir value during the 
study, the reference points noted above should be changed from ULN or baseline to the nadir 
value for subsequent assessments.  Baseline is defined as t he average of all on -study, predose 
values (including Screening Visit and Day 1).  A nadir value is defined as the average of at least 
[ADDRESS_755759] value, regardless of when it occurs 
(ie, on or off treatment).  Repeat and unscheduled visits will be included in the determination of the nadir value.  A new nadir value may develop over the course of the study if liver biochemistries improve over time.  
Page 166 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 167 
 
Confidential and Proprietary  APPENDIX C. COMMON TERMINOLOGY CRITERIA FOR ADVERSE 
EVENTS 
 
Page 167 of 364
1. CTCAE 4.03
 
 
Common Terminology Criteria for
Adverse Events (CTCAE)
Version 4.0
Published: May 28, 2009 (v4.03: June 14, 2010)
U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute
Page 168 of 364
__________ 
â€  CTCAE v4.0 incorporates certain elements of the MedDRA terminology. For further details on MedDRA refer to the MedDRA MSSO Web site ( http://www.meddramsso.com ). Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 
Publish Date: May 28, 2009
Quick Reference  
The NCI Common Terminology Criteria for 
Adverse Events is a descriptive terminology which 
can be utilized for Adverse Event (AE) reporting.  
A grading (severity) scale is provided for each AE 
term. 
Components and Organization  
SOC 
System Organ Class, the highest level of the 
MedDRA hierarchy, is identified by [CONTACT_575893], etiology, or purpose (e.g., 
SOC Investigations for laboratory test results).  
CTCAE terms are grouped by [CONTACT_575894]. Within each SOC, AEs are listed and 
accompanied by [CONTACT_75494] (Grade). 
CTCAE Terms  
An Adverse Event (AE) is any unfavorable and 
unintended sign (including an abnormal 
laboratory finding), symptom, or disease 
temporally associated with the use of a medical 
treatment or procedure that may or may not be 
considered related to the medical treatment or 
procedure.  An AE is a term that is a unique 
representation of a specific event used for 
medical documentation and scientific analyses.  
Each CTCAE v4.0 term is a MedDRA LLT (Lowest 
Level Term). 
 Definitions 
A brief definition is provided to clarify the 
meaning of each AE term. 
Grades 
Grade refers to the severity of the AE.  The CTCAE 
displays Grades 1 through 5 with unique clinical 
descriptions of severity for each AE based on this 
general guideline: 
 Grade 1 Mild; asymptomatic or mild 
symptoms; clinical or diagnostic 
observations only; intervention not 
indicated. 
 Grade 2 Moderate; minimal, local or 
noninvasive intervention indicated; 
limiting age-appropriate 
instrumental ADL*. 
 Grade 3 Severe or medically significant but 
not immediately life-threatening; 
hospi[INVESTIGATOR_24599]; disabling; 
limiting self care ADL**. 
 Grade 4 Life-threatening consequences; 
urgent intervention indicated. 
 Grade 5 Death related to AE. 
A Semi-colon indicates â€˜orâ€™ within the description 
of the grade. 
A single dash (-) indicates a grade is not available. Not all Grades are appropriate for all AEs. 
Therefore, some AEs are listed with fewer than 
five options for Grade selection. 
Grade 5 
Grade 5 (Death) is not appropriate for some AEs 
and therefore is not an option. 
Activities of Daily Living (ADL) 
*Instrumental ADL refer to preparing meals, 
shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc. 
**Self care ADL refer to bathing, dressing and 
undressing, feeding self, using the toilet, taking 
medications, and not bedridden. Page 169 of 364
CONTENTS
SOC Page
Blood and lymphatic system disorders 3
Cardiac disorders 4
Congenital, familial and genetic disorders 7
Ear and laby[CONTACT_33994] 8
Endocrine disorders 9
Eye disorders 10
Gastrointestinal disorders 12
General disorders and administration site conditions 22
Hepatobiliary disorders 24
Immune system disorders 26
Infections and infestations 27
Injury, poisoning and procedural complications 34
Investigations 41
Metabolism and nutrition disorders 44
Musculoskeletal and connective tissue disorders 46
Neoplasms benign, malignant and unspecified (incl cysts and polyps) [ADDRESS_755760] disorders 61
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 65
Skin and subcutaneous tissue disorders 71
Social circumstances 75
Surgical and medical procedures 76
Vascular disorders 77
Page 170 of 364
CTCAE 4.03 - June 14, 2010 : Blood and lymphatic system disorders 
32. Blood and lymphatic system disorders
Blood and lymphatic system disorders
Grade
Adverse Event 1 2 3 4 5
Anemia Hemoglobin (Hgb) <LLN - 10.0
g/dL; <LLN - 6.2 mmol/L; <LLN -
100 g/LHgb <10.0 - 8.0 g/dL; <6.2 - 4.9
mmol/L;  <100 - 80g/LHgb <8.0 g/dL; <4.9 mmol/L;
<80 g/L; transfusion indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575895] 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous
membranes, shortness of breath, palpi[INVESTIGATOR_575605], soft systolic murmurs, lethargy, and fatigability.
Bone marrow hypocellular Mildly hypocellular or <=25%
reduction from normal cellularity
for ageModerately hypocellular or >25 -
<50% reduction from normal
cellularity for ageSeverely hypocellular or >50 -
<=75% reduction cellularity from
normal for ageAplastic persistent for longer
than 2 weeksDeath
Definition: A disorder characterized by [CONTACT_575896].
Disseminated intravascular
coagulation - Laboratory findings with no
bleedingLaboratory findings and
bleedingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575897]. There is an increase in the
risk of hemorrhage as the body is depleted of platelets and coagulation factors.
Febrile neutropenia  -  - ANC <1000/mm3 with a single
temperature of >38.3 degrees C
(101 degrees F) or a sustained
temperature of >=38 degrees C
(100.4 degrees F) for more than
one hour.Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_217779] <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4
degrees F) for more than one hour.
Hemolysis Laboratory evidence of
hemolysis only (e.g., direct
antiglobulin test; DAT; Coombs';
schistocytes; decreased
haptoglobin)Evidence of hemolysis and >=2
gm decrease in hemoglobin.Transfusion or medical
intervention indicated (e.g.,
steroids)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575898].
Hemolytic uremic syndrome Evidence of RBC destruction
(schistocytosis) without clinical
consequences - Laboratory findings with clinical
consequences (e.g., renal
insufficiency, petechiae)Life-threatening consequences,
(e.g., CNS hemorrhage or
thrombosis/embolism or renal
failure)Death
Definition: A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.
Leukocytosis  -  - >100,000/mm3 Clinical manifestations of
leucostasis; urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575899].
Lymph node pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in a lymph node.
Spleen disorder Incidental findings (e.g., Howell-
Jolly bodies); mild degree of
thrombocytosis and
leukocytosisProphylactic antibiotics
indicated - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder of the spleen.
Thrombotic thrombocytopenic
purpuraEvidence of RBC destruction
(schistocytosis) without clinical
consequences - Laboratory findings with clinical
consequences (e.g., renal
insufficiency, petechiae)Life-threatening consequences,
(e.g., CNS hemorrhage or
thrombosis/embolism or renal
failure)Death
Definition: A disorder characterized by [CONTACT_108149], thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such
as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.
Blood and lymphatic system
disorders - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 171 of 364
CTCAE 4.03 - June 14, 2010 : Cardiac disorders 
43. Cardiac disorders
Cardiac disorders
Grade
Adverse Event 1 2 3 4 5
Acute coronary syndrome  - Symptomatic, progressive
angina; cardiac enzymes
normal; hemodynamically stableSymptomatic, unstable angina
and/or acute myocardial
infarction, cardiac enzymes
abnormal, hemodynamically
stableSymptomatic, unstable angina
and/or acute myocardial
infarction, cardiac enzymes
abnormal, hemodynamically
unstableDeath
Definition: A disorder characterized by [CONTACT_572121]. The clinical presentation covers a
spectrum of heart diseases from unstable angina to myocardial infarction.
Aortic valve disease Asymptomatic valvular
thickening with or without mild
valvular regurgitation or
stenosis by [CONTACT_575900]; moderate
regurgitation or stenosis by
[CONTACT_575901]; severe
regurgitation or stenosis by
[CONTACT_9661]; symptoms controlled
with medical interventionLife-threatening consequences;
urgent intervention indicated
(e.g., valve replacement,
valvuloplasty)Death
Definition: A disorder characterized by a defect in aortic valve function or structure.
Asystole Periods of asystole; non-urgent
medical management indicated -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia without cardiac electrical activity. Typi[INVESTIGATOR_897], this is accompanied by [CONTACT_575902][INVESTIGATOR_575607].
Atrial fibrillation Asymptomatic, intervention not
indicatedNon-urgent medical intervention
indicatedSymptomatic and incompletely
controlled medically, or
controlled with device (e.g.,
pacemaker), or ablationLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance
originates above the ventricles.
Atrial flutter Asymptomatic, intervention not
indicatedNon-urgent medical intervention
indicatedSymptomatic and incompletely
controlled medically, or
controlled with device (e.g.,
pacemaker), or ablationLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the
atria.
Atrioventricular block complete  - Non-urgent intervention
indicatedSymptomatic and incompletely
controlled medically, or
controlled with device (e.g.,
pacemaker)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.
Atrioventricular block first
degreeAsymptomatic, intervention not
indicatedNon-urgent intervention
indicated -  -  -
Definition: A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2
seconds; prolongation of the PR interval greater than [ADDRESS_755761]  -  -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575902][INVESTIGATOR_575607].
Chest pain - cardiac Mild pain Moderate pain; limiting
instrumental ADLPain at rest; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_575903].
Conduction disorder Mild symptoms; intervention not
indicatedModerate symptoms Severe symptoms; intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575904].
Constrictive pericarditis
 -  - Symptomatic heart failure or
other cardiac symptoms,
responsive to interventionRefractory heart failure or other
poorly controlled cardiac
symptomsDeath
Definition: A disorder characterized by a thickened and fibrotic pericardial sac; these fibrotic changes impede normal myocardial function by [CONTACT_575905].
Heart failure Asymptomatic with laboratory
(e.g., BNP [B-Natriuretic
Peptide ]) or cardiac imaging
abnormalitiesSymptoms with mild to
moderate activity or exertionSevere with symptoms at rest or
with minimal activity or exertion;
intervention indicatedLife-threatening consequences;
urgent intervention indicated
(e.g., continuous IV therapy or
mechanical hemodynamic
support)Death
Definition: A disorder characterized by [CONTACT_575906], or, the ability to do so only at an elevation
in the filling pressure.
Page 172 of 364
CTCAE 4.03 - June 14, 2010 : Cardiac disorders 
5Cardiac disorders
Grade
Adverse Event 1 2 3 4 5
Left ventricular systolic
dysfunction -  - Symptomatic due to drop in
ejection fraction responsive to
interventionRefractory or poorly controlled
heart failure due to drop in
ejection fraction; intervention
such as ventricular assist
device, intravenous vasopressor
support, or heart transplant
indicatedDeath
Definition: A disorder characterized by [CONTACT_575907][INVESTIGATOR_575608]-diastolic volume. Clinical
manifestations mayinclude dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.
Mitral valve disease Asymptomatic valvular
thickening with or without mild
valvular regurgitation or
stenosis by [CONTACT_575900]; moderate
regurgitation or stenosis by
[CONTACT_575901]; severe
regurgitation or stenosis by
[CONTACT_9661]; symptoms controlled
with medical interventionLife-threatening consequences;
urgent intervention indicated
(e.g., valve replacement,
valvuloplasty)Death
Definition: A disorder characterized by a defect in mitral valve function or structure.
Mobitz (type) II atrioventricular
blockAsymptomatic, intervention not
indicatedSymptomatic; medical
intervention indicatedSymptomatic and incompletely
controlled medically, or
controlled with device (e.g.,
pacemaker)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical
impulse conduction through the atrioventricular (AV) node to the ventricles.
Mobitz type I Asymptomatic, intervention not
indicatedSymptomatic; medical
intervention indicatedSymptomatic and incompletely
controlled medically, or
controlled with device (e.g.,
pacemaker)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of
atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.
Myocardial infarction  - Asymptomatic and cardiac
enzymes minimally abnormal
and no evidence of ischemic
ECG changesSevere symptoms; cardiac
enzymes abnormal;
hemodynamically stable; ECG
changes consistent with
infarctionLife-threatening consequences;
hemodynamically unstableDeath
Definition: A disorder characterized by [CONTACT_572122]; this is due to an interruption of blood supply to the area.
Myocarditis Asymptomatic with laboratory
(e.g., BNP [B-Natriuretic
Peptide ]) or cardiac imaging
abnormalitiesSymptoms with mild to
moderate activity or exertionSevere with symptoms at rest or
with minimal activity or exertion;
intervention indicatedLife-threatening consequences;
urgent intervention indicated
(e.g., continuous IV therapy or
mechanical hemodynamic
support)Death
Definition: A disorder characterized by [CONTACT_575908].
Palpi[INVESTIGATOR_575609]; intervention not
indicatedIntervention indicated  -  -  -
Definition: A disorder characterized by [CONTACT_575909]/or forceful beating of the heart.
Paroxysmal atrial tachycardia Asymptomatic, intervention not
indicatedSymptomatic; medical
management indicatedIV medication indicated Life-threatening consequences;
incompletely controlled
medically; cardioversion
indicatedDeath
Definition: A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance
originates in the atria.
Pericardial effusion  - Asymptomatic effusion size
small to moderateEffusion with physiologic
consequencesLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_94546], usually due to inflammation.
Pericardial tamponade
 -  -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_94547].
Pericarditis Asymptomatic, ECG or physical
findings (e.g., rub) consistent
with pericarditisSymptomatic pericarditis (e.g.,
chest pain)Pericarditis with physiologic
consequences (e.g., pericardial
constriction)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575910] (the protective sac around the heart).
Page 173 of 364
CTCAE 4.03 - June 14, 2010 : Cardiac disorders 
6Cardiac disorders
Grade
Adverse Event 1 2 3 4 5
Pulmonary valve disease Asymptomatic valvular
thickening with or without mild
valvular regurgitation or
stenosis by [CONTACT_575900]; moderate
regurgitation or stenosis by
[CONTACT_575901]; severe
regurgitation or stenosis by
[CONTACT_9661]; symptoms controlled
with medical interventionLife-threatening consequences;
urgent intervention indicated
(e.g., valve replacement,
valvuloplasty)Death
Definition: A disorder characterized by a defect in pulmonary valve function or structure.
Restrictive cardiomyopathy  -  - Symptomatic heart failure or
other cardiac symptoms,
responsive to interventionRefractory heart failure or other
poorly controlled cardiac
symptomsDeath
Definition: A disorder characterized by [CONTACT_575911] (heart muscle) stiffens and loses its flexibility.
Right ventricular dysfunction
Asymptomatic with laboratory
(e.g., BNP [B-Natriuretic
Peptide ]) or cardiac imaging
abnormalitiesSymptoms with mild to
moderate activity or exertionSevere symptoms, associated
with hypoxemia, right heart
failure; oxygen indicatedLife-threatening consequences;
urgent intervention indicated
(e.g., ventricular assist device);
heart transplant indicatedDeath
Definition: A disorder characterized by [CONTACT_575912] a decrease in motility of the right ventricular wall.
Sick sinus syndrome Asymptomatic, intervention not
indicatedNon-urgent intervention
indicatedSevere, medically significant;
medical intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by [CONTACT_337494], fatigue and dizziness.
Sinus bradycardia Asymptomatic, intervention not
indicatedSymptomatic, medical
intervention indicatedSevere, medically significant,
medical intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.
Sinus tachycardia Asymptomatic, intervention not
indicatedSymptomatic; non-urgent
medical intervention indicatedUrgent medical intervention
indicated -  -
Definition: A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.
Supraventricular tachycardia Asymptomatic, intervention not
indicatedNon-urgent medical intervention
indicatedMedical intervention indicated Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.
Tricuspid valve disease Asymptomatic valvular
thickening with or without mild
valvular regurgitation or
stenosisAsymptomatic; moderate
regurgitation or stenosis by
[CONTACT_575901]; severe
regurgitation or stenosis;
symptoms controlled with
medical interventionLife-threatening consequences;
urgent intervention indicated
(e.g., valve replacement,
valvuloplasty)Death
Definition: A disorder characterized by a defect in tricuspid valve function or structure.
Ventricular arrhythmia Asymptomatic, intervention not
indicatedNon-urgent medical intervention
indicatedMedical intervention indicated Life-threatening consequences;
hemodynamic compromise;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia that originates in the ventricles.
Ventricular fibrillation  -  -  - Life-threatening consequences;
hemodynamic compromise;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the
ventricles.
Ventricular tachycardia  - Non-urgent medical intervention
indicatedMedical intervention indicated Life-threatening consequences;
hemodynamic compromise;
urgent intervention indicatedDeath
Definition: A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.
Wolff-Parkinson-White
syndromeAsymptomatic, intervention not
indicatedNon-urgent medical intervention
indicatedSymptomatic and incompletely
controlled medically or
controlled with procedureLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575913].
Cardiac disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 174 of 364
CTCAE 4.03 - June 14, 2010 : Congenital, familial and genetic disorders 
74. Congenital, familial and genetic disorders
Congenital, familial and genetic disorders
Grade
Adverse Event 1 2 3 4 5
Congenital, familial and genetic
disorders - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 175 of 364
CTCAE 4.03 - June 14, 2010 : Ear and laby[CONTACT_33994] 
85. Ear and laby[CONTACT_575914] 1 2 3 4 5
Ear pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the ear.
External ear inflammation External otitis with erythema or
dry desquamationExternal otitis with moist
desquamation, edema,
enhanced cerumen or
discharge; tympanic membrane
perforation; tympanostomyExternal otitis with mastoiditis;
stenosis or osteomyelitis;
necrosis of soft tissue or boneUrgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_2898], swelling and redness to the outer ear and ear canal.
External ear pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the external ear region.
Hearing impaired Adults enrolled on a Monitoring
Program (on a 1, 2, 3, 4, 6 and
8 kHz audiogram): Threshold
shift of [ADDRESS_755762] one ear.
Adults not enrolled in Monitoring
Program: subjective change in
hearing in the absence of
documented hearing loss.
Pediatric (on a 1, 2, 3, 4, 6 and
8 kHz audiogram): Threshold
shift >[ADDRESS_755763]
one ear.Adults enrolled in Monitoring
Program (on a 1, 2, 3, 4, 6 and
8 kHz  audiogram):  Threshold
shift of >[ADDRESS_755764] one ear.
Adults not enrolled in Monitoring
Program: hearing loss but
hearing aid or intervention not
indicated; limiting instrumental
ADL.
Pediatric (on a 1, 2, 3, 4, 6 and
8 kHz audiogram): Threshold
shift >[ADDRESS_755765] one ear.Adults enrolled in Monitoring
Program (on a 1, 2, 3, 4, 6 and
8 kHz audiogram): Threshold
shift of >[ADDRESS_755766] one ear; therapeutic
intervention indicated.
Adults not enrolled in Monitoring
Program:  hearing loss with
hearing aid or intervention
indicated; limiting self care ADL.
Pediatric (on a 1, 2, 3, 4, 6 and
8 kHz audiogram): hearing loss
sufficient to indicate therapeutic
intervention, including hearing
aids; threshold shift >[ADDRESS_755767] one
ear; additional speech-language
related services indicated.Adults: Decrease in hearing to
profound bilateral loss (absolute
threshold >80 dB HL  at 2 kHz
and above); non-servicable
hearing.
Pediatric: Audiologic indication
for cochlear implant and
additional speech-language
related services indicated. -
Definition: A disorder characterized by [CONTACT_575915].
Middle ear inflammation Serous otitis Serous otitis, medical
intervention indicatedMastoiditis; necrosis of canal
soft tissue or boneLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_2898] (physiologic response to irritation), swelling and redness to the middle ear.
Tinnitus Mild symptoms; intervention not
indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_575916], such as ringing, buzzing, roaring or clicking.
Vertigo Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective
vertigo).
Vestibular disorder  - Symptomatic; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_80355], imbalance, nausea, and vision problems.
Ear and laby[CONTACT_33994] -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 176 of 364
CTCAE 4.03 - June 14, 2010 : Endocrine disorders 
96. Endocrine disorders
Endocrine disorders
Grade
Adverse Event 1 2 3 4 5
Adrenal insufficiency Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; medical
intervention indicatedSevere symptoms;
hospi[INVESTIGATOR_151467]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder
of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.
Cushingoid Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicatedSevere symptoms, medical
intervention or hospi[INVESTIGATOR_20579] -  -
Definition: A disorder characterized by [CONTACT_575917]'s disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and
osteoporosis, usually due to exogenous corticosteroids.
Delayed puberty  - No breast development by [CONTACT_654]
13 yrs for females; testes
volume of <[ADDRESS_755768] development by [CONTACT_654]
14 yrs for females; no increase
in testes volume or no Tanner
Stage 2 by [CONTACT_654] 16 yrs for
males; hormone replacement
indicated -  -
Definition: A disorder characterized by [CONTACT_575918].
Growth accelerated  - >= +2 SD (standard deviation)
above mid parental height or
target height -  -  -
Definition: A disorder characterized by [CONTACT_575919].
Hyperparathyroidism Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated -  -  -
Definition: A disorder characterized by [CONTACT_575920]. This results in hypercalcemia (abnormally high levels of calcium in
the blood).
Hyperthyroidism Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; thyroid
suppression therapy indicated;
limiting instrumental ADLSevere symptoms; limiting self
care ADL; hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575921]. Common causes include an overactive thyroid gland or thyroid hormone overdose.
Hypoparathyroidism Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; medical
intervention indicatedSevere symptoms; medical
intervention or hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a decrease in production of parathyroid hormone by [CONTACT_149249].
Hypothyroidism Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; thyroid
replacement indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a decrease in production of thyroid hormone by [CONTACT_516778].
Precocious puberty Physical signs of puberty with
no biochemical markers for
females <8 years and males <9
yearsPhysical signs and biochemical
markers of puberty for females
<8 years and males <9 years -  -  -
Definition: A disorder characterized by [CONTACT_575922]; the onset of sexual maturation begins usually before age 8 for girls and before age
9 for boys.
Virilization Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated -  -  -
Definition: A disorder characterized by [CONTACT_575923] a female or prepubertal male.
Endocrine disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 177 of 364
CTCAE 4.03 - June 14, 2010 : Eye disorders 
107. Eye disorders
Eye disorders
Grade
Adverse Event 1 2 3 4 5
Blurred vision Intervention not indicated Symptomatic; limiting
instrumental ADLLimiting self care ADL  -  -
Definition: A disorder characterized by [CONTACT_439843].
Cataract Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; moderate
decrease in visual acuity
(20/40 or better)Symptomatic with marked
decrease in visual acuity
(worse than 20/40 but better
than 20/200); operative
intervention indicated (e.g.,
cataract surgery)Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575924]. This results in a decrease in visual acuity and eventual blindness if
untreated.
Conjunctivitis Asymptomatic or mild
symptoms; intervention not
indicatedSymptomatic; topi[INVESTIGATOR_575611] (e.g.,
antibiotics); limiting
instrumental ADLLimiting self care ADL
 -  -
Definition: A disorder characterized by [CONTACT_2898], swelling and redness to the conjunctiva of the eye.
Corneal ulcer  - Symptomatic; medical
intervention indicated (e.g.,
topi[INVESTIGATOR_12450]); limiting
instrumental ADLLimiting self care ADL;
declining vision (worse than
20/40 but better than 20/200)Perforation or blindness
(20/200 or worse) in the
affected eye -
Definition: A disorder characterized by [CONTACT_575925][INVESTIGATOR_575612]. It is associated with inflammatory cells in the cornea and anterior chamber.
Dry eye Asymptomatic; clinical or
diagnostic observations only;
mild symptoms relieved by
[CONTACT_575926]; multiple
agents indicated; limiting
instrumental ADLDecrease in visual acuity
(<20/40); limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_575927].
Extraocular muscle paresis Asymptomatic; clinical or
diagnostic observations onlySymptomatic; limiting
instrumental ADLLimiting self care ADL;
disabling -  -
Definition: A disorder characterized by [CONTACT_575928].
Eye pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self
care ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the eye.
Eyelid function disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; nonoperative
intervention indicated;
limiting instrumental ADLLimiting self care ADL;
operative intervention
indicated -  -
Definition: A disorder characterized by [CONTACT_575929].
Flashing lights Symptomatic but not limiting
ADLLimiting instrumental ADL Limiting self care ADL  -  -
Definition: A disorder characterized by a sudden or brief burst of light.
Floaters Symptomatic but not limiting
ADLLimiting instrumental ADL Limiting self care ADL  -  -
Definition: A disorder characterized by [CONTACT_575930]. The spots are shadows of opaque cell fragments in the vitreous humor or lens.
Glaucoma Elevated intraocular
pressure (EIOP) with single
topi[INVESTIGATOR_575613];
no visual field deficitEIOP causing early visual
field deficits; multiple topi[INVESTIGATOR_575614];
limiting instrumental ADLEIOP causing marked visual
field deficits (e.g., involving
both superior and inferior
visual fields); operative
intervention indicated;
limiting self care ADLBlindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575931].
Keratitis  - Symptomatic; medical
intervention indicated (e.g.,
topi[INVESTIGATOR_12450]); limiting
instrumental ADLDecline in vision (worse than
20/40 but better than
20/200); limiting self care
ADLPerforation or blindness
(20/200 or worse) in the
affected eye -
Definition: A disorder characterized by [CONTACT_575932].
Night blindness Symptomatic but not limiting
ADLLimiting instrumental ADL Limiting self care ADL Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575933].
Page 178 of 364
CTCAE 4.03 - June 14, 2010 : Eye disorders 
11Eye disorders
Grade
Adverse Event 1 2 3 4 5
Optic nerve disorder Asymptomatic; clinical or
diagnostic observations onlyLimiting vision of the affected
eye (20/40 or better)Limiting vision in the affected
eye (worse than 20/40 but
better than 20/200)Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575934] (second cranial nerve).
Papi[INVESTIGATOR_575615]; no visual field
defectsSymptomatic decline in
vision; visual field defect
present sparing the central
[ADDRESS_755769]
(worse than 20/40 but better
than 20/200)Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575935].
Photophobia Symptomatic but not limiting
ADLLimiting instrumental ADL Limiting self care ADL
 -  -
Definition: A disorder characterized by [CONTACT_575936].
Retinal detachment Asymptomatic Exudative and visual acuity
20/40 or betterRhegmatogenous or
exudative detachment;
operative intervention
indicated; decline in vision
(worse than 20/40 but better
than 20/200)Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575937][INVESTIGATOR_1836].
Retinal tear  - Laser therapy or
pneumopexy indicatedVitroretinal surgical repair
indicatedBlindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.
Retinal vascular disorder  - Topi[INVESTIGATOR_575616];
operative intervention
indicated -  -
Definition: A disorder characterized by [CONTACT_575938].
Retinopathy Asymptomatic; clinical or
diagnostic observations onlySymptomatic with moderate
decrease in visual acuity
(20/40 or better); limiting
instrumental ADLSymptomatic with marked
decrease in visual acuity
(worse than 20/40);
disabling; limiting self care
ADLBlindness (20/200 or worse)
in the affected eye -
Definition: A disorder involving the retina.
Scleral disorder Asymptomatic; clinical or
diagnostic observations onlySymptomatic, limiting
instrumental ADL; moderate
decrease in visual acuity
(20/40 or better)Symptomatic, limiting self
care ADL; marked decrease
in visual acuity (worse than
20/40)Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575939].
Uveitis Asymptomatic; clinical or
diagnostic observations onlyAnterior uveitis; medical
intervention indicatedPosterior or pan-uveitis Blindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575940].
Vitreous hemorrhage Asymptomatic or mild
symptoms; clinical or
diagnostic observations onlySymptomatic; limiting
instrumental ADLLimiting self care ADL;
vitrectomy indicatedBlindness (20/200 or worse)
in the affected eye -
Definition: A disorder characterized by [CONTACT_575941].
Watering eyes Intervention not indicated Intervention indicated Operative intervention
indicated -  -
Definition: A disorder of excessive tearing in the eyes; it can be caused by [CONTACT_575942].
Eye disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or
diagnostic observations only;
intervention not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental
ADLSevere or medically
significant but not
immediately sight-
threatening; hospi[INVESTIGATOR_575617];
disabling;  limiting self care
ADLSight-threatening
consequences; urgent
intervention indicated;
blindness (20/200 or worse)
in the affected eye -
Page 179 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
128. Gastrointestinal disorders
Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Abdominal distension Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; limiting
instrumental ADLSevere discomfort; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_575943].
Abdominal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the abdominal region.
Anal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding, TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575944].
Anal hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575945].
Anal mucositis Asymptomatic or mild
symptoms; intervention not
indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575946].
Anal necrosis  -  - TPN or hospi[INVESTIGATOR_374];
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the anal region.
Anal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the anal region.
Anal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSymptomatic and severely
altered GI function; non-
emergent operative intervention
indicated; TPN or hospi[INVESTIGATOR_575610]-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the anal canal.
Anal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the anal canal.
Ascites Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; invasive
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_94545].
Bloating No change in bowel function or
oral intakeSymptomatic, decreased oral
intake; change in bowel function -  -  -
Definition: A disorder characterized by [CONTACT_1130]-reported feeling of uncomfortable fullness of the abdomen.
Cecal hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575947].
Cheilitis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; intervention indicated -  -
Definition: A disorder characterized by [CONTACT_575948].
Page 180 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
13Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Colitis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedAbdominal pain; mucus or blood
in stoolSevere abdominal pain; change
in bowel habits; medical
intervention indicated;
peritoneal signsLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575949].
Colonic fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
bowel rest, TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575950].
Colonic hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_89668].
Colonic obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionHospi[INVESTIGATOR_374];
elective operative intervention
indicated; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575951].
Colonic perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a rupture in the colonic wall.
Colonic stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding or hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the colon.
Colonic ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the colon.
Constipation Occasional or intermittent
symptoms; occasional use of
stool softeners, laxatives,
dietary modification, or enemaPersistent symptoms with
regular use of laxatives or
enemas; limiting instrumental
ADLObstipation with manual
evacuation indicated; limiting
self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575952].
Dental caries One or more dental caries, not
involving the rootDental caries involving the root Dental caries resulting in pulpi[INVESTIGATOR_575618] -  -
Definition: A disorder characterized by [CONTACT_575953] a tooth, in which it becomes softened, discolored and/or porous.
Diarrhea Increase of <4 stools per day
over baseline; mild increase in
ostomy output compared to
baselineIncrease of 4 - 6 stools per day
over baseline; moderate
increase in ostomy output
compared to baselineIncrease of >=7 stools per day
over baseline; incontinence;
hospi[INVESTIGATOR_374]; severe
increase in ostomy output
compared to baseline; limiting
self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575954].
Dry mouth Symptomatic (e.g., dry or thick
saliva) without significant dietary
alteration; unstimulated saliva
flow >0.2 ml/minModerate symptoms; oral intake
alterations (e.g., copi[INVESTIGATOR_575619],
other lubricants, diet limited to
purees and/or soft, moist foods);
unstimulated saliva 0.1 to 0.2
ml/minInability to adequately aliment
orally; tube feeding or TPN
indicated; unstimulated saliva
<0.1 ml/min -  -
Definition: A disorder characterized by [CONTACT_575955].
Page 181 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
14Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Duodenal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding, TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575956].
Duodenal hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_89672].
Duodenal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionHospi[INVESTIGATOR_575620];
disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575957].
Duodenal perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the duodenal wall.
Duodenal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding; hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the duodenum.
Duodenal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; medical
intervention indicated; limiting
instrumental ADLSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; limiting
self care ADL; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the duodenal wall.
Dyspepsia Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicatedSevere symptoms; surgical
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_89674], often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating,
heartburn, nausea and vomiting.
Dysphagia Symptomatic, able to eat
regular dietSymptomatic and altered
eating/swallowingSeverely altered
eating/swallowing; tube feeding
or TPN or hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575958].
Enterocolitis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedAbdominal pain; mucus or blood
in stoolSevere or persistent abdominal
pain; fever; ileus; peritoneal
signsLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575959].
Enterovesical fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; noninvasive
intervention indicatedSevere, medically significant;
medical intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575960].
Esophageal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding, TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575961].
Esophageal hemorrhage Mild; intervention not indicated
Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575962].
Page 182 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
15Gastrointestinal disorders
Grade
Adverse Event [ADDRESS_755770]; radiologic,
endoscopic, or operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the esophageal wall.
Esophageal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLHospi[INVESTIGATOR_374];
elective operative intervention
indicated; limiting self care ADL;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575963].
Esophageal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the esophageal region.
Esophageal perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the wall of the esophagus.
Esophageal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding; hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the esophagus.
Esophageal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; limiting
self care ADL; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the esophageal wall.
Esophageal varices
hemorrhage - Self-limited; intervention not
indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575964].
Esophagitis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered
eating/swallowing;  oral
supplements indicatedSeverely altered
eating/swallowing; tube feeding,
TPN or hospi[INVESTIGATOR_151467]-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575965].
Fecal incontinence Occasional use of pads required
Daily use of pads required Severe symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_575966].
Flatulence Mild symptoms; intervention not
indicatedModerate; persistent;
psychosocial sequelae -  -  -
Definition: A disorder characterized by a state of excessive gas in the alimentary canal.
Gastric fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
bowel rest; tube feeding, TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575967].
Gastric hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575968].
Gastric necrosis  -  - Inability to aliment adequately
by [CONTACT_575969]; radiologic,
endoscopic, or operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the gastric wall.
Page 183 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
16Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Gastric perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the stomach wall.
Gastric stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding; hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the stomach.
Gastric ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; medical intervention
indicated; limiting instrumental
ADLSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; limiting
self care ADL; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the stomach.
Gastritis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; medical intervention
indicatedSeverely altered eating or
gastric function; TPN or
hospi[INVESTIGATOR_151467]-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_89679].
Gastroesophageal reflux
diseaseMild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicatedSevere symptoms; surgical
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_575970]/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by [CONTACT_575971], and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.
Gastrointestinal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding, TPN or
hospi[INVESTIGATOR_151467]-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575972].
Gastrointestinal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.
Gastroparesis Mild nausea, early satiety and
bloating, able to maintain caloric
intake on regular dietModerate symptoms; able to
maintain nutrition with dietary
and lifestyle modifications; may
need pharmacologic
interventionWeight loss; refractory to
medical intervention; unable to
maintain nutrition orally -  -
Definition: A disorder characterized by [CONTACT_575973].
Gingival pain Mild pain Moderate pain interfering with
oral intakeSevere pain; inability to aliment
orally -  -
Definition: A disorder characterized by a sensation of marked discomfort in the gingival region.
Hemorrhoidal hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575974].
Hemorrhoids Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; banding or
medical intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_575975].
Ileal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN or hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575976].
Ileal hemorrhage Mild; intervention not indicated
Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_89684].
Page 184 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
17Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Ileal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLHospi[INVESTIGATOR_374];
elective operative intervention
indicated; limiting self care ADL;
disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575977].
Ileal perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the ileal wall.
Ileal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding or hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the ileum.
Ileal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the ileum.
Ileus  - Symptomatic; altered GI
function; bowel rest indicatedSeverely altered GI function;
TPN indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575978].
Intra-abdominal hemorrhage  - Medical intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575979].
Jejunal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN or hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575980].
Jejunal hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575981].
Jejunal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLHospi[INVESTIGATOR_374];
elective operative intervention
indicated; limiting self care ADL;
disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575982].
Jejunal perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the jejunal wall.
Jejunal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding or hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the jejunum.
Jejunal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the jejunum.
Lip pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort of the lip.
Page 185 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
18Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Lower gastrointestinal
hemorrhageMild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575983] (small intestine, large intestine, and anus).
Malabsorption  - Altered diet; oral intervention
indicatedInability to aliment adequately;
TPN indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575984]. Symptoms include abdominal marked discomfort, bloating and diarrhea.
Mucositis oral Asymptomatic or mild
symptoms; intervention not
indicatedModerate pain; not interfering
with oral intake; modified diet
indicatedSevere pain; interfering with oral
intakeLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575985].
Nausea Loss of appetite without
alteration in eating habitsOral intake decreased without
significant weight loss,
dehydration or malnutritionInadequate oral caloric or fluid
intake; tube feeding, TPN, or
hospi[INVESTIGATOR_374] -  -
Definition: A disorder characterized by a queasy sensation and/or the urge to vomit.
Obstruction gastric Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLHospi[INVESTIGATOR_374];
elective operative intervention
indicated; limiting self care ADL;
disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575986].
Oral cavity fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN or hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575987].
Oral dysesthesia Mild discomfort; not interfering
with oral intakeModerate pain; interfering with
oral intakeDisabling pain; tube feeding or
TPN indicated -  -
Definition: A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.
Oral hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575988].
Oral pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.
Pancreatic duct stenosis
Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding or hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the pancreatic duct.
Pancreatic fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding or TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575989].
Pancreatic hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_89694].
Pancreatic necrosis  -  - Tube feeding or TPN indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the pancreas.
Pancreatitis  - Enzyme elevation or radiologic
findings onlySevere pain; vomiting; medical
intervention indicated (e.g.,
analgesia, nutritional support)Life-threatening consequences;
urgent intervention indicatedDeath
Page 186 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
19Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_89695].
Periodontal disease Gingival recession or gingivitis;
limited bleeding on probing; mild
local bone lossModerate gingival recession or
gingivitis; multiple sites of
bleeding on probing; moderate
bone lossSpontaneous bleeding; severe
bone loss with or without tooth
loss; osteonecrosis of maxilla or
mandible -  -
Definition: A disorder in the gingival tissue around the teeth.
Peritoneal necrosis  -  - Tube feeding or TPN  indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the peritoneum.
Proctitis Rectal discomfort, intervention
not indicatedSymptoms (e.g., rectal
discomfort, passing blood or
mucus); medical intervention
indicated; limiting instrumental
ADLSevere symptoms; fecal
urgency or stool incontinence;
limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575990].
Rectal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
TPN or hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575991].
Rectal hemorrhage Mild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575992].
Rectal mucositis Asymptomatic or mild
symptoms; intervention not
indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575993].
Rectal necrosis  -  - Tube feeding or TPN indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the rectal wall.
Rectal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLHospi[INVESTIGATOR_374];
elective operative intervention
indicated; limiting self care ADL;
disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575994].
Rectal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the rectal region.
Rectal perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the rectal wall.
Rectal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSeverely altered GI function;
tube feeding or hospi[INVESTIGATOR_20579]; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the rectum.
Rectal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function (e.g. altered dietary
habits, vomiting, diarrhea)Severely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the rectum.
Page 187 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
20Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Retroperitoneal hemorrhage  - Self-limited; intervention
indicatedTransfusion, medical, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575995].
Salivary duct inflammation Slightly thickened saliva; slightly
altered taste (e.g., metallic)Thick, ropy, sticky saliva;
markedly altered taste;
alteration in diet indicated;
secretion-induced symptoms;
limiting instrumental ADLAcute salivary gland necrosis;
severe secretion-induced
symptoms (e.g., thick saliva/oral
secretions or gagging);  tube
feeding or TPN indicated;
limiting self care ADL; disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575996].
Salivary gland fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; tube feeding indicatedSeverely altered GI function;
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575997] a salivary gland and another organ or anatomic site.
Small intestinal mucositis
Asymptomatic or mild
symptoms; intervention not
indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADLSevere pain; interfering with oral
intake; tube feeding, TPN or
hospi[INVESTIGATOR_374]; limiting
self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575998].
Small intestinal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLHospi[INVESTIGATOR_374];
elective operative intervention
indicated; limiting self care ADL;
disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_575999].
Small intestinal perforation  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the small intestine wall.
Small intestinal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
functionSymptomatic and severely
altered GI function; tube
feeding, TPN or hospi[INVESTIGATOR_20579]; non-emergent
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the small intestine.
Small intestine ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; limiting instrumental
ADLSeverely altered GI function;
TPN indicated; elective
operative or endoscopic
intervention indicated; limiting
self care ADL; disablingLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the mucosal surface of the small intestine.
Stomach pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the stomach.
Tooth development disorder Asymptomatic; hypoplasia of
tooth or enamelImpairment correctable with oral
surgeryMaldevelopment with
impairment not surgically
correctable; disabling -  -
Definition: A disorder characterized by a pathological process of the teeth occurring during tooth development.
Tooth discoloration Surface stains  -  -  -  -
Definition: A disorder characterized by a change in tooth hue or tint.
Toothache Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the tooth.
Page 188 of 364
CTCAE 4.03 - June 14, 2010 : Gastrointestinal disorders 
21Gastrointestinal disorders
Grade
Adverse Event 1 2 3 4 5
Typhlitis  -  - Symptomatic (e.g., abdominal
pain, fever, change in bowel
habits with ileus); peritoneal
signsLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576000].
Upper gastrointestinal
hemorrhageMild; intervention not indicated Moderate symptoms; medical
intervention or minor
cauterization indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576001] (oral cavity, pharynx, esophagus, and stomach).
Vomiting 1 - 2 epi[INVESTIGATOR_1841] (separated by 5
minutes) in 24 hrs3 - 5 epi[INVESTIGATOR_1841] (separated by 5
minutes) in 24 hrs>=6 epi[INVESTIGATOR_1841] (separated by 5
minutes) in 24 hrs; tube feeding,
TPN or hospi[INVESTIGATOR_151467]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576002].
Gastrointestinal disorders -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 189 of 364
CTCAE 4.03 - June 14, 2010 : General disorders and administration site conditions 
229. General disorders and administration site conditions
General disorders and administration site conditions
Grade
Adverse Event 1 2 3 4 5
Chills Mild sensation of cold;
shivering; chattering of teethModerate tremor of the entire
body; narcotics indicatedSevere or prolonged, not
responsive to narcotics -  -
Definition: A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.
Death neonatal  -  -  -  - Death
Definition: A disorder characterized by [CONTACT_52372] 28 days of life.
Death NOS  -  -  -  - Death
Definition: A cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.
Edema face Localized facial edema Moderate localized facial
edema; limiting instrumental
ADLSevere swelling; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_94550].
Edema limbs 5 - 10% inter-limb discrepancy
in volume or circumference at
point of greatest visible
difference; swelling or
obscuration of anatomic
architecture on close inspection>10 - 30% inter-limb
discrepancy in volume or
circumference at point of
greatest visible difference;
readily apparent obscuration of
anatomic architecture;
obliteration of skin folds; readily
apparent deviation from normal
anatomic contour; limiting
instrumental ADL>30% inter-limb discrepancy in
volume; gross deviation from
normal anatomic contour;
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_94551].
Edema trunk Swelling or obscuration of
anatomic architecture on close
inspectionReadily apparent obscuration of
anatomic architecture;
obliteration of skin folds; readily
apparent deviation from normal
anatomic contour; limiting
instrumental ADLGross deviation from normal
anatomic contour; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_94527].
Facial pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the face.
Fatigue Fatigue relieved by [CONTACT_576003];
limiting instrumental ADLFatigue not relieved by [CONTACT_9075],
limiting self care ADL -  -
Definition: A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.
Fever 38.0 - 39.0 degrees C  (100.4 -
102.2 degrees F)>39.0 - 40.0 degrees C (102.3 -
104.0 degrees F)>40.0 degrees C (>104.0
degrees F) for <=24 hrs>40.0 degrees C (>104.0
degrees F) for >24 hrsDeath
Definition: A disorder characterized by [CONTACT_576004]'s temperature above the upper limit of normal.
Flu like symptoms Mild flu-like symptoms present
Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry
cough.
Gait disturbance Mild change in gait (e.g., wide-
based, limpi[INVESTIGATOR_575621])Moderate change in gait (e.g.,
wide-based, limpi[INVESTIGATOR_575622]); assistive device
indicated; limiting instrumental
ADLDisabling; limiting self care ADL  -  -
Definition: A disorder characterized by [CONTACT_576005].
Hypothermia  - 35 - >32 degrees C;  95 - >89.6
degrees F32 - >28 degrees C;  89.6 -
>82.4 degrees F<=28 degrees C; 82.4 degrees
F; life-threatening
consequences (e.g., coma,
hypotension, pulmonary edema,
acidemia, ventricular fibrillation)Death
Definition: A disorder characterized by [CONTACT_576006]. Treatment is required when the body temperature is 35C (95F) or below.
Page 190 of 364
CTCAE 4.03 - June 14, 2010 : General disorders and administration site conditions 
23General disorders and administration site conditions
Grade
Adverse Event 1 2 3 4 5
Infusion related reaction Mild transient reaction; infusion
interruption not indicated;
intervention not indicatedTherapy or infusion interruption
indicated but responds promptly
to symptomatic treatment (e.g.,
antihistamines, NSAIDS,
narcotics, IV fluids); prophylactic
medications indicated for <=24
hrsProlonged (e.g., not rapi[INVESTIGATOR_575623]/or brief
interruption of infusion);
recurrence of symptoms
following initial improvement;
hospi[INVESTIGATOR_575624]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_318929].
Infusion site extravasation  - Erythema with associated
symptoms (e.g., edema, pain,
induration, phlebitis)Ulceration or necrosis; severe
tissue damage; operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576007] a pharmacologic or a biologic substance from the infusion site into the surrounding tissue. Signs and symptoms include induration,
erythema, swelling, burning sensation and marked discomfort at the infusion site.
Injection site reaction Tenderness with or without
associated symptoms (e.g.,
warmth, erythema, itching)Pain; lipodystrophy; edema;
phlebitisUlceration or necrosis; severe
tissue damage; operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_48016] (usually immunologic) developi[INVESTIGATOR_58359].
Irritability Mild; easily consolable
Moderate; limiting instrumental
ADL; increased attention
indicatedSevere abnormal or excessive
response; limiting self care ADL;
inconsolable -  -
Definition: A disorder characterized by [CONTACT_576008]; may be in response to pain, fright, a drug, an emotional situation or a medical
condition.
Localized edema Localized to dependent areas,
no disability or functional
impairmentModerate localized edema and
intervention indicated; limiting
instrumental ADLSevere localized edema and
intervention indicated; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_94552] a specific anatomic site.
Malaise Uneasiness or lack of well being Uneasiness or lack of well
being; limiting instrumental ADL -  -  -
Definition: A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.
Multi-organ failure  -  - Shock with azotemia and acid-
base disturbances; significant
coagulation abnormalitiesLife-threatening consequences
(e.g., vasopressor dependent
and oliguric or anuric or
ischemic colitis or lactic
acidosis)Death
Definition: A disorder characterized by [CONTACT_576009], liver, kidney and clotting mechanisms.
Neck edema Asymptomatic localized neck
edemaModerate neck edema; slight
obliteration of anatomic
landmarks; limiting instrumental
ADLGeneralized neck edema (e.g.,
difficulty in turning neck);
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576010].
Non-cardiac chest pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576011] a heart disorder.
Pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576012], distress or agony.
Sudden death NOS  -  -  -  - Death
Definition: An unexpected cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.
General disorders and
administration site conditions -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 191 of 364
CTCAE 4.03 - June 14, 2010 : Hepatobiliary disorders 
2410. Hepatobiliary disorders
Hepatobiliary disorders
Grade
Adverse Event [ADDRESS_755771] stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; IV fluids indicated <24
hrsSeverely altered GI function;
radiologic, endoscopic or
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the lumen of the bile duct.
Biliary fistula  - Symptomatic and intervention
not indicatedSeverely altered GI function;
TPN indicated; endoscopic
intervention indicated; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576013].
Cholecystitis  - Symptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576014]. It may be associated with the presence of gallstones.
Gallbladder fistula Asymptomatic clinical or
diagnostic observations only;
intervention not indicatedSymptomatic and intervention
not indicatedSymptomatic or severely altered
GI function; TPN indicated;
radiologic, endoscopic or
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576015].
Gallbladder necrosis  -  -  - Life-threatening consequences;
urgent radiologic or operative
intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the gallbladder.
Gallbladder obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; altered GI
function; IV fluids indicated  <24
hrsSymptomatic and severely
altered GI function; tube
feeding, TPN or hospi[INVESTIGATOR_20579]; non-emergent
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576016].
Gallbladder pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the gallbladder region.
Gallbladder perforation  -  -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a rupture in the gallbladder wall.
Hepatic failure  -  - Asterixis; mild encephalopathy;
limiting self care ADLModerate to severe
encephalopathy; coma; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576017]. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic
dehydrogenase, and alkaline phosphatase.
Hepatic hemorrhage Mild; intervention not indicated
Symptomatic; medical
intervention indicatedTransfusion indicated Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576018].
Hepatic necrosis  -  -  - Life-threatening consequences;
urgent radiologic or operative
intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the hepatic parenchyma.
Hepatic pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the liver region.
Perforation bile duct  -  - Radiologic, endoscopic or
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.
Page 192 of 364
CTCAE 4.03 - June 14, 2010 : Hepatobiliary disorders 
25Hepatobiliary disorders
Grade
Adverse Event 1 2 3 4 5
Portal hypertension  - Decreased portal vein flow Reversal/retrograde portal vein
flow; associated with varices
and/or ascitesLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576019].
Portal vein thrombosis  - Intervention not indicated Medical intervention indicated
Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_61172] a thrombus (blood clot) in the portal vein.
Hepatobiliary disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 193 of 364
CTCAE 4.03 - June 14, 2010 : Immune system disorders 
2611. Immune system disorders
Immune system disorders
Grade
Adverse Event 1 2 3 4 5
Allergic reaction Transient flushing or rash, drug
fever <38 degrees C (<100.4
degrees F); intervention not
indicatedIntervention or infusion
interruption indicated; responds
promptly to symptomatic
treatment (e.g., antihistamines,
NSAIDS, narcotics);
prophylactic medications
indicated for <=24 hrsProlonged (e.g., not rapi[INVESTIGATOR_575623]/or brief
interruption of infusion);
recurrence of symptoms
following initial improvement;
hospi[INVESTIGATOR_575625] (e.g., renal
impairment, pulmonary
infiltrates)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_221742].
Anaphylaxis  -  - Symptomatic bronchospasm,
with or without urticaria;
parenteral intervention
indicated; allergy-related
edema/angioedema;
hypotensionLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_364307]-like substances from mast cells, causing a hypersensitivity
immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.
Autoimmune disorder Asymptomatic; serologic or
other evidence of autoimmune
reaction, with normal organ
function;  intervention not
indicatedEvidence of autoimmune
reaction involving a non-
essential organ or function (e.g.,
hypothyroidism)Autoimmune reactions involving
major organ (e.g., colitis,
anemia, myocarditis, kidney)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own
tissue constituents.
Cytokine release syndrome Mild reaction; infusion
interruption not indicated;
intervention not indicatedTherapy or infusion interruption
indicated but responds promptly
to symptomatic treatment (e.g.,
antihistamines, NSAIDS,
narcotics, IV fluids); prophylactic
medications indicated for <=24
hrsProlonged (e.g., not rapi[INVESTIGATOR_575623]/or brief
interruption of infusion);
recurrence of symptoms
following initial improvement;
hospi[INVESTIGATOR_575625] (e.g., renal
impairment, pulmonary
infiltrates)Life-threatening consequences;
pressor or ventilatory support
indicatedDeath
Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and shortness of breath; it is caused by [CONTACT_210939].
Serum sickness Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate arthralgia; fever, rash,
urticaria, antihistamines
indicatedSevere arthralgia or arthritis;
extensive rash; steroids or IV
fluids indicatedLife-threatening consequences;
pressor or ventilatory support
indicatedDeath
Definition: A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days
following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.
Immune system disorders -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 194 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
2712. Infections and infestations
Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Abdominal infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576020].
Anorectal infection Localized; local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576021].
Appendicitis  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576022] a pathogenic agent.
Appendicitis perforated  - Symptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576022] a pathogenic agent with gangrenous changes resulting in the rupture of the
appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.
Arteritis infective  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576023].
Biliary tract infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576024].
Bladder infection  - Oral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576025].
Bone infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576026].
Breast infection  - Local infection with moderate
symptoms; oral intervention
indicated (e.g., antibiotic,
antifungal, antiviral)Severe infection; axillary
adenitis;  IV antibacterial,
antifungal, or antiviral
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576027].
Bronchial infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576028].
Catheter related infection  - Localized; local intervention
indicated; oral intervention
indicated (e.g., antibiotic,
antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576029].
Cecal infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Page 195 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
28Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_576030].
Cervicitis infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576031].
Conjunctivitis infective  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576032]. Clinical manifestations include pi[INVESTIGATOR_575626].
Corneal infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576033].
Cranial nerve infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576034] a cranial nerve.
Device related infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576035] a medical device.
Duodenal infection  - Moderate symptoms; medical
intervention indicated (e.g., oral
antibiotics)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576036].
Encephalitis infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
severe changes in mental
status; self-limited seizure
activity; focal neurologic
abnormalitiesLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576037].
Encephalomyelitis infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576038][INVESTIGATOR_575627].
Endocarditis infective  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576039].
Endophthalmitis  - Local intervention indicated
Systemic intervention or
hospi[INVESTIGATOR_575628] (20/200 or worse)  -
Definition: A disorder characterized by [CONTACT_576040].
Page 196 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
29Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Enterocolitis infectious  - Passage of >3 unformed stools
per 24 hrs or duration of illness
>48 hrs; moderate abdominal
painIV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicated;
profuse watery diarrhea with
signs of hypovolemia;  bloody
diarrhea; fever; severe
abdominal pain; hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576041].
Esophageal infection  - Local intervention indicated
(e.g., oral antibiotic, antifungal,
antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576042].
Eye infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicated;
enucleationDeath
Definition: A disorder characterized by [CONTACT_576043].
Gallbladder infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576044].
Gum infection Local therapy indicated (swish
and swallow)Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576045].
Hepatic infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576046].
Hepatitis viral Asymptomatic, treatment not
indicated - Symptomatic liver dysfunction;
fibrosis by [CONTACT_9256]; compensated
cirrhosis; reactivation of chronic
hepatitisDecompensated liver function
(e.g., ascites, coagulopathy,
encephalopathy, coma)Death
Definition: A disorder characterized by a viral pathologic process involving the liver parenchyma.
Infective myositis  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576047].
Joint infection  - Localized; local intervention
indicated; oral intervention
indicated (e.g., antibiotic,
antifungal, antiviral); needle
aspi[INVESTIGATOR_575629] (single or
multiple)Arthroscopic intervention
indicated (e.g., drainage) or
arthrotomy (e.g., open surgical
drainage)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576034] a joint.
Kidney infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576048].
Page 197 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
30Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Laryngitis  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576049].
Lip infection Localized, local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576050].
Lung infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576051].
Lymph gland infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576052].
Mediastinal infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576053].
Meningitis  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicated; focal
neurologic deficitLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576054]/or spi[INVESTIGATOR_1831].
Mucosal infection Localized, local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576034] a mucosal surface.
Nail infection Localized, local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576055].
Otitis externa  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576056]. Contributory factors include excessive water exposure (swimmer's ear infection)
and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.
Otitis media  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576057].
Ovarian infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576058].
Page 198 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
31Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Pancreas infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576059].
Papulopustular rash Papules and/or pustules
covering <10% BSA, which may
or may not be associated with
symptoms of pruritus or
tendernessPapules and/or pustules
covering 10-30% BSA, which
may or may not be associated
with symptoms of pruritus or
tenderness; associated with
psychosocial impact; limiting
instrumental ADLPapules and/or pustules
covering >30% BSA, which may
or may not be associated with
symptoms of pruritus or
tenderness; limiting self-care
ADL; associated with local
superinfection with oral
antibiotics indicatedPapules and/or pustules
covering  any % BSA, which
may or may not be associated
with symptoms of pruritus or
tenderness and are associated
with extensive superinfection
with IV antibiotics indicated; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576060] (a small, raised pi[INVESTIGATOR_45886]) and pustules (a small pus filled blister), typi[INVESTIGATOR_168028], scalp, and upper
chest and back Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.
Paronychia Nail fold edema or erythema;
disruption of the cuticleLocalized intervention indicated;
oral intervention indicated (e.g.,
antibiotic, antifungal, antiviral);
nail fold edema or erythema
with pain; associated with
discharge or nail plate
separation; limiting instrumental
ADLSurgical intervention or IV
antibiotics indicated; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576061].
Pelvic infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576062].
Penile infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576063].
Periorbital infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576064].
Peripheral nerve infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576065].
Peritoneal infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576066].
Pharyngitis  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576067].
Phlebitis infective  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Page 199 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
32Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_576068]. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course
of the infected vein.
Pleural infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576069].
Prostate infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576070].
Rash pustular  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicated -  -
Definition: A disorder characterized by a circumscribed and elevated skin lesion filled with pus.
Rhinitis infective  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral) -  -  -
Definition: A disorder characterized by [CONTACT_576071].
Salivary gland infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576072].
Scrotal infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576073].
Sepsis  -  -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576074] a rapi[INVESTIGATOR_575630].
Sinusitis  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576075].
Skin infection Localized, local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576076].
Small intestine infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576077].
Soft tissue infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576078].
Splenic infection  -  - IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Page 200 of 364
CTCAE 4.03 - June 14, 2010 : Infections and infestations 
33Infections and infestations
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_576079].
Stoma site infection Localized, local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576034] a stoma (surgically created opening on the surface of the body).
Tooth infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576034] a tooth.
Tracheitis  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576080].
Upper respi[INVESTIGATOR_4416]  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576081][INVESTIGATOR_4352] (nose, paranasal sinuses, pharynx, larynx, or trachea).
Urethral infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic, endoscopic, or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576082].
Urinary tract infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576083], most commonly the bladder and the urethra.
Uterine infection  - Moderate symptoms; oral
intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576084]. It may extend to the myometrium and parametrial tissues.
Vaginal infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576085].
Vulval infection Localized, local intervention
indicatedOral intervention indicated (e.g.,
antibiotic, antifungal, antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576086].
Wound infection  - Localized; local intervention
indicated (e.g., topi[INVESTIGATOR_11978],
antifungal, or antiviral)IV antibiotic, antifungal, or
antiviral intervention indicated;
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576087].
Infections and infestations -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling; limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 201 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
3413. Injury, poisoning and procedural complications
Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Ankle fracture Mild; non-surgical intervention
indicatedLimiting instrumental ADL;
operative intervention indicatedLimiting self care ADL; elective
surgery indicated -  -
Definition: A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the
affected leg and foot.
Aortic injury  -  - Severe symptoms; limiting self
care ADL; disabling; repair or
revision indicatedLife-threatening consequences;
evidence of end organ damage;
urgent operative intervention
indicatedDeath
Definition: A finding of damage to the aorta.
Arterial injury Asymptomatic diagnostic
finding; intervention not
indicatedSymptomatic (e.g.,
claudication); repair or revision
not indicatedSevere symptoms; limiting self
care ADL; disabling; repair or
revision indicatedLife-threatening consequences;
evidence of end organ damage;
urgent operative intervention
indicatedDeath
Definition: A finding of damage to an artery.
Biliary anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).
Bladder anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).
Bruising Localized or in a dependent
areaGeneralized  -  -  -
Definition: A finding of injury of the soft tissues or bone characterized by [CONTACT_576088].
Burn Minimal symptoms; intervention
not indicatedMedical intervention; minimal
debridement indicatedModerate to major debridement
or reconstruction indicatedLife-threatening consequences
Death
Definition: A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by [CONTACT_576089], direct heat, electricity, flames and
radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.
Dermatitis radiation Faint erythema or dry
desquamationModerate to brisk erythema;
patchy moist desquamation,
mostly confined to skin folds
and creases; moderate edemaMoist desquamation in areas
other than skin folds and
creases; bleeding induced by
[CONTACT_576090]-threatening consequences;
skin necrosis or ulceration of full
thickness dermis; spontaneous
bleeding from involved site; skin
graft indicatedDeath
Definition: A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.
Esophageal anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).
Fall Minor with no resultant injuries;
intervention not indicatedSymptomatic; noninvasive
intervention indicatedHospi[INVESTIGATOR_374]  -  -
Definition: A finding of sudden movement downward, usually resulting in injury.
Fallopi[INVESTIGATOR_575631]; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a fallopi[INVESTIGATOR_575632] (surgical connection of two separate anatomic structures).
Fallopi[INVESTIGATOR_575633]; intervention
not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicated (e.g., organ resection)Death
Definition: A finding of rupture of the fallopi[INVESTIGATOR_575634].
Fracture Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic but non-displaced;
immobilization indicatedSevere symptoms; displaced or
open wound with bone
exposure; disabling; operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of traumatic injury to the bone in which the continuity of the bone is broken.
Page 202 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
35Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Gastric anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).
Gastrointestinal anastomotic
leakAsymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).
Gastrointestinal stoma necrosis  - Superficial necrosis;
intervention not indicatedSevere symptoms;
hospi[INVESTIGATOR_575635]-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of a necrotic process occurring in the gastrointestinal tract stoma.
Hip fracture  - Hairline fracture; mild pain;
limiting instrumental ADL; non-
surgical intervention indicatedSevere pain; hospi[INVESTIGATOR_575636] (e.g., traction); operative
intervention indicatedLife-threatening consequences;
symptoms associated with
neurovascular compromise -
Definition: A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.
Injury to carotid artery  -  - Severe symptoms; limiting self
care ADL (e.g., transient
cerebral ischemia); repair or
revision indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the carotid artery.
Injury to inferior vena cava
 -  -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the inferior vena cava.
Injury to jugular vein  -  - Symptomatic limiting self care
ADL; disabling; repair or
revision indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the jugular vein.
Injury to superior vena cava Asymptomatic diagnostic
finding; intervention not
indicatedSymptomatic; repair or revision
not indicatedSevere symptoms; limiting self
care ADL; disabling; repair or
revision indicatedLife-threatening consequences;
evidence of end organ damage;
urgent operative intervention
indicatedDeath
Definition: A finding of damage to the superior vena cava.
Intestinal stoma leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).
Intestinal stoma obstruction  - Self-limited; intervention not
indicatedSevere symptoms; IV fluids,
tube feeding, or TPN indicated
>=24 hrs; elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of blockage of the normal flow of the contents of the intestinal stoma.
Intestinal stoma site bleeding Minimal bleeding identified on
clinical exam; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of blood leakage from the intestinal stoma.
Intraoperative arterial injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to an artery during a surgical procedure.
Intraoperative breast injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Page 203 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
36Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Definition: A finding of damage to the breast parenchyma during a surgical procedure.
Intraoperative cardiac injury  -  - Primary repair of injured
organ/structure indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the heart during a surgical procedure.
Intraoperative ear injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection of injured
organ/structure indicated;
disabling (e.g., impaired
hearing; impaired balance)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the ear during a surgical procedure.
Intraoperative endocrine injury
Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the endocrine gland during a surgical procedure.
Intraoperative gastrointestinal
injuryPrimary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the gastrointestinal system during a surgical procedure.
Intraoperative head and neck
injuryPrimary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the head and neck during a surgical procedure.
Intraoperative hemorrhage  -  - Postoperative radiologic,
endoscopic, or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of uncontrolled bleeding during a surgical procedure.
Intraoperative hepatobiliary
injuryPrimary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.
Intraoperative musculoskeletal
injuryPrimary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the musculoskeletal system during a surgical procedure.
Intraoperative neurological
injuryPrimary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the nervous system during a surgical procedure.
Intraoperative ocular injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the eye during a surgical procedure.
Intraoperative renal injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the kidney during a surgical procedure.
Intraoperative reproductive tract
injuryPrimary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Page 204 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
37Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Definition: A finding of damage to the reproductive organs during a surgical procedure.
Intraoperative respi[INVESTIGATOR_575637]/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the respi[INVESTIGATOR_575638] a surgical procedure.
Intraoperative skin injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the skin during a surgical procedure.
Intraoperative splenic injury
 - Primary repair of injured
organ/structure indicatedResection or reconstruction of
injured organ/structure
indicated; disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the spleen during a surgical procedure.
Intraoperative urinary injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to the urinary system during a surgical procedure.
Intraoperative venous injury Primary repair of injured
organ/structure indicatedPartial resection of injured
organ/structure indicatedComplete resection or
reconstruction of injured
organ/structure indicated;
disablingLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of damage to a vein during a surgical procedure.
Kidney anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).
Large intestinal anastomotic
leakAsymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.
Pancreatic anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).
Pharyngeal anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).
Postoperative hemorrhage Minimal bleeding identified on
clinical exam; intervention not
indicatedModerate bleeding; radiologic,
endoscopic, or operative
intervention indicatedTransfusion indicated of >=2
units (10 cc/kg for pediatrics)
pRBCs beyond protocol
specification; urgent radiologic,
endoscopic, or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of bleeding occurring after a surgical procedure.
Postoperative thoracic
procedure complication - Extubated within 24 - 72 hrs
postoperativelyExtubated >[ADDRESS_755772]
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A finding of a previously undocumented problem that occurs after a thoracic procedure.
Prolapse of intestinal stoma Asymptomatic; reducible Recurrent after manual
reduction; local irritation or stool
leakage; difficulty to fit
appliance; limiting instrumental
ADLSevere symptoms; elective
operative intervention indicated;
limiting self care ADLLife-threatening consequences;
urgent operative intervention
indicatedDeath
Page 205 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
38Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Definition: A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.
Prolapse of urostomy Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedLocal care or maintenance;
minor revision indicatedDysfunctional stoma; elective
operative intervention or major
stomal revision indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of displacement of the urostomy.
Radiation recall reaction
(dermatologic)Faint erythema or dry
desquamationModerate to brisk erythema;
patchy moist desquamation,
mostly confined to skin folds
and creases; moderate edemaMoist desquamation in areas
other than skin folds and
creases; bleeding induced by
[CONTACT_576090]-threatening consequences;
skin necrosis or ulceration of full
thickness dermis; spontaneous
bleeding from involved site; skin
graft indicatedDeath
Definition: A finding of acute skin inflammatory reaction caused by [CONTACT_8422], especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction
is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.
Rectal anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).
Seroma Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; simple aspi[INVESTIGATOR_575639], elective radiologic
or operative intervention
indicated -  -
Definition: A finding of tumor-like collection of serum in the tissues.
Small intestinal anastomotic
leakAsymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.
Spermatic cord anastomotic
leakAsymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).
Spi[INVESTIGATOR_575640]; nonprescription
analgesics indicatedModerate back pain;
prescription analgesics
indicated; limiting instrumental
ADLSevere back pain;
hospi[INVESTIGATOR_575641] (e.g.,
vertebroplasty); limiting self care
ADL; disabilityLife-threatening consequences;
symptoms associated with
neurovascular compromiseDeath
Definition: A finding of traumatic injury to the spi[INVESTIGATOR_575642] a vertebral bone is broken.
Stenosis of gastrointestinal
stoma - Symptomatic; IV fluids indicated
<24 hrs; manual dilation at
bedsideSeverely altered GI function;
tube feeding, TPN or
hospi[INVESTIGATOR_374];
elective operative intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).
Stomal ulcer Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by a circumscribed, inflammatory and necrotic erosive lesion on the jejunal mucosal surface close to the anastomosis site following a
gastroenterostomy procedure.
Tracheal hemorrhage Minimal bleeding identified on
clinical or diagnostic exam;
intervention not indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of bleeding from the trachea.
Tracheal obstruction Partial asymptomatic
obstruction on examination
(e.g., visual, radiologic or
endoscopic)Symptomatic (e.g., noisy airway
breathing), no respi[INVESTIGATOR_575643]; medical intervention
indicated (e.g., steroids); limiting
instrumental ADLStridor; radiologic or endoscopic
intervention indicated (e.g.,
stent, laser); limiting self care
ADLLife-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A finding of blockage of the lumen of the trachea.
Page 206 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
39Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Tracheostomy site bleeding Minimal bleeding identified on
clinical exam; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of blood leakage from the tracheostomy site.
Ureteric anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).
Urethral anastomotic leak
Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).
Urostomy leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage of contents from a urostomy.
Urostomy obstruction Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; dilation or
endoscopic repair or stent
placement indicatedAltered organ function (e.g.,
sepsis or hydronephrosis, or
renal dysfunction); elective
operative intervention indicatedLife-threatening consequences;
organ failure; urgent operative
intervention indicatedDeath
Definition: A finding of blockage of the urostomy.
Urostomy site bleeding Minimal bleeding identified on
clinical exam; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A finding of bleeding from the urostomy site.
Urostomy stenosis  - Symptomatic but no
hydronephrosis, no sepsis or no
renal dysfunction; dilation or
endoscopic repair or stent
placement indicatedSymptomatic (e.g.,
hydronephrosis, or renal
dysfunction); elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of narrowing of the opening of a urostomy.
Uterine anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).
Uterine perforation Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a rupture in the uterine wall.
Vaginal anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).
Vas deferens anastomotic leak Asymptomatic diagnostic
observations only; intervention
not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).
Vascular access complication  - Device dislodgement, blockage,
leak, or malposition; device
replacement indicatedDeep vein or cardiac
thrombosis; intervention
indicated (e.g., anticoagulation,
lysis, filter, invasive procedure)Embolic event including
pulmonary embolism or life-
threatening thrombusDeath
Definition: A finding of a previously undocumented problem related to the vascular access site.
Page 207 of 364
CTCAE 4.03 - June 14, 2010 : Injury, poisoning and procedural complications 
40Injury, poisoning and procedural complications
Grade
Adverse Event 1 2 3 4 5
Venous injury Asymptomatic diagnostic
finding; intervention not
indicatedSymptomatic (e.g.,
claudication); repair or revision
not indicatedSevere symptoms; limiting self
care ADL; repair or revision
indicated; disablingLife-threatening consequences;
evidence of end organ damage;
urgent operative intervention
indicatedDeath
Definition: A finding of damage to a vein.
Wound complication Incisional separation of <=25%
of wound, no deeper than
superficial fasciaIncisional separation >25% of
wound; local care indicatedHernia without evidence of
strangulation; fascial
disruption/dehiscence; primary
wound closure or revision by
[CONTACT_576091]; major
reconstruction flap, grafting,
resection, or amputation
indicatedDeath
Definition: A finding of development of a new problem at the site of an existing wound.
Wound dehiscence Incisional separation of <=25%
of wound, no deeper than
superficial fasciaIncisional separation >25% of
wound with local care;
asymptomatic hernia or
symptomatic hernia without
evidence of strangulationFascial disruption or dehiscence
without evisceration; primary
wound closure or revision by
[CONTACT_576092]-threatening consequences;
symptomatic hernia with
evidence of strangulation;
fascial disruption with
evisceration; major
reconstruction flap, grafting,
resection, or amputation
indicatedDeath
Definition: A finding of separation of the approximated margins of a surgical wound.
Wrist fracture Mild; non-surgical intervention
indicatedLimiting instrumental ADL;
operative intervention indicatedLimiting self care ADL; elective
surgery indicated -  -
Definition: A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.
Injury, poisoning and procedural
complications - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling; limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 208 of 364
CTCAE 4.03 - June 14, 2010 : Investigations 
4114. Investigations
Investigations
Grade
Adverse Event 1 2 3 4 5
Activated partial thromboplastin
time prolonged>ULN - 1.[ADDRESS_755773] >1.[ADDRESS_755774] >2.[ADDRESS_755775]; hemorrhage  -  -
Definition: An abnormal laboratory test result in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged
partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.
Alanine aminotransferase
increased>ULN - 3.[ADDRESS_755776] >3.[ADDRESS_755777] >5.[ADDRESS_755778] >20.[ADDRESS_755779]  -
Definition: A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.
Alkaline phosphatase increased >ULN - 2.[ADDRESS_755780] >2.[ADDRESS_755781] >5.[ADDRESS_755782] >20.[ADDRESS_755783]  -
Definition: A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.
Aspartate aminotransferase
increased>ULN - 3.[ADDRESS_755784] >3.[ADDRESS_755785] >5.[ADDRESS_755786] >20.[ADDRESS_755787]  -
Definition: A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.
Blood antidiuretic hormone
abnormalAsymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicatedHospi[INVESTIGATOR_374]
 -  -
Definition: A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.
Blood bilirubin increased >ULN - 1.[ADDRESS_755788] >1.[ADDRESS_755789] >3.[ADDRESS_755790] >10.[ADDRESS_755791]  -
Definition: A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.
Blood corticotrophin decreased Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicatedHospi[INVESTIGATOR_374]  -  -
Definition: A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.
Blood gonadotrophin abnormal Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.
Blood prolactin abnormal Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADL -  -  -
Definition: A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.
Carbon monoxide diffusing
capacity decreased3 - [ADDRESS_755792]; for follow-
up, a decrease of 3 - 5 units
(ml/min/mm Hg) below the
baseline value6 - [ADDRESS_755793]; for follow-
up, an asymptomatic decrease
of >5 - 8 units (ml/min/mm Hg)
below the baseline valueAsymptomatic decrease  of >8
units drop;  >5 units drop along
with the presence of pulmonary
symptoms (e.g. , >Grade 2
hypoxia or >Grade 2 or higher
dyspnea) -  -
Definition: A finding based on lung function test results that indicate  a decrease in the lung capacity to absorb carbon monoxide.
Cardiac troponin I increased Levels above the upper limit of
normal and below the level of
myocardial infarction as defined
by [CONTACT_3455] - Levels consistent with
myocardial infarction as defined
by [CONTACT_3455] -  -
Definition: A laboratory test result which indicates increased levels of cardiac troponin I in a biological specimen.
Cardiac troponin T increased Levels above the upper limit of
normal and below the level of
myocardial infarction as defined
by [CONTACT_3455] - Levels consistent with
myocardial infarction as defined
by [CONTACT_3455] -  -
Definition: A laboratory test result which indicates increased levels of cardiac troponin T in a biological specimen.
CD4 lymphocytes decreased <LLN - 500/mm3;  <LLN - 0.5 x
10e9 /L<500 - 200/mm3; <0.5 - 0.2 x
10e9 /L<200 - 50/mm3; <0.2 x 0.05 -
10e9 /L<50/mm3; <0.05 x 10e9 /L  -
Definition: A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.
Cholesterol high >ULN - 300 mg/dL; >ULN - 7.75
mmol/L>300 - 400 mg/dL; >7.75 - 10.34
mmol/L>400 - 500 mg/dL; >10.34 -
12.92 mmol/L>500 mg/dL; >12.92 mmol/L  -
Definition: A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.
CPK increased >ULN - 2.[ADDRESS_755794] >2.[ADDRESS_755795] >[ADDRESS_755796] >[ADDRESS_755797]  -
Definition: A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.
Page 209 of 364
CTCAE 4.03 - June 14, 2010 : Investigations 
42Investigations
Grade
Adverse Event 1 2 3 4 5
Creatinine increased >1 - 1.5 x baseline; >ULN - 1.[ADDRESS_755798]>1.5 - 3.0 x baseline; >1.[ADDRESS_755799]>3.0 baseline; >3.[ADDRESS_755800] >6.[ADDRESS_755801]  -
Definition: A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.
Ejection fraction decreased  - Resting ejection fraction (EF) 50
- 40%; 10 - 19% drop from
baselineResting ejection fraction (EF) 39
- 20%; >20% drop from baselineResting ejection fraction (EF)
<20% -
Definition: The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the
contraction.
Electrocardiogram QT corrected
interval prolongedQTc 450 - 480 ms QTc 481 - 500 ms QTc >= [ADDRESS_755802] two
separate ECGsQTc >= 501 or >60 ms change
from baseline and Torsade de
pointes or polymorphic
ventricular tachycardia or
signs/symptoms of serious
arrhythmia -
Definition: A finding of a cardiac dysrhythmia characterized by [CONTACT_576093].
Fibrinogen decreased <1.[ADDRESS_755803]  or <25%
decrease from baseline<0.[ADDRESS_755804] or 25 - <50%
decrease from baseline<0.[ADDRESS_755805] or 50 - <75%
decrease from baseline<0.[ADDRESS_755806]  or 75% decrease
from baseline or absolute value
<50 mg/dL -
Definition: A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.
Forced expi[INVESTIGATOR_575644]1% (percentages of
observed FEV1 and FVC
related to their respective
predicted values)  99 - 70%
predictedFEV1 60 - 69% 50 - 59% <= 49%  -
Definition: A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.
GGT increased >ULN - 2.[ADDRESS_755807] >2.[ADDRESS_755808] >5.[ADDRESS_755809] >20.[ADDRESS_755810]  -
Definition: A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-
glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.
Growth hormone abnormal
Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADL -  -  -
Definition: A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.
Haptoglobin decreased <LLN  -  -  -  -
Definition: A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.
Hemoglobin increased Increase in >0 - 2 gm/dL above
ULN or above baseline if
baseline is above ULNIncrease in >2 - 4 gm/dL above
ULN or above baseline if
baseline is above ULNIncrease in >4 gm/dL above
ULN or above baseline if
baseline is above ULN -  -
Definition: A finding based on laboratory test results that indicate increased levels of hemoglobin in a biological specimen.
INR increased >[ADDRESS_755811]; >1 - 1.5 times
above baseline if on
anticoagulation>1.[ADDRESS_755812]; >1.5 - 2.5
times above baseline if on
anticoagulation>2.[ADDRESS_755813]; >2.5 times above
baseline if on anticoagulation -  -
Definition: A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood.
Lipase increased >ULN - 1.[ADDRESS_755814] >1.[ADDRESS_755815] >2.[ADDRESS_755816] >5.[ADDRESS_755817]  -
Definition: A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.
Lymphocyte count decreased  <LLN - 800/mm3; <LLN - 0.8 x
10e9 /L<800 - 500/mm3; <0.8 - 0.5 x
10e9 /L<500 - 200/mm3; <0.5 - 0.2 x
10e9 /L<200/mm3; <0.2 x 10e9 /L  -
Definition: A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.
Lymphocyte count increased  - >4000/mm3 - 20,000/mm3 >20,000/mm3  -  -
Definition: A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.
Neutrophil count decreased <LLN - 1500/mm3; <LLN - 1.5 x
10e9 /L<1500 - 1000/mm3; <1.5 - 1.0 x
10e9 /L<1000 - 500/mm3; <1.0 - 0.5 x
10e9 /L<500/mm3; <0.5 x 10e9 /L  -
Definition: A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.
Pancreatic enzymes decreased <LLN and asymptomatic Increase in stool frequency,
bulk, or odor; steatorrheaSequelae of absorption
deficiency -  -
Definition: A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.
Page 210 of 364
CTCAE 4.03 - June 14, 2010 : Investigations 
43Investigations
Grade
Adverse Event 1 2 3 4 5
Platelet count decreased <LLN - 75,000/mm3; <LLN -
75.0 x 10e9 /L<75,000 - 50,000/mm3; <75.0 -
50.0 x 10e9 /L<50,000 - 25,000/mm3; <50.0 -
25.0 x 10e9 /L<25,000/mm3; <25.0 x 10e9 /L  -
Definition: A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.
Serum amylase increased
>ULN - 1.[ADDRESS_755818] >1.[ADDRESS_755819] >2.[ADDRESS_755820] >5.[ADDRESS_755821]  -
Definition: A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.
Urine output decreased  -  - Oliguria (<80 ml in 8 hr) Anuria (<240 ml in 24 hr)  -
Definition: A finding based on test results that indicate urine production is less relative to previous output.
Vital capacity abnormal 90 - 75% of predicted value <75 - 50% of predicted value;
limiting instrumental ADL<50% of predicted value;
limiting self care ADL -  -
Definition: A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted
value.
Weight gain 5 - <10% from baseline 10 - <20% from baseline >=20% from baseline  -  -
Definition: A finding characterized by [CONTACT_576094]; for pediatrics, greater than the baseline growth curve.
Weight loss 5 to <10% from baseline;
intervention not indicated10 - <20% from baseline;
nutritional support indicated>=20% from baseline; tube
feeding or TPN indicated -  -
Definition: A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.
White blood cell decreased <LLN - 3000/mm3; <LLN - 3.0 x
10e9 /L<3000 - 2000/mm3; <3.0 - 2.0 x
10e9 /L<2000 - 1000/mm3; <2.0 - 1.0 x
10e9 /L<1000/mm3; <1.0 x 10e9 /L  -
Definition: A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.
Investigations - Other, specify Asymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling; limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 211 of 364
CTCAE 4.03 - June 14, 2010 : Metabolism and nutrition disorders 
4415. Metabolism and nutrition disorders
Metabolism and nutrition disorders
Grade
Adverse Event 1 2 3 4 5
Acidosis pH <normal, but >=7.3  - pH <7.3 Life-threatening consequences Death
Definition: A disorder characterized by [CONTACT_576095] (high hydrogen-ion concentration) of the blood and other body tissues.
Alcohol intolerance  - Present Severe symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576096], which can include nasal congestion, skin flushes, heart dysrhythmias, nausea,
vomiting, indigestion and headaches.
Alkalosis pH >normal, but <=7.5
 - pH >7.5 Life-threatening consequences Death
Definition: A disorder characterized by [CONTACT_576097] (low hydrogen-ion concentration) of the blood and other body tissues.
Anorexia Loss of appetite without
alteration in eating habitsOral intake altered without
significant weight loss or
malnutrition; oral nutritional
supplements indicatedAssociated with significant
weight loss or malnutrition (e.g.,
inadequate oral caloric and/or
fluid intake); tube feeding or
TPN indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a loss of appetite.
Dehydration Increased oral fluids indicated;
dry mucous membranes;
diminished skin turgorIV fluids indicated <24 hrs IV fluids or hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576098]. It is usually caused by [CONTACT_576099], vomiting or diaphoresis.
Glucose intolerance Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; dietary
modification or oral agent
indicatedSevere symptoms; insulin
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576100].
Hypercalcemia Corrected serum calcium of
>ULN - 11.5 mg/dL; >ULN - 2.9
mmol/L;  Ionized calcium  >ULN
- 1.5 mmol/LCorrected serum calcium of
>11.5 - 12.5 mg/dL; >2.9 - 3.1
mmol/L;  Ionized calcium >1.5 -
1.6 mmol/L; symptomaticCorrected serum calcium of
>12.5 - 13.5 mg/dL; >3.1 - 3.4
mmol/L;  Ionized calcium  >1.6 -
1.8 mmol/L; hospi[INVESTIGATOR_575645]
>13.5 mg/dL; >3.4 mmol/L;
Ionized calcium  >1.8 mmol/L;
life-threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576101] (corrected for albumin) in blood.
Hyperglycemia Fasting glucose value >ULN -
160 mg/dL; Fasting glucose
value >ULN - 8.9 mmol/LFasting glucose value >160 -
250 mg/dL; Fasting glucose
value >8.9 - 13.9 mmol/L>250 - 500 mg/dL; >13.9 - 27.8
mmol/L; hospi[INVESTIGATOR_20579]>500 mg/dL; >27.8 mmol/L; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576102]. It is usually an indication of diabetes mellitus or glucose
intolerance.
Hyperkalemia >ULN - 5.5 mmol/L >5.5 - 6.0 mmol/L >6.0 - 7.0 mmol/L;
hospi[INVESTIGATOR_374]>7.0 mmol/L; life-threatening
consequencesDeath
Definition: A disorder characterized by [CONTACT_576103]; associated with kidney failure or sometimes with
the use of diuretic drugs.
Hypermagnesemia >ULN - 3.0 mg/dL; >ULN - 1.23
mmol/L - >3.0 - 8.0 mg/dL; >1.23 - 3.30
mmol/L>8.0 mg/dL; >3.30 mmol/L; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576104].
Hypernatremia >ULN - 150 mmol/L >150 - 155 mmol/L >155 - 160 mmol/L;
hospi[INVESTIGATOR_374]>160 mmol/L; life-threatening
consequencesDeath
Definition: A disorder characterized by [CONTACT_576105].
Hypertriglyceridemia 150 mg/dL - 300 mg/dL; 1.71
mmol/L - 3.42 mmol/L>300 mg/dL - 500 mg/dL;  >3.42
mmol/L - 5.7 mmol/L>500 mg/dL - 1000 mg/dL;  >5.7
mmol/L - 11.4 mmol/L>1000 mg/dL; >11.4 mmol/L;
life-threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576106].
Hyperuricemia >ULN - 10 mg/dL (0.59 mmol/L)
without physiologic
consequences - >ULN - 10 mg/dL (0.59 mmol/L)
with physiologic consequences>10 mg/dL; >0.59 mmol/L; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_576107].
Hypoalbuminemia <LLN - 3 g/dL; <LLN - 30 g/L <3 - 2 g/dL; <30 - 20 g/L <2 g/dL; <20 g/L Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of albumin in the blood.
Page 212 of 364
CTCAE 4.03 - June 14, 2010 : Metabolism and nutrition disorders 
45Metabolism and nutrition disorders
Grade
Adverse Event 1 2 3 4 5
Hypocalcemia Corrected serum calcium of
<LLN - 8.0 mg/dL; <LLN - 2.0
mmol/L; Ionized calcium  <LLN -
1.0 mmol/LCorrected serum calcium of
<8.0 - 7.0 mg/dL; <2.0 - 1.75
mmol/L; Ionized calcium  <1.0 -
0.9 mmol/L; symptomaticCorrected serum calcium of
<7.0 - 6.0 mg/dL; <1.75 - 1.5
mmol/L;  Ionized calcium  <0.9 -
0.8 mmol/L; hospi[INVESTIGATOR_575645]
<6.0 mg/dL; <1.5 mmol/L;
Ionized calcium  <0.8 mmol/L;
life-threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of calcium (corrected for albumin) in the  blood.
Hypoglycemia <LLN - 55 mg/dL; <LLN - 3.0
mmol/L<55 - 40 mg/dL; <3.0 - 2.2
mmol/L<40 - 30 mg/dL; <2.2 - 1.7
mmol/L<30 mg/dL; <1.7 mmol/L; life-
threatening consequences;
seizuresDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of glucose in the blood.
Hypokalemia <LLN - 3.0 mmol/L <LLN - 3.0 mmol/L;
symptomatic; intervention
indicated<3.0 - 2.5 mmol/L;
hospi[INVESTIGATOR_374]<2.5 mmol/L; life-threatening
consequencesDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of potassium in the  blood.
Hypomagnesemia <LLN - 1.2 mg/dL; <LLN - 0.5
mmol/L<1.2 - 0.9 mg/dL; <0.5 - 0.4
mmol/L<0.9 - 0.7 mg/dL; <0.4 - 0.3
mmol/L<0.7 mg/dL; <0.3 mmol/L; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of magnesium in the  blood.
Hyponatremia <LLN - 130 mmol/L  - <130 - 120 mmol/L <120 mmol/L; life-threatening
consequencesDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of sodium in the blood.
Hypophosphatemia <LLN - 2.5 mg/dL; <LLN - 0.8
mmol/L<2.5 - 2.0 mg/dL; <0.8 - 0.6
mmol/L<2.0 - 1.0 mg/dL; <0.6 - 0.3
mmol/L<1.0 mg/dL; <0.3 mmol/L; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_94554] a low concentration of phosphates in the  blood.
Iron overload  - Moderate symptoms;
intervention not indicatedSevere symptoms; intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576108].
Obesity  - BMI 25 - 29.9 kg/m2 BMI 30 - 39.9 kg/m2 BMI >=40 kg/m2  -
Definition: A disorder characterized by [CONTACT_7661] a high amount of body fat.
Tumor lysis syndrome  -  - Present Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576109] a spontaneous or therapy-related cytolysis of tumor cells.
Metabolism and nutrition
disorders - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 213 of 364
CTCAE 4.03 - June 14, 2010 : Musculoskeletal and connective tissue disorders 
4616. Musculoskeletal and connective tissue disorders
Musculoskeletal and connective tissue disorders
Grade
Adverse Event 1 2 3 4 5
Abdominal soft tissue necrosis  - Local wound care; medical
intervention indicated (e.g.,
dressings or topi[INVESTIGATOR_144430])Operative debridement or other
invasive intervention indicated
(e.g. tissue reconstruction, flap
or grafting)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.
Arthralgia Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in a joint.
Arthritis Mild pain with inflammation,
erythema, or joint swellingModerate pain associated with
signs of inflammation,
erythema, or joint swelling;
limiting instrumental ADLSevere pain associated with
signs of inflammation,
erythema, or joint swelling;
irreversible joint damage;
disabling; limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576110] a joint.
Avascular necrosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; elective operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576111]. Most often affecting the epi[INVESTIGATOR_575646], the necrotic
changes result in the collapse and the destruction of the bone structure.
Back pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576112].
Bone pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576113].
Buttock pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576114].
Chest wall pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576115].
Exostosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; elective operative
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_105]-neoplastic overgrowth of bone.
Fibrosis deep connective tissue Mild induration, able to move
skin parallel to plane (sliding)
and perpendicular to skin
(pi[INVESTIGATOR_470889])Moderate induration, able to
slide skin, unable to pi[INVESTIGATOR_470890];
limiting instrumental ADLSevere induration; unable to
slide or pi[INVESTIGATOR_470890]; limiting joint
or orifice movement (e.g.
mouth, anus); limiting self care
ADLGeneralized; associated with
signs or symptoms of impaired
breathing or feedingDeath
Definition: A disorder characterized by [CONTACT_576116].
Flank pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576117].
Generalized muscle weakness
Symptomatic; weakness
perceived by [CONTACT_576118]; weakness evident
on physical exam; weakness
limiting instrumental ADLWeakness limiting self care
ADL; disabling -  -
Definition: A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.
Growth suppression Reduction in growth velocity by
10 - 29% ideally measured over
the period of a yearReduction in growth velocity by
30 - 49% ideally measured over
the period of a year or 0 - 49%
reduction in growth from the
baseline growth curveReduction in growth velocity of
>=50% ideally measured over
the period of a year -  -
Definition: A disorder characterized by [CONTACT_576119].
Page 214 of 364
CTCAE 4.03 - June 14, 2010 : Musculoskeletal and connective tissue disorders 
47Musculoskeletal and connective tissue disorders
Grade
Adverse Event 1 2 3 4 5
Head soft tissue necrosis  - Local wound care; medical
intervention indicated (e.g.,
dressings or topi[INVESTIGATOR_144430])Operative debridement or other
invasive intervention indicated
(e.g., tissue reconstruction, flap
or grafting)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the soft tissues of the head.
Joint effusion Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; elective operative
intervention indicated; disabling -  -
Definition: A disorder characterized by [CONTACT_576120] a joint, usually as a result of joint inflammation.
Joint range of motion decreased <=25% loss of ROM (range of
motion); decreased ROM
limiting athletic activity>25 - 50% decrease in ROM;
limiting instrumental ADL>50% decrease in ROM; limiting
self care ADL; disabling -  -
Definition: A disorder characterized by a decrease in joint flexibility of any joint.
Joint range of motion decreased
cervical spi[INVESTIGATOR_575647] 60 - 70 degreesRotation <60 degrees to right or
left; <60 degrees of flexionAnkylosed/fused over multiple
segments with no C-spi[INVESTIGATOR_575648] -  -
Definition: A disorder characterized by a decrease in flexibility of a cervical spi[INVESTIGATOR_575649].
Joint range of motion decreased
lumbar spi[INVESTIGATOR_575650]; difficulty bending to
the floor to pi[INVESTIGATOR_7049] a very light
object but able to do athletic
activityPain with range of motion
(ROM) in lumbar spi[INVESTIGATOR_050]; requires
a reaching aid to pi[INVESTIGATOR_7049] a very
light object from the floor<50% lumbar spi[INVESTIGATOR_18191];
associated with symptoms of
ankylosis or fused over multiple
segments with no L-spi[INVESTIGATOR_575651] (e.g., unable to reach to
floor to pi[INVESTIGATOR_7049] a very light
object) -  -
Definition: A disorder characterized by a decrease in flexibility of a lumbar spi[INVESTIGATOR_575649].
Kyphosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate accentuation; limiting
instrumental ADLSevere accentuation; operative
intervention indicated; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_576121][INVESTIGATOR_050].
Lordosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate accentuation; limiting
instrumental ADLSevere accentuation; operative
intervention indicated; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_576122][INVESTIGATOR_050].
Muscle weakness left-sided
Symptomatic; perceived by
[CONTACT_576123]; evident on
physical exam; limiting
instrumental ADLLimiting self care ADL; disabling  -  -
Definition: A disorder characterized by a reduction in the strength of the muscles on the left side of the body.
Muscle weakness lower limb Symptomatic; perceived by
[CONTACT_576123]; evident on
physical exam; limiting
instrumental ADLLimiting self care ADL; disabling  -  -
Definition: A disorder characterized by a reduction in the strength of the lower limb muscles.
Muscle weakness right-sided Symptomatic; perceived by
[CONTACT_576123]; evident on
physical exam; limiting
instrumental ADLLimiting self care ADL; disabling  -  -
Definition: A disorder characterized by a reduction in the strength of the muscles on the right side of the body.
Muscle weakness trunk Symptomatic; perceived by
[CONTACT_576123]; evident on
physical exam; limiting
instrumental ADLLimiting self care ADL; disabling  -  -
Definition: A disorder characterized by a reduction in the strength of the trunk muscles.
Muscle weakness upper limb Symptomatic; perceived by
[CONTACT_576123]; evident on
physical exam; limiting
instrumental ADLLimiting self care ADL; disabling  -  -
Definition: A disorder characterized by a reduction in the strength of the upper limb muscles.
Page 215 of 364
CTCAE 4.03 - June 14, 2010 : Musculoskeletal and connective tissue disorders 
48Musculoskeletal and connective tissue disorders
Grade
Adverse Event 1 2 3 4 5
Musculoskeletal deformity Cosmetically and functionally
insignificant hypoplasiaDeformity, hypoplasia, or
asymmetry able to be
remediated by [CONTACT_185487] (e.g.,
shoe insert) or covered by
[CONTACT_576124],
hypoplasia, or asymmetry,
unable to be remediated by
[CONTACT_576125]; disabling -  -
Definition: A disorder characterized by [CONTACT_4007] a malformation of the musculoskeletal system.
Myalgia Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576126] a muscle or group of muscles.
Myositis Mild pain Moderate pain associated with
weakness; pain limiting
instrumental ADLPain associated with severe
weakness; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576127].
Neck pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576128].
Neck soft tissue necrosis  - Local wound care; medical
intervention indicated (e.g.,
dressings or topi[INVESTIGATOR_144430])Operative debridement or other
invasive intervention indicated
(e.g., tissue reconstruction, flap
or grafting)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the soft tissues of the neck.
Osteonecrosis of jaw Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicated (e.g.,
topi[INVESTIGATOR_12450]); limiting
instrumental ADLSevere symptoms; limiting self
care ADL; elective operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the bone of the mandible.
Osteoporosis Radiologic evidence of
osteoporosis or Bone Mineral
Density (BMD) t-score -1 to -2.5
(osteopenia); no loss of height
or intervention indicatedBMD t-score <-2.5; loss of
height <2 cm; anti-osteoporotic
therapy indicated; limiting
instrumental ADLLoss of height >=2 cm;
hospi[INVESTIGATOR_374]; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_576129], with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical
composition), resulting in increased fracture incidence.
Pain in extremity Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576130].
Pelvic soft tissue necrosis
 - Local wound care; medical
intervention indicated (e.g.,
dressings or topi[INVESTIGATOR_144430])Operative debridement or other
invasive intervention indicated
(e.g., tissue reconstruction, flap
or grafting)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.
Scoliosis <20 degrees; clinically
undetectable>20 - 45 degrees; visible by
[CONTACT_576131]; limiting
instrumental ADL>45 degrees; scapular
prominence in forward flexion;
operative intervention indicated;
limiting self care ADL; disabling -  -
Definition: A disorder characterized by a malformed, lateral curvature of the spi[INVESTIGATOR_050].
Soft tissue necrosis lower limb  - Local wound care; medical
intervention indicated (e.g.,
dressings or topi[INVESTIGATOR_144430])Operative debridement or other
invasive intervention indicated
(e.g., tissue reconstruction, flap
or grafting)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.
Soft tissue necrosis upper limb  - Local wound care; medical
intervention indicated (e.g.,
dressings or topi[INVESTIGATOR_144430])Operative debridement or other
invasive intervention indicated
(e.g., tissue reconstruction, flap
or grafting)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.
Page 216 of 364
CTCAE 4.03 - June 14, 2010 : Musculoskeletal and connective tissue disorders 
49Musculoskeletal and connective tissue disorders
Grade
Adverse Event [ADDRESS_755822] (sliding)
and perpendicular to skin
(pi[INVESTIGATOR_470889])Moderate induration, able to
slide skin, unable to pi[INVESTIGATOR_470890];
limiting instrumental ADLSevere induration; unable to
slide or pi[INVESTIGATOR_470890]; limiting joint
or orifice movement (e.g.,
mouth, anus); limiting self care
ADLGeneralized; associated with
signs or symptoms of impaired
breathing or feedingDeath
Definition: A disorder characterized by [CONTACT_576132].
Trismus Decreased ROM (range of
motion) without impaired eatingDecreased ROM requiring small
bites, soft foods or pureesDecreased ROM with inability to
adequately aliment or hydrate
orally -  -
Definition: A disorder characterized by [CONTACT_576133] a decrease in the range of motion of the muscles of mastication.
Unequal limb length Mild length discrepancy <2 cm Moderate length discrepancy 2 -
5 cm; shoe lift indicated; limiting
instrumental ADLSevere length discrepancy >5
cm; limiting self care ADL;
disabling; operative intervention
indicated -  -
Definition: A disorder characterized by [CONTACT_4007] a discrepancy between the lengths of the lower or upper extremities.
Musculoskeletal and connective
tissue disorder -  Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 217 of 364
CTCAE 4.03 - June 14, 2010 : Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
5017. Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Grade
Adverse Event 1 2 3 4 5
Leukemia secondary to
oncology chemotherapy -  -  - Present Death
Definition: A disorder characterized by [CONTACT_576134] a result of the mutagenic effect of chemotherapy agents.
Myelodysplastic syndrome  -  -  - Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576135].
Treatment related secondary
malignancy -  - Non life-threatening secondary
malignancyAcute life-threatening secondary
malignancy; blast crisis in
leukemiaDeath
Definition: A disorder characterized by [CONTACT_170566] a malignancy most probably as a result of treatment for a previously existing malignancy.
Tumor pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576136] a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.
Neoplasms benign, malignant
and unspecified (incl cysts and
polyps) - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 218 of 364
CTCAE 4.03 - June 14, 2010 : Nervous system disorders 
5118. Nervous system disorders
Nervous system disorders
Grade
Adverse Event 1 2 3 4 5
Abducens nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576137] (sixth cranial nerve).
Accessory nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576138] (eleventh cranial nerve).
Acoustic nerve disorder NOS
Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576139] (eighth cranial nerve).
Akathisia Mild restlessness or increased
motor activityModerate restlessness or
increased motor activity; limiting
instrumental ADLSevere restlessness or
increased motor activity; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_576140]; this is a side effect of some psychotropic drugs.
Amnesia Mild; transient memory loss Moderate; short term memory
loss; limiting instrumental ADLSevere; long term memory loss;
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576141].
Aphonia  -  - Voicelessness; unable to speak  -  -
Definition: A disorder characterized by [CONTACT_576142]. It may result from injuries to the vocal cords or may be functional (psychogenic).
Arachnoiditis Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576143].
Ataxia Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; mechanical
assistance indicated -  -
Definition: A disorder characterized by [CONTACT_576144].
Brachial plexopathy Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576145], marked discomfort and muscle weakness, and limited movement in the arm or hand.
Central nervous system
necrosisAsymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms;
corticosteroids indicatedSevere symptoms; medical
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a necrotic process occurring in the brain and/or spi[INVESTIGATOR_1831].
Cerebrospi[INVESTIGATOR_575652]-craniotomy: asymptomatic;
Post-lumbar puncture: transient
headache; postural care
indicatedPost-craniotomy: moderate
symptoms; medical intervention
indicated; Post-lumbar
puncture: persistent moderate
symptoms; blood patch
indicatedSevere symptoms; medical
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576146][INVESTIGATOR_575653].
Cognitive disturbance Mild cognitive disability; not
interfering with work/school/life
performance; specialized
educational services/devices
not indicatedModerate cognitive disability;
interfering with work/school/life
performance but capable of
independent living; specialized
resources on part time basis
indicatedSevere cognitive disability;
significant impairment of
work/school/life performance -  -
Definition: A disorder characterized by a conspi[INVESTIGATOR_575654].
Concentration impairment Mild inattention or decreased
level of concentrationModerate impairment in
attention or decreased level of
concentration; limiting
instrumental ADLSevere impairment in attention
or decreased level of
concentration; limiting self care
ADL -  -
Definition: A disorder characterized by a deterioration in the ability to concentrate.
Page 219 of 364
CTCAE 4.03 - June 14, 2010 : Nervous system disorders 
52Nervous system disorders
Grade
Adverse Event 1 2 3 4 5
Depressed level of
consciousnessDecreased level of alertness Sedation; slow response to
stimuli; limiting instrumental
ADLDifficult to arouse Life-threatening consequences Death
Definition: A disorder characterized by a decrease in ability to perceive and respond.
Dizziness Mild unsteadiness or sensation
of movementModerate unsteadiness or
sensation of movement; limiting
instrumental ADLSevere unsteadiness or
sensation of movement; limiting
self care ADL -  -
Definition: A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spi[INVESTIGATOR_439188].
Dysarthria Mild slurred speech Moderate impairment of
articulation or slurred speechSevere impairment of
articulation or slurred speech -  -
Definition: A disorder characterized by [CONTACT_576147].
Dysesthesia Mild sensory alteration
Moderate sensory alteration;
limiting instrumental ADLSevere sensory alteration;
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_95337], resulting in an abnormal and unpleasant sensation.
Dysgeusia Altered taste but no change in
dietAltered taste with change in diet
(e.g., oral supplements);
noxious or unpleasant taste;
loss of taste -  -  -
Definition: A disorder characterized by [CONTACT_576148]; it can be related to a decrease in the sense of smell.
Dysphasia Awareness of receptive or
expressive characteristics; not
impairing ability to communicateModerate receptive or
expressive characteristics;
impairing ability to communicate
spontaneouslySevere receptive or expressive
characteristics; impairing ability
to read, write or communicate
intelligibly -  -
Definition: A disorder characterized by [CONTACT_576149], often resulting from brain damage.
Edema cerebral  -  -  - Life-threatening consequences;
urgent intervention indicated -
Definition: A disorder characterized by [CONTACT_576150].
Encephalopathy Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a pathologic process involving the brain.
Extrapyramidal disorder Mild involuntary movements Moderate involuntary
movements; limiting
instrumental ADLSevere involuntary movements
or torticollis; limiting self care
ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_88086], repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.
Facial muscle weakness Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by a reduction in the strength of the facial muscles.
Facial nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576151] (seventh cranial nerve).
Glossopharyngeal nerve
disorderAsymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576152] (ninth cranial nerve).
Headache Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.
Hydrocephalus Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms;
intervention not indicatedSevere symptoms or
neurological deficit; intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576153][INVESTIGATOR_575655].
Hypersomnia Mild increased need for sleep Moderate increased need for
sleepSevere increased need for
sleep -  -
Definition: A disorder characterized by [CONTACT_576154][INVESTIGATOR_575656].
Page 220 of 364
CTCAE 4.03 - June 14, 2010 : Nervous system disorders 
53Nervous system disorders
Grade
Adverse Event 1 2 3 4 5
Hypoglossal nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576155] (twelfth cranial nerve).
Intracranial hemorrhage Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; medical
intervention indicatedVentriculostomy, ICP
monitoring, intraventricular
thrombolysis, or operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576156].
Ischemia cerebrovascular
Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms  -  -  -
Definition: A disorder characterized by a decrease or absence of blood supply to the brain caused by [CONTACT_357853] (thrombosis or embolism) of an artery resulting in neurological
damage.
IVth nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576157] (fourth cranial nerve).
Lethargy Mild symptoms; reduced
alertness and awarenessModerate symptoms; limiting
instrumental ADL -  -  -
Definition: A disorder characterized by a decrease in consciousness characterized by [CONTACT_576158].
Leukoencephalopathy Asymptomatic; small focal
T2/FLAIR hyperintensities;
involving periventricular white
matter or <1/3 of susceptible
areas of cerebrum +/- mild
increase in subarachnoid space
(SAS) and/or mild
ventriculomegalyModerate symptoms; focal
T2/FLAIR hyperintensities,
involving periventricular white
matter extending into centrum
semiovale or involving 1/3 to 2/3
of susceptible areas of
cerebrum +/- moderate increase
in SAS and/or moderate
ventriculomegalySevere symptoms; extensive
T2/FLAIR hyperintensities,
involving periventricular white
matter involving 2/3 or more of
susceptible areas of cerebrum
+/- moderate to severe increase
in SAS and/or moderate to
severe ventriculomegalyLife-threatening consequences;
extensive T2/FLAIR
hyperintensities, involving
periventricular white matter
involving most of susceptible
areas of cerebrum +/- moderate
to severe increase in SAS
and/or moderate to severe
ventriculomegalyDeath
Definition: A disorder characterized by [CONTACT_576159].
Memory impairment Mild memory impairment Moderate memory impairment;
limiting instrumental ADLSevere memory impairment;
limiting self care ADL -  -
Definition: A disorder characterized by a deterioration in memory function.
Meningismus Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_388073], headache, and photophobia resulting from irritation of the cerebral meninges.
Movements involuntary Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576160].
Myelitis Asymptomatic; mild signs (e.g.,
Babinski's reflex or Lhermitte's
sign)Moderate weakness or sensory
loss; limiting instrumental ADLSevere weakness or sensory
loss; limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576161][INVESTIGATOR_1831]. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.
Neuralgia Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576162] a nerve or group of nerves.
Nystagmus  - Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576163].
Oculomotor nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576164] (third cranial nerve).
Olfactory nerve disorder  - Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576165] (first cranial nerve).
Page 221 of 364
CTCAE 4.03 - June 14, 2010 : Nervous system disorders 
54Nervous system disorders
Grade
Adverse Event 1 2 3 4 5
Paresthesia Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576166], numbness, pressure, cold, and warmth that
are experienced in the absence of a stimulus.
Peripheral motor neuropathy Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; assistive device
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576167].
Peripheral sensory neuropathy Asymptomatic; loss of deep
tendon reflexes or paresthesiaModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576168].
Phantom pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576169] a limb or an organ that is removed from or is not physically part of the body.
Presyncope  - Present (e.g., near fainting)
 -  -  -
Definition: A disorder characterized by [CONTACT_45809][INVESTIGATOR_575657].
Pyramidal tract syndrome Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576170][INVESTIGATOR_1304] (pyramidal) tracts of the spi[INVESTIGATOR_1831]. Symptoms include  an increase in the muscle tone in the lower extremities,
hyperreflexia, positive Babinski and a decrease in fine motor coordination.
Radiculitis Mild symptoms Moderate symptoms; limiting
instrumental ADL; medical
intervention indicatedSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576110] a nerve root. Patients experience marked discomfort radiating along a nerve path because of spi[INVESTIGATOR_575658].
Recurrent laryngeal nerve palsy Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms Severe symptoms; medical
intervention indicated (e.g.,
thyroplasty, vocal cord injection)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576171].
Reversible posterior
leukoencephalopathy syndromeAsymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; abnormal
imaging studies; limiting
instrumental ADLSevere symptoms; very
abnormal imaging studies;
limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_566391], mental status changes, visual disturbances, and seizures associated with imaging findings of posterior leukoencephalopathy. It has
been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition.
Seizure Brief partial seizure; no loss of
consciousnessBrief generalized seizure Multiple seizures despi[INVESTIGATOR_575659]-threatening; prolonged
repetitive seizuresDeath
Definition: A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.
Sinus pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576172], between the eyes, or upper teeth originating from the sinuses.
Somnolence Mild but more than usual
drowsiness or sleepi[INVESTIGATOR_575660]; limiting
instrumental ADLObtundation or stupor Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576154][INVESTIGATOR_575661].
Spasticity Mild or slight increase in muscle
toneModerate increase in muscle
tone and increase in resistance
through range of motionSevere increase in muscle tone
and increase in resistance
through range of motionLife-threatening; unable to move
active or passive range of
motionDeath
Definition: A disorder characterized by [CONTACT_576173]. It results in gait, movement, and speech
disturbances.
Stroke Asymptomatic or mild
neurologic deficit; radiographic
findings onlyModerate neurologic deficit Severe neurologic deficit Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a sudden loss of sensory function due to an intracranial vascular event.
Syncope  -  - Fainting; orthostatic collapse  -  -
Definition: A disorder characterized by [CONTACT_576174].
Page 222 of 364
CTCAE 4.03 - June 14, 2010 : Nervous system disorders 
55Nervous system disorders
Grade
Adverse Event 1 2 3 4 5
Transient ischemic attacks Mild neurologic deficit with or
without imaging confirmationModerate neurologic deficit with
or without imaging confirmation -  -  -
Definition: A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.
Tremor Mild symptoms Moderate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576175].
Trigeminal nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576176] (fifth cranial nerve).
Vagus nerve disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576177] (tenth cranial nerve).
Vasovagal reaction  -  - Present Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an
increase in the stimulation of the vagus nerve.
Nervous system disorders -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 223 of 364
CTCAE 4.03 - June 14, 2010 : Pregnancy, puerperium and perinatal conditions 
5619. Pregnancy, puerperium and perinatal conditions
Pregnancy, puerperium and perinatal conditions
Grade
Adverse Event 1 2 3 4 5
Fetal death  -  -  -  - Fetal loss at
any
gestational
age
Definition: A disorder characterized by [CONTACT_260765]; failure of the product of conception to show evidence of respi[INVESTIGATOR_1516], heartbeat, or definite movement of a voluntary muscle after
expulsion from the uterus, without possibility of resuscitation.
Fetal growth retardation  - <10% percentile of weight for
gestational age<5% percentile of weight for
gestational age<1% percentile of weight for
gestational age -
Definition: A disorder characterized by [CONTACT_576178].
Premature delivery Delivery of a liveborn infant at
>34 to 37 weeks gestationDelivery of a liveborn infant at
>28 to 34 weeks gestationDelivery of a liveborn infant at
24 to 28 weeks gestationDelivery of a liveborn infant at
24 weeks of gestation or less -
Definition: A disorder characterized by [CONTACT_370398] a viable infant before the normal end of gestation. Typi[INVESTIGATOR_897], viability is achievable between the twentieth and thirty-seventh week of
gestation.
Unintended pregnancy  -  - Unintended pregnancy
 -  -
Definition: A disorder characterized by [CONTACT_576179].
Pregnancy, puerperium and
perinatal conditions - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate, local or noninvasive
intervention indicated; limiting
instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 224 of 364
CTCAE 4.03 - June 14, 2010 : Psychiatric disorders 
5720. Psychiatric disorders
Psychiatric disorders
Grade
Adverse Event 1 2 3 4 5
Agitation Mild mood alteration Moderate mood alteration Severe agitation; hospi[INVESTIGATOR_575662]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.
Anorgasmia Inability to achieve orgasm not
adversely affecting relationshipI[INVESTIGATOR_575663] -  -  -
Definition: A disorder characterized by [CONTACT_576180].
Anxiety Mild symptoms; intervention not
indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; hospi[INVESTIGATOR_575664]-threatening; hospi[INVESTIGATOR_575665]: A disorder characterized by [CONTACT_576181], tension, tachycardia, and dyspnea unattached to a clearly identifiable
stimulus.
Confusion Mild disorientation Moderate disorientation; limiting
instrumental ADLSevere disorientation; limiting
self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a lack of clear and orderly thought and behavior.
Delayed orgasm Delay in achieving orgasm not
adversely affecting relationshipDelay in achieving orgasm
adversely affecting relationship -  -  -
Definition: A disorder characterized by [CONTACT_576182] a delay in climax.
Delirium Mild acute confusional state Moderate and acute confusional
state; limiting instrumental ADLSevere and acute confusional
state; limiting self care ADL;
hospi[INVESTIGATOR_151467]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575666]: A disorder characterized by [CONTACT_576183], illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a
reversible condition.
Delusions  - Moderate delusional symptoms
Severe delusional symptoms;
hospi[INVESTIGATOR_575667]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575666]: A disorder characterized by [CONTACT_576184], despi[INVESTIGATOR_575668].
Depression Mild depressive symptoms Moderate depressive
symptoms; limiting instrumental
ADLSevere depressive symptoms;
limiting self care ADL;
hospi[INVESTIGATOR_575667]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575666]: A disorder characterized by [CONTACT_576185][INVESTIGATOR_008].
Euphoria Mild mood elevation Moderate mood elevation Severe mood elevation (e.g.,
hypomania) -  -
Definition: A disorder characterized by [CONTACT_576186]-being which is disproportionate to events and stimuli.
Hallucinations Mild hallucinations (e.g.,
perceptual distortions)Moderate hallucinations Severe hallucinations;
hospi[INVESTIGATOR_575667]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575666]: A disorder characterized by a false sensory perception in the absence of an external stimulus.
Insomnia Mild difficulty falling asleep,
staying asleep or waking up
earlyModerate difficulty falling
asleep, staying asleep or
waking up earlySevere difficulty in falling
asleep, staying asleep or
waking up early -  -
Definition: A disorder characterized by [CONTACT_576187]/or remaining asleep.
Libido decreased Decrease in sexual interest not
adversely affecting relationshipDecrease in sexual interest
adversely affecting relationship -  -  -
Definition: A disorder characterized by a decrease in sexual desire.
Libido increased Mild increase in sexual interest
not adversely affecting
relationshipModerate increase in sexual
interest adversely affecting
relationshipSevere increase in sexual
interest leading to dangerous
behavior -  -
Definition: A disorder characterized by [CONTACT_576188].
Mania Mild manic symptoms (e.g.,
elevated mood, rapid thoughts,
rapid speech, decreased need
for sleep)Moderate manic symptoms
(e.g., relationship and work
difficulties; poor hygiene)Severe manic symptoms (e.g.,
hypomania; major sexual or
financial indiscretions);
hospi[INVESTIGATOR_575667]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575666]: A disorder characterized by [CONTACT_576189], disorganization of behavior and elevation of mood.
Personality change Mild personality change Moderate personality change Severe personality change;
hospi[INVESTIGATOR_575667]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575669] 225 of 364
CTCAE 4.03 - June 14, 2010 : Psychiatric disorders 
58Psychiatric disorders
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by a conspi[INVESTIGATOR_575670] a person's behavior and thinking.
Psychosis Mild psychotic symptoms Moderate psychotic symptoms
(e.g., disorganized speech;
impaired reality testing)Severe psychotic symptoms
(e.g., paranoid; extreme
disorganization); hospi[INVESTIGATOR_575662]-threatening consequences,
threats of harm to self or others;
hospi[INVESTIGATOR_575666]: A disorder characterized by [CONTACT_527996], impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain
tumor.
Restlessness Mild symptoms; intervention not
indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576190], relax or be still.
Suicidal ideation Increased thoughts of death but
no wish to kill oneselfSuicidal ideation with no specific
plan or intentSpecific plan to commit suicide
without serious intent to die
which may not require
hospi[INVESTIGATOR_575671] -
Definition: A disorder characterized by [CONTACT_576191]'s own life.
Suicide attempt  -  - Suicide attempt or gesture
without intent to die which may
not require hospi[INVESTIGATOR_575672]: A disorder characterized by [CONTACT_6270]-inflicted harm in an attempt to end one's own life.
Psychiatric disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; disabling;  limiting
self care ADLLife-threatening consequences;
hospi[INVESTIGATOR_575673] 226 of 364
CTCAE 4.03 - June 14, 2010 : Renal and urinary disorders 
5921. Renal and urinary disorders
Renal and urinary disorders
Grade
Adverse Event 1 2 3 4 5
Acute kidney injury Creatinine level increase of >0.3
mg/dL; creatinine 1.5 - 2.0 x
above baselineCreatinine 2 - 3 x above
baselineCreatinine >3 x baseline or >4.0
mg/dL; hospi[INVESTIGATOR_151467]-threatening consequences;
dialysis indicatedDeath
Definition: A disorder characterized by [CONTACT_576192]-renal (low blood flow into kidney), renal (kidney damage) and post-renal
causes (ureteral or bladder outflow obstruction).
Bladder perforation  - Extraperitoneal perforation,
indwelling catheter indicatedIntraperitoneal perforation;
elective radiologic, endoscopic
or operative intervention
indicatedLife-threatening consequences;
organ failure; urgent operative
intervention indicatedDeath
Definition: A disorder characterized by a rupture in the bladder wall.
Bladder spasm Intervention not indicated Antispasmodics indicated Hospi[INVESTIGATOR_374]
 -  -
Definition: A disorder characterized by a sudden and involuntary contraction of the bladder wall.
Chronic kidney disease eGFR (estimated Glomerular
Filtration Rate) or CrCl
(creatinine clearance) <LLN - 60
ml/min/1.73 m2 or proteinuria
2+ present; urine
protein/creatinine >0.5eGFR or CrCl 59 - 30
ml/min/1.73 m2eGFR or CrCl 29 - 15
ml/min/1.73 m2eGFR or CrCl <15 ml/min/1.73
m2; dialysis or renal transplant
indicatedDeath
Definition: A disorder characterized by [CONTACT_576193].
Cystitis noninfective Microscopic hematuria; minimal
increase in frequency, urgency,
dysuria, or nocturia; new onset
of incontinenceModerate hematuria; moderate
increase in frequency, urgency,
dysuria, nocturia or
incontinence; urinary catheter
placement or bladder irrigation
indicated; limiting instrumental
ADLGross hematuria; transfusion, IV
medications or hospi[INVESTIGATOR_20579]; elective endoscopic,
radiologic or operative
intervention indicatedLife-threatening consequences;
urgent radiologic or operative
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576194].
Hematuria Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; urinary catheter
or bladder irrigation indicated;
limiting instrumental ADLGross hematuria; transfusion, IV
medications or hospi[INVESTIGATOR_20579]; elective endoscopic,
radiologic or operative
intervention indicated; limiting
self care ADLLife-threatening consequences;
urgent radiologic or operative
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576195].
Hemoglobinuria Asymptomatic; clinical or
diagnostic observations only;
intervention not indicated -  -  -  -
Definition: A disorder characterized by [CONTACT_576196].
Proteinuria 1+ proteinuria; urinary protein
<1.0 g/24 hrsAdults: 2+ proteinuria; urinary
protein 1.0 - 3.4 g/24 hrs;
Pediatric: urine P/C
(Protein/Creatinine) ratio 0.5 -
1.9Adults: urinary protein >=3.5
g/24 hrs;
Pediatric: urine P/C >1.9 -  -
Definition: A disorder characterized by [CONTACT_576197]. It is predominantly albumin, but also globulin.
Renal calculi Asymptomatic or mild
symptoms; occasional use of
nonprescription analgesics
indicatedSymptomatic; oral antiemetics
indicated; around the clock
nonprescription analgesics or
any oral narcotic analgesics
indicatedHospi[INVESTIGATOR_374]; IV
intervention (e.g., analgesics,
antiemetics); elective
endoscopic or radiologic
intervention indicatedLife-threatening consequences;
urgent radiologic, endoscopic or
operative intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576198].
Renal colic Mild pain not interfering with
activity; nonprescription
medication indicatedModerate pain; limiting
instrumental ADL; prescription
medication indicatedHospi[INVESTIGATOR_374];
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576199]. Often, the cause is the passage of kidney stones.
Page 227 of 364
CTCAE 4.03 - June 14, 2010 : Renal and urinary disorders 
60Renal and urinary disorders
Grade
Adverse Event 1 2 3 4 5
Renal hemorrhage Mild symptoms; intervention not
indicatedAnalgesics and hematocrit
monitoring indicatedTransfusion, radiation, or
hospi[INVESTIGATOR_374];
elective radiologic, endoscopic
or operative intervention
indicatedLife-threatening consequences;
urgent radiologic or operative
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576200].
Urinary fistula  - Noninvasive intervention
indicated; urinary or suprapubic
catheter placement indicatedLimiting self care ADL; elective
radiologic, endoscopic or
operative intervention indicated;
permanent urinary diversion
indicatedLife-threatening consequences;
urgent radiologic or operative
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576201].
Urinary frequency Present Limiting instrumental ADL;
medical management indicated -  -  -
Definition: A disorder characterized by [CONTACT_576202].
Urinary incontinence Occasional (e.g., with coughing,
sneezing, etc.), pads not
indicatedSpontaneous; pads indicated;
limiting instrumental ADLIntervention indicated (e.g.,
clamp, collagen injections);
operative intervention indicated;
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576203].
Urinary retention Urinary, suprapubic or
intermittent catheter placement
not indicated; able to void with
some residualPlacement of urinary,
suprapubic or intermittent
catheter placement indicated;
medication indicatedElective operative or radiologic
intervention indicated;
substantial loss of affected
kidney function or massLife-threatening consequences;
organ failure; urgent operative
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576204].
Urinary tract obstruction Asymptomatic; clinical or
diagnostic observations onlySymptomatic but no
hydronephrosis, sepsis or renal
dysfunction; urethral dilation,
urinary or suprapubic catheter
indicatedSymptomatic and altered organ
function (e.g., hydronephrosis,
or renal dysfunction); elective
radiologic, endoscopic or
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576205].
Urinary tract pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the urinary tract.
Urinary urgency Present Limiting instrumental ADL;
medical management indicated -  -  -
Definition: A disorder characterized by a sudden compelling urge to urinate.
Urine discoloration Present  -  -  -  -
Definition: A disorder characterized by a change in the color of the urine.
Renal and urinary disorders -
Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate, local or noninvasive
intervention indicated; limiting
instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 228 of 364
CTCAE 4.03 - June 14, 2010 : Reproductive system and breast disorders 
6122. Reproductive system and breast disorders
Reproductive system and breast disorders
Grade
Adverse Event 1 2 3 4 5
Azoospermia  -  - Absence of sperm in ejaculate  -  -
Definition: A disorder characterized by [CONTACT_576206].
Breast atrophy Minimal asymmetry; minimal
atrophyModerate asymmetry; moderate
atrophyAsymmetry >1/[ADDRESS_755823]
volume; severe atrophy -  -
Definition: A disorder characterized by [CONTACT_576207].
Breast pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576208].
Dysmenorrhea Mild symptoms; intervention not
indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576209].
Dyspareunia Mild discomfort or pain
associated with vaginal
penetration; discomfort relieved
with use of vaginal lubricants or
estrogenModerate discomfort or pain
associated with vaginal
penetration; discomfort or pain
partially relieved with use of
vaginal lubricants or estrogenSevere discomfort or pain
associated with vaginal
penetration; discomfort or pain
unrelieved by [CONTACT_576210] -  -
Definition: A disorder characterized by [CONTACT_576211].
Ejaculation disorder Diminished ejaculation Anejaculation or retrograde
ejaculation -  -  -
Definition: A disorder characterized by [CONTACT_576212]. This category includes premature, delayed, retrograde and painful ejaculation.
Erectile dysfunction Decrease in erectile function
(frequency or rigidity of
erections) but intervention not
indicated (e.g., medication or
use of mechanical device,
penile pump)Decrease in erectile function
(frequency/rigidity of erections),
erectile intervention indicated,
(e.g., medication or mechanical
devices such as penile pump)Decrease in erectile function
(frequency/rigidity of erections)
but erectile intervention not
helpful (e.g., medication or
mechanical devices such as
penile pump); placement of a
permanent penile prosthesis
indicated (not previously
present) -  -
Definition: A disorder characterized by [CONTACT_576213].
Fallopi[INVESTIGATOR_575674];
intervention not indicatedMild symptoms; elective
intervention indicatedSevere symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576214][INVESTIGATOR_8916].
Fallopi[INVESTIGATOR_575675];
intervention not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicated (e.g., organ resection)Death
Definition: A disorder characterized by a narrowing of the fallopi[INVESTIGATOR_575676].
Female genital tract fistula Asymptomatic clinical or
diagnostic observations only;
intervention not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_575997] a female reproductive system organ and another organ or anatomic site.
Feminization acquired Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated -  -  -
Definition: A disorder characterized by [CONTACT_576215].
Genital edema Mild swelling or obscuration of
anatomic architecture on close
inspectionReadily apparent obscuration of
anatomic architecture;
obliteration of skin folds; readily
apparent deviation from normal
anatomic contourLymphorrhea; gross deviation
from normal anatomic contour;
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576216].
Gynecomastia Asymptomatic breast
enlargementSymptomatic (e.g., pain or
psychosocial impact)Severe symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576217].
Hematosalpi[INVESTIGATOR_575677];
intervention not indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Page 229 of 364
CTCAE 4.03 - June 14, 2010 : Reproductive system and breast disorders 
62Reproductive system and breast disorders
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_576218] a fallopi[INVESTIGATOR_8916].
Irregular menstruation Intermittent menses with
skipped menses for no more
than 1 to 3 monthsIntermittent menses with
skipped menses for more than 4
to 6 monthsPersistent amenorrhea for more
than 6 months -  -
Definition: A disorder characterized by [CONTACT_299547].
Lactation disorder Mild changes in lactation, not
significantly affecting production
or expression of breast milkChanges in lactation,
significantly affecting breast
production or expression of
breast milk -  -  -
Definition: A disorder characterized by [CONTACT_576219]. It is not necessarily related to pregnancy that is observed in females and can be observed in males.
Menorrhagia Mild; iron supplements indicated Moderate symptoms; medical
intervention indicated (e.g.,
hormones)Severe; transfusion indicated;
surgical intervention indicated
(e.g., hysterectomy)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576220].
Nipple deformity Asymptomatic; asymmetry with
slight retraction and/or
thickening of the nipple areolar
complexSymptomatic; asymmetry of
nipple areolar complex with
moderate retraction and/or
thickening of the nipple areolar
complex -  -  -
Definition: A disorder characterized by a malformation of the nipple.
Oligospermia Sperm concentration >48
million/mL or motility >68%Sperm concentration 13 - 48
million/mL or motility 32 - 68%Sperm concentration <13
million/mL or motility <32% -  -
Definition: A disorder characterized by a decrease in the number of spermatozoa in the semen.
Ovarian hemorrhage Minimal bleeding identified on
imaging study or laproscopy;
intervention not indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic  intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576221].
Ovarian rupture Asymptomatic clinical or
diagnostic observations only;
intervention not indicatedSymptomatic and intervention
not indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576222].
Ovulation pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576223], around the time of the discharge of the ovum from the
ovarian follicle.
Pelvic floor muscle weakness Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic, not interfering
with bladder, bowel, or vaginal
function; limiting instrumental
ADLSevere symptoms; limiting self
care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.
Pelvic pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576224].
Penile pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576225].
Perineal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.
Premature menopause
 -  - Present  -  -
Definition: A disorder characterized by [CONTACT_576226] 40. Symptoms include hot flashes, night sweats, mood swings and a decrease in sex drive.
Prostatic hemorrhage Minimal bleeding identified on
imaging study; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Page 230 of 364
CTCAE 4.03 - June 14, 2010 : Reproductive system and breast disorders 
63Reproductive system and breast disorders
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_576227].
Prostatic obstruction Diagnostic observations only;
intervention not indicatedMild symptoms; elective
intervention indicatedSevere symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576228]. This results in voiding difficulties (straining to void, slow urine
stream, and incomplete emptying of the bladder).
Prostatic pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the prostate gland.
Scrotal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576229].
Spermatic cord hemorrhage Minimal bleeding identified on
imaging study; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576230].
Spermatic cord obstruction Diagnostic observations only;
intervention not indicatedMild symptoms; elective
intervention indicatedSevere symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576231].
Testicular disorder Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic but not interfering
with urination or sexual
activities; intervention not
indicated; limiting instrumental
ADLSevere symptoms; interfering
with urination or sexual function;
limiting self care ADL;
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576232].
Testicular hemorrhage
Minimal bleeding identified on
imaging study; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576233].
Testicular pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the testis.
Uterine fistula Asymptomatic clinical or
diagnostic observations only;
intervention not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576234].
Uterine hemorrhage Minimal bleeding identified on
imaging study; intervention not
indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576235].
Uterine obstruction Diagnostic observations only;
intervention not indicatedMild symptoms; elective
intervention indicatedSevere symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576236].
Uterine pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the uterus.
Vaginal discharge Mild vaginal discharge (greater
than baseline for patient)Moderate to heavy vaginal
discharge; use of perineal pad
or tampon indicated -  -  -
Definition: A disorder characterized by [CONTACT_576237]. Mucus produced by [CONTACT_576238], especially during the childbearing years.
Vaginal dryness Mild vaginal dryness not
interfering with sexual functionModerate vaginal dryness
interfering with sexual function
or causing frequent discomfortSevere vaginal dryness
resulting in dyspareunia or
severe discomfort -  -
Definition: A disorder characterized by [CONTACT_576239].
Page 231 of 364
CTCAE 4.03 - June 14, 2010 : Reproductive system and breast disorders 
64Reproductive system and breast disorders
Grade
Adverse Event 1 2 3 4 5
Vaginal fistula Asymptomatic clinical or
diagnostic observations only;
intervention not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576240].
Vaginal hemorrhage Minimal bleeding identified on
clinical exam or imaging study;
intervention not indicatedModerate bleeding; medical
intervention indicatedSevere bleeding; transfusion
indicated; radiologic or
endoscopic intervention
indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576241].
Vaginal inflammation Mild discomfort or pain, edema,
or rednessModerate discomfort or pain,
edema, or redness; limiting
instrumental ADLSevere discomfort or pain,
edema, or redness; limiting self
care ADL; small areas of
mucosal ulcerationWidespread areas of mucosal
ulceration; life-threatening
consequences; urgent
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576242]. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.
Vaginal obstruction Diagnostic observations only;
intervention not indicatedMild symptoms; elective
intervention indicatedSevere symptoms; elective
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576243].
Vaginal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by a sensation of marked discomfort in the vagina.
Vaginal perforation Asymptomatic clinical or
diagnostic observations only;
intervention not indicatedSymptomatic and intervention
not indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a rupture in the vaginal wall.
Vaginal stricture Asymptomatic; mild vaginal
shortening or narrowingVaginal narrowing and/or
shortening not interfering with
physical examinationVaginal narrowing and/or
shortening interfering with the
use of tampons, sexual activity
or physical examination - Death
Definition: A disorder characterized by a narrowing of the vaginal canal.
Vaginismus Mild discomfort or pain
associated with vaginal
spasm/tightening; no impact
upon sexual function or physical
examinationModerate discomfort or pain
associated with vaginal
spasm/tightening; disruption in
sexual function and physical
examinationSevere discomfort or pain
associated with vaginal
spasm/tightening; unable to
tolerate vaginal penetration or
physical examination -  -
Definition: A disorder characterized by [CONTACT_576244], resulting in pathologic tightness of the vaginal wall during penetration such as during sexual
intercourse.
Reproductive system and breast
disorders - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 232 of 364
CTCAE 4.03 - June 14, 2010 : Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 
6523. Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Grade
Adverse Event 1 2 3 4 5
Adult respi[INVESTIGATOR_475777] -  - Present with radiologic findings;
intubation not indicatedLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576245]-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or
surgery.
Allergic rhinitis Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated -  -  -
Definition: A disorder characterized by [CONTACT_576246]-mediated response to external allergens. The inflammation may also
involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.
Apnea  -  - Present; medical intervention
indicatedLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576247].
Aspi[INVESTIGATOR_575679]; clinical or
diagnostic observations only;
intervention not indicatedAltered eating habits; coughing
or choking epi[INVESTIGATOR_575680]; medical
intervention indicated (e.g.,
suction or oxygen)Dyspnea and pneumonia
symptoms (e.g., aspi[INVESTIGATOR_575681]); hospi[INVESTIGATOR_20579]; unable to aliment
orallyLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576248].
Atelectasis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., dyspnea,
cough); medical intervention
indicated (e.g., chest
physiotherapy, suctioning);
bronchoscopic suctioningOxygen indicated;
hospi[INVESTIGATOR_575620]
(e.g., stent, laser)Life-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576249].
Bronchial fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; tube
thoracostomy or medical
management indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; endoscopic or
operative intervention indicated
(e.g., stent or primary closure)Life-threatening consequences;
urgent operative intervention
with thoracoplasty, chronic open
drainage or multiple
thoracotomies indicatedDeath
Definition: A disorder characterized by [CONTACT_576250].
Bronchial obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., mild
wheezing); endoscopic
evaluation indicated;
radiographic evidence of
atelectasis/lobar collapse;
medical management indicated
(e.g., steroids, bronchodilators)Shortness of breath with stridor;
endoscopic intervention
indicated (e.g., laser, stent
placement)Life-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576251] a bronchus passage, most often by [CONTACT_576252].
Bronchial stricture Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., rhonchi or
wheezing) but without
respi[INVESTIGATOR_1506]; medical
intervention indicated (e.g.,
steroids, bronchodilators)Shortness of breath with stridor;
endoscopic intervention
indicated (e.g., laser, stent
placement)Life-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by a narrowing of the bronchial tube.
Bronchopleural fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; tube
thoracostomy or medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; endoscopic or
operative intervention indicated
(e.g., stent or primary closure)Life-threatening consequences;
urgent operative intervention
with thoracoplasty, chronic open
drainage or multiple
thoracotomies indicatedDeath
Definition: A disorder characterized by [CONTACT_575997] a bronchus and the pleural cavity.
Bronchopulmonary hemorrhage Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicatedTransfusion, radiologic,
endoscopic, or operative
intervention indicated (e.g.,
hemostasis of bleeding site)Life-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576253]/or lung parenchyma.
Page 233 of 364
CTCAE 4.03 - June 14, 2010 : Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 
66Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Grade
Adverse Event 1 2 3 4 5
Bronchospasm Mild symptoms; intervention not
indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADLLimiting self care ADL; oxygen
saturation decreasedLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.
Chylothorax Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; thoracentesis or
tube drainage indicatedSevere symptoms; elective
operative intervention indicatedLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576254] (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.
Cough Mild symptoms; nonprescription
intervention indicatedModerate symptoms, medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_5157], often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied
by a distinctive sound.
Dyspnea Shortness of breath with
moderate exertionShortness of breath with
minimal exertion; limiting
instrumental ADLShortness of breath at rest;
limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_439842].
Epi[INVESTIGATOR_575682]; intervention not
indicatedModerate symptoms; medical
intervention indicated (e.g.,
nasal packing, cauterization;
topi[INVESTIGATOR_575683])Transfusion, radiologic,
endoscopic, or operative
intervention indicated (e.g.,
hemostasis of bleeding site)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576255].
Hiccups Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated; limiting
instrumental ADLSevere symptoms; interfering
with sleep; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576256]. This is attributed to a spasm of the diaphragm.
Hoarseness Mild or intermittent voice
change; fully understandable;
self-resolvesModerate or persistent voice
changes; may require
occasional repetition but
understandable on telephone;
medical evaluation indicatedSevere voice changes including
predominantly whispered
speech -  -
Definition: A disorder characterized by [CONTACT_576257].
Hypoxia  - Decreased oxygen saturation
with exercise (e.g., pulse
oximeter <88%); intermittent
supplemental oxygenDecreased oxygen saturation at
rest (e.g., pulse oximeter <88%
or PaO2 <=55 mm Hg)Life-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by a decrease in the level of oxygen in the body.
Laryngeal edema Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicated (e.g.,
dexamethasone, epi[INVESTIGATOR_238],
antihistamines)Stridor; respi[INVESTIGATOR_1506];
hospi[INVESTIGATOR_151467]-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by [CONTACT_576258].
Laryngeal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; tube
thoracostomy or medical
management indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; endoscopic or
operative intervention indicated
(e.g., stent or primary closure)Life-threatening consequences;
urgent operative intervention
indicated (e.g., thoracoplasty,
chronic open drainage or
multiple thoracotomies)Death
Definition: A disorder characterized by [CONTACT_576259].
Laryngeal hemorrhage Mild cough or trace hemoptysis;
laryngoscopic findingsModerate symptoms; medical
intervention indicatedTransfusion, radiologic,
endoscopic, or operative
intervention indicated (e.g.,
hemostasis of bleeding site)Life-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by [CONTACT_576260].
Laryngeal inflammation Mild sore throat; raspy voice
Moderate sore throat;
analgesics indicatedSevere throat pain; endoscopic
intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576261].
Page 234 of 364
CTCAE 4.03 - June 14, 2010 : Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 
67Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Grade
Adverse Event 1 2 3 4 5
Laryngeal mucositis Endoscopic findings only; mild
discomfort with normal intakeModerate discomfort; altered
oral intakeSevere pain; severely altered
eating/swallowing; medical
intervention indicatedLife-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by [CONTACT_576262].
Laryngeal obstruction Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., noisy airway
breathing), but causing no
respi[INVESTIGATOR_1506]; medical
management indicated (e.g.,
steroids); limiting instrumental
ADLLimiting self care ADL; stridor;
endoscopic intervention
indicated (e.g., stent, laser)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576263].
Laryngeal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., noisy airway
breathing), but causing no
respi[INVESTIGATOR_1506]; medical
management indicated (e.g.,
steroids)Limiting self care ADL; stridor;
endoscopic intervention
indicated (e.g., stent, laser)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a narrowing of the laryngeal airway.
Laryngopharyngeal dysesthesia Mild symptoms; no anxiety;
intervention not indicatedModerate symptoms; mild
anxiety, but no dyspnea; short
duration of observation and or
anxiolytic indicated; limiting
instrumental ADLSevere symptoms; dyspnea and
swallowing difficulty; limiting self
care ADLLife-threatening consequences Death
Definition: A disorder characterized by [CONTACT_576264].
Laryngospasm  - Transient epi[INVESTIGATOR_1865]; intervention
not indicatedRecurrent epi[INVESTIGATOR_1841];
noninvasive intervention
indicated (e.g., breathing
technique, pressure point
massage)Persistent or severe epi[INVESTIGATOR_575684]; urgent
intervention indicated (e.g.,
fiberoptic laryngoscopy,
intubation, botox injection)Death
Definition: A disorder characterized by [CONTACT_576265].
Mediastinal hemorrhage
Radiologic evidence only;
minimal symptoms; intervention
not indicatedModerate symptoms; medical
intervention indicatedTransfusion, radiologic,
endoscopic, or elective
operative intervention indicated
(e.g., hemostasis of bleeding
site)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576266].
Nasal congestion Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicatedAssociated with bloody nasal
discharge or epi[INVESTIGATOR_3940] -  -
Definition: A disorder characterized by [CONTACT_576267].
Pharyngeal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; tube
thoracostomy or medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; endoscopic or
operative intervention indicated
(e.g., stent or primary closure)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576268].
Pharyngeal hemorrhage Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicatedTransfusion, radiologic,
endoscopic, or operative
intervention indicated (e.g.,
hemostasis of bleeding site)Life-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576269].
Pharyngeal mucositis Endoscopic findings only;
minimal symptoms with normal
oral intake; mild pain but
analgesics not indicatedModerate pain and analgesics
indicated; altered oral intake;
limiting instrumental ADLSevere pain; unable to
adequately aliment or hydrate
orally; limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576270].
Pharyngeal necrosis  -  - Inability to aliment adequately
by [CONTACT_575969]; tube feeding or TPN
indicated; radiologic,
endoscopic, or operative
intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Page 235 of 364
CTCAE 4.03 - June 14, 2010 : Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 
68Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by a necrotic process occurring in the pharynx.
Pharyngeal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., noisy airway
breathing), but causing no
respi[INVESTIGATOR_1506]; medical
management indicated (e.g.,
steroids); limiting instrumental
ADLLimiting self care ADL; stridor;
endoscopic intervention
indicated (e.g., stent, laser)Life-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by a narrowing of the pharyngeal airway.
Pharyngolaryngeal pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576271].
Pleural effusion Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; intervention
indicated (e.g., diuretics or
limited therapeutic
thoracentesis)Symptomatic with respi[INVESTIGATOR_575685]; surgical
intervention including chest tube
or pleurodesis indicatedLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_94548]. Symptoms include shortness of breath, cough and marked chest discomfort.
Pleural hemorrhage Asymptomatic; mild hemorrhage
confirmed by [CONTACT_576272]; chest tube
drainage indicated>1000 ml of blood evacuated;
persistent bleeding (150-200
ml/hr for 2 - 4 hr); persistent
transfusion indicated; elective
operative intervention indicatedLife-threatening respi[INVESTIGATOR_575678];
intubation or urgent intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576273].
Pleuritic pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576274].
Pneumonitis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; oxygen indicatedLife-threatening respi[INVESTIGATOR_398919]; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by [CONTACT_242957].
Pneumothorax Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; intervention
indicated (e.g., tube placement
without sclerosis)Sclerosis and/or operative
intervention indicated;
hospi[INVESTIGATOR_151467]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576275].
Postnasal drip Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated -  -  -
Definition: A disorder characterized by [CONTACT_576276], causing sore throat and/or coughing.
Productive cough Occasional/minimal production
of sputum with coughModerate sputum production;
limiting instrumental ADLPersistent or copi[INVESTIGATOR_575686]; limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_576277].
Pulmonary edema Radiologic findings only;
minimal dyspnea on exertionModerate dyspnea on exertion;
medical intervention indicated;
limiting instrumental ADLSevere dyspnea or dyspnea at
rest; oxygen indicated; limiting
self care ADLLife-threatening respi[INVESTIGATOR_398919]; urgent intervention
or intubation with ventilatory
support indicatedDeath
Definition: A disorder characterized by [CONTACT_576278] a disturbance of the gas exchange that may lead to respi[INVESTIGATOR_1399].
Pulmonary fibrosis Mild hypoxemia; radiologic
pulmonary fibrosis <25% of lung
volumeModerate hypoxemia; evidence
of pulmonary hypertension;
radiographic pulmonary fibrosis
25 - 50%Severe hypoxemia; evidence of
right-sided heart failure;
radiographic pulmonary fibrosis
>50 - 75%Life-threatening consequences
(e.g., hemodynamic/pulmonary
complications); intubation with
ventilatory support indicated;
radiographic pulmonary fibrosis
>75% with severe
honeycombingDeath
Definition: A disorder characterized by [CONTACT_576279], leading to progressive dyspnea, respi[INVESTIGATOR_575687].
Pulmonary fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; tube
thoracostomy or medical
management indicated; limiting
instrumental ADLLimiting self care ADL;
endoscopic stenting or
operative intervention indicatedLife-threatening consequences;
urgent operative intervention
indicatedDeath
Page 236 of 364
CTCAE 4.03 - June 14, 2010 : Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 
69Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Grade
Adverse Event 1 2 3 4 5
Definition: A disorder characterized by [CONTACT_576280].
Pulmonary hypertension Minimal dyspnea; findings on
physical exam or other
evaluationModerate dyspnea, cough;
requiring evaluation by [CONTACT_576281], associated
with hypoxemia, right heart
failure; oxygen indicatedLife-threatening airway
consequences; urgent
intervention indicated (e.g.,
tracheotomy or intubation)Death
Definition: A disorder characterized by [CONTACT_576282].
Respi[INVESTIGATOR_1399]  -  -  - Life-threatening consequences;
urgent intervention, intubation,
or ventilatory support indicatedDeath
Definition: A disorder characterized by [CONTACT_527997][INVESTIGATOR_575688] a decrease in oxygenation of the tissues that may be associated
with an increase in arterial levels of carbon dioxide.
Retinoic acid syndrome Fluid retention; <3 kg of weight
gain; intervention with fluid
restriction and/or diuretics
indicatedModerate signs or symptoms;
steroids indicatedSevere symptoms;
hospi[INVESTIGATOR_151467]-threatening consequences;
ventilatory support indicatedDeath
Definition: A disorder characterized by [CONTACT_163389], dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans
retinoic acid.
Sinus disorder Asymptomatic mucosal crusting;
blood-tinged secretionsSymptomatic stenosis or
edema/narrowing interfering
with airflow; limiting instrumental
ADLStenosis with significant nasal
obstruction; limiting self care
ADLNecrosis of soft tissue or bone;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576283].
Sleep apnea Snoring and nocturnal sleep
arousal without apneic periodsModerate apnea and oxygen
desaturation; excessive daytime
sleepi[INVESTIGATOR_008]; medical evaluation
indicated; limiting instrumental
ADLOxygen desaturation;
associated with hypertension;
medical intervention indicated;
limiting self care ADLCardiovascular or
neuropsychiatric symptoms;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576284].
Sneezing Mild symptoms; intervention not
indicatedModerate symptoms; medical
intervention indicated -  -  -
Definition: A disorder characterized by [CONTACT_576285].
Sore throat Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL; limiting ability to swallow -  -
Definition: A disorder characterized by [CONTACT_576286]  -  - Respi[INVESTIGATOR_575689]; medical intervention
indicatedLife-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by a high pi[INVESTIGATOR_575690].
Tracheal fistula Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; tube
thoracostomy or medical
intervention indicated; limiting
instrumental ADLSevere symptoms; limiting self
care ADL; endoscopic or
operative intervention indicated
(e.g., stent or primary closure)Life-threatening consequences;
urgent operative intervention
indicated (e.g., thoracoplasty,
chronic open drainage or
multiple thoracotomies)Death
Definition: A disorder characterized by [CONTACT_576287].
Tracheal mucositis Endoscopic findings only;
minimal hemoptysis, pain, or
respi[INVESTIGATOR_575691]; medical
intervention indicated; limiting
instrumental ADLSevere pain; hemorrhage or
respi[INVESTIGATOR_1856]; limiting
self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576288].
Tracheal stenosis Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic (e.g., noisy airway
breathing), but causing no
respi[INVESTIGATOR_1506]; medical
management indicated (e.g.,
steroids)Stridor or respi[INVESTIGATOR_575692];
endoscopic intervention
indicated (e.g., stent, laser)Life-threatening airway
compromise; urgent intervention
indicated (e.g., tracheotomy or
intubation)Death
Definition: A disorder characterized by a narrowing of the trachea.
Page 237 of 364
CTCAE 4.03 - June 14, 2010 : Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 
70Respi[INVESTIGATOR_696], thoracic and mediastinal disorders
Grade
Adverse Event 1 2 3 4 5
Voice alteration Mild or intermittent change from
normal voiceModerate or persistent change
from normal voice; still
understandableSevere voice changes including
predominantly whispered
speech; may require frequent
repetition or face-to-face contact
[CONTACT_576289]; may
require assistive technology -  -
Definition: A disorder characterized by a change in the sound and/or speed of the voice.
Wheezing Detectable airway noise with
minimal symptomsModerate symptoms; medical
intervention indicated; limiting
instrumental ADLSevere respi[INVESTIGATOR_575693]; oxygen
therapy or hospi[INVESTIGATOR_575610]-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a high-pi[INVESTIGATOR_411759], whistling sound during breathing. It results from the narrowing or obstruction of the respi[INVESTIGATOR_439815].
Respi[INVESTIGATOR_696], thoracic and
mediastinal disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling; limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 238 of 364
CTCAE 4.03 - June 14, 2010 : Skin and subcutaneous tissue disorders 
7124. Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders
Grade
Adverse Event 1 2 3 4 5
Alopecia Hair loss of <50% of normal for
that individual that is not
obvious from a distance but only
on close inspection; a different
hair style may be required to
cover the hair loss but it does
not require a wig or hair pi[INVESTIGATOR_575694] >=50% normal for
that individual that is readily
apparent to others; a wig or hair
pi[INVESTIGATOR_575695];
associated with psychosocial
impact -  -  -
Definition: A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.
Body odor Mild odor; physician intervention
not indicated; self care
interventionsPronounced odor; psychosocial
impact; patient seeks medical
intervention -  -  -
Definition: A disorder characterized by [CONTACT_576290].
Bullous dermatitis Asymptomatic; blisters covering
<10% BSABlisters covering 10 - 30% BSA;
painful blisters; limiting
instrumental ADLBlisters covering >30% BSA;
limiting self care ADLBlisters covering >30% BSA;
associated with fluid or
electrolyte abnormalities; ICU
care or burn unit indicatedDeath
Definition: A disorder characterized by [CONTACT_576291].
Dry skin Covering <10% BSA and no
associated erythema or pruritusCovering 10 - 30% BSA and
associated with erythema or
pruritus; limiting instrumental
ADLCovering >30% BSA and
associated with pruritus; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_576292]; the pores are generally fine, the texture is a papery thin texture.
Erythema multiforme Target lesions covering <10%
BSA and not associated with
skin tendernessTarget lesions covering 10 -
30% BSA and associated with
skin tendernessTarget lesions covering >30%
BSA and associated with oral or
genital erosionsTarget lesions covering >30%
BSA; associated with fluid or
electrolyte abnormalities; ICU
care or burn unit indicatedDeath
Definition: A disorder characterized by [CONTACT_94556] (a pi[INVESTIGATOR_8745]-red ring around a pale center).
Erythroderma  - Erythema covering >90% BSA
without associated symptoms;
limiting instrumental ADLErythema covering >90% BSA
with associated symptoms (e.g.,
pruritus or tenderness); limiting
self care ADLErythema covering >90% BSA
with associated fluid or
electrolyte abnormalities; ICU
care or burn unit indicatedDeath
Definition: A disorder characterized by [CONTACT_576293]. The inflammatory process involves > 90% of the body surface area.
Fat atrophy Covering <10% BSA and
asymptomaticCovering 10 - 30% BSA and
associated with erythema or
tenderness; limiting instrumental
ADLCovering >30% BSA;
associated with erythema or
tenderness; limiting self-care
ADL -  -
Definition: A disorder characterized by [CONTACT_576294].
Hirsutism In women, increase in length,
thickness or density of hair in a
male distribution that the patient
is able to camouflage by
[CONTACT_324719], bleaching, or
removal of hairIn women, increase in length,
thickness or density of hair in a
male distribution that requires
daily shaving or consistent
destructive means of hair
removal to camouflage;
associated with psychosocial
impact -  -  -
Definition: A disorder characterized by [CONTACT_576295] a secondary male characteristic and under
androgen control (beard, moustache, chest, abdomen)
Hyperhidrosis Limited to one site (palms,
soles, or axillae); self care
interventionsInvolving >1 site; patient seeks
medical intervention; associated
with psychosocial impactGeneralized involving sites
other than palms, soles, or
axillae; associated with
electrolyte/hemodynamic
imbalance -  -
Definition: A disorder characterized by [CONTACT_576296][INVESTIGATOR_1516].
Page 239 of 364
CTCAE 4.03 - June 14, 2010 : Skin and subcutaneous tissue disorders 
72Skin and subcutaneous tissue disorders
Grade
Adverse Event [ADDRESS_755824] on the
usual exposed areas of the
body [face (not limited to
beard/moustache area)
plus/minus arms] that requires
frequent  shaving or use of
destructive means of hair
removal to camouflage;
associated with psychosocial
impact -  -  -
Definition: A disorder characterized by [CONTACT_576297] a particular body region, for a particular age or race.
Hypohidrosis  - Symptomatic; limiting
instrumental ADLIncrease in body temperature;
limiting self care ADLHeat stroke Death
Definition: A disorder characterized by [CONTACT_576298].
Lipohypertrophy Asymptomatic and covering
<10% BSACovering 10 - 30% BSA and
associated tenderness; limiting
instrumental ADLCovering >30% BSA and
associated tenderness and
narcotics or NSAIDs indicated;
lipohypertrophy; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576299].
Nail discoloration Asymptomatic; clinical or
diagnostic observations only;
intervention not indicated -  -  -  -
Definition: A disorder characterized by a change in the color of the nail plate.
Nail loss Asymptomatic separation of the
nail bed from the nail plate or
nail lossSymptomatic separation of the
nail bed from the nail plate or
nail loss; limiting instrumental
ADL -  -  -
Definition: A disorder characterized by [CONTACT_576300] a portion of the nail.
Nail ridging Asymptomatic; clinical or
diagnostic observations only;
intervention not indicated -  -  -  -
Definition: A disorder characterized by [CONTACT_576301].
Pain of skin Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576302].
Palmar-plantar
erythrodysesthesia syndromeMinimal skin changes or
dermatitis (e.g., erythema,
edema, or hyperkeratosis)
without painSkin changes (e.g., peeling,
blisters, bleeding, edema, or
hyperkeratosis) with pain;
limiting instrumental ADLSevere skin changes (e.g.,
peeling, blisters, bleeding,
edema, or hyperkeratosis) with
pain; limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_12070], marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet.
Periorbital edema Soft or non-pi[INVESTIGATOR_94477];
topi[INVESTIGATOR_575696]; increased
intraocular pressure, glaucoma
or retinal hemorrhage; optic
neuritis; diuretics indicated;
operative intervention indicated -  -
Definition: A disorder characterized by [CONTACT_94553].
Photosensitivity Painless erythema and
erythema covering <10% BSATender erythema covering 10 -
30% BSAErythema covering >30% BSA
and erythema with blistering;
photosensitivity; oral
corticosteroid therapy indicated;
pain control indicated (e.g.,
narcotics or NSAIDs)Life-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_94557].
Page 240 of 364
CTCAE 4.03 - June 14, 2010 : Skin and subcutaneous tissue disorders 
73Skin and subcutaneous tissue disorders
Grade
Adverse Event 1 2 3 4 5
Pruritus Mild or localized; topi[INVESTIGATOR_575697];
intermittent; skin changes from
scratching (e.g., edema,
papulation, excoriations,
lichenification, oozing/crusts);
oral intervention indicated;
limiting instrumental ADLIntense or widespread;
constant; limiting self care ADL
or sleep; oral corticosteroid or
immunosuppressive therapy
indicated -  -
Definition: A disorder characterized by [CONTACT_168100].
Purpura Combined area of lesions
covering <10% BSACombined area of lesions
covering 10 - 30% BSA;
bleeding with traumaCombined area of lesions
covering >30% BSA;
spontaneous bleeding -  -
Definition: A disorder characterized by [CONTACT_168101]. Newer lesions appear reddish in color. Older lesions are usually a darker purple color
and eventually become a brownish-yellow color.
Rash acneiform Papules and/or pustules
covering <10% BSA, which may
or may not be associated with
symptoms of pruritus or
tendernessPapules and/or pustules
covering 10 - 30% BSA, which
may or may not be associated
with symptoms of pruritus or
tenderness; associated with
psychosocial impact; limiting
instrumental ADLPapules and/or pustules
covering >30% BSA, which may
or may not be associated with
symptoms of pruritus or
tenderness; limiting self care
ADL; associated with local
superinfection with oral
antibiotics indicatedPapules and/or pustules
covering any % BSA, which
may or may not be associated
with symptoms of pruritus or
tenderness and are associated
with extensive superinfection
with IV antibiotics indicated; life-
threatening consequencesDeath
Definition: A disorder characterized by [CONTACT_168102], typi[INVESTIGATOR_168028], scalp, upper chest and back.
Rash maculo-papular Macules/papules covering
<10% BSA with or without
symptoms (e.g., pruritus,
burning, tightness)Macules/papules covering 10 -
30% BSA with or without
symptoms (e.g., pruritus,
burning, tightness); limiting
instrumental ADLMacules/papules covering
>30% BSA with or without
associated symptoms; limiting
self care ADL -  -
Definition: A disorder characterized by [CONTACT_90829] (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse
events, frequently affecting the upper trunk, spreading centripetally and associated with pruritus.
Scalp pain Mild pain Moderate pain; limiting
instrumental ADLSevere pain; limiting self care
ADL -  -
Definition: A disorder characterized by [CONTACT_576303].
Skin atrophy Covering <10% BSA;
associated with telangiectasias
or changes in skin colorCovering 10 - 30% BSA;
associated with striae or
adnexal structure lossCovering >30% BSA;
associated with ulceration -  -
Definition: A disorder characterized by [CONTACT_576304][INVESTIGATOR_80131].
Skin hyperpi[INVESTIGATOR_575698]
<10% BSA; no psychosocial
impactHyperpi[INVESTIGATOR_575699]
>10% BSA; associated
psychosocial impact -  -  -
Definition: A disorder characterized by [CONTACT_576305].
Skin hypopi[INVESTIGATOR_575700] <10%
BSA; no psychosocial impactHypopi[INVESTIGATOR_575701] >10%
BSA; associated psychosocial
impact -  -  -
Definition: A disorder characterized by [CONTACT_576306][INVESTIGATOR_2517].
Skin induration Mild induration, able to move
skin parallel to plane (sliding)
and perpendicular to skin
(pi[INVESTIGATOR_470889])Moderate induration, able to
slide skin, unable to pi[INVESTIGATOR_470890];
limiting instrumental ADLSevere induration, unable to
slide or pi[INVESTIGATOR_470890]; limiting joint
movement or orifice (e.g.,
mouth, anus); limiting self care
ADLGeneralized; associated with
signs or symptoms of impaired
breathing or feedingDeath
Definition: A disorder characterized by [CONTACT_576307].
Skin ulceration Combined area of ulcers <1 cm;
nonblanchable erythema of
intact skin with associated
warmth or edemaCombined area of ulcers 1 - 2
cm; partial thickness skin loss
involving skin or subcutaneous
fatCombined area of ulcers >2 cm;
full-thickness skin loss involving
damage to or necrosis of
subcutaneous tissue that may
extend down to fasciaAny size ulcer with extensive
destruction, tissue necrosis, or
damage to muscle, bone, or
supporting structures with or
without full thickness skin lossDeath
Definition: A disorder characterized by [CONTACT_576308], inflammatory and necrotic erosive lesion on the skin.
Page 241 of 364
CTCAE 4.03 - June 14, 2010 : Skin and subcutaneous tissue disorders 
74Skin and subcutaneous tissue disorders
Grade
Adverse Event 1 2 3 4 5
Stevens-Johnson syndrome  -  - Skin sloughing covering <10%
BSA with associated signs (e.g.,
erythema, purpura, epi[INVESTIGATOR_575702])Skin sloughing covering 10 -
30% BSA with associated signs
(e.g., erythema, purpura,
epi[INVESTIGATOR_575703])Death
Definition: A disorder characterized by [CONTACT_21316] 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the
mucous membranes.
Telangiectasia Telangiectasias covering <10%
BSATelangiectasias covering >10%
BSA; associated with
psychosocial impact -  -  -
Definition: A disorder characterized by [CONTACT_576309].
Toxic epi[INVESTIGATOR_194]  -  -  - Skin sloughing covering >=30%
BSA with associated symptoms
(e.g., erythema, purpura, or
epi[INVESTIGATOR_89152])Death
Definition: A disorder characterized by [CONTACT_7809] 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the
mucous membranes.
Urticaria Urticarial lesions covering <10%
BSA; topi[INVESTIGATOR_575704] 10 -
30% BSA; oral intervention
indicatedUrticarial lesions covering >30%
BSA; IV intervention indicated -  -
Definition: A disorder characterized by [CONTACT_576310]-defined red margins.
Skin and subcutaneous tissue
disorders - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 242 of 364
CTCAE 4.03 - June 14, 2010 : Social circumstances 
7525. Social circumstances
Social circumstances
Grade
Adverse Event 1 2 3 4 5
Menopause Menopause occurring at age 46
- 53 years of ageMenopause occurring at age 40
- 45 years of ageMenopause occurring before
age 40 years of age -  -
Definition: A disorder characterized by [CONTACT_576311], usually defined by 12 consecutive months of amenorrhea in a woman over 45 years of age.
Social circumstances - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 243 of 364
CTCAE 4.03 - June 14, 2010 : Surgical and medical procedures 
7626. Surgical and medical procedures
Surgical and medical procedures
Grade
Adverse Event 1 2 3 4 5
Surgical and medical
procedures - Other, specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 244 of 364
CTCAE 4.03 - June 14, 2010 : Vascular disorders 
7727. Vascular disorders
Vascular disorders
Grade
Adverse Event 1 2 3 4 5
Capi[INVESTIGATOR_12737]  - Symptomatic; medical
intervention indicatedSevere symptoms; intervention
indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_94549]. This syndrome is observed in patients who demonstrate a state of generalized
leaky capi[INVESTIGATOR_94476], low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ
failure.
Flushing Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedModerate symptoms; medical
intervention indicated; limiting
instrumental ADLSymptomatic, associated with
hypotension and/or tachycardia;
limiting self care ADL -  -
Definition: A disorder characterized by [CONTACT_14198][INVESTIGATOR_575705].
Hematoma Mild symptoms; intervention not
indicatedMinimally invasive evacuation or
aspi[INVESTIGATOR_575706], radiologic,
endoscopic, or elective
operative intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.
Hot flashes Mild symptoms; intervention not
indicatedModerate symptoms; limiting
instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576312], flushing, sometimes accompanied by [CONTACT_576313].
Hypertension Prehypertension (systolic BP
120 - 139 mm Hg or diastolic
BP  80 - 89 mm Hg)Stage 1 hypertension (systolic
BP 140 - 159 mm Hg or
diastolic BP 90 - 99 mm Hg);
medical intervention indicated;
recurrent or persistent (>=24
hrs); symptomatic increase by
>20 mm Hg (diastolic) or to
>140/90 mm Hg if previously
WNL; monotherapy indicated
Pediatric: recurrent or persistent
(>=24 hrs) BP >ULN;
monotherapy indicatedStage 2 hypertension (systolic
BP >=160 mm Hg or diastolic
BP >=100 mm Hg); medical
intervention indicated; more
than one drug or more intensive
therapy than previously used
indicated
Pediatric: Same as adultLife-threatening consequences
(e.g., malignant hypertension,
transient or permanent
neurologic deficit, hypertensive
crisis); urgent intervention
indicated
Pediatric: Same as adultDeath
Definition: A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressure exceeding 140 over 90 mm Hg.
Hypotension Asymptomatic, intervention not
indicatedNon-urgent medical intervention
indicatedMedical intervention or
hospi[INVESTIGATOR_151467]-threatening and urgent
intervention indicatedDeath
Definition: A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.
Lymph leakage  - Symptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicatedLife-threatening consequences;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576314].
Lymphedema Trace thickening or faint
discolorationMarked discoloration; leathery
skin texture; papi[INVESTIGATOR_131725];
limiting instrumental ADLSevere symptoms; limiting self
care ADL -  -
Definition: A disorder characterized by [CONTACT_576315].
Lymphocele Asymptomatic; clinical or
diagnostic observations only;
intervention not indicatedSymptomatic; medical
intervention indicatedSevere symptoms; radiologic,
endoscopic or elective operative
intervention indicated -  -
Definition: A disorder characterized by a cystic lesion containing lymph.
Peripheral ischemia  - Brief (<24 hrs) epi[INVESTIGATOR_575707]-
surgically and without
permanent deficitRecurring or prolonged (>=24
hrs) and/or invasive intervention
indicatedLife-threatening consequences;
evidence of end organ damage;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by [CONTACT_576316].
Phlebitis  - Present  -  -  -
Definition: A disorder characterized by [CONTACT_576317] a vein.
Superficial thrombophlebitis  - Present  -  -  -
Definition: A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.
Page 245 of 364
CTCAE 4.03 - June 14, 2010 : Vascular disorders 
78Vascular disorders
Grade
Adverse Event 1 2 3 4 5
Superior vena cava syndrome Asymptomatic; incidental finding
of SVC thrombosisSymptomatic; medical
intervention indicated (e.g.,
anticoagulation, radiation or
chemotherapy)Severe symptoms; multi-
modality intervention indicated
(e.g., anticoagulation,
chemotherapy, radiation,
stenting)Life-threatening consequences;
urgent multi-modality
intervention indicated (e.g.,
lysis, thrombectomy, surgery)Death
Definition: A disorder characterized by [CONTACT_576318]. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms,
cough, orthopnea and headache.
Thromboembolic event Venous thrombosis (e.g.,
superficial thrombosis)Venous thrombosis (e.g.,
uncomplicated deep vein
thrombosis), medical
intervention indicatedThrombosis (e.g.,
uncomplicated pulmonary
embolism [venous], non-embolic
cardiac mural [arterial]
thrombus), medical intervention
indicatedLife-threatening (e.g.,
pulmonary embolism,
cerebrovascular event, arterial
insufficiency); hemodynamic or
neurologic instability; urgent
intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_108155] a vessel by a thrombus that has migrated from a distal site via the blood stream.
Vasculitis Asymptomatic, intervention not
indicatedModerate symptoms, medical
intervention indicatedSevere symptoms, medical
intervention indicated (e.g.,
steroids)Life-threatening; evidence of
peripheral or visceral ischemia;
urgent intervention indicatedDeath
Definition: A disorder characterized by [CONTACT_576319] a vessel.
Visceral arterial ischemia
 - Brief (<24 hrs) epi[INVESTIGATOR_575708] (>=24 hrs) or
recurring symptoms and/or
invasive intervention indicatedLife-threatening consequences;
evidence of end organ damage;
urgent operative intervention
indicatedDeath
Definition: A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.
Vascular disorders - Other,
specifyAsymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention
not indicatedModerate; minimal, local or
noninvasive intervention
indicated; limiting age-
appropriate instrumental ADLSevere or medically significant
but not immediately life-
threatening; hospi[INVESTIGATOR_575606];
disabling;  limiting self care ADLLife-threatening consequences;
urgent intervention indicatedDeath
Page 246 of 364
3XEOLFDWLRQ,QIRUPDWLRQ
1,+3XEOLFDWLRQ1R
5HYLVHG-XQH
5HSULQWHG-XQH
Page 247 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 248 
 
Confidential and Proprietary  APPENDIX D. STANDARDIZED DEFINIT IONS FOR CARDIOVASCULAR ENDPOINT EVENTS  
Event Definitions  
Cardiovascular (CV) Death:  
Death due to Acute MI  Death due to Acute MI refers to a death by [CONTACT_576320] (eg, arrhythmia, sudden death, HF, stroke, 
pulmonary embolus, peripheral arterial disease) â‰¤30 daysa after a MI related to the immediate consequences of 
the MI, such as progressive HF or recalcitrant arrhythmia.  There may be assessable mechanisms of CV death 
during this time period, but for simplicity, if the CV death occurs â‰¤30 days of the MI, it will be considered a 
death due to MI.  
Acute MI should be verified to the extent possible by [CONTACT_576321] (Clinical Data 
Interchange Standards Consortium [CDISC], Chapter 4) or by [CONTACT_576322].  
Death resulting from a procedure to treat a MI (percutaneous coronary intervention (PCI), coronary artery by[CONTACT_10956] [CABG]), or to treat a complication resulting from MI, should also be considered death due 
to acute MI.  
Death resulting from an elective coronary procedure to treat myocardial ischemia (ie, chronic stable angina) or death due to a MI that occurs as  a direct consequence of a CV investigation/procedure/operation should be 
considered as a death due to a CV procedure.  
Page 248 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 249 
 
Confidential and Proprietary  Event Definitions  
Sudden Cardiac Death  Sudden Cardiac Death refers to a death that occurs unexpectedly, not following an acute MI, and includes the 
following deaths:  
a. Death witnessed  and occurring  without new or worsening  symptoms  
b. Death witnessed  within [ADDRESS_755825] acute MI 
c. Death witnessed  and attributed  to an identified  arrhythmia  (eg, captured on an electrocardiographic 
(ECG) recording,  witnessed  on a monitor, or unwitnessed  but found on implantable  cardioverter -
defibrillator  review) 
d. Death after unsuccessful  resuscitation  from cardiac arrest (eg, implantable  cardioverter  defibrillator  
(ICD) unresponsive  sudden cardiac death, pulseless electrical activity arrest) 
e. Death after successful  resuscitation  from cardiac arrest and without identification  of a specific cardiac or 
non-cardiac etiology 
f. Unwitnessed  death in a subject seen alive and clinically stable â‰¤24 hours prior to being found  dead 
without any evidence supporting  a specific non-CV cause of death (information  regarding the subjectâ€™s 
clinical status preceding  death should be provided,  if available). 
Unless additional information suggests an alternate specific cause of death (eg, death due to Other CV Causes), 
if a subject is seen alive â‰¤ 24 hours of being found dead, sudden cardiac death (criterion f above) should be recorded.  For subjects who were not observed alive within 24 hours of death, undetermined cause of death 
should be recorded (eg, a subject found dead in bed, but who had not been seen by [CONTACT_576323]).  
Death due to HF  Death due to HF refers to a death in association with clinically worsening s ymptoms and/or signs of HF 
regardless of HF etiology (CDISC, Chapter 7).  Deaths due to HF can have various etiologies, including single 
or recurrent MIs, ischemic or non -ischemic cardiomyopathy, hypertension, or valvular disease.  
Death due to Stroke  Death due to Stroke refers to death after a stroke (hemorrhagic, ischemic, or undetermined) that is either a direct 
consequence of the stroke or a complication of the stroke.  Acute stroke should be verified to the extent possible 
by [CONTACT_576324] (CDISC, Chapter 6).  
Death due to CV Procedures  Death due to CV Procedures refers to death caused by [CONTACT_576325] a cardiac procedure.  
Death due to CV Hemorrhage  Death due to CV Hemorrhage refers to death related to hemorrhage such as a non -stroke intracranial 
hemorrhage (CDISC, Chapter 6), non -procedural or non -traumatic vascular rupture (eg, aortic aneurysm), or 
hemorrhage causing cardiac tamponade.  
Death due to Other CV Causes  Death due to Other CV Causes refers to a CV death not included in the above categories but with a specific, known cause (eg, pulmonary embolism or peripheral arterial disease).  
Page 249 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 250 
 
Confidential and Proprietary  Event Definitions  
Non-CV Death:  
The following is a suggested list of non -
CV causes of death:  
â€¢ Pulmonary  
â€¢ Renal 
â€¢ Gastrointestinal  
â€¢ Hepatobiliary  
â€¢ Pancreatic 
â€¢ Infection (includes sepsis)  
â€¢ Inflammatory (eg, Systemic 
Inflammatory Response 
Syndrome (SIRS) / immune (including autoimmune; may  
include anaphylaxis from environmental [eg, food] 
allergies) 
â€¢ Hemorrhage that is neither CV bleeding no r a stroke (see 
Chapter 1, Section 6, and 
Chapter 6)  
â€¢ Non-CV procedure or surgery  
â€¢ Trauma 
â€¢ Suicide 
â€¢ Non-prescription drug reaction 
or overdose  
â€¢ Prescription drug reaction or overdose (may include anaphylaxis)  
â€¢ Neurological (non- CV) 
â€¢ Malignancy  
â€¢ Other non- CV Non-CV death is defined as any death with a specific cause that is not thought to be CV in nature, as listed in 
CDISC Chapter 1, or as listed for CV Death.   
Page 250 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 251 
 
Confidential and Proprietary  Event Definitions  
Undetermined Cause of Death:  
Undetermined Cause of Death (will 
be classified as a CV death)  Undetermined cause of death refers to a death not attributable to one of the above categories of CV death or is 
due to a non -CV cause.  Inability to classify the cause of death may be due to lack of information (eg, the only 
available information is â€œsubject diedâ€) or there is insufficient supporting information or detail to assign the 
cause of death.  In general, most deaths should be classifiable as CV or non -CV, and the use of this category of 
death, therefore, should be discouraged and should apply to f ew subjects in well -run clinical trials.    
Cardiovascular Events:  
Myocardial Infarctionb a) Clinical Presentation  
The clinical presentation should be consistent with diagnosis of myocardial ischemia and infarction.  Other 
findings that might support the diagnosis of MI should be taken into account because a number of conditions are 
associated with elevations in cardiac biomarkers (eg, trauma, surgery, pacing, ablation, HF, hypertrophic cardiomyopathy, pulmonary embolism, severe pulmonary hypertension, str oke or subarachnoid hemorrhage, 
infiltrative and inflammatory disorders of cardiac muscle, drug toxicity, burns, critical illness, extreme exertion, and chronic kidney disease).  
Supporting information can also be considered from myocardial imaging and coronary imaging.  The totality of the data may help differentiate acute MI from the background disease process.  
b) Biomarker Elevations  
For cardiac biomarkers, laboratories should report an upper reference limit (URL).  If the ninety -ninth percentile 
of the URL from the respective laboratory performing the assay is not available, then the URL for myocardial 
necrosis from the laboratory should be used.  If the ninety -ninth percentile of the URL or the URL for 
myocardial necrosis is not available, the MI decision limit for the particular laboratory should be used as the URL.  Laboratories can also report both the ninety -ninth percentile of the upper reference limit and the MI 
decision limit.  Reference limits from the laboratory performing the assay are preferred over the manufacturerâ€™s 
listed reference limits in an assayâ€™s instructions for use.  In general, troponins are preferred.  Creatine kinase -
myocardial band (CK -MB) should be used if troponins are not available, and total creatine kinase (CK) may be 
used in the absence of CK -MB and troponin.  
For MI subtypes, different biomarker elevations for CK, CK -MB, or troponin will be required.  The specific 
criteria will be referenced to the URL.  
Since it is not practical to stipulate the use of a single biomarker or assa y, the locally available results are to be 
used as the basis for adjudication.  However, if possible, using the same cardiac biomarker assay and preferably, 
a core laboratory, for all measurements reduces inter -assay variability.  
Since the prognostic signi ficance of different types of MIs (eg, periprocedural MI versus spontaneous MI) may 
be different, outcomes for these subsets of subjects may be evaluated separately.  
Page 251 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 252 
 
Confidential and Proprietary  Event Definitions  
c) ECG Changes  
Electrocardiographic changes can be used to support or confirm a MI. Supporting evidence may be ischemic 
changes and confirmatory information may be new Q waves.  
ECG manifestations of acute myocardial ischemia (in absence of left ventricular hypertrophy [LVH] and left 
bundle branch block [LBBB]) include:  
â€¢ ST elevation: New S T elevation at the J point in two contiguous leads with the cut -points: â‰¥0.1 mV in 
all leads other than leads V2 -V3 where the following cut -points apply: â‰¥0.2 mV in men â‰¥40 years 
(â‰¥0.25 mV in men <40 years) or â‰¥0.15 mV in women 
â€¢ ST depression and T -wave cha nges: New horizontal or down -slopi[INVESTIGATOR_345482] â‰¥0.05  mV in two 
contiguous leads and/or new T inversion â‰¥ 0.[ADDRESS_755826] or R/S ratio >1.  
The above ECG criteria illustrate patterns consistent with myocardial ischemia.  In subjects with abnormal 
biomarkers, it is recognized that lesser ECG abnormalities may represent an ischemic response and may be 
accepted under the category of abnormal ECG findings.  
â€¢ Criteria for pathological Q -wave 
âˆ’ Any Q-wave in leads V2 -V3 â‰¥0.02 seconds or QS complex in leads V2 and V3 
âˆ’ Q-wave â‰¥0.03 seconds and â‰¥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4 -V6 in 
any two leads of a contiguous lead groupi[INVESTIGATOR_007] (I, aVL; V1- V6; II, III, and aVF)c 
â€¢ ECG changes associated with prior MI  
âˆ’ Pathologi cal Q-waves, as defined above 
âˆ’ R-wave â‰¥0.04 seconds in V1 -V2 and R/S â‰¥[ADDRESS_755827]  
â€¢ Criteria for prior MI:  Any one of the following criteria meets the diagnosis for prior MI: 
âˆ’ Pathological Q waves with or without symptoms in the absence of non -ischemic causes  
âˆ’ Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in 
the absence of a non -ischemic cause  
Pathological findings of a prior myocardial infarction 
Page 252 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 253 
 
Confidential and Proprietary  Event Definitions  
Hospi[INVESTIGATOR_575709]:  
1. Ischemic discomfort (angina, or symptoms thought to be equivalent) â‰¥10 minutes in 
duration occurring 
â€¢ at rest, or  
â€¢ in an accelerating pattern with frequent epi[INVESTIGATOR_575710]. 
AND 
2. Prompting an unscheduled hospi[INVESTIGATOR_21342] [ADDRESS_755828] a 24  hour stay (or a change in 
calendar date if the hospi[INVESTIGATOR_575711]).  
AND 
3. At least one of the following: 
a. New or worsening ST or T wave changes on resting ECG (in the absence of confounders, such as 
LBBB or LVH)  
â€¢ Transient ST elevation (duration <20  minutes) New ST elevation at the J point in two 
contiguous leads with the cut -points: â‰¥0.1 mV in all leads other than leads V2 -V3 where the 
following cut- points apply: â‰¥0.2 mV in men â‰¥40 years (â‰¥0.25 mV in men <40 years) or 
â‰¥0.15 mV in women.  
â€¢ ST depression  and T-wave changes  
â€¢ New horizontal  or down-slopi[INVESTIGATOR_345482] â‰¥0.05 mV in two contiguous leads and/or new 
T inversion â‰¥0.[ADDRESS_755829] or R/S ratio >1. 
b. Definite ev idence of inducible myocardial ischemia event  as demonstrated by:  
â€¢ an early positive exercise stress test, defined as ST elevation or â‰¥[ADDRESS_755830] depression prior to 
5 mets OR 
â€¢ stress echocardiography (reversible wall motion abnormality) OR  
â€¢ myocardial scintigraphy (reversible perfusion defect), OR  
â€¢ magnetic resonance imaging (MRI; myocardial perfusion deficit under pharmacologic stress).  
â€¢ And believed to be responsible for the myocardial ischemic symptoms/signs.  
c. Angiographic evidence of new or worse â‰¥70% lesion (â‰¥ 50% for left main lesion) and/or thrombus 
in an epi[INVESTIGATOR_575712]/signs.  
Page 253 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 254 
 
Confidential and Proprietary  Event Definitions  
d. Need for coronary revascularization procedure (PCI or CABG) for the presumed culprit lesion(s).  
This criterion would be fulfilled if revascularization was undertaken during the unscheduled 
hospi[INVESTIGATOR_059], or subsequent to transfer to another institution without interceding home discharge.  
AND 
Negative cardiac biomarkers and no evidence of acute MI  
Transient Ischemic Attack (TIA)  TIA is defined as a transient epi[INVESTIGATOR_361849], spi[INVESTIGATOR_1831], or retinal 
ischemia, without acute infarction.  
Stroke (Includes Ischemic Stroke, 
Hemorrhagic Stroke, Undetermined Stroke, or Stroke Disability)  
 Stroke is defined as an acute epi[INVESTIGATOR_256815], spi[INVESTIGATOR_1831], or 
retinal vascular injury as a result of hemorrhage or infarction.  
A. Ischemic Stroke: Ischemic stroke is defined as an acute epi[INVESTIGATOR_196545], spi[INVESTIGATOR_1304], or retinal 
dysfunction caused by [CONTACT_256904].  
Hemorrhage may be a consequence of ischemic stroke.  In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke.  
B. Hemorrhagic Stroke:  Hemorrhagic stroke is defined as an acute epi[INVESTIGATOR_575713], intraventricular, or subarachnoid hemorrhage.  
C. Undetermined Stroke: Undetermined stroke is defined as an acute epi[INVESTIGATOR_575714], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of 
hemorrhage or infarction but with insufficient information to allow categorization as A or B.   
Stroke Disability:  Disability should be measured by a reliable and valid scale in all cases, typi[INVESTIGATOR_256818] 90 days after the event.  For example, the modified Rankin Scale may be used to address this requirement:  
Scale Disability  
0 No symptoms  at all 
1 No significant  disability despi[INVESTIGATOR_5119];  able to carry out all usual duties and activities  
2 Slight disability; unable to carry out all previous activities,  but able to look after own  affairs 
without assistance  
3 Moderate disability; requiring some help, but able to walk without assistance  
4 Moderately  severe disability; unable to walk without assistance  and unable to attend to 
own bodily needs without assistance  
5 Severe disability;  bedridden,  incontinent  and requiring constant nursing care and attention  
6 Dead 
 
Page 254 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 255 
 
Confidential and Proprietary  Event Definitions  
Heart Failure ( A HF event includes 
hospi[INVESTIGATOR_575715])  A HF hospi[INVESTIGATOR_575716]:  
1. The subject is admitted  to the hospi[INVESTIGATOR_4791] a primary diagnosis of HF 
2. The subjectâ€™s length -of-stay in hospi[INVESTIGATOR_118949] 24 hours (or a change in 
calendar date if the hospi[INVESTIGATOR_118950])  
3. The subject exhibits documented new or worsening symptoms due to HF on 
presentation, including at least ONE of the following: 
â€¢ Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal nocturnal dyspnea)  
â€¢ Decreased exercise tolerance  
â€¢ Fatigue 
â€¢ Other symptoms of worsened end- organ perfu sion or volume overload (must be specified and 
described by [CONTACT_760])  
4. The subject has objective evidence of new or worsening HF, consisting of at least 
TWO physical examination findings OR one physical examination finding and at least 
ONE laboratory cr iterion), including: 
a. Physical examination findings considered to be due to HF, including new or worsened:  
i.Peripheral edema  
ii.Increasing abdominal distention or ascites (in the absence of primary hepatic disease)  
iii.Pulmonary rales/crackles/crepi[INVESTIGATOR_575717].Increased jugular venous pressure and/or hepatojugular reflux  
v.S3 gallop 
vi.Clinically significant or rapid weight gain thought to be related to fluid retention  
b. Laboratory evidence of new or worsening HF, if obtained within 24 hours of presentat ion, 
including:  
i. Increased B -type natriuretic peptide (BNP)/ N- terminal pro -BNP (NT pro -BNP) 
concentrations consistent with decompensation of HF (such as BNP > 500 pg/mL or NT -
proBNP >2,000  pg/mL).  In subjects with chronically elevated natriuretic peptides, a 
significant increase should be noted above baseline.  
ii.Radiological evidence of pulmonary congestion  
Page 255 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 256 
 
Confidential and Proprietary  Event Definitions  
iii. Non-invasive diagnostic evidence of clinically significant elevated left - or right-sided 
ventricular filling pressure or low cardiac output.  For example, ECG criteria could include: 
E/eâ€™ >[ADDRESS_755831] (LVOT) minute stroke distance (time veloci ty integral [TVI])  
OR 
iv. Invasive diagnostic evidence with right heart catheterization showing a pulmonary capi[INVESTIGATOR_47469] (pulmonary artery occlusion pressure) â‰¥18 mmHg, central venous pressure â‰¥12 mmHg, or a cardiac index <2.2 L/min/m
2 
Note: All results from diagnostic tests should be reported, if available, even if they do not meet the above criteria, because they provide important information for the adjudication of these events.  
5. The subject receives initiation or intensification of treatment specifically for HF, 
including at least ONE of the following:  
a. Augmentation in oral diuretic therapy  
b. Intravenous diuretic or vasoactive agent (eg, inotrope, vasopressor, or vasodilator)  
c. Mechanical or surgical intervention, including:  
i. Mechanical circulatory support (eg, intra -aortic balloon pump, ventricular assist device, 
extracorporeal membrane oxygenation, total artificial heart)  
ii.Mechanical fluid removal (eg, ultrafiltration, hemofiltration, dialysis)  
An urgent HF visit is defined as an eve nt that meets all of the following:  
6. The subject has an urgent, unscheduled office/practice or emergency department visit 
for a primary diagnosis of HF, but not meeting the criteria for a HF hospi[INVESTIGATOR_059] (i.e. urgent outpatient visit) 
7. All signs and symptoms for HF hospi[INVESTIGATOR_059] (ie, symptoms and physical examination findings/laboratory evidence of new or worsening HF, as indicated above) must be met 
8. The subject receives initiation or intensification of treatment specifically for HF, as detailed in the a bove section with the exception of oral diuretic therapy, which will 
not be sufficient. 
 
Page 256 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 257 
 
Confidential and Proprietary  Event Definitions  
Interventional Cardiology:  Clinical Definitions  
Clinically -Driven Target Lesion 
Revascularization:  Revascularization is clinically -driven if the target lesion diameter stenosis is >50% by [CONTACT_576326] (QCA) and the subject has clinical or functional ischemia which cannot be explained by [CONTACT_576327]. Clinical or functional ischemia includes any  of the following:  
a. A history of angina pectoris, presumably related to the target  vessel 
b. Objective signs of ischemia at rest (electrocardiographic changes) or during exercise test (or equivalent), presumably related to the target vessel  
c. Abnormal results of  any invasive functional diagnostic test [e.g., coronary  flow reserve (CFR) or 
fractional flow reserve (FFR)]  
Comment :  Target lesion revascularization of a >70% diameter stenosis by [CONTACT_576328]-driven. 
Comment :  In the absence of QCA data or if a â‰¤50% stenosis is present, TLR may  be considered clinically -
driven by [CONTACT_350952] (AC) if severe ischemic signs and symptoms attributed to the target lesion are present.  
Non-Target Lesion and Non -Target 
Lesion Revascularization:  A lesion for which revascularization is not attempted or one in which revascularization is performed using a non-study device, respectively. 
Non-Target Vessel and Non -Target 
Vessel Revascularization:  A vessel for which revascularization is not attempted or one in which revascularization is performed using a 
non-study device, respectively. 
Percutaneous Coronary Intervention (PCI) Status: a. Elective: The procedure can be performed on an outpatient basis or durin g a subsequent hospi[INVESTIGATOR_575718].  For stable inpatients, the procedure is being performed during this hospi[INVESTIGATOR_575719]'s clinical situation 
demands the  procedure prior to discharge.  
b. Urgent: The procedure should be performed on an inpatient basis and prior  to discharge because of 
significant concerns that there is risk of myocardial ischemia, MI, and/or death.  Subjects who are 
outpatients or in the emergency department at the time that the cardiac catheterization is requested would 
warrant hospi[INVESTIGATOR_575720].  
c. Emergency:  The procedure should be performed as soon as possible because of substantial concerns that 
ongoing myocardial ischemia and/or MI could lead to death.  "As soon as possible" refers to a subject who 
is of sufficient acuity that one would cancel a scheduled case to perform this procedure immediately in the next available room during business hours, or  one would activate the on -call team were this to occur 
during off -hours. 
Page 257 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 258 
 
Confidential and Proprietary  Event Definitions  
d. Salvage:  The procedure is a last resort. The subject is in cardiogenic shock when the PCI begins (ie, the 
time at which the first guide wire or intracoronary device is introduced in to a coronary artery or by[CONTACT_576329]) OR within the last ten minutes prior to the start of 
the case or during the diagnostic portion of the case, the subject has also received chest compressions or 
has been o n unanticipated circulatory support (eg, intra -aortic balloon pump, extracorporeal membrane 
oxygenation, or cardiopulmonary support).  
Percutaneous Coronary Intervention (PCI): Placement of an angioplasty guide wire, balloon, or other device (e.g., stent, atherectomy catheter, 
brachytherapy delivery device, or thrombectomy catheter) into a native coronary artery or coronary artery by[CONTACT_576330].  In the assessment of the severity of coronary lesions wi th the use of intravascular ultrasound, coronary flow reserve (CFR), or fractional flow 
reserve (FFR), insertion of a guide wire will NOT be considered PCI.  
Procedural Success:  Achievement of <30 % residual diameter stenosis of the target lesion assessed by [CONTACT_576331]-hospi[INVESTIGATOR_478125] (MACE, a composite of death, MI, or repeat coronary 
revascularization of the target lesion).  Ideally, the assessment of the residual stenosis at the end of the procedure should be  performed by [CONTACT_256911].  
Comment: For some device interventions (eg, balloon angioplasty), achievement of <50% diameter stenosis 
by [CONTACT_576332].  
Target Lesion:  Any lesion treated or attempted to be treated during the PCI with the study device.  The target lesion includes 
the arterial segment treated with the study device (stent, in most cases) plus 5 mm proximal and 5 mm distal to the treatment site.  
Target Lesion Failure (TLF):  The composite of ischemia -driven revascularization of the target lesion, MI related to the target vessel, or 
cardiac death related to the target vessel.  If it cannot be determined with certainty whether the MI or death was related to the tar get vessel, it is considered a TLF. 
Target Lesion Revascularization (TLR): Any repeat percutaneous intervention of the target lesion (including 5 mm proximal and 5 mm distal to the target lesion) or surgical by[CONTACT_576333].  In the assessment of TLR, angiograms should be assessed by [CONTACT_256911] 
(if designated) and made available to the AC for review upon request.  
Target Vessel:  A major native coronary artery (eg, left main coronary artery, left anterior descending coronary artery, left circumflex coronary artery, or right coronary artery) or by[CONTACT_256914].  A native coronary artery target vessel includes the arterial segments upstream and downstream to the target lesion plus major side branches. 
Target Vessel Failure (TVF):  The composite of ischemia -driven revascularization of the target vessel, MI related to the target vessel, or 
cardiac death related to the target vessel.  If it cannot be determined with certainty whether the MI or death was 
related to the target vessel, it is considered a TVF.  
Page 258 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 259 
 
Confidential and Proprietary  Event Definitions  
Target Vessel, Non -Target Lesion, 
and Target Vessel, Non -Target 
Lesion Revascularization:  Any lesion or revascularization of a lesion in the target vessel other than the target lesion, respectively.  
Target Vessel Revascularization 
(TVR): Any repeat percutaneous intervention or surgical by[CONTACT_256915]. In the assessment of TVR, angiograms should be asse ssed by [CONTACT_256911] (if designated) and made available 
to the CEC for review upon request.  
Vascular Complications : â€¢ Access site hematoma :  Development of a new, localized collection of blood at a vascular access site 
sufficient to produ ce a palpable mass within 72  hours of a procedure.  
â€¢ Arteriovenous fistula: Development of a new, unintended communication between an artery and a vein occurring at a vascular access site within 72  hours of a procedure.  
â€¢ Peripheral ischemia:  Development of new arterial insufficiency sufficient to produce clinical signs or 
symptoms of ischemia (pallor, pain, paresthesia) distal to a vascular access site within 72 hours of a procedure. 
â€¢ Peripheral nerve injury:  Development of new sensory or motor loss of periph eral nerve function 
from external nerve compression (e.g., as a result of positioning during a procedure), or internal 
compression or direct nerve damage from the procedure, occurring within 72 hours of a procedure.  
â€¢ Pseudoaneurysm:  Development of a new lo calized collection of blood with a persistent 
communication (neck) originating at a vascular access site and occurring within 72h of a procedure.  
â€¢ Retroperitoneal hemorrhage:  Development of new bleeding into the retroperitoneal space 
originating at a vascular access site and occurring within 72 hours of a procedure.  
Interventional Cardiology:  Angiographic Definitions  
Abrupt Closure : New intra -procedural severely reduced flow (TIMI grade 0 -1) within the target vessel that persists and requires 
intervention by [CONTACT_13774], or results in MI or death. Abrupt closure requires an association with a vascular dissection, thrombus, or severe spasm at the treatment site or within the instrumented vessel.  
Coronary Lesions Treated  Coronary  Artery 
Segments  Definitions  
Right coronary artery ostium Origin of the right coronary artery, including the first [ADDRESS_755832] right ventricular branch (pRCA)  
Page 259 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755833] right 
ventricular branch to the acute margin (mRCA)  
Distal right coronary 
artery Distal portion of the right coronary artery, from the acute margin to the origin 
of the posterior descending artery (dRCA)  
Right posterior 
descending artery  In right dominant and mixed circulations, the vessel that runs in the posterior 
interventricular groove a nd supplies septal perforator branches (PDA)  
Posterolateral segmental 
artery In right dominant circulations, the distal continuation of the right coronary artery in the posterior atrioventricular groove after the origin of the right 
posterior descending artery (PLSA)  
First right posterolateral 
branch In right dominant circulations, the first posterolateral branch originating from the right posterior atrioventricular artery (RPL1)  
Second right posterolateral branch  In right dominant circulations, the sec ond posterolateral branch originating 
from the right posterior atrioventricular artery (RPL2)  
Third right posterolateral branch In right dominant circulations, the third posterolateral branch originating from the right posterior atrioventricular artery (R PL3) 
Posterior descending 
septal perforator  Septal perforator vessel originating from the posterior descending artery  
Right ventricular branch  Branch arising from the right coronary artery to supply the right ventricular 
wall (RV)  
Left main coronary art ery 
ostium Origin of the left coronary artery, including the first 3 mm of the artery  
Left main coronary artery body Body of the left main coronary artery, from the ostium to the bifu rcation (LM)  
Left main coronary artery 
bifucation  Distal end of the left main, including the terminal [ADDRESS_755834] septal (pLAD)  
Mid left anterior descending artery  Middle portion of the left anter ior descending coronary artery, from the origin 
of the first septal artery to the origin of the third septal artery (mLAD)  
Page 260 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755835] septal artery to the terminus (dLAD)  
First diagonal branch  First of the three longest branches originating from the left anterior descending  
artery to supply the anterolateral wall of the left ventricle (D1)  
First diagonal lateral 
branch Branch of the first diagonal branch  
Second diagonal branch  Second of the three longest branches originating from the left anterior 
descending  artery to supply the anterolateral wall of the left ventricle (D2)  
Second diagonal lateral branch Branch of the second diagona l branch 
Third diagonal branch  Third of the three longest branches originating from the left anterior descending  
artery to supply the anterolateral wall of the left ventricle (D3)  
Third diagonal lateral 
branch Branch of the third diagonal branch  
Anterior descending 
septal perforator  Septal perforator vessel originating from the left anterior descending artery to 
supply the interventricular septum  
Left circumflex artery 
ostium Origin of the left circumflex coronary artery, including the first 3 mm of the  
artery 
Proximal left circumflex artery Proximal portion of the left circumflex coronary artery, from the ostium to the origin (or the nominal location of) the first marginal branch (pLCX)  
Mid left circumflex artery  Middle portion of the left circumflex coronary artery, from the origins of (or 
nominal locations of) the first marginal to the second marginal (mLCX)  
Distal left circumflex 
artery Distal portion of the left circumflex coronary artery, from the origin of (or the nominal location of) the second  marginal to the terminus (in right dominant 
systems), or to the origin of the 1st left posterolateral in all other dominance 
systems (dLCX)  
First obtuse marginal 
branch First of the three longest branches originating from the left circumflex artery to supply the lateral wall of the left ventricle (OM1)  
First obtuse marginal lateral branch  Branch of the first marginal branch  
Second obtuse marginal 
branch Second of the three longest branches originating from the left circumflex artery 
to supply the lateral wall of the left ventricle (OM2)  
Page 261 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755836] branches originating from the left circumflex artery to supply the lateral wall of the left ventricle (OM3)  
Third obtuse marginal 
lateral branch  Branch of the third marginal branch  
Left atrioventricular 
artery In left dominant and mixed circulations, the distal continuation of the left circumflex coronary artery in the posteri or atrioventricular groove  
Left posterior descending artery In left dominant circulations, the vessel that arises from the distal continuation of the left atrioventricular artery, travels in the posterior interventricular groove, 
and supplies septal perfo rator branches (LPDA)  
First left posterolateral 
branch In left dominant and mixed circulations, the first posterolateral branch originating from the posterior atrioventricular left circumflex artery (LPL1)  
Second left posterolateral branch In left domina nt and mixed circulations, the second posterolateral branch 
originating from the posterior atrioventricular left circumflex artery (LPL2)  
Third left posterolateral 
branch In left dominant and mixed circulations, the third posterolateral branch 
originating  from the posterior atrioventricular left circumflex artery (LPL3)  
Ramus intermedius 
branch Branch vessel whose origin bisects the origins of the left anterior descending and circumflex arteries (RI)  
Ramus intermedius 
lateral branch  Branch of the ramus intermedius branch  
 
Dissection:  Based on the National Heart, Lung, and Blood Institute (NHLBI) Dissection Classification System:  
â€¢ Grade A: Minor radiolucencies within the lumen during contrast injection with no persistence after dye 
clearance  
â€¢ Grade B: Parallel tracts or double lumen separated by a radiolucent area during contrast injection with no 
persistence after dye clearance  
â€¢ Grade C: Extraluminal cap with persistence of contrast after dye clearance from the lumen 
â€¢ Grade D: Spi[INVESTIGATOR_256823]  
â€¢ Grade E: New persistent filling defect with delayed antegrade flow  
â€¢ Grade F: Non-A-E types with total coronary occlusion and no distal antegrade flow  
Note: Grade E and F dissections may represent thrombus  
Page 262 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 263 
 
Confidential and Proprietary  Event Definitions  
Late Loss:  Minimum lumen diameter (MLD) assessed at follow -up angiography minus the MLD assessed immediately 
after the index procedure.  MLDs are measured by [CONTACT_13775].  
Minimum Lumen Diameter (MLD):  The mean minimum lumen diameter (typi[INVESTIGATOR_575721] -lesion, in-stent, and in-segment) derived from two 
orthogonal views by [CONTACT_13775].  
No Reflow:  An acute reduction in coronary flow (TIMI grade 0 -1) in the absence of dissection, thrombus, spasm, or high -
grade residual stenosis at the original target lesion.  
Percent Diameter Sten osis (% DS):  The value calculated as 100 x (1 â€“ MLD/RVD) using the mean values determined by [CONTACT_576334] (when possible).  
Reference Vessel Diameter (RVD): Defined as the average of normal segments within 10 mm proximal and 10 mm distal t o the target lesion from 
two orthogonal views using QCA.  
Restenosis:  Re-narrowing of the vessel following the treatment of a prior stenosis  
â€¢ Binary restenosis: A diameter stenosis of > 50% at the previously treated lesion site, including the 
originally treated site plus the adjacent vascular segments 5 mm proximal and 5 mm distal to the site.  
â€¢ In-stent restenosis (ISR): A previously stented lesion with a > 50% diameter  stenosis. 
Thrombus (Angiographic):  A discrete, mobile, intraluminal filling defect wit h defined borders with or without associated contrast staining.  
TIMI (Thrombolysis in Myocardial 
Infarction) Flow Grades:  â€¢ Grade 0 (no perfusion): There is no antegrade flow beyond the point of occlusion.  
â€¢ Grade 1 (penetration without perfusion): The contra st material passes beyond the area of 
obstruction but â€œhangs upâ€ and fails to opacify the entire coronary bed distal to the obstruction for the duration of the cineangiographic filming sequence.  
â€¢ Grade 2 (partial perfusion): The contrast material passes across the obstruction and opacifies the 
coronary bed distal to the obstruction. However, the rate of entry of contrast material into the vessel distal to the obstruction or its rate of clearance from the distal bed (or both) is perceptibly slower than its entry into or clearance from comparable areas not perfused by [CONTACT_256917] (eg, 
the opposite coronary artery or the coronary bed proximal to the obstruction).  
â€¢ Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction occurs as 
promptly as antegrade flow into the bed proximal to the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved bed in the same vessel or the opposite artery.  
Vessels â€¢ Left main coronary artery (LMCA)  
â€¢ Left anterior descending artery (LAD) with septal and diagonal branches  
Page 263 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 264 
 
Confidential and Proprietary  Event Definitions  
â€¢ Left circumflex artery (LCX) with obtuse marginal branches  
â€¢ Ramus intermedius artery  
â€¢ Right coronary artery (RCA) and any of its branches  
â€¢ Posterior descending artery  
â€¢ Saphenous vein by[CONTACT_9292](s)  
â€¢ Arterial by[CONTACT_9292](s): Right internal mammary graft, left internal mammary graft, radial artery graft, 
and gastroepi[INVESTIGATOR_256825].  
Peripheral Vascular Intervention  
Peripheral Vascular Intervention 
(PVI): Peripheral vascular interventiond is a catheter based or open surgical procedure designed to improve arterial or 
venous blood flow or otherwise modify or revise vascular conduits. Procedures may include, but are not limited to, percutaneous transluminal balloon angio plasty, stent placement, thrombectomy, embolectomy, atherectomy, 
dissection repair, aneurysm exclusion, treatment of dialysis conduits, placement of various devices, intravascular thrombolysis or other pharmacotherapi[INVESTIGATOR_014], and open surgical by[CONTACT_576335].  
In general, the intention to perform percutaneous peripheral vascular intervention is denoted by [CONTACT_434338] 
a guide wire into a peripheral artery or vein.  
The target vessel(s) and the type of revascularization procedure (e.g., surgical by[CONTACT_6476], thr ombectomy, 
endarterectomy, percutaneous transluminal angioplasty, stent placement, thromboembolectomy, and thrombolysis) should be specified and recorded. For the sake of simplicity, this definition applies to the extracranial carotid artery and other non -cardiac arteries and veins and excludes the intracranial vessels and 
lymphatics.  
Procedural Success:  In the case of percutaneous intervention for obstructive lesions, procedural success is defined as the achievement of a satisfactory final residual diameter stenosis by [CONTACT_576336] (and without flow limiting dissection or hemodynamically significant translesional pressure gradient). The specific parameter for final percent residual stenosis is typi[INVESTIGATOR_32270] <30% and <50%; selection of the appropriate percentage may vary depending upon the specific intervention applied, the vascular territory, and anticipated or desired therapeutic response.  Procedural success also implies absence of in- hospi[INVESTIGATOR_575722] (eg, 
death, stroke, myocardial infarction, acute onset of limb ischemia, need for urgent/emergent vascular surgery, 
and other procedure -specific major adverse events).  The balloon inflation, stent placement, or other therapeutic 
intervention may be preceded by [CONTACT_576337] (eg, percutaneous mechanical thrombectomy, directional or rotational atherectomy, laser, and chronic total occlusion crossing device), as predefined in the protocol. 
Page 264 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 265 
 
Confidential and Proprietary  Event Definitions  
Procedural Status: Non- Elective and 
Elective: e. Non-Elective: Non -elective procedures include emergent and urgent procedures.  A non elective 
procedure is a procedure that is performed without delay, because there is clinical consensus that the 
procedure should occur imminently. Non- elective procedures imply a degree of instability of the subject, 
urgency of the medical condition, or instability of the threatening lesion.  
âˆ’ Emergent: A procedure that is performed immediately because of the acute nature of the 
medical condition (e.g., acute limb ischemia, acute aortic dissection), and the increased morbidity or mortality associated with a temporal delay in treatment.  
âˆ’ Urgent: An urgent procedure is one that is not an emergency but is required to be performed on a timely basis (â‰¤24 hrs) (e.g., a subject who has been stabilized following initial treatment 
of acute limb ischemia, and there is clinical consensus that a definitive procedure should 
occur within the next 24 hours).  
f. Elective: An elective procedure is one that is scheduled and is performed on a subject with s table 
disease, or in whom there is no urgency and/or increased morbidity or mortality associated with a planned procedure.  
Target Lesion:  A target lesion is any vascular segment treated or attempted to be treated during the trial procedure with the 
index device. The target lesion is the treated segment starting 10 mm proximal and ending 10  mm distal to the 
index device or therapy (stent, balloon, atherectomy catheter, or aortic stent -graft). 
Target Vessel : A target vessel is any vessel (eg, non -cardiac or non-intracranial) that contains the target lesion treated with the 
study device. The target vessel includes the target lesion as well as the entire length of native vessel upstream 
and downstream from the target lesion, including side branches. For the arteries of the leg, the vasculature is divided into 3 vessel â€œlevels:â€ aorto -iliac, femoral -popliteal, and tibial- crural. 
Non-Target Lesion and Non -Target 
Lesion Revascularization:  A lesion for which revascularization is not attempted or one in which reva scularization is performed using a 
non-study device, respectively. 
Non-Target Vessel and Non -Target 
Vessel Revascularization : A vessel for which revascularization is not attempted or one in which revascularization is performed using a 
non-study device, respectively.  
Target Vessel, Non -Target Lesion 
and Target Vessel, Non -Target 
Lesion Revascularization:  Any lesion or revascularization of a lesion in the target vessel other than the target lesion, respectively.  
Target Lesion Revascularization 
(TLR): Target lesion revascularization is any repeat intervention of the target lesion (including 10 mm proximal and 
10 mm distal to the index device, as target lesion is defined above) or surgical intervention/by[CONTACT_576338]. In the assessment of TLR, 
angiograms should be assessed by [CONTACT_256911] (if designated).  Angiograms (and core 
laboratory assessment thereof) and other source documentation should be made available to the CEC for 
review upon request.  
Page 265 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 266 
 
Confidential and Proprietary  Event Definitions  
Target Vessel Revascularization 
(TVR): Target vessel revascularization is any repeat intervention or surgical by[CONTACT_256915]. In the assessment of TVR, angiograms should be assessed  by [CONTACT_256911] (if designated).  
Angiograms (and core laboratory assessment thereof) and other source documentation should be made 
available to the CEC for review upon request.  
Clinically -Driven Target Lesion 
Revascularization:  Clinically -driven target lesion revascularization is defined as target lesion revascularization performed due to 
target lesion diameter stenosis >50% AND either evidence of clinical or functional ischemia (eg, 
recurrent/progressive intermittent claudication, cri tical limb ischemia) OR recurrence of the clinical syndrome 
for which the initial procedure was performed.  Clinically -driven target lesion revascularization occurs in the 
absence of protocol -directed surveillance ultrasound or angiography.  
Vessel Patency : Vessel patency at a given time point will be determined by [CONTACT_576339] -driven target lesion 
revascularization and/or absence of recurrent target lesion diameter stenosis >50% by [CONTACT_9661] (eg, invasive angiography or most commonly, duplex ult rasonography). If patency data are incorporated within the primary 
endpoint of a clinical trial, the angiographic images or duplex ultrasonographic images should be assessed by 
[CONTACT_576340]. 
Restenosis:  Re-narrowing of the artery following the treatment of a prior stenosis  
â€¢ Binary restenosis: A diameter stenosis of >50% at the previously treated lesion site, including the 
originally treated site plus the adjacent vascular segments 10 mm proximal and 10 mm distal to the site 
(or as otherwise defined by [CONTACT_760], as noted above).  
â€¢ In-stent restenosis (ISR): A previously stented lesion that has >50% diameter stenosis.  
  
Page 266 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 267 
 
Confidential and Proprietary  Event Definitions  
Stent Thrombosis  
Stent Thrombosis: Timing  Stent thrombosis should be reported as a cumulative value over time and at the various individual time points 
as specified below. Time [ADDRESS_755837] has left the cardiac catheterization laboratory.  
 
Stent Thrombosis: Timing  
Acute stent thrombosis1 0-[ADDRESS_755838] stent implantation  
Subacute stent thrombosis1 >24 hours â€“ [ADDRESS_755839] stent implantation 
Late stent thrombosis2 >30 days â€“ [ADDRESS_755840] stent implantation  
Very late stent thrombosis2 >[ADDRESS_755841] stent implantation  
1 Acute or subacute can also be replaced by [CONTACT_13796]. Early stent thrombosis (0 -30 days) will be 
used herein.  
2 Includes â€œprimaryâ€ as well as â€œsecondaryâ€ late stent thrombosis; â€œsecondaryâ€ late stent thrombosis is a stent thrombosis 
after a target lesion revascularization.  
 
Stent Thrombosis Categories  1. Definite Stent Thrombosis  
 Definite stent thrombosis is considered to have occurred by [CONTACT_576341]: 
a. Angiographic confirmation  of stent thrombosise 
â€¢ The presence of a thrombusf that originates in the stent or in the segment [ADDRESS_755842] 1 of the following criteria within a 48 -hour time window:  
âˆ’ Acute onset of ischemic symptoms at rest 
âˆ’ New ischemic ECG changes that suggest acute ischemia  
âˆ’ Typi[INVESTIGATOR_196543] (refer to definition of spontaneous MI) 
âˆ’ Nonocclusive thrombus:  Intracoronary thrombus is defined as a (spheric, ovoid, or irregular) 
noncalcified filling  defect or lucency surrounded by [CONTACT_13800] (on 3 sides or within a 
coronary stenosis) seen in multiple projections, or persistence of contrast material within the lumen, or a visible embolization of intraluminal material downstream  
âˆ’ Occlusive thromb us:  TIMI [ADDRESS_755843] 
adjacent proximal side branch or main branch (if originates from the side branch).  
Page 267 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 268 
 
Confidential and Proprietary  Event Definitions  
b. Pathological Confirmation of Stent Thrombosis:  Evidence of recent thrombus within the stent 
determined at autopsy or via examination of tissue retrieved following thrombectomy.  
2. Probable Stent Thrombosis:  Clinical definition of probable stent thrombosis is considered to have 
occurred after intracoronary stenting in the following cases:  
a.Any unexplained death within the first 30 daysg 
b. Irrespective of the time after the index procedure, any MI that is related to documented acute 
ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause  
3. Possible Stent Thrombosis:  Clinical definition of possible stent thrombosis is considered to have 
occurred with any unexplained death from [ADDRESS_755844] lead groupi[INVESTIGATOR_007].  
d Peripheral vascular disease includes veins, arteries, an d lymphatics. However, for simplicity, this definition focuses on peripheral artery and venous 
interventions.  
e The incidental angiographic documentation of stent occlusion in the absence of clinical signs or symptoms is not considered a  confirmed stent th rombosis 
(silent occlusion).  
f Intracoronary thrombus.  
g  For studies with ST -elevation MI population, one may consider the exclusion of unexplained death within 30 days as evidence of probable stent 
thrombosis.  
Source:  â€œStandardized Definitions for Cardi ovascular and Stroke Endpoint Events in Clinical Trials,â€ dated August 20, 2014, and available at the CDISC 
website (http://www.cdisc.org/system/files/all/standard/Draft%20Definitions%20for%20CDISC%20August%2020,%202014.pdf ). 
Note:  CEC = Cardiovascular Events Committee, which is referred to in the body of the protocol as the CAC = Cardiovascular Ad judication Committee  
 
  
Page 268 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 269 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
Hospi[INVESTIGATOR_575723] 
1. Escalation of pharmacotherapy for ischemia, such 
as intravenous nitrates or increasing dosages of Î²-blockers, should be considered supportive but not diagnostic of unstable angina.  However, a typi[INVESTIGATOR_575724], without any of the additional findings listed under item 3 above, would be insufficient to support classification as hospi[INVESTIGATOR_10929]. 
2. If subjects are admitted with suspected unstable angina, and subsequent testing reveals a non- cardiac or non-ischemic etiology, this event should not be recorded as hospi[INVESTIGATOR_10929].  Potential ischemic events meeting the 
criteria for MI should not be adjudicated as 
unstable angina.  
3. Planned hospi[INVESTIGATOR_575725] a hospi[INVESTIGATOR_10929].   
â€¢ Hospi[INVESTIGATOR_58170] a subject with stable exertional 
angina for coronary angiography and PCI that is prompted by a positive outpatient stre ss test should 
not be considered hospi[INVESTIGATOR_10929]. 
â€¢ Rehospi[INVESTIGATOR_58170] a subject meeting the criteria 
for unstable angina who was stabilized, discharged, 
and subsequently readmitted for revascularization, Unstable angina requiring hospi[INVESTIGATOR_31561]:  
1. Ischemic discomfort (angina, or symptoms 
thought to be equivalent) â‰¥10 minutes in duration occurring 
â€¢ 
at rest, or  
â€¢ in an accelerating pattern with frequent epi[INVESTIGATOR_575726]. 
AND 
2. Prompting an unscheduled hospi[INVESTIGATOR_9648] [ADDRESS_755845] 
a 24 hour stay (or a change in calendar date 
if the hospi[INVESTIGATOR_575711]).  
AND 
3. At least one of the following: 
a. New or worsening ST or T wave changes on 
resting ECG (in the absence of confounders, such as LBBB or LVH) 
â€¢ Transient ST elevation (duration 
<20 minutes) New ST elevation at the 
J point in two contiguous leads with the cut -
points: â‰¥0.1 mV in all leads other than leads 
V2-V3 where the following cut -points 
apply: â‰¥0.2 mV in men â‰¥40 years (â‰¥ 0.25mV 
in men <40 y ears) or â‰¥0.15 mV in women.  
Page 269 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 270 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
Hospi[INVESTIGATOR_575727] 
(Continued)  does not constitute a second ho spi[INVESTIGATOR_148842]. 
A subject who undergoes an elective catheterization where incidental coronary artery disease is found and who subsequently undergoes 
coronary revascularization will not be considered as meeting the hospi[INVESTIGATOR_575728].  â€¢ ST depression  and T-wave changes  
â€¢ New horizontal  or down-slopi[INVESTIGATOR_575729] â‰¥0.05 mV in two contiguous 
leads and/or new T inversion â‰¥0.[ADDRESS_755846] or R/S ratio >1.  
b. Definite evidence of inducible myocardial ischemia event  as demonstrated by:  
â€¢ an early positive exercise stress test, defined 
as ST elevation or â‰¥[ADDRESS_755847] depression 
prior to 5 mets OR  
â€¢ stress echocardiography (reversible wall motion abnormality) OR  
â€¢ myocardial scintigraphy (reversible 
perfusion defect), OR  
â€¢ magnetic resonance imaging (MRI; 
myocardial perfusion deficit under pharmacologic stress).  
â€¢ And believed to be responsible for the myocardial ischemic symptoms/signs.  
c. Angiographic evidence of new or worse â‰¥70% 
lesion (â‰¥50% for left main lesion) and/or thrombus in an epi[INVESTIGATOR_575712]/signs.  
d. Need for coronary revascularization procedure (PCI or CABG) for the presumed culprit lesion(s).  This criterion would be fulfilled if revascularization was undertaken during the unscheduled hospi[INVESTIGATOR_059], or subsequent to transfer to another institution without interceding 
home discharge.  
Page 270 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 271 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
AND 
4. Negative cardiac biomarkers and no 
evidence of acute MI  
Transient 
Ischemic Attack (TIA) 
and Stroke  
 
    
 
    TIA TIA is defined as a transient epi[INVESTIGATOR_575730], spi[INVESTIGATOR_1831], or retinal ischemia, without acute infarction.  
Stroke Classification:  
A. Ischemic Stroke  
Ischemic stroke is defined as an acute epi[INVESTIGATOR_196545], spi[INVESTIGATOR_1304], or retinal dysfunction caused by [CONTACT_256904].  
Hemorrhage may be a consequence of ischemic stroke.  In this situation, the stroke is an ischemic  stroke with hemorrhagic 
transformation and not a hemorrhagic stroke.  
B. Hemorrhagic Stroke  
Hemorrhagic stroke is defined as an acute epi[INVESTIGATOR_575731], intraventricular, or subarachnoid hemo rrhage. 
C. Undetermined Stroke  
Undetermined stroke is defined as an acute epi[INVESTIGATOR_575732], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of hemorrhage or infarction but with insufficient info rmation to allow categorization as A or B.  
 Stroke is defined as an acute epi[INVESTIGATOR_575733], spi[INVESTIGATOR_1831], or 
retinal vascular injury as a result of hemorrhage or infarction.  
 
 
        
Page 271 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 272 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
 
 
Transient 
Ischemic Attack (TIA) and Stroke (Continued)   
 
D. Stroke Disability  
Disability should be measured by a reliable and valid scale in all 
cases, typi[INVESTIGATOR_575734] 90 days after the event.  For example, the modified Rankin Scale may be used to address this requirement:  
Scale Disability  
0 No symptoms  at all 
1 No significant  disability despi[INVESTIGATOR_5119];  able to 
carry out all usual duties and activities  
2 Slight disability; unable to carry out all previous 
activities,  but able to look after own  affairs without 
assistance  
3 Moderate disability; requiring some help, but able to 
walk without assistance  
4 Moderately  severe disability; unable to walk 
without assistance  and unable to attend to own 
bodily needs without assistance  
5 Severe disability;  bedridden,  incontinent  and requiring 
constant nursing care and attention  
6 Dead 
 
  
Page 272 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 273 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
HF Event : 
A HF event 
includes 
hospi[INVESTIGATOR_575735].  HF hospi[INVESTIGATOR_575736].  If urgent visits are included in the HF endpoint, 
the number of 
urgent visits needs to be explicitly presented 
separately from 
the hospi[INVESTIGATOR_602].  
 
  
 
      A HF hospi[INVESTIGATOR_575737]: 
1. The subject is admitted to the hospi[INVESTIGATOR_4791] a  
primary diagnosis of HF 
2. The subjectâ€™s length -of-stay in hospi[INVESTIGATOR_575738] 24 hours (or a change in 
calendar date if the hospi[INVESTIGATOR_118950])  
3. The subject exhibits documented new or worsening symptoms due to HF on presentation, including at least ONE of the following: 
â€¢ Dyspnea (dyspnea with exertion, dyspnea at 
rest, orthopnea, paroxysmal nocturnal 
dyspnea) 
â€¢ Decreased exercise tolerance  
â€¢ Fatigue 
â€¢ Other symptoms of worsened end- organ 
perfusion or volume overload (mus t be 
specified and described by [CONTACT_760])  
4. The subject has objective evidence of new 
or worsening HF, consisting of at least TWO physical examination findings OR one physical examination finding and at least ONE laboratory criterion), including: 
a. Physical examination findings considered to be 
due to HF, including new or worsened:  
i.Peripheral edema  
Page 273 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 274 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
HF Event 
(Continued):  
A HF event 
includes 
hospi[INVESTIGATOR_575739].  HF 
hospi[INVESTIGATOR_575740].  If urgent visits are included in the 
HF endpoint, 
the number of urgent visits needs to be explicitly 
presented 
separately from 
the hospi[INVESTIGATOR_602].  
 
 
 
     ii.Increasing abdominal distention or ascites (in 
the absence of primary hepatic disease) 
iii.Pulmonary rales/crackles/crepi[INVESTIGATOR_575741].Increased jugular venous pressure and/or 
hepatojugular reflux  
v.S3 gallop 
vi.Clinically significant or rapid weight gain 
thought to be related to fluid retention  
b. Laboratory evidence of new or worsening HF, if 
obtained within 24 hours of presentation, 
including:  
i.Increased  B-type natriuretic peptide 
(BNP)/ N-terminal pro -BNP (NT pro -BNP) 
concentrations consistent with decompensation of HF (such as BNP >500 pg/mL or NT -proBNP 
>2,000 pg/mL).  In subjects with chronically elevated natriuretic peptides, a significant increase s hould be noted above baseline.  
ii.Radiological evidence of pulmonary 
congestion  
iii.Non-invasive diagnostic evidence of clinically 
significant elevated left - or right-sided 
ventricular filling pressure or low cardiac output.  For example, ECG criteria could include: E/eâ€™ 
>[ADDRESS_755848] (LVOT) minute stroke distance (time velocity integral [TVI])  
OR 
iv.Invasive diagnostic evidence with right heart 
catheterization showing a pulmonary capi[INVESTIGATOR_171438] (pulmonary artery occlusion 
Page 274 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 275 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
HF Event 
(Continued):  
A HF event 
includes 
hospi[INVESTIGATOR_575739].  HF 
hospi[INVESTIGATOR_575740].  If urgent visits are included in the 
HF endpoint, the number of urgent visits needs to be explicitly 
presented 
separately from the hospi[INVESTIGATOR_602].  
 pressure) â‰¥18 mmHg, central venous pressure 
â‰¥12 mmHg, or a cardiac index <2.2 L/min/m2 
Note: All results from diagnostic tests should be reported, if 
available, even if they do not meet the above criteria, because they provide important information for the adjudication of these events.  
5. The subject receives initiation or 
intensification of treatment specifically for HF, including a t least ONE of the following: 
a. Augmentation in oral diuretic therapy  
b. Intravenous diuretic or vasoactive agent (eg, 
inotrope, vasopressor, or vasodilator)  
c. Mechanical or surgical intervention, including:  
i.Mechanical circulatory support (eg, intra -aortic 
balloon pump, ventricular assist device, 
extracorporeal membrane oxygenation, total artificial heart)  
ii.Mechanical fluid removal (eg, ultrafiltration, 
hemofiltration, dialysis)  
An urgent HF visit is defined as an event that meets all of the following:  
6. The subject has an urgent, unscheduled 
office/practice or emergency department 
visit for a primary diagnosis of HF, but not meeting the criteria for a HF hospi[INVESTIGATOR_059] (i.e. urgent outpatient visit) 
7. All signs and symptoms for HF hospi[INVESTIGATOR_059] (ie, symptoms and physical 
examination findings/laboratory evidence of 
Page 275 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 276 
 
Confidential and Proprietary  Event Mechanism/Classification  Definitions  
new or worsening HF, as indicated above) 
must be met 
8. The subject receives initiation or 
intensification of treatment specifically for HF, as detailed in the above section with the exception of oral diuretic therapy, which will not be sufficient.  
a  ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non ST - 954 Elevation Myocardial Infarction: Executive Summary.  A 
Report of the American College of 955 Cardiology/American Heart Association Task Force on Practice Guidelines (Writing 956 Committee to Revise the 
2002 Guidelines for the Management of Patients With Unstable 957 Angina/Non ST -Elevation Myocardial Infarct ion):  Developed in Collaboration with 
the 958 American College of Emergency Physicians, the Society for Cardiovascular Angiography 959 and Interventions, and the S ociety of Thoracic 
Surgeons: Endorsed by [CONTACT_317921] 960 Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic 961 Emergency 
Medicine, Circulation, 2007, 116:803- 877. 
b The same criteria are used for supplemental leads V7 -V9, and for the Cabrera frontal plane lead groupi[INVESTIGATOR_007].  
Source:  â€œStandardized Definitions for  Cardiovascular and Stroke Endpoint Events in Clinical Trials,â€ dated August 20, 2014, and available at the CDISC 
website (http://www.cdisc.org/system/files/all/standard/Draft%20Definitions%20for%20CDISC%20August%2020,%202014.pdf)  
 
 
Page 276 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 277 
 
Confidential and Proprietary  APPENDIX E.  ATORVASTATIN PRESCRIBING INFORMATION 
 
 
 
  
Page 277 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]ATORVASTATIN CALCIUM- atorvastatin calcium trihydrate tablet, film coated 
Greenstone LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use atorvastatin calcium tablets safely and effectively. See full prescribing information for atorvastatin calcium tablets.
 Atorvastatin Calcium Tablets for oral administration
 Initial U.S. Approval: 1996
INDICATIONS AND [LOCATION_003]GE
Atorvastatin calcium is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors (1.1).
Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors ( 1.1).
Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospi[INVESTIGATOR_245045], and angina in patients with CHD ( 1.1).
Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipi[INVESTIGATOR_035] (heterozygous familial and nonfamilial) and mixed dyslipi[INVESTIGATOR_035] (1.2).
Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( 1.2).
Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( 1.2).
Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( 1.2).
Limitations of UseAtorvastatin calcium tablets have not been studied in Fredrickson
 Types I and V dyslipi[INVESTIGATOR_125270].
DOSAGE AND ADMINISTRATION
Dose range: 10 to 80 mg once daily ( 2.1).
Recommended start dose: 10 or 20 mg once daily ( 2.1).
Patients requiring large LDL-C reduction (>45%) may start at 40 mg once daily ( 2.1).
Pediatric starting dose: 10 mg once daily; maximum recommended dose: 20 mg once daily ( 2.2).
DOSAGE FORMS AND STRENGTHS
10, 20, 40, and 80 mg tablets ( 3).
CONTRAINDICATIONS
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels ( 4.1).
Women who are pregnant or may become pregnant ( 4.3).
Nursing mothers (4.4).Hypersensitivity to any component of this medication ( 4.2).
WARNINGS AND PRECAUTIONS
Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole,
Page 276 of 356Page 278 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] HIV protease inhibitors). Predisposing factors include advanced age
 (> 65), uncontrolled hypothyroidism, and renal impairment. Rare
 cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. Atorvastatin therapy should be discontinued if myopathy is diagnosed or suspected ( 5.1, 8.5).
Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter ( 5.2).
A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the atorvastatin calcium tablets 80 mg group vs. placebo ( 5.5).
ADVERSE REACTIONS
The most commonly reported adverse reactions (incidence â‰¥ 2%) in
 patients treated with atorvastatin calcium tablets in placebo-controlled trials regardless of causality were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact
 [CONTACT_576342] [PHONE_183] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Drug Interactions Associated with Increased Risk of
 Myopathy/Rhabdomyolysis ( 2.6, 5.1, 7, 12.3)
Interacting Agents Prescribing Recommendations
Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)Avoid atorvastatin
HIV protease inhibitor (lopi[INVESTIGATOR_245049])Use with caution and lowest dose necessary
Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir )Do not exceed 20 mg atorvastatin daily
HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir)Do not exceed 40 mg atorvastatin daily
Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses ( â‰¥1 g/day) of niacin increases the risk of
 adverse skeletal muscle effects. Caution should be used when prescribing with atorvastatin calcium tablets ( 7).
Digoxin: Patients should be monitored appropriately ( 7.8).
Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased ( 7.9).
Rifampin should be simultaneously co-administered with atorvastatin calcium tablets ( 7.7).
USE IN SPECIFIC POPULATIONS
Hepatic impairment: Plasma concentrations markedly increased in
 patients with chronic alcoholic liver disease ( 12.3).
Page 277 of 356Page 279 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]See 17 for PATIENT COUNSELING INFORMATION and FDA-
approved patient labeling.
Revised: 3/2015
FULL PRESCRIBING INFORMATION:
 CONTENTS*1 INDICATIONS AND [LOCATION_003]GE
1.1 Prevention of Cardiovascular Disease1.2 Hyperlipi[INVESTIGATOR_035]1.3 Limitations of Use
2 DOSAGE AND ADMINISTRATION
2.1 Hyperlipi[INVESTIGATOR_035] (Heterozygous Familial and Nonfamilial) and Mixed Dyslipi[INVESTIGATOR_035] (Fredrickson
 Types IIa and IIb)2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10â€“17 years of age)2.3 Homozygous Familial Hypercholesterolemia2.4 Concomitant Lipid-Lowering Therapy2.5 Dosage in Patients With Renal Impairment2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors
3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS
4.1 Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels4.2 Hypersensitivity to any component of this medication4.3 Pregnancy4.4 Nursing mothers
5 WARNINGS AND PRECAUTIONS
5.1 Skeletal Muscle5.2 Liver Dysfunction5.3 Endocrine Function5.4 CNS Toxicity5.5 Use in Patients with Recent Stroke or TIA
6 ADVERSE REACTIONS
6.1 Clinical Trial Adverse Experiences6.2 Postmarketing Experience6.3 Pediatric Patients (ages 10â€“17 years)
7 DRUG INTERACTIONS
7.1 Strong Inhibitors of CYP 3A47.2 Grapefruit Juice7.3 Cyclosporine7.4 Gemfibrozil7.5 Other Fibrates7.6 Niacin7.7 Rifampin or other Inducers of Cytochrome P450
 3A4
Page 278 of 356Page 280 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]7.8 Digoxin
7.9 Oral Contraceptives
7.10 Warfarin7.11 Colchicine
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy8.3 Nursing Mothers8.4 Pediatric Use8.5 Geriatric Use8.6 Hepatic Impairment
10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Prevention of Cardiovascular Disease14.2 Hyperlipi[INVESTIGATOR_035] (Heterozygous Familial and Nonfamilial) and Mixed Dyslipi[INVESTIGATOR_035] ( Fredrickson
 Types IIa and IIb)14.3 Hypertriglyceridemia ( Fredrickson Type IV)
14.4 Dysbetalipoproteinemia ( Fredrickson Type III)
14.5 Homozygous Familial Hypercholesterolemia14.6 Heterozygous Familial Hypercholesterolemia in Pediatric Patients
15 REFERENCES16 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATION
17.[ADDRESS_755849]-feeding
*
FULL PRESCRIBING INFORMATION
[ADDRESS_755850] to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.Sections or subsections omitted from the full prescribing
 information are not listed.
Page 279 of 356Page 281 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]1.1 Prevention of Cardiovascular Disease
In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart
 disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to:
Reduce the risk of myocardial infarction
Reduce the risk of stroke
Reduce the risk for revascularization procedures and angina
In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to:
Reduce the risk of myocardial infarction
Reduce the risk of stroke
In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to:
Reduce the risk of non-fatal myocardial infarction
Reduce the risk of fatal and non-fatal stroke
Reduce the risk for revascularization procedures
Reduce the risk of hospi[INVESTIGATOR_575742]
1.2 Hyperlipi[INVESTIGATOR_575743]:
As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients
 with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipi[INVESTIGATOR_035] (Fredrickson
 Types IIa and IIb);
As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond
 adequately to diet;
To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;
As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:a. LDL-C remains â‰¥ 190 mg/dL or
b. LDL-C remains â‰¥ 160 mg/dL and:
there is a positive family history of premature cardiovascular disease or
two or more other CVD risk factors are present in the pediatric patient
1.[ADDRESS_755851] not been studied in conditions where the major lipoprotein abnormality is elevation
 of chylomicrons (Fredrickson Types I and V).
2 DOSAGE AND ADMINISTRATION
Page 280 of 356Page 282 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]2.1 Hyperlipi[INVESTIGATOR_035] (Heterozygous Familial and Nonfamilial) and Mixed Dyslipi[INVESTIGATOR_035] (Fredrickson Types IIa
 and IIb)
The recommended starting dose of atorvastatin calcium tablets is 10 or 20 mg once daily. Patients who require a large
 reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets is 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response (see current NCEP
 Guidelines). After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10â€“17 years of age)
The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the maximum recommended dose is 20
 mg/day (doses greater than [ADDRESS_755852] not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current  NCEP Pediatric Panel Guidelines , Clinical
 Pharmacology (12), and Indications and Usage (1.2)
]. Adjustments should be made at intervals of [ADDRESS_755853] to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
2.4 Concomitant Lipid-Lowering Therapy
Atorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors
 (statins) and fibrates should generally be used with caution [see Warnings and Precautions, Skeletal Muscle (5.1) ,
 Drug Interactions (7)].
2.[ADDRESS_755854] the plasma concentrations nor LDL-C reduction of atorvastatin calcium tablets; thus,
 dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions, Skeletal
 Muscle (5.1), Clinical Pharmacology, Pharmacokinetics (12.3) ].
2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors
In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease
 inhibitor (telaprevir), therapy with atorvastatin calcium tablets should be avoided. In patients with HIV taking lopi[INVESTIGATOR_245049], caution should be used when prescribing atorvastatin calcium tablets and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with atorvastatin calcium tablets should be limited to [ADDRESS_755855] dose necessary of atorvastatin calcium tablets is employed [see Warnings and Precautions, Skeletal Muscle (5.1) , Drug Interactions
 (7)].
3 DOSAGE FORMS AND STRENGTHS
Page 281 of 356Page 283 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]White, elliptical, film-coated tablets containing 10, 20, 40, and [ADDRESS_755856] on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of atorvastatin calcium tablets use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. ATORVASTATIN CALCIUM TABLETS SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, atorvastatin calcium tablets should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1) ].
4.4 Nursing mothers
It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this
 class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require atorvastatin calcium tablets treatment should not breastfeed their infants [see Use in Specific
 Populations (8.3)].
[ADDRESS_755857] been reported with
 atorvastatin calcium tablets and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.
Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in
 conjunction with increases in creatine phosphokinase (CPK) values >[ADDRESS_755858]. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.
There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy,
 associated with statin use. IMNM is characterized by: [CONTACT_576343],
Page 282 of 356Page 284 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] which persist despi[INVESTIGATOR_575744]; muscle biopsy showing necrotizing myopathy without
 significant inflammation; improvement with immunosuppressive agents.
Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked
 elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by [CONTACT_245160]. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of
 cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopi[INVESTIGATOR_245049], tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with atorvastatin and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopi[INVESTIGATOR_245049], darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs (see Drug Interactions (7)). Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy.
Prescribing recommendations for interacting agents are summarized in Table 1 [see also Dosage and Administration
 (2.6), Drug Interactions (7), Clinical Pharmacology (12.3) ].
Table 1. Drug Interactions Associated with Increased Risk of
 Myopathy/Rhabdomyolysis
Interacting Agents Prescribing Recommendations
*Cyclosporine, HIV protease
 inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)Avoid atorvastatin
HIV protease inhibitor (lopi[INVESTIGATOR_245049])Use with caution and lowest dose necessary
Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir , darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)Do not exceed 20 mg atorvastatin daily
HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir)Do not exceed [ADDRESS_755859] been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see Drug Interactions (7.11)].
Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).
Use with caution and with the lowest dose necessary ( 12.3)*
Page 283 of 356Page 285 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]5.[ADDRESS_755860] been associated with biochemical abnormalities of liver
 function. Persistent elevations (>3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin calcium tablets in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.
One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not
 associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of [ADDRESS_755861] been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with atorvastatin calcium tablets, promptly interrupt therapy. If an alternate etiology is not found, do not restart atorvastatin calcium tablets.
Atorvastatin calcium tablets should be used with caution in patients who consume substantial quantities of alcohol
 and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of atorvastatin calcium tablets [see Contraindications (4.1) ].
5.[ADDRESS_755862] been reported with HMG-CoA reductase inhibitors,
 including atorvastatin calcium tablets.
Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.
 Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pi[INVESTIGATOR_2117]-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spi[INVESTIGATOR_8407], and cimetidine.
5.4 CNS Toxicity
Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve
 vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0â€“24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0â€“24) based on the maximum recommended human dose of 80 mg/day.
CNS vascular lesions, characterized by [CONTACT_245161], edema, and mononuclear cell infiltration of
 perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about [ADDRESS_755863]-hoc analysis of the Stroke Prevention by [CONTACT_245162] (SPARCL) study
 where atorvastatin calcium tablets 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a
Page 284 of 356Page 286 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin
 calcium tablets 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI:
 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see Adverse Reactions (6.1) ].
6 ADVERSE REACTIONS
The following serious adverse reactions are discussed in greater detail in other sections of the label:Rhabdomyolysis and myopathy [see Warnings and Precautions (5.1)]
Liver enzyme abnormalities [see Warnings and Precautions (5.2)]
6.[ADDRESS_755864] the rates observed in clinical practice.
In the atorvastatin calcium tablets placebo-controlled clinical trial database of 16,066 patients (8755 atorvastatin
 calcium tablets vs. 7311 placebo; age range 10â€“93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin calcium tablets and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with atorvastatin calcium tablets that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%).
The most commonly reported adverse reactions (incidence â‰¥ 2% and greater than placebo) regardless of causality, in
 patients treated with atorvastatin calcium tablets in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%),
 arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%).
Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in â‰¥ 2% and at a rate
 greater than placebo in patients treated with atorvastatin calcium tablets (n=8755), from seventeen placebo-controlled
 trials.
Table 2. Clinical adverse reactions occurring in â‰¥ 2% in patients treated with any dose
 of atorvastatin calcium tablets and at an incidence greater than placebo regardless of
 causality (% of patients).
Adverse ReactionAny doseN=875510 mgN=390820 mgN=[ZIP_CODE] mgN=[ZIP_CODE] mgN=4055PlaceboN=[ADDRESS_755865] infection 5.7 6.9 6.4 8.0 4.1 5.6
Dyspepsia 4.7 5.9 3.2 6.0 3.3 4.3
Nausea 4.0 3.7 3.7 7.1 3.8 3.5
Musculoskeletal pain 3.8 5.2 3.2 5.1 2.3 3.6
Muscle Spasms 3.6 4.6 4.8 5.1 2.4 3.0
*
Page 285 of 356Page 287 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]*Myalgia 3.5 3.6 5.9 8.4 2.7 3.1
Insomnia 3.0 2.8 1.1 5.3 2.8 2.9
Pharyngolaryngeal
 pain2.3 3.9 1.6 2.8 0.7 2.1
Other adverse reactions reported in placebo-controlled studies include:
Body as a whole: malaise, pyrexia; Digestive system: abdominal discomfort, eructation, flatulence, hepatitis,
 cholestasis; Musculoskeletal system : musculoskeletal pain, muscle fatigue, neck pain, joint swelling; Metabolic and
 nutritional system : transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine
 phosphokinase increase, hyperglycemia; Nervous system: nightmare; Respi[INVESTIGATOR_2133]: epi[INVESTIGATOR_3940]; Skin and
 appendages: urticaria; Special senses: vision blurred, tinnitus; Urogenital system: white blood cells urine positive.
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)In ASCOT [see Clinical Studies (14.1) ] involving 10,305 participants (age range 40â€“80 years, 19% women; 94.6%
 Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with atorvastatin calcium tablets 10 mg
 daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin calcium tablets was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.
Collaborative Atorvastatin Diabetes Study (CARDS)
In CARDS [see Clinical Studies (14.1) ] involving 2,838 subjects (age range 39â€“77 years, 32% women; 94.3%
 Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with atorvastatin
 calcium tablets 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported.
Treating to New Targets Study (TNT)
In TNT [see Clinical Studies (14.1) ] involving 10,001 subjects (age range 29â€“78 years, 19% women; 94.1%
 Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin calcium
 tablets 10 mg daily (n=5006) or atorvastatin calcium tablets 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations ( â‰¥3 Ã— ULN twice within 4â€“10 days) occurred in 62 (1.3%) individuals
 with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK ( â‰¥ 10 Ã— ULN) were
 low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).
Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)
In IDEAL [see Clinical Studies (14.1) ] involving 8,888 subjects (age range 26â€“80 years, 19% women; 99.3%
 Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with atorvastatin calcium tablets 80 mg/day (n=4439)
 or simvastatin 20â€“40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.
Stroke Prevention by [CONTACT_245162] (SPARCL)
In SPARCL involving 4731 subjects (age range 21â€“92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6%
 Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin calcium tablets 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations ( â‰¥ 3 Ã— ULN twiceAdverse Reaction â‰¥ 2% in any dose greater than placebo
Page 286 of 356Page 288 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] within 4â€“10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (>10 Ã— ULN) were
 rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an
 adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see Warnings and Precautions (5.5)].
In a post-hoc analysis, atorvastatin calcium tablets 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2%
 vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 atorvastatin calcium tablets vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) atorvastatin calcium tablets vs. 2 (4%) placebo].
There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the
 atorvastatin calcium tablets 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the atorvastatin calcium tablets 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular death were numerically larger in the atorvastatin calcium tablets 80 mg group (5.0%) than in the placebo group (4.0%).
6.[ADDRESS_755866] been identified during postapproval use of atorvastatin calcium tablets. Because
 these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reactions associated with atorvastatin therapy reported since market introduction, that are not listed above,
 regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epi[INVESTIGATOR_194]), rhabdomyolysis, myositis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, and pancreatitis.
There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see Warnings and
 Precautions (5.1)].There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia,
 memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).
6.3 Pediatric Patients (ages 10â€“17 years)
In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks,
 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin calcium tablets 10 to 20 mg daily was generally similar to that of placebo [see Clinical Studies (14.6)  and 
Use in Special Populations, Pediatric Use (8.4) ].
7 DRUG INTERACTIONS
The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid
 derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1)  and Clinical
 Pharmacology (12.3)].
7.1 Strong Inhibitors of CYP 3A4
Page 287 of 356Page 289 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]Atorvastatin is metabolized by [CONTACT_9058] P450 3A4. Concomitant administration of atorvastatin calcium tablets
 with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of
 interaction and potentiation of effects depend on the variability of effect on CYP 3A4.
 Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin
 calcium tablets 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin calcium tablets alone [see Clinical Pharmacology (12.3) ]. Therefore, in patients taking clarithromycin, caution should be used when
 the atorvastatin dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1)  and Dosage and
 Administration (2.6) ].
Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium tablets with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin calcium tablets alone [see Clinical
 Pharmacology (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin calcium tablets should be avoided. In patients taking the HIV protease inhibitor lopi[INVESTIGATOR_245049], caution should be used when prescribing atorvastatin calcium tablets and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin calcium tablets should not exceed 20 mg and should be used with caution [see Warnings and
 Precautions, Skeletal Muscle (5.1)  and Dosage and Administration (2.6)]. In patients taking the HIV protease
 inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin calcium tablets should not exceed 40 mg and close clinical monitoring is recommended.
Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium
 tablets 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3) ]. Therefore, in patients taking
 itraconazole, caution should be used when the atorvastatin dose exceeds 20 mg [see Warnings and Precautions,
 Skeletal Muscle (5.1)  and Dosage and Administration (2.6)].
7.2 Grapefruit Juice
Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin,
 especially with excessive grapefruit juice consumption (>1.2 liters per day).
7.3 Cyclosporine
Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1
 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium tablets 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin calcium tablets alone [see Clinical Pharmacology (12.3) ]. The co-administration of atorvastatin
 calcium tablets with cyclosporine should be avoided [see Warnings and Precautions, Skeletal Muscle (5.1) ].
7.4 Gemfibrozil
Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with
 gemfibrozil, concomitant administration of atorvastatin calcium tablets with gemfibrozil should be avoided [see Warnings and Precautions (5.1)].
7.5 Other Fibrates
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with
 concurrent administration of other fibrates, atorvastatin calcium tablets should be administered with caution when
Page 288 of 356Page 290 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] used concomitantly with other fibrates [see Warnings and Precautions (5.1)].
7.6 Niacin
The risk of skeletal muscle effects may be enhanced when atorvastatin calcium tablets are used in combination with
 niacin; a reduction in atorvastatin calcium tablets dosage should be considered in this setting [see Warnings and
 Precautions (5.1)].
7.7 Rifampin or other Inducers of Cytochrome P450 3A4
Concomitant administration of atorvastatin calcium tablets with inducers of cytochrome P450 3A4 (e.g., efavirenz,
 rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin calcium tablets with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
7.8 Digoxin
When multiple doses of atorvastatin calcium tablets and digoxin were coadministered, steady state plasma digoxin
 concentrations increased by [CONTACT_3450] 20%. Patients taking digoxin should be monitored appropriately.
7.9 Oral Contraceptives
Co-administration of atorvastatin calcium tablets and an oral contraceptive increased AUC values for norethindrone
 and ethinyl estradiol [see Clinical Pharmacology (12.3) ]. These increases should be considered when selecting an
 oral contraceptive for a woman taking atorvastatin.
7.[ADDRESS_755867] been rare reports
Page 289 of 356Page 291 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] of congenital anomalies following intrauterine exposure to statins. In a review of about 100 prospectively followed
 pregnancies in women exposed to other statins, the incidences of congenital anomalies, spontaneous abortions, and
 fetal deaths/stillbirths did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-four-fold increased risk of congenital anomalies over background incidence. In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified.
Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma.
 Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure based on surface area (mg/m ) [see Contraindications, Pregnancy (4.3) ].
In a study in rats given 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 21 (weaning), there was decreased pup survival at birth, neonate, weaning, and maturity in pups of mothers dosed with 225 mg/kg/day. Body weight was decreased on days 4 and 21 in pups of mothers dosed at 100 mg/kg/day; pup body weight was decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pi[INVESTIGATOR_575745]-opening at 225 mg/kg/day). These doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human AUC at 80 mg/day.
Statins may cause fetal harm when administered to a pregnant woman. Atorvastatin calcium tablets should be
 administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the woman becomes pregnant while taking atorvastatin, it should be discontinued immediately and the patient advised again as to the potential hazards to the fetus and the lack of known clinical benefit with continued use during pregnancy.
8.[ADDRESS_755868] milk. Nursing rat pups had plasma and liver drug levels of 50% and 40%, respectively, of that in their mother's milk. Animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because statins have a potential to cause serious adverse reactions in nursing infants, women requiring atorvastatin treatment should be advised not to nurse their infants [see Contraindications (4) ].
8.4 Pediatric Use
Safety and effectiveness in patients 10â€“[ADDRESS_755869] been
 evaluated in a controlled clinical trial of 6 months' duration in adolescent boys and postmenarchal girls. Patients treated with atorvastatin calcium tablets had an adverse experience profile generally similar to that of patients treated with placebo. The most common adverse experiences observed in both groups, regardless of causality assessment, were infections. Doses greater than [ADDRESS_755870] on growth or sexual maturation in boys or on menstrual cycle length in girls [see Clinical Studies (14.6) ; Adverse Reactions, Pediatric Patients (ages 10â€“17 years) (6.3) ; and Dosage and
 Administration, Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10â€“17 years of age) (2.2) ].
 Adolescent females should be counseled on appropriate contraceptive methods while on atorvastatin therapy [see Contraindications, Pregnancy (4.3)  and Use in Specific Populations, Pregnancy (8.1) ]. Atorvastatin calcium
 tablets have not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age.
Clinical efficacy with doses up to 80 mg/day for [ADDRESS_755871] been evaluated in an uncontrolled study of patients with
 homozygous FH including 8 pediatric patients [see Clinical Studies, Homozygous Familial Hypercholesterolemia
 (14.5)].
8.5 Geriatric Use
Of the 39,828 patients who received atorvastatin calcium tablets in clinical studies, 15,813 (40%) were â‰¥65 years old2
Page 290 of 356Page 292 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] and 2,800 (7%) were â‰¥75 years old. No overall differences in safety or effectiveness were observed between these
 subjects and younger subjects, and other reported clinical experience has not identified differences in responses
 between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age ( â‰¥65 years) is a predisposing factor for myopathy, atorvastatin should be prescribed with caution in the
 elderly.
8.6 Hepatic Impairment
Atorvastatin calcium tablets are contraindicated in patients with active liver disease which may include unexplained
 persistent elevations in hepatic transaminase levels [see Contraindications (4)  and Pharmacokinetics (12.3) ].
10 OVERDOSAGE
There is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated
 symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.
11 DESCRIPTION
Atorvastatin calcium is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
Atorvastatin calcium is [R-(R*, R*)]-2-(4-fluorophenyl)-ÃŸ, Î´
-dihydroxy-5-(1-methylethyl)-3-phenyl-4-
[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate. The empi[INVESTIGATOR_575746] (C H FN
O ) Caâ€¢3H O and its molecular weight is 1209.42. Its structural formula is:
Atorvastatin calcium is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol.
Atorvastatin calcium tablets for oral administration contain 10, 20, 40, or 80 mg atorvastatin and the following
 inactive ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that33 34 2 5 2 2
Page 291 of 356Page 293 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.
 Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation,
 these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developi[INVESTIGATOR_245055], while increased levels of HDL-C are associated with a decreased cardiovascular risk.
In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by [CONTACT_245163]-CoA reductase
 and cholesterol synthesis in the liver and by [CONTACT_576344]; atorvastatin also reduces LDL production and the number of LDL particles. Atorvastatin reduces LDL-C in some patients with homozygous familial hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering medication(s).
A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and apo B (a membrane
 complex for LDL-C) promote human atherosclerosis. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of atherosclerosis. Epi[INVESTIGATOR_575747]-C and LDL-C, and inversely with the level of HDL-C.
Atorvastatin reduces total-C, LDL-C, and apo B in patients with homozygous and heterozygous FH, nonfamilial
 forms of hypercholesterolemia, and mixed dyslipi[INVESTIGATOR_035]. Atorvastatin also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1. Atorvastatin reduces total-C, LDL-C, VLDL-C, apo B, TG, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia. Atorvastatin reduces intermediate density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinemia.
Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein
 (IDL), and remnants, can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
12.2 Pharmacodynamics
Atorvastatin calcium, as well as some of its metabolites, is pharmacologically active in humans. The liver is the
 primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see  Dosage and Administration (2)].
12.3 Pharmacokinetics
Absorption: 
Atorvastatin calcium tablets are rapi[INVESTIGATOR_89385]; maximum plasma
 concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin calcium dose.
 The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by [CONTACT_3450] 25% and 9%, respectively, as assessed by [CONTACT_64072], LDL-C reduction is similar whether atorvastatin calcium tablets are given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see Dosage and Administration (2)].
Page 292 of 356Page 294 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is â‰¥98% bound to
 plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells.
 Based on observations in rats, atorvastatin is likely to be secreted in human milk [see Contraindications, Nursing
 Mothers (4.4) and Use in Specific Populations, Nursing Mothers (8.3) ].
Metabolism: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by [CONTACT_245166]- and parahydroxylated metabolites is
 equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by [CONTACT_9058]
 P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7.1)]. In animals, the ortho-hydroxy
 metabolite undergoes further glucuronidation.
Excretion: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic
 metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin calcium tablets is recovered in urine following oral administration.
Specific PopulationsGeriatric: Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in
 healthy elderly subjects (age â‰¥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering
 at any dose of drug in the elderly patient population compared to younger adults [see Use in Specific Populations,
 Geriatric Use (8.5)].Pediatric: Pharmacokinetic data in the pediatric population are not available.
Gender: Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for
 Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women.
Renal Impairment: Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin;
 thus, dose adjustment in patients with renal dysfunction is not necessary [see  Dosage and Administration, Dosage in
 Patients with Renal Impairment (2.5) , Warnings and Precautions, Skeletal Muscle (5.1) ].
Hemodialysis: While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins.
Hepatic Impairment: In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are
 markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see Contraindications (4.1) ].
TABLE 3. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin
Co-administered drug and dosing regimen Atorvastatin
Change in
Page 293 of 356Page 295 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]Dose (mg) Change in AUC Cmax
*
â€ 
â€¡
Â§
Â¶
#Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days â†‘ 8.7 fold â†‘10.7 fold
Tipranavir 500 mg BID/ritonavir 200 mg BID,
 7 days10 mg, SD â†‘ 9.4 fold â†‘ 8.6 fold
Telaprevir 750 mg q8h, 10 days 20 mg, SD â†‘ 7.88 fold â†‘ 10.6 fold
Saquinavir 400 mg BID/ ritonavir 400 mg
 BID, 15 days40 mg QD for 4 days â†‘ 3.9 fold â†‘ 4.3 fold
Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days â†‘ 4.4 fold â†‘ 5.4 fold
Darunavir 300 mg BID/ritonavir 100 mg BID, 9
 days10 mg QD for 4 days â†‘ 3.4 fold â†‘ 2.25 fold
Itraconazole 200 mg QD, 4 days 40 mg SD â†‘ 3.3 fold â†‘ 20%
Fosamprenavir 700 mg BID/ritonavir 100 mg
 BID, 14 days10 mg QD for 4 days â†‘ 2.53 fold â†‘ 2.84 fold
Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days â†‘ 2.3 fold â†‘ 4.04 fold
Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days â†‘ 74% â†‘ 2.2 fold
Grapefruit Juice, 240 mL QD 40 mg, SD â†‘ 37% â†‘ 16%
Diltiazem 240 mg QD, 28 days 40 mg, SD â†‘ 51% No change
Erythromycin 500 mg QID, 7 days 10 mg, SD â†‘ 33% â†‘ 38%
Amlodipi[INVESTIGATOR_050] 10 mg, single dose 80 mg, SD â†‘ 15% â†“ 12 %
Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks â†“ Less than 1% â†“ 11%
Colestipol 10 mg BID, 28 weeks 40 mg QD for 28 weeks Not determined â†“ 26%
Maalox TCÂ® 30 mL QD, 17 days 10 mg QD for 15 days â†“ 33% â†“ 34%
Efavirenz 600 mg QD, 14 days 10 mg for 3 days â†“ 41% â†“ 1%
Rifampin 600 mg QD, 7 days (co-administered)
 40 mg SD â†‘ 30% â†‘ 2.7 fold
Rifampin 600 mg QD, 5 days (doses separated)
 40 mg SD â†“ 80% â†“ 40%
Gemfibrozil 600mg BID, 7 days 40mg SD â†‘ 35% â†“ Less than 1%
Fenofibrate 160mg QD, 7 days 40mg SD â†‘ 3% â†‘ 2%
Boceprevir 800 mg TID, 7 days 40 mg SD â†‘2.30 fold â†‘2.[ADDRESS_755872] of Atorvastatin on the Pharmacokinetics of Co-administered Drugs
Atorvastatin Co-administered drug and dosing regimen**
Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change).
 Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).
See Sections 5.[ADDRESS_755873] dose necessary should be used.
Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption ( â‰¥
 750 mL â€“ 1.2 liters per day).Single sample taken 8â€“[ADDRESS_755874] dose.Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended,
 as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.â€ 
â€ 
â€ 
â€ ,â€¡
â€ 
â€ 
â€ 
â€ 
â€ 
â€ â€  Â§
Â¶
â€ 
#
â€ 
#
â€ â€ 
Page 294 of 356Page 296 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]Drug/Dose (mg) Change in AUC Change in Cmax
*80 mg QD for 15 days Antipyrine, 600 mg SD â†‘ 3% â†“ 11%
80 mg QD for 14 days Digoxin 0.25 mg QD, 20
 daysâ†‘ 15% â†‘ 20 %
40 mg QD for 22 daysOral contraceptive QD, 2
 months
- norethindrone 1mg
- ethinyl estradiol 35Âµgâ†‘ 28%â†‘ 19%â†‘ 23%â†‘ 30%
10 mg, SDTipranavir 500 mg BID/ritonavir 200 mg BID, 7 daysNo change No change
10 mg QD for 4 daysFosamprenavir 1400 mg BID, 14 daysâ†“ 27% â†“ 18%
10 mg QD for 4 daysFosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 daysNo change No change
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in
 muscle in high-dose females: in one, there was a rhabdomyosarcoma and, in another, there was a fibrosarcoma. This dose represents a plasma AUC (0â€“24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose.
A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver
 adenomas in high-dose males and liver carcinomas in high-dose females. These findings occurred at plasma AUC (0â€“24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.
In vitro, atorvastatin was not mutagenic or clastogenic in the following tests with and without metabolic activation:
 the Ames test with Salmonella typhimurium  and Escherichia coli,  the HGPRT forward mutation assay in Chinese
 hamster lung cells, and the chromosomal aberration assay in Chinese hamster lung cells. Atorvastatin was negative in the in vivo mouse micronucleus test.
Studies in rats performed at doses up to 175 mg/kg (15 times the human exposure) produced no changes in fertility. There was aplasia and aspermia in the epi[INVESTIGATOR_245057] 2 of 10 rats treated with 100 mg/kg/day of atorvastatin for 3 months (16 times the human AUC at the 80 mg dose); testis weights were significantly lower at 30 and 100 mg/kg and epi[INVESTIGATOR_245058] 100 mg/kg. Male rats given 100 mg/kg/day for 11 weeks prior to mating had decreased sperm motility, spermatid head concentration, and increased abnormal sperm. Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of 10, 40, or 120 mg/kg for two years.
14 CLINICAL STUDIES
14.1 Prevention of Cardiovascular Disease
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of atorvastatin on fatal and non-fatalSee Section 7 for clinical significance.*
Page 295 of 356Page 297 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] coronary heart disease was assessed in 10,305 hypertensive patients 40â€“80 years of age (mean of 63 years), without a
 previous myocardial infarction and with TC levels â‰¤251 mg/dL (6.5 mmol/L). Additionally, all patients had at least 3
 of the following cardiovascular risk factors: male gender (81.1%), age >55 years (84.5%), smoking (33.2%), diabetes
 (24.3%), history of CHD in a first-degree relative (26%), TC:HDL >6 (14.3%), peripheral vascular disease (5.1%), left ventricular hypertrophy (14.4%), prior cerebrovascular event (9.8%), specific ECG abnormality (14.3%), proteinuria/albuminuria (62.4%). In this double-blind, placebo-controlled study, patients were treated with anti-hypertensive therapy (Goal BP <140/90 mm Hg for non-diabetic patients; <130/80 mm Hg for diabetic patients) and allocated to either atorvastatin calcium tablets 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.[ADDRESS_755875] of 10 mg/day of atorvastatin calcium tablets on lipid levels was similar to that seen in previous clinical
 trials.
Atorvastatin significantly reduced the rate of coronary events [either fatal coronary heart disease (46 events in the
 placebo group vs. 40 events in the atorvastatin calcium tablets group) or non-fatal MI (108 events in the placebo group vs. 60 events in the atorvastatin calcium tablets group)] with a relative risk reduction of 36% [(based on incidences of 1.9% for atorvastatin calcium tablets vs. 3.0% for placebo), p=0.0005 (see  Figure 1)]. The risk
 reduction was consistent regardless of age, smoking status, obesity, or presence of renal dysfunction. The effect of atorvastatin was seen regardless of baseline LDL levels. Due to the small number of events, results for women were inconclusive.
Figure 1: Effect of Atorvastatin 10 mg/day on Cumulative Incidence of Non-Fatal Myocardial Infarction or
 Coronary Heart Disease Death (in ASCOT-LLA)
Atorvastatin also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal strokes did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for atorvastatin calcium tablets and 2.3% for placebo). There was no significant difference between the treatment groups for death due to cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17).
In the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of atorvastatin on cardiovascular disease
 (CVD) endpoints was assessed in 2838 subjects (94% white, 68% male), ages 40â€“75 with type 2 diabetes based on WHO criteria, without prior history of cardiovascular disease and with LDL â‰¤ 160 mg/dL and TG â‰¤ 600 mg/dL. In
 addition to diabetes, subjects had 1 or more of the following risk factors: current smoking (23%), hypertension (80%), retinopathy (30%), or microalbuminuria (9%) or macroalbuminuria (3%). No subjects on hemodialysis were
Page 296 of 356Page 298 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly
 allocated to either atorvastatin calcium tablets 10 mg daily (1429) or placebo (1411) in a 1:1 ratio and were followed
 for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke. The primary analysis was the time to first occurrence of the primary endpoint.
Baseline characteristics of subjects were: mean age of 62 years, mean HbA  7.7%; median LDL-C 120 mg/dL;
 median TC 207 mg/dL; median TG 151 mg/dL; median HDL-C 52 mg/dL.
The effect of atorvastatin 10 mg/day on lipid levels was similar to that seen in previous clinical trials.Atorvastatin significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the
 atorvastatin calcium tablets group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48, 0.83) (p=0.001) (see Figure 2). An effect of atorvastatin calcium tablets was seen regardless of age, sex, or baseline lipid levels.
Atorvastatin significantly reduced the risk of stroke by 48% (21 events in the atorvastatin calcium tablets group vs. 39
 events in the placebo group), HR 0.52, 95% CI (0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the atorvastatin calcium tablets group vs. 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for angina, revascularization procedures, and acute CHD death.
There were 61 deaths in the atorvastatin calcium tablets group vs. 82 deaths in the placebo group (HR 0.73, p=0.059). Figure 2: Effect of Atorvastatin 10 mg/day on Time to Occurrence of Major Cardiovascular Event
 (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) in CARDS
In the Treating to New Targets Study (TNT), the effect of atorvastatin calcium tablets 80 mg/day vs. atorvastatin calcium tablets 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% â‰¥65 years) with clinically evident coronary heart disease who had achieved a target LDL-C level
 <130 mg/dL after completing an 8-week, open-label, run-in period with atorvastatin calcium tablets 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of atorvastatin calcium tablets and followed for a median duration of 4.[ADDRESS_755876] occurrence of any of the following major cardiovascular events (MCVE): death due to CHD, non-fatal myocardial infarction, resuscitated cardiac arrest, and fatal and non-fatal stroke. The mean LDL-C, TC, TG, non-HDL, and HDL cholesterol levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 mg of atorvastatin calcium tablets and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of atorvastatin calcium tablets.
Treatment with atorvastatin calcium tablets 80 mg/day significantly reduced the rate of MCVE (434 events in the 80
 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69,1c
Page 297 of 356Page 299 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] 0.89), p=0.0002 (see Figure 3 and Table 5 ). The overall risk reduction was consistent regardless of age (<65, â‰¥65) or
 gender.
Figure 3: Effect of Atorvastatin 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular
 Events (TNT)
TABLE 5. Overview of Efficacy Results in TNT
EndpointAtorvastatin
10 mg
(N=5006)Atorvastatin
80 mg
(N=4995)HR  (95%CI)
PRIMARY ENDPOINT n (%) n (%)
First major cardiovascular endpoint 548 (10.9) 434 (8.7) 0.78 (0.69, 0.89)
Components of the Primary Endpoint
  CHD death 127 (2.5) 101 (2.0) 0.80 (0.61, 1.03)
  Non-fatal, non-procedure related MI 308 (6.2) 243 (4.9) 0.78 (0.66, 0.93)
  
Resuscitated cardiac arrest 26 (0.5) 25 (0.5) 0.96 (0.56, 1.67)
  
Stroke (fatal and non-fatal) 155 (3.1) 117 (2.3) 0.75 (0.59, 0.96)
SECONDARY ENDPOINTSFirst CHF with hospi[INVESTIGATOR_059] 164
(3.3) 122 (2.4) 0.74 (0.59, 0.94)
First PVD endpoint 282 (5.6)
275 (5.5) 0.97 (0.83, 1.15)
First CABG or other coronary revascularization
 procedure904 (18.1) 667 (13.4) 0.72 (0.65, 0.80)
First documented angina endpoint 615 (12.3) 545 (10.9) 0.88 (0.79, 0.99)
All-cause mortality 282 (5.6) 284 (5.7) 1.01 (0.85, 1.19)
Components of All-Cause Mortality
  Cardiovascular death 155 (3.1) 126 (2.5) 0.81 (0.64, 1.03)
  Noncardiovascular death 127 (2.5) 158 (3.2) 1.25 (0.99, 1.57)
    
Cancer death 75 (1.5) 85 (1.7) 1.13 (0.83, 1.55)
    
Other non-CV death 43 (0.9) 58 (1.2) 1.35 (0.91, 2.00)
    
Suicide, homicide, and other traumatic non-CV*
â€ 
â€¡
â€¡
Page 298 of 356Page 300 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=myocardial infarction;
 CHF=congestive heart failure; CV=cardiovascular; PVD=peripheral vascular disease; CABG=coronary artery by[CONTACT_576345]
*
â€ â€¡ death9 (0.2) 15 (0.3) 1.67 (0.73, 3.82)
Of the events that comprised the primary efficacy endpoint, treatment with atorvastatin calcium tablets 80 mg/day
 significantly reduced the rate of non-fatal, non-procedure related MI and fatal and non-fatal stroke, but not CHD death or resuscitated cardiac arrest (Table 5). Of the predefined secondary endpoints, treatment with atorvastatin calcium tablets 80 mg/day significantly reduced the rate of coronary revascularization, angina, and hospi[INVESTIGATOR_19934], but not peripheral vascular disease. The reduction in the rate of CHF with hospi[INVESTIGATOR_245059] 8% of patients with a prior history of CHF.
There was no significant difference between the treatment groups for all-cause mortality (Table 5). The proportions of
 subjects who experienced cardiovascular death, including the components of CHD death and fatal stroke, were numerically smaller in the atorvastatin calcium tablets 80 mg group than in the atorvastatin calcium tablets 10 mg treatment group. The proportions of subjects who experienced noncardiovascular death were numerically larger in the atorvastatin calcium tablets 80 mg group than in the atorvastatin calcium tablets 10 mg treatment group.
In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with
 atorvastatin calcium tablets 80 mg/day was compared to treatment with simvastatin 20â€“40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean LDL-C, TC, TG, HDL, and non-HDL cholesterol levels at Week 12 were 78, 145, 115, 45, and 100 mg/dL during treatment with 80 mg of atorvastatin calcium tablets and 105, 179, 142, 47, and 132 mg/dL during treatment with 20â€“[ADDRESS_755877] major
 coronary event (fatal CHD, non-fatal MI, and resuscitated cardiac arrest): 411 (9.3%) in the atorvastatin calcium tablets 80 mg/day group vs. 463 (10.4%) in the simvastatin 20â€“40 mg/day group, HR 0.89, 95% CI ( 0.78, 1.01), p=0.07.
There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the
 atorvastatin calcium tablets 80 mg/day group vs. 374 (8.4%) in the simvastatin 20â€“40 mg/day group. The proportions of subjects who experienced CV or non-CV death were similar for the atorvastatin calcium tablets 80 mg group and the simvastatin 20â€“40 mg group.
14.2 Hyperlipi[INVESTIGATOR_035] (Heterozygous Familial and Nonfamilial) and Mixed Dyslipi[INVESTIGATOR_035] ( Fredrickson Types IIa
 and IIb)
Atorvastatin reduces total-C, LDL-C, VLDL-C, apo B, and TG, and increases HDL-C in patients with hyperlipi[INVESTIGATOR_575748]. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.
Atorvastatin calcium tablets are effective in a wide variety of patient populations with hyperlipi[INVESTIGATOR_035], with and
 without hypertriglyceridemia, in men and women, and in the elderly.
In two multicenter, placebo-controlled, dose-response studies in patients with hyperlipi[INVESTIGATOR_035], atorvastatin calcium
 tablets given as a single dose over 6 weeks, significantly reduced total-C, LDL-C, apo B, and TG. (Pooled results are provided in Table 6.)Atorvastatin 80 mg: atorvastatin 10 mg
Secondary endpoints not included in primary endpointComponent of other secondary endpoints
Page 299 of 356Page 301 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]TABLE 6. Dose Response in Patients With Primary Hyperlipi[INVESTIGATOR_035] (Adjusted
 Mean % Change From Baseline)
Dose N TC LDL-C Apo B TG HDL-CNon-HDL-
C/ HDL-C
*Placebo 21 4 4 3 10 -3 7
10 22 -29 -39 -32 -19 6 -34
20 20 -33 -43 -35 -26 9 -41
40 21 -37 -50 -42 -29 6 -45
80 23 -45 -60 -50 -37 5 -53
In patients with Fredrickson Types IIa and IIb hyperlipoproteinemia pooled from 24 controlled trials, the median
 (25  and 75  percentile) percent changes from baseline in HDL-C for atorvastatin calcium tablets 10, 20, 40, and 80
 mg were 6.4 (-1.4, 14), 8.7 (0, 17), 7.8 (0, 16), and 5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.
In three multicenter, double-blind studies in patients with hyperlipi[INVESTIGATOR_035], atorvastatin was compared to other statins.
 After randomization, patients were treated for 16 weeks with either atorvastatin calcium tablets 10 mg per day or a fixed dose of the comparative agent (Table 7).
TABLE 7. Mean Percentage Change From Baseline at Endpoint (Double-Blind, Randomized, Active-
Controlled Trials)
Treatment
(Daily Dose) N Total-C LDL-C Apo B TG HDL-CNon-HDL-
C/ HDL-C
*
â€ 
â€¡
Â§Study 1
Atorvastatin 10
 mg707 -27 -36 -28 -17 +7 -37
Lovastatin 20 mg 191 -19 -27 -20 -6 +7 -28
95% CI for Diff -9.2, -6.5 -10.7, -7.1 -10.0, -6.5 -15.2, -7.1 -1.7, 2.0 -11.1, -7.1
Study 2
Atorvastatin 10
 mg222 -25 -35 -27 -17 +6 -36
Pravastatin 20 mg 77 -17 -23 -17 -9 +8 -28
95% CI for Diff -10.8, -6.1 -14.5, -8.2 -13.4, -7.4 -14.1, -0.7 -4.9, 1.6 -11.5, -4.1
Study 3
Atorvastatin 10
 mg132 -29 -37 -34 -23 +7 -39
Simvastatin 10 mg 45 -24 -30 -30 -15 +7 -33
95% CI for Diff -8.7, -2.[ADDRESS_755878] on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 7 is*
Results are pooled from 2 dose-response studies.
th th
Significantly different from lovastatin, ANCOVA, p â‰¤0.05
A negative value for the 95% CI for the difference between treatments favors atorvastatin for all except HDL-C, for which a
 positive value favors atorvastatin. If the range does not include 0, this indicates a statistically significant difference.
Significantly different from pravastatin, ANCOVA, p â‰¤0.05
Significantly different from simvastatin, ANCOVA, p â‰¤0.05* * * * *
â€ 
â€¡ â€¡ â€¡ â€¡ â€¡
â€ 
Â§ Â§ Â§ Â§ Â§
â€ 
Page 300 of 356Page 302 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM] not known. Table 7 does not contain data comparing the effects of atorvastatin 10 mg and higher doses of lovastatin,
 pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily
 interchangeable.
14.3 Hypertriglyceridemia ( Fredrickson Type IV)
The response to atorvastatin in 64 patients with isolated hypertriglyceridemia treated across several clinical trials is
 shown in the table below (Table 8). For the atorvastatin calcium tablets-treated patients, median (min, max) baseline TG level was 565 (267â€“1502).
TABLE 8. Combined Patients With Isolated Elevated TG: Median (min, max) Percentage Change From
 Baseline
Placebo
(N=12)atorvastatin 10 mg
(N=37)atorvastatin 20 mg
(N=13)atorvastatin 80 mg
(N=14)
Triglycerides -12.4 (-36.6, 82.7) -41.0 (-76.2, 49.4) -38.7 (-62.7, 29.5) -51.8 (-82.8, 41.3)
Total-C -2.3 (-15.5, 24.4) -28.2 (-44.9, -6.8) -34.9 (-49.6, -15.2) -44.4 (-63.5, -3.8)
LDL-C 3.6 (-31.3, 31.6) -26.5 (-57.7, 9.8) -30.4 (-53.9, 0.3) -40.5 (-60.6, -13.8)
HDL-C 3.8 (-18.6, 13.4) 13.8 (-9.7, 61.5) 11.0 (-3.2, 25.2) 7.5 (-10.8, 37.2)
VLDL-C -1.0 (-31.9, 53.2) -48.8 (-85.8, 57.3) -44.6 (-62.2, -10.8) -62.0 (-88.2, 37.6)
non-HDL-C -2.8 (-17.6, 30.0) -33.0 (-52.1, -13.3) -42.7 (-53.7, -17.4) -51.5 (-72.9, -4.3)
14.4 Dysbetalipoproteinemia (Fredrickson Type III)
The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with
 dysbetalipoproteinemia (Fredrickson Type III) are shown in the table below (Table 9).
TABLE 9. Open-Label Crossover Study of 16 Patients With
 Dysbetalipoproteinemia (Fredrickson Type III)
Median % Change (min, max)
Median (min, max) at
 Baseline (mg/dL)atorvastatin 10
 mgatorvastatin 80
 mg
Total-C 442 (225, 1320) -37 (-85, 17) -58 (-90, -31)
Triglycerides 678 (273, 5990) -39 (-92, -8) -53 (-95, -30)
IDL-C + VLDL-C 215 (111, 613) -32 (-76, 9) -63 (-90, -8)
non-HDL-C 411 (218, 1272) -43 (-87, -19) -64 (-92, -36)
14.5 Homozygous Familial Hypercholesterolemia
In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum
 daily doses of 20 to 80 mg of atorvastatin calcium tablets. The mean LDL-C reduction in this study was 18%. Twenty-five patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients also had a portacaval shunt and had no significant reduction in LDL-C. The remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%.
Page 301 of 356Page 303 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]14.6 Heterozygous Familial Hypercholesterolemia in Pediatric Patients
In a double-blind, placebo-controlled study followed by [CONTACT_3440]-label phase, 187 boys and postmenarchal girls 10â€“17
 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolemia (FH) or severe hypercholesterolemia, were randomized to atorvastatin calcium tablets (n=140) or placebo (n=47) for 26 weeks and then all received atorvastatin calcium tablets for 26 weeks. Inclusion in the study required 1) a baseline LDL-C level â‰¥ 190 mg/dL or 2) a baseline LDL-C level â‰¥ 160 mg/dL and positive family history of FH or documented premature
 cardiovascular disease in a first or second-degree relative. The mean baseline LDL-C value was 218.6 mg/dL (range: 138.5â€“385.0 mg/dL) in the atorvastatin calcium tablets group compared to 230.0 mg/dL (range: 160.0â€“324.5 mg/dL) in the placebo group. The dosage of atorvastatin calcium tablets (once daily) was [ADDRESS_755879] 4 weeks and uptitrated to 20 mg if the LDL-C level was > 130 mg/dL. The number of atorvastatin calcium tablets-treated patients who required uptitration to 20 mg after Week 4 during the double-blind phase was 78 (55.7%).
Atorvastatin significantly decreased plasma levels of total-C, LDL-C, triglycerides, and apolipoprotein B during the
 26-week double-blind phase (see  Table 10 ).
TABLE 10. Lipid-altering Effects of Atorvastatin in Adolescent Boys and Girls
 with Heterozygous Familial Hypercholesterolemia or Severe
 Hypercholesterolemia (Mean Percentage Change From Baseline at Endpoint in
 Intention-to-Treat Population)
DOSAGE N Total-C LDL-C HDL-C TGApolipoprotein
 B
Placebo 47 -1.5 -0.4 -1.9 1.0 0.7
Atorvastatin 140 -31.4 -39.6 2.8 -12.0 -34.0
The mean achieved LDL-C value was 130.7 mg/dL (range: 70.0â€“242.0 mg/dL) in the atorvastatin group compared to 228.5 mg/dL (range: 152.0â€“385.0 mg/dL) in the placebo group during the 26-week double-blind phase.
The safety and efficacy of doses above [ADDRESS_755880] not been studied in controlled trials in children. The long-term
 efficacy of atorvastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.
15 REFERENCES
National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol
 Levels in Children and Adolescents, Pediatrics.  89(3):495â€“501. 1992.
16 HOW SUPPLIED/STORAGE AND HANDLING
10 mg tablets: coded "PD 155" on one side and "10" on the other.
NDC [ZIP_CODE]-1 bottles of 90NDC [ZIP_CODE]-2 bottles of 1000
20 mg tablets: coded "PD 156" on one side and "20" on the other.
NDC [ZIP_CODE]-1 bottles of 90NDC [ZIP_CODE]-2 bottles of 1000
40 mg tablets: coded "PD 157" on one side and "40" on the other.
NDC [ZIP_CODE]-1 bottles of 901
Page 302 of 356Page 304 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]NDC [ZIP_CODE]-2 bottles of 500
80 mg tablets: coded "PD 158" on one side and "80" on the other.
NDC [ZIP_CODE]-1 bottles of 90NDC [ZIP_CODE]-2 bottles of 500
Storage
Store at controlled room temperature 20 â€“ 25Â°C (68 â€“ 77Â°F) [see USP].
17 PATIENT COUNSELING INFORMATION
Patients taking atorvastatin calcium tablets should be advised that cholesterol is a chronic condition and they should
 adhere to their medication along with their National Cholesterol Education Program (NCEP)-recommended diet, a regular exercise program as appropriate, and periodic testing of a fasting lipid panel to determine goal attainment.
Patients should be advised about substances they should not take concomitantly with atorvastatin [see
 Warnings and Precautions (5.1) ]. Patients should also be advised to inform other healthcare professionals
 prescribing a new medication that they are taking atorvastatin calcium tablets.
17.[ADDRESS_755881] after discontinuing atorvastatin calcium tablets. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities (>1 liter) of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional.
17.[ADDRESS_755882]-feeding, should be advised to discuss the options with their healthcare professional.
Page 303 of 356Page 305 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]
LAB-0644-3.[ADDRESS_755883].What Are Atorvastatin Calcium Tablets?Atorvastatin calcium is a prescription medicine that lowers cholesterol in your blood. It lowers the LDL-C ("bad"
 cholesterol) and triglycerides in your blood. It can raise your HDL-C ("good" cholesterol) as well. Atorvastatin calcium tablets are for adults and children over [ADDRESS_755884] heart disease or risk factors for heart disease such as:
age, smoking, high blood pressure, low HDL-C, heart disease in the family.
Atorvastatin calcium tablets can lower the risk for heart attack or stroke in patients with diabetes and risk factors such as:
eye problems, kidney problems, smoking, or high blood pressure.
Atorvastatin calcium tablets start to work in about 2 weeks.
What is Cholesterol?Cholesterol and triglycerides are fats that are made in your body. They are also found in foods. You need some
 cholesterol for good health, but too much is not good for you. Cholesterol and triglycerides can clog your blood vessels. It is especially important to lower your cholesterol if you have heart disease, smoke, have diabetes or high blood pressure, are older, or if heart disease starts early in your family.
Who Should Not Take Atorvastatin Calcium Tablets?Do not take atorvastatin calcium tablets if you:
are pregnant or think you may be pregnant, or are planning to become pregnant. Atorvastatin calcium tablets may
 harm your unborn baby. If you get pregnant, stop taking atorvastatin calcium tablets and call your doctor right away.
are breast feeding . Atorvastatin calcium tablets can pass into your breast milk and may harm your baby.
have liver problems.
are allergic to atorvastatin calcium tablets or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in atorvastatin calcium tablets.
Atorvastatin calcium tablets have not been studied in children under 10 years of age.
Before You Start Atorvastatin Calcium TabletsTell your doctor if you:
have muscle aches or weakness
Page 304 of 356Page 306 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]drink more than [ADDRESS_755885] causing serious side effects. Especially tell your doctor if you take medicines for:
your immune system
cholesterol
infections
birth control
heart failure
HIV or AIDS
Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.
How Should I Take Atorvastatin Calcium Tablets?
Take atorvastatin calcium tablets exactly as prescribed by [CONTACT_4904]. Do not change your dose or stop
 atorvastatin calcium tablets without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with atorvastatin calcium tablets. Your dose of atorvastatin calcium tablets may be changed based on these blood test results.
Take atorvastatin calcium tablets each day at any time of day at about the same time each day. Atorvastatin calcium tablets can be taken with or without food.
Don't break atorvastatin calcium tablets before taking.
Your doctor should start you on a low-fat diet before giving you atorvastatin calcium tablets. Stay on this low-fat
 diet when you take atorvastatin calcium tablets.
If you miss a dose of atorvastatin calcium tablets, take it as soon as you remember. Do not take atorvastatin calcium tablets if it has been more than [ADDRESS_755886] emergency room.
What Should I Avoid While Taking Atorvastatin Calcium Tablets?
Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. Atorvastatin calcium tablets and certain other medicines can interact causing serious side effects.
Do not get pregnant. If you get pregnant, stop taking atorvastatin calcium tablets right away and call your doctor.
What are the Possible Side Effects of Atorvastatin Calcium Tablets?
Atorvastatin calcium tablets can cause serious side effects. These side effects have happened only to a small
 number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or atorvastatin calcium tablets are stopped.
These serious side effects include:
Muscle problems. Atorvastatin calcium tablets can cause serious muscle problems that can lead to kidney
 problems, including kidney failure. You have a higher chance for muscle problems if you are taking certain other medicines with atorvastatin calcium tablets.
Liver problems. Your doctor should do blood tests to check your liver before you start taking atorvastatin calcium tablets, and if you have symptoms of liver problems while you take atorvastatin calcium tablets. Call your doctor right away if you have the following symptoms of liver problems:
feel tired or weak
loss of appetite
Page 305 of 356Page 307 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]upper belly pain
dark amber colored urine
yellowing of your skin or the whites of your eyes
Call your doctor right away if you have:
muscle problems like weakness, tenderness, or pain that happen without a good reason, especially if you also have
 a fever or feel more tired than usual. This may be an early sign of a rare muscle problem.
muscle problems that do not go away even after your doctor has advised you to stop taking atorvastatin calcium tablets. Your doctor may do further tests to diagnose the cause of your muscle problems.
allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away.
nausea and vomiting.
passing brown or dark-colored urine.
you feel more tired than usual
your skin and whites of your eyes get yellow.
stomach pain.
allergic skin reactions.
In clinical studies, patients reported the following common side effects while taking atorvastatin calcium tablets: diarrhea, upset stomach, muscle and joint pain, and alterations in some laboratory blood tests.
The following additional side effects have been reported with atorvastatin calcium tablets: tiredness, tendon
 problems, memory loss, and confusion.
Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.These are not all the side effects of atorvastatin calcium tablets. Ask your doctor or pharmacist for a complete list.How do I store Atorvastatin Calcium Tablets?
Store atorvastatin calcium tablets at room temperature, 68 to 77Â°F (20 to 25Â°C).
Do not keep medicine that is out of date or that you no longer need.
Keep atorvastatin calcium tablets and all medicines out of the reach of children. Be sure that if you throw
 medicine away, it is out of the reach of children.
General Information about Atorvastatin Calcium TabletsMedicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use
 atorvastatin calcium tablets for a condition for which it was not prescribed. Do not give atorvastatin calcium tablets to other people, even if they have the same problem you have. It may harm them.
This leaflet summarizes the most important information about atorvastatin calcium tablets. If you would like more
 information, talk with your doctor. You can ask your doctor or pharmacist for information about atorvastatin calcium tablets that is written for health professionals.
What are the Ingredients in Atorvastatin Calcium Tablets?Active Ingredient: atorvastatin calciumInactive Ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl
 cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.
Page 306 of 356Page 308 of 364
http://labeling.greenstonellc.com/ShowLabeling.aspx?id=983[10/8/2015 12:57:02 PM]Greenstone LLCLAB-0645-1.0 November 2012
 Revised: 3/2015
Page 307 of 356Page 309 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755887].  
Protocol 747-209 Version  2 (dated 22 October 2015) incorporates suggestions made by [CONTACT_576346] 747-303 protocol 
that are also relevant to this study.   
Rationale 
Protocol 747-209 Version 2 has been prepared  to: 
1. Clarify stoppi[INVESTIGATOR_575749] a CTCAE of â‰¥Grade 3, per FDAâ€™s comments on the 747-303 protocol. 
2. Clarify that subjects discontinued due to significant drug-induced liver injury will be followed until the AE has resolved, 
stabilized, or is not of clinical concern.  
3. Clarify atorvastatin safety profile . 
4. Include a description for the cardiovascular events adjudication committee, and add  Appendix D to define major 
cardiovascular events.  
In addition, Protocol 747-209 Version 2 also: 
1. Clarifies contraception requirements . 
2. Adds additional exploratory object ives:  markers of cardiovascular safety  
3. Clarifies exclusion criteria related to chronic liver diseases at Screening . 
4. Removes the requirement that a study site must have prior experience treating patients with NASH to participate in this study. 
5. Clarifies PD assessments; markers of inflamma tion, fibrosis, and apoptosis; and PK assessments in the Schedule of Study 
Procedures tables, and in the text. 
6. Clarifies timepoints for PK blood sample collection.  
7. Corrects the title of Appendix A to reflect  ACA/AHA guidance for the use of statins. 
Page 310 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 311 
 
Confidential and Proprietary  Summary  of Changes 
The following revisions were made to the protocol in Protocol Version 2.  
Note:  (1) Revised text in Version  2 is indicated in bold font, and the text deleted from the Original protocol  is crossed out in the 
table below.  (2) Minor/editorial changes , including additional abbreviations defined are not listed individually in the summary 
table below.   
Section Original Text (Original protocol)  Revised Text (Version  2) 
Global changes 
(throughout 
document)  CK-18-M65 added in addition to CK-18-M30 assessment as a 
marker for hepatic apoptosis and fibrosis under Exploratory 
Endpoints 
  Data and Safety Monitoring Committee (DSMC) changed to Data Monitoring Committee (DMC) 
Study Personnel Contact 
[CONTACT_7171] 
(Cover Page)  Emergency Contact [CONTACT_388863] â€“ 24-hour Emergency Reporting Medical Monitor  
Investigators are encouraged to call the NASH medical 
monitor hotline at [PHONE_11940]  250 6396 or send an email to the 
NASH medical monitor at 
[EMAIL_10980] with safety questions as 
these lines of contact [CONTACT_575759] [ADDRESS_755888]: Roya Hooshmand-Rad, MD PhD,  
Executive Director, Clinical Research  
Intercept Pharmaceuticals, Inc. 
(Intercept)  
Telephone: +[PHONE_11933]  
Email: rhooshmand-
[EMAIL_382] 
SAE Fax:  + [PHONE_352] 
SAE Email:  [EMAIL_380]  
 Primary Medical Monitor 
Contact: [CONTACT_576347]-Rad, MD PhD 
Executive Director, Clinical Research  
Intercept Pharmaceuticals, Inc. (Intercept  
Email: [EMAIL_10981] 
  
 
 Or if Not Available:   
 
Page 311 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 312 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
Contact: [CONTACT_575761], MD,  
Medical Director, Drug Safety  
Intercept 
Telephone: +[PHONE_11933]  
Email: [EMAIL_379]  
 Secondary Contact: [CONTACT_575761], MD,  
Medical Director, Drug Safety  
Intercept 
Telephone:  +[PHONE_11930] (Pacific time 
zone) 
Email: [EMAIL_10982]
m 
 
Synopsis 
(Exploratory 
Objectives)  Liver 
biochemistry and 
markers of liver 
function Albumin, ALP, ALT, AST, , direct bilirubin, GGT, INR,  total 
bilirubin  
 Liver biochemistry 
and markers of liver function  Albumin, ALP (isoenzymes) , ALT, 
AST, , direct bilirubin, GGT, INR,  total bilirubin  
 
NOTE: ALP (isoenzyme)  was also added to the list of 
laboratory assessments in Section 11.1 (Table 4) and 
Section 12.2.6 (Table 9).  
Synopsis (Exploratory Objectives)  
And  
Section 6.3 
(Exploratory 
Objectives)   Cardiovascular risk scores (eg, Framingham Risk Score [FRS] and Reyn olds score)  
Synopsis (Methodology) 
And 
Section 7.1 Overall Study 
Design 
(Double-Blind 
Phase)  Subjects who discontinue investigational product or atorvastatin during the double -blind phase are still 
expected to attend scheduled study visits and are to be 
followed through the Week 16 Visit.  
Subjects who discontinue atorvastatin during the double -
blind phase are eligible to continue OCA during the 
double-blind phase and enroll into the LTSE at the 
discretion of the Investigator, provided they continue to 
meet exclusion criteria #4 (LDL <200 mg/dL).    
Page 312 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 313 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
Synopsis 
(Study Design 
Diagram)  
And 
Section 7.1.1 
Study Design, 
Figure 1  Footnote Added: 
Î” = Telephone safety contact [CONTACT_314811] 6, Week 10, and 
Week 14 
Synopsis 
(Key Inclusion 
Criteria) 
And 
Section 8.[ADDRESS_755889] Inclusion 
Criteria 6.  Contraception:  Female subjects of childbearing potential must use â‰¥[ADDRESS_755890] o r at study termination (whichever is greater).  
Effective methods of contraception are considered to be those listed as follows:  
â€¢Double-barrier method, ie, (a) condom (male or female) 
or (b) diaphragm, with spermicide ; or 
â€¢Intrauterine device ; or 
â€¢Vasectomy (partner); or 
â€¢Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular implant or injection) ; or 
â€¢Abstinence, if in line with the preferred and usual lifestyle 
of the subject   6.  Contraception:  Female subjects of childbearing potential must use â‰¥[ADDRESS_755891].  Effective methods of contraception are considered to be those listed below. 
â€¢Double-barrier method, ie, (a) condom (male or female) or 
(b) diaphragm, with spermicide 
â€¢Intrauterine device â€¢Vasectomy (partner)  
â€¢Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular 
implant or injection)  
â€¢Abstinence (defined as refraining from heterosexual 
intercourse)  
Synopsis 
(Key Exclusion 
Criteria) 3.LDL cholesterol >190 mg/dL and already on statin 
therapy at Screening Visit 1.  3.LDL cholesterol â‰¥190 mg/dL and already on statin therapy 
at Screening Visit 1.  
And 
Section 8.[ADDRESS_755892] Exclusion 
Criteria 10.  Evidence of other forms of chronic liver disease including but not limited to:  
â€¢Concomitant hepatitis B or C virus infection      
â€¢ 10.  Evidence of other forms of chronic liver disease including but not limited to:  
â€¢Positive test result at Screeni ng for hepatitis B surface 
antigen or hepatitis C antibody (and positive hepatitis C virus [HCV] ribonucleic acid [RNA]) 
Page 313 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 314 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
 11.  Presence of clinically significant hepatic 
decompensation, including:  
â€¢History of liver transplant, current placement on a liver 
transplant list, or current Model for End- Stage Liver 
Disease (MELD) score >12.  Subjects who are placed on a 
transplant list despi[INVESTIGATOR_040] a relatively early disease stage (eg, 
per regional guidelines) may be eligible as long as they do 
not meet any of the other exclusion criteria.  
â€¢History (within the past 12 months) or presence of: 
oVariceal bleed  
oUncontrolled ascites  
oHepatic encephalopathy  
oSpontaneous bacterial peritonitis 
oHepatorenal or hepatopulmonary syndromes 11.  History of liver transplant, current placement on a liver 
transplant list, or current Model for End- Stage Liver Disease 
(MELD) score >12.  Subjects who are placed on a transplant list despi[INVESTIGATOR_040] a relatively early disease stage (eg, per regional 
guidelines) may be eligible as long as they do not meet any of 
the other exclusion criteria.  
 
  12.  Presence of hepatic decompensation, including:  
- Gastroesophageal varices 
- Ascites 
- Hepatic encephalopathy 
- Spontaneous bacterial peritonitis 
- Hepatorenal or hepatopulmonary syndromes 
 14.  Creatine phosphokinase >5x ULN at any Screening 
visit. 14.  Creatine phosphokinase >5x ULN at Screening Visit 2 . 
 19a.  Coronary revascularization (percutaneous coronary 
intervention or coronary artery by[CONTACT_15806]) 19a.  Peripheral or Coronary revascularization (percutaneous 
coronary intervention or coronary artery by[CONTACT_15806])  
  Note:  Exclusion criteria numbered 12 through 27 in the Original Protocol updated to numbers 13 through 28 in Version 2 as a result of new exclusion criteria number 12 
above. 
Page 314 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 315 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
Synopsis 
(Statistical 
Methods) Secondary Endpoints 
Safety and 
tolerability  TEAEs, physical exams, ECGs, vital signs, clinical laboratory assessments (including lipid profile 
changes)  
 Secondary Endpoints 
Safety and 
tolerability  TEAEs (including cardiovascular 
events), physical exams, ECGs, vital 
signs, clinical laboratory assessments 
(including lipid profile changes)  
 
Synopsis 
(Statistical Methods) 
And 
Section 11.1 
Efficacy 
Assessments  
(Table 4) Exploratory Endpoints 
Liver biochemistry 
and markers of 
liver function  Albumin, ALP, ALT, AST, 
creatinine,  GGT, total bilirubin, 
conjugated ( direct) bilirubin, INR 
Marker for hepatic 
apoptosis and fibrosis CK-18-M30 
 Exploratory Endpoints 
Liver biochemistry 
and markers of liver 
function Albumin, ALP, ALT, AST, direct 
bilirubin, GGT, INR, total bilirubin  
Marker for hepatic 
apoptosis and fibrosis CK-18-M30 and CK -18-M65 
Cardiovascular risk scores  FRS and Reynolds scores  
 
Synopsis 
(Sample Size 
Justification)  
And 
Section 13.2 Determination of 
Sample Size  It is the intent of this study to characterize the components of LDL metabolism (cholesterol concentration, particle 
size, particle concentration) in subjects with NASH before and after treatment with OCA and t o assess the changes 
induced by [CONTACT_575768] A reductase inhibitor (atorvastatin) therapy.  Assuming a 22 U/L  increase from 
baseline with a standard deviation of 20  in LDL in the 
OCA 25 mg group, a sample size of 20 subjects per group will provide greater than 99.9% power to demonstrate the 
statistically significant difference of LDL increase from baseline with a 2 -sided type I error of 0.05 It is the intent of this study to characterize the components of 
LDL metabolism (cholesterol concentration, particle size, 
particle concentration) in subjects with NASH before and 
after treatment with OCA and to assess the changes induced by [CONTACT_575768] A reductase inhibitor (atorvastatin) 
therapy.  Assuming, 22 mg/dL  increase from baseline with a 
standard deviation of  24 in LDL in the OCA  25 mg group 
without atorvastatin therapy after 16 weeks of treatment 
based on data from FLINT, a sample size of 20  subjects per 
group will provide greater than 97.3 % power to demonstrate 
the statistically significant difference of LDL increase from 
baseline with a 2 -sided type  I error of 0.05.  
Section [IP_ADDRESS] 
Rationale for At risk subjects include subjects with existing cardiovascular disease (including but not limited to stable 
or unstable angina, previous myocardial infarction or At risk subjects include subjects with existing cardiovascular disease (including but not limited to stable or unstable angina, 
previous myoc ardial infarction or stroke or a previous 
Page 315 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 316 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
statin withdrawal  
(Paragraph 5)  stroke or a previous coronary revascularization procedure), 
significant dyslipi[INVESTIGATOR_035] (as defin ed by [CONTACT_31620] >190 mg/dL) 
despi[INVESTIGATOR_575554], unstable hypertension, 
and familial hypercholesterolemia.  peripheral or coronary revascularization procedure), 
significant dyslipi[INVESTIGATOR_035] (as defined by [CONTACT_31620] â‰¥190 mg/dL) 
despi[INVESTIGATOR_575554], unstable hypertension, and familial hypercholesterolemia  
Section 5.8. Summary of 
Known Potential 
Risks with Atorvastatin  (Section 5.8 added to Version 2) Muscle complaints are the most frequent adverse reports among patients treated with statins , with the most severe 
side effects including myopathy and rhabdomyolysis.  The  
Statin Muscle Safety Task Force (Rosenson 2014) has provided a classification of the spectrum of statin -
associated muscle AEs that may be seen in clinical 
practice and can be used in characterizing reports of 
muscle-related events.  
a. Myalgia â€“ unexplained muscle discomfort 
often described as â€œflu -likeâ€ symptoms  
âˆ’ Muscle aches  
âˆ’ Muscle soreness  
âˆ’ Muscle stiffness  
âˆ’ Muscle tenderness  
âˆ’ Muscle cramps with or shortly after exercise (not nocturnal crampi[INVESTIGATOR_007])  
b. Myopathy â€“ muscle weakness (not attributed 
to pain and not necessarily associated with 
elevated CPK)  
c. Myositis â€“ muscle inflammation  
d. Myonecrosis â€“ muscle enzyme elevations or 
hyperCPKemia  
âˆ’ Mild >3x baseline or ULN  
âˆ’ Moderate â‰¥10x baseline or ULN 
âˆ’ Severe â‰¥50x baseline or ULN 
Page 316 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 317 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
e. Clinical Rhabdomyolysis - Myonecrosis with 
myoglobinuria or acute renal failure (increase 
in serum creatinine â‰¥0.5 mg/dL  
There is no evidence that these muscle- related AEs are a 
continuum beginning with myalgia and progressing to 
more severe manifestations of myopathy; rather events 
occur independen t of each other.  Myalgia events, with 
frequencies ranging from 1 % to 5% in clinical trial s to 
11% to 29% in observational cohorts, typi[INVESTIGATOR_575750] 1 month of statin initiation and resolve within 2 
weeks of statin cessation (Rosenson 2014).  Retrospective 
analyses have suggested that patients who discontinue 
statins due to intolerance are able to tolerate statins long -
term following re -challenge (Zhang 2013, Mampuya 
2013).   
Historically, statins have been associated with biochemical 
abnormali ties of liver function, but available data suggest 
that increases in liver transaminases associated with 
statins are asymptomatic and generally reversible (Desai 
2014).  In the absence of liver disease, US guidelines 
(Stone 2013) recommend that baseline tr ansaminase levels 
should be checked before initiating statin therapy and subsequent testing should only be done in the presence of symptoms suggestive of hepatic disease.  As this study is 
being conducted in subjects with confirmed NASH, liver 
enzymes will  be frequently monitored and Section [IP_ADDRESS], 
Section [IP_ADDRESS], and Appendix B provide detailed guidance for handling elevated liver biochemistry values.  
Statins modestly increase the risk of type 2 diabetes 
mellitus in individuals with risk factors for di abetes.  
Individuals receiving statin therapy should be evaluated 
for new-onset diabetes according to the current diabetes 
screening guidelines (American Diabetes Association 2013). 
Page 317 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 318 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
Confusion and memory loss have been reported with 
statins, but medical evi dence supporting a causal effect is 
weak or nonexistent (Simic 2015).  However, any reports 
of cognitive events should be appropriately evaluated, 
particularly in individuals whose symptoms persist 
despi[INVESTIGATOR_575751].  
In this study, any AEs (including signs and symptoms 
described above) regardless of relationship to investigational p roduct or study medication, must be 
documented appropriately (See Section 12 )  
7.1 
Overall Study 
Design 
(Table 1)  Added Week 6 (Contact), Week 10 (Contact), and Week 14 
(Contact) with associated X in AEs, Prior and Concomitant 
Medications, and Collect bottles/Investigational Product 
Accountability/Compliance; Collect Bottles/Atorvastatin 
Accountability/Compliance (for Week 10 and Week 14). 
  Added procedure â€œHepatitis B Virus and Hepatitis C Virus Testsâ€ at Screening Visit 1.  
  
 Transient Elastography timepoint added:  ET/EOS.  
(Also, added this procedure to Section 9.7.15) 
  The list of assessments replaced with [ADDRESS_755893] subcategories:  
PD Assessments; Markers of Inflammation, F ibrosis, or 
Apoptosis; and Vitamin D.  
   Added footnote l to Serum Chemistry  
 Urine  Based Î²- hCG Pregnancy Testq Pregnancy Testq 
  Added hepatitis B and hepatitis C tests at Screening Visit 1 
 d Heart rate, blood pressure, temperature, and respi[INVESTIGATOR_862] d Sitting heart rate, blood pressure, temperature, and 
respi[INVESTIGATOR_575752] 318 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 319 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
 n Serum samples will be collected for lipoprotein 
analysesâ€¦ n Serum and plasma  samples will be collected for lipoprotein 
analysesâ€¦ 
 q Serum pregnancy test will be administered if urine- based 
Î²-hCG pregnancy test is positive. q Serum pregnancy test will b e administered if urine- based 
Î²-hCG pregnancy test is positive.  Screening pregnancy 
tests will be serum -based tests. 
 r Blood sample for future exploratory analysis, including  
markers of cardiovascular risk (adiponectin, plasminogen 
activator inhibitor -[(PAI-1], and B- type natriuretic peptide 
[BNP]). r Includes  markers of cardiovascular risk (adiponectin, 
plasminogen activator inhibitor -[(PAI-1], and B- type 
natriuretic peptide [BNP]). 
 s At selected investigational sites, subjects will have the 
option to provide blood samples for measurement of OCA PK. s At selected investigational sites, subjects will have the 
option to provide blood samples for measurement of OCA PK.  PK samples will be collected within [ADDRESS_755894] and will remain fasted until the 1 hour sample is 
collected.
 
7.1 
Overall Study Design 
(Table 2) Header row updated as follows 
Month [ADDRESS_755895] subcategories:  
PD Assessments; Markers of Inflammation, Fibrosis, or 
Apoptosis; and Vitamin D.  
  Additional timepoints added as follows: 
AUDIT alcohol measures:  EOS/ET 
(Also, added this procedure to Section 9.7.20.) 
  Timepoints removed as follows:  
Reverse Cholesterol Transport analysis:  Month 3, Month 9, 
Month 15, and Month 21. 
Page 319 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 320 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
 d Heart rate, blood pressure, temperature, and respi[INVESTIGATOR_862]. d Sitting heart rate, blood pressure, temperature, and 
respi[INVESTIGATOR_697].  
  i NOTE:  Any time atorvastatin is up- titrated or re-
initiated, a telephone safety contact [CONTACT_576348], concomitant medications, and atorvastatin 
compliance.  
  All subsequent footnotes have been adjusted by [CONTACT_31806] 
7.4.2 
Atorvastatin Dose 
Adjustments  Added: 
If at any time during the double -blind or LTSE phases, 
serum chemistry results indicate LDLc <40  mg/dL, the 
subject should be brought back to the site within [ADDRESS_755896] result is obtained for an unscheduled 
(repeat) laboratory assessment.  If LDLc <40 mg/dL is 
obtained on [ADDRESS_755897] may 
discontinue or reduce the dose of atorvastatin.  
Subjects may also interrupt or discontinue atorvastatin due to tolerability issues including muscle- related 
symptoms (Section 5.8) and abnormal li ver biochemistry.  
Any muscle -related complaints should be assessed per the 
ACC/AHA Guidelines (Appendix A) and statin dose adjusted accordingly:   
â€¢ To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline prior to initiation 
of statin therapy . 
â€¢ If mild to moderate muscle symptoms develop 
during statin therapy:  
Page 320 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 321 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
o Discontinue the statin until symptoms can 
be evaluated . 
o Evaluate the patient for other conditions 
that might increase the risk for muscle 
symptoms. 
o If muscle symptoms resolve, and if no contraindication exists, re -challenge the 
subject with the same or a reduced dose of 
atorvastatin to establish a causal 
relationship between the muscle symptoms and statin therapy . 
o Once a low dose stat in is tolerated, the 
dose may be gradually increased as tolerated and clinically indicated . 
o If after 2 months without statin treatment, muscle symptoms or elevated CPK levels do not completely resolve, consider other 
causes of muscle symptoms. 
o If persisten t muscle symptoms are 
determined to arise from a condition unrelated to statin therapy, or if the 
predisposing condition has been treated, resume statin therapy at the original dose. 
â€¢ If unexplained severe muscle symptoms or fatigue develop during statin th erapy, discontinue the 
statin and
 address the possibility of 
rhabdomyolysis by [CONTACT_576349] 321 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 322 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
creatinine , and performing urinalysis for 
myoglobinuria. 
Elevations in liver biochemistry should be monitored per 
protocol subject withdrawal criteria (Sectio n 8.4 and 
Appendix B).  
Subjects who discontinue atorvastatin may continue on 
investigational product through the double -blind and 
LTSE phases, as deemed appropriate by [CONTACT_24318], and provided they continue to meet 
exclusion crite ria #4 (LDL <200 mg/dL).  
8.[ADDRESS_755898] 
Withdrawal Criteria Subsections were rearranged as follows: 
8.4.[ADDRESS_755899]  
[IP_ADDRESS] Pregnancy  
[IP_ADDRESS]  Severe Drug -Induced Liver Injury 
[IP_ADDRESS]  Clinical Laboratory Values 
 
 
  
 
 
 
  
8.4.[ADDRESS_755900] or Atorvastatin  
[IP_ADDRESS] Adverse Events â‰¥Grade [ADDRESS_755901] 
[IP_ADDRESS]  Pregnancy  
[IP_ADDRESS]  Severe Drug -Induced Liver Injury 
[IP_ADDRESS]  Myonecrosis  
8.4.[ADDRESS_755902]  
[IP_ADDRESS]  Adverse Events â‰¥Grade [ADDRESS_755903]  
[IP_ADDRESS]  Suspected Mild or Moderate Drug- Induced Liver 
Injury 
Page 322 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 323 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
8.4.[ADDRESS_755904] Discontinuation Notification 
[IP_ADDRESS] 
Adverse Events 
â‰¥Grade 3 in 
Severityâ€¦  If a subject experiences an AE that is â‰¥Grade 3 in severity 
(Section 12.1.4) that is considered possibly, probably, or 
definitely related to investigational product, the 
investigational product must be discontinued.  
[IP_ADDRESS] 
Pregnancy  Whenever the site is notified of a possible pregnancy, the 
subject should be asked to come in for an unscheduled 
visit to perform a serum pregnancy test.  If a female subject becomes pregnant, the subject must stop taking 
investigational product immediately and be withdrawn 
from the study.  The subject must be followed by [CONTACT_576350].  The mother (and infant) will be followed as considered appropriate by [CONTACT_512235].  For reporting 
purposes, pregnancy i s not considered an AE. Whenever the site is notified of a possible pregnancy, the subject should be asked to come in for an unscheduled visit to 
perform a serum pregnancy test.  If a female subject becomes pregnant, she must discontinue treatment with  
investigational product and atorvastatin  immediately , but 
should continue with the study visit schedule and must be 
followed by [CONTACT_22108].  
The mother (and infant) will be followed as considered 
appropriate by [CONTACT_82171].  As 
described in Section [IP_ADDRESS], pregnancy is not considered an 
AE for reporting purposes.  
[IP_ADDRESS] 
Severe Drug -
Induced Liver 
Injury 
(Paragraph  2) Subjects should be encouraged to continue study visits 
despi[INVESTIGATOR_575753]. Subjects who discontinue due to significant drug -induced 
liver injury must be followed until the AE has resolved, 
stabilized, or is not of clinical concern.  
[IP_ADDRESS] 
Myonecrosis   Moderate myonecrosis as defined by [CONTACT_575795] â‰¥10x 
the untreated baseline levels or ULN.  Muscle -related 
symptoms that do not necessitate mandatory 
discontinuation of investigational product or atorvastatin 
are detailed in Section 5.8.  
[IP_ADDRESS] 
Adverse Events  If a subject experiences an AE categorized as â‰¥Grade 4 in 
severity and not or unlikely related to investigational 
Page 323 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 324 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
â‰¥Grade [ADDRESS_755905] is required.  
[IP_ADDRESS] 
Suspected Mild 
or Moderate 
Drug-Induced 
Liver Injury Deleted Section [IP_ADDRESS]. (Clinical Laboratory Values) of the Original Protocol, and replaced with Section [IP_ADDRESS] 
(new text shown in the right column) . 
 
Development of the following clinical laborator y values 
during the course of the double-blind and LTSE phases of 
the study mandates investigational product 
discontinuation: 
â€¢An aminotransferase (aspartate aminotransferase [AST] 
or ALT) elevation that is > 3x ULN/baseline/nadir, or 
â€¢Total bilirubin >1 .5 mg/dL (25.7 Î¼mol/L) AND >2x the 
predose value (average of all pretreatment values), or  
â€¢When myopathy is diagnosed or suspected (confirm with 
CPK prior to permanent discontinuation; discontinue if 
CPK >10x ULN)  
Note:  The mean of all Screening and Base line values 
constitute the predose values.  
If a subject is required to discontinue investigational 
product due to an increase in aminotransferase or bilirubin, 
the subject must be followed at appropriate intervals until 
these parameters have returned to within the normal range 
or prestudy values, and/or are stable, or there is no ongoing 
clinical concern.   
 
 
Because transient fluctuations of ALT or AST are 
common, and progression to severe drug- induced liver 
injury or acute liver failure is uncommon, automatic 
discontinuation of investigational product with an 
elevation of ALT or AST that is >3x ULN/baseline/n adir 
or total bilirubin >2x ULN/baseline/nadir, as described in 
Appendix  B, may be unnecessary.  If a subject develops 
signs of a mild or moderate event of drug -induced liver 
injury, regardless of causality, investigational product 
should be interrupted un til the event has resolved or 
returned to baseline, but the subject should continue with 
the study visit schedule.  The subject may restart 
treatment after resolution of the event or return to 
baseline.  Follow -up procedures, including laboratory 
evaluations and physical examinations, must be 
performed after a maximum of [ADDRESS_755906] will be allowed to continue treatment.  
9.2. Concomitant Medications  Relevant information about all concomitant medications (including prescribed, over-the- counter, or herbal 
preparations) taken prior to (ie, within 30 days of Day 1) 
and during the study must be recorded in the source documents and eCRF , as well as any dose or dose regimen 
changes that occur during the study. Relevant information about all concomitant medications (including prescribed, over-the- counter, or herbal 
preparations) taken prior to (ie, within 12 months of Day 1) 
and during the study must be recorded in the source documents and eCRF , as well as any dose or dose regimen 
changes that occur during the study. 
Page 324 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 325 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
9.2.3  
Management of 
Changes i n 
Cholesterol During the double -blind phase of the study, the dose of 
atorvastatin administration should be as described in this protocol through Week 12.  At the Week  12 Visit, 
Investigators may increase or decrease the dose of atorvastatin as clinically indicated.  
 During the double -blind phase of the study, the dose of 
atorvastatin administration should be as described in this protocol through Week 12 unless tolerability issues develop 
as referenced in Section 7.4.2 .  At the Week  12 Visit, 
Investigators may increase or decrease the dose of 
atorvastatin as clinically indicated.  
9.2.4 Prohibited Medications 
And 
Table 3 
 â€¢Prohibited throughout the double-blind phase of the study: 
 â€¢Prohibited throughout the double-blind phase of the study: 
- Medications contraindicated in the atorvastatin 
label, including HIV and Hepatitis C protease 
inhibitors, clarithromycin, and itraconazole (refer 
to atorvastatin prescribing information in Appendix E for complete list).  These medications 
are also prohibit ed during the LTSE phase if the 
subject continues to receive atorvastatin during the LTSE. 
 
Note:  These medications were also added to Table 3.  
9.4.2 
Emergency 
Unblinding 
Procedures The DSMC (refer to Section 13.8) will have access to the 
IWRS and will b e able to unblind individual subjects.  The 
DSMC will be provided aggregate data to review during 
closed sessions.  The DMC (refer to Section 13.8) will have access to the 
IWRS and will be able to unblind individual subjects.  The 
DMC will review aggregate data during closed sessions.  
9.6.[ADDRESS_755907] 8 hours 
prior to Screening Visit 2 (Week -1 Visit) and all 
subsequent study visits, as all analytes will be assayed in 
fasting blood or plasma samples (Table 1 and Table 2).  All subjects must have been fasting for at least 8 hours prior 
to Screening Visit 2 (Week -1 Visit) and all subsequent study 
visits, as all analytes will be assayed in fasting blood , serum, 
or plasma samples (Table 1  and Table 2).  
9.6.2 
Grapefruit and 
Grapefruit Juice  Grapefruit and grapefruit juice consumption should be 
discouraged following initiation of atorvastatin (please 
refer to atorvastatin prescribing information [reference: 
Appendix A]). Grapefruit and grap efruit juice consumption should be 
discouraged following initiation of atorvastatin due to 
possible increases in plasma concentration of atorvastatin  
(please refer to atorvastatin prescribing information 
[Appendix E ]). 
Page 325 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 326 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
9.7.1 
Visit Windows The Week -1 Visit should occur within Â±1 days of the visit 
day. The Week -1 Visit should occur within Â±1 days of the 
Randomization /Day 1 Visit. 
  (A row added to in- text table)  
Week 6, Week 10, and Week 14  
(Contact [CONTACT_41995])  Â±4 days 
 
9.7.3 Screening Visit 1 
Procedures Subjects who are statin free (ie, no statin use within 4 
weeks of Screening) must return for fasted serum 
chemistry labs and may proceed to the Randomization/Day 
1 Visit once screening labs are available and eligibility is confirmed; subjects who need to wash out statin therapy 
are required to have a Week -1 Visit 4 weeks after 
Screening Visit 1.  
 
â€¢Record prior (if within 6 months of Day 1) and current 
concomitant medications.  
 
 
 
  
â€¢Perform a urine -based Î²-hCG pregnancy test for female 
subjects of childbearing potential.  Perform serum 
pregnancy test in females of childbearing potential, if urine 
Î²-hCG pregnancy test is positive. Subjects who are statin free (ie, no statin use within 4 weeks 
of Screening) must return for fasted serum chemistry labs at 
Screening Visit 2 , and may proceed to the 
Randomization/Day 1 Visit once screening labs are available 
and eligibility is confirmed ; subjects who need to wash out 
statin therapy are requir ed to have a Week -1 Visit 4 weeks 
after Screening Visit 1.  
 
â€¢Record prior (if within 12 months  of Day 1) and current 
concomitant medications.  
 
â€¢Obtain serum sample for hepatitis B surface antigen or 
hepatitis C antibody (and positive HCV ribonucleic acid 
[RNA]) testing to confirm study eligibility . 
 
â€¢Perform serum pregnancy test in females of childbearing 
potential. 
9.7.5. 
Randomization/Day 1 Visit 
Procedures â€¢Record prior ( within 30 days of Day 1) and current 
concomitant medications.  â€¢Record prior ( since Screening Visit  1) and current 
concomitant medications.  
9.7.5 Serial blood samples will be obtained for measurement of 
OCA and its conjugates prior to dosing and at 0.5, 0.75, 1, Serial blood samples will be obtained for measurement of 
OCA and its conjugates  30 minutes  prior to dosing and at 
Page 326 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 327 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
Additional Day 1 
Procedures for 
PK Subjects  
And 
[IP_ADDRESS] 
Additional Week 
[ADDRESS_755908] and will remain fasted until the 
4-hour sample is collected.  Lunch will be provided 
following collection of the 4-hour PK sample; the lunch 
will be a meal replacement drink with nutrition 
information that has been submitted to and approved by 
[CONTACT_22134]. 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, and [ADDRESS_755909] and will remain 
fasted until the 1-hour sample is collected.  Meal will be 
provided fol lowing collection of the 1- hour PK sample; the 
lunch will be a meal replacement drink with nutrition 
information that has been submitted to and approved by [CONTACT_576351] . 
9.7.5 
Randomization/D
ay 1 Visit 
Procedures 
And 
Sections 9.7.7, 9.7.9, 9.7.11, 9.7.13, 9.7.15, 
9.7.18, 9.7.19, 
9.7.20 â€“ Plasma bile acids, 7Î±-hydroxy-4- cholesten -3-one (C4), 
and FGF-19; serum IL-6, cytokeratin- 18 neoepi[INVESTIGATOR_9230] M30 
(CK-18-M30), high- sensitivity C -reactive protein (hs -
CRP), TNF -Î±, and Vitamin D; and markers of glucose 
metabolism (C-peptide, insulin, fasting plasma glucose, 
and HbA1c) 
 â€“ PD assessments; markers of inflammation, fibrosis and 
apoptosis; and markers of glucose metabolism (see Table 
4 and Table 9) 
â€“ Vitamin D  
9.7.8 
(Week [ADDRESS_755910]) 
And 
9.7.10 
(Week [ADDRESS_755911]) 
And 
9.7.12 
(Week [ADDRESS_755912]) Note:  The numbering of 9.7 subsections is changed in 
Version 2 compared to that in the Original protocol from 
Section 9.7.9 onwards due to the addition of new 
Subsections 9.7.8, 9.7 10, and 9.7.12. â€¢ This is a telephone contact [CONTACT_575801]  
- Review and record AEs  
- Review and record concomitant medications  
- Assess investigational product and 
atorvastatin compliance  
Page 327 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 328 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
9.7.18 
LTSE Month 3, 
Month 6, Month 
9, Month 15, 
Month 18, and 
Month 21 Visit 
Procedures â€¢Perform a physical examination (only at Month  3 Visit). â€¢Perform a physical examination (only at Month  3 and 
Month 15 Visits). 
(Section 9.7.15 of 
Original 
Protocol) â€¢Determine alcohol consumption (using AUDIT 
questionnaire [only at Month 6 Visit]).  â€¢Determine alcohol consumption (using AUDIT questionnaire 
[only at Month 6 and Month 18 Visits]). 
 â€¢Collect used bottles of atorvastatin, assess atorvastatin 
compliance, and perform atorvastatin accountability. â€¢Collect used bottles of atorvastatin, assess atorvastatin 
compliance, and perform atorvastatin accountability.  
- NOTE:  If atorvastatin dose is up- titrated or re -
initiated after dose interruption, a telephone 
safety contact [CONTACT_575802] [ADDRESS_755913] and atorvastatin compliance.  
 â€¢Obtain blood samples for:  
- Lipoprotein analyses and reverse cholesterol 
transport analytes  â€¢Obtain blood samples for:  
- Lipoprotein analyses  
- Reverse cholesterol transport analytes (only at 
Month 6 and Month 18 Visits)  
9.7.20 LTSE End of Study/Early 
Termination Procedures  â€¢Determine alcohol consumption (using AUDIT 
questionnaire).  
9.7.21 Unscheduled 
Safety Visits  An increase in aminotransferases (ALT or AST) to >3Ã— 
baseline (and >ULN) or total bilirubin >2Ã— baseline (and 
>ULN) should be followed by [CONTACT_94525] 48 to 
72 hours of the serum chemistry to confirm the An increase in aminotransferases (ALT or AST) to >3Ã— 
baseline (and >ULN) or total bilirubin >2Ã— baseline (and 
>ULN) should be followed by [CONTACT_94525] 48 to 72 
hours of the serum chemistry to confirm the abnormalities 
Page 328 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 329 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
abnormalities and to determine if they are increasing or 
decreasing.  and to determine i f they are increasing or decreasing 
(Appendix B) . 
10.5 
Atorvastatin 
Tablets Atorvastatin tablets for oral administration contain 10  mg, 
20 mg, 40 mg, or 80 mg atorvastatin â€¦ Atorvastatin tablets for oral administration contain [ADDRESS_755914] 
may take multiple atorvastatin tablets for a total dose of 
40 mg or 80 mg, as clinically indicated.  
11.1 Efficacy 
Assessments 
(Table 4) (Deleted the following row)  
Bile acid synthesis 
and concentrations  C4 (7Î±-hydroxy-4-cholesten -3-one), 
conjugated and unconjugated bile 
acids (possible)  
  
11.1.[ADDRESS_755915] of planned laboratory assessments supporting primary, secondary, and exploratory objectives of the study is shown in Table 4, and includes parameters related 
to LDL metabolism, lipoprotein metabolism, reverse cholesterol transport, liver biochemistry and markers of liver 
function, markers of inflammation, glycemic control, OCA 
PD markers,  and NASH disease severity markers  CK-18-
M30 and CK -18-M65. 
[IP_ADDRESS] 
Central Reading 
of Liver 
Histology  Kleiner 2012 Kleiner 2005 
11.2 Pharmacokinetic 
and 
Pharmacodynamic 
Assessments   
 
 
  Added the following new subsection: 
 
11.2.1 Pharmacodynamic Assessments  
 
Page 329 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 330 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
 
11.2.1. OCA, Bile Acids, and FGF-19 Original subsection 11.2.1 is now 11.2.2. and is re -named as 
below 
 
11.2.2. Pharmacokinetic Assessments  
11.2.1. 
Pharmacodynami
c Assessments   11.2.1. Pharmacodynamic Assessments  
PD assessments will be collected according to the Schedule of Study Procedures (Table 1 and Table 2) from all 
subjects to measure C4, FGF -19, and possibly conjugated 
and unconjugated bile acids (dependent on the results of the C4 and FGF -19 assessments).  
11.2.2 Pharmacokinetic 
Assessments  
(Paragraph  1) 11.2.1. OCA, Bile Acids, and FGF-19 
Subjects who participate in the PK and/or PD  assessment 
will provide blood samples for the measurement of OCA 
and its conjugates , C4, FGF -19, and possibly bile acids, 
prior to administration of investigational product (predose) on Day [ADDRESS_755916] 
(predose) on Day 1 and at the Week 16 Visit. 
11.2.2 Pharmacokinetic 
Assessments  
(Paragraph  2) Paragraph 2 deleted: 
 
Instructions rega rding the number and type of samples, 
including the PK assessments, to be collected at each visit, 
the required sample volumes, sample collection methods, 
sample processing, labeling, and shippi[INVESTIGATOR_575754] a study- specific laboratory manual.  All necessary 
collection supplies will be provided by [CONTACT_576352].   
[IP_ADDRESS] 
Pregnancy and 
Follow-Up Pregnancies are not considered AEs in and of themselves; 
however, if a female study participant becomes pregnant 
while she is enrolled in the clinical study, she must 
discontinue treatment with investigational product 
immediately (see Section [IP_ADDRESS]) and the Sponsor must be Pregnancies are not considered AEs in and of themselves; however, if a female study participant becomes pregnant 
while she is enrolled in the clinical study, she must 
discontinue treatment with investigational product and 
atorvastatin immediately  (see Section [IP_ADDRESS]) and the 
Page 330 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 331 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
notified within 24 hours of the Inves tigatorâ€™s learning of 
the pregnancy by [CONTACT_576353].  
 
Women who discontinue the study due to pregnancy may 
not re-enroll in the study at any point.  Sponsor must be notified within 24 hours of t he Investigatorâ€™s 
learning of the pregnancy by [CONTACT_576354].  
 
Women who discontinue the study due to pregnancy may not 
re-enroll in the study at any point, but should continue with 
the study visit schedule and must  be followed by [CONTACT_576350] . 
12.2.6 
Laboratory 
Assessments 
(Table 9) Serum 
chemistry  Albumin, BUN, creatinine, conjugated 
(direct) bilirubin, total bilirubin, AST, 
ALT, ALP, GGT, creat inine, electrolytes 
(calcium, chloride,  magnesium, 
phosphorus, potassium, sodium), total 
protein, bicarbonate, free fatty acids; and blood lipi[INVESTIGATOR_805] (total cholesterol, LDL, HDL, and VLDL fractions and TGs)  
 Serum 
chemistry  Albumin, BUN, creatinine, conjugated 
(direct) bilirubin, total bilirubin , AST, 
ALT, ALP, GGT, creatine phosphokinase , electrolytes (calcium, 
chloride, magnesium, phosphorus, potassium, sodium), total protein, bicarbonate, free fatty acids; and blood lipi[INVESTIGATOR_805] (total cholesterol, LDL, HDL, and 
VLDL fractions and TGs)  
 
  Hepatiti
s virus screenin
g tests Hepatitis B surface antigen, 
hepatitis C antibody, and HCV ribonucleic acid 
[RNA] 
 
[IP_ADDRESS] 
Cardiovascular 
Risk Scores  New Section [IP_ADDRESS] Added The cardiovascular risk score includes the FRS and 
Reynolds scores .  Each score is derived from a subjectâ€™s 
age, sex, smoking status, total cholesterol and HDL levels, 
systolic blood pressure, and other factors including family history, BMI, ethnicity, and medications.  Cardiovascular 
scores will be calculated at the time of data analysis.  
These markers will be summarized by [CONTACT_576355] -
study evaluation.  The change and percentage change 
from Baseline will also be summarized.  
Page 331 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 332 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
13.9. 
Adjudication 
Committees   All suspected major adverse cardiovascular events 
(MACE), and drug -related hepatic injury events that 
occur after administration of the first dose of 
investigational product will be reviewed by [CONTACT_576356], depending on event  
type, before inclusion in any analysis.  The 2 committees and event types they are responsible for adjudicating are 
as follows:  
â€¢Cardiovascular Events Committee (CEC):  Adjudicates 
all suspected MACE (Appendix D)  
â€¢Hepatic Safety Committee:  Adjudicates all suspected 
drug-related hepatic injury events  
Each adjudication committee will have a charter that documents the reporting of events by [CONTACT_3452] ; 
definition of the suspected events to be adjudicated ; 
supply of source documentation to the committee ; and the 
entire data flow and process from committee membership, review of the events by [CONTACT_942], reporting of the final assessment, and the working procedures of the 
committee.   
The adjudication committee members will include experts with relevant  adjudication experience; they will not be 
involved in the study as Investigators, DMC members, or 
consultants.  Any candidate found to have a conflict or 
whose name [CONTACT_576377].  Conflicts of interest are assessed 
regularly, and if members are found to have a new 
conflict of interest they will be replaced.  
The adjudication of suspected events will be based on 
available source documentation, including but not limited 
to individual clinical study data, h ospi[INVESTIGATOR_1097], 
histology, discharge summaries, and/or death certificates.  
The adjudication committees will not receive any 
Page 332 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 333 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
individual subject treatment or site -specific information.  
The assessment of events will be conducted in compliance 
with study -specific procedures, manuals, GCP, and all 
other applicable regulatory requirements, including the archiving of essential documents.    
19. List of 
References   American Diabetes Association.  Standards of medical care 
in diabetes -2013. Diabetes Care.  2013;36(Suppl 1):S11-
S66. 
Desai CS, Martin SS, Blumenthal RS.  Non-cardiovascular 
effects associated with statins.  BMJ 2014;349:g3743 
Kleiner D, Brunt E, Van Natta M, et al. Design and 
validation of a h istological scoring system for nonalcoholic 
fatty liver disease. Hepatology 2005;41:1313-1321. 
Mampuya WM, Frid D, Rocco M, et al. Treatment 
strategies in patients with statin intolerance:  the 
Cleveland Clinic experience.   Am Heart J. 2013;166:597-
603. 
Rosenson RS, Baker SK, Jacobson TA et al. An 
assessment by  [CONTACT_576357]: 2014 
update. J Clin Lipid. 2014;8:S58-S71. 
Simic I, Reiner Z. Adverse effects of statins â€“ myths and 
reality. Curr Pharm Des. 2015;21:1220-1226. 
Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of 
statins in routine care settings: a cohort study.  Ann Intern 
Med. 2013;158:526-534.  
 
Page 333 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 334 
 
Confidential and Proprietary  Section Original Text (Original protocol)  Revised Text (Version  2) 
Appendix A APPENDIX A.EUROPEAN AND NICE  GUIDANCE 
FOR THE USE OF STATINS APPENDIX A.   AMERICAN COLLEGE OF 
CARDIOLOGY/AMERICAN HEART ASSOCIATION 
GUIDANCE FOR THE USE OF STATINS  
Appendix B For subjects who progress to cirrhosis and decompensation 
while participating in the study, elevation in liver biochemistry and development of other laboratory and 
clinical abnormalities may be expected.  Clinical outcomes 
should be reported and recorded as described in Section 
12.1.[ADDRESS_755917] use and study participation as 
described in Section 8.4. 
 
In subjects with abnormal ALT/AST or bilirubin at 
baseline, fold increase should be assessed against baseline levels instead of ULN as follows:  3Ã— 
baseline ALT/AST  (and >200 IU/L) , or total bilirubin 
>2Ã— baseline (and >2 mg/dL).  For subjects who progress to cirrhosis and decompensation 
while participating in the study, elevation in liver biochemistry and development of other laboratory and 
clinical abnormalities may be expected.  Clinical adverse 
events (AEs) should be reported and recorded as described in 
Section 12.1.[ADDRESS_755918] use and study participation 
as described in Section 8.4. 
 
In subjects with abnormal ALT/AST or bilirubin at baseline, 
fold increase should be  assessed against baseline levels 
instead of ULN as follows:  3Ã— baseline ALT/AST, or total 
bilirubin >2Ã— baseline (and >2 mg/dL). 
Appendix D  APPENDIX D.   STANDARDIZED DEFINITIONS FOR 
CARDIOVASCULAR ENDPOINT EVENTS  
 
  
Page 334 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755919] of conjugates or metabolites of OCA for assessment was expanded to include OCA glucuronide.  
Additionally, various aspects of the study design and study population were clarified.   
Summary of Changes 
The following revisions were made to the protocol in Protocol Version 3.  Revised and new text in Version 3 is indicated in bold 
font, and the text deleted from Protocol Version 3 is crossed out in the table below.  Minor/editorial changes are not listed 
individually in the summary table below. 
Section Original Text  Revised Text  
Global change  Oral temperature  Body temperature  
Global change  OCA, tauro-OCA, glyco -OCA, total OCA, potentially other 
conjugates or metabolites not yet identified  OCA, tauro -OCA, glyco -OCA, total OCA, OCA glucuronide , 
potentially other conjugates or metabolites not yet identified  
Title Page   
 
  
Version 2: 22 October 2015  The CONTROL Study  
Combination OCA aNd STatin for Monito Ring Of Lipi[INVESTIGATOR_575755] 3: [ADDRESS_755920]: Roya Hooshmand- Rad, MD, PhD  
Executive Director, Clinical Research  
Intercept Pharmaceuticals, Inc. (Intercept)  
Email: rhooshmand -[EMAIL_382]  
 
 
 
     The following individual medical monitors may also be 
contact[CONTACT_576358].  
Primary Medical 
Monitor 
Contact: 
 
[CONTACT_133297]:  
Email Emad Basta, MD  
(Lead) Medical Monitor/Medical 
Expert 
[CONTACT_30372]  
+[PHONE_11936] 
[EMAIL_10983]  
NASH Medical Monitor Hotline: +[PHONE_11933]  
 
[EMAIL_10980]  
Page 335 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755921]:  
 
 
   Barbara Scholz, MD  
Medical Director, Drug Safety  
Intercept  
Telephone : 
Email: +[PHONE_11930] (Pacific time zone)  
[EMAIL_379]  
 Email 
 
 
Secondary 
Contact: [CONTACT_576347]- Rad, MD, PhD  
Executive Director,  Medical Safety and 
Pharmacovigilance  
Intercept Pharmaceuticals, Inc. (Intercept)  
Mobile Phone: 
Email: 
 
Secondary 
Contact:  
 
[CONTACT_576359]: 
Email: +[PHONE_353] (Pacific time zone)  
rhooshmand -[EMAIL_382]  
 
Barbara Scholz, MD  
Medical Director, Drug Safety  
Intercept 
+[PHONE_11930] (Pacific time zone)  
[EMAIL_379]  
 
Synopsis 
Objectives, 
6.3 Exploratory 
Objectives  To evaluate improvement in noninvasive -radiological assessment 
of fibrosis via transient elastography  (TE; at sites where available, 
and evaluated at the end of LTSE) To evaluate improvement in noninvasive -radiological 
assessment of fibrosis via transient elastography  (TE; at sites 
where available)  
Synopsis Methodology,  
7.1 Overall Study 
Design Statin-treated subjects will be required to stop statin treatment 
(after signing informed consent) for a total of 5 weeks prior to 
randomization.   
Screening Period:  
Subjects using statins within 30 days of the initial Screening visit (Screening Visit 1) are required to stop statin therapy immediately 
following this initial visit and must undergo a 4 -week statin 
washout period.  One week prior to randomization (Screeni ng 
Visit 2; Week -1), these subjects will have a pre- randomization 
visit for assessment of their fasting LDL cholesterol levels.  Statin-treated subjects will be required to stop statin treatment 
(after signing informed consent) for up to 5 weeks, including a 
4-week statin washout period, prior to Randomization /Day1.   
Screening Period:  
Subjects using statins within 30 days of the initial Screening 
visit (Screeni ng Visit 1) are required to stop statin therapy 
immediately following this initial visit and must undergo a [ADDRESS_755922] a pre- randomization 
visit for assessment of  their fasting LDL cholesterol levels.  
Page 336 of 364
3URWRFRO 9HUVLRQ'HF 
3DJH

&RQILGHQWLDODQG3URSULHWDU\ 6HFWLRQ 2ULJLQDO7H[W 5HYLVHG7H[W
6XEMHFWVZLWKIDVWLQJ/'/FKROHVWHUROYDOXHV!PJG/DW
:HHNZLOOEHH[FOXGHGIURPWKHVWXG\DQGWKHLU1$6+VKRXOG
EHPDQDJHGDFFRUGLQJWRVWDQGDUGRIFDUH
'RXEOH%OLQG
6XEMHFWVZKRGLVFRQWLQXHDWRUYDVWDWLQGXULQJWKHGRXEOHEOLQG
SKDVHDUHHOLJLEOHWRFRQWLQXH2&$GXULQJWKHGRXEOHEOLQGSKDV H
DQGHQUROOLQWRWKH/76(DWWKHGLVFUHWLRQRIWKH,QYHVWLJDWRU 
SURYLGHGWKH\FRQWLQXHWRPHHWH[FOXVLRQFULWHULD/'/
PJG/
/76(3KDVH
'XULQJWKH/76(SKDVHDOOVXEMHFWVZLOOEHWUHDWHGZLWK2&$
6XEMHFWVUDQGRPL]HGWRSODFHERRU2&$PJGXULQJWKHGRXEOH
EOLQGSKDVHZLOOUHFHLYH2&$PJXSRQHQWU\LQWRDQG
WKURXJKRXWWKH/76(SKDVH6XE MHFWVUDQGRPL]HGWR2&$PJ
ZLWKQRWROHUDELOLW\FRQFHUQVZLOOWLWUDWHWR2&$PJ6XEMH FWV
ZKRDUHUDQGRPL]HGWRWKH2&$PJWUHDWPHQWJURXSZLOO
FRQWLQXHUHFHLYLQJ2&$PJGXULQJWKH/76(6XEMHFWVZLWKIDVWLQJ/'/FKROHVWHUROYDOXHV!PJG/DW
6FUHHQLQJ9LVLW ZLOOEHH[FOXGHGIURPWKHVWXG\DQGWKHLU
G\VOLSLGHPLD VKRXOGEHPDQDJHGDFFRUGLQJWRVWDQGDUGRIFDUH
'RXEOH%OLQG
6XEMHFWVZKRGLVFRQWLQXHDWRUYDVWDWLQGXULQJWKHGRXEOHEOLQG
SKDVHDUHHOLJLEOHWRFRQWLQXH2&$GXULQJWKHGRXEOHEOLQGSKDVHDQGHQUROOLQWRWKH/76(DWWKHGLVFUHWLRQRIWKH
,QYHVWLJDWRUSURYLGHGWKH\FRQWLQXHWRPHHW WKH/'/FFXWRIIRI 
H[FOXVLRQFULWHULD LH/'/FPJG/
/76(3KDVH
'XULQJWKH/76(SKDVHDOOVXEMHFWVZLOOEHWUHDWHGZLWK RSHQ
ODEHO2&$PJRU2&$PJ 6XEMHFWVUDQGRPL]HGWR
SODFHERRU2&$PJGXULQJWK HGRXEOHEOLQGSKDVHZLOO EH
UDQGRPL]HGLQDUDWLRWR UHFHLYH2&$PJRU 2&$
PJXSRQHQWU\LQWRDQGWKURXJKRXWWKH/76(SKDVH6XEMHFWV
UDQGRPL]HGWR2&$PJRU2&$PJ GXULQJWKHGRXEOH
EOLQGSKDVHZLOO FRQWLQXHRQWKHVDPHGRVHWKURXJKRXW WKH
/76(
6\QRSVLV0HWKRGRORJ\
6WXG\
'HVLJQ
PJ2&$7LWUDWHG
6WDWLQ6WDWLQ
PJ6WDWLQ
PJ

6XEMHFWVLQLWLDWLQJWKH/76(DUH
UHTXLUHGWRKDYHDVDIHW\FRQWDFW
ZHHNVLQWRWKH/76(6FUHHQLQJ	
6WDWLQ
:DVKRXW6WDWLQXVHSHU(886*XLGHOLQHV<HDU2SHQ/DEHO/76( 'RXEOH%OLQG7UHDWPHQW3HULRG
:N :N
'D\:N :N :N :N4XDUWHUO\9LVLWV
PJ2&$3ODFHER
PJ2&$PJ2&$PJ2&$5DQGRPL]DWLRQ
'''
 
6\QRSVLV1XPEHU
RI6XEMHFWV
1XPEHURI
6XEMHFWV$WOHDVWQ RIV XEMHFWVHQUROOHGLQWKH
VWXG\ZLOOKDYHILEURVL VVWDJHDQGXSWRQ $PD[LPXPRIRIVXEMHFWVZLOOKDYH
VWDJHILEURVLV
Page 337 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 338 
 
Confidential and Proprietary  Section Original Text  Revised Text  
26) of subjects will have fibrosis stage 2, stage 3, or 
stage [ADDRESS_755923] 
Inclusion Criteria  
 6. Contraception:  Female subjects of childbearing 
potential must use â‰¥[ADDRESS_755924].  Effective methods of contraception are considered to be those listed below. 
â€¢ Double-barrier method, ie, (a) condom (male or 
female) or (b) diaphragm , with spermicide  
â€¢ Intrauterine device  
â€¢ Vasectomy (partner)  
â€¢ Hormonal (eg, contracepti ve pi[INVESTIGATOR_4382], patch, 
intramuscular implant or injection)  
â€¢ Abstinence (defined as refraining from heterosexual 
intercourse)  6. Contraception:  Female subjects of 
childbearing potential must use â‰¥[ADDRESS_755925].  Effective methods of contraception are considered to be those listed below. 
â€¢ Barrier method, ie, condom (male or female) with 
spermicide  or diaphragm with spermicide  
â€¢ Intrauterine device  
â€¢ Vasectomy (partner ) 
â€¢ Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, 
intramuscular implant or injection)  
â€¢ Abstinence (defined as refraining from heterosexual intercourse)  
Synopsis, Key 
Exclusion Criteria 
8.[ADDRESS_755926] 
Exclusion Criteria 8. Uncontrolled diabetes defined as HbA1câ‰¥9.0% 
within 60 days prior to randomization (Day 1). 
9. Administration of any of the following 
medications as specified below:  
â€¢ Prohibited 30 days prior to Day  1:   
- bile acid sequestrants including cholestyramine  
â€¢ Prohibited 3 months prior to Day  1:   
- nicotinic ac id and derivatives, ezetimibe, or  
- any prescription or over -the-counter medication 
or herbal remedy with putative NASH efficacy 
(except Vitamin  E or TZDs), 
- fenofibrate or other fibrates, or  8. Uncontrolled diabetes defined as 
HbA1câ‰¥9.5% within 60 days prior to randomization (Day 1) 
9. Administration of any of the following medications as specified below:  
â€¢ 
Prohibited 30 days prior to Day 1:  
âˆ’ bile acid sequestrants including 
cholestyramine , and its derivatives  
â€¢ Prohibited 3 months prior to Day  1:   
âˆ’ nicotinic acid and derivatives, ezetimibe, or  
Page 338 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 339 
 
Confidential and Proprietary  Section Original Text  Revised Text  
- Any over -the-counter or health foods used to 
treat lipi[INVESTIGATOR_575543]  
 
   
10. Evidence of other forms of chronic liver disease 
including but not limited to:  
â€¢ Positive test result at Screening for hepatitis B surface 
antigen or hepatitis C antibody (and positive hepatitis 
C virus [HCV] ribonucleic acid [RNA])  
â€¢ Primary biliary cirrhosis, primary sclerosing 
cholangitis, autoimmune hepatitis or overlap syndrome  
â€¢ Alcoholic liver disease  
â€¢ Wilsonâ€™s disease or hemochromatosis or iron overload as defined by [CONTACT_18451] 3+ or 4+  stainable 
iron on liver biopsy  
â€¢ Alpha-1-antitrypsin (A1AT) deficiency as defined by 
[CONTACT_575764] (confirmed by 
A1AT level less than normal; exclusion at the 
Investigatorâ€™s discretion)  
â€¢ Prior known drug -induced liver injury within 5  years 
before Day  1 
â€¢ Known or suspected hepatocellular carcinoma  
 
 
17. Platelet count < 100,000/mm3 at any Screening Visit  
24. Receipt of any investigational product not being 
evaluated for the treatment of diabetes or NASH within 30 days prior to Day 1 or within 5 half -lives of the 
compound (whichever was longer)  before Day 1  âˆ’ any prescription or over -the-counter 
medication or herbal remedy with putative 
NASH efficacy (except Vitamin  E or TZDs), 
or 
âˆ’ ursodeoxycholic acid, or  
âˆ’ fenofibrate or other fibrates, or  
âˆ’ Any over -the-counter or health foods used to 
treat lipi[INVESTIGATOR_575756] 
10. Evidence of other forms of known chronic 
liver disease including but not limited to:  
â€¢ Positive test result at Screening for hepatitis B 
surface antigen  
â€¢ Active hepatitis C virus (HCV) infection (positive 
for HCV ribonucleic acid [RNA] at Screening) or 
history of positive HCV RNA test result   
â€¢ Primary biliary cirrhosis (also known as  primary 
biliary cholangitis) , primary sclerosing 
cholangitis, autoimmune hepatitis or overlap syndrome  
â€¢ Alcoholic liver disease  
â€¢ Wilsonâ€™s disease or hemochromatosis or iron overload as defined by [CONTACT_18451] 3+ or 4+ stainable iron on liver biopsy  
â€¢ Alpha-1-antitrypsin (A1AT) deficiency as defined 
by [CONTACT_575764] (confirmed 
by A1AT level less than normal; exclusion at the Investigatorâ€™s discretion)  
Page 339 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 340 
 
Confidential and Proprietary  Section Original Text  Revised Text  
 â€¢ Prior known drug -induced liver injury within 
5 years before Day  1 
â€¢ Known or suspected hepatocellular carcinoma  
17. Platelet count < 75 000/mm3 at any Screening Visit  
24. Receipt of any investigational product not being 
evaluated for the treatment of diabetes or NASH from Screening Visit 1 to Day 1, within 30 days 
prior to Day 1 , or within 5 half -lives of the 
compound before Day 1 (whichever was longer)  
29.
â†’Acute cholecystitis or acute biliary obstruction  
 
Synopsis, 
Duration of 
Subject Participation  Screening period for statin -using subjects:  4-week statin 
washout period + Screening (5 weeks (statin -using subjects 
only)  Screening period for statin -using subjects:  Up to 5 weeks 
(including a 4 -week statin washout period)   
Synopsis, Criteria for Evaluation  
11.1 Efficacy Assessments, 
Table 4 Exploratory Endpoints  
OCA 
pharmacokinetics  OCA, tauro -OCA, glyco -OCA, total 
OCA, potentially other conjugates or metabolites not yet identified  
Noninvasive radiological liver fibrosis 
measurements  By [CONTACT_783] (where available, and evaluated 
at the end of LTSE ) 
 Exploratory Endpoints  
OCA 
pharmacokinetics  OCA, tauro -OCA, glyco -OCA, total 
OCA, OCA glucuronide,  potentially 
other conjugates or metabolites not yet identified  
Noninvasive radiological liver 
fibrosis 
measurements  By [CONTACT_783] (where available)  
 
List of Abbreviations and Definitions 
of Terms PBC primary biliary cirrhosis  
 PBC primary biliary cholangitis  (also known as  
primary biliary cirrhosis) 
CAC Cardiovascular Adjudication 
Committee  
 
Page 340 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 341 
 
Confidential and Proprietary  Section Original Text  Revised Text  
5.5 Clinical 
Experience with 
Obeticholic Acid  OCA is under investigation for the treatment of multiple chronic 
liver diseases, including the treatment of NASH, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and biliary 
atresia.  The clinical development program for OCA includes the following 3 studies conducted using subjects with NAFLD or 
NASH: â€œ 
â€œ 
â€¢ Study D8602001:  A n ongoing Phase 2 study being 
conducted by [CONTACT_575782]â€™s development partner (Sumitomo Dainippon Pharma Co., Ltd) to evaluate the efficacy and safety of 3 doses of OCA versus placebo in NASH.  
Study D8602001 is ongoing and remains blinded. OCA is under investigation for the treatment of multiple chronic liver diseases, including the treatment of NASH, primary biliary 
cholangitis (PBC, also called primary biliary cholangitis ( PBC, 
also known as  primary biliary cirrhosis [Beuers 2015a, 
Beuers 2015b, Beuers 2015c ]), primary sclerosing cholangitis 
(PSC), and biliary atresia.  The clinical development program for 
OCA includes the following 3 studies conducted using subjects 
with NAFLD or NASH:  
â€¢ Study D860200 1:  A Phase 2 study conducted by 
[CONTACT_575782]â€™s Asian  development partner (Sumitomo 
Dainippon Pharma Co., Ltd) to evaluate the efficacy and 
safety of 3 doses of OCA versus placebo in NASH  
Study D8602001 demonstrated a dose -dependent increase in 
the percentage of OCA-treated subjects compared to placebo 
subjects who achieved the primary endpoint (p = 0.053, not significant).   The 40 mg OCA dose group achieved statistical significance for the primary endpoint compared to placebo (p = 0.0496).  Dose -dependent trends not reaching statistical 
significance were also observed for several other pre-
specified histologic endpoints, including the proportion of 
subjects with steatosis and inflammation improvement, ballooning resolution, and NASH resolution.  In the completer analysis, similar dose -dependent effects were 
observed, with 51% of patients in the 40 mg dose group compared to 22% in the placebo group meeting the primary 
endpoint (p = 0.0061).  With the exception of dose -dependent 
pruritus, OCA appeared to be gene rally safe and well 
tolerated.  The number of pruritus -associated 
discontinuations were 0, 0, 2, and 5 subjects in the placebo, 
10 mg, 20 mg, and 40 mg OCA groups, respectively.  
Changes in lipid parameters were directionally similar to 
those observed in the FLINT study.  No other meaningful differences in the rate of AEs between the OCA and placebo groups were noted .  
Page 341 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 342 
 
Confidential and Proprietary  Section Original Text  Revised Text  
5.6.6 Rationale 
for Timing of 
Unblinding 
Process and Implications in LTSE 
 For those subjects continuing into the LTSE :  Following 
completion of all study procedures associated with the double-
blind period, subjects will be unblinded via the interactive web 
response system (IWRS) to determine the open -label OCA dose to 
be initiated in the LTSE.  This will allow double -blind, placebo-
treated subjects to initiate OCA at an appropriate dose, and OCA -
treated subjects to maintain or increase their dose based on 
therapeutic response and tolerability rather than forcing fixed 
dosing to maintain the blind.   As Study 747 -209 is a randomized, do uble-blind study, the 
double-blind data will not be unblinded until all double -
blind data are final and the database is locked.  Accordingly, 
all subjects continuing in the LTSE, investigators, and the Sponsor will remain blinded to subjectsâ€™ DB treatment regimen.  Subjects who were receiving placebo or [ADDRESS_755927] be informed that statin use is contraindicated during pregnancy.  Methods of contraception should be reviewed and modified, if necessary, to ensure highly 
effective methods with failure rates <1% per year, such as 
implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or history of vasectomy of partner are used. 
7.1.[ADDRESS_755928] 8  hours prior to the visit.  For 
subjects undergoing a 4- week washout period, this visit will 
occur at Week -1.  For subjects not taking statins at 
Screening  Visit 1, this visit can occur at any time after Screening 
Visit 1 and up to 1 week prior to randomization .  For subjects Added Weeks row to clarify timing of Screening Visits  
Modified Visit windows for  Screening Visit 1:  Day -35 to Day 
-7 
Modified Visit window for  Screening Vi sit 2:  Day -[ADDRESS_755929] 8  hours prior to the visit.  The 
Randomization/Day 1 Visit may occur as soon as screening 
labs are available and eligibility is confirmed for all 
subjects.  For subjects undergoing a 4 -week washout period, 
Screening Visit 2 may occur on day 28 ( Â±1) day of the 
washout period .  For subjects not taking statins at 
Screening  Visit 1, Screening Visit 2 can occur at any time 
Page 342 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755930]â€™s last statin dose.   
d  Sitting heart rate, blood pressure, temperature, and respi[INVESTIGATOR_862] 
i  and none of the exclusion criteria, may be randomized .â€ 
  
k  Blood samples for all analyses will be collected predose (before 
administering investigational product) on indicated visit days.  
 within [ADDRESS_755931] be completed â‰¤35 days prior to the 
Randomization/Day [ADDRESS_755932] bo or OCA 5 mg during the 
double-blind period will be randomized to OCA 10 or 25 mg 
during the LTSE  
k  Blood samples for all analyses will be collected predose (before 
administering investigational product  or atorvastatin ) on 
indicated visit days.  
 
7.1.[ADDRESS_755933] visit after start of LTSE (Month  1 Visit) is relative to 
Week 16 Visit of the double -blind phase (LTSE Day  1 Visit).  
This is not a study site visit.  The subject should be contact[CONTACT_576360] 1 month after the start of the LTSE, and 
compliance with OCA treatment instructions, concomitant 
medications, and AEs should be assessed.  
d  Sitting heart rate, blood pressure, temperature, and respi[INVESTIGATOR_575757] 1 
Added: 
â€¢ Fast â‰¥8 h Prior  to Visit 
â€¢ Vital Signs  
â€¢ Collect Bottles/Atorvastatin 
Accountability/Compliance  
â€¢ Serum Chemistry/Hematology/Coagulation Parameters  
â€¢ Markers of glucose metabolism, including C -peptide, 
insulin, fasting plasma glucose, HbA1c  
â€¢ Urine Based Î² -hCG Pregnancy Test  
 
a  The first visit after start of LTSE (Month  1 Visit) is relative to 
Week 16 Visit of the double -blind phase (LTSE Day  1 Visit).   
d  Sitting heart rate, blood pressure, body temperature, and 
respi[INVESTIGATOR_697]  
 
7.3 Treatment Assignment  Eligible subjects will be randomized into 4 groups in a 1:1:1:1 ratio to receive OCA 5  mg, OCA 10  mg, OCA 25  mg, or placebo 
during the double -blind phase of the study.  Randomization will Eligible subjects will be randomized into 4 groups in a 1:1:1:1 ratio to receive OCA 5  mg, OCA 10  mg, OCA 25  mg, or 
placebo during the double -blind phase of the study.  
Page 343 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 344 
 
Confidential and Proprietary  Section Original Text  Revised Text  
be stratified by [CONTACT_575789] (fasting serum LDL cholesterol 
at Screening Visit  2; â‰¤125 mg/dL or >125 mg/dL) and baseline 
fibrosis stage (stage 1, 2 or stage 3, 4).  All subjects will also 
receive atorvastatin starting at Week  4 at 10 mg daily, escalating 
to 20 mg at Week  8 (if 10 mg daily is tolerated), with further dose 
adjustments to be performed as clinically indicated at Week  12, 
and throughout the LTSE phase.  Subjects randomized to placebo 
or OCA 5  mg will receive OCA 10  mg during the LTSE; subjects 
randomized to OCA 10 mg or OCA 25 mg will receive OCA 
25 mg during the LTSE.  The study design schematic is shown in 
Figure 1.  Randomization will be stratified by [CONTACT_575789] (fasting 
serum LDL cholesterol at Screening Visit  2; â‰¤125 mg/dL or 
>125 mg/dL) and baseline fibrosis stage (stage 1, 2 or stage 3, 
4).  All subjects will also receive atorvastatin starting at Week  4 
at 10 mg daily, escalatin g to 20 mg at Week  8 (if 10 mg daily is 
tolerated), with further dose adjustments to be performed as clinically indicated at Week  12, and throughout the LTSE phase.  
Subjects will receive open-label OCA 10 mg or OCA 25  mg 
during the LTSE depending on their  double-blind randomized 
dose (see Section 7.1) .  The study design schematic is shown in 
Figre 1.  
7.4.[ADDRESS_755934] Dose Adjustments  During the LTSE phase, all subjects will be treated with OCA.  Subjects randomized to placebo or OCA 5  mg during the double -
blind phase will receive OCA 10  mg upon entry into and 
throughout the LTSE phase.  Subjects randomized to OCA 10  mg 
with no tolerability concerns  will titrate to OCA 25  mg.  Subjects 
randomized to OCA 25 mg will continue to receive this dose 
throughout the LTSE.  Subjects may continue with atorvastatin therapy as clinically indicated.  During the LTSE phase, all subjects will be treated with OCA.  Subjects randomized to placebo or OCA 5  mg during the 
double-blind phase will be re-randomized i n a 1:1 ratio 
through IWRS to OCA 10 mg or OCA 25 mg upon entry into 
and throughout the LTSE phase.  Subjects randomized to OCA 10 mg will continue to receive OCA 10 mg throughout the 
LTSE.  Subjects randomized to OCA 25 mg will continue to 
receive OCA 25 mg throughout the LTSE.  Subjects may 
continue with atorvastatin therapy as clinically indicated.  
[IP_ADDRESS] Severe Drug-Induced 
Liver Injury Subjects who develop significant drug -induced liver injury, which 
is considered to be causally related to the inves tigational product, 
should be discontinued from investigational product and should not be rechallenged.  Significant injury as described in  
Appendix  B, or evidence of functional hepatic impairment as 
indicated by [CONTACT_310177].  Natural progression of the underlying condition and other causal factors such as a common 
bile duct stone or development of other concurrent liver disease 
should be considered before the investigational product is permanently discontinued.    
Severe drug induced -liver injur y that is not considered related to 
investigational product must be discussed with the Sponsor before resuming treatment .  Subjects who discontinue due to significant 
drug-induced liver injury must be followed until the AE has 
resolved, stabilized, or is n ot of clinical concern.  If a subject develops signs and symptoms of a severe drug -
induced liver injury, regardless of causality, investigational 
product and atorvastatin should be interrupted until the 
event has resolved or returned to baseline, but the su bject 
should continue with the study visit schedule.  Subjects who 
develop significant drug- induced liver injury, which is 
considered to be causally related to the investigational product 
or atorvastatin , should be discontinued from investigational 
product or atorvastatin, as appropriate and should not be 
rechallenged.  Significant injury as described in  Appendix B , 
and includes  evidence of functional hepatic impairment as 
indicated by [CONTACT_310274].  Natural progression of the 
underlying condition and other causal factors such as a common bile duct stone or development of other concurrent liver disease 
should be considered before the investigational product is permanently discontinued.    
Page 344 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755935] refers to OCA or placebo , 
and study medication, where used, refers to atorvastatin.  
9.1.2 LTSE  Following completion of Week  16 Visit procedures, subjects who 
are participating in the LTSE will be unblinded via the IWRS .  
Subjects who were receiving OCA  during the double -blind phase 
will continue to receive either OCA 10  mg or OCA 25 mg once 
daily during the LTSE.  Subjects randomized to placebo or 5 mg 
OCA during the double -blind phase will initiate dosing at OCA 
10 mg in the LTSE.  Subjects randomized to OCA 10 mg during 
the double -blind phase will titrate to OCA 25  mg on Day 1 of the 
LTSE.  Subjects randomized to OCA 25 mg during the double -
blind phase will continue to receive OCA 25  mg. Following completion of Week  16 Visit procedures, all subjects 
will be treated with open -label OCA 10 mg or OCA 25 mg.  
Subjects randomized to placebo or OCA 5 mg during the 
double-blind phase will be randomized in a 1:[ADDRESS_755936] 4  hours between doses of 
the BAS and/or antacids and the investigational product (ie, BAS should be administered [ADDRESS_755937] administration).  Subjects taking BAS (including cholestyramine and its 
derivatives, colestipol, colesevelam, or other sequestrants)  or 
aluminum hydroxide - or smectite -containing antacids should be 
instructed to stagger their dosing of investigational produ ct, 
ensuring at least 4  hours between doses of the BAS and/or 
antacids and the investigational product (ie, BAS should be 
Page 345 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755938] administration).  
Taken concomitantly, OCA and warfarin may decrease INR, 
thus INR should be monitored and the dosage of warfarin 
adjusted, as needed, to maintain the target INR range.  
The effect of OCA on drug metabolizing enzymes has been evaluated in both in vitro and clinical studies.  The PK 
profile of caffein e, a sensitive CYP1A2 substrate, showed 
weak effect of OCA on CYP1A2.  Based on these results, 
OCA may increase the exposure of narrow therapeutic index drugs that are substrates for CYP1A2, such as theophylline and tizanidine.  
9.[ADDRESS_755939] (OCA or placebo) dispensing information 
will be provided (eg, bottle numbers allocated) while maintaining the study blind.  The subjects, Investigator, and study site staff will be blinded to the subjectâ€™s treatment allocation during the  
subjectâ€™s participation in the double -blind phase of the study.  
 The Investigator or designee will be required to register the subject in the IWRS and may be prompted to provide patient data necessary to properly randomize and allocate the subject to 
treatment.  A randomization number will be assigned and 
investigational product  (OCA or placebo) dispensing 
information will be provided (eg, bottle numbers allocated) 
while maintaining the study blind.  The subjects, Investigator, and study site staff will be  blinded to the subjectâ€™s treatment 
allocation in the double -blind phase of the study until all 
subjects have completed the double -blind phase of the study 
and the database locked. 
In the LTSE phase, all subjects will be treated with open-
label OCA 10 mg or OCA 25 mg: subjects randomized to placebo or OCA 5 mg during the double -blind phase will be 
randomized in a 1:1 ratio to receive OCA 10 mg or OCA 25 mg upon entry into and throughout the LTSE phase and subjects randomized to OCA 10 mg or OCA 25 mg during the double -blind phase will continue on the same dose 
throughout the LTSE.   
9.4.2 Emergency Unblinding 
Procedures  Randomization codes and corresponding treatment assignments 
will be made available to the Investigator for emergency use only 
through the I WRS system.  When possible, the Medical Monitor Randomization codes and  corresponding treatment assignments 
will be made available to the Investigator  and the Medical 
Monitor for emergency use only through the IWRS system.  
Page 346 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 347 
 
Confidential and Proprietary  Section Original Text  Revised Text  
should be consulted in the event that a medical emergency 
necessitates unblinding (ie, in situations where knowledge of the 
blinded treatment is necessary for further medical management of 
the subject).  If i t is not reasonable to inform the Medical Monitor 
in advance of unblinding, the Investigator must promptly document the case in the subjectâ€™s source record.  Subsequently, the Investigator should contact [CONTACT_576361] (eg, accidental 
unblinding or unblinding due to a serious AE [SAE]).  Procedures 
for unblinding a subjectâ€™s treatment will be provided separately to the Investigator.  Similarly, if the Medical Monitor breaks the 
blind for the p urpose of evaluating an emergent safety issue or for 
regulatory reporting purposes, the  Medical Monitor will document 
within study correspondence the rationale, circumstances, and the person(s) being informed about the unblinding.   When possible, the Medical Monitor should be consulted in the 
event that a medical emergency necessitat es unblinding (ie, in 
situations where knowledge of the blinded treatment is necessary for further medical management of the subject).  If it is not reasonable to inform the Medical Monitor in advance of unblinding, the Investigator must promptly document the case in 
the subjectâ€™s source record.  Subsequently, the Investigator 
should contact [CONTACT_576362] (eg, accidental unblinding or unblinding due to a serious AE [SAE]).  Procedures for unblinding a subjectâ€™s treatment will be provided separately to 
the Investigator.  The Medical Monitor will document within 
study correspondence the rationale, circumstances, and the 
person(s) being informed about the unblinding.   
9.7.1 Visit 
Windows  Screening Visit 1  should occur â‰¤35 days prior to the Day  1 Visit.  
Subjects who are taking statins at the time of screening or within 4 weeks of Screening Visit  1 are required to stop statin therapy for 
4 weeks, and provide a fasting blood sample at Screening Vi sit 2 
(Week -1 Visit) to confirm eligibility.  Subjects who have not 
taken statins within 4 weeks of Screening Visit  1 are not required 
to enter into the washout period and may proceed to Screening Visit 2 (Week -1) to provide a fasting blood sample. The Week -1 
Visit should occur within Â±1 days of the Randomization/Day1 
Visit. 
 
Visit or Procedure Visit Window and/or Interval  
Screening Visit  1 Visit(s) are to occur â‰¤5 weeks (35 days) before Day 1.  
LTSE Visits: Month  3, 
Month 6, Month 9, 
Month 12, Month 15, 
Month 18, and 
Month 21 Â±1 week (7 days); the LTSE visits are 
relative to LTSE Day  1 (ie, Week  16 
of double -blind phase)  
 All Screening assessments  should occur â‰¤35 days prior to the 
Randomization /Day 1 Visit.  Subjects who are taking statins at 
the time of screening or within 30 days of Screening Visit  1 are 
required to stop statin therapy for 4  weeks (28 (Â±1) days) , and 
provide a fasting blood sample at Screening Visit  [ADDRESS_755940] not taken statins within 30 days 
of Screening Visit  1 are not required to enter into the washout 
period and may proceed to Screening Visit  2 to provide a fasting 
blood sample. The Randomization/Day 1 Visit may occur as 
soon as all screening labs are available and eligibility is 
confirmed . 
 
Visit or Procedure Visit Window and/or Interval  
Screening Visit  1 Visit(s) are to occur â‰¤5 weeks 
(35 days) prior to Day 1.  
Page 347 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 348 
 
Confidential and Proprietary  Section Original Text  Revised Text  
LTSE Visits:  Month 
1, Month 3, Month 6, 
Month 9, Month 12, 
Month 15, Month  18, 
and Month 21 Â±1 week (7 days); the LTSE visits 
are relative to LTSE Day  1 (ie, 
Week 16 of double -blind phase)  
 
9.7.3 Screening 
Visit 1 
Procedures (â‰¤35 
Days Before Day 
1) The Screening Visit assessments must be performed within 
â‰¤[ADDRESS_755941] meets 
all the inclusion criteria and none of the exclusion criteria.  Subjects who do not fulfill all eligibility criteria will not be enrolled in the study.   
Subjects who are statin -free (ie, no s tatin use within 4 weeks of 
Screening) must return for fasted serum chemistry labs at 
Screening Visit  2, and may proceed to the Randomization/Day  1 
Visit once screening labs are available and eligibility is confirmed; 
subjects who need to wash out statin therapy are required to â€œhave 
a Week -1 Visit 4 weeks after Screening Visit 1 .â€ 
Additional Screening Visit 1 procedure for subjects currently 
taking statins:  
â€¢ Subjects who are currently taking statins, defined as 
statin use within [ADDRESS_755942] complete a 5 -week statin washout 
prior to being randomized.   After 4 weeks of statin 
washout, subjects will return for Screening Visit  2/Week 
-[ADDRESS_755943] be performed â‰¤[ADDRESS_755944] meets all the 
inclusion criteria and none of the exclusion criteria.  Subjects who do not fulfill all eligibility criteria will not be enrolled in the 
study.   
Subjects who are statin -free (ie, no statin use within 30 days of 
Screening) must return for fasted serum chemistry labs at 
Screening Visit  2, and may proceed to the Randomization/Day  1 
Visit once screening labs are available and eligibility is 
confirmed; subjects who need to wash out statin therapy are required to return for Screening Visit 2 following the washout 
period.   
Additional Screening Visit 1 procedure for subjects currently 
taking statins:  
â€¢  Subjects who are currently  taking statins, defined as statin 
use within [ADDRESS_755945] ed 
serum chemistry.  
9.7.4 Screening Visit 2/Week -1 
Visit Procedures  Subjects who were receiving statin therapy at the time of screening.  
â€¢ Verify that subjects have completed a 4 -week washout 
period. 
All Subjects : All subjects will return for Screening Visit 2 to confirm 
eligibility criteria and provide blood samples for fasted serum chemistry.  
For subjects who were receiving statin therapy at the time of 
screening.  
â€¢ Verify that subjects have completed a 4 -week washout 
period. 
Page 348 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 349 
 
Confidential and Proprietary  Section Original Text  Revised Text  
For all subjects:â€¦  
9.7.14 Additional 
Procedures at 
Week 16/LTSE Day [ADDRESS_755946] who will continue into the LTSE phase after completing 
the procedures listed for the Week 16 Visitâ€¦  
â€¢ Dispense investigational product as instructed  Subjects who continue into the LTSE phase after completing  the 
procedures listed for the Week 16 Visitâ€¦  
â€¢ Record the visit in IWRS, randomize the subject to one of the open- label treatment groups, and dispense open-
label investigational product according to IWRS instructions.  
9.7.16 LTSE Visits LTSE Visits  will occur every 3 months (eg, at Months 3, 6, 9, and 
12) following completion of the Week 16/LTSE Day [ADDRESS_755947] completes a year (Month 12 Visit)  in the LTSE, their next visit should be 3 
months later and the procedures described for the Month 3 LTSE 
Visit should be followed.  LTSE Visits should occur within Â±1 week of the visit day and 
the timing of all visits should be relative to the double -blind 
Week 16 Visit (ie, the start of the LTSE; LTSE Day  1).  For 
example, if the Month 6 Visit occurred 1 week late, the Month 9 Visit should still be approximately 9  months after 
the Week  16 Visit.  
9.7.16 LTSE Visits LTSE Visits should occur within Â±1 week of the visit day and the 
timing of all visits should be relative to the double -blind Week  16 
Visit (ie, the start of the LTSE; LTSE Day  1).  For example, if the 
Month [ADDRESS_755948] LTSE visit following LTSE Day 1 will occur at 
LTSE Month 1.  The next  visit will occur at LTSE Month 3 
and every 3 months thereafter (eg, at Months 6, 9, and 12) for 
the duration of the LTSE.  The quarterly  visit procedures  
described below will repeat annually for the duration of the 
LTSE.  For example, once a subject completes a year (Month 12 
Visit) in the LTSE, their next visit should be [ADDRESS_755949]/Visit 
Procedures  Approximately [ADDRESS_755950] is not repeated in subsequent 
years of participation.   â€¢ Verify that the subject has fasted for at least 8 
hours. 
âˆ’ Record fasting status in the source and eCRF.  
âˆ’ If the subject reports having eaten within [ADDRESS_755951] that fasting is 
Page 349 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 350 
 
Confidential and Proprietary  Section Original Text  Revised Text  
required prior to all study visits, but water is 
permitted.  
â€¢ Assess and record vital signs (body temperature, 
sitting heart rate, respi[INVESTIGATOR_697], and sitting blood 
pressure). 
â€¢ Assess and record AEs.  
â€¢ Review and record concomitant medications.  
â€¢ Collect used bottles of investigational product, assess 
investigational product compliance, and perform investigational product accountability.   Following 
product accountability, redispense the same bottle of 
investigational product for use until the next visit.  
â€¢ Collect used bottles of atorvastatin, assess 
atorvastatin compliance, and perform atorvastatin accountability.  Following atorvastatin 
accountability, if the subjects is continuing with the 
same dose of at orvastatin, redispense the same 
bottle for use until the next visit.  
â€¢ NOTE:  If atorvastatin dose is up -titrated or re-
initiated after dose interruption, a telephone safety 
contact [CONTACT_575802] [ADDRESS_755952] and atorvastatin compliance.  
â€¢ Obtain blood samples for:  
â€¢ Serum chemistry (will include basic lipid panel and liver biochemistry panel), hematology, and coagulation  
â€¢ Markers of glucose metabolism  
â€¢ CPK, if myop athy suspected  
Page 350 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 351 
 
Confidential and Proprietary  Section Original Text  Revised Text  
â€¢ Perform a urine based Î² -hCG pregnancy test in 
female subjects of childbearing potential.  Perform 
serum pregnancy test in females of childbearing potential if urine Î² -hCG pregnancy test is positive.  
â€¢ Reiterate dosing instructions for investig ational 
product and advise the subject:  
âˆ’ Take the investigational product at 
approximately the same time each day  
âˆ’ NOT to take investigational product  or 
atorvastatin (if applicable) or on the morning 
of the next visit  
âˆ’ To bring the investigational product  and 
atorvastatin (if applicable) bottle(s); s/he will dose at the clinic  
âˆ’ To fast overnight (at least 8 hours) prior to the next visit.  Fasting is required prior to all study visits, but water is permitted.
 
[ADDRESS_755953] (OCA or Placebo) LTSE 
Phase: 5-mg, 10-mg and 25 -mg OCA tablets for the LTSE Phase will be 
supplied as white or yellow  tablets.   
â€¢ White OCA tablets are round and debossed with 
â€œINTâ€ on one side and â€œ3547â€ on the other side . 
â€¢ 5 mg yellow tablets:  Round and debossed with 
â€œINTâ€ on one side and â€œ5â€ on the other side.  10-mg and 25 -mg OCA tablets for the LTSE Phase will be 
supplied as white or yellow  tablets.   
â€¢ White OCA tablets are round and debossed with â€œINTâ€ 
on one side and â€œ3547â€ on the other side.  
 
Page 351 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 352 
 
Confidential and Proprietary  Section Original Text  Revised Text  
â€¢ 10 mg yellow tablets:  Triangular and debossed with 
â€œINTâ€ on one side and â€œ10â€ on  the other side.  
â€¢ 5 mg yellow tablets:  Oval and debossed with â€œINTâ€ on 
one side and â€œ25â€ on the other side.  
 
10.[ADDRESS_755954]  should be stored at the clinical study sites  
in the containers in which they are received from the Sponsorâ€™s 
supplier, at 15 -25Â°C and protected from ex cess humidity . Investigational product  should be stored in the containers in 
which they are received from the Sponsorâ€™s supplier, at 15 -25Â°C. 
[IP_ADDRESS] Central 
Reading of Liver 
Histology  All biopsy assessments, including determination of study 
eligibility based on NASH diagnosis and fibrosis staging during 
Screening, will be performed centrally by [CONTACT_576363].  Key features of NASH (ie, steatosis, lobular inflammation, and hepatocellular ballooning) will be graded in accordance with the NASH CRN criteria for scoring 
(Kleiner 2005).  Fibrosis sta ging for eligibility will also be 
performed in accordance with NASH CRN criteria for fibrosis staging.   All biopsy assessments, including determination of study 
eligibility based on NASH diagnosis and fibrosis staging during 
Screening, will be performed centrally by [CONTACT_575803].  The central pathologist must confirm 
histological presence of NA SH and a minimum NAS of [ADDRESS_755955] 1 in each component of NAS.   Key 
features of NASH (ie, steatosis, lobular inflammation, and 
hepatocellular ballooning) will be graded in accordance with the 
NASH CRN criteria for scoring ( Kleiner 2005) as summarized 
in Table 5 .  Fibrosis staging for eligibility will also be 
performed in accordance with NASH CRN criteria for fibrosis staging.   
Table 5:  NASH CRN Scoring System for Determining 
Eligibility and Primary Histological Endpoint Assessment  
NAFLD Activity Score 
(NAS) Fibrosis Staging  
Parameter Scoring Criteria Parameter Staging Criteria 
Page 352 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 353 
 
Confidential and Proprietary  Section Original Text  Revised Text  
Steatosis 0 = <5%  
1 = 5% - 
33% 
2 = >33% 
- 66%  
3 = >66%  Stage 0 No Fibrosis  
Lobular Inflammation 0 = No Foci 
1 = <2 Foci per 
200 Ã— 
field  
2 = 2-4 
Foci per 200 Ã— field   
3 = > 4 Foci per 200 Ã— field  Stage 1  
Stage 1a 
Stage 1b 
Stage 1c  Perisinusoidal 
or Periportal  
Mild, zone 3, persinusoidal  
Moderate, zone 3, perisinusoidal 
Portal / 
periportal   
Ballooning  0 = None  
1 = Few balloon 
cells  
2 = Many 
cells / prominent balloonin
g  Stage 2 Perisinusoidal 
and portal / periportal  
Stage 3 Bridging 
fibrosis 
Stage 4 Cirrhosis  
In addition to the primary scoring system of NASH CRN, 
biopsy samples will also be scored based on modified Ishak 
Page 353 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 354 
 
Confidential and Proprietary  Section Original Text  Revised Text  
scoring (Ishak 1995) for all subjects.  Any extra biopsy tissue 
may undergo exploratory histological evaluations.  
11.2.[ADDRESS_755956] (predose) on Day [ADDRESS_755957] (predose) on Day [ADDRESS_755958] or Study 
Medication   If the relationship between a SAE and the atorvastatin is 
determined to be â€œdefinite,â€ â€œprobable,â€ or â€œpossible,â€ the event will be considered to be related to atorvastatin for the purpose of assessing expedited safety reporting and 
reporting to the manufacturer.  
[IP_ADDRESS] Severity 
of Pruritus (as 
and AE)  
Since pruritus is a subjective symptom and the occurrence 
and magnitude of which are not readily measured by 
[CONTACT_575805], clinical judgment needs to be applied in the 
management of each subject.  Managing OCA -related 
pruritus may help improve tolerance in those subjects who experience problematic pruritus and may otherwise 
discontinue from the study prematurely.  General guidance 
for the management of subjects experiencing significant pruritus includes:  
â€¢ Drug holiday:  A drug holiday is defined as an Investigator â€˜prescribedâ€™ complete interruption of dosing for 1 or more consecutive days (ie, non -daily 
dosing does not constitut e a drug holiday).  For 
subjects with severe pruritus, instruct the subject to stop taking investigational product until the pruritus subsides to an acceptable level, at which time it should be restarted.  Details of drug holidays and/or nondaily dosing regimens should be recorded 
in the CRF.     
â€¢ Prescribe BAS.  Subjects taking BAS (including 
colestyramine and its derivatives, colestipol, 
colesevelam, or other sequestrants) should be 
Page 354 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755959].   
â€¢ Other therapi[INVESTIGATOR_575758].  
â€¢ Less frequent dosing of investigational product (eg, on alternate days) may be tried, after which subjects 
may return to their original daily dose as soon as 
tolerated.   
[IP_ADDRESS] Pregnancy and Follow-Up Pregnancies are not considered AEs in and of themse lves; 
however, if a female study participant becomes pregnant while she is enrolled in the clinical study, she must discontinue treatment with investigational product and atorvastatin immediately (see Section [IP_ADDRESS]) and the Sponsor must be notified withi n 24 hours 
of the Investigatorâ€™s learning of the pregnancy by [CONTACT_576364] .  Entering the 
pregnancy report into the EDC system will automatically notify 
the Sponsor of the pregnancy.  The subject and neonate must b e 
followed for outcome information and/or as considered appropriate by [CONTACT_2725].  
Women who discontinue the study due to pregnancy may not re -
enroll in the study at any point, but should continue with the study visit schedule and must be followed by [CONTACT_22108].  Similarly, if a subjectâ€™s pregnancy is terminated early (planned or unplanned), the subject will also be removed from the study.  
Completing the Pregnancy Report in the EDC  is not a substitute 
for reporting an AE/SAE when an AE/SAE has occurred.  In the 
situation when an AE/SAE has occurred, the AE/SAE reporting procedures described in Section 17.[ADDRESS_755960] also be followed.  Pregnancies are not considered AEs in and of themselves; however, if a female study participant becomes pregnant while 
she is enrolled in the clinical study, she must discontinue treatment with investigational product and atorvastatin immediately (see Section [IP_ADDRESS]) and the Sponsor must be 
notified within 24  hours of the Investigatorâ€™s awareness  of the 
pregnancy by [CONTACT_576365] .  The Pregnancy Report Form must be emailed 
to [EMAIL_380]  or faxed to +1- [PHONE_11937].  
The subject and neonate must be followed for outcome 
information and/or as considered appropriate by [CONTACT_332500].  
Women who discontinue the study due to pregnancy may not re -
enroll in the study at any point, but should continue with the study visit  schedule and must be followed by [CONTACT_575812].  Similarly, if a subjectâ€™s pregnancy 
is terminated early (planned or unplanned), the subject will also 
be removed from the study.  
Completing the Pregnancy Report Form is not a su bstitute for 
reporting an AE/SAE if an AE/SAE has occurred related to or 
concurrent with the pregnancy .  In the situation when an 
AE/SAE has occurred, the AE/SAE reporting procedures 
described in  Section 1.7.[ADDRESS_755961] also be followed.  
Page 355 of 364
Protocol 747 -209  Version 4:  [ADDRESS_755962]â€™s initials,  Subject ID number, date, 
and time.  Full instructions will be provided for forwarding the 12-
lead ECGs for central reading.  Investigative sites must retain a copy of all [ADDRESS_755963] been collected.   
[IP_ADDRESS] Pharmacokinetic 
Analysis 
 The PK Population will be used for analysis of PK parameters, 
which include plasma OCA (parent) and its conjugates (glyco -
OCA and tauro -OCA), total OCA, and potentially other 
conjugates or metabolites not yet identified.  PK analysis will be done using non -compartmen tal methods.   The PK Population will be used for analysis of PK parameters, which include plasma OCA (parent) and its conjugates (glyco -
OCA and tauro -OCA), total OCA, OCA glucuronide and 
potentially other conjugates or metabolites not yet identified.  PK analysis will be done using non -compartmental methods.   
13.7.5 Adjudicated Cardiovascular Events  Adjudicated cardiovascular events include core MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) and expanded MACE (unstable angina 
requiring hospi[INVESTIGATOR_059], transient ischemic attack, 
peripheral or coronary revascularization procedures, 
hospi[INVESTIGATOR_126042]).  Other events potentially related to adverse cardiovascular outcomes are defined in Appendix D  and will be included in the 
Cardiovascular Adjudication Committee Charter for adjudication.   Undetermined cause of death will be classified 
as a cardiovascular death by [CONTACT_576366].  
Summaries of adjudicated cardiovascular even ts will include 
the incidence of TEAEs and the incidence of serious TEAEs.  All summaries of incidence will include the associated exact binomial 95% CI.  
13.9 Adjudication 
Committees  â€¢ Cardiovascular Events Committee  (CEC):  Adjudicates all 
suspected MACE  â€¢ Cardiovascular Adjudication Committee  (CAC):  
Adjudicates all suspected MACE , including all deaths  
16.[ADDRESS_755964] will be regarded a s confidential and 
Page 356 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 357 
 
Confidential and Proprietary  Section Original Text  Revised Text  
and Data 
Protection  confidentiality of all subjects will be maintained.  Monitors (eg, 
CRA, Medical Monitor), auditors and inspectors will require 
access to a subjectâ€™s medical notes for the purpose of source 
document verification but the subjectâ€™s confidential ity will be 
maintained at all times.  An agreement for disclosure of any such information will be obtained in writing and is included in the statement of informed consent.  The study data shall not be 
disclosed to a third party (with the exception of auditors and/or 
regulatory authorities) without the written consent of the Sponsor.  All data shall be secured against unauthorized access.  
The Investigator will maintain a list of subject names and identifying information (eg, subjectsâ€™ hospi[INVESTIGATOR_42871], uniqu e 
subject numbers).  This list will not be collected by [CONTACT_1034].  
The written information sheet will explain that study data will be stored in a computer database, maintaining confidentiality in accordance with national data protection legislation.  All  data 
computer processed by [CONTACT_22122]/randomization code/ subject initials/site 
number, only.   confidentiality of all subjects will be maintained.  Monitors (eg, 
CRA, Medical Monitor), auditors and inspectors will require 
access to a subjectâ€™s medical notes for the purpose of source 
document verification but the subjectâ€™s confiden tiality will be 
maintained at all times.  An agreement for disclosure of any such information will be obtained in writing and is included in the statement of informed consent.  The study data shall not be 
disclosed to a third party (with the exception of a uditors and/or 
regulatory authorities) without the written consent of the 
Sponsor.  All reports and communications relating to 
subjects in this study that are disclosed to an authorized third party will identify subjects only by [CONTACT_576367] r and will be shared in a secure manner.   All 
data shall be secured against unauthorized access.  
The Investigator will maintain a list of subject names and 
identifying information (eg, subjectsâ€™ hospi[INVESTIGATOR_42871], unique subject numbers).  This list will no t be collected by [CONTACT_1034].  
The written information sheet will explain that study data will be stored in a computer database, maintaining confidentiality in 
accordance with national data protection legislation.  All data 
computer processed by [CONTACT_13099] r or designee will be 
identified by [CONTACT_576368]/randomization code/  site 
number, only.   
[ADDRESS_755965] of References   Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Dig Liver Dis. 2015a;47(11):924 -6. 
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Gastroenterology. 2015b;149(6):1627- 9. 
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology. 2015c;62(5):1620- 2. 
Page 357 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 358 
 
Confidential and Proprietary  Section Original Text  Revised Text  
Appendix D  Appendix D included Major Adverse Cardiovascular Event 
Definitions from Chapters 1 through 7 of  â€œStandardized 
Definitions for Cardiovascular and Stroke Endpoint Events in 
Clinical Trials,â€ dated August 20, 2014  Appendix D was updated to add definitions from Chapters 8 through 10 of â€œStandardized Definitions for Cardiovascular 
and Stroke Endpoint Events in Clinical Trials,â€ dated 
August 20, 2014 
Page 358 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 359 
 
Confidential and Proprietary  APPENDIX H.  747-209 PROTOCOL VERSION 4 SUMMARY OF CHANGES  
Protocol 747-209 was revised to include the following information: 
â€¢ Incorporation of the evaluation the bioanalytical concentrations of atorvastatin and its metabolite s. 
â€¢ Updating the maximum percentage of subjects with stage 4 fibrosis from 20% to 30%. 
â€¢ Removing t he obeticholic acid ( OCA) glucuronide component of PK as that bioanalysis will be conducted  in another 
study. 
â€¢ Additional clarifications.    
Summary of Changes 
The following revisions were made to the protocol in Protocol Version 4.  Revised and new text in Version 4 is indicated in bold 
font, and the text deleted from Protocol Version 3 is crossed out in the table below.  Minor/editorial changes are not listed 
individually in the summary table below. 
Section Original Text (Version 3)  Revised Text (Version 4)  Key Change  
Reasons /  
Justification for Change  
Study Personnel 
Contact [CONTACT_576369] [PHONE_11941] 6 or send an email to 
the NASH medical monitor at NASH209@interceptpharma .com with safety questions 
as these lines of contact [CONTACT_575759] 24 hours a day.  The following individual medical monitors may also be 
contact[CONTACT_576370] . Investigators are encouraged to call the PRA Medical 
Support Center phone number for the United 
States and Canada  at +[PHONE_5343] or send an 
email to the NASH medical monitor at 
[EMAIL_10976] with safety questions as these lines of contact [CONTACT_575759] 24 hours a day.   The PRA Medical Support Center phone number and 
email address were updated.  
Page 359 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 360 
 
Confidential and Proprietary  Section Original Text (Version 3)  Revised Text (Version 4)  Key Change  
Reasons /  
Justification for Change  
Study Personnel 
Contact [CONTACT_576371] +[PHONE_11933]  
 
[EMAIL_10980]  Deletion Removed the NASH Medical 
Monitor Hotline Email (n o 
longer applicable ). 
Study Personnel 
Contact [CONTACT_576372]: 
 
Phone: 
Email Emad Basta, MD  
(Lead) Medical Monitor/Medical 
Expert 
[CONTACT_30372]  
+[PHONE_5343] 
CONTROL@ PRAHS.com Primary Medical 
Monitor Contact:  
 
[CONTACT_7626]: 
Email Emad Basta, MD  
(Lead) Medical Monitor/Medical 
Expert 
[CONTACT_30372]  
+[PHONE_5343] 
CONTROL@ prahs.com Updated email address. 
Secondary 
Contact: [CONTACT_576347]-Rad , MD PhD 
Executive  Director, Medical Safety 
and Pharmacovigilance  
Intercept Pharmaceuticals, Inc. 
(Intercept)  Secondary 
Contact: [CONTACT_575760], MD, PhD  
Medical Director, Clinical 
Development  
Intercept Pharmaceuticals, Inc. (Intercept)  Tolga Baykal was added as 
secondary contact.  
Mobile Phone:  
Email +[PHONE_353] (Pacific time zone)  
rhooshmand-rad 
@interceptpharma.com Mobile Phone:  
Email +[PHONE_11938] (Pacific time 
zone) 
tolga.baykal @interceptpharma.c
om 
Synopsis 
Objectives:  
Exploratory Objectives  
6.3 Exploratory 
Objectives  Insertion â€¢ To evaluate the bioanalytical concentrations of 
atorvastatin and its metabolites     New exploratory objective for the determinations of the concentrations of atorvastatin 
and its metabolites.  
Synopsis 
Number of Subjects (Planned)  
 Approximately 80 subjects with biopsy -confirmed 
NASH and evidence of liver fibrosis, but no hepatic 
decompensation, who meet eligibility criteria, will be 
randomized in a 1:1:1:1 ratio to 1 of 4 treatment 
groups.  A maximum of 20% of subjects will have 
stage 4 fibrosis.  Approximately 80 subjects with biopsy -confirmed 
NASH and evidence of liver fibrosis, but no hepatic decompensation, who meet eligibility criteria, will be 
randomized in a 1:1:1:1 ratio to 1 of 4 treatment 
groups.  A maximum of 30% of subject s will have 
stage 4 fibrosis.  The rapid rate of enrollment of subjects with stage 4 fibrosis allowed patients already in 
screening to be enrolled after 
the initial maximum of 20% was met (the overall number of 
subjects remains at ~ 80).   
Page 360 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 361 
 
Confidential and Proprietary  Section Original Text (Version 3)  Revised Text (Version 4)  Key Change  
Reasons /  
Justification for Change  
Synopsis 
Statistical Methods  
11.1, Efficacy  
Assessments  
Table 4, List of 
Planned Assessments  OCA 
pharmacokinetics   OCA, tauro -OCA, glyco -OCA, 
total OCA , OCA glucuronide , 
potentially other conjugates or 
metabolites not yet identified  OCA 
pharmacokinetics  OCA, tauro-OCA, glyco -OCA, 
total OCA, potentially other 
conjugates or metabolites not yet identified  Removal of OCA glucuronide  
as that bioanalysis will be conducted in another study . 
Insertion Exploratory Endpoints  Addition of the determination of the concentration of 
atorvastatin and its metabolites  
to characterize atorvastatin concentrations with and 
without OCA .  Atorvastatin bioanalytical concentrations  Atorvastatin and its metabolites   
Synopsis 
Analysis Populations  
13.1, Analysis Sets  Pharmacokinetic Population : 
The PK Population will include all OCA subjects who 
consent to participate in the PK assessments and have 
at least one confirmed fasted analyzable sample.  Subjects must have been fasting for approximately [ADDRESS_755966] exposure levels.   Pharmacokinetic Population s: 
The OCA PK Population will include all OCA 
subjects who consent to participate in the PK assessments and have at least one confirmed fasted 
analyzable sample.  Subjects must have been fasting for approximately [ADDRESS_755967] one confirmed fasted analyzable 
sample.   Differentiation of OCA PK Population and i ncorporation 
of the Atorvastatin PK 
Population.  
7.1.2, Schedule of 
Study Procedures  
Table 1, Schedule of 
Study Procedures:  
Double-Blind Period s At selected investigational sites, subjects will have the 
option to provide blood samples for measurement of OCA PK.  PK samples will be collected within [ADDRESS_755968] 
the option to provide blood samples for measurement 
of  PK for OCA (Day 1 and Week 16), and for 
atorvastatin (Week  16).  PK samples will be 
collected within [ADDRESS_755969] and will remain fasted until the 1 hour sample 
is collected.  Clarification on the PK sampling of OCA and incorporation of atorvastatin PK sampling.  
7.2,  Number of 
Subjects Approximately 80 subjects who meet the eligibility criteria, including biopsy -confirmed NASH and 
evidence of liver fibrosis, but no hepatic decompensation, will be included in this study.  A 
maximum of 20% of subjects will have stage 4 f ibrosis. Approximately 80 subjects who meet the eligibility 
criteria, including biopsy -confirmed NASH and 
evidence of liver fibrosis, but no hepatic decompensation, will be included in this study.  A 
maximum of 30% of subjects will have stage 4 
fibrosis. The rapid rate of enrollment of 
subjects with stage 4 fibrosis 
allowed patients already in screening to be enrolled after 
the initial maximum of 20% 
Page 361 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 362 
 
Confidential and Proprietary  Section Original Text (Version 3)  Revised Text (Version 4)  Key Change  
Reasons /  
Justification for Change  
was met (the overall number of 
subjects remains at ~ 80).   
[IP_ADDRESS], Additional 
Week [ADDRESS_755970] with 
water.  Serial blood samples will be obtained for measurement of OCA and its conjugates , and 
atorvastatin and its metabolites,  30 minutes prior to 
dosing and at 0.5,  0.75, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 
hours postdose.   Clarification of study phase.  
Incorporation of PK sampling 
for atorvastatin.  
11.2, 
Pharmacokinetic and 
Pharmacodynamic Assessments  Parent OCA and its major conjugates (glyco -OCA and 
tauro-OCA), C4,  and FGF-19 concentrations will be 
determined for OCA PK and FXR activity in OCA-treated subjects.   Samples will be obtained for 
possible assessment of conjugated and unconjugated bile acids.  Parent OCA and its major conjugates (glyco -OCA and 
tauro-OCA), C4, and FGF -[ADDRESS_755971] (predose) on Day  [ADDRESS_755972] (predose) on Day  [ADDRESS_755973] with approximately 240 mL of water.  Serial blood samples 
will be obtained for measurement of OCA and its 
conjugates , and atorvastatin and its metabolites,  at 
0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 hours postdose.  Incorporation of atorvastatin PK and sampling.  
Page 362 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 363 
 
Confidential and Proprietary  Section Original Text (Version 3)  Revised Text (Version 4)  Key Change  
Reasons /  
Justification for Change  
[IP_ADDRESS], Severity of 
Pruritus (as  an AE) â€¢ Drug holiday:  A drug holiday is defined as an 
Investigator â€˜prescribedâ€™ complete interruption of 
dosing for 1 or more consecutive days (ie, non-daily dosing does not constitute a drug holiday).  For 
subjects with severe pruritus, instruct the subject to 
stop taking i nvestigational product until the pruritus 
subsides to an acceptable level, at which time it should 
be restarted.   Details of drug holidays and/or nondaily 
dosing regimens should be recorded in the CRF.     â€¢ Drug holiday:  A drug holiday is defined as an 
Investigator â€˜prescribedâ€™ complete interruption of 
dosing for 1 or more consecutive days (ie, non-daily 
dosing does not constitute a drug holiday).  Details of 
drug holidays and/or nondaily dosing regimens 
should be recorded in the CRF .  Per Section [IP_ADDRESS] , 
subjects with pruritus â‰¥Grade [ADDRESS_755974].      Instructions for severity of 
pruritus were removed.  The 
instructions for the handling of 
â‰¥Grade [ADDRESS_755975] of 
Laboratory Analytes to be Tested  Subset of Subjects  Subset of Subjects  Removal of OCA glucuronide . 
Addition of atorvastatin and its 
metabolites .   PK analytes  OCA, tauro -OCA, glyco -OCA, OCA 
glucuronide  and possible other 
conjugates or metabolites not yet 
identified  PK analytes  OCA, tauro -OCA, glyco -OCA,  
and possible other conjugates or 
metabolites not yet identified  
Atorvastatin and its metabolites  
a NMR-based panel will be used for (a) LDL, HDL, and 
VLDL cholesterol concentrations, particle sizes, and 
particle concentrations , and (b) ApoA1, ApoB, ApoE, 
ApoCII, ApoCIII and Lp(a) concentrations.  Serum 
chemistry panel will be used for LDL, HDL, VLDL, TG, and total cholesterol concentration.  a NMR-based panel will be used for LDL, HDL, and 
VLDL cholesterol concentrations, particle sizes, and particle concentrations .  ApoA1, ApoB, ApoE, 
ApoCII, ApoCIII,  Lp(a) and PCSK9  
concentrations  will be measured usin g 
appropriate methods at central or specialty 
laboratories .  Serum chemistry panel will be used 
for LDL, HDL, VLDL, TG, and total cholesterol 
concentration.  Clarification of methods to be 
used for the determination of ApoA1, ApoB, ApoE, ApoCII, ApoCIII, Lp(a), and PCSK9 
concentrations.  
[IP_ADDRESS],
Pharmacokinetic 
Analysis The PK Population will be used for analysis of PK 
parameters, which include plasma OCA (parent) and its 
conjugates (glyco -OCA and tauro -OCA), total OCA, 
OCA glucuronide , and potentially other conjugates or 
metabolites  not yet identified.  PK analysis will be done 
using non-compartmental methods.   
The values will be summarized by [CONTACT_576373].  Only samples that have a confirmed fas ting of approximately 8 hours or 
more before their visit will be included in the analysis.   
Further details regarding specific parameters and 
methods will be described in the SAP. The PK Population will be used for analysis of PK 
parameters, which include plasma OCA (parent) and 
its conjugates (glyco -OCA and tauro-OCA), total 
OCA, atorvastatin and its metabolites , and 
potentially other analytes not yet identified.  PK 
analysis will be conducted  using standard  
non-compartmental methodologies .   
For the anal ysis of OCA and its conjugates, values 
will be summarized by [CONTACT_576374].  Only samples that have a 
confirmed fasting of approximately 8 hours or more before their visit will be included in the analysis.   Incorporation of clarifications 
for OCA and atorvastatin PK 
analysis. 
Page 363 of 364
Protocol 747 -209  Version 4:  19 Dec 2016   
Page 364 
 
Confidential and Proprietary  Section Original Text (Version 3)  Revised Text (Version 4)  Key Change  
Reasons /  
Justification for Change  
Further de tails regarding the methods for 
calculating PK and the  specific parameters to be 
reported will be described in the SAP.  
 
Page 364 of 364